0000899866-20-000088.txt : 20201029 0000899866-20-000088.hdr.sgml : 20201029 20201029071352 ACCESSION NUMBER: 0000899866-20-000088 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 117 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201029 DATE AS OF CHANGE: 20201029 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALEXION PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000899866 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133648318 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-27756 FILM NUMBER: 201270491 BUSINESS ADDRESS: STREET 1: 121 SEAPORT BOULEVARD CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 4752302596 MAIL ADDRESS: STREET 1: 121 SEAPORT BOULEVARD CITY: BOSTON STATE: MA ZIP: 02210 FORMER COMPANY: FORMER CONFORMED NAME: ALEXION PHARMACEUTICALS INC DATE OF NAME CHANGE: 19960111 10-Q 1 alxn-20200930.htm 10-Q alxn-20200930
000089986612/312020Q3FALSE00008998662020-01-012020-09-30xbrli:shares00008998662020-10-27iso4217:USD00008998662020-09-3000008998662019-12-31iso4217:USDxbrli:shares0000899866alxn:NetProductSalesMember2020-07-012020-09-300000899866alxn:NetProductSalesMember2019-07-012019-09-300000899866alxn:NetProductSalesMember2020-01-012020-09-300000899866alxn:NetProductSalesMember2019-01-012019-09-300000899866alxn:OtherRevenueMember2020-07-012020-09-300000899866alxn:OtherRevenueMember2019-07-012019-09-300000899866alxn:OtherRevenueMember2020-01-012020-09-300000899866alxn:OtherRevenueMember2019-01-012019-09-3000008998662020-07-012020-09-3000008998662019-07-012019-09-3000008998662019-01-012019-09-300000899866us-gaap:CommonStockMember2020-06-300000899866us-gaap:AdditionalPaidInCapitalMember2020-06-300000899866us-gaap:TreasuryStockMember2020-06-300000899866us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300000899866us-gaap:RetainedEarningsMember2020-06-3000008998662020-06-300000899866us-gaap:TreasuryStockMember2020-07-012020-09-300000899866us-gaap:CommonStockMember2020-07-012020-09-300000899866us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300000899866us-gaap:RetainedEarningsMember2020-07-012020-09-300000899866us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300000899866us-gaap:CommonStockMember2020-09-300000899866us-gaap:AdditionalPaidInCapitalMember2020-09-300000899866us-gaap:TreasuryStockMember2020-09-300000899866us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300000899866us-gaap:RetainedEarningsMember2020-09-300000899866us-gaap:CommonStockMember2019-06-300000899866us-gaap:AdditionalPaidInCapitalMember2019-06-300000899866us-gaap:TreasuryStockMember2019-06-300000899866us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-300000899866us-gaap:RetainedEarningsMember2019-06-3000008998662019-06-300000899866us-gaap:TreasuryStockMember2019-07-012019-09-300000899866us-gaap:CommonStockMember2019-07-012019-09-300000899866us-gaap:AdditionalPaidInCapitalMember2019-07-012019-09-300000899866us-gaap:RetainedEarningsMember2019-07-012019-09-300000899866us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-07-012019-09-300000899866us-gaap:CommonStockMember2019-09-300000899866us-gaap:AdditionalPaidInCapitalMember2019-09-300000899866us-gaap:TreasuryStockMember2019-09-300000899866us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-09-300000899866us-gaap:RetainedEarningsMember2019-09-3000008998662019-09-300000899866us-gaap:CommonStockMember2019-12-310000899866us-gaap:AdditionalPaidInCapitalMember2019-12-310000899866us-gaap:TreasuryStockMember2019-12-310000899866us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310000899866us-gaap:RetainedEarningsMember2019-12-310000899866us-gaap:TreasuryStockMember2020-01-012020-09-300000899866us-gaap:CommonStockMember2020-01-012020-09-300000899866us-gaap:AdditionalPaidInCapitalMember2020-01-012020-09-300000899866us-gaap:RetainedEarningsMember2020-01-012020-09-300000899866us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-09-300000899866us-gaap:CommonStockMember2018-12-310000899866us-gaap:AdditionalPaidInCapitalMember2018-12-310000899866us-gaap:TreasuryStockMember2018-12-310000899866us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310000899866us-gaap:RetainedEarningsMember2018-12-3100008998662018-12-310000899866us-gaap:TreasuryStockMember2019-01-012019-09-300000899866us-gaap:CommonStockMember2019-01-012019-09-300000899866us-gaap:AdditionalPaidInCapitalMember2019-01-012019-09-300000899866us-gaap:RetainedEarningsMember2019-01-012019-09-300000899866us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-09-300000899866alxn:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2018-12-310000899866alxn:CumulativeEffectPeriodOfAdoptionAdjustmentMember2018-12-310000899866alxn:AchillionMember2020-01-282020-01-280000899866alxn:DanicopanMemberalxn:AchillionMember2020-01-282020-01-280000899866alxn:ACH5528Phase3Memberalxn:AchillionMember2020-01-282020-01-280000899866alxn:AchillionMember2020-01-280000899866alxn:AcquiredIprdMemberalxn:AchillionMember2020-01-280000899866alxn:AchillionMember2020-04-012020-06-30xbrli:pure0000899866us-gaap:FairValueInputsLevel3Memberalxn:AcquisitionRelatedContingentConsiderationMembersrt:MinimumMember2020-01-282020-01-280000899866us-gaap:FairValueInputsLevel3Memberalxn:AcquisitionRelatedContingentConsiderationMembersrt:MaximumMember2020-01-282020-01-280000899866alxn:AchillionMembersrt:MinimumMember2020-01-280000899866srt:MaximumMemberalxn:AchillionMember2020-01-280000899866alxn:AchillionMember2020-09-300000899866us-gaap:FairValueInputsLevel3Memberalxn:AcquisitionRelatedContingentConsiderationMembersrt:MinimumMember2020-01-012020-09-300000899866us-gaap:FairValueInputsLevel3Memberalxn:AcquisitionRelatedContingentConsiderationMembersrt:MaximumMember2020-01-012020-09-300000899866alxn:AchillionMember2020-07-012020-09-300000899866alxn:AchillionMember2020-01-012020-09-300000899866alxn:AcquiredIprdMember2020-04-012020-06-300000899866alxn:PortolaPharmaceuticalsIncMember2020-07-022020-07-020000899866alxn:PortolaPharmaceuticalsMember2020-03-012020-03-310000899866alxn:PortolaPharmaceuticalsMember2020-04-012020-04-300000899866alxn:PortolaPharmaceuticalsMember2020-07-020000899866alxn:PortolaPharmaceuticalsIncMember2020-07-020000899866alxn:PortolaPharmaceuticalsIncMemberalxn:AndexxaProductLineMember2020-07-022020-07-020000899866alxn:PurchasedTechnologyMemberalxn:PortolaPharmaceuticalsIncMember2020-07-020000899866alxn:PortolaPharmaceuticalsIncMemberalxn:AcquiredIprdMember2020-09-300000899866alxn:PurchasedTechnologyMemberalxn:PortolaPharmaceuticalsIncMember2020-07-022020-07-020000899866alxn:PortolaPharmaceuticalsIncMemberalxn:HealthCareRoyaltyPartnersMemberalxn:RoyaltyBasedFinancingAgreementMember2017-02-280000899866alxn:PortolaPharmaceuticalsIncMemberalxn:HealthCareRoyaltyPartnersMemberalxn:RoyaltyBasedFinancingAgreementMember2020-07-022020-07-020000899866alxn:PortolaPharmaceuticalsIncMemberalxn:HealthCareRoyaltyPartnersMemberalxn:RoyaltyBasedFinancingAgreementMember2020-07-020000899866alxn:PortolaPharmaceuticalsIncMembersrt:MinimumMember2020-07-022020-07-020000899866alxn:PortolaPharmaceuticalsIncMembersrt:MaximumMember2020-07-022020-07-020000899866alxn:PortolaPharmaceuticalsIncMember2020-01-012020-09-300000899866alxn:PortolaPharmaceuticalsIncMember2020-07-012020-09-300000899866alxn:PortolaPharmaceuticalsIncMember2019-07-012019-09-300000899866alxn:PortolaPharmaceuticalsIncMember2019-01-012019-09-300000899866us-gaap:InventoriesMember2020-09-300000899866us-gaap:InventoriesMember2019-12-310000899866us-gaap:OtherAssetsMember2020-09-300000899866us-gaap:OtherAssetsMember2019-12-310000899866alxn:PreApprovalInventoryMember2020-09-300000899866alxn:PreApprovalInventoryMember2019-12-310000899866srt:MinimumMemberus-gaap:LicensingAgreementsMember2020-01-012020-09-300000899866srt:MaximumMemberus-gaap:LicensingAgreementsMember2020-01-012020-09-300000899866us-gaap:LicensingAgreementsMember2020-09-300000899866us-gaap:LicensingAgreementsMember2019-12-310000899866us-gaap:PatentsMember2020-01-012020-09-300000899866us-gaap:PatentsMember2020-09-300000899866us-gaap:PatentsMember2019-12-310000899866alxn:PurchasedTechnologyMembersrt:MinimumMember2020-01-012020-09-300000899866alxn:PurchasedTechnologyMembersrt:MaximumMember2020-01-012020-09-300000899866alxn:PurchasedTechnologyMember2020-09-300000899866alxn:PurchasedTechnologyMember2019-12-310000899866us-gaap:OtherIntangibleAssetsMember2020-01-012020-09-300000899866us-gaap:OtherIntangibleAssetsMember2020-09-300000899866us-gaap:OtherIntangibleAssetsMember2019-12-310000899866alxn:AcquiredIprdMember2020-09-300000899866alxn:AcquiredIprdMember2019-12-310000899866alxn:PurchasedTechnologyMember2020-04-012020-06-300000899866alxn:KanumaProductLineMember2020-06-300000899866alxn:CreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2018-06-070000899866alxn:SeniorSecuredTermLoanMemberus-gaap:LineOfCreditMemberalxn:CreditAgreementMember2018-06-070000899866alxn:CreditAgreementMember2019-01-012019-03-310000899866alxn:SeniorSecuredTermLoanMemberus-gaap:LineOfCreditMemberalxn:CreditAgreementMember2020-07-012020-09-300000899866alxn:SeniorSecuredTermLoanMemberus-gaap:LineOfCreditMemberalxn:CreditAgreementMember2020-01-012020-09-300000899866alxn:SeniorSecuredTermLoanMemberus-gaap:LineOfCreditMemberalxn:CreditAgreementMember2020-09-300000899866alxn:CreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2020-09-300000899866alxn:PortolaPharmaceuticalsIncMemberalxn:HealthCareRoyaltyPartnersMemberalxn:RoyaltyBasedFinancingAgreementMember2017-02-012017-02-280000899866alxn:PortolaPharmaceuticalsIncMemberalxn:HealthCareRoyaltyPartnersMemberalxn:RoyaltyBasedFinancingAgreementMember2018-05-310000899866alxn:PortolaPharmaceuticalsIncMemberalxn:HealthCareRoyaltyPartnersMemberalxn:RoyaltyBasedFinancingAgreementMembersrt:MinimumMember2017-02-280000899866alxn:PortolaPharmaceuticalsIncMemberalxn:HealthCareRoyaltyPartnersMemberalxn:RoyaltyBasedFinancingAgreementMembersrt:MaximumMember2017-02-280000899866alxn:HealthCareRoyaltyPartnersMemberalxn:RoyaltyBasedFinancingAgreementMember2020-09-300000899866alxn:HealthCareRoyaltyPartnersMemberalxn:RoyaltyBasedFinancingAgreementMember2020-07-012020-09-300000899866alxn:HealthCareRoyaltyPartnersMemberalxn:RoyaltyBasedFinancingAgreementMember2020-01-012020-09-300000899866alxn:HealthCareRoyaltyPartnersMemberalxn:RoyaltyBasedFinancingAgreementMembersrt:ScenarioForecastMember2020-10-012020-12-3100008998662020-07-032020-09-300000899866alxn:HealthCareRoyaltyPartnersMemberalxn:RoyaltyBasedFinancingAgreementMember2020-07-032020-09-300000899866us-gaap:CommercialPaperMember2019-12-310000899866us-gaap:CorporateBondSecuritiesMember2019-12-310000899866us-gaap:USGovernmentAgenciesDebtSecuritiesMember2019-12-310000899866us-gaap:CertificatesOfDepositMember2019-12-310000899866us-gaap:DebtSecuritiesMember2019-12-310000899866us-gaap:CashAndCashEquivalentsMember2020-09-300000899866us-gaap:CashAndCashEquivalentsMember2019-12-310000899866alxn:MarketableSecuritiesMember2020-09-300000899866alxn:MarketableSecuritiesMember2019-12-310000899866us-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-09-300000899866us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2020-09-300000899866us-gaap:DesignatedAsHedgingInstrumentMemberalxn:ForeignExchangeForwardOpenExpenseMember2020-09-300000899866us-gaap:DesignatedAsHedgingInstrumentMemberalxn:InterestRateSwapTwoMember2020-09-300000899866us-gaap:DesignatedAsHedgingInstrumentMemberalxn:InterestRateSwapTwoMembersrt:MinimumMember2020-09-300000899866us-gaap:DesignatedAsHedgingInstrumentMemberalxn:InterestRateSwapTwoMembersrt:MaximumMember2020-09-300000899866alxn:InterestRateSwapFourMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-09-300000899866alxn:InterestRateSwapFourMemberus-gaap:DesignatedAsHedgingInstrumentMembersrt:MinimumMember2020-09-300000899866alxn:InterestRateSwapFourMemberus-gaap:DesignatedAsHedgingInstrumentMembersrt:MaximumMember2020-09-300000899866us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ForeignExchangeForwardMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300000899866us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ForeignExchangeForwardMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-07-012019-09-300000899866us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:InterestRateContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300000899866us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:InterestRateContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-07-012019-09-300000899866us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ForeignExchangeForwardMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-09-300000899866us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ForeignExchangeForwardMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-01-012019-09-300000899866us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:InterestRateContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-09-300000899866us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:InterestRateContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-01-012019-09-300000899866us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMember2020-07-012020-09-300000899866us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMember2019-07-012019-09-300000899866us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMember2020-01-012020-09-300000899866us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMember2019-01-012019-09-300000899866us-gaap:SalesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMember2020-07-012020-09-300000899866us-gaap:SalesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMember2019-07-012019-09-300000899866us-gaap:SalesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMember2020-01-012020-09-300000899866us-gaap:SalesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMember2019-01-012019-09-300000899866us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2020-07-012020-09-300000899866us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2019-07-012019-09-300000899866us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2020-01-012020-09-300000899866us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2019-01-012019-09-300000899866us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestExpenseMember2020-07-012020-09-300000899866us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestExpenseMember2019-07-012019-09-300000899866us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestExpenseMember2020-01-012020-09-300000899866us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestExpenseMember2019-01-012019-09-300000899866us-gaap:SalesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2020-07-012020-09-300000899866us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMember2020-07-012020-09-300000899866us-gaap:NondesignatedMember2020-07-012020-09-300000899866us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2020-09-300000899866us-gaap:NondesignatedMember2019-07-012019-09-300000899866us-gaap:NondesignatedMember2020-01-012020-09-300000899866us-gaap:NondesignatedMember2019-01-012019-09-300000899866us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2020-09-300000899866us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeForwardMember2020-09-300000899866us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:OtherNoncurrentAssetsMember2020-09-300000899866us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2020-09-300000899866us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMember2020-09-300000899866us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:InterestRateContractMember2020-09-300000899866us-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMemberus-gaap:OtherNoncurrentAssetsMember2020-09-300000899866us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMember2020-09-300000899866us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMemberus-gaap:ForeignExchangeForwardMember2020-09-300000899866us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeForwardMember2020-09-300000899866us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2019-12-310000899866us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeForwardMember2019-12-310000899866us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:OtherNoncurrentAssetsMember2019-12-310000899866us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2019-12-310000899866us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMember2019-12-310000899866us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:InterestRateContractMember2019-12-310000899866us-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMemberus-gaap:OtherNoncurrentAssetsMember2019-12-310000899866us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMember2019-12-310000899866us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMemberus-gaap:ForeignExchangeForwardMember2019-12-310000899866us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeForwardMember2019-12-310000899866us-gaap:ForeignExchangeForwardMember2020-09-300000899866us-gaap:ForeignExchangeForwardMember2019-12-310000899866alxn:ModernaLLCMember2014-01-012014-12-310000899866alxn:ModernaLLCMember2019-07-012019-09-300000899866alxn:ModernaLLCMember2019-01-012019-09-300000899866alxn:ModernaLLCMember2019-12-092019-12-090000899866alxn:DicernaMember2018-10-012018-10-310000899866alxn:DicernaMember2020-07-012020-09-300000899866alxn:DicernaMember2020-01-012020-09-300000899866alxn:DicernaMember2019-07-012019-09-300000899866alxn:DicernaMember2019-01-012019-09-300000899866alxn:DicernaMember2020-09-300000899866alxn:DicernaMember2019-12-310000899866alxn:CaelumBiosciencesMember2019-01-012019-01-310000899866alxn:CaelumBiosciencesMember2019-10-012019-12-310000899866us-gaap:CollaborativeArrangementMemberalxn:CaelumBiosciencesMember2019-10-012019-12-310000899866alxn:CollaborativeAgreementAmendmentMemberalxn:CaelumBiosciencesMember2019-10-012019-12-310000899866alxn:CaelumBiosciencesMember2019-01-012019-12-310000899866alxn:CaelumBiosciencesMember2020-01-012020-09-300000899866alxn:CaelumBiosciencesOptionMember2020-01-012020-09-300000899866alxn:CaelumBiosciencesOptionMember2019-01-012019-12-310000899866alxn:ZealandMember2019-03-012019-03-310000899866alxn:ZealandMember2020-07-012020-09-300000899866alxn:ZealandMember2020-01-012020-09-300000899866alxn:ZealandMember2019-07-012019-09-300000899866alxn:ZealandMember2019-01-012019-09-300000899866alxn:ZealandMember2020-09-300000899866alxn:ZealandMember2019-12-310000899866alxn:EidosMemberMember2019-09-012019-09-300000899866alxn:EidosMemberMember2020-07-012020-09-300000899866alxn:EidosMemberMember2020-01-012020-09-300000899866alxn:EidosMemberMember2019-07-012019-09-300000899866alxn:EidosMemberMember2019-01-012019-09-300000899866alxn:EidosMemberMember2020-09-300000899866alxn:EidosMemberMember2019-12-310000899866alxn:StealthMember2019-10-012019-10-310000899866alxn:StealthMember2020-07-012020-09-300000899866alxn:StealthMember2020-01-012020-09-300000899866alxn:StealthMember2020-09-300000899866alxn:StealthMember2019-12-310000899866alxn:PortolaPharmaceuticalsMember2020-07-012020-09-300000899866alxn:PortolaPharmaceuticalsMember2020-01-012020-09-300000899866alxn:PortolaPharmaceuticalsMember2020-07-022020-07-020000899866alxn:InozymeMember2020-07-172020-07-170000899866alxn:InozymeMember2020-01-012020-09-300000899866alxn:InozymeMember2020-07-012020-09-300000899866alxn:InozymeMember2020-09-300000899866us-gaap:CommonStockMember2017-02-280000899866us-gaap:CommonStockMember2019-10-220000899866us-gaap:CommonStockMember2020-07-280000899866us-gaap:SubsequentEventMemberus-gaap:CommonStockMember2020-10-012020-10-290000899866us-gaap:SubsequentEventMemberus-gaap:CommonStockMember2020-10-270000899866us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-12-310000899866us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-12-310000899866us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2019-12-310000899866us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310000899866us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-01-012020-09-300000899866us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-01-012020-09-300000899866us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2020-01-012020-09-300000899866us-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-09-300000899866us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-09-300000899866us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-09-300000899866us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2020-09-300000899866us-gaap:AccumulatedTranslationAdjustmentMember2020-09-300000899866us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2018-12-310000899866us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2018-12-310000899866us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2018-12-310000899866us-gaap:AccumulatedTranslationAdjustmentMember2018-12-310000899866us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-01-012019-09-300000899866us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-01-012019-09-300000899866us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2019-01-012019-09-300000899866us-gaap:AccumulatedTranslationAdjustmentMember2019-01-012019-09-300000899866us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-09-300000899866us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-09-300000899866us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2019-09-300000899866us-gaap:AccumulatedTranslationAdjustmentMember2019-09-300000899866us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300000899866us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-07-012019-09-300000899866us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-09-300000899866us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-01-012019-09-300000899866us-gaap:CashEquivalentsMemberus-gaap:MoneyMarketFundsMember2020-09-300000899866us-gaap:CashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2020-09-300000899866us-gaap:CashEquivalentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2020-09-300000899866us-gaap:FairValueInputsLevel3Memberus-gaap:CashEquivalentsMemberus-gaap:MoneyMarketFundsMember2020-09-300000899866alxn:MutualFundsMemberalxn:MarketableSecuritiesMember2020-09-300000899866us-gaap:FairValueInputsLevel1Memberalxn:MutualFundsMemberalxn:MarketableSecuritiesMember2020-09-300000899866us-gaap:FairValueInputsLevel2Memberalxn:MutualFundsMemberalxn:MarketableSecuritiesMember2020-09-300000899866us-gaap:FairValueInputsLevel3Memberalxn:MutualFundsMemberalxn:MarketableSecuritiesMember2020-09-300000899866us-gaap:OtherAssetsMemberus-gaap:EquitySecuritiesMember2020-09-300000899866us-gaap:OtherAssetsMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel1Member2020-09-300000899866us-gaap:OtherAssetsMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Member2020-09-300000899866us-gaap:FairValueInputsLevel3Memberus-gaap:OtherAssetsMemberus-gaap:EquitySecuritiesMember2020-09-300000899866us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeForwardMember2020-09-300000899866us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeForwardMemberus-gaap:FairValueInputsLevel1Member2020-09-300000899866us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeForwardMemberus-gaap:FairValueInputsLevel2Member2020-09-300000899866us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeForwardMember2020-09-300000899866us-gaap:ForeignExchangeForwardMemberus-gaap:OtherNoncurrentAssetsMember2020-09-300000899866us-gaap:ForeignExchangeForwardMemberus-gaap:FairValueInputsLevel1Memberus-gaap:OtherNoncurrentAssetsMember2020-09-300000899866us-gaap:ForeignExchangeForwardMemberus-gaap:FairValueInputsLevel2Memberus-gaap:OtherNoncurrentAssetsMember2020-09-300000899866us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeForwardMemberus-gaap:OtherNoncurrentAssetsMember2020-09-300000899866us-gaap:ForeignExchangeForwardMemberus-gaap:OtherCurrentLiabilitiesMember2020-09-300000899866us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeForwardMemberus-gaap:OtherCurrentLiabilitiesMember2020-09-300000899866us-gaap:ForeignExchangeForwardMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueInputsLevel2Member2020-09-300000899866us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeForwardMemberus-gaap:OtherCurrentLiabilitiesMember2020-09-300000899866us-gaap:ForeignExchangeForwardMemberus-gaap:OtherNoncurrentLiabilitiesMember2020-09-300000899866us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeForwardMemberus-gaap:OtherNoncurrentLiabilitiesMember2020-09-300000899866us-gaap:ForeignExchangeForwardMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel2Member2020-09-300000899866us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeForwardMemberus-gaap:OtherNoncurrentLiabilitiesMember2020-09-300000899866us-gaap:InterestRateContractMemberus-gaap:OtherCurrentLiabilitiesMember2020-09-300000899866us-gaap:InterestRateContractMemberus-gaap:FairValueInputsLevel1Memberus-gaap:OtherCurrentLiabilitiesMember2020-09-300000899866us-gaap:InterestRateContractMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueInputsLevel2Member2020-09-300000899866us-gaap:FairValueInputsLevel3Memberus-gaap:InterestRateContractMemberus-gaap:OtherCurrentLiabilitiesMember2020-09-300000899866us-gaap:InterestRateContractMemberus-gaap:OtherLiabilitiesMember2020-09-300000899866us-gaap:InterestRateContractMemberus-gaap:FairValueInputsLevel1Memberus-gaap:OtherLiabilitiesMember2020-09-300000899866us-gaap:InterestRateContractMemberus-gaap:FairValueInputsLevel2Memberus-gaap:OtherLiabilitiesMember2020-09-300000899866us-gaap:FairValueInputsLevel3Memberus-gaap:InterestRateContractMemberus-gaap:OtherLiabilitiesMember2020-09-300000899866alxn:ContingentConsiderationMemberalxn:AcquisitionRelatedContingentConsiderationMember2020-09-300000899866alxn:ContingentConsiderationMemberus-gaap:FairValueInputsLevel1Memberalxn:AcquisitionRelatedContingentConsiderationMember2020-09-300000899866alxn:ContingentConsiderationMemberalxn:AcquisitionRelatedContingentConsiderationMemberus-gaap:FairValueInputsLevel2Member2020-09-300000899866alxn:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Memberalxn:AcquisitionRelatedContingentConsiderationMember2020-09-300000899866us-gaap:CashEquivalentsMemberus-gaap:MoneyMarketFundsMember2019-12-310000899866us-gaap:CashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2019-12-310000899866us-gaap:CashEquivalentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2019-12-310000899866us-gaap:FairValueInputsLevel3Memberus-gaap:CashEquivalentsMemberus-gaap:MoneyMarketFundsMember2019-12-310000899866us-gaap:CashEquivalentsMemberus-gaap:CommercialPaperMember2019-12-310000899866us-gaap:CashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMember2019-12-310000899866us-gaap:CashEquivalentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2019-12-310000899866us-gaap:FairValueInputsLevel3Memberus-gaap:CashEquivalentsMemberus-gaap:CommercialPaperMember2019-12-310000899866us-gaap:CashEquivalentsMemberus-gaap:CorporateBondSecuritiesMember2019-12-310000899866us-gaap:CashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CorporateBondSecuritiesMember2019-12-310000899866us-gaap:CashEquivalentsMemberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel2Member2019-12-310000899866us-gaap:FairValueInputsLevel3Memberus-gaap:CashEquivalentsMemberus-gaap:CorporateBondSecuritiesMember2019-12-310000899866us-gaap:CashEquivalentsMemberus-gaap:CertificatesOfDepositMember2019-12-310000899866us-gaap:CashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMember2019-12-310000899866us-gaap:CashEquivalentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMember2019-12-310000899866us-gaap:FairValueInputsLevel3Memberus-gaap:CashEquivalentsMemberus-gaap:CertificatesOfDepositMember2019-12-310000899866us-gaap:CashEquivalentsMemberalxn:OtherGovernmentObligationsMember2019-12-310000899866us-gaap:CashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberalxn:OtherGovernmentObligationsMember2019-12-310000899866us-gaap:CashEquivalentsMemberalxn:OtherGovernmentObligationsMemberus-gaap:FairValueInputsLevel2Member2019-12-310000899866us-gaap:FairValueInputsLevel3Memberus-gaap:CashEquivalentsMemberalxn:OtherGovernmentObligationsMember2019-12-310000899866alxn:MutualFundsMemberalxn:MarketableSecuritiesMember2019-12-310000899866us-gaap:FairValueInputsLevel1Memberalxn:MutualFundsMemberalxn:MarketableSecuritiesMember2019-12-310000899866us-gaap:FairValueInputsLevel2Memberalxn:MutualFundsMemberalxn:MarketableSecuritiesMember2019-12-310000899866us-gaap:FairValueInputsLevel3Memberalxn:MutualFundsMemberalxn:MarketableSecuritiesMember2019-12-310000899866us-gaap:CommercialPaperMemberalxn:MarketableSecuritiesMember2019-12-310000899866us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMemberalxn:MarketableSecuritiesMember2019-12-310000899866us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberalxn:MarketableSecuritiesMember2019-12-310000899866us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMemberalxn:MarketableSecuritiesMember2019-12-310000899866us-gaap:CorporateBondSecuritiesMemberalxn:MarketableSecuritiesMember2019-12-310000899866us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateBondSecuritiesMemberalxn:MarketableSecuritiesMember2019-12-310000899866us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel2Memberalxn:MarketableSecuritiesMember2019-12-310000899866us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateBondSecuritiesMemberalxn:MarketableSecuritiesMember2019-12-310000899866alxn:OtherGovernmentObligationsMemberalxn:MarketableSecuritiesMember2019-12-310000899866us-gaap:FairValueInputsLevel1Memberalxn:OtherGovernmentObligationsMemberalxn:MarketableSecuritiesMember2019-12-310000899866alxn:OtherGovernmentObligationsMemberus-gaap:FairValueInputsLevel2Memberalxn:MarketableSecuritiesMember2019-12-310000899866us-gaap:FairValueInputsLevel3Memberalxn:OtherGovernmentObligationsMemberalxn:MarketableSecuritiesMember2019-12-310000899866alxn:MarketableSecuritiesMemberus-gaap:CertificatesOfDepositMember2019-12-310000899866us-gaap:FairValueInputsLevel1Memberalxn:MarketableSecuritiesMemberus-gaap:CertificatesOfDepositMember2019-12-310000899866us-gaap:FairValueInputsLevel2Memberalxn:MarketableSecuritiesMemberus-gaap:CertificatesOfDepositMember2019-12-310000899866us-gaap:FairValueInputsLevel3Memberalxn:MarketableSecuritiesMemberus-gaap:CertificatesOfDepositMember2019-12-310000899866us-gaap:OtherAssetsMemberus-gaap:EquitySecuritiesMember2019-12-310000899866us-gaap:OtherAssetsMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel1Member2019-12-310000899866us-gaap:OtherAssetsMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Member2019-12-310000899866us-gaap:FairValueInputsLevel3Memberus-gaap:OtherAssetsMemberus-gaap:EquitySecuritiesMember2019-12-310000899866us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeForwardMember2019-12-310000899866us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeForwardMemberus-gaap:FairValueInputsLevel1Member2019-12-310000899866us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeForwardMemberus-gaap:FairValueInputsLevel2Member2019-12-310000899866us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeForwardMember2019-12-310000899866us-gaap:ForeignExchangeForwardMemberus-gaap:OtherNoncurrentAssetsMember2019-12-310000899866us-gaap:ForeignExchangeForwardMemberus-gaap:FairValueInputsLevel1Memberus-gaap:OtherNoncurrentAssetsMember2019-12-310000899866us-gaap:ForeignExchangeForwardMemberus-gaap:FairValueInputsLevel2Memberus-gaap:OtherNoncurrentAssetsMember2019-12-310000899866us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeForwardMemberus-gaap:OtherNoncurrentAssetsMember2019-12-310000899866us-gaap:ForeignExchangeForwardMemberus-gaap:OtherCurrentLiabilitiesMember2019-12-310000899866us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeForwardMemberus-gaap:OtherCurrentLiabilitiesMember2019-12-310000899866us-gaap:ForeignExchangeForwardMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueInputsLevel2Member2019-12-310000899866us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeForwardMemberus-gaap:OtherCurrentLiabilitiesMember2019-12-310000899866us-gaap:ForeignExchangeForwardMemberus-gaap:OtherNoncurrentLiabilitiesMember2019-12-310000899866us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeForwardMemberus-gaap:OtherNoncurrentLiabilitiesMember2019-12-310000899866us-gaap:ForeignExchangeForwardMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel2Member2019-12-310000899866us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeForwardMemberus-gaap:OtherNoncurrentLiabilitiesMember2019-12-310000899866us-gaap:InterestRateContractMemberus-gaap:OtherCurrentLiabilitiesMember2019-12-310000899866us-gaap:InterestRateContractMemberus-gaap:FairValueInputsLevel1Memberus-gaap:OtherCurrentLiabilitiesMember2019-12-310000899866us-gaap:InterestRateContractMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueInputsLevel2Member2019-12-310000899866us-gaap:FairValueInputsLevel3Memberus-gaap:InterestRateContractMemberus-gaap:OtherCurrentLiabilitiesMember2019-12-310000899866us-gaap:InterestRateContractMemberus-gaap:OtherLiabilitiesMember2019-12-310000899866us-gaap:InterestRateContractMemberus-gaap:FairValueInputsLevel1Memberus-gaap:OtherLiabilitiesMember2019-12-310000899866us-gaap:InterestRateContractMemberus-gaap:FairValueInputsLevel2Memberus-gaap:OtherLiabilitiesMember2019-12-310000899866us-gaap:FairValueInputsLevel3Memberus-gaap:InterestRateContractMemberus-gaap:OtherLiabilitiesMember2019-12-310000899866alxn:ContingentConsiderationMemberalxn:AcquisitionRelatedContingentConsiderationMember2019-12-310000899866alxn:ContingentConsiderationMemberus-gaap:FairValueInputsLevel1Memberalxn:AcquisitionRelatedContingentConsiderationMember2019-12-310000899866alxn:ContingentConsiderationMemberalxn:AcquisitionRelatedContingentConsiderationMemberus-gaap:FairValueInputsLevel2Member2019-12-310000899866alxn:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Memberalxn:AcquisitionRelatedContingentConsiderationMember2019-12-310000899866us-gaap:OtherCurrentLiabilitiesMemberalxn:OtherContingentPaymentsMember2019-12-310000899866us-gaap:FairValueInputsLevel1Memberus-gaap:OtherCurrentLiabilitiesMemberalxn:OtherContingentPaymentsMember2019-12-310000899866us-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueInputsLevel2Memberalxn:OtherContingentPaymentsMember2019-12-310000899866us-gaap:FairValueInputsLevel3Memberus-gaap:OtherCurrentLiabilitiesMemberalxn:OtherContingentPaymentsMember2019-12-310000899866us-gaap:FairValueInputsLevel3Memberalxn:AcquisitionRelatedContingentConsiderationMember2019-12-310000899866us-gaap:FairValueInputsLevel3Memberalxn:AcquisitionRelatedContingentConsiderationMember2020-01-012020-09-300000899866us-gaap:FairValueInputsLevel3Memberalxn:AcquisitionRelatedContingentConsiderationMember2020-09-300000899866us-gaap:CollaborativeArrangementMemberalxn:CaelumBiosciencesMember2019-01-012019-01-310000899866us-gaap:CollaborativeArrangementMemberalxn:CaelumBiosciencesMember2019-12-310000899866us-gaap:CollaborativeArrangementMemberalxn:CaelumBiosciencesMembersrt:MinimumMember2019-01-012019-01-310000899866srt:MaximumMemberus-gaap:CollaborativeArrangementMemberalxn:CaelumBiosciencesMember2019-01-012019-01-310000899866us-gaap:CollaborativeArrangementMemberalxn:CaelumBiosciencesMember2019-12-012019-12-310000899866us-gaap:CollaborativeArrangementMemberalxn:CaelumBiosciencesMember2020-04-012020-06-300000899866us-gaap:CollaborativeArrangementMemberalxn:CaelumBiosciencesMember2020-07-012020-09-300000899866us-gaap:CollaborativeArrangementMemberalxn:CaelumBiosciencesMember2020-04-012020-09-300000899866us-gaap:CollaborativeArrangementMemberalxn:CaelumBiosciencesMember2020-01-012020-09-300000899866us-gaap:CollaborativeArrangementMemberalxn:CaelumBiosciencesMember2019-07-012019-09-300000899866us-gaap:CollaborativeArrangementMemberalxn:CaelumBiosciencesMember2019-01-012019-09-300000899866alxn:SolirisMembercountry:US2020-07-012020-09-300000899866alxn:SolirisMembercountry:US2019-07-012019-09-300000899866alxn:SolirisMembercountry:US2020-01-012020-09-300000899866alxn:SolirisMembercountry:US2019-01-012019-09-300000899866alxn:SolirisMembersrt:EuropeMember2020-07-012020-09-300000899866alxn:SolirisMembersrt:EuropeMember2019-07-012019-09-300000899866alxn:SolirisMembersrt:EuropeMember2020-01-012020-09-300000899866alxn:SolirisMembersrt:EuropeMember2019-01-012019-09-300000899866srt:AsiaPacificMemberalxn:SolirisMember2020-07-012020-09-300000899866srt:AsiaPacificMemberalxn:SolirisMember2019-07-012019-09-300000899866srt:AsiaPacificMemberalxn:SolirisMember2020-01-012020-09-300000899866srt:AsiaPacificMemberalxn:SolirisMember2019-01-012019-09-300000899866alxn:OtherNonUsExcludingEuropeAndAsiaPacificMemberalxn:SolirisMember2020-07-012020-09-300000899866alxn:OtherNonUsExcludingEuropeAndAsiaPacificMemberalxn:SolirisMember2019-07-012019-09-300000899866alxn:OtherNonUsExcludingEuropeAndAsiaPacificMemberalxn:SolirisMember2020-01-012020-09-300000899866alxn:OtherNonUsExcludingEuropeAndAsiaPacificMemberalxn:SolirisMember2019-01-012019-09-300000899866alxn:SolirisMember2020-07-012020-09-300000899866alxn:SolirisMember2019-07-012019-09-300000899866alxn:SolirisMember2020-01-012020-09-300000899866alxn:SolirisMember2019-01-012019-09-300000899866alxn:UltomirisMembercountry:US2020-07-012020-09-300000899866alxn:UltomirisMembercountry:US2019-07-012019-09-300000899866alxn:UltomirisMembercountry:US2020-01-012020-09-300000899866alxn:UltomirisMembercountry:US2019-01-012019-09-300000899866alxn:UltomirisMembersrt:EuropeMember2020-07-012020-09-300000899866alxn:UltomirisMembersrt:EuropeMember2019-07-012019-09-300000899866alxn:UltomirisMembersrt:EuropeMember2020-01-012020-09-300000899866alxn:UltomirisMembersrt:EuropeMember2019-01-012019-09-300000899866alxn:UltomirisMembersrt:AsiaPacificMember2020-07-012020-09-300000899866alxn:UltomirisMembersrt:AsiaPacificMember2019-07-012019-09-300000899866alxn:UltomirisMembersrt:AsiaPacificMember2020-01-012020-09-300000899866alxn:UltomirisMembersrt:AsiaPacificMember2019-01-012019-09-300000899866alxn:UltomirisMemberalxn:OtherNonUsExcludingEuropeAndAsiaPacificMember2020-07-012020-09-300000899866alxn:UltomirisMemberalxn:OtherNonUsExcludingEuropeAndAsiaPacificMember2019-07-012019-09-300000899866alxn:UltomirisMemberalxn:OtherNonUsExcludingEuropeAndAsiaPacificMember2020-01-012020-09-300000899866alxn:UltomirisMemberalxn:OtherNonUsExcludingEuropeAndAsiaPacificMember2019-01-012019-09-300000899866alxn:UltomirisMember2020-07-012020-09-300000899866alxn:UltomirisMember2019-07-012019-09-300000899866alxn:UltomirisMember2020-01-012020-09-300000899866alxn:UltomirisMember2019-01-012019-09-300000899866alxn:StrensiqProductLineMembercountry:US2020-07-012020-09-300000899866alxn:StrensiqProductLineMembercountry:US2019-07-012019-09-300000899866alxn:StrensiqProductLineMembercountry:US2020-01-012020-09-300000899866alxn:StrensiqProductLineMembercountry:US2019-01-012019-09-300000899866alxn:StrensiqProductLineMembersrt:EuropeMember2020-07-012020-09-300000899866alxn:StrensiqProductLineMembersrt:EuropeMember2019-07-012019-09-300000899866alxn:StrensiqProductLineMembersrt:EuropeMember2020-01-012020-09-300000899866alxn:StrensiqProductLineMembersrt:EuropeMember2019-01-012019-09-300000899866alxn:StrensiqProductLineMembersrt:AsiaPacificMember2020-07-012020-09-300000899866alxn:StrensiqProductLineMembersrt:AsiaPacificMember2019-07-012019-09-300000899866alxn:StrensiqProductLineMembersrt:AsiaPacificMember2020-01-012020-09-300000899866alxn:StrensiqProductLineMembersrt:AsiaPacificMember2019-01-012019-09-300000899866alxn:StrensiqProductLineMemberalxn:OtherNonUsExcludingEuropeAndAsiaPacificMember2020-07-012020-09-300000899866alxn:StrensiqProductLineMemberalxn:OtherNonUsExcludingEuropeAndAsiaPacificMember2019-07-012019-09-300000899866alxn:StrensiqProductLineMemberalxn:OtherNonUsExcludingEuropeAndAsiaPacificMember2020-01-012020-09-300000899866alxn:StrensiqProductLineMemberalxn:OtherNonUsExcludingEuropeAndAsiaPacificMember2019-01-012019-09-300000899866alxn:StrensiqProductLineMember2020-07-012020-09-300000899866alxn:StrensiqProductLineMember2019-07-012019-09-300000899866alxn:StrensiqProductLineMember2020-01-012020-09-300000899866alxn:StrensiqProductLineMember2019-01-012019-09-300000899866alxn:AndexxaProductLineMembercountry:US2020-07-012020-09-300000899866alxn:AndexxaProductLineMembercountry:US2019-07-012019-09-300000899866alxn:AndexxaProductLineMembercountry:US2020-01-012020-09-300000899866alxn:AndexxaProductLineMembercountry:US2019-01-012019-09-300000899866alxn:AndexxaProductLineMembersrt:EuropeMember2020-07-012020-09-300000899866alxn:AndexxaProductLineMembersrt:EuropeMember2019-07-012019-09-300000899866alxn:AndexxaProductLineMembersrt:EuropeMember2020-01-012020-09-300000899866alxn:AndexxaProductLineMembersrt:EuropeMember2019-01-012019-09-300000899866alxn:AndexxaProductLineMembersrt:AsiaPacificMember2020-07-012020-09-300000899866alxn:AndexxaProductLineMembersrt:AsiaPacificMember2019-07-012019-09-300000899866alxn:AndexxaProductLineMembersrt:AsiaPacificMember2020-01-012020-09-300000899866alxn:AndexxaProductLineMembersrt:AsiaPacificMember2019-01-012019-09-300000899866alxn:OtherNonUsExcludingEuropeAndAsiaPacificMemberalxn:AndexxaProductLineMember2020-07-012020-09-300000899866alxn:OtherNonUsExcludingEuropeAndAsiaPacificMemberalxn:AndexxaProductLineMember2019-07-012019-09-300000899866alxn:OtherNonUsExcludingEuropeAndAsiaPacificMemberalxn:AndexxaProductLineMember2020-01-012020-09-300000899866alxn:OtherNonUsExcludingEuropeAndAsiaPacificMemberalxn:AndexxaProductLineMember2019-01-012019-09-300000899866alxn:AndexxaProductLineMember2020-07-012020-09-300000899866alxn:AndexxaProductLineMember2019-07-012019-09-300000899866alxn:AndexxaProductLineMember2020-01-012020-09-300000899866alxn:AndexxaProductLineMember2019-01-012019-09-300000899866alxn:KanumaProductLineMembercountry:US2020-07-012020-09-300000899866alxn:KanumaProductLineMembercountry:US2019-07-012019-09-300000899866alxn:KanumaProductLineMembercountry:US2020-01-012020-09-300000899866alxn:KanumaProductLineMembercountry:US2019-01-012019-09-300000899866alxn:KanumaProductLineMembersrt:EuropeMember2020-07-012020-09-300000899866alxn:KanumaProductLineMembersrt:EuropeMember2019-07-012019-09-300000899866alxn:KanumaProductLineMembersrt:EuropeMember2020-01-012020-09-300000899866alxn:KanumaProductLineMembersrt:EuropeMember2019-01-012019-09-300000899866alxn:KanumaProductLineMembersrt:AsiaPacificMember2020-07-012020-09-300000899866alxn:KanumaProductLineMembersrt:AsiaPacificMember2019-07-012019-09-300000899866alxn:KanumaProductLineMembersrt:AsiaPacificMember2020-01-012020-09-300000899866alxn:KanumaProductLineMembersrt:AsiaPacificMember2019-01-012019-09-300000899866alxn:OtherNonUsExcludingEuropeAndAsiaPacificMemberalxn:KanumaProductLineMember2020-07-012020-09-300000899866alxn:OtherNonUsExcludingEuropeAndAsiaPacificMemberalxn:KanumaProductLineMember2019-07-012019-09-300000899866alxn:OtherNonUsExcludingEuropeAndAsiaPacificMemberalxn:KanumaProductLineMember2020-01-012020-09-300000899866alxn:OtherNonUsExcludingEuropeAndAsiaPacificMemberalxn:KanumaProductLineMember2019-01-012019-09-300000899866alxn:KanumaProductLineMember2020-07-012020-09-300000899866alxn:KanumaProductLineMember2019-07-012019-09-300000899866alxn:KanumaProductLineMember2020-01-012020-09-300000899866alxn:KanumaProductLineMember2019-01-012019-09-300000899866us-gaap:ProductMember2020-07-012020-09-300000899866us-gaap:ProductMember2019-07-012019-09-300000899866us-gaap:ProductMember2020-01-012020-09-300000899866us-gaap:ProductMember2019-01-012019-09-300000899866alxn:IntangibleAssetImpairmentMember2020-04-012020-06-300000899866alxn:IntellectualPropertyElectionMember2019-01-012019-09-300000899866alxn:ValuationAllowanceReleaseMember2019-01-012019-09-3000008998662018-01-012018-12-310000899866us-gaap:CollaborativeArrangementMemberalxn:CaelumBiosciencesMember2019-01-310000899866alxn:ZealandPharmaMemberalxn:ZealandMember2019-03-012019-03-310000899866alxn:ZealandPharmaMemberalxn:ZealandMember2019-03-310000899866alxn:ZealandPharmaMemberalxn:ZealandMember2019-01-012019-03-310000899866alxn:ZealandPharmaMemberalxn:ZealandMember2020-01-012020-09-300000899866alxn:AffibodyABDomainalxn:AffibodyMember2019-04-012019-04-300000899866alxn:AffibodyABDomainalxn:EidosMemberMember2019-09-012019-09-300000899866alxn:AffibodyABDomainalxn:EidosMemberMember2019-07-012019-09-300000899866alxn:AffibodyABDomainalxn:EidosMemberMember2020-01-012020-09-300000899866alxn:DicernaPharmaceuticalCollaborationAgreementMemberalxn:DicernaMember2018-10-012018-10-310000899866alxn:DicernaPharmaceuticalCollaborationAgreementMemberalxn:DicernaMember2018-10-012018-12-310000899866alxn:DicernaPharmaceuticalCollaborationAgreementMemberalxn:DicernaMember2019-10-012019-12-310000899866alxn:DicernaPharmaceuticalCollaborationAgreementMemberalxn:DicernaMember2020-09-300000899866alxn:LicenseAgreement1Memberalxn:HalozymeTherapeuticsIncMember2017-10-012017-12-310000899866alxn:LicenseAgreement1Memberalxn:HalozymeTherapeuticsIncMember2020-09-300000899866alxn:SyntimmuneIncMember2018-11-012018-11-300000899866alxn:SyntimmuneIncMemberalxn:SubcutaneousFormulationMember2018-11-012018-11-300000899866alxn:CollaborationandLicenseAgreementMember2020-01-012020-09-300000899866alxn:AstellasPharamMember2020-07-012020-09-300000899866alxn:LonzaGroupAGMember2020-09-300000899866alxn:OtherThirdPartyManufacturersMember2020-09-300000899866alxn:SECMember2020-07-022020-07-020000899866alxn:DOJAndOIGMember2019-04-012019-04-300000899866us-gaap:SubsequentEventMemberalxn:CanadianPatentedMedicinePricesReviewBoardMember2020-10-270000899866alxn:CanadianPatentedMedicinePricesReviewBoardMember2020-09-300000899866us-gaap:EmployeeSeveranceMember2020-07-012020-09-300000899866us-gaap:OtherRestructuringMember2020-07-012020-09-300000899866us-gaap:EmployeeSeveranceMember2019-07-012019-09-300000899866us-gaap:OtherRestructuringMember2019-07-012019-09-300000899866us-gaap:EmployeeSeveranceMember2020-01-012020-09-300000899866us-gaap:OtherRestructuringMember2020-01-012020-09-300000899866us-gaap:EmployeeSeveranceMember2019-01-012019-09-300000899866us-gaap:OtherRestructuringMember2019-01-012019-09-300000899866us-gaap:EmployeeSeveranceMember2020-06-300000899866us-gaap:OtherRestructuringMember2020-06-300000899866us-gaap:EmployeeSeveranceMember2019-12-310000899866us-gaap:OtherRestructuringMember2019-12-310000899866us-gaap:EmployeeSeveranceMember2020-09-300000899866us-gaap:OtherRestructuringMember2020-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-Q
☒Quarterly report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934
For the quarterly period ended September 30, 2020
or
☐Transition report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934
For the transition period from              to             
Commission file number: 0-27756
 alxn-20200930_g1.jpg
ALEXION PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware13-3648318
(State or Other Jurisdiction of Incorporation or Organization)(I.R.S. Employer Identification No.)
121 Seaport Boulevard, Boston Massachusetts 02210
(Address of Principal Executive Offices) (Zip Code)
475-230-2596
(Registrant’s telephone number, including area code)
N/A
(Former name, former address, and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock $0.0001 par valueALXNNASDAQ Stock Market LLC
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x  No  ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  x   No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer  x   Accelerated filer  ☐ Non-accelerated filer  ☐
Smaller reporting company  ☐ Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  x
Common Stock $0.0001 par value218,845,432
ClassOutstanding as of October 27, 2020


 
Alexion Pharmaceuticals, Inc.
Table of Contents

 
Page
PART I.
Item 1.
Item 2.
Item 3.
Item 4.
PART II.
Item 1.
Item 1A.
Item 2.
Item 5.
Item 6.
SIGNATURES


Alexion Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(unaudited)
(amounts in millions, except per share amounts)
 September 30,December 31,
 20202019
Assets
Current Assets:
Cash and cash equivalents$2,268.0 $2,685.5 
Marketable securities28.9 64.0 
Trade accounts receivable, net1,437.1 1,243.2 
Inventories729.0 627.6 
Prepaid expenses and other current assets604.8 456.1 
Total current assets5,067.8 5,076.4 
Property, plant and equipment, net1,214.5 1,163.3 
Intangible assets, net3,056.6 3,344.3 
Goodwill5,100.7 5,037.4 
Right of use operating assets220.1 204.0 
Deferred tax assets2,270.5 2,290.2 
Other assets618.2 429.0 
Total assets$17,548.4 $17,544.6 
Liabilities and Stockholders' Equity
Current Liabilities:
Accounts payable$89.2 $74.0 
Accrued expenses978.4 892.7 
Current portion of long-term debt138.6 126.7 
Other current liabilities124.8 100.9 
Total current liabilities1,331.0 1,194.3 
Long-term debt, less current portion2,453.3 2,375.0 
Contingent consideration398.1 192.4 
Deferred tax liabilities1,818.2 2,081.4 
Noncurrent operating lease liabilities175.8 164.1 
Other liabilities297.1 265.6 
Total liabilities6,473.5 6,272.8 
Commitments and contingencies (Note 16)
Stockholders' Equity:
Common stock, $0.0001 par value; 290.0 shares authorized; 239.7 and 237.8 shares issued at September 30, 2020 and December 31, 2019, respectively
— — 
Additional paid-in capital9,030.4 8,804.7 
Treasury stock, at cost, 20.7 and 16.5 shares at September 30, 2020 and December 31, 2019, respectively
(2,543.7)(2,105.9)
Accumulated other comprehensive loss(119.2)(66.8)
Retained earnings4,707.4 4,639.8 
Total stockholders' equity11,074.9 11,271.8 
Total liabilities and stockholders' equity$17,548.4 $17,544.6 

The accompanying notes are an integral part of these condensed consolidated financial statements.
2

Alexion Pharmaceuticals, Inc.
Condensed Consolidated Statements of Operations
(unaudited)
(amounts in millions, except per share amounts)
 Three months ended September 30,Nine months ended September 30,
 2020201920202019
Net product sales$1,588.3 $1,263.1 $4,477.4 $3,605.8 
Other revenue0.4 — 0.7 1.0 
Total revenues1,588.7 1,263.1 4,478.1 3,606.8 
Costs and expenses:
Cost of sales (exclusive of amortization of purchased intangible assets)144.7 95.2 401.3 280.2 
Research and development285.9 232.9 707.9 616.4 
Selling, general and administrative334.2 299.3 955.5 880.1 
Acquired in-process research and development— — — (4.1)
Amortization of purchased intangible assets53.1 75.6 200.5 235.7 
Change in fair value of contingent consideration23.4 29.8 45.0 7.2 
Acquisition-related costs63.0 — 105.7 — 
Restructuring expenses14.3 0.3 13.5 11.9 
Impairment of intangible assets— — 2,053.3 — 
Gain on sale of asset(14.8)— (14.8)— 
Total costs and expenses903.8 733.1 4,467.9 2,027.4 
Operating income684.9 530.0 10.2 1,579.4 
Other income and expense:
Investment income, net11.5 23.0 47.8 50.6 
Interest expense(27.6)(17.9)(77.0)(56.1)
Other income and (expense)(1.9)0.4 (2.6)2.9 
Income (loss) before income taxes666.9 535.5 (21.6)1,576.8 
Income tax expense (benefit)88.8 67.9 (89.2)61.5 
Net income$578.1 $467.6 $67.6 $1,515.3 
Earnings per common share
Basic$2.64 $2.09 $0.31 $6.77 
Diluted$2.62 $2.08 $0.30 $6.72 
Shares used in computing earnings per common share
Basic219.1 223.3 220.4 223.8 
Diluted220.6 224.5 221.9 225.4 

The accompanying notes are an integral part of these condensed consolidated financial statements.
3

Alexion Pharmaceuticals, Inc.
Condensed Consolidated Statements of Comprehensive Income
(unaudited)
(amounts in millions)
Three months ended September 30,Nine months ended September 30,
2020201920202019
Net income$578.1 $467.6 $67.6 $1,515.3 
Other comprehensive (loss) income, net of tax:
Foreign currency translation1.2 (2.5)(5.3)(3.0)
Unrealized gains on debt securities— — 0.1 0.2 
Unrealized (gains) losses on hedging activities, net of tax of $(2.8), $3.5, $(14.3) and $(10.8), respectively
(9.5)12.2 (47.2)(35.7)
Other comprehensive (loss) income, net of tax(8.3)9.7 (52.4)(38.5)
Comprehensive income$569.8 $477.3 $15.2 $1,476.8 

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

Alexion Pharmaceuticals, Inc.
Condensed Consolidated Statements of Changes in Stockholders’ Equity
(unaudited)
(amounts in millions)
Three months ended September 30, 2020Common StockAdditional
Paid-In
Capital		Treasury Stock
at Cost		Accumulated Other
Comprehensive
Income (Loss)		Retained EarningsTotal
Stockholders’
Equity
 Shares IssuedAmountSharesAmount
Balances, June 30, 2020239.2 $— $8,942.4 20.1 $(2,470.0)$(110.9)$4,129.3 $10,490.8 
Repurchase of common stock— — — 0.6 (73.5)— — (73.5)
Issuance of common stock under stock option and stock purchase plans0.2 — 10.5 — — — — 10.5 
Issuance of restricted common stock0.3 — — — — — — — 
Share-based compensation expense— — 70.3 — (0.2)— — 70.1 
Portola replacement equity awards attributable to the pre-combination period— — 7.2 — — — — 7.2 
Net income— — — — — — 578.1 578.1 
Other comprehensive loss— — — — — (8.3)— (8.3)
Balances, September 30, 2020239.7 $— $9,030.4 20.7 $(2,543.7)$(119.2)$4,707.4 $11,074.9 
Three months ended September 30, 2019Common StockAdditional
Paid-In
Capital		Treasury Stock
at Cost		Accumulated Other
Comprehensive
Income (Loss)		Retained EarningsTotal
Stockholders’
Equity
 Shares IssuedAmountSharesAmount
Balances, June 30, 2019237.3 $— $8,677.0 13.1 $(1,738.8)$(57.9)$3,283.2 $10,163.5 
Repurchase of common stock— — — 3.1 (334.6)— — (334.6)
Issuance of common stock under stock option and stock purchase plans0.1 — 1.9 — — — — 1.9 
Issuance of restricted common stock0.1 — — — — — — — 
Share-based compensation expense— — 59.1 — — — — 59.1 
Net income— — — — — — 467.6 467.6 
Other comprehensive income— — — — — 9.7 — 9.7 
Balances, September 30, 2019237.5 $— $8,738.0 16.2 $(2,073.4)$(48.2)$3,750.8 $10,367.2 
Nine months ended September 30, 2020Common StockAdditional Paid-In CapitalTreasury Stock at CostAccumulated Other Comprehensive Income (Loss)Retained EarningsTotal Stockholders’ Equity
Shares IssuedAmountSharesAmount
Balances, December 31, 2019237.8 $— $8,804.7 16.5 $(2,105.9)$(66.8)$4,639.8 $11,271.8 
Repurchase of common stock— — — 4.2 (434.3)— — (434.3)
Issuance of common stock under stock option and stock purchase plans0.4 — 23.4 — — — — 23.4 
Issuance of restricted common stock1.5 — — — — — — — 
Share-based compensation expense— — 195.1 — (3.5)— — 191.6 
Portola replacement equity awards attributable to the pre-combination period— — 7.2 — — — — 7.2 
Net income— — — — — — 67.6 67.6 
Other comprehensive loss— — — — — (52.4)— (52.4)
Balances, September 30, 2020239.7 $— $9,030.4 20.7 $(2,543.7)$(119.2)$4,707.4 $11,074.9 
5

Nine months ended September 30, 2019Common StockAdditional Paid-In CapitalTreasury Stock at CostAccumulated Other Comprehensive Income (Loss)Retained EarningsTotal Stockholders’ Equity
Shares IssuedAmountSharesAmount
Balances, December 31, 2018236.2 $— $8,539.1 12.7 $(1,689.9)$(9.7)$2,325.8 $9,165.3 
Repurchase of common stock— — — 3.5 (383.5)— — (383.5)
Issuance of common stock under stock option and stock purchase plans0.3 — 23.2 — — — — 23.2 
Issuance of restricted common stock1.0 — — — — — — — 
Share-based compensation expense— — 175.7 — — — — 175.7 
Net income— — — — — — 1,515.3 1,515.3 
Other comprehensive loss— — — — — (38.5)— (38.5)
Adoption of new accounting standards— — — — — — (90.3)(90.3)
Balances, September 30, 2019237.5 $— $8,738.0 16.2 $(2,073.4)$(48.2)$3,750.8 $10,367.2 
The accompanying notes are an integral part of these condensed consolidated financial statements.

6

Alexion Pharmaceuticals, Inc.
Condensed Consolidated Statements of Cash Flows
(unaudited)
(amounts in millions)
 Nine months ended September 30,
 20202019
Cash flows from operating activities:
Net income$67.6 $1,515.3 
Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation and amortization254.3 286.2 
Change in fair value of contingent consideration45.0 7.2 
Payments of contingent consideration— (100.0)
Share-based compensation expense195.6 176.8 
Deferred taxes (benefit)(174.2)(136.1)
Unrealized foreign currency loss (gain)0.9 (3.3)
Unrealized gain on forward contracts(3.9)(15.3)
Unrealized gain on strategic equity investments(4.6)(20.6)
Gain on sale of asset(14.8)— 
Gain on derecognition of Portola strategic equity investment(29.7)— 
Inventory obsolescence charge24.6 — 
Impairment of intangible assets2,053.3 — 
Other10.7 (2.3)
Changes in operating assets and liabilities, excluding the effect of acquisitions:
Accounts receivable(183.5)(199.1)
Inventories(10.3)(105.9)
Prepaid expenses, right of use operating assets and other assets(92.3)(42.2)
Accounts payable, accrued expenses, lease liabilities and other liabilities23.7 207.1 
Net cash provided by operating activities2,162.4 1,567.8 
Cash flows from investing activities:
Purchases of available-for-sale debt securities(19.4)(51.2)
Proceeds from maturity or sale of available-for-sale debt securities184.2 211.0 
Purchases of mutual funds related to nonqualified deferred compensation plan(14.1)(13.4)
Proceeds from sale of mutual funds related to nonqualified deferred compensation plan9.6 11.4 
Purchases of property, plant and equipment(29.2)(124.7)
Payment for acquisition of businesses, net of cash and restricted cash acquired(2,111.9)— 
Purchases of strategic equity investments and options(38.1)(63.7)
Purchase of intangible assets— (16.0)
Net cash used in investing activities(2,018.9)(46.6)
Cash flows from financing activities:
Payments on term loan(97.9)(65.4)
Payments on revolving credit facility— (250.0)
Repurchases of common stock(434.3)(383.5)
Net proceeds from issuance of common stock under share-based compensation arrangements22.1 23.2 
Other(28.0)(3.7)
Net cash used in financing activities(538.1)(679.4)
Effect of exchange rate changes on cash and cash equivalents and restricted cash(0.5)(6.1)
Net change in cash and cash equivalents and restricted cash(395.1)835.7 
Cash and cash equivalents and restricted cash at beginning of period2,723.6 1,367.4 
Cash and cash equivalents and restricted cash at end of period$2,328.5 $2,203.1 

7

 Nine months ended September 30,
 20202019
Supplemental cash flow disclosures from investing and financing activities:
Contingent consideration issued in acquisitions$155.0 $— 
Fair value of equity shares in Portola settled at closing of the acquisition$47.8 $— 
Fair value of replacement equity awards issued to Portola employees attributable to the pre-combination period$7.2 $— 
Exchange of intellectual property rights for equity shares in Inozyme$14.8 $— 
Fair value of strategic investment and purchase option acquired, less upfront cash paid
$— $27.6 
Operating ROU lease assets obtained in exchange for operating lease liabilities$21.2 $23.9 
Accounts payable and accrued expenses for purchases of property, plant and equipment and intangible assets$14.3 $3.1 
The following provides a reconciliation of cash and cash equivalents and restricted cash reported within the condensed consolidated balance sheets to the total of such amounts shown in the condensed consolidated statement of cash flows:
 Nine months ended September 30,
 20202019
Cash and cash equivalents$2,268.0 $2,171.3 
Restricted cash included in other current assets60.4 31.5 
Restricted cash included in other noncurrent assets0.1 0.3 
Total cash and cash equivalents and restricted cash reported in the condensed consolidated statement of cash flows$2,328.5 $2,203.1 
Amounts included in restricted cash primarily represent funds placed in escrow as a result of the judicial order issued by the Federal Court of Canada related to SOLIRIS pricing (Note 16, Commitments and Contingencies).

The accompanying notes are an integral part of these condensed consolidated financial statements.

8
Alexion Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(amounts in millions, except per share amounts)

1.Business
Alexion Pharmaceuticals, Inc. (Alexion, the Company, we, our or us) is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines.
As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD) in patients who are anti-aquaporin-4 (AQP4) antibody positive. Alexion also has two highly innovative enzyme replacement therapies and the first and only approved therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). With the acquisition of Portola Pharmaceuticals, Inc. (Portola) in July 2020, we added the first and only approved Factor Xa inhibitor reversal agent for patients treated with rivaroxaban or apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
In addition to our marketed therapies, we have a diverse pipeline resulting from internal innovation and business development. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. We were incorporated in 1992 under the laws of the State of Delaware.
2.Basis of Presentation and Principles of Consolidation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. These accounting principles were applied on a basis consistent with those of the consolidated financial statements contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2019. In our opinion, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of our financial statements for interim periods presented in accordance with accounting principles generally accepted in the United States. The condensed consolidated balance sheet as of December 31, 2019 was derived from audited annual financial statements but does not include all disclosures required by accounting principles generally accepted in the United States. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2019 included in our Annual Report on Form 10-K for the year ended December 31, 2019. The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the results to be expected for the full year or any other future periods.
The financial statements of our subsidiaries with functional currencies other than the U.S. dollar are translated into U.S. dollars using period-end exchange rates for assets and liabilities, historical exchange rates for stockholders' equity and weighted average exchange rates for operating results. Translation gains and losses are included in accumulated other comprehensive income (loss), net of tax, in stockholders' equity. Foreign currency transaction gains and losses are included in the results of operations in other income and expense.
The accompanying unaudited condensed consolidated financial statements include the accounts of Alexion Pharmaceuticals, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Our significant accounting policies are described in Note 1 of the notes to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2019. Updates to our accounting policies, including impacts from the adoption of new accounting standards, are discussed below in this Note 2.
Reclassifications
Certain items in the prior period’s condensed consolidated financial statements have been reclassified to conform to the current presentation.
9
Alexion Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(amounts in millions, except per share amounts)
Use of Estimates
Preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues, expenses and disclosure of contingent liabilities in our condensed consolidated financial statements.
Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain. We are not aware of any specific event or circumstance that would require an update to our estimates, judgments and assumptions or a revision of the carrying value of our assets or liabilities as of October 29, 2020, the date of issuance of this Quarterly Report on Form 10-Q. These estimates may change, as new events occur and additional information is obtained. Actual results may differ from these estimates under different assumptions or conditions and such differences may be material.
New Accounting Pronouncements
Accounting Standards Update (ASU) 2019-12, “Income Taxes: Simplifying the Accounting for Income Taxes”: In December 2019, the Financial Accounting Standards Board (FASB) issued a new standard intended to simplify the accounting for income taxes by eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new standard also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for annual periods beginning after December 15, 2020 and interim periods within, with early adoption permitted. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. We do not expect the adoption of this standard to have a material impact on our financial condition and results of operations.
ASU 2020-01, “Investments - Equity Securities, Investments - Equity Method and Joint Ventures, and Derivatives and Hedging - Clarifying the Interactions Between Topic 321, Topic 323, and Topic 815”: In January 2020, the FASB issued a new standard intended to clarify the interactions between Accounting Standards Codification (ASC) 321, ASC 323 and ASC 815. The new standard addresses accounting for the transition into and out of the equity method and measurement of certain purchased options and forward contracts to acquire investments. The standard is effective for annual and interim periods beginning after December 15, 2020, with early adoption permitted. Adoption of the standard requires changes to be made prospectively. We do not expect the adoption of this standard to have a material impact on our financial condition and results of operations.
ASU 2020-04, “Reference Rate Reform, Facilitation of the Effects of Reference Rate Reform on Financial Reporting": In response to concerns about structural risks of interbank offered rates, and, particularly, the risk of cessation of the London Interbank Offered Rate (LIBOR), regulators around the world have undertaken reference rate reform initiatives to identify alternative reference rates that are more observable or transaction-based and less susceptible to manipulation. In March 2020, the FASB issued a new standard that provides optional guidance for a limited time to ease the potential burden in accounting for the effects of reference rate reform, including optional expedients and exceptions for the accounting implications of contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met.
The amendments in this new standard only apply to contracts and hedging relationships that reference LIBOR or another reference rate expected to be discontinued due to reference rate reform. The expedients and exceptions provided by the standard do not apply to contract modifications made and hedging relationships entered into or evaluated after December 31, 2022. We are currently reviewing our contracts impacted by reference rate reform and are assessing the impact of this standard on our financial condition and results of operations.
Recently Adopted Accounting Pronouncements
ASU 2018-15, "Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract": In August 2018, the FASB issued a new standard on a customer's accounting for implementation, set-up, and other upfront costs incurred in a cloud computing arrangement (CCA) that aligns the requirements for capitalizing implementation costs in a CCA service contract with existing internal-use software guidance. The standard also provides classification guidance on these implementation costs as well as additional
10
Alexion Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(amounts in millions, except per share amounts)
quantitative and qualitative disclosures. The standard is effective for interim and annual periods beginning after December 15, 2019, with early adoption permitted, and can be adopted prospectively or retrospectively.
We adopted the new standard on January 1, 2020 on a prospective basis. The adoption of this standard had no impact on our financial statements at the date of adoption; however, we anticipate the adoption of this standard will result in an increase in capitalized assets related to qualifying CCA implementation costs in future periods.
Qualifying CCA implementation, set-up and other upfront costs incurred after January 1, 2020 are capitalized as other assets in our condensed consolidated balance sheets. These assets will be expensed over the term of the hosting arrangement and such expense will be presented within the same line item in our condensed consolidated statements of operations as the expense for fees for the associated hosting arrangement. These capitalized costs will be evaluated for impairment when events or changes in circumstances indicate that the carrying value of the capitalized implementation costs is not recoverable. For the nine months ended September 30, 2020, capitalized CCA implementation costs were not material.
ASU 2016-13, "Measurement of Credit Losses on Financial Instruments": In June 2016, the FASB issued a new standard intended to improve reporting requirements specific to loans, receivables and other financial instruments. The new standard requires that credit losses on financial assets measured at amortized cost be determined using an expected loss model, instead of the current incurred loss model, and requires that credit losses related to available-for-sale debt securities be recorded through an allowance for credit losses and limited to the amount by which carrying value exceeds fair value. The new standard also requires enhanced disclosure of credit risk associated with financial assets. The standard is effective for interim and annual periods beginning after December 15, 2019 with early adoption permitted.
We adopted the new standard on January 1, 2020 and have completed our assessment of the standard based on the composition of our portfolio of financial instruments and current and forecasted economic conditions at that date. Our significant financial assets that are within the scope of the new standard consist of trade accounts receivable and available for sale debt securities. We have not historically experienced any material credit losses associated with our trade accounts receivable or available for debt securities.
We monitor economic conditions, including volatility associated with international economies and the associated impacts on the financial markets and our business. We disaggregate our trade accounts receivable population into pools of similar risk characteristics based on underlying customer type and geographical location. Current expected credit loss allowances are estimated for each risk pool based on available information, including i) historical credit loss experience, ii) current economic conditions and, iii) reasonable and supportable forecasts of future economic conditions that may affect the collectibility of the recorded amounts. Based on the relevant facts and economic conditions as of the date of adoption, we concluded that the expected credit losses on our trade accounts receivable were immaterial. Additionally, unrealized losses on our available for sale investment portfolio were immaterial.
As of September 30, 2020, we reassessed our estimated credit losses on our trade accounts receivable, including consideration of the potential impacts of the COVID-19 global pandemic. Based on the relevant facts and economic conditions as of September 30, 2020, we concluded that the expected credit losses on our trade accounts receivable continued to be immaterial.
3.Acquisitions
Business Combinations
Achillion Pharmaceuticals, Inc.
In October 2019, Alexion entered into a definitive agreement to acquire Achillion Pharmaceuticals, Inc. (Achillion), a clinical-stage biopharmaceutical company focused on the development of oral Factor D inhibitors. Achillion was developing oral small molecule Factor D inhibitors to treat people with complement alternative pathway-mediated rare diseases, such as PNH and C3 glomerulopathy (C3G). Achillion had two clinical stage medicines in development, including danicopan (ACH-4471/ALXN2040) and ACH-5228 (ALXN2050).
The acquisition of Achillion closed on January 28, 2020. Under the terms of the agreement, we acquired all outstanding common stock of Achillion for $6.30 per share, or an aggregate of $926.2, inclusive of the settlement of Achillion's outstanding equity awards. The acquisition was funded with cash on hand. The transaction includes the potential for additional consideration in the form of non-tradeable contingent value rights (CVRs), which will be paid to Achillion shareholders if certain clinical and regulatory milestones are achieved within specified periods. These
11
Alexion Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(amounts in millions, except per share amounts)
include $1.00 per share for the U.S. Food and Drug Administration (FDA) approval of danicopan and $1.00 per share for the initiation of a Phase III clinical trial in ACH-5228.
The transaction was accounted for as a business combination. The following table summarizes the total consideration transferred to acquire Achillion and the estimated fair value of the identified assets acquired and liabilities assumed at the acquisition date:
Consideration
Upfront payment to shareholders and option holders$926.2 
Upfront payment, fair value of equity compensation attributable to the post-combination service period(20.0)
Upfront cash paid, net906.2 
Contingent consideration160.7 
Contingent consideration, fair value of equity compensation attributable to the post-combination service period(5.7)
Total consideration$1,061.2 
Assets Acquired and Liabilities Assumed
Cash and cash equivalents$68.5 
Marketable securities106.1 
In-process research & development assets (IPR&D)918.0 
Goodwill37.8 
Deferred tax liabilities, net(62.9)
Other assets and liabilities, net(6.3)
Total net assets acquired$1,061.2 

Our accounting for this acquisition was finalized during the second quarter of 2020. Measurement period adjustments increased goodwill by $3.1 during the second quarter of 2020 due to purchase price allocation increases to deferred tax liabilities, net. Measurement period adjustments were recorded as a result of studies completed during the second quarter of 2020 to determine the tax deductibility of certain acquisition-related costs and the valuation of historical net operating loss and income tax credit carryforwards.
The initial fair value estimate of the contingent consideration in the form of non-tradeable CVRs was $160.7, which was recorded as a noncurrent liability in our condensed consolidated balance sheet, including $5.7 related to compensation attributable to the post-combination service period. We determined the fair value of these milestone-related payment obligations using various estimates, including probabilities of success prior to expiration of the specified period, discount rates and the amount of time until the conditions of the milestone payments are expected to be met. This fair value measurement was based on significant inputs not observable in the market, representing Level 3 measurements within the fair value hierarchy. The resulting probability-weighted cash flows were discounted using a cost of debt rate ranging from 2.1% to 2.3%. The range of estimated milestone payments upon closing of the acquisition is from zero, if no milestones are achieved for any product, to $306.3 if certain development and regulatory milestones are achieved.
Subsequent to the acquisition date, we have adjusted the contingent consideration to fair value with changes in fair value recognized in operating earnings. Changes in fair values reflect new information about the probability and timing of meeting the conditions of the milestone payments. In the absence of new information, changes in fair value will only reflect the interest component of contingent consideration related to the passage of time as development work progresses towards the potential achievement of the milestones. At September 30, 2020, the fair value of the contingent consideration for the Achillion acquisition was $209.4 based on the probability-weighted cash flows, discounted using a cost of debt ranging from 3.9% to 4.3%. Changes in fair value of the contingent consideration associated with the Achillion acquisition for the three and nine months ended September 30, 2020 was $19.3 and $48.6, respectively.
The aggregate fair value of equity compensation attributable to the post-combination service period was $25.7. This amount was excluded from the total consideration transferred and was recognized as a charge to acquisition-related costs in our condensed consolidated statements of operations. These amounts were associated with the
12
Alexion Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(amounts in millions, except per share amounts)
accelerated vesting of stock options previously granted to Achillion employees. Excluding the $5.7 of contingent consideration related to equity compensation attributable to the post-combination service period, such amounts were paid during the first quarter 2020.
Intangible assets associated with IPR&D relate to two development-stage programs, ACH-4471 (ALXN2040) and ACH-5228 (ALXN2050). The estimated fair value of $918.0 was determined using the excess earnings valuation method, a variation of the income valuation approach. The excess earnings valuation method estimates the value of an intangible asset equal to the present value of the incremental after-tax cash flows attributable to that intangible asset. Some of the more significant assumptions utilized in our asset valuations included the estimated net cash flows for each asset, including net revenues, cost of sales, research and development and other operating expenses, the potential regulatory and commercial success rates, competitive trends impacting the assets, and tax rates. The fair value using the excess earnings valuation method was determined using an estimated weighted average cost of capital for Achillion of 11.5%, which represents a rate of return that a market participant would expect for these assets. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements. In the second quarter 2020, we recognized an impairment charge of $11.0 to write off our ACHN-4471 (ALXN2040) IPR&D asset due to clinical results received during the quarter.
The excess of purchase price over the fair value of the assets acquired and liabilities assumed represents the goodwill resulting from the acquisition. The goodwill, which is not tax-deductible, has been recorded as a noncurrent asset and is not amortized, but is subject to an annual review for impairment. The factors that contributed to the recognition of goodwill include the value of the acquired workforce, synergies that are specific to our business and not available to market participants, and early research in preclinical Factor D inhibitors, as well as the effects of the establishment of a deferred tax liability for the acquired IPR&D intangible assets, which has no tax basis.
We recorded a net deferred tax liability of $62.9, inclusive of measurement period adjustments recorded during the second quarter 2020. This amount was primarily comprised of $205.3 of deferred tax liabilities relating to the IPR&D acquired, offset by $142.4 of deferred tax assets related to net operating loss carryforwards (NOLs), income tax credits, and other temporary differences.
Achillion's results of operations are included in the condensed consolidated financial statements from the date of acquisition. For the three and nine months ended September 30, 2020 we recorded $24.6 and $51.4 of pre-tax operating losses exclusive of transaction costs, $19.3 and $48.6, respectively, of changes in contingent consideration and zero and $11.0, respectively, of impairment charges, associated with the operations of Achillion in our condensed consolidated statements of operations. We also recorded acquisition-related costs in connection with the acquisition during the three and nine months ended September 30, 2020 as presented below. No revenues were recorded in the results of operations during the three and nine months ended September 30, 2020 as neither ALXN2040 nor ALXN2050 has been approved for commercial sale by any regulatory agency.
Portola Pharmaceuticals, Inc.
In May 2020, Alexion entered into a definitive merger agreement to acquire Portola Pharmaceuticals, Inc. (Portola), a commercial-stage biopharmaceutical company focused on life-threatening blood-related disorders. Portola’s commercialized medicine, ANDEXXA®, marketed as ONDEXXYA® in Europe, is the first and only approved Factor Xa inhibitor reversal agent, and has demonstrated transformative clinical value by rapidly reversing the anticoagulant effects of Factor Xa inhibitors rivaroxaban and apixaban in severe and uncontrolled bleeding. The acquisition provides the opportunity to grow Alexion's commercial portfolio and is a strategic fit with our existing expertise in acute care, hematology and neurology.
Alexion completed the acquisition through a tender offer and subsequent merger of Portola which closed on July 2, 2020. Under the terms of the tender offer and merger agreement, Alexion purchased all outstanding common stock of Portola for $18.00 per share, or an aggregate of approximately $1,380.8, including the settlement of certain of Portola's outstanding equity awards but excluding shares of Portola stock held by Alexion at closing. The acquisition was funded by cash on hand.
Prior to the acquisition of Portola, in March 2020 and April 2020, we purchased $14.5 and $3.6, respectively, of common stock of Portola, which we recorded at fair value. Upon the closing of the acquisition of Portola, the fair value of the equity investment of $47.8 was derecognized and included in the fair value of consideration transferred. For additional information on our Portola equity investment, please see Note 10, Other Investments.
13
Alexion Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(amounts in millions, except per share amounts)
The aggregate fair value of equity compensation attributable to the post-combination service period was $11.1. This amount was excluded from the total consideration transferred and was recognized as a charge to acquisition-related costs in our condensed consolidated statements of operations. These amounts were primarily associated with the accelerated vesting of stock options previously granted to Portola employees and were paid during the third quarter 2020.
We issued $41.5 of equity compensation replacement awards, of which the portion attributable to services performed prior to the acquisition date, or $7.2, was allocated to purchase consideration. The remaining fair value is attributable to future services and will be expensed as share-based compensation over the remaining service periods. Expense associated with the accelerated-vesting of the replacement awards in connection with employee terminations will be recognized as acquisition-related employee separation costs.
In connection with the acquisition, Alexion also paid $196.9 to settle certain debt held by Portola that was subject to preexisting change of control provisions.
The transaction was accounted for as a business combination. The following table summarizes the total consideration transferred to acquire Portola and the estimated fair value of the identified assets acquired and liabilities assumed at the acquisition date:
Consideration
Upfront payment to shareholders and equity holders$1,380.8 
Upfront payment, fair value of equity compensation attributable to the post-combination service period(11.1)
Upfront cash paid, net1,369.7 
Fair value of equity shares held by Alexion at closing 47.8 
Fair value of replacement equity awards attributable to the pre-combination period7.2 
Total consideration to acquire outstanding equity, net1,424.7 
Total consideration to settle preexisting debt196.9 
Total consideration$1,621.6 
Assets Acquired and Liabilities Assumed
Cash and cash equivalents$288.5 
Marketable securities17.8 
Inventories, including noncurrent portion of $169.1 and validation batches of $60.9
362.5 
Intangible assets1,051.0 
Goodwill25.5 
Deferred tax assets, net116.0 
Other assets41.9 
Accounts payable and accrued expenses(75.6)
Long-term debt, including current portion of $7.7
(182.0)
Other liabilities(24.0)
Total net assets acquired$1,621.6 

Our accounting for this acquisition is preliminary. The fair value estimates for the assets acquired and liabilities assumed were based on preliminary calculations, and our estimates and assumptions are subject to change as we obtain additional information for our estimates during the measurement period. The areas that rely on preliminary estimates that are not yet finalized relate to the valuation of acquired intangible assets, an ongoing assessment of the condition of certain inventory and deferred taxes, net, as a result of ongoing studies to determine the tax deductibility of certain acquisition-related costs and the valuation of historical net operating loss and income tax credit carryforwards.
14
Alexion Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(amounts in millions, except per share amounts)
We acquired $362.5 of ANDEXXA inventory, inclusive of $60.9 of validation batches manufactured under processes which are subject to regulatory approval and expected to be commercially saleable following approval. The estimated fair value of raw material inventory was valued at replacement cost, which is equal to the value a market participant would pay to acquire the inventory. The estimated fair value of work-in-process and finished goods inventory was based on the expected selling price of the inventory, adjusted for incremental costs to complete the manufacturing process, for direct selling efforts, and for a normal profit on the remaining manufacturing and selling costs. Additionally, as the inventory acquired, inclusive of validation batches, is expected to be realized over a period of approximately 3.0 years, the fair value of the inventory was determined using a discount rate of 17.5%, representing the rate of return that a market participant would expect for the inventory, which shares risk that is similar to the underlying intellectual property. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements. The acquired inventory, inclusive of the acquisition-date fair value step-up, will be expensed within cost of sales as the inventory is sold to customers. We classified the ANDEXXA inventory that is expected to be utilized beyond our normal operating cycle as a long-term asset. The fair value of the non-current portion of inventory, in addition to the validation batches, are classified within other assets in our condensed consolidated balance sheet.
Intangible assets consist of purchased technology of $1,036.0 and IPR&D of $15.0. The purchased technology intangible asset relates to Portola's lead product ANDEXXA. The estimated fair value was determined using the excess earnings valuation method, a variation of the income valuation approach. The excess earnings valuation method estimates the value of an intangible asset equal to the present value of the incremental after-tax cash flows attributable to that intangible asset. Some of the more significant assumptions utilized in our asset valuation included the estimated net cash flows for ANDEXXA, including net revenues, cost of sales, research and development and other operating expenses, the potential regulatory and commercial success rates associated with ANDEXXA's current conditional approval status and planned extension into the urgent surgery setting, competitive trends impacting the assets, and tax rates. The fair value using the excess earnings valuation method was determined using a discount rate commensurate with the risks of ANDEXXA of 17.5%, which represents a rate of return that a market participant would expect for the asset. The acquired purchased technology intangible asset is being amortized over an estimated useful life of approximately 10 years. IPR&D relates to the cerdulatinib development-stage asset. The estimated fair value of the IPR&D asset was determined using a relief from royalty (RFR) method, a variation of the income approach that is based on the cost savings that accrue to the owner of an intangible asset who would otherwise have to pay royalties on revenues earned through the use of the asset. The RFR method was modified to reflect the cash flow forecast of Portola's pre-existing in-license of cerdulatinib from Astellas Pharma, Inc. The acquired fair value of $15.0 represents an increase in the value of the asset relative to when it was initially in-licensed by Portola. Some of the more significant assumptions utilized in the IPR&D asset valuation included the estimated net revenue, royalty rate, and tax rates. The fair value using the RFR method was determined using an estimated discount rate commensurate with the risks of cerdulatinib of 17.5%, which represents a rate of return that a market participant would expect for the asset. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements.
In connection with the acquisition, we assumed royalty-based debt which requires repayment through tiered royalties on future net worldwide sales of ANDEXXA. Total potential royalty payments are capped at $290.6, of which $13.7 were paid by Portola prior to the acquisition. The fair value of the remaining $276.9 in royalty-based payments as of the date of acquisition was $182.0. The estimated fair value was measured using Level 3 inputs and was calculated using a real options method, which runs simulations using various estimates, including probability-weighted net sales of ANDEXXA and volatility. Using the simulation results, the fair value was calculated based on the expected probability-weighted risk-neutral royalties, discounted at our estimated cost of debt, ranging from 3.3% to 7.1%, commensurate with the cost of debt at each period in which the royalty-based payments are estimated to be made.
We recorded net deferred tax assets of $116.0. This amount was primarily comprised of $301.0, $42.0, $42.4 and $39.1 of deferred tax assets relating to net operating loss carryforwards (NOLs), income tax credits, royalty-based debt, and other temporary differences, respectively, offset by $245.1 and $63.4 of deferred tax liabilities relating to intangible assets acquired and inventory fair value adjustments, respectively.
15
Alexion Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(amounts in millions, except per share amounts)
The excess of purchase price over the fair value of the assets acquired and liabilities assumed represents the goodwill resulting from the acquisition. The goodwill, which is not tax-deductible, has been recorded as a noncurrent asset and is not amortized, but is subject to an annual review for impairment. The factors that contributed to the recognition of goodwill primarily include the value of the acquired workforce and the effects of the establishment of a deferred tax liability for the fair value step-up of acquired inventory and intangible assets which exceed the incremental book value of acquired deferred tax assets over their fair value.
Portola's results of operations are included in the condensed consolidated financial statements from the date of acquisition. For the three and nine months ended September 30, 2020, we recorded $38.9 of revenue associated with ANDEXXA in our condensed consolidated statements of operations. For the three and nine months ended September 30, 2020, we recorded $35.4 of pre-tax operating losses excluding transaction costs and $25.9 of intangible asset amortization, associated with the operations of Portola in our condensed consolidated statements of operations. We also recorded acquisition-related costs in connection with the acquisition during the three and nine months ended September 30, 2020 as presented below.
Pro forma financial information (unaudited)
The following unaudited pro forma information presents the combined results of Alexion, Achillion, and Portola as if the acquisitions of Achillion and Portola had been completed on January 1, 2019, with adjustments to give effect to pro forma events that are directly attributable to the acquisitions. The unaudited pro forma results do not reflect operating efficiencies or potential cost savings that may have resulted from the consolidation of operations. Accordingly, the unaudited pro forma financial information is not necessarily indicative of the results of operations had we completed the transaction on January 1, 2019.
 Three months ended September 30Nine months ended September 30
 2020201920202019
Pro forma revenue$1,589.5 $1,299.9 $4,526.5 $3,694.2 
Pro forma net income (loss)$625.4 $372.0 $(23.2)$1,063.7 

The unaudited pro forma consolidated results for the three and nine months ended September 30, 2020 and 2019 primarily include the following pro forma adjustments related to non-recurring activity, net of tax:
•Reclassification of Alexion, Achillion and Portola acquisition-related costs. Acquisition-related costs of $72.2 and $143.5, respectively, were excluded from net income for the three and nine months ended September 30, 2020. Expenses of $129.3 were included in net income for the nine months ended September 30, 2020.
•Incremental amortization expense related to Portola purchased technology intangible assets for the three and nine months ended September 30, 2019 was $19.9 and $59.6, respectively, and for the nine months ended September 30, 2020 was $39.7.
•Incremental cost of goods sold related to Portola inventory fair value step-up adjustments calculated based on the fair value of finished goods inventory for the three and nine months ended September 30, 2019 was $10.1 and $16.7, respectively, and for the nine months ended September 30, 2020 was $10.9.
16
Alexion Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(amounts in millions, except per share amounts)
Acquisition-Related Costs
Acquisition-related costs recorded within the condensed consolidated statement of operations associated with our acquisitions of Achillion and Portola for the three and nine months ended September 30, 2020 and 2019 include the following:
 Three months ended September 30,Nine months ended September 30,
 2020201920202019
Transaction costs (1)
$1.8 $— $7.4 $— 
Integration costs4.6 — 5.6 — 
Fair value of equity compensation attributable to the post-combination service period11.1 — 36.8 — 
Employee separation costs (2)
45.5 — 55.9 — 
$63.0 $— $105.7 $— 
(1) Transaction costs primarily include legal fees related to the acquisition of Portola as well as costs incurred to effectuate the settlement of the Achillion outstanding options
(2) Employee separation costs include liabilities recognized, and subsequent changes in estimates recorded for, severance payments, one-time short-term retention awards agreed to in connection with the acquisition of Achillion and share-based compensation expense relating to awards accelerated in connection with terminations of Portola employees.
Acquisition-related costs attributable to the Achillion acquisition for the nine months ended September 30, 2020 were $38.0. There were immaterial acquisition-related costs attributable to the Achillion acquisition for the three months ended September 30, 2020. Acquisition-related costs attributable to the Portola acquisition for three and nine months ended September 30, 2020 were $63.0 and $67.7, respectively.

4.Inventories
The components of inventory are as follows:
 September 30,December 31,
 20202019
Raw materials$94.2 $41.2 
Work-in-process256.6 180.8 
Finished goods510.5 405.6 
Total inventories$861.3 $627.6 
Balance Sheet Classification:
Inventories$729.0 $627.6 
Other assets$132.3 $— 

Total inventories include ANDEXXA inventory acquired in connection with the July 2, 2020 Portola acquisition, but exclude acquired ANDEXXA validation batches of $60.9 that were manufactured under processes which are subject to regulatory approval. The acquired ANDEXXA inventory includes the acquisition-date fair value step-up, which is expensed within cost of sales as the inventory is sold to customers. For additional information on our acquisition of Portola, please see Note 3, Acquisitions.
We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in other assets in our condensed consolidated balance sheets. Inventories classified as long-term relate to ANDEXXA inventory acquired in connection with the Portola acquisition.
As of September 30, 2020 and December 31, 2019, the carrying value of capitalized inventory manufactured at production facilities that have not yet received regulatory approval was $117.2 and $60.5, respectively.
17
Alexion Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(amounts in millions, except per share amounts)
5.Intangible Assets and Goodwill
The following table summarizes the carrying amount of our intangible assets and goodwill, net of accumulated amortization and impairment charges: 
September 30, 2020December 31, 2019
Estimated
Life (years)		CostAccumulated
Amortization 		NetCostAccumulated
Amortization 		Net
Licensing rights
3-8
$57.0 $(37.5)$19.5 $57.0 $(34.7)$22.3 
Patents710.5 (10.5)— 10.5 (10.5)— 
Purchased technology
6-16
5,746.5 (3,631.5)(a)2,115.0 4,710.5 (1,388.7)3,321.8 
Other intangibles50.4 (0.3)0.1 0.4 (0.2)0.2 
Acquired IPR&DIndefinite922.0 — 922.0 — — — 
Total$6,736.4 $(3,679.8)$3,056.6 $4,778.4 $(1,434.1)$3,344.3 
GoodwillIndefinite$5,103.6 $(2.9)$5,100.7 $5,040.3 $(2.9)$5,037.4 
(a) Includes an impairment charge of $2,042.3 recognized during the second quarter 2020 related to the KANUMA intangible asset
In connection with our acquisition of Achillion during the first quarter 2020, we acquired IPR&D programs with a fair value of $918.0 and recorded goodwill of $37.8. For additional information on our acquisition of Achillion, please see Note 3, Acquisitions. In the second quarter 2020, we recognized an impairment charge of $11.0 to write off the cost basis of our ACHN-4471 (ALXN2040) acquired in-process research and development asset due to clinical results received during the quarter.
In connection with our acquisition of Portola during the third quarter 2020, we acquired purchased technology and IPR&D programs with a fair value of $1,036.0 and $15.0, respectively and recorded goodwill of $25.5. For additional information on our acquisition of Portola, please see Note 3, Acquisitions.
Amortization expense for the three months ended September 30, 2020 and 2019 was $54.1 and $77.5, respectively. Amortization expense for the nine months ended September 30, 2020 and 2019 was $203.4 and $239.2, respectively. As of September 30, 2020, assuming no changes in the gross cost basis of intangible assets, the total estimated amortization expense for finite-lived intangible assets is $54.1 for the three months ending December 31, 2020, and approximately $216.0 for each of the years ending December 31, 2021 through December 31, 2025.
During the quarter ended June 30, 2020, based on continued challenges expanding patient growth and new alternative commercial opportunities, the Company revised its strategic view of KANUMA and determined that we have exhausted commercially viable initiatives related to KANUMA and will have difficulty expanding patient growth over the long term as we focus on promoting other commercial programs and growing our pipeline. As a result, we no longer expect to increase the number of KANUMA patients in the long term at the rate previously assumed. This determination resulted in reduced cash flow projections for KANUMA, which indicated that the related intangible asset value was not fully recoverable on an undiscounted cash flows basis. On June 30, 2020, the Company utilized market participant assumptions to determine its best estimate of the fair value of the intangible asset related to KANUMA that, when compared with its related carrying value, resulted in an impairment charge of $2,042.3.
The estimated fair value of the KANUMA asset as of June 30, 2020 was determined using the excess earnings method, a variation of the income approach. The excess earnings method estimates the value of an intangible asset equal to the present value of the incremental after-tax cash flows attributable to that intangible asset over its remaining economic life. Long term cash flow projections for the asset require the use of significant estimates and judgements, including discount rates and revenue growth rates, and were based on the Company’s most recent strategic plan. The fair value of the asset was determined using an estimated weighted average cost of capital of 10.0%, which reflects the risks inherent in future cash flow projections and represents a rate of return that a market participant would expect for this asset. The estimated revenue growth rates fluctuate over the life of the asset, with a weighted average growth rate in the low single digits. The Company believes its assumptions are consistent with the plans and estimates that a market participant would use to manage the business. The estimated fair value of the KANUMA intangible asset as of June 30, 2020 was $820.0 and will continue to be amortized over its remaining estimated useful life. This fair value measurement was based on significant inputs not observable in the market and thus represents a Level 3 fair value measurement.
18
Alexion Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(amounts in millions, except per share amounts)
The following summarizes the changes in the carrying amount of goodwill:
September 30, 2020
Balance at December 31, 2019$5,037.4 
Goodwill resulting from the acquisitions of Achillion and Portola63.3 
Balance at September 30, 2020$5,100.7 
6.Debt
Credit Agreement
On June 7, 2018, we entered into an Amended and Restated Credit Agreement (the Credit Agreement), with Bank of America, N.A. as Administrative Agent. The Credit Agreement amended and restated our credit agreement dated as of June 22, 2015 (the Prior Credit Agreement).
The Credit Agreement provides for a $1,000.0 revolving credit facility and a $2,612.5 term loan facility. The revolving credit facility and the term loan facility mature on June 7, 2023. Beginning with the quarter ending June 30, 2019, we are required to make payments of 5.00% of the original principal amount of the term loan facility annually, payable in equal quarterly installments.
In connection with entering into the Credit Agreement and the Prior Credit Agreement, we paid an aggregate of $53.1 in financing costs in 2018. Financing costs are amortized as interest expense over the life of the debt. Amortization expense associated with deferred financing costs for the three months ended September 30, 2020 and 2019 was $1.2 and $1.3, respectively. Amortization expense associated with deferred financing costs for the nine months ended September 30, 2020 and 2019 was $3.6 and $3.8, respectively. Remaining unamortized deferred financing costs as of September 30, 2020 and December 31, 2019 were $12.2 and $15.8, respectively.
We made principal payments of $32.6 and $97.9 on the term loan during the three and nine months ended September 30, 2020, respectively, and as of September 30, 2020, we had $2,416.6 outstanding on the term loan. We had no outstanding borrowings under the revolving credit facility as of September 30, 2020. As of September 30, 2020, we had open letters of credit of $1.0 that offset our availability in the revolving credit facility.
The amount outstanding under the term loan of $2,416.6 as of September 30, 2020 is subject to variable interest rates, which are based on current market rates, and as such, the Company believes the carrying amount of the obligation approximates fair value.
We were in compliance with all applicable covenants under the Credit Agreement as of September 30, 2020.
Royalty-based Financing
In connection with our acquisition of Portola during the third quarter 2020, we assumed royalty-based debt relating to a royalty sales agreement Portola had entered into with HealthCare Royalty Partners (HCR) whereby HCR acquired a tiered royalty interest in future worldwide net sales of ANDEXXA. Portola received $50.0 upon closing of the agreement in February 2017 and an additional $100.0 following the U.S. regulatory approval of ANDEXXA in May 2018. Tiered royalties ranging from 4.2% to 8.5% are required to be paid to HCR based on net worldwide sales of ANDEXXA. The applicable rate decreases as worldwide net annual sales levels increase above defined thresholds. Total potential royalty payments are capped at 195% of the funding received less certain transaction expenses, or $290.6. As of the date of acquisition, the remaining due to HCR was $276.9 in royalty-based payments.
We recorded the HCR debt at its fair value of $182.0 upon closing of the acquisition, representing an initial debt discount of $94.9. We have also recognized a deferred tax asset of $42.4 related to the royalty-based debt as of the acquisition date. For additional information on our acquisition of Portola, please see Note 3, Acquisitions. Interest expense is recognized using the effective interest rate method over the estimated period the related debt will be paid. This requires estimation of the timing and amount of future royalty payments to be generated from future sales of ANDEXXA. We reassess the expected royalty payments each reporting period and account for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt require that we make estimates that could impact the short and long term classification of the debt carrying values.
Each period, we amortize the initial debt discount using the effective interest rate implied from the projected timing of royalty payments to HCR. The effective interest rate for the HCR royalty-based debt as of September 30, 2020 was 11.4%. During the three and nine months ended September 30, 2020, we recognized interest expense
19
Alexion Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(amounts in millions, except per share amounts)
associated with the amortization of the debt discount of $4.9. We made royalty-based debt payments of $1.7 during the three and nine months ended September 30, 2020. As of September 30, 2020, the carrying value of the royalty-based debt includes approximately $3.0 of royalty payments on third quarter sales of ANDEXXA which will be paid during the fourth quarter 2020.
As of September 30, 2020, the carrying value of the HCR royalty-based debt was $185.2, of which $11.7 was recorded within current portion of long-term debt and $173.5 was recorded within long-term debt, less current portion on our condensed consolidated balance sheet. Our payment obligations for HCR royalty-based debt are as follows:
Nine Months Ended September 30, 2020
Total repayment obligation as of the acquisition date$276.9 
Less: interest to be accreted in future periods(90.0)
Less: payments made(1.7)
Carrying value as of September 30, 2020$185.2 
The carrying value of the royalty based debt as of September 30, 2020 approximates fair value due to the proximity to the acquisition date.

7.Earnings Per Common Share
Basic earnings per common share (EPS) is computed by dividing net income by the weighted-average number of shares of common stock outstanding. For purposes of calculating diluted EPS, the denominator reflects the potential dilution that could occur if stock options, unvested restricted stock units or other contracts to issue common stock were exercised or converted into common stock, using the treasury stock method.
The following table summarizes the calculation of basic and diluted EPS for the three and nine months ended September 30, 2020 and 2019:
Three months endedNine months ended
 September 30,September 30,
 2020201920202019
Net income used for basic and diluted calculation$578.1 $467.6 $67.6 $1,515.3 
Shares used in computing earnings per common share—basic219.1 223.3 220.4 223.8 
Weighted-average effect of dilutive securities:
Stock awards1.5 1.2 1.5 1.6 
Shares used in computing earnings per common share—diluted220.6 224.5 221.9 225.4 
Earnings per common share:
Basic$2.64 $2.09 $0.31 $6.77 
Diluted$2.62 $2.08 $0.30 $6.72 

We exclude from diluted EPS the weighted-average number of securities whose effect is anti-dilutive. Excluded from the calculation of EPS for the three and nine months ended September 30, 2020 were 2.5 and 1.8 shares of common stock, respectively, because their effect is anti-dilutive. Excluded from the calculation of EPS for the three and nine months ended September 30, 2019 were 3.3 and 3.1 shares of common stock, respectively, because their effect is anti-dilutive.
8.Marketable Securities
The proceeds from maturities and sales of available-for-sale debt securities and resulting realized gains and losses are summarized below. In the second quarter of 2020, we liquidated all of our available-for-sale debt securities to fund the acquisition of Portola. Additionally, we liquidated all available-for-sale debt securities acquired in connection with the Portola acquisition.
20
Alexion Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(amounts in millions, except per share amounts)
Three months endedNine months ended
September 30,September 30,
2020201920202019
Proceeds from maturities and sales (1)
$25.5 $645.4 $1,042.4 $2,271.7 
Realized gains$— $— $— $— 
Realized losses$— $— $— $— 
 (1) Proceeds from maturities and sales of available-for-sale debt securities include securities previously classified as cash and cash equivalents and marketable securities in the condensed consolidated balance sheet.
We utilize the specific identification method in computing realized gains and losses.
As a result of our liquidation of all available-for-sale debt securities during the second and third quarters of 2020, we have no remaining available-for-sale debt securities as of September 30, 2020. The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of available-for-sale debt securities by type of security as of December 31, 2019 were as follows:
December 31, 2019
Amortized CostGross Unrealized Holding GainsGross Unrealized Holding LossesFair Value
Commercial paper$246.9 $— $— $246.9 
Corporate bonds24.3 — — 24.3 
Other government-related obligations:
U.S.70.4 — — 70.4 
Bank certificates of deposit27.4 — — 27.4 
Total available-for-sale debt securities$369.0 $— $— $369.0 

The aggregate fair value of available-for-sale debt securities in an unrealized loss position as of December 31, 2019 was $21.5. We did not have any investments in a continuous unrealized loss position for more than twelve months as of December 31, 2019.
The fair values of available-for-sale debt securities by classification in the condensed consolidated balance sheets were as follows:
September 30, 2020December 31, 2019
Cash and cash equivalents$— $328.1 
Marketable securities— 40.9 
$— $369.0 

We sponsor a nonqualified deferred compensation plan which allows certain highly-compensated employees to elect to defer income to future periods. Participants in the plan earn a return on their deferrals based on several investment options, which mirror returns on underlying mutual fund investments. We choose to invest in the underlying mutual fund investments to offset the liability associated with our nonqualified deferred compensation plan. These mutual fund investments are valued at net asset value per share and are carried at fair value with gains and losses included in investment income. The changes in the underlying liability to the employee are recorded in operating expenses. As of September 30, 2020 and December 31, 2019, the fair value of these investments was $28.9 and $23.1, respectively.
21
Alexion Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(amounts in millions, except per share amounts)
9.Derivative Instruments and Hedging Activities
We operate internationally and, in the normal course of business, are exposed to fluctuations in foreign currency exchange rates. The exposures result from portions of our revenues, as well as the related receivables, and expenses that are denominated in currencies other than the U.S. dollar, primarily the Euro and Japanese Yen. We are also exposed to fluctuations in interest rates on outstanding borrowings under our revolving credit facility, if any, and term loan facility. We manage these exposures within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes.
We enter into foreign exchange forward contracts, with durations of up to 60 months, to hedge exposures resulting from portions of our forecasted revenues, including intercompany revenues, and certain forecasted expenses that are denominated in currencies other than the U.S. dollar. The purpose of these hedges is to reduce the volatility of exchange rate fluctuations on our operating results. These hedges are designated as cash flow hedges upon contract inception. As of September 30, 2020, we had open revenue related foreign exchange forward contracts with notional amounts totaling $1,029.0 that qualified for hedge accounting with current contract maturities through June 2022. As of September 30, 2020, we had open expense related foreign exchange forward contracts with notional amounts totaling $10.0 that qualified for hedge accounting with contract maturities through September 2022.
To achieve a desired mix of floating and fixed interest rates on our term loan, we enter into interest rate swap agreements that qualify for and are designated as cash flow hedges. These contracts convert the floating interest rate on a portion of our debt to a fixed rate, plus a borrowing spread.
The following table summarizes the total interest rate swap contracts executed as of September 30, 2020:
Type of Interest Rate Swap ContractNotional AmountEffective DateTermination DateFixed Interest Rate or Rate Range
Floating to Fixed$450.0December 2018December 2022
2.60% - 2.79%
Floating to Fixed$1,300.0December 2019December 2022
2.37% - 2.83%

The amount of gains and (losses) recognized in the condensed consolidated statements of operations for the three and nine months ended September 30, 2020 and 2019 from foreign exchange and interest rate swap contracts that qualified as cash flow hedges were as follows:
Three months endedThree months ended
 September 30, 2020September 30, 2019
Financial Statement Line Item in which the Effects of Cash Flow Hedges are RecordedNet Product SalesInterest ExpenseNet Product SalesInterest Expense
Total amount presented in the Condensed Consolidated Statements of Operations$1,588.3 $(27.6)$1,263.1 $(17.9)
Impact of cash flow hedging relationships:
Foreign exchange forward contracts$(5.0)$— $11.0 $— 
Interest rate swap contracts$— $(11.3)$— $3.4 
Nine months endedNine months ended
 September 30, 2020September 30, 2019
Financial Statement Line Item in which the Effects of Cash Flow Hedges are RecordedNet Product SalesInterest ExpenseNet Product SalesInterest Expense
Total amount presented in the Condensed Consolidated Statements of Operations$4,477.4 $(77.0)$3,605.8 $(56.1)
Impact of cash flow hedging relationships:
Foreign exchange forward contracts$15.9 $— $27.1 $— 
Interest rate swap contracts$— $(25.9)$— $12.5 

22
Alexion Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(amounts in millions, except per share amounts)
The impact on accumulated other comprehensive income (AOCI) and earnings from foreign exchange and interest rate swap contracts that qualified as cash flow hedges, for the three and nine months ended September 30, 2020 and 2019 were as follows:
Three months endedNine months ended
 September 30,September 30,
 2020201920202019
Foreign Exchange Forward Contracts:
(Loss) gain recognized in AOCI, net of tax$(22.9)$30.5 $(3.0)$40.8 
(Loss) gain reclassified from AOCI to net product sales, net of tax$(4.0)$8.6 $12.2 $21.0 
Interest Rate Swap Contracts:
Gain (loss) recognized in AOCI, net of tax$0.1 $(7.1)$(52.6)$(45.9)
(Loss) gain reclassified from AOCI to interest expense, net of tax$(8.8)$2.6 $(20.1)$9.6 

Assuming no change in foreign exchange rates from market rates at September 30, 2020, $13.6 of losses recognized in AOCI will be reclassified to revenue over the next 12 months. Assuming no change in LIBOR-based interest rates from market rates at September 30, 2020, $45.6 of losses recognized in AOCI will be reclassified to interest expense over the next 12 months. Amounts recognized in AOCI for expense related foreign exchange forward contracts were immaterial as of September 30, 2020.
We enter into foreign exchange forward contracts, with durations of up to 6 months, designed to limit the balance sheet exposure of monetary assets and liabilities. We enter into these hedges to reduce the impact of fluctuating exchange rates on our operating results. Hedge accounting is not applied to these derivative instruments as gains and losses on these hedge transactions are designed to offset gains and losses on underlying balance sheet exposures. As of September 30, 2020, the notional amount of foreign exchange contracts where hedge accounting is not applied was $1,253.0.
We recognized a (loss) gain of $(6.2) and $1.4, in other income and (expense) for the three months ended September 30, 2020 and 2019, respectively, associated with the foreign exchange contracts not designated as hedging instruments. We recognized a gain (loss) of $6.8 and $(1.2), in other income and (expense) for the nine months ended September 30, 2020 and 2019, respectively, associated with the foreign exchange contracts not designated as hedging instruments. These amounts were partially offset by gains or losses on monetary assets and liabilities.
23
Alexion Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(amounts in millions, except per share amounts)
The following tables summarize the fair value of outstanding derivatives as of September 30, 2020 and December 31, 2019: 
September 30, 2020
 Derivative AssetsDerivative Liabilities
Balance Sheet
Location		Fair
Value		Balance Sheet
Location		Fair
Value
Derivatives designated as hedging instruments:
Foreign exchange forward contractsPrepaid expenses and other current assets$3.0 Other current liabilities$16.8 
Foreign exchange forward contractsOther assets0.4 Other liabilities0.3 
Interest rate swap contractsPrepaid expenses and other current assets— Other current liabilities45.6 
Interest rate swap contractsOther assets— Other liabilities57.6 
Derivatives not designated as hedging instruments:
Foreign exchange forward contractsPrepaid expenses and other current assets8.7 Other current liabilities8.0 
Total fair value of derivative instruments$12.1 $128.3 
December 31, 2019
 Derivative AssetsDerivative Liabilities
Balance Sheet
Location		Fair
Value		Balance Sheet
Location		Fair
Value
Derivatives designated as hedging instruments:
Foreign exchange forward contractsPrepaid expenses and other current assets$12.7 Other current liabilities$6.2 
Foreign exchange forward contractsOther assets0.6 Other liabilities1.1 
Interest rate swap contractsPrepaid expenses and other current assets— Other current liabilities19.5 
Interest rate swap contractsOther assets— Other liabilities41.9 
Derivatives not designated as hedging instruments:
Foreign exchange forward contractsPrepaid expenses and other current assets17.2 Other current liabilities20.4 
Total fair value of derivative instruments$30.5 $89.1 

24
Alexion Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(amounts in millions, except per share amounts)
Although we do not offset derivative assets and liabilities within our condensed consolidated balance sheets, our International Swap and Derivatives Association agreements provide for net settlement of transactions that are due to or from the same counterparty upon early termination of the agreement due to an event of default or other termination event. The following tables summarize the potential effect on our condensed consolidated balance sheets of offsetting our foreign exchange forward contracts and interest rate contracts subject to such provisions:
September 30, 2020
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet
DescriptionGross Amounts of Recognized Assets/LiabilitiesGross Amounts Offset in the Condensed Consolidated Balance SheetNet Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance SheetDerivative Financial InstrumentsCash Collateral Received (Pledged)Net Amount
Derivative assets$12.1 $— $12.1 $(11.4)$— $0.7 
Derivative liabilities$(128.3)$— $(128.3)$11.4 $— $(116.9)
December 31, 2019
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet
DescriptionGross Amounts of Recognized Assets/LiabilitiesGross Amounts Offset in the Condensed Consolidated Balance SheetNet Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance SheetDerivative Financial InstrumentsCash Collateral Received (Pledged)Net Amount
Derivative assets$30.5 $— $30.5 $(21.4)$— $9.1 
Derivative liabilities$(89.1)$— $(89.1)$21.4 $— $(67.7)

10.Other Investments    
Other investments include strategic investments in equity securities of certain biotechnology companies which we acquired in connection with strategic business development transactions, including license and option agreements. These investments are included in other assets in our condensed consolidated balance sheets.
Moderna
During 2014, we purchased $37.5 of preferred stock of Moderna Therapeutics, Inc. (Moderna), a privately held biotechnology company, which was initially recorded at cost. We began recording the investment at fair value, with the effects of a holding period restriction estimated using an option pricing valuation model, upon Moderna's completion of its initial public offering (IPO) in 2018. During the three and nine months ended September 30, 2019, we recognized an unrealized gain of $12.3 and $13.1, respectively, in investment income to adjust our investment in Moderna to fair value. On December 9, 2019, we sold our investment in Moderna for $114.7 in net proceeds, resulting in a realized gain of $77.2 on our initial investment.
Dicerna
In October 2018, we purchased $10.3 of Dicerna Pharmaceuticals Inc. (Dicerna) common stock in connection with an agreement that we entered into with Dicerna, a publicly-traded biopharmaceutical company. As our equity investment in Dicerna common stock has a readily determinable fair value, we are recording the investment at fair value. During the three and nine months ended September 30, 2020, we recognized an unrealized loss of $6.2 and $3.4, respectively, in investment income to adjust our equity investment in Dicerna to fair value. During the three and nine months ended September 30, 2019, we recognized an unrealized loss of $1.1 and unrealized gain of $3.1, respectively, in investment income to adjust our equity investment in Dicerna to fair value.
The fair value of this investment was $15.0 and $18.4 as of September 30, 2020 and December 31, 2019, respectively.
25
Alexion Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(amounts in millions, except per share amounts)
Caelum
In January 2019, we purchased $41.0 of preferred stock of Caelum Biosciences (Caelum), a privately-held biotechnology company, and a $16.1 option to acquire the remaining equity in Caelum, based on Phase II data, in connection with an agreement that we entered into with Caelum. Following discussions with the FDA, Caelum changed its clinical development plan for CAEL-101 in the fourth quarter 2019. A Phase II trial for CAEL-101 subsequently commenced during the first quarter of 2020 and met its primary objectives, supporting the safety and tolerability of CAEL-101 and confirmed the dose and regimen to be adopted for the Phase III studies. In December 2019, we amended the terms of the agreement with respect to the option to acquire the remaining equity in Caelum based on data from the modified Phase II/III trials. We accounted for the amendment as an exchange transaction as the terms of the modified option were determined to be substantially different than the terms of the original option. In conjunction with this amendment, we recognized a gain of $32.0 during the fourth quarter 2019 in other income and (expense), which reflects an increase in the fair value of the option, less $20.0 in incremental upfront funding which we accrued as of December 31, 2019 and paid during the first quarter 2020, and $4.1 associated with the change in the fair value of contingent payments which we also modified as part of the amendment. See Note 16, Commitments and Contingencies, for additional information on the agreement. As our equity investment in Caelum and the option to acquire the remaining equity in Caelum do not have a readily determinable fair value, we only adjust the carrying value of the assets for impairment and any subsequent changes resulting from an observable price change in an orderly transaction for identical or similar equity securities of the same issuer.
There were no observable price changes associated with these assets during the three and nine months ended September 30, 2020 and 2019. As of September 30, 2020, the carrying value of the investment and option, respectively, was $41.0 and $64.0. As of December 31, 2019, the carrying value of the investment and option, respectively, was $41.0 and $64.0. The investment and option were not impaired as of September 30, 2020.
Zealand
In March 2019, we purchased $13.8 of Zealand Pharma A/S (Zealand) common stock in connection with an agreement that we entered into with Zealand, a publicly-traded biopharmaceutical company based in Copenhagen, Denmark. See Note 16, Commitments and Contingencies, for additional information on the agreement. As our equity investment in Zealand common stock has a readily determinable fair value, we are recording the investment at fair value. During the three and nine months ended September 30, 2020, we recognized an unrealized gain of $1.8 and $0.8, respectively, in investment income to adjust our equity investment in Zealand to fair value. During the three and nine months ended September 30, 2019, we recognized an unrealized gain of $3.7 and $7.3, respectively, in investment income to adjust our equity investment in Zealand to fair value.
The fair value of this investment was $30.5 and $28.5 as of September 30, 2020 and December 31, 2019, respectively.
Eidos
In September 2019, we purchased $19.9 of Eidos Therapeutics, Inc. (Eidos) common stock, in connection with an agreement that we entered into with Eidos, a publicly-traded biopharmaceutical company and subsidiary of BridgeBio Pharma, Inc. See Note 16, Commitments and Contingencies, for additional information on the agreement. As our equity investment in Eidos common stock has a readily determinable fair value, we are recording the investment at fair value. During the three and nine months ended September 30, 2020, we recognized an unrealized gain of $3.4 and $0.3, respectively, in investment income to adjust our equity investment in Eidos to fair value. During the three and nine months ended September 30, 2019, we recognized an unrealized loss of $2.9, in investment income to adjust our equity investment in Eidos to fair value.
The fair value of this investment was $28.1 and $27.8 as of September 30, 2020 and December 31, 2019, respectively.
Stealth
In October 2019, we purchased $9.6 of Stealth BioTherapeutics Corp. (Stealth) common stock, in connection with an agreement that we entered into with Stealth, a publicly traded clinical-stage biotechnology company. As our equity investment in Stealth common stock has a readily determinable fair value, we are recording the investment at fair value. During the three and nine months ended September 30, 2020, we recognized an unrealized loss of $0.7 and $2.6, respectively, in investment income to adjust our equity investment in Stealth to fair value.
The fair value of this investment was $1.8 and $4.4 as of September 30, 2020 and December 31, 2019, respectively.
26
Alexion Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(amounts in millions, except per share amounts)
Portola
In March 2020 and April 2020, we purchased $14.5 and $3.6, respectively, of common stock of Portola Pharmaceuticals, Inc., a publicly traded commercial-stage biological company which we acquired on July 2, 2020. As our equity investment in Portola common stock had a readily determinable fair value, we recorded the investment at fair value. During the three and nine months ended September 30, 2020, we recognized a net gain of $0.1 and $29.7 in investment income, respectively, relating to our Portola investment. Upon the closing of the acquisition of Portola on July 2, 2020, the fair value of the equity investment of $47.8 was derecognized and included in the fair value of consideration transferred, resulting in a realized gain of $29.7 on our initial investment.
Inozyme
On July 17, 2020, we sold certain intellectual property rights and assets focusing on ENPP1 gene deficiencies to Inozyme Pharma (Inozyme), a publicly traded biopharmaceutical company, in exchange for $14.8 of Inozyme Pharma common stock, which was initially recorded at its IPO offering price, net of the effects of a nine month holding period restriction. We recognized the $14.8 of consideration received as a gain within gain on sale of asset in our condensed consolidated statement of operations. As our equity investment in Inozyme common stock has a readily determinable fair value, we are recording the investment at fair value, with the effects of a nine month holding period restriction estimated using an option pricing valuation model. During the three and nine months ended September 30, 2020, we recognized an unrealized gain of $10.2, in investment income to adjust our investment to fair value.
The fair value of this investment was $25.0 as of September 30, 2020.
11.Stockholders' Equity
Share Repurchases
In November 2012, our Board of Directors authorized a share repurchase program. In February 2017, our Board of Directors increased the amount that we are authorized to expend on future repurchases to $1,000.0 under our repurchase program, which superseded all prior repurchase programs. The entire amount authorized pursuant to this February 2017 Board approval has been utilized. On October 22, 2019, the Board of Directors approved a share repurchase authorization of up to $1,000.0. On July 28, 2020, the Board of Directors approved a new share repurchase authorization of up to an additional $1,500.0. The repurchase program does not have an expiration date and we are not obligated to acquire a particular number of shares. The repurchase program may be discontinued at any time at our discretion. Under the program, we repurchased 0.6 and 3.1 shares of our common stock at a cost of $73.5 and $334.6 during the three months ended September 30, 2020 and 2019, respectively. During the nine months ended September 30, 2020 and 2019, we repurchased 4.2 and 3.5 shares of our common stock at a cost of $434.3 and $383.5, respectively.
Subsequent to September 30, 2020, we repurchased 0.4 shares of common stock under our repurchase program at a cost of $45.2. As of October 27, 2020, there is a total of $2,055.9 remaining for repurchases under the repurchase program.
12.Other Comprehensive Income and Accumulated Other Comprehensive Income
The following tables summarize the changes in AOCI, by component, for the nine months ended September 30, 2020 and 2019:
Defined Benefit Pension PlansUnrealized Gains (Losses) from Debt SecuritiesUnrealized Gains (Losses) from Hedging ActivitiesForeign Currency Translation AdjustmentTotal Accumulated Other Comprehensive Income (Loss)
Balances, December 31, 2019$(9.2)$(0.1)$(40.1)$(17.4)$(66.8)
Other comprehensive income (loss) before reclassifications— 0.1 (55.1)(5.3)(60.3)
Amounts reclassified from other comprehensive income— — 7.9 — 7.9 
Net other comprehensive income (loss)— 0.1 (47.2)(5.3)(52.4)
Balances, September 30, 2020$(9.2)$— $(87.3)$(22.7)$(119.2)
27
Alexion Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(amounts in millions, except per share amounts)
Defined Benefit Pension PlansUnrealized Gains (Losses) from Debt SecuritiesUnrealized Gains (Losses) from Hedging ActivitiesForeign Currency Translation AdjustmentTotal Accumulated Other Comprehensive Income (Loss)
Balances, December 31, 2018$(2.6)$(0.3)$9.6 $(16.4)$(9.7)
Other comprehensive income (loss) before reclassifications— 0.2 (5.1)(3.0)(7.9)
Amounts reclassified from other comprehensive income— — (30.6)— (30.6)
Net other comprehensive income (loss)— 0.2 (35.7)(3.0)(38.5)
Balances, September 30, 2019$(2.6)$(0.1)$(26.1)$(19.4)$(48.2)

The table below provides details regarding significant reclassifications from AOCI during the three and nine months ended September 30, 2020 and 2019:
Details about Accumulated Other Comprehensive Income ComponentsAmount Reclassified From Accumulated Other Comprehensive Income during the three months ended September 30,Amount Reclassified From Accumulated Other Comprehensive Income during the nine months ended September 30,Affected Line Item in the Condensed Consolidated Statements of Operations
2020201920202019
Unrealized Gains (Losses) on Hedging Activity
Foreign exchange forward contracts$(5.0)$11.0 $15.9 $27.1 Net product sales
Interest rate swap contracts(11.3)3.4 (25.9)12.5 Interest expense
(16.3)14.4 (10.0)39.6 
3.5 (3.2)2.1 (9.0)Income tax (benefit) expense
$(12.8)$11.2 $(7.9)$30.6 

13.Fair Value Measurement
Authoritative guidance establishes a valuation hierarchy for disclosure of the inputs to the valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value.
28
Alexion Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(amounts in millions, except per share amounts)
The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2020 and December 31, 2019, and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair value.
  Fair Value Measurement at
September 30, 2020
Balance Sheet
Classification		Type of InstrumentTotalLevel 1Level 2Level 3
Cash equivalentsMoney market funds$424.9 $— $424.9 $— 
Marketable securitiesMutual funds$28.9 $28.9 $— $— 
Other assetsEquity securities$100.4 $75.4 $25.0 $— 
Prepaid expenses and other current assetsForeign exchange forward contracts$11.7 $— $11.7 $— 
Other assetsForeign exchange forward contracts$0.4 $— $0.4 $— 
Other current liabilitiesForeign exchange forward contracts$24.8 $— $24.8 $— 
Other liabilitiesForeign exchange forward contracts$0.3 $— $0.3 $— 
Other current liabilitiesInterest rate contracts$45.6 $— $45.6 $— 
Other liabilitiesInterest rate contracts$57.6 $— $57.6 $— 
Contingent considerationAcquisition-related contingent consideration$398.1 $— $— $398.1 
 
  Fair Value Measurement at
December 31, 2019
Balance Sheet
Classification		Type of InstrumentTotalLevel 1Level 2Level 3
Cash equivalentsMoney market funds$635.9 $— $635.9 $— 
Cash equivalentsCommercial paper$227.9 $— $227.9 $— 
Cash equivalentsCorporate bonds$20.6 $— $20.6 $— 
Cash equivalentsBank certificates of deposit$19.2 $— $19.2 $— 
Cash equivalentsOther government-related obligations$60.4 $— $60.4 $— 
Marketable securitiesMutual funds$23.1 $23.1 $— $— 
Marketable securitiesCommercial paper$19.0 $— $19.0 $— 
Marketable securitiesCorporate bonds$3.7 $— $3.7 $— 
Marketable securitiesOther government-related obligations$10.0 $— $10.0 $— 
Marketable securitiesBank certificates of deposit$8.2 $— $8.2 $— 
Other assetsEquity securities$79.0 $51.2 $27.8 $— 
Prepaid expenses and other current assetsForeign exchange forward contracts$29.9 $— $29.9 $— 
Other assetsForeign exchange forward contracts$0.6 $— $0.6 $— 
Other current liabilitiesForeign exchange forward contracts$26.6 $— $26.6 $— 
Other liabilitiesForeign exchange forward contracts$1.1 $— $1.1 $— 
Other current liabilitiesInterest rate contracts$19.5 $— $19.5 $— 
Other liabilitiesInterest rate contracts$41.9 $— $41.9 $— 
Contingent considerationAcquisition-related contingent consideration$192.4 $— $— $192.4 
Other current liabilitiesOther contingent payments$24.0 $— $— $24.0 

There were no securities transferred between Level 1, 2 and 3 during the nine months ended September 30, 2020.

29
Alexion Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(amounts in millions, except per share amounts)
Valuation Techniques
We classify mutual fund investments and equity securities, which are valued based on quoted market prices in active markets with no valuation adjustment, as Level 1 assets within the fair value hierarchy.
Cash equivalents and marketable securities classified as Level 2 within the valuation hierarchy include money market funds, commercial paper, U.S. and foreign government-related debt, corporate debt securities and certificates of deposit. We estimate the fair values of these marketable securities by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for similar securities, issuer credit spreads, benchmark yields, and other observable inputs. We validate the prices provided by our third-party pricing sources by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances.
Other investments in equity securities of publicly traded companies which are subject to holding period restrictions are carried at fair value using an option pricing valuation model and classified as Level 2 equity securities within the fair value hierarchy. The most significant assumptions within the option pricing valuation model are the term of the restrictions and the stock price volatility, which is based upon the historical volatility of the applicable company or similar companies. We also use a constant maturity risk-free interest rate to match the remaining term of the restrictions on such investments.
Our derivative assets and liabilities include foreign exchange and interest rate derivatives that are measured at fair value using observable market inputs such as forward rates, interest rates, our own credit risk as well as an evaluation of our counterparties’ credit risks. Based on these inputs, the derivative assets and liabilities are classified within Level 2 of the valuation hierarchy.
Contingent consideration liabilities related to business acquisitions and derivative liabilities associated with other contingent payments are classified as Level 3 within the valuation hierarchy and are valued based on various estimates, including probability of success, discount rates and amount of time until the conditions of the milestone payments are anticipated to be met.
As of September 30, 2020, there has not been any impact to the fair value of our derivative liabilities due to our own credit risk. Similarly, there has not been any significant adverse impact to our derivative assets based on our evaluation of our counterparties’ credit risks.
Acquisition-Related Contingent Consideration
In connection with our prior business combinations, we may be required to pay future consideration that is contingent upon the achievement of specified development, regulatory approvals or sales-based milestone events. We determine the fair value of these obligations using various estimates that are not observable in the market and represent a Level 3 measurement within the fair value hierarchy. As of September 30, 2020, the resulting probability-weighted cash flows were discounted using a cost of debt ranging from 3.9% to 4.3% for developmental and regulatory milestones and a weighted average cost of capital of 9.0% for sales-based milestones. As of December 31, 2019, the resulting probability-weighted cash flows were discounted using a weighted average cost of capital of 9.0% for sales-based milestones.
Each reporting period, we adjust the contingent consideration to fair value with changes in fair value recognized in operating earnings. Changes in fair values reflect new information about the probability and anticipated timing of meeting the conditions of the milestone payments. In the absence of new information, changes in fair value will only reflect the interest component of contingent consideration related to the passage of time.
As of September 30, 2020, estimated future contingent milestone payments related to our business combinations range from zero if no milestone events are achieved, to a maximum of $905.6 if all development, regulatory and sales-based milestones are reached.
As of September 30, 2020, the fair value of acquisition-related contingent consideration was $398.1. Amounts issued during the nine months ended September 30, 2020, represent the fair value of the non-tradeable CVRs recorded in connection with the acquisition of Achillion. See Note 3, Acquisitions. The following table represents a roll-forward of our acquisition-related contingent consideration:
30
Alexion Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(amounts in millions, except per share amounts)
Nine Months Ended September 30, 2020
Balance as of December 31, 2019$192.4 
Amounts issued160.7 
Changes in fair value45.0 
Balance as of September 30, 2020$398.1 
Other Contingent Payments
In January 2019, we entered into an agreement with Caelum, a biotechnology company that is developing CAEL-101 for light chain (AL) amyloidosis.  Under the terms of the agreement, we acquired a minority equity interest in preferred stock of Caelum and an exclusive option to acquire the remaining equity in Caelum based on Phase II data, for pre-negotiated economics. We paid $30.0 during the first quarter 2019 and agreed to pay up to an additional $30.0 in contingent development milestones prior to our exercise of the option to acquire the remaining equity in Caelum. These contingent payments met the definition of a derivative liability and were initially recorded at fair value of $27.1, based on the probability-weighted cash flows, discounted using a cost of debt ranging from 3.3% to 3.5%.
In December 2019, following FDA feedback which resulted in the redesign and expansion of Caelum's planned clinical development program for CAEL-101, we amended the terms of our existing option agreement with Caelum. The amendment modified the terms of the option to acquire the remaining equity in Caelum based on data from the expanded Phase II/III trials. The amendment also modified the development-related milestone events associated with the initial $30.0 in contingent payments, provided for an additional $20.0 in upfront funding, which we accrued as of December 31, 2019 and paid during the first quarter 2020, as well as funding of $60.0 in exchange for an additional equity interest at fair value upon achievement of a specific development-related milestone event. During the second quarter 2020, we paid an aggregate of $15.0 of contingent payments to Caelum related to two development-based milestones and during the third quarter 2020, we paid a $15.0 contingent payment to Caelum related to another development-based milestone.
Each reporting period, we adjust the derivative liability associated with the contingent payments to fair value with changes in fair value recognized in other income and (expense). Changes in fair values reflect new information about the probability and anticipated timing of meeting the conditions of the milestone payments. In the absence of new information, changes in fair value will only reflect the interest component of the liability related to the passage of time. The aggregate $30.0 milestone payments made during the second and third quarter 2020 settled the derivative liability and reduced the derivative liability balance to zero. We recorded $3.6 and $6.0 of expense in other income and (expense) during the three and nine months ended September 30, 2020, respectively, related to the change in the fair value of the liability. We recorded $0.2 and $0.5 of expense in other income and (expense) during the three and nine months ended September 30, 2019, respectively, related to the change in the fair value of the liability.
31
Alexion Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(amounts in millions, except per share amounts)
14.Revenue Recognition
Disaggregation of Revenue
The Company disaggregates revenue from contracts with customers into product and geographical regions as summarized below.
Three months ended September 30,Nine months ended September 30,
2020201920202019
SOLIRIS
United States$562.8 $496.8 $1,672.3 $1,456.8 
Europe254.3 255.5 765.7 800.2 
Asia Pacific86.0 118.0 255.5 329.2 
Rest of World139.2 120.2 347.2 347.1 
Total$1,042.3 $990.5 $3,040.7 $2,933.3 
ULTOMIRIS
United States$170.7 $65.1 $460.3 $143.9 
Europe46.6 21.1 112.4 21.1 
Asia Pacific69.6 3.7 186.3 3.7 
Rest of World2.4 — 4.2 — 
Total$289.3 $89.9 $763.2 $168.7 
STRENSIQ
United States$149.3 $118.0 $418.1 $323.7 
Europe19.3 19.0 61.6 56.0 
Asia Pacific16.1 14.0 44.7 36.0 
Rest of World4.7 3.3 21.5 10.0 
Total$189.4 $154.3 $545.9 $425.7 
ANDEXXA
United States$36.2 $— $36.2 $— 
Europe2.7 — 2.7 — 
Asia Pacific— — — — 
Rest of World— — — — 
Total$38.9 $— $38.9 $— 
KANUMA
United States$15.8 $16.0 $47.6 $45.1 
Europe9.5 6.3 25.4 19.4 
Asia Pacific1.1 1.3 2.9 3.4 
Rest of World2.0 4.8 12.8 10.2 
Total$28.4 $28.4 $88.7 $78.1 
Total Net Product Sales$1,588.3 $1,263.1 $4,477.4 $3,605.8 

32
Alexion Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(amounts in millions, except per share amounts)
Contract Balances and Receivables
Contract liabilities primarily relate to consideration received and/or billed for goods that have not been delivered to the customer and for which the performance obligation has not yet been completed. These amounts are included within other current liabilities in the condensed consolidated balance sheets.
The following table provides information about receivables and contract liabilities from our contracts with customers.
September 30, 2020December 31, 2019
Receivables, which are included in "Trade accounts receivable, net"$1,437.1 $1,243.2 
Contract liabilities, which are included in "Other current liabilities"$22.7 $6.8 
Contract balances and receivables associated with collaboration agreements assumed through the acquisition of Portola in the third quarter 2020, which were included in the table above, were not material as of September 30, 2020.

15.Income Taxes
Coronavirus Aid, Relief and Economic Security Act
In response to the market volatility and instability resulting from the COVID-19 pandemic, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was signed into law on March 27, 2020. The CARES Act lifts certain deduction limitations originally imposed by the Tax Cuts and Jobs Act of 2017 (2017 Tax Act). Under the 2017 Tax Act, federal net operating losses (NOLs) generated after 2017 could not be carried back and utilization was limited to 80% of taxable income. The CARES Act allows for a five-year carryback of federal NOLs generated in 2018 through 2020 and eliminates the 80% taxable income limitation by allowing corporate entities to fully utilize NOL carryforwards to offset taxable income in 2018 through 2020. In addition, the CARES Act generally allows taxpayers to deduct interest up to 50% of adjusted taxable income (30% limit under the 2017 Tax Act) for tax years 2019 and 2020. The CARES Act also allows taxpayers with prior year alternative minimum tax (repealed by the 2017 Tax Act) (AMT) credits to accelerate refund claims to tax years beginning in 2018 and 2019 instead of recovering the credits over a period of years, as originally enacted by the 2017 Tax Act.
Additionally, the CARES Act raises the corporate charitable deduction limit to 25% of taxable income and provides a technical correction to the 2017 Tax Act to generally provide qualified improvement property a 15-year cost-recovery period and allow 100% bonus depreciation. The enactment of the CARES Act did not result in any material adjustments to our income tax provision for the three and nine months ended September 30, 2020, or to our U.S. federal and state net deferred tax liabilities as of September 30, 2020.
Tax Rate
The following table provides a comparative summary of our income tax expense and effective income tax rate for the three and nine months ended September 30, 2020:
Three months endedNine months ended
September 30,September 30,
2020201920202019
Income tax expense (benefit)$88.8$67.9 $(89.2)$61.5 
Effective income tax rate13.3 %12.7 %413.0 %3.9 %

Income tax expense (benefit) is attributable to the U.S. federal, state and foreign income taxes on our profitable operations.
During the second quarter 2020, we recognized an impairment charge of $2,042.3 related to the KANUMA intangible asset, resulting in a deferred tax benefit of $377.3. See Note 5, Intangible Assets and Goodwill, for additional information on the impairment charge. These deferred tax benefits increased the effective tax rate for the nine months ended September 30, 2020 by approximately 399.6%.
The income tax expense for the nine months ended September 30, 2019 includes one-time tax benefits recorded during the first quarter 2019, in connection with the future integration of intellectual property of Wilson
33
Alexion Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(amounts in millions, except per share amounts)
Therapeutics into the Alexion corporate structure. The deferred tax benefits included $95.7 and $30.3 associated with a tax election made with respect to intellectual property of Wilson Therapeutics and a valuation allowance release and corresponding recognition of net operating losses, respectively. These deferred tax benefits decreased the effective tax rate for the nine months ended September 30, 2019 by approximately 8.0%. Additionally, during the third quarter 2019, we completed a comprehensive analysis of our current and prior year estimates related to our foreign-derived intangible income based on additional guidance provided in the proposed regulations issued by the U.S. Treasury Department in 2019. The analysis resulted in income tax benefits of approximately $29.9, including $17.0 related to prior year estimated tax benefits, which were recorded as a change in estimate in income tax expense in our consolidated statements of operations during the three and nine months ended September 30, 2019. These tax benefits decreased the effective tax rate for the three and nine months ended September 30, 2019 by approximately 5.6% and 1.9%, respectively.
In April 2020 we became aware of a European withholding tax regulation that could be interpreted to apply to certain of our previous intra-group transactions. We continue to evaluate whether the interpretation of this regulation applies to our facts and circumstances, and, based on our preliminary analysis, we recorded an immaterial reserve related to this matter during the second quarter of 2020.
In August 2020, we received a notice of examination from the Dutch Tax Authorities (“DTA”) regarding certain matters relating to our 2014 through 2017 tax years. Discussions with the DTA are currently ongoing and, at Alexion’s request, we have expanded these discussions to include the 2018 and 2019 tax years as well. We have not received any final findings on any of these tax years, nor have we received any proposed adjustments or any tax assessments related to any of the tax years under discussion with the DTA. Accordingly, we have not recorded any related reserves and an estimate of the possible loss or range of loss, if any, cannot be made at this time.
During the third quarter of 2020, the U.S. Treasury Department released certain proposed and final regulations which were originally enacted under the 2017 Tax Act. The impact of these regulations did not have a material impact on our financial condition and results of operations.
In 2017, the Internal Revenue Service (IRS) commenced an examination of our U.S. income tax returns for 2015. During the second quarter of 2020 we received a Revenue Agent Report (RAR) and held discussions with the IRS regarding a proposed adjustment related to the valuation of certain intellectual property that was contributed into our captive partnership during 2015. The Company agreed with the adjustment outlined in the RAR and recognized a previously unrecognized tax benefit in the second quarter of 2020 that did not result in a significant impact to the financial statements. The IRS concluded its examination during the third quarter 2020 without additional adjustments.
We have recorded tax on the undistributed earnings of our controlled foreign corporation (CFC) subsidiaries. To the extent CFC earnings may not be repatriated to the U.S. as a dividend distribution due to limitations imposed by law, we have not recorded the related potential withholding, foreign, local, and U.S. state income taxes.
We continue to maintain a valuation allowance against certain deferred tax assets where realization is not certain.
16.Commitments and Contingencies
Asset Acquisition and In-License Agreements
We have entered into asset purchase agreements, license agreements, and option arrangements in order to advance and obtain technologies and services related to our business. These agreements generally require us to pay an initial fee and certain agreements call for future payments upon the attainment of agreed upon development, regulatory and/or commercial milestones. These agreements may also require minimum royalty payments based on sales of products developed from the applicable technologies, if any.
In January 2019, we entered into an agreement with Caelum, a biotechnology company that is developing CAEL101 for light chain (AL) amyloidosis. Under the terms of the agreement, we acquired a minority equity interest in preferred stock of Caelum and an exclusive option to acquire the remaining equity in Caelum based on Phase II data, for pre-negotiated economics. We paid $30.0 in the first quarter 2019 and agreed to pay up to an additional $30.0 in contingent development milestones prior to the exercise the option to acquire the remaining equity in Caelum. These contingent payments meet the definition of a derivative liability and were initially recorded at fair value of $27.1. We allocated the total consideration of $57.1, inclusive of the fair value of the contingent payments, to the equity investment in Caelum and the option to acquire the remaining equity in Caelum based on the relative fair values of the assets. Following discussions with the FDA, Caelum changed its clinical development plan for
34
Alexion Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(amounts in millions, except per share amounts)
CAEL-101 in the fourth quarter 2019. A Phase II trial for CAEL-101 subsequently commenced during the first quarter of 2020 and met its primary objectives, supporting the safety and tolerability of CAEL-101 and confirmed the dose and regimen to be adopted for the Phase III studies. In September 2020, Alexion and Caelum announced the initiation of the Cardiac Amyloid Reaching for Extended Survival (CARES) program. This includes two parallel Phase III trials to evaluate the survival benefits of CAEL-101. In December 2019, we amended the terms of the agreement with Caelum to modify the option to acquire the remaining equity in Caelum based on data from the modified Phase II/III trials. The amendment also modified the development-related milestone events associated with the initial $30.0 in contingent payments, provided for an additional $20.0 in upfront funding, which we accrued as of December 31, 2019 and paid during the first quarter 2020, as well as funding of $60.0 in exchange for an additional equity interest at fair value upon achievement of a specific development-related milestone event. The agreement with Caelum also provides for additional payments, in the event Alexion exercises the purchase option, for up to $500.0, which includes an upfront option exercise payment and potential regulatory and commercial milestone payments. During the second quarter 2020, we paid an aggregate of $15.0 of contingent payments to Caelum related to two development-based milestones and during the third quarter 2020, we paid a $15.0 contingent payment to Caelum related to another development-based milestone.
In March 2019, we entered into an agreement with Zealand which provides us with exclusive worldwide licenses, as well as development and commercial rights, for subcutaneously delivered preclinical peptide therapies directed at up to four complement pathway targets. Pursuant to the agreement, Zealand will lead joint discovery and research efforts through the preclinical stage, and Alexion will lead development efforts beginning with the investigational new drug filing and Phase I studies. In addition to the agreement, we made an equity investment in Zealand (see Note 10, Other Investments). Under the terms of the agreement, we made an upfront payment of $40.0 for an exclusive license to the lead target and the equity investment, as well as for preclinical research services to be performed by Zealand in relation to the lead target. The market value of the equity investment was $13.8 as of the date of acquisition, which we recorded in other assets in our condensed consolidated balance sheets. We also recognized prepaid research and development expense of $5.0 within the condensed consolidated balance sheets associated with the research activities to be performed by Zealand. Due to the early stage of the asset we are licensing, we recorded the upfront license payment of $21.2 as research and development expense during the first quarter 2019. As of September 30, 2020, we could be required to pay up to $610.0, for the lead target, upon the achievement of specified development, regulatory and commercial milestones, as well as royalties on commercial sales. In addition, we could be required to pay up to an additional $115.0 in development and regulatory milestones if both a long-acting and short-acting product are developed with respect to the lead target. Each of the three subsequent targets can be selected for an option fee of $15.0 and has the potential for additional development, regulatory and commercial milestones, as well as royalty payments, at a reduced price to the lead target.
In April 2019, we entered into an agreement with Affibody AB (Affibody), through which Alexion obtained an exclusive worldwide license, as well as development and commercial rights, to ABY-039, a bivalent antibody-mimetic that targets the neonatal Fc receptor (FcRn). Under the terms of the agreement, we made an upfront payment of $25.0 for the exclusive license to ABY-039. Due to the early stage of the asset we licensed, we recorded the upfront license payment as research and development expense during the second quarter 2019. In February 2020, based on data from our Phase I study, we terminated the agreement to co-develop ABY-039 with Affibody.
In September 2019, we entered into an agreement with Eidos through which Alexion obtained an exclusive license to develop and commercialize AG10 in Japan. AG10 is a small molecule designed to treat the root cause of transthyretin amyloidosis (ATTR) and is currently in a Phase III study in the U.S. and Europe for ATTR cardiomyopathy (ATTR-CM). In addition, we made an equity investment in Eidos (see Note 10, Other Investments). Under the terms of the agreement, we made an upfront payment of $50.0 for the exclusive license to AG10 in Japan and the equity investment. The market value of the equity investment was $19.9 as of the date of acquisition, which we recorded in other assets in our condensed consolidated balance sheets. Due to the early stage of the asset we are licensing, we recorded the upfront license payment of $30.1 as research and development expense during the third quarter 2019. As of September 30, 2020, we could also be required to pay $30.0 upon achievement of a Japanese-based regulatory milestone as well as royalties on commercial sales.
In October 2018, we entered into a collaboration agreement with Dicerna that provides us with exclusive worldwide licenses and development and commercial rights for two preclinical RNA interference (RNAi) subcutaneously delivered molecules for complement-mediated diseases, as well as an exclusive option for other preclinical RNAi molecules for two additional targets within the complement pathway. In addition to the collaboration agreement, we made an equity investment in Dicerna. Under the terms of the agreements, we made an upfront payment of $37.0 for the exclusive licenses and the equity investment. The market value of the equity investment
35
Alexion Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(amounts in millions, except per share amounts)
was $10.3 as of the date of acquisition, which we recorded in other assets in our condensed consolidated balance sheets. Due to the early stage of the assets we are licensing, we recorded the upfront license payment of $26.7 as research and development expense during the fourth quarter 2018. In December 2019, we exercised our option for exclusive rights to two additional targets within the complement pathway under an existing agreement with Dicerna, which expands our existing research collaboration and license agreement with Dicerna to include a total of four targets within the complement pathway. In connection with the option exercise, we paid Dicerna $20.0, which we recorded as research and development expense in the fourth quarter 2019. As of September 30, 2020, excluding accrued milestones, we could be required to pay up to $604.1 for amounts due upon the achievement of specified research, development, regulatory and commercial milestones on the four licensed targets, as well as royalties on commercial sales.
In December 2017, we entered into a collaboration and license agreement with Halozyme Therapeutics, Inc. that allows us to use drug-delivery technology in the development of subcutaneous formulations for our portfolio of products for up to four targets. Under the terms of the agreement, we made an upfront payment of $40.0 for an exclusive license to two of the four potential targets and due to the early stage of the assets we are licensing, we recorded an expense for the upfront payment during the fourth quarter 2017. During the second quarter 2020, we forfeited our rights to one of the two targets we initially licensed. As of September 30, 2020, we could be required to pay up to $155.0 for the remaining licensed target upon achievement of specified development, regulatory and sales-based milestones, as well as royalties on commercial sales. Each of the two subsequent targets can be licensed for an option fee of $8.0, with contingent payments of up to $160.0 per target, subject to development, regulatory and commercial milestones, as well as royalties on commercial sales.
In connection with our prior acquisition of Syntimmune, Inc., a clinical-stage biotechnology company developing an antibody therapy targeting the FcRn, we could be required to pay up to $800.0 upon the achievement of specified development, regulatory and commercial milestones, of which $130.0 is specific to the subcutaneous formulation.
In addition, excluding accrued milestones, as of September 30, 2020, we have other license agreements under which we may be required to pay up to an additional $114.0 for currently licensed targets, if certain development, regulatory and commercial milestones are met, including up to $71.5 for the development of cerdulatinib in multiple indications pursuant to an in-licensing agreement with Astellas Pharma, Inc. which was assumed through the acquisition of Portola in the third quarter 2020. Additional amounts may be payable if we elect to acquire licenses to additional targets, as applicable, under the terms of these agreements.
Asset Sale and Out-License Arrangements
In connection with prior asset sale and out-license arrangements, including those assumed by Alexion through the acquisition of Portola in the third quarter 2020, Alexion is entitled to receive contingent payments upon the achievement of various regulatory and commercial milestones and other events, as well as royalties on commercial sales. The amount of contingent consideration related to these agreements is fully constrained and therefore has not been recognized as of September 30, 2020.
Manufacturing Agreements
We have various manufacturing development and license agreements to support our clinical and commercial product needs.
We rely on Lonza, a third party manufacturer, to produce a portion of commercial and clinical quantities of our commercial products and product candidates. We have various manufacturing and license agreements with Lonza, with remaining total non-cancellable future commitments of approximately $1,432.3 through 2031. This amount includes $105.5 of undiscounted, fixed payments applicable to our Contract Manufacturing Organization (CMO) embedded lease arrangement with Lonza. If we terminate certain supply agreements with Lonza without cause, we will be required to pay for product scheduled for manufacture under our arrangement. Under an existing arrangement with Lonza, we also pay Lonza a royalty on sales of SOLIRIS that was manufactured at the Alexion Rhode Island Manufacturing Facility (ARIMF facility) prior to the sale of the facility and a payment with respect to sales of SOLIRIS manufactured at Lonza facilities. We also pay Lonza a royalty on the sales of ULTOMIRIS.
In addition to our commitments with Lonza, as of September 30, 2020 we have non-cancellable commitments of approximately $78.6 through 2021 with other third party manufacturers.
36
Alexion Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(amounts in millions, except per share amounts)
Contingent Liabilities
We are currently involved in various claims, disputes, lawsuits, investigations, administrative proceedings and legal proceedings. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure. In accordance with generally accepted accounting principles, if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, we accrue a liability for the estimated loss. Because of uncertainties related to claims, proceedings and litigation, accruals are based on our best estimates based on information available at the time of the assessment. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation, court decisions or settlement of claims (and offers of settlement), we may reassess the potential liability related to these matters and may revise these estimates, which could result in a material adverse adjustment to our operating results. Costs associated with our involvement in legal proceedings are expensed as incurred. The outcome of any such proceedings, regardless of the merits, is inherently uncertain. If we were unable to prevail in any such proceedings, our consolidated financial position, results of operations, and future cash flows may be materially impacted.
We have received, and may in the future receive, notices from third parties claiming that their patents may be infringed by the use, development, manufacture, importation or sale of our products or product candidates. Under the guidance of ASC 450, Contingencies, we record a royalty accrual based on our best estimate of the fair value percent of net sales of our products that we could be required to pay the owners of patents for technology used in the manufacture and sale of our products. A costly license, or inability to obtain a necessary license, could have a material adverse effect on our financial results.
In May 2015, we received a subpoena in connection with an investigation by the Enforcement Division of the Securities and Exchange Commission (SEC) requesting information related to our grant-making activities and compliance with the Foreign Corrupt Practices Act (FCPA) in various countries. In addition, in October 2015, we received a request from the Department of Justice (DOJ) for the voluntary production of documents and other information pertaining to Alexion’s compliance with the FCPA. The SEC and DOJ also sought information related to Alexion’s recalls of specific lots of SOLIRIS and related securities disclosures.
The investigations focused on operations in various countries, including Brazil, Colombia, Japan, Russia and Turkey, and Alexion's compliance with the FCPA and other applicable laws.
In May 2020, DOJ informed us that it has closed its inquiry into these matters.
On July 2, 2020, we reached a civil settlement with the SEC fully resolving the SEC’s investigation into possible violations of the FCPA. Alexion neither admitted nor denied any wrongdoing in connection with the settlement but agreed to pay $21.5 to the SEC, consisting of amounts attributable to disgorgement, civil penalties, and pre-judgment interest. In connection with this settlement, in July 2020, we paid $21.5 to the SEC.
Following the settlement with the SEC, the Ministry of Health in Turkey initiated an investigation regarding the matters referenced in the SEC Order as they relate to the Company’s operations in Turkey between 2010 and 2015. We are cooperating with this investigation.
Alexion is committed to continually focusing on its compliance program and continues to enhance its comprehensive company-wide program that is designed to enhance our business processes, structures, controls, training, talent, and systems across Alexion’s global operations.
As previously reported, on December 29, 2016, a shareholder filed a putative class action against the Company and certain former employees in the U.S. District Court for the District of Connecticut, alleging that defendants made misrepresentations and omissions about SOLIRIS. On April 12, 2017, the court appointed a lead plaintiff. On July 14, 2017, the lead plaintiff filed an amended putative class action complaint against the Company and seven current or former employees. Defendants moved to dismiss the amended complaint on September 12, 2017. Plaintiffs filed an opposition to defendants’ motion to dismiss on November 13, 2017, and defendants filed a reply brief in further support of their motion on December 28, 2017. On March 26, 2019, the court held a telephonic status conference.  During that conference, the court informed counsel that it was preparing a ruling granting the defendants’ pending motion to dismiss.  The court inquired of plaintiffs’ counsel whether they intended to seek leave to amend their complaint, and indicated that if they wished to file a second amended complaint, they would be allowed to do so.  On April 2, 2019, the court granted plaintiffs until May 31, 2019 to file a second amended complaint, thereby rendering moot defendants’ pending motion to dismiss. On June 2, 2019, plaintiffs filed a second amended complaint against the same defendants. The complaint alleges that defendants engaged in securities
37
Alexion Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(amounts in millions, except per share amounts)
fraud, including by making misrepresentations and omissions in its public disclosures concerning the Company’s SOLIRIS sales practices, management changes, and related investigations, between January 30, 2014 and May 26, 2017, and that the Company's stock price dropped upon the purported disclosure of the alleged fraud. The plaintiffs seek to recover unspecified monetary relief, unspecified equitable and injunctive relief, interest, and attorneys’ fees and costs. Defendants’ filed a motion to dismiss the amended complaint on August 2, 2019; plaintiffs’ filed their opposition to that motion on October 2, 2019; and defendants’ filed their reply in further support of their motion on November 15, 2019. Given the early stage of these proceedings, we cannot presently predict the likelihood of obtaining dismissal of the case (or the ultimate outcome of the case if the motion to dismiss is denied by the court), nor can we estimate the possible loss or range of loss at this time.
In December 2016, we received a subpoena from the U.S. Attorney's Office for the District of Massachusetts requesting documents relating generally to our support of Patient Services, Inc. (PSI) and National Organization for Rare Disorders (NORD), 501(c)(3) organizations that provide financial assistance to Medicare patients taking drugs sold by Alexion; Alexion’s provision of free drug to Medicare patients; and Alexion compliance policies and training materials concerning the anti-kickback statute and information on donations to PSI and NORD from 2010 through 2016. In April 2019, we entered into a civil settlement agreement with the DOJ and the Office of Inspector General (OIG) of the U.S. Department of Health and Human Services to resolve this matter. As part of the settlement agreement, Alexion paid $13.1 to the DOJ and OIG. OIG did not require a Corporate Integrity Agreement with Alexion because it made fundamental organizational changes, including hiring a new executive leadership team, replacing half of the members of its Board of Directors, and effecting a significant change in the workforce.
In May 2017, Brazilian authorities seized records and data from our São Paulo, Brazil offices as part of an investigation being conducted into Alexion’s Brazilian operations. We are cooperating with this inquiry.
In June 2017, we received a demand to inspect certain of our books and records pursuant to Section 220 of the General Corporation Law of the State of Delaware on behalf of a purported stockholder. Among other things, the demand sought to determine whether to institute a derivative lawsuit against certain of the Company’s directors and officers in relation to the investigation by our Audit and Finance Committee announced in November 2016 and the investigations instituted by the SEC, DOJ, U.S. Attorney’s Office for the District of Massachusetts, and Brazilian law enforcement officials that are described above. We have responded to the demand. Given the early stages of this matter, an estimate of the possible loss or range of loss cannot be made at this time.
On September 27, 2017, a hearing panel of the Canadian Patented Medicine Prices Review Board (PMPRB) issued a decision in a previously pending administrative pricing matter that we had excessively priced SOLIRIS in a manner inconsistent with the Canadian pricing rules and guidelines. In its decision, the PMPRB ordered Alexion to decrease the price of SOLIRIS to an upper limit based upon pricing in certain other countries, and to forfeit excess revenues for the period between 2009 and 2017. The amount of excess revenues for the period between 2009 and 2017 was not determined to be a material amount and was paid in 2018. In October 2017, Alexion filed an application for judicial review of the PMPRB’s decision in the Federal Court of Canada. On May 23, 2019, the Federal Court of Canada dismissed Alexion's application for judicial review and, as a consequence, affirmed the decision of the PMPRB that we had excessively priced SOLIRIS. On June 21, 2019, Alexion filed a notice of appeal of the Federal Court of Canada's ruling, and, on October 17, 2019, Alexion filed a memorandum of fact and law in support of the appeal. On December 3, 2019, the Attorney General of Canada filed its memorandum of fact and law in support of the Federal Court of Canada's dismissal of Alexion's appeal of the PMPRB's decision. On December 19, 2019, the intervenor, the Minister of Health for the Province of British Columbia, filed a separate memorandum of fact and law in support of the Federal Court of Canada's decision. The Canadian Federal Court of Appeal heard the appeal on October 21 and 22, 2020, but has not issued a decision as of the date of this filing. Pursuant to an order made by the Federal Court of Canada, as of October 27, 2020, we have placed approximately $61.5 in escrow to secure our obligations pending the final resolution of all appeals in this matter. This amount reflects the difference between the list price for SOLIRIS and the price determined by the PMPRB to be non-excessive for sales of SOLIRIS in Canada for the period beginning September 2017 through September 30, 2020. In addition, on a quarterly basis, until the appeals process has concluded, Alexion will be required to place amounts into escrow for each vial of SOLIRIS sold in the applicable quarter equal to the list price for SOLIRIS and the price determined by the PMPRB to be non-excessive. Our revenues in Canada have been reduced by $42.2 cumulatively to date, which is our current best estimate of our liability through September 30, 2020 if we lose the appeal of this matter (the amount of our ultimate liability, however, may be greater than this estimate when the appeal process for this matter is concluded).
Chugai Pharmaceutical Co., Ltd. has filed three lawsuits against Alexion.  The first was filed in November 2018 in the United States District Court for the District of Delaware against Alexion Pharmaceuticals, Inc. alleging that
38
Alexion Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(amounts in millions, except per share amounts)
ULTOMIRIS infringes one U.S. patent held by Chugai Pharmaceutical Co., Ltd.  Upon issuance of a new U.S. patent on November 12, 2019, Chugai filed a second lawsuit in the United States alleging that ULTOMIRIS infringes the new patent. The parties have agreed to consolidate the November 2018 and November 2019 lawsuits. Chugai filed a third lawsuit in December 2018 in the Tokyo District Court against Alexion Pharma GK (a wholly-owned subsidiary of Alexion) in Japan, and alleges that ULTOMIRIS infringes two Japanese patents held by Chugai Pharmaceutical Co., Ltd.  Chugai’s complaints seek unspecified damages and certain injunctive relief. On March 5, 2020, the Supreme Court of Japan dismissed Chugai's appeal against an earlier IP High Court of Japan decision which held that one of the Chugai patents-in-suit is invalid. Subsequently Chugai filed a correction to the claims of this patents-in-suit and Alexion has countered that the corrected claims are still invalid and not infringed. In all cases, Alexion has denied the charges and countered that the patents are neither valid nor infringed. A trial date for the U.S. case which was initially set for July 2021 has been re-scheduled for October 2021. The case is still at the briefing stage in Japan.  Given the early stages of these litigations, an estimate of the possible loss or range of loss cannot be made at this time.
On February 28, 2019, Amgen Inc. (Amgen) petitioned the U.S. Patent and Trademark Office (PTO) to institute Inter Partes Review (IPR) of three patents owned by Alexion that relate to SOLIRIS:  U.S. Patent Nos. 9,725,504; 9,718,880; and 9,732,149. In each case, Amgen alleged the patented subject matter was anticipated and/or obvious in view of prior art, and that the patent claims are therefore invalid. On August 30, 2019, the PTO instituted IPRs of each of the three patents. On May 28, 2020, we entered into a Confidential Settlement and License Agreement (the “Settlement Agreement”) with Amgen to settle the three IPRs at the Patent Trial and Appeal Board (“PTAB”) of the PTO. Pursuant to the Settlement Agreement, Alexion and Amgen have terminated each of the pending IPRs. In addition, effective March 1, 2025 (or an earlier date in certain circumstances), the Company grants to Amgen (and its affiliates and certain partners) a non-exclusive, royalty-free, license under U.S. patents and patent applications related to eculizumab and various aspects of the eculizumab product that Alexion currently markets and sells under the tradename SOLIRIS. This license will allow Amgen (and its affiliates and certain partners), effective March 1, 2025, the right to make, have made, use, import, have imported, sell, have sold, offer for sale, have offered for sale, distribute, and have distributed in, or for, the U.S., an eculizumab product.
In connection with an ongoing matter, in August 2019, the Brazilian Federal Revenue Service provided a Notice of Tax and Description of the Facts (the “Tax Assessment”) to two Alexion subsidiaries (the "Brazil Subsidiaries"), as well as to two additional entities, a logistics provider utilized by Alexion and a distributor. The Tax Assessment focuses on the importation of SOLIRIS vials pursuant to Alexion’s free drug supply to patients program (referred to as Global Access to Medicines, or GATM) in Brazil. In September 2019, the Brazil Subsidiaries filed defenses to the Tax Assessment disputing the basis for liability under the Tax Assessment, based on, among others, the following: in connection with the operation of GATM, during the period from September 2014 to June 2019: (i) the importers responsible for the importation of the GATM SOLIRIS vials into Brazil were correctly identified and (ii) the correct customs value was utilized for the purpose of importing the GATM SOLIRIS vials provided to the patients free of charge. The defenses filed by Alexion are pending judgment at the first level of administrative appeals within the Brazilian federal administrative proceeding system. There are three separate levels of administrative appeals within the Brazilian federal administrative proceeding system and, if the outcome of these administrative appeals is unfavorable, the final decision of the federal administrative proceeding system can be disputed to the federal court systems in Brazil (at this time, Alexion intends to appeal the Tax Assessment if it is not overturned in the course of administrative appeals). Given the early stage of these proceedings, Alexion is unable to predict the duration, scope or outcome of this matter, but we expect that a final resolution will take three years or more. While it is possible that a loss related to the Tax Assessment may be incurred, given its ongoing nature, we cannot reasonably estimate the potential magnitude of any such possible loss or range of loss, or the cost of the ongoing administrative appeals (and potential appeals to the federal court system) of the Tax Assessment. Any determination that any aspects of the importation of free of charge medications into Brazil as set forth in the Tax Assessment are not, or were not, in compliance with existing laws or regulations could result in the imposition of fines, civil penalties and, potentially criminal penalties, and/or other sanctions against us, and could have an adverse impact on our Brazilian operations.
In connection with Alexion’s acquisition of Portola, we have assumed litigation to which Portola was a party. Among the litigation assumed is a securities fraud class action filed against Portola and certain of its officers, directors and underwriters (“Defendants”) under the Securities Act of 1933 and the Securities Exchange Act of 1934. Specifically, on January 16, 2020, February 7, 2020, and February 28, 2020, stockholders filed three putative class actions in the U.S. District Court for the Northern District of California, captioned Hayden v. Portola Pharmaceuticals, Inc., et al., No. 3:20-cv-00367-VC (N.D. Cal.); McCutcheon v. Portola Pharmaceuticals, Inc., et al., No. 3:20-cv-00949 (N.D. Cal.); and Southeastern Pennsylvania Transportation Authority v. Portola Pharmaceuticals, Inc., et
39
Alexion Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(amounts in millions, except per share amounts)
al., No. 3:20-cv-01501 (N.D. Cal.). These cases have since been consolidated, and on April 22, 2020, the Court issued an Order appointing the Alameda County Employees’ Retirement Association (“ACERA”) as Lead Plaintiff in the litigation. ACERA filed its amended consolidated complaint on May 20, 2020, asserting that Defendants made misrepresentations and omissions in public disclosures (including in materials issued in connection with the August 7, 2019 securities offering) concerning Portola’s sales of andexanet alfa, marketed as ANDEXXA in the United States and ONDEXXYA in Europe, between January 8, 2019 and February 26, 2020. Specifically, plaintiffs allege that Defendants made materially false and/or misleading statements about the demand for ANDEXXA, usage of ANDEXXA by hospitals and healthcare organizations, and about Portola’s accounting for its return reserves. Plaintiffs contend that the alleged fraud was revealed on January 9, 2020, when Portola announced its preliminary unaudited financial results for the fourth quarter of 2019, and again on February 26, 2020, when Portola issued its fourth quarter 2019 financial results. In July 2020, Portola and the Portola Defendants filed a motion to dismiss with the Court. The court heard oral argument on September 24, 2020 and granted defendants’ pending motion to dismiss, but with leave for plaintiffs to amend further their complaint. Plaintiffs have until November 5, 2020 to file a second amended complaint. Plaintiffs seek to recover unspecified monetary relief, interest, and attorneys’ fees and costs. Given the early stage of these proceedings, we cannot presently predict the likelihood of obtaining dismissal of the case which the Company intends to submit following the filing of the second amended complaint (or the ultimate outcome of the case if that motion to dismiss is denied by the court), nor can we estimate the possible loss or range of loss at this time.

17.     Restructuring and Related Expenses
During the third quarter 2020, we initiated restructuring activities primarily within our commercial organization as part of an initiative intended to redefine our operating model. The actions are intended to reallocate resources necessary to align our organization with our diversifying portfolio of new products and strategic objectives, and will include investments in digital capabilities, technologies and solutions to support a more virtual and digital customer experience and tailored to the markets in which we operate.
The actions are expected to be substantially completed by the end of 2021, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $25.0. We expect that the pretax costs will primarily result in cash outlays, as the costs primarily relate to employee separation expenses.
In the first quarter 2019, we initiated corporate restructuring activities to re-align our international commercial organization through re-prioritization of certain geographical markets and to implement operational excellence through strategic reallocation of resources. Actions under the previous restructuring programs have been completed.
The following table summarizes the total expenses recorded related to the restructuring activities by type of activity and the locations recognized within the consolidated statements of operations:
Three months ended September 30,Three months ended September 30,
20202019
Employee Separation CostsOtherTotalEmployee Separation CostsOtherTotal
Restructuring expenses$14.3 $— $14.3 $(2.8)$3.1 $0.3 
Nine months ended September 30,Nine months ended September 30,
20202019
Employee Separation CostsOtherTotalEmployee Separation CostsOtherTotal
Restructuring expenses$14.0 $(0.5)$13.5 $8.7 $3.2 $11.9 

40
Alexion Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(amounts in millions, except per share amounts)
The following table presents a reconciliation of the restructuring reserve recorded within accounts payable and accrued expenses on the Company's consolidated balance sheets as of September 30, 2020
Three months ended September 30,Nine months ended September 30,
20202020
Employee Separation CostsOtherTotalEmployee Separation CostsOtherTotal
Liability, beginning of period$1.6 $— $1.6 $3.3 $3.5 $6.8 
Charges14.3 — 14.3 14.3 — 14.3 
Settlements— — — (1.4)(3.0)(4.4)
Adjustments to previous estimates— — — (0.3)(0.5)(0.8)
Liability, end of period$15.9 $— $15.9 $15.9 $— $15.9 
The restructuring reserve of $15.9 and $6.8 is recorded in accounts payable and accrued expenses on the Company's condensed consolidated balance sheet as of September 30, 2020 and December 31, 2019, respectively. The accrued amounts are expected to be paid in the next twelve months. We currently estimate incurring up to an additional $11.0 in restructuring expenses related to the third quarter 2020 action.
41
Alexion Pharmaceuticals, Inc.
(amounts in millions, except per share amounts)
Item 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
Note Regarding Forward-Looking Statements
This quarterly report on Form 10-Q contains forward-looking statements. Words such as “anticipates,” "may," "forecasts," “expects,” “intends,” “plans,” "potentially," “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict; therefore, actual results may differ materially from those expressed or forecasted in any such statements. Such forward-looking statements are based on current expectations, estimates and projections about our industry and business, management's beliefs, and certain assumptions made by our management, and may include, but are not limited to, statements regarding:
•the potential benefits and commercial potential of ULTOMIRIS®, SOLIRIS®, STRENSIQ®, KANUMA® and ANDEXXA® for approved indications and any expanded uses;
•sales of our products in various markets worldwide, pricing for our products, level of insurance coverage and reimbursement for our products, timing regarding development and regulatory approvals for our products or for additional indications or in additional territories;
•plans for clinical trials (and proof of concept trials and exploratory clinical studies), status of our ongoing clinical trials for our product candidates, commencement dates for new clinical trials, clinical trial results and evaluation of our clinical trial results by regulatory agencies;
•potential benefits offered by product candidates, including improved dosing intervals and potential to improve treatment in a number of IgG-mediated and neurological diseases;
•the medical and commercial potential of additional indications for our products;
•the expected timing for the completion and/or regulatory approval of our facilities and facilities of our third-party manufacturers;
•future expansion of our commercial organization and transition to third parties in certain jurisdictions to perform sales, marketing and distribution functions;
•future governmental and regulatory decisions that directly or indirectly impact drug pricing (and discounts) and the adoption, implementation and interpretation of healthcare laws and regulations (and the impact on our business);
•plans, prospects and expected timing for future regulatory approval of products and product candidates;
•competitors, potential competitors and future competitive products (including biosimilars);
•plans to grow our product pipeline (and diversify our business, including through acquisitions) and anticipated benefits to the Company;
•future objective to expand business and sales;
•future plans to retain earnings and not pay dividends;
•expected decisions to appeal certain litigation and intellectual property decisions;
•expectations to realize the carrying value of product inventory;
•impact of accounting standards;
•future costs, operating expenses (including research and development, sales, general and administrative and restructuring expenses) and capital requirements, capital investment, sufficiency of cash to fund operations for at least the next 12 months, ability to make payment on our credit facility and make contingent payment obligations, the sufficiency of our existing capital resources and projected cash needs, price approval and funding processes in various countries;
•the sources of expected increases in cash flow from operations, if any;
•anticipated impact of interest rate changes on financial statements;
•anticipated future milestone, contingent and royalty payments and lease payments (and, in each case, expected impact on liquidity);
•anticipated impact of the COVID-19 pandemic on our business;                                
42
Alexion Pharmaceuticals, Inc.
(amounts in millions, except per share amounts)
•timing and anticipated amounts of future tax payments and benefits (including the potential recognition of unrecognized tax benefits), as well as timing of conclusion of tax audits;
•collection of accounts receivable and impact of any delay in the future in collecting accounts receivable on financial condition and operations, as well as the ability of counterparties to our derivatives to perform their obligations;
•the safety and efficacy of our products and our product candidates;
•the adequacy of our pharmacovigilance and drug safety reporting processes;
•the uncertainties involved in the drug development process and manufacturing;
•performance and reliance on third party service providers;
•our future research and development activities, plans for acquired programs, our ability to develop and commercialize products with our collaborators, anticipated regulatory approval of acquisitions and anticipated closing of acquisitions;
•periods of patent, regulatory and market exclusivity for our products;
•the scope of our intellectual property and the outcome of any challenges or opposition to our intellectual property; and
•estimates of the capacity of manufacturing and other service facilities to support our business operations, products and product candidates.
Such risks and uncertainties include, but are not limited to, the impact of the COVID-19 pandemic on our business (including our financial results and clinical trials), increased competition, actions by regulatory agencies, product candidates not receiving regulatory approvals, the possibility that expected tax benefits will not be realized, changes in healthcare and tax laws and regulations following the U.S. 2020 presidential election, assessment of impact of recent accounting pronouncements, potential declines in sovereign credit ratings or sovereign defaults in countries where we sell our products, delay of collection or reduction in reimbursement due to adverse economic conditions or changes in government and private insurer regulations and approaches to reimbursement, uncertainties surrounding legal proceedings, company investigations and government investigations and assessments, pending securities class action litigations, the investigation of our Brazilian operations by Brazilian authorities, the tax assessment by the Brazilian Federal Revenue Service and potential future tax assessments or liabilities by other revenue or tax regulators, risks related to the short and long-term effects of other government healthcare measures, intellectual property lawsuits, and the effect of shifting foreign exchange rates, as well as those risks and uncertainties discussed later in this report under the section entitled “Risk Factors.” Unless required by law, we undertake no obligation to update publicly any forward-looking statements, whether because of new information, future events or otherwise. However, readers should carefully review the risk factors set forth in this and other reports or documents we file from time to time with the SEC.
Overview
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines.
As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD) in patients who are anti-aquaporin-4 (AQP4) antibody positive. Alexion also has two highly innovative enzyme replacement therapies and the first and only approved therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). With the acquisition of Portola Pharmaceuticals, Inc. (Portola) in July 2020, we added the first and only approved Factor Xa inhibitor reversal agent for patients treated with rivaroxaban or apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
In addition to our marketed therapies, we have a diverse pipeline resulting from internal innovation and business development. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and development efforts on the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care.
43
Alexion Pharmaceuticals, Inc.
(amounts in millions, except per share amounts)
Recent Developments
On October 12, 2020, we announced that the U.S. Food and Drug Administration (FDA) approved the ULTOMIRIS (ravulizumab-cwvz) 100 mg/mL intravenous (IV) formulation for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) and for atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy for adult and pediatric (one month age and older) patients. ULTOMIRIS 100 mg/mL is an advancement in the treatment experience for patients with aHUS and PNH, as it reduces average annual infusion times by approximately 60 percent compared to ULTOMIRIS 10 mg/mL while delivering comparable safety and efficacy.
On September 25, 2020, we announced that Japan's Ministry of Health, Labour, and Welfare (MHLW) approved ULTOMIRIS for the treatment of adults and children living with aHUS.
On September 21, 2020, we announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorization in the European Union for a new 100 mg/mL IV advanced formulation of ULTOMIRIS.
On September 14, 2020, Alexion and Caelum Biosciences (Caelum) announced the initiation of the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase III clinical program to evaluate CAEL-101, a first-in-class amyloid fibril targeted therapy, in combination with standard-of-care therapy in light chain (AL) amyloidosis. The CARES clinical program includes two parallel Phase III studies - one in patients with Mayo stage IIIa disease and one in patients with Mayo stage IIIb disease and will collectively enroll approximately 370 patients globally. Enrollment is underway in both studies. The primary objective of the clinical program is to assess overall survival.
COVID-19 Pandemic
During the first quarter of 2020, the World Health Organization (WHO) declared the COVID-19 public health crisis a pandemic and recommended containment and mitigation measures worldwide. On March 13, 2020, U.S. President Trump announced a National Emergency relating to the pandemic. Government authorities worldwide have recommended or imposed various social distancing, quarantine and isolation measures on large portions of the population. While the impact of the COVID-19 pandemic to date on our business has been less than we had initially forecast, it is evolving rapidly and its future effects are difficult to predict with meaningful precision as the impact will depend on many factors beyond the Company’s control and knowledge. As the pandemic continues, we are taking steps that are designed to respond proactively to evolving events and planning for COVID-19 uncertainties. We remain focused on continuing to serve patients, protecting the health and safety of our employees and the communities in which we live and work, and supporting our patients in clinical trials.
In early March 2020, we activated a task force designed to assess, mitigate and manage the risks related to COVID-19 to avoid or minimize business disruption, including safeguarding of our facilities, and to ensure the safety and sense of security for our staff. In early March 2020, Alexion closed all sites to non-essential employees and the Company has suspended all travel indefinitely. In early June 2020, Alexion gradually allowed re-entry to certain sites in some geographies through a pilot program, including Switzerland, Germany, Australia, and Japan in accordance with local government laws, regulations and restrictions and our own safety procedures and checklists. In September 2020, we extended our global guidance to employees to strongly encourage working remotely until July 2021, while offering limited access to physical sites through pilot programs. Office sites are being reconfigured to maintain physical distancing and we expect to adopt and implement additional precautions commensurate with any expansion of employees returning to worksites. To date, our remote working arrangements have not significantly affected our ability to maintain critical business operations.
We are focused on protecting patient and customer safety as well as providing an uninterrupted supply of medicines for patients around the world. We have taken proactive measures that are designed to mitigate the risk of potential supply interruptions, and we strive to maintain sufficient inventory levels to continue serving current and new patients receiving our medicines for approved indications, as well as those participating in ongoing clinical trials. We and our third-party contract manufacturing partners continue to operate manufacturing facilities at near normal levels.
We are monitoring the demand for our products as there may continue to be fewer patient/doctor in-person interactions, fewer visits between our representatives and health care providers and the potential inability of patients to access hospitals or infusion centers (voluntarily or involuntarily), all of which may result in a reduction in future sales. We have been proactively engaging with healthcare professionals virtually and through enhanced digital channels in an effort to mitigate this risk, however we have noted that the new patient productivity and initiation queue has decreased since the COVID-19 outbreak, particularly in neurological indications. Additionally, we continue to actively monitor potential further impacts on our business such as growth in unemployment and loss of commercial insurance coverage and/or growth in Medicaid with higher discounts.
44
Alexion Pharmaceuticals, Inc.
(amounts in millions, except per share amounts)

We have preclinical studies and clinical testing ongoing across the globe. We have a business continuity plan for our preclinical and clinical trials, including a pandemic response plan. A number of clinical trial sites are restricting site visits and imposing restrictions on the initiation of new trials and patient visits to protect both site staff and patients from possible COVID-19 exposure. Given the safety concerns around COVID-19 and the associated risk to maintaining normal clinical trial operations, we are making decisions study-by-study and country-by-country to minimize the risk to the patients and facilities, and there has been and may continue to be an impact on the timing of trials that are under active enrollment. The majority of clinical trials that were paused at the onset of the pandemic have resumed, however we are continuing to experience impact to enrollment for some studies. We are actively implementing remote and local procedures per recent guidance of the FDA.
In May 2020, Alexion initiated a global Phase III study to investigate ULTOMIRIS® (ravulizumab-cwvz) in a subset of adult patients with COVID-19 who are hospitalized with severe pneumonia or acute respiratory distress syndrome (ARDS). The study is actively enrolling patients and is expected to enroll approximately 270 patients across the U.S., E.U. and Japan and is evaluating the impact of ULTOMIRIS on survival, duration of mechanical ventilation, and duration of hospital stay compared to best supportive care. This follows the FDA's rapid review and acceptance of Alexion’s investigational new drug (IND) application for ULTOMIRIS for severe COVID-19. In recognition of the urgent needs of some patients and in order to streamline the emergency access process, Alexion has opened emergency Expanded Access Programs (EAP) in the U.S. and France for SOLIRIS in severe COVID-19 pneumonia. 
The extent to which the COVID-19 pandemic impacts our business, including our commercial results and clinical trials, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the virus, the duration of the outbreak, governmental regulations and restrictions, travel restrictions and actions to contain the outbreak or treat its impact. We continue to be responsive to the ever-changing situation while remaining true to our core values.
Products and Development Programs
We focus our product development programs on life-transforming therapeutics for rare diseases and devastating conditions for which current treatments are either non-existent or inadequate. We have developed or are developing innovative products for, among others, the following indications:
Paroxysmal Nocturnal Hemoglobinuria (PNH)
PNH is a chronic, progressive, debilitating and life-threatening ultra-rare blood disorder characterized by intravascular hemolysis (destruction of red blood cells) that is mediated by an uncontrolled activation of the complement system, a part of the immune system. PNH red blood cells are exquisitely vulnerable to activated complement, resulting in chronic intravascular hemolysis. Chronic intravascular hemolysis in patients with PNH may be associated with life-threatening thromboses, recurrent pain, kidney disease, disabling fatigue, impaired quality of life, severe anemia, pulmonary hypertension, shortness of breath and intermittent episodes of dark-colored urine (hemoglobinuria). A small sub-set of PNH patients on C5-inhibitor treatment may experience clinically evident extravascular hemolysis (PNH-EVH).
Atypical Hemolytic Uremic Syndrome (aHUS)
aHUS is a severe and life-threatening, ultra-rare genetic disease characterized by chronic uncontrolled complement activation and thrombotic microangiopathy (TMA), the formation of blood clots in small blood vessels throughout the body, causing a reduction in platelet count (thrombocytopenia) and life-threatening damage to the kidney, brain, heart and other vital organs.
Generalized Myasthenia Gravis (gMG)
Myasthenia Gravis (MG) is a debilitating, complement-mediated neuromuscular disease in which patients suffer profound muscle weakness throughout the body, resulting in slurred speech, impaired swallowing and choking, double vision, upper and lower extremity weakness, disabling fatigue, shortness of breath due to respiratory muscle weakness and episodes of respiratory failure.
Hypophosphatasia (HPP)
HPP is an ultra-rare genetic and progressive metabolic disease in which patients experience devastating effects on multiple systems of the body, leading to debilitating or life-threatening complications. HPP is characterized by defective bone mineralization that can lead to deformity of bones and other skeletal abnormalities, as well as systemic complications such as profound muscle weakness, seizures, pain, and respiratory failure leading to premature death in infants.
Lysosomal Acid Lipase Deficiency (LAL Deficiency or LAL-D)
LAL-D is a serious, life-threatening ultra-rare disease associated with premature mortality and significant morbidity. LAL-D is a chronic disease in which genetic mutations result in decreased activity of the LAL enzyme that leads to marked accumulation of lipids in vital organs, blood vessels, and other tissues, resulting in progressive and systemic organ damage including hepatic fibrosis, cirrhosis, liver failure, accelerated atherosclerosis, cardiovascular disease, and other devastating consequences.
45
Alexion Pharmaceuticals, Inc.
(amounts in millions, except per share amounts)
Neuromyelitis Optica Spectrum Disorder (NMOSD)
NMOSD is a severe and ultra-rare autoimmune disease of the central nervous system (CNS) that primarily affects the optic nerves and the spinal cord. Each relapse of the disorder results in a stepwise accumulation of disability, including blindness and paralysis, and sometimes premature death. Complement activation due to anti-AQP4 antibodies is one of the primary underlying causes of the destruction of vital cells in the central nervous system in patients with NMOSD.
Anticoagulant Effects of Factor Xa Inhibitors
Factor Xa Inhibitors (i.e. apixaban, rivaroxaban and edoxaban), may rarely cause patients to be hospitalized with life-threatening or uncontrolled bleeding. Potential events include intracranial hemorrhage; intraocular, pericardial, intraspinal, intraarticular bleeding at critical sites; major gastrointestinal, retroperitoneal, or genitourinary bleeding; and bleeding associated with major blunt or penetrating injury.
Wilson Disease
Wilson disease is a rare disorder, characterized by excess copper stored in various body tissues, that can lead to severe liver disease, including cirrhosis and acute liver failure, as well as debilitating neurological morbidities such as impaired movement, gait, speech, swallowing, and psychiatric disorders.
Warm Autoimmune Hemolytic Anemia (WAIHA)
WAIHA is a rare autoimmune disorder caused by pathogenic Immunoglobulin G (IgG) antibodies that react with and cause the premature destruction of red blood cells at normal body temperature. The disease is often characterized by profound, and potentially life-threatening anemia and other acute complications, including severe and life-threatening hemolysis, severe weakness, enlarged spleen and/or liver, rapid heart rate (tachycardia), chest pain, heart failure and fainting (syncope).
Amyotrophic Lateral Sclerosis (ALS)
ALS is a progressive neurodegenerative disease of the CNS characterized by the loss of upper (brain) and lower (spinal cord) motor neurons. Ongoing loss of motor neurons and muscle strength leads to loss of independence, paralysis and death, typically due to respiratory insufficiency.
 C3 Glomerulopathy (C3G)
C3G is a rare, chronic disease affecting the kidneys in which the alternative pathway of the complement system is dysregulated due to genetic mutations or autoantibodies affecting the regulation of the alternative pathway. This lack of regulation results in the alternative pathway overactivation and the excessive deposition of C3 protein fragments in the glomeruli, a key filtration component of the kidney, often leading to serious kidney damage.
Relapsed/refractory B-and T-cell malignancies
The B cell non-Hodgkin lymphomas (NHLs) are a diverse group of disorders of proliferating malignant B cells. Collectively, NHL is the eighth leading type of cancer in the U.S., with B-cell lymphomas diagnosed in approximately 85% to 90% of patients. In 2019, an estimated 74,200 new cases of NHL will be diagnosed along with nearly 20,000 deaths. Patients present with fever, night sweats, and unintentional weight loss. With progressive disease, the malignant cells metastasize from lymph nodes and bone marrow to other organs, ultimately resulting in organ failure. Front-line therapy consists of combination chemotherapy with rituximab. Experimental agents are in development to address patients who relapse or are refractory to front-line therapy. There are no curative therapies in the relapsed/refractory setting.

The T cell lymphomas are represented by diverse histologies depending on the malignant cell of origin. T-cell NHL comprises approximately 10% to 15% of the total cases of NHL, resulting in approximately 7,000 to 10,000 cases a year in the U.S. Symptoms are similar to those of the B cell malignancies, however, the 5 year overall survival rates are typically lower for T cell NHL vs B cell NHL with rates of approximately 35% being found in several studies. These are highly aggressive lymphomas for which there is no optimal standard of care.
COVID-19
Coronaviruses are a family of viruses that can cause illnesses such as the common cold, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). In 2019, a new coronavirus was identified as the cause of a disease outbreak that likely originated in China. The virus is now known as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the disease it causes is called coronavirus disease 2019 (COVID-19). In March 2020, the World Health Organization (WHO) declared the COVID-19 outbreak a pandemic. Signs and symptoms of COVID-19 may appear two to 14 days after exposure and can include fever, cough, shortness of breath or difficulty breathing. The severity of COVID-19 symptoms can range from very mild to very severe. Some people may have no symptoms at all and spread the infection inadvertently. People who are older or who have pre-existing diagnosed or undiagnosed medical conditions, such as heart disease, lung disease and/or diabetes, or who have a compromised or overreacting immune system may be at higher risk of serious illness or complications and may require assisted ventilation as well as urgent critical care.

46
Alexion Pharmaceuticals, Inc.
(amounts in millions, except per share amounts)
Marketed Products
Our marketed products consist of the following:
ProductTherapeutic AreaApproved Indication
alxn-20200930_g2.jpg
HematologyParoxysmal Nocturnal Hemoglobinuria (PNH)
Hematology/Nephrology
Atypical Hemolytic Uremic Syndrome (aHUS)

alxn-20200930_g3.jpg
HematologyParoxysmal Nocturnal Hemoglobinuria (PNH)
Hematology/NephrologyAtypical Hemolytic Uremic Syndrome (aHUS)
NeurologyGeneralized Myasthenia Gravis (gMG)
NeurologyNeuromyelitis Optica Spectrum Disorder (NMOSD)
alxn-20200930_g4.jpg
Metabolic DisordersHypophosphatasia (HPP)
alxn-20200930_g5.jpg
Metabolic DisordersLysosomal Acid Lipase Deficiency (LAL-D)
alxn-20200930_g6.jpg
Acute CareReversal of anticoagulation in patients treated with Factor Xa inhibitors when experiencing life-theatening or uncontrolled bleeding.

ULTOMIRIS (ALXN1210/ravulizumab-cwvz)
ULTOMIRIS is an innovative, long-acting C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. In clinical studies, ULTOMIRIS demonstrated rapid, complete, and sustained reduction of free C5 levels.
In December 2018, ULTOMIRIS was approved by the FDA as a new treatment option for adult patients with PNH in the U.S.
ULTOMIRIS was approved as a new treatment option for adult patients with PNH by Japan's MHLW in June 2019. ULTOMIRIS was approved by the European Commission (EC) in July 2019 as a treatment for adult patients with PNH with hemolysis with clinical symptoms indicative of high disease activity, and also for adult patients who are clinically stable after having been treated with SOLIRIS for at least the past six months.
In October 2019, the FDA approved the use of ULTOMIRIS as a treatment for adult and pediatric (one month of age or older) patients with aHUS to inhibit complement-mediated TMA.
In June 2020, the EC approved ULTOMIRIS for the treatment of adults and children with a body
weight of 10kg or above with aHUS who are complement inhibitor treatment-naïve or have received SOLIRIS (eculizumab) for at least three months and have evidence of response to eculizumab.
In September 2020, ULTOMIRIS was approved by Japan's MHLW as a new treatment option for adult and pediatric patients with aHUS.
In October 2020, ULTOMIRIS 100 mg/mL formulation was approved by the FDA for the treatment of adult patients with PNH and for adults and pediatric (one month of age or older) patients with aHUS to inhibit complement-mediated TMA.
SOLIRIS (eculizumab)
SOLIRIS is an innovative C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. SOLIRIS is a humanized monoclonal antibody that effectively blocks terminal complement activity at the doses currently prescribed.
SOLIRIS is approved for the treatment of PNH and aHUS in pediatric and adult patients in the U.S., Europe, Japan and in several other countries. Alexion is sponsoring multinational registries to gather information regarding the natural history of patients with PNH and aHUS and the longer-term outcomes during SOLIRIS treatment.
47
Alexion Pharmaceuticals, Inc.
(amounts in millions, except per share amounts)
In 2017, the FDA and EC regulatory authorities approved SOLIRIS for the treatment of gMG in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Additionally, in 2017, the MHLW in Japan approved SOLIRIS as a treatment for patients with gMG who are AChR antibody-positive and whose symptoms are difficult to control with high-dose intravenous immunoglobulin therapy or plasmapheresis (PLEX).
In June 2019, SOLIRIS became the first FDA-approved treatment option for adult patients with NMOSD who are AQP4 auto antibody positive. In August 2019, the EC approved SOLIRIS as the first treatment in Europe for NMOSD in adults who are AQP4 antibody-positive with a relapsing course of the disease. In November 2019, the Japanese MHLW approved SOLIRIS as a treatment for the prevention of relapse in patients with AQP4 antibody-positive NMOSD, including Neuromyelitis Optica.
STRENSIQ (asfotase alfa)
STRENSIQ, a targeted enzyme replacement therapy, is the first and only approved therapy for patients with HPP and is designed to directly address underlying causes of HPP by aiming to restore the genetically defective metabolic process, thereby preventing or reversing the severe and potentially life-threatening complications in patients with HPP. STRENSIQ is approved in the U.S. for patients with perinatal-, infantile- and juvenile-onset HPP, in Europe for the treatment of patients with pediatric-onset HPP, and in Japan for the treatment of patients with HPP. Alexion is sponsoring a multinational registry to gather information regarding the natural history of patients with HPP and the longer-term outcomes during STRENSIQ treatment.
KANUMA (sebelipase alfa)
KANUMA, a recombinant form of the human LAL enzyme, is the only enzyme-replacement therapy that is approved for the treatment for patients with LAL-D. KANUMA is approved in the U.S. for the treatment of patients with LAL-D, in Europe for long-term enzyme replacement therapy in patients with LAL-D, and in Japan for the treatment of patients with LAL-D. Alexion is sponsoring a multinational registry to gather information regarding the natural history of patients with LAL-D and the longer-term outcomes during KANUMA treatment.

ANDEXXA (coagulation factor Xa - [recombinant] inactivated-zhzo)
ANDEXXA is approved by the FDA as a reversal agent for patients treated with rivaroxaban or apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. ANDEXXA was approved under the FDA’s Accelerated Approval Pathway, and received conditional marketing authorization in the EU based on the change from baseline in anti-Factor Xa activity in healthy volunteers and in patients through the ANDEXXA-4 trial demonstrating hemostatic efficacy. Continued approval for this indication is contingent upon post-marketing study results that verify that clinical benefit is conferred to patients.
48
Alexion Pharmaceuticals, Inc.
(amounts in millions, except per share amounts)
Clinical Development Programs
Our ongoing clinical development programs include the following:
ProductMechanism of ActionDevelopment AreaIndicationPhase IPhase IIPhase IIIPhase IVFiled
ULTOMIRIS (ALXN1210/ravulizumab-cwwz) (Intravenous)Anti-C5Neurology
Pulmonology		gMG/NMOSD/ALS
COVID-19		l
ULTOMIRIS (ALXN1210/ravulizumab-cwvz)
(Subcutaneous)		Anti-C5Hematology/NephrologyPNH/aHUSl
ALXN1720 (Subcutaneous)Anti-C5Next Generation Subcutaneous Complement Inhibitorl
ALXN1830
(SYNT001)
(Subcutaneous)		Anti-FcRNFcRNl
ALXN1840
(WTX101)		High-affinity, specific Cu binderMetabolic DisordersWilson diseasel
ALXN2040
(ACH-4771)		Factor D InhibitorHematology/NephrologyPNH-EVH / C3Gl
ALXN2050
(ACH-5228)		Factor D InhibitorHematology/NephrologyPNHl
ALXN2070
(ANDEXXA)		Anti Factor Xa ReversalAcute Care
Reversal of anticoagulation in patients treated with Factor Xa inhibitors when experiencing life-theatening or uncontrolled bleeding.
l
ALXN2075
(Cerdulatinib)		Dual spleen tyrosine kinase and janus kinase (SYK/JAK) inhibitorAcute Care/ OncologyRelapsed/refractory chronic lymphocytic leukemia or B-cell or T-cell NHLl
In addition to our ongoing development programs, Alexion holds a minority interest in and an option to acquire Caelum Biosciences (Caelum), a biotechnology company that is developing CAEL-101 for light chain (AL) amyloidosis.  CAEL-101 is a first-in-class chimeric monoclonal antibody (mAb) designed to improve organ function by reducing or eliminating amyloid deposits in the tissues and organs of patients with AL amyloidosis, a rare systemic disorder caused by an abnormality of plasma cells in the bone marrow. A Phase Ia/Ib study for CAEL-101 has been completed. Following discussions with the FDA, a Phase II trial for CAEL-101 commenced during the first quarter of 2020 and met its primary objectives, supporting the safety and tolerability of CAEL-101 and confirmed the dose and regimen to be adopted for the Phase III studies. In September 2020, Alexion and Caelum announced the initiation of the Cardiac Amyloid Reaching for Extended Survival (CARES) program. This includes two parallel Phase III trials to evaluate the survival benefits of CAEL-101. Enrollment is underway in both studies.

ULTOMIRIS (ALXN1210/ravulizumab-cwvz)
ULTOMIRIS is an innovative, long-acting C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. In clinical studies, ALXN1210 demonstrated rapid, complete, and sustained reduction of free C5 levels.
Intravenous (IV)
In January 2019, Alexion announced that the Phase III, global, single arm, multicenter study evaluating the safety and efficacy of ALXN1210 administered by IV infusion every 8 weeks to adult patients with aHUS who had never been treated with a
complement inhibitor (inhibitor-naïve patients) met its primary objective. In the study's initial 26-week treatment period, 53.6 percent of patients demonstrated complete TMA response. A second Phase III, single arm, multicenter study to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmaco-dynamics (PD) of ALXN1210 administered by IV infusion every 8 weeks in inhibitor-naïve pediatric patients (including adolescents) with aHUS is ongoing.
In November 2019, the Extension Application to register the ULTOMIRIS 100 mg/ml formulation (which is a higher concentration formulation of ULTOMIRIS than the formulation currently commercialized) was submitted to the EMA. In August 2020, Alexion
49
Alexion Pharmaceuticals, Inc.
(amounts in millions, except per share amounts)
submitted an application to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to register the ULTOMIRIS 100mg/ml formulation. In September 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending marketing authorization in the European Union for the 100 mg/ml formulation.
In March 2019, Alexion initiated a Phase III double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of ALXN1210 in adult patients for the treatment of gMG. Additionally, in December 2019, Alexion initiated a Phase III, single arm, open-label, multicenter study to evaluate the safety and efficacy of ALXN1210 in adult patients with NMOSD.
In March 2020, Alexion initiated a Phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of ALXN1210 in patients with ALS.
In May 2020, following the FDA's acceptance of Alexion's IND application, Alexion initiated a Phase III open-label, randomized, controlled clinical trial of ALXN1210 in adult patients with COVID-19 who are hospitalized with severe pneumonia or Acute Respiratory Distress Syndrome (ARDS). The trial is investigating the role of terminal complement inhibition in managing patients with severe COVID-19.
In addition to aHUS, NMOSD, gMG, ALS and COVID-19, Alexion plans to initiate: (i) Phase III studies of ALXN1210 in adult and pediatric hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) in the fourth quarter 2020; (ii) a Phase III study of ALXN1210 in complement mediated thrombotic microanglopathy (CM-TMA) and (iii) a proof of concept basket study in renal indications, including Lupus Nephritis (LN) and Immunoglobulin A Nephropathy (IgAN).
Subcutaneous (SC) Delivery
In March 2019, Alexion initiated a single, PK-based Phase III study of ALXN1210 delivered subcutaneously once per week to PNH patients to support regulatory approval submissions in both PNH and aHUS. In June 2020, Alexion announced that the ongoing study met its primary objective of pharmacokinetic-based non-inferiority of ULTOMIRIS SC versus intravenous (IV) ULTOMIRIS at Day 71. Pending completion of the study and collection of required 12-month safety data, Alexion expects to file for approval in the U.S. and E.U. for the SC formulation and device combination in PNH and aHUS in the third quarter of 2021.
ALXN1720 Subcutaneous (SC) Delivery
ALXN1720 is a novel humanized bi-specific minibody antibody that binds selectively and with high affinity to C5. ALXN1720 is designed for subcutaneous administration as a concentrated formulation for the treatment of disease states involving dysregulated terminal complement activity. In September 2019, Alexion initiated a Phase I healthy volunteer study of ALXN1720 to assess its safety and tolerability. This trial was paused due to the COVID-19 pandemic, but was re-initiated in August 2020. Additionally, we plan to initiate trials in gMG and dermatomyositis (DM), a rare autoimmune inflammatory myopathy characterized by chronic inflammation and degeneration of muscle and skin.
ALXN1810 Subcutaneous (SC) Delivery
ALXN1810 combines ravulizumab-cwvz with recombinant human hyaluronidase enzyme (rHuPH20), licensed from Halozyme Therapeutics, Inc., to potentially further extend the dosing interval for ALXN1210 SC from once per week to once every two weeks or more. Alexion completed a SC healthy volunteer study with ALXN1810 in December 2018. We are no longer pursuing this combination therapy.
ALXN1830 (SYNT001)
ALXN1830 (SYNT001) is a humanized monoclonal antibody that is designed to inhibit the interaction of the neonatal Fc receptor (FcRn) with IgG and IgG immune complexes and has the potential to improve treatment in a number of rare IgG-mediated diseases. Alexion re-initiated a Phase II trial of the IV formulation in WAIHA in early 2020. In addition, Alexion initiated a Phase I study of a SC formulation of ALXN1830 in healthy volunteers in December 2019. Due to the COVID-19 pandemic, Alexion discontinued the Phase II trial in WAIHA and paused the Phase I healthy volunteer study. Phase I healthy volunteer study and Phase II studies in WAIHA and gMG exclusively with the SC formulation are planned to start in 2021.
ALXN1840 (WTX101)
ALXN1840 (WTX101), an innovative product candidate that addresses the underlying cause of Wilson disease, is a first-in-class oral copper-binding agent with a unique mechanism of action and the ability to access and bind copper from serum and remove it from the liver.
In February 2020, Alexion completed enrollment in a Phase III study of ALXN 1840 for the treatment of Wilson disease. ALXN1840 has received Fast Track designation in the U.S.
Alexion planned to initiate a Phase II study for ALXN1840 in Primary Biliary Cholangitis, a chronic liver disease resulting from progressive destruction of
50
Alexion Pharmaceuticals, Inc.
(amounts in millions, except per share amounts)
the bile ducts in the liver, however, we are no longer pursuing this study.
ALXN2040 (danicopan/ACH-4771)
ALXN2040 is an oral Factor D inhibitor designed to treat diseases associated with dysregulation of the complement alternative pathway. ALXN2040 as an add on therapy for PNH patients with clinically evident extravascular hemolysis (EVH) has received orphan drug and breakthrough therapy designation by the FDA and both orphan and PRIME designation by EMA. Two Phase II studies of ALXN2040 as an oral add-on therapy for PNH-EVH are ongoing, and a Phase III trial is planned to commence by the end of 2020. Two Phase II studies evaluating the safety, efficacy, pharmacokinetics, and pharmaco-dynamics of ALXN2040 in patients with C3G are in the process of being wound down. We will no longer continue to pursue ALXN2040 as a treatment for C3G. Alexion plans to develop ALXN2050 in C3G, which has improved PK/PD and inhibition of the alternative pathway of the complement system as compared to ALXN2040.
We plan to initiate a Phase II study of ALXN2040 in Geographic Atrophy, a chronic and progressive degeneration of the portion of the retina responsible for central and color vision, in 2021.
ALXN2040 was added to the pipeline portfolio as a result of the acquisition of Achillion.
ALXN2050 (ACH-5228)
ALXN2050 is an oral Factor D inhibitor designed to treat rare diseases associated with dysregulation of the complement alternative pathway. ALXN2050 is in Phase II trials as a potential monotherapy treatment for PNH and is being evaluated for development in other alternative pathway-mediated rare diseases. Additionally, Alexion plans to initiate proof-of-concept trials of ALXN2050 in patients with various renal diseases in 2021.
ALXN2050 was added to the pipeline portfolio as a result of the acquisition of Achillion.
ALXN2060 (AG10)
In September 2019, Alexion entered into an agreement with Eidos Therapeutics, Inc. (Eidos), through which Alexion obtained an exclusive license to develop and commercialize AG10 in Japan for transthyretin amyloidosis (ATTR). AG10 is an orally administered small molecule in development designed to target the root cause of ATTR by stabilizing transthyretin (TTR) in the blood. Eidos is currently evaluating AG10 in a Phase III study in the United States and Europe for ATTR cardiomyopathy (ATTR-CM) and plans to initiate a Phase III study in ATTR polyneuropathy (ATTR-PN) by the end of 2020. Alexion plans to expand the AG10 program into Japan through the initiation of a clinical trial for which data would
serve as the basis for seeking regulatory approval to commercialize AG10 in Japan.
ALXN2070 (ANDEXXA)
The acquisition of Portola added Portola’s commercialized medicine, ANDEXXA, for which additional clinical trials are currently being conducted to obtain full regulatory approvals and expand approved indications. It has obtained accelerated approval in the US and conditional marketing authorization in the EU based on the change from baseline in anti-Factor Xa activity in healthy volunteers, and in patients through the ANNEXA-4 trial. Full approval in the US and EU for current indications requires completion of ANNEXA-I, a Phase IV randomized controlled clinical trial currently underway evaluating the safety and efficacy of ANDEXXA versus standard of care in patients presenting with acute intracranial hemorrhage while taking an oral Factor Xa inhibitor. A Japan J-NDA filing is under evaluation. A US sBLA submission for a label expansion for the reversal of edoxaban and enoxaparin associated bleeds is anticipated for late 2020 or early 2021.
Additionally, we plan to initiate a Phase II study in 2021 for the reversal of anticoagulation in patients taking apixaban, rivaroxaban, edoxaban, or enoxaparin who require urgent surgery.
ALXN2075 (Cerdulatinib)
ALXN2075 (Cerdulatinib) is a small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies. We are reviewing preliminary clinical data and considering Follicular Lymphoma as a next step in the program. A Phase II study is ongoing. ALXN2075 was added to the pipeline portfolio as a result of the acquisition of Portola.
SOLIRIS (eculizumab)
SOLIRIS is an innovative C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. SOLIRIS is a humanized monoclonal antibody that effectively blocks terminal complement activity at the doses currently prescribed.
In June 2020, Japan’s MHLW granted SAKIGAKE designation for SOLIRIS in Guillain-Barré syndrome (GBS). Results from the Japanese Eculizumab Trial for GBS (JET-GBS study) suggested the potential efficacy and safety of SOLIRIS as a treatment for GBS. Complement activation may play a role in the pathophysiology of GBS. Alexion plans to initiate a Phase III study of SOLIRIS in GBS in Japan in 2021.
51
Alexion Pharmaceuticals, Inc.
(amounts in millions, except per share amounts)
Manufacturing
We utilize both internal manufacturing facilities and third-party contract manufacturers to supply clinical and commercial quantities of our products and product candidates. Our internal manufacturing capability includes our Ireland facilities, a fill/finish facility in Athlone, and a packaging facility in Dublin, as well as a production facility in Georgia. Third party contract manufacturers, including Lonza Group AG and its affiliates (Lonza), provide bulk drug substance as well as other manufacturing services like purification, product filling, finishing, packaging, and labeling.
We have various agreements with Lonza through 2031, with remaining total non-cancellable commitments of approximately $1,432.3. If we terminate certain supply agreements with Lonza without cause, we will be required to pay for product scheduled for manufacture under our arrangements. Under an existing arrangement, we pay Lonza a royalty on sales of SOLIRIS that was manufactured at the Alexion Rhode Island Manufacturing Facility (ARIMF) prior to the sale of the facility in 2018. We also pay Lonza a royalty on the sales of ULTOMIRIS and a payment with respect to sales of SOLIRIS manufactured at Lonza facilities. Lonza also manufactures ANDEXXA for Alexion. Lonza is in the process of qualifying a new manufacturing facility in New Hampshire that would, if and when such facility is approved by regulatory authorities, manufacture STRENSIQ for commercial use (and commitments entered into under this arrangement are included in the non-cancellable commitments amount noted in the first sentence of this paragraph).
In addition, we have non-cancellable commitments of approximately $78.6 through 2021 with other third-party manufacturers.
In April 2014, we purchased a fill/finish facility in Athlone, Ireland, which has been refurbished to become our first company-owned fill/finish facility. We have also completed construction of a new biologics manufacturing facility at this site and we are currently pursuing regulatory approval.
In May 2015, we announced plans to construct a new biologics manufacturing facility on our existing property in Dublin, Ireland. Construction of this facility has been completed and we are currently pursuing regulatory approval.
While we continue to actively engage with regulators, the timing of regulatory approvals for each of these facilities may be delayed as a result of the COVID-19 pandemic.
Critical Accounting Policies and Estimates
The significant accounting policies and basis of preparation of our consolidated financial statements are described in Note 1, Business Overview and Summary of Significant Accounting Policies of the Consolidated Financial Statements included in our Form 10-K for the year ended December 31, 2019. Under accounting principles generally accepted in the U.S., we are required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and disclosure of contingent assets and liabilities in our financial statements. We believe the most complex judgments result primarily from the need to make estimates about the effects of matters that are inherently uncertain and are significant to our consolidated financial statements. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. We evaluate our estimates, judgments and assumptions on an ongoing basis. Actual results could differ materially from those estimates.
We believe the judgments, estimates and assumptions associated with the following critical accounting policies have the greatest potential impact on our consolidated financial statements:
•Revenue recognition;
•Contingent liabilities;
•Share-based compensation;
•Valuation of acquired assets, including goodwill, intangible assets and inventory;
•Valuation of contingent consideration; and
•Income taxes.
For a complete discussion of these critical accounting policies, refer to “Critical Accounting Policies and Use of Estimates” within “Item 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations” included within our Annual Report on Form 10-K for the year ended December 31, 2019. There have been no significant changes to the critical accounting policies.
Valuation of Acquired Assets, Including Goodwill, Intangible Assets and Inventory
We have recorded goodwill, acquired intangible assets and inventory related to our business combinations. When identifiable intangible assets, including IPR&D, are acquired, we determine the fair values of the assets as of the acquisition date. An income approach, which generally relies upon forecasted cash flow models, is typically used in these valuations if quoted market prices are not available. These valuations require the use of
52
Alexion Pharmaceuticals, Inc.
(amounts in millions, except per share amounts)
significant estimates and assumptions including but not limited to:
•timing and costs to complete the in-process projects;
•timing and probability of success of clinical events or regulatory approvals;
•estimated future cash flows from product sales resulting from completed products and in-process projects, which consider competitive trends impacting the assets;
•tax rates; and
•discount rates
We may also utilize a cost approach, which estimates the costs that would be incurred to replace the assets being purchased. Significant inputs into the cost approach include estimated rates of return on historical costs that a market participant would expect to pay for these assets.
Intangible assets with indefinite lives are not amortized, but are tested for impairment at least annually or when a triggering event occurs that could indicate a potential impairment. Intangible assets with definite useful lives are amortized to their estimated residual values over their estimated useful lives and reviewed for impairment if triggering events occur. When performing our impairment assessment for definite-lived intangible assets, we rely upon cash flow projections attributable to the asset to determine if the carrying value of the asset is recoverable, on an undiscounted cash flow basis. If the carrying value of a definite lived intangible asset is not recoverable, or if there is an indicator of impairment on an indefinite-lived intangible asset, we will recognize an impairment in the amount by which the carrying value of the asset exceeds its fair value. We calculate the fair value of these assets using discounted cash flow models which require the use of significant estimates and judgements which include, but are not limited to, probability of success of clinical events or regulatory approvals, discount rates, and estimated future cash flows from product sales. Changes to assumptions used in our cash flow projections could result in an impairment. Impairments are recorded within impairment of intangible assets in our consolidated statements of income.
During the quarter ended June 30, 2020, based on continued challenges expanding patient growth and new alternative commercial opportunities, the Company revised its strategic view of KANUMA and determined that we have exhausted commercially viable initiatives related to KANUMA and will have difficulty expanding patient growth over the long term as we focus on promoting other commercial programs and growing our pipeline. As a result, we no longer expect to increase the number of KANUMA patients in
the long term at the rate previously assumed. This determination resulted in reduced cash flow projections for KANUMA, which indicated that the related intangible asset value was not fully recoverable on an undiscounted cash flows basis. On June 30, 2020, the Company utilized market participant assumptions to determine its best estimate of the fair value of the intangible asset related to KANUMA that, when compared with its related carrying value, resulted in an impairment charge of $2,042.3.
The estimated fair value of the KANUMA asset as of June 30, 2020 was determined using the excess earnings method, a variation of the income approach. The excess earnings method estimates the value of an intangible asset equal to the present value of the incremental after-tax cash flows attributable to that intangible asset over its remaining economic life. Long term cash flow projections for the asset require the use of significant estimates and judgements, including discount rates and revenue growth rates, and were based on the Company’s most recent strategic plan. The fair value of the asset was determined using an estimated weighted average cost of capital of 10.0%, which reflects the risks inherent in future cash flow projections and represents a rate of return that a market participant would expect for this asset. The estimated revenue growth rates fluctuate over the life of the asset, with a weighted average growth rate in the low single digits. The Company believes its assumptions are consistent with the plans and estimates that a market participant would use to manage the business. The estimated fair value of the KANUMA intangible asset as of June 30, 2020 was $820.0 and will continue to be amortized over its remaining estimated useful life. This fair value measurement was based on significant inputs not observable in the market and thus represents a Level 3 fair value measurement.
Inventory acquired in connection with the acquisition of a business is measured at fair value as of the acquisition date and requires the use of significant estimates, which include the expected selling price of the inventory, estimated costs to complete the manufacturing process and dispose of the inventory, a reasonable profit allowance for the remaining manufacturing and selling effort, estimated holding periods based on internal forecasts of demand and discount rates. We exclude from the value of acquired inventory any excess quantities that we do not expect to be salable based on future projected inventory requirements. If future demand or market conditions are lower than our projections as of the acquisition date, we may be required to write down the value of inventory through a charge to cost of sales in the period the revision is made.
53
Alexion Pharmaceuticals, Inc.
(amounts in millions, except per share amounts)
Goodwill represents the excess of purchase price over fair value of net assets acquired in a business combination and is not amortized. Goodwill is subject to impairment testing at least annually or when a triggering event occurs that could indicate a potential impairment. We are organized and operate as a single reporting unit and therefore the goodwill impairment test is performed using our overall market value, as determined by our traded share price, compared to our book value of net assets.
New Accounting Pronouncements
For information on new accounting pronouncements adopted in the current period and recently issued standards, see Note 2, Basis of Presentation and Principles, to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

54
Alexion Pharmaceuticals, Inc.
(amounts in millions, except per share amounts)
Results of Operations
Net Product Sales
Net product sales by significant geographic region for the three and nine months ended September 30, 2020 and 2019 are as follows:
Three months endedNine months ended
September 30,%September 30,%
20202019Change20202019Change
SOLIRIS
United States$562.8 $496.8 13.3 %$1,672.3 $1,456.8 14.8 %
Europe254.3 255.5 (0.5)%765.7 800.2 (4.3)%
Asia Pacific86.0 118.0 (27.1)%255.5 329.2 (22.4)%
Rest of World139.2 120.2 15.8 %347.2 347.1 — %
Total$1,042.3 $990.5 5.2 %$3,040.7 $2,933.3 3.7 %
ULTOMIRIS
United States$170.7 $65.1 162.2 %$460.3 $143.9 219.9 %
Europe46.6 21.1 120.9 %112.4 21.1 432.7 %
Asia Pacific69.6 3.7 **186.3 3.7 **
Rest of World2.4 — **4.2 — **
Total$289.3 $89.9 221.8 %$763.2 $168.7 352.4 %
STRENSIQ
United States$149.3 $118.0 26.5 %$418.1 $323.7 29.2 %
Europe19.3 19.0 1.6 %61.6 56.0 10.0 %
Asia Pacific16.1 14.0 15.0 %44.7 36.0 24.2 %
Rest of World4.7 3.3 42.4 %21.5 10.0 115.0 %
Total$189.4 $154.3 22.7 %$545.9 $425.7 28.2 %
ANDEXXA
United States$36.2 $— **$36.2 $— **
Europe2.7 — **2.7 — **
Asia Pacific— — **— — **
Rest of World— — **— — **
Total$38.9 $— **$38.9 $— **
KANUMA
United States$15.8 $16.0 (1.3)%$47.6 $45.1 5.5 %
Europe9.5 6.3 50.8 %25.4 19.4 30.9 %
Asia Pacific1.1 1.3 (15.4)%2.9 3.4 (14.7)%
Rest of World2.0 4.8 (58.3)%12.8 10.2 25.5 %
Total$28.4 $28.4 — %$88.7 $78.1 13.6 %
Total Net Product Sales$1,588.3 $1,263.1 25.7 %$4,477.4 $3,605.8 24.2 %

** Percentages not meaningful
55
Alexion Pharmaceuticals, Inc.
(amounts in millions, except per share amounts)
Net Product Sales
alxn-20200930_g7.jpg
United StatesAsia Pacific
EuropeRest of World

SOLIRIS net product sales
alxn-20200930_g8.jpg
United StatesAsia Pacific
EuropeRest of World

ULTOMIRIS net product sales
alxn-20200930_g9.jpg
United StatesAsia Pacific
EuropeRest of World

STRENSIQ net product sales
alxn-20200930_g10.jpg
United StatesAsia Pacific
EuropeRest of World

ANDEXXA net product sales
alxn-20200930_g11.jpg
United StatesAsia Pacific
EuropeRest of World

KANUMA net product sales
alxn-20200930_g12.jpg
United StatesAsia Pacific
EuropeRest of World
56
Alexion Pharmaceuticals, Inc.
(amounts in millions, except per share amounts)
The increase in net product sales for the three and nine months ended September 30, 2020, as compared to the same periods in 2019, was primarily due to an increase in unit volumes. The increase in unit volumes was primarily due to increased global demand for SOLIRIS therapy, with sales to patients with gMG and NMOSD being the largest drivers. As a result of continued patient conversion, ULTOMIRIS unit volumes for PNH and aHUS also increased due to an increase in PNH and aHUS patients on ULTOMIRIS therapy, inclusive of the loading dose impact required in a patient's first year on therapy. Partially offsetting this increase was the continued conversion of PNH and aHUS patients from SOLIRIS to ULTOMIRIS, resulting in a decrease in SOLIRIS PNH and aHUS revenues for the three and nine months ended September 30, 2020, as compared to the same periods in 2019. Additional unit volume increases were due primarily to increased demand for STRENSIQ during 2020 and contributions of $38.9 from ANDEXXA as a result of the Portola acquisition that closed on July 2, 2020.
As a result of patient conversion from SOLIRIS to ULTOMIRIS, we expect variability in our revenues in future quarters due to the extended ULTOMIRIS dosing interval and infusion timing which may result in either one or two infusions in a quarter. ULTOMIRIS loading doses for PNH patients will result in increased revenues during a patient’s first year on therapy. The ULTOMIRIS annual maintenance dose for PNH and aHUS requires fewer vials as compared to the annual dose for SOLIRIS. Due to the decision to price ULTOMIRIS lower than SOLIRIS on an annual basis, we anticipate U.S. revenues will be unfavorably impacted by the lower annual cost per patient in maintenance years, with the impact more pronounced for aHUS due to the greater decrease in vials for aHUS ULTOMIRIS patients.
Foreign exchange had a negative impact of 2.0% and 1.5% for the three and nine months ended September 30, 2020, respectively, as compared to the same periods in 2019, with the largest impact relating to the weakening of the Brazilian Real versus the U.S. Dollar.
In response to the COVID-19 pandemic, we have taken proactive measures that are designed to mitigate the risk of potential supply interruptions, and we strive to maintain sufficient inventory levels to continue serving current and new patients receiving our medicines for approved indications. Additionally, we expect fewer patient/doctor interactions, fewer visits between our representatives and health care providers and the potential inability of patients to access hospitals or infusion centers (voluntarily or involuntarily) which may result in a reduction in future sales. However, we are proactively engaging with healthcare professionals virtually and through
enhanced digital channels in an effort to mitigate this risk. We have observed that the new patient productivity and initiation queue has decreased since the COVID-19 outbreak, particularly in neurological indications.
Cost of Sales (exclusive of amortization of purchased intangible assets)
Cost of sales includes manufacturing costs, actual and estimated royalty expenses associated with sales of our products, and amortization of licensing rights.
The following table summarizes cost of sales for the three and nine months ended September 30, 2020 and 2019:
alxn-20200930_g13.jpg
2020 Cost of Sales
2019 Cost of Sales
●Cost of sales as a percentage of net product sales

Cost of sales as a percentage of net product sales was 9.1% and 7.5% for the three months ended September 30, 2020 and 2019, respectively, and 9.0% and 7.8% for the nine months ended September 30, 2020 and 2019.
The increase in cost of sales as a percentage of net product sales for the three months ended September 30, 2020 as compared to the same period in 2019, was primarily associated with the amortization of the ANDEXXA inventory fair value step-up recognized in purchase accounting for Portola.
The increase of cost of sales as a percentage of net product sales for the nine months ended September 30, 2020 as compared to the same period in 2019, was primarily due to the amortization of the ANDEXXA inventory fair value step-up recognized in purchase accounting for Portola, inventory obsolescence reserves recorded, and higher period costs related to COVID-19 manufacturing capacity levels.
57
Alexion Pharmaceuticals, Inc.
(amounts in millions, except per share amounts)
As a result of the Portola acquisition completed on July 2, 2020, we expect cost of goods sold to increase in future periods as compared to prior periods due to the amortization of ANDEXXA inventory fair value step-up adjustments.
Research and Development Expense
alxn-20200930_g14.jpg
2020 Research and Development Expense (R&D)
2019 Research and Development Expense (R&D)
●R&D as a % of net product sales

Our research and development expense includes personnel, facility and direct costs associated with the research and development (R&D) of our product candidates, as well as product development costs.
R&D expenses are comprised of costs paid for clinical development, product development and discovery research, as well as costs associated with certain strategic licensing agreements and R&D-related asset purchase agreements which we have entered into with third parties. Clinical development costs are comprised of costs to conduct and manage clinical trials related to product candidates. Product development costs are those incurred in performing duties related to manufacturing development and regulatory functions, including manufacturing of material for clinical and research activities and other administrative costs incurred during product development. Discovery research costs are incurred in conducting laboratory studies and performing preclinical research for other uses of our current products and other new product candidates. Upfront payments include upfront payments related to strategic licensing agreements and R&D-related asset purchase agreements. Subsequent milestone payments incurred under such agreements which relate to R&D activities are classified as clinical, discovery or product development costs based on the nature of the underlying milestone event. Clinical development costs have been accumulated and allocated to each of our programs, while product development and discovery research costs have not been allocated.
Other R&D expenses consist of costs to compensate personnel, to maintain our facilities and equipment, and other occupancy costs associated with our research and development efforts. These costs relate to efforts for our clinical and preclinical candidates, our product development and our discovery research efforts. These costs have not been allocated directly to each program.
The following graph provides information regarding R&D expenses for the three and nine months ended September 30, 2020 and 2019: 

alxn-20200930_g15.jpg
Clinical DevelopmentDiscovery
Product DevelopmentPayroll and Benefits
Upfront PaymentsFacilities and Other

For the three months ended September 30, 2020, the increase in research and development expense, as compared to the same period in the prior year, was primarily related to the following:
•Increase of $53.9 in clinical development primarily driven by increased clinical expenses related to ALXN1210 for multiple ongoing studies; shared expenses related to investments in enhanced systems and processes to support our clinical trial expansion; and clinical expenses related to assets acquired from Achillion and Portola in 2020. See chart below for additional details by program.
•Increase of $16.3 in payroll and benefits primarily related to headcount increases.
58
Alexion Pharmaceuticals, Inc.
(amounts in millions, except per share amounts)
•Decrease of $30.1 in upfront payments relating to the license payment made during the third quarter 2019 in connection with the arrangement we entered into with Eidos. No upfront payments related to licensing arrangements were made during the three months ended September 30, 2020.
For the nine months ended September 30, 2020, the increase in research and development expense, as compared to the same period in the prior year, was primarily related to the following
•Increase of $105.6 in clinical development primarily driven by increased clinical expenses related to ALXN1210 for multiple ongoing studies; shared expenses related to investments in enhanced systems and processes to support our clinical trial expansion; and clinical expenses related to assets acquired from Achillion and Portola in 2020. See chart below for additional details by program.
•Increase of $40.9 in payroll and benefits primarily related to headcount increases.
•Decrease of $76.3 in upfront payments relating to the license payments made during the nine months ended September 30, 2019 in connection with the arrangements we entered into with Zealand Pharma A/S, Affibody AB, and Eidos. No upfront payments related to licensing arrangements were made during the nine months ended September 30, 2020.
The following graph summarizes R&D expenses related to our clinical development programs. Please refer to "Clinical Development Programs" above for a description of certain of these programs:
alxn-20200930_g16.jpg
20202019

alxn-20200930_g17.jpg
20202019

The successful development of our drug candidates is uncertain and subject to a number of risks. We cannot guarantee that results of clinical
59
Alexion Pharmaceuticals, Inc.
(amounts in millions, except per share amounts)
trials will be favorable or sufficient to support regulatory approvals for any of our product development programs. We could decide to abandon development or be required to spend considerable resources not otherwise contemplated. For additional discussion regarding the risks and uncertainties regarding our research and development programs, please refer to Item 1A “Risk Factors” in this Quarterly Report on Form 10-Q.
Selling, General and Administrative Expense
alxn-20200930_g18.jpg
2020 Selling General and Administrative Expense (SG&A)
2019 Selling General and Administrative Expense (SG&A)
●SG&A as a % of net product sales

Our selling, general and administrative expense includes commercial and administrative personnel, corporate facility and external costs required to support the marketing and sales of our commercialized products. These selling, general and administrative costs include: corporate facility operating expenses and depreciation; marketing and sales operations in support of our products; human resources; finance, legal, information technology and support personnel expenses; and other corporate costs such as telecommunications, insurance, audit, government affairs and our global corporate compliance program.
The graph below provides information regarding selling, general and administrative expense:alxn-20200930_g19.jpg
Salary, benefits and other labor expense
External selling, general and administrative expense

For the three months ended September 30, 2020 as compared to the three months ended September 30, 2019, the increase of $34.9 in selling, general and administrative expense, was primarily attributable to an increase  in salary, benefits and other labor expenses related to increases in headcount offset by decreases in travel and entertainment (T&E) expenses as a result of the COVID-19 pandemic.
For the nine months ended September 30, 2020 as compared to the nine months ended September 30, 2019, the increase of $75.4 in selling, general and administrative expense, was primarily related to the following:
•Increase in salary, benefits and other labor expenses of $53.7, primarily related to increases in headcount offset by decreases in T&E expenses as a result of the COVID-19 pandemic.
•Increase in external selling, general and administrative expense of $21.7, primarily related to increased costs relating to businesses acquired. In addition, there was an increase of $21.5 in litigation charges recorded during the first quarter 2020 in connection with legal proceedings, offset by a decrease of $22.0 in professional services.
Amortization of Purchased Intangible Assets
For the three months ended September 30, 2020 and 2019, we recorded $53.1 and $75.6, respectively, and $200.5 and $235.7 for the nine months ended September 30, 2020 and 2019, respectively, in amortization expense related to
60
Alexion Pharmaceuticals, Inc.
(amounts in millions, except per share amounts)
purchased intangible assets. Amortization expense is primarily associated with intangible assets related to STRENSIQ, KANUMA and ANDEXXA.
alxn-20200930_g20.jpg
The decrease in amortization of purchased intangible assets for the three and nine months ended September 30, 2020, as compared to the same periods in 2019, was primarily due to a decrease in amortization associated with the KANUMA and STRENSIQ intangible assets, both of which are explained below. This decrease was partially offset by an increase in amortization associated with the ANDEXXA intangible asset acquired in connection with the Portola acquisition, which closed during the third quarter 2020.
During the second quarter 2020, we recorded an impairment charge of $2,042.3 to write-down the KANUMA intangible asset to fair value. The lower asset value is contributing to lower amortization expense for the three and nine months ended September 30, 2020 as compared to the three and nine months ended September 30, 2019.
During the third quarter 2019, the U.S. patent term extension to a composition of matter patent for STRENSIQ was granted, which resulted in an increase in the estimated useful life of the STRENSIQ intangible asset and is contributing to lower amortization for the three and nine months ended September 30, 2020 as compared to the three and nine months ended September 30, 2019.
We expect amortization for finite-lived intangible assets to decrease in future periods as compared to prior periods as a result of the KANUMA impairment charge recognized during the second quarter of 2020, offset by amortization expense associated with the ANDEXXA intangible asset.
Change in Fair Value of Contingent Consideration
For the three and nine months ended September 30, 2020, the expense resulting from the change in fair value of contingent consideration associated with our business combinations was $23.4 and $45.0, respectively, as compared to $29.8 and $7.2 for the three and nine months ended September 30, 2019. The change in the fair value of
contingent consideration will fluctuate based on the timing of recognition of changes in the probability of achieving and the expected timing of milestone payments in connection with our business combinations.
alxn-20200930_g21.jpg

For the three and nine months ended September 30, 2020 changes in the fair value of contingent consideration expense reflected changes in the expected timing and probability of achieving contingent milestone payments, and the interest component of contingent consideration related to the passage of time. For the three and nine months ended September 30, 2019, changes in the fair value of contingent consideration expense reflected changes in the expected timing of achieving contingent milestone payments and the interest component of contingent consideration related to the passage of time.
Acquisition-related Costs
alxn-20200930_g22.jpg
For the three and nine months ended September 30, 2020, we recorded $63.0 and $105.7, respectively, of acquisition-related costs in connection with the Achillion and Portola acquisitions. Acquisition-related costs consist primarily of transaction costs, costs associated with the accelerated vesting of equity awards previously granted to Achillion and Portola employees, and Achillion and Portola employee separation costs. No
61
Alexion Pharmaceuticals, Inc.
(amounts in millions, except per share amounts)
acquisition-related costs were incurred during the three and nine months ended September 30, 2019.
Impairment of Intangible Assets
For the nine months ended September 30, 2020, we recorded impairment charges of $2,053.3, relating to ACHN-4471 (ALXN2040) and primarily KANUMA. No impairment charges were incurred during the three months ended September 30, 2020 and 2019 and nine months ended September 30, 2019.
During the quarter ended June 30, 2020, based on continued challenges expanding patient growth and new alternative commercial opportunities, the Company revised its strategic view of KANUMA and determined that we have exhausted commercially viable initiatives related to KANUMA and will have difficulty expanding patient growth over the long term as we focus on promoting other commercial programs and growing our pipeline. As a result, we no longer expect to increase the number of KANUMA patients in the long term at the rate previously assumed. This determination resulted in reduced cash flow projections for KANUMA, which indicated that the related intangible asset value was not fully recoverable on an undiscounted cash flows basis. On June 30, 2020, the Company utilized market participant assumptions to determine its best estimate of the fair value of the intangible asset related to KANUMA that, when compared with its related carrying value, resulted in an impairment charge of $2,042.3.
During the quarter ended June 30, 2020, we recognized an impairment charge of $11.0 to write off the cost basis of our ACHN-4471 (ALXN2040) acquired in-process research and development asset due to clinical results received during the quarter.alxn-20200930_g23.jpg
Restructuring Expenses
During the third quarter 2020, we initiated restructuring activities primarily within our commercial organization as part of an initiative intended to redefine our operating model. The actions are intended to reallocate resources necessary to align our organization with our diversifying portfolio of new products and strategic objectives, and will include
investments in digital capabilities, technologies and solutions to support a more virtual and digital customer experience and tailored to the markets in which we operate.
The actions are expected to be substantially completed by the end of 2021, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $25.0. We expect that the pretax costs will primarily result in cash outlays, as the costs primarily relate to employee separation expenses.
In the first quarter 2019, we initiated corporate restructuring activities to re-align our international commercial organization through re-prioritization of certain geographical markets and to implement operational excellence through strategic reallocation of resources. Actions under the previous restructuring programs have been completed.
alxn-20200930_g24.jpg

62
Alexion Pharmaceuticals, Inc.
(amounts in millions, except per share amounts)
Other Income and (Expense)

The following table provides information regarding other income and expense:
alxn-20200930_g25.jpg
Investment (expense) Income
Interest Expense
Other Income and (expense)

For the three and nine months ended September 30, 2020, we recognized investment income of $11.5 and $47.8, respectively, primarily related to the recognition of gains of $8.6 and $35.0, respectively, on our strategic equity investments recorded at fair value. Gains recorded during the three months ended September 30, 2020 on our strategic equity investments were primarily driven by an unrealized gain from our equity investment in Inozyme Pharma (Inozyme). Gains recorded during the nine months ended September 30, 2020 on our strategic equity investments were primarily driven by an unrealized gain from our Inozyme equity investment and a realized gain from our Portola equity investment which was derecognized and included in the fair value of consideration transferred in connection with the Portola acquisition. For the three and nine months ended September 30, 2019, we recognized investment income of $23.0 and $50.6, respectively, primarily related to the recognition of unrealized gains of $12.0 and $20.6, respectively, on our strategic equity investments recorded at fair value, with the largest component related to our Moderna Therapeutics Inc. equity investment, which was sold in the fourth quarter of 2019.
For the three and nine months ended September 30, 2020, interest expense was $27.6
and $77.0, respectively as compared to $17.9 and $56.1 for the three and nine months ended September 30, 2019. The increase in interest expense for the three and nine months ended September 30, 2020 as compared to the same periods in the prior year is primarily due to an increase in the average interest rates associated with our interest rate swaps, partially offset by lower term loan borrowings and lower interest rates, which are based on market rates, on the unhedged portion of our outstanding term loan.

Income Taxes
alxn-20200930_g26.jpg
2020 Income tax benefit (expense)
2019 Income tax benefit (expense)
●Effective tax rate

During the three and nine months ended September 30, 2020, we recorded an income tax expense (benefit) of $88.8 and $(89.2) and an effective tax rate of 13.3% and 413.0%, respectively, compared to an income tax expense of $67.9 and $61.5 and an effective tax rate of 12.7% and 3.9%, respectively, for the three and nine months ended September 30, 2019.
Income tax (benefit) expense is attributable to the U.S. federal, state and foreign income taxes on our profitable operations.
During the second quarter 2020, we recognized an impairment charge of $2,042.3 related to the KANUMA intangible asset, resulting in a deferred tax benefit of $377.3. See Note 5, Intangible Assets and Goodwill, for additional information on the impairment charge. These deferred tax benefits increased the effective tax rate for the nine months
63
Alexion Pharmaceuticals, Inc.
(amounts in millions, except per share amounts)
ended September 30, 2020 by approximately 399.6%.
The income tax expense for the nine months ended September 30, 2019 includes one-time tax benefits recorded during the first quarter 2019, in connection with the future integration of intellectual property of Wilson Therapeutics into the Alexion corporate structure. The deferred tax benefits included $95.7 and $30.3 associated with a tax election made with respect to intellectual property of Wilson Therapeutics and a valuation allowance release and corresponding recognition of net operating losses, respectively. These deferred tax benefits decreased the effective tax rate for the nine months ended September 30, 2019 by approximately 8.0%. Additionally, during the third quarter 2019, we completed a comprehensive analysis of our current and prior year estimates related to our foreign-derived intangible income based on additional guidance provided in the proposed regulations issued by the U.S. Treasury Department in 2019. The analysis resulted in income tax benefits of approximately $29.9, including $17.0 related to prior year estimated tax benefits, which were recorded as a change in estimate in income tax expense in our consolidated statements of operations during the three and nine months ended September 30, 2019. These tax benefits decreased the effective tax rate for the three and nine months ended September 30, 2019 by approximately 5.6% and 1.9%, respectively.
In April 2020 we became aware of a European withholding tax regulation that could be interpreted to apply to certain of our previous intra-group transactions. We continue to evaluate whether the interpretation of this regulation applies to our facts and circumstances, and, based on our preliminary analysis, we recorded an immaterial reserve related to this matter during the second quarter of 2020.
In August 2020, we received a notice of examination from the Dutch Tax Authorities (“DTA”) regarding certain matters relating to our 2014 through 2017 tax years. Discussions with the DTA are currently ongoing and, at Alexion’s request, we have expanded these discussions to include the 2018 and 2019 tax years as well. We have not received any final findings on any of these tax years, nor have we received any proposed adjustments or any tax assessments related to any of the tax years under discussion with the DTA. Accordingly, we have not recorded any related reserves and an estimate of the possible loss or range of loss, if any, cannot be made at this time.
During the third quarter of 2020, the U.S. Treasury Department released certain proposed and final regulations which were originally enacted under the 2017 Tax Act. The impact of these regulations did
not have a material impact on our financial condition and results of operations.
In 2017, the Internal Revenue Service (IRS) commenced an examination of our U.S. income tax returns for 2015. During the second quarter of 2020 we received a Revenue Agent Report (RAR) and held discussions with the IRS regarding a proposed adjustment related to the valuation of certain intellectual property that was contributed into our captive partnership during 2015. The Company agreed with the adjustment outlined in the RAR and recognized a previously unrecognized tax benefit in the second quarter of 2020 that did not result in a significant impact to the financial statements. The IRS concluded its examination during the third quarter 2020 without additional adjustments.
We continue to benefit from a reduced tax rate as a result of our centralized global supply chain and technical operations in Ireland.
We continue to maintain a valuation allowance against certain other deferred tax assets where realization is not certain. We periodically evaluate the likelihood of realizing deferred tax assets and reduce the carrying amount of these deferred tax assets by a valuation allowance to the extent we believe a portion will not be realized.

64
Alexion Pharmaceuticals, Inc.
(amounts in millions, except per share amounts)
Financial Condition, Liquidity and Capital Resources
The following table summarizes the components of our financial condition as of September 30, 2020 and December 31, 2019:
September 30, 2020December 31, 2019$
Change
Cash and cash equivalents$2,268.0 $2,685.5 $(417.5)
Marketable securities
$28.9 $64.0 $(35.1)
Long-term debt (includes current portion & revolving credit facility)
$2,601.8 $2,514.5 $87.3 
Current assets$5,067.8 $5,076.4 $(8.6)
Current liabilities$1,331.0 $1,194.3 $136.7 
Working capital$3,736.8 $3,882.1 $(145.3)
 
The aggregate decrease in cash and cash equivalents and marketable securities of $452.6 at September 30, 2020 as compared to December 31, 2019 was primarily attributable to $2,023.0 of cash utilized to fund the Achillion and Portola acquisitions, net of $480.9 of cash and cash equivalents and marketable securities acquired in the transactions and net of $196.9 of cash paid to settle preexisting debt held by Portola. Additionally, the decrease is due to cash utilized to repurchase shares of common stock, payments on our term loan facility, purchases of property, plant, and equipment and strategic equity investments, partially offset by cash generated from operations and proceeds from the sale of available-for-sale debt securities.
Excluding the impact of any significant future asset acquisitions, licenses or collaboration agreements, we expect our annual operating expenses to increase as a percentage of sales in 2020 as compared to 2019, primarily due to the impairments of intangible assets of $2,053.3 recorded during the second quarter 2020. We also expect reduced capital investment in 2020 as compared to 2019. We anticipate that cash generated from operations and our existing available cash, cash equivalents and marketable securities should provide us adequate resources to fund our operations as currently planned for at least the next twelve months.
We have financed our operations and capital expenditures primarily through positive cash flows from operations. We expect to continue to be able to fund our operations, including principal and interest payments on our Amended and Restated Credit Agreement, royalty-based debt and contingent payments associated with our in-licenses and acquisitions principally through our cash flows from
operations. We may, from time to time, also seek additional funding through a combination of equity or debt financings or from other sources, if necessary for future acquisitions or other strategic purposes. New sources of financing through equity and/or debt financing(s), especially in light of increased volatility within the global financial markets as a result of the COVID-19 pandemic, may not always be available on acceptable terms, or at all, and we may be required to obtain certain consents in connection with completing such financings.
Financial Instruments
Until required for use in the business, we may invest our cash reserves in money market funds, bank deposits, and high quality marketable debt securities in accordance with our investment policy. The stated objectives of our investment policy are to preserve capital, provide liquidity consistent with forecasted cash flow requirements, maintain appropriate diversification and generate returns relative to these investment objectives and prevailing market conditions.
Financial instruments that potentially expose us to concentrations of credit risk are cash equivalents, marketable securities, accounts receivable and our derivative contracts. At September 30, 2020, four customers accounted for 65.6% of the accounts receivable balance, with these individual customers accounting for 11.2% to 21.5% of the accounts receivable balance. At December 31, 2019, four customers accounted for 66.9% of the accounts receivable balance, with these individual customers accounting for 11.6% to 20.3% of the accounts receivable balance.
For the three months ended September 30, 2020, three customers accounted for 56.1% of our net product sales with these individual customers accounting for 14.3% to 16.2% of our net product sales. For the nine months ended September 30, 2020, four customers accounted for 58.2% of our net product sales with these individual customers accounting for 10.1% to 17.0% of our net product sales. For the three months ended September 30, 2019, three customers accounted for 46.6% of our net product sales with these individual customers accounting for 14.2% to 16.7% of our net product sales. For the nine months ended September 30, 2019, three customers accounted for 45.7% of our net product sales with these individual customers accounting for 13.8% to 16.9% of our net product sales.
We continue to monitor economic conditions, including volatility associated with international economies and the COVID-19 pandemic, and the associated impacts on the financial markets and our business. Substantially all of our accounts receivable are due from wholesale distributors, public hospitals
65
Alexion Pharmaceuticals, Inc.
(amounts in millions, except per share amounts)
and other government entities. We monitor the financial performance of our customers so that we can appropriately respond to changes in their credit worthiness. We operate in certain jurisdictions where weakness in economic conditions can result in extended collection periods. We continue to monitor these conditions and assess their possible impact on our business. As a result of the COVID-19 pandemic, we have experienced an increase in requests for extended payment terms with certain customers. To date, we have not experienced any significant losses with respect to collection of our accounts receivable and do not currently anticipate any material credit losses on our accounts receivable as a result of the pandemic.
We manage our foreign currency transaction risk and interest rate risk within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes. As of September 30, 2020, we had foreign exchange forward contracts with notional amounts totaling $2,292.0. These outstanding foreign exchange forward contracts had a net fair value liability of $13.0, of which $12.1 is included in other current assets and other noncurrent assets and $25.1 is included in other current liabilities and other noncurrent liabilities. As of September 30, 2020, we had interest rate swap contracts with notional amounts totaling $1,750.0. These outstanding interest rate swap contracts had a net fair value liability of $103.2 included in other current liabilities and other noncurrent liabilities. The counterparties to these contracts are large domestic and multinational commercial banks, and we believe the risk of nonperformance is not material.
As of September 30, 2020, our financial assets and liabilities were recorded at fair value. We have classified our financial assets and liabilities as Level 1, 2 or 3 within the fair value hierarchy. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Our Level 1 assets consist of mutual fund investments and equity securities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Our Level 2 assets consist primarily of money market funds, equity securities subject to holding period restrictions and derivative contracts. Our Level 2 liabilities consist also of derivative contracts. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. Our Level 3 liabilities consist of contingent consideration related to business acquisitions and derivative liabilities associated with other contingent payments.
Business Combinations and Contingent Consideration Obligations
On July 2, 2020, we completed the acquisition of Portola. Under the terms of the agreement, we acquired all outstanding common stock of Portola for $18.00 per share, or an aggregate of approximately $1,380.8, including the settlement of certain of Portola's outstanding equity awards but excluding shares of Portola stock held by Alexion at closing. The acquisition was funded with cash on hand. In connection with the acquisition, we also paid $196.9 to settle certain debt held by Portola that was subject to preexisting change of control provisions. The repayment of Portola's debt was funded with cash acquired from Portola. Additionally, we assumed royalty-based debt which requires repayment through tiered royalties on future net worldwide sales of ANDEXXA.
On January 28, 2020, we completed the acquisition of Achillion. Under the terms of the agreement, we acquired all outstanding common stock of Achillion for $6.30 per share, or an aggregate of $926.2, inclusive of the settlement of Achillion's outstanding equity awards. The acquisition was funded with cash on hand. The transaction includes the potential for additional consideration in the form of non-tradeable contingent value rights (CVRs), which will be paid to Achillion shareholders if certain clinical and regulatory milestones are achieved within specified periods. These include $1.00 per share for the U.S. Food and Drug Administration (FDA) approval of danicopan and $1.00 per share for the initiation of a Phase III clinical trial in ACH-5228.
 At September 30, 2020, the purchase agreements for our business combinations, including Achillion, include contingent payments totaling up to $905.6 that will become payable if and when certain development and commercial milestones are achieved. Of these milestone amounts, $670.6 of the contingent payments relate to development and regulatory milestones and $235.0 of the contingent payments relate to commercial milestones, respectively. We do not expect these amounts to have a significant impact on our liquidity in the near-term, and, during the next 12 months, we do not expect to make milestone payments associated with our prior business combinations. 
As additional future payments become probable, we will evaluate methods of funding payments, which could be made from available cash and marketable securities, cash generated from operations, or proceeds from the sale of equity securities or debt.
Asset Acquisitions and In-License Agreements
In January 2019, we entered into an agreement with Caelum, a biotechnology company that is developing CAEL101 for AL amyloidosis. Under the
66
Alexion Pharmaceuticals, Inc.
(amounts in millions, except per share amounts)
terms of the agreement, we acquired a minority equity interest in preferred stock of Caelum and an exclusive option to acquire the remaining equity in Caelum based on Phase II data, for pre-negotiated economics. We paid $30.0 in the first quarter 2019 and agreed to pay up to an additional $30.0 in contingent development milestones prior to the exercise the option to acquire the remaining equity in Caelum. These contingent payments meet the definition of a derivative liability and were initially recorded at fair value of $27.1. We allocated the total consideration of $57.1, inclusive of the fair value of the contingent payments, to the equity investment in Caelum and the option to acquire the remaining equity in Caelum based on the relative fair values of the assets. Following discussions with the FDA, Caelum changed its clinical development plan for CAEL-101 in the fourth quarter 2019. A Phase II trial for CAEL-101 subsequently commenced during the first quarter of 2020 and met its primary objectives, supporting the safety and tolerability of CAEL-101 and confirmed the dose and regimen to be adopted for the Phase III studies. In September 2020, Alexion and Caelum announced the initiation of the CARES program. This includes two parallel Phase III trials, the primary objective of these trials are to evaluate the survival benefits of CAEL-101. In December 2019, we amended the terms of the agreement with Caelum to modify the option to acquire the remaining equity in Caelum based on data from the modified Phase II/III trials. The amendment also modified the development-related milestone events associated with the initial $30.0 in contingent payments, provided for an additional $20.0 in upfront funding, which we accrued as of December 31, 2019 and paid during the first quarter 2020, as well as funding of $60.0 in exchange for an additional equity interest at fair value upon achievement of a specific development-related milestone event. The agreement with Caelum also provides for additional payments, in the event Alexion exercises the purchase option, for up to $500.0, which includes an upfront option exercise payment and potential regulatory and commercial milestone payments. During the second quarter 2020, we paid an aggregate of $15.0 of contingent payments to Caelum related to two development-based milestones and during the third quarter 2020, we paid a $15.0 contingent payment to Caelum related to another development-based milestone.
In March 2019, we entered into an agreement with Zealand which provides us with exclusive worldwide licenses, as well as development and commercial rights, for subcutaneously delivered preclinical peptide therapies directed at up to four complement pathway targets. Pursuant to the agreement, Zealand will lead joint discovery and research efforts through the preclinical stage, and Alexion will lead development efforts beginning with
the investigational new drug filing and Phase I studies. In addition to the agreement, we made an equity investment in Zealand (see Note 10, Other Investments). Under the terms of the agreement, we made an upfront payment of $40.0 for an exclusive license to the lead target and the equity investment, as well as for preclinical research services to be performed by Zealand in relation to the lead target. As of September 30, 2020, we could be required to pay up to $610.0, for the lead target, upon the achievement of specified development, regulatory and commercial milestones, as well as royalties on commercial sales. In addition, we could be required to pay up to an additional $115.0 in development and regulatory milestones if both a long-acting and short-acting product are developed with respect to the lead target. Each of the three subsequent targets can be selected for an option fee of $15.0 and has the potential for additional development, regulatory and commercial milestones, as well as royalty payments, at a reduced price to the lead target.
In September 2019, we entered into an agreement with Eidos through which Alexion obtained an exclusive license to develop and commercialize AG10 in Japan. AG10 is a small molecule designed to treat the root cause of ATTR and is currently in a Phase III study in the U.S. and Europe for ATTR-CM. In addition, we made an equity investment in Eidos (see Note 10, Other Investments). Under the terms of the agreement, we made an upfront payment of $50.0 for the exclusive license to AG10 in Japan and the equity investment. As of September 30, 2020, we could also be required to pay $30.0 upon achievement of a Japanese-based regulatory milestone as well as royalties on commercial sales.
In October 2018, we entered into a collaboration agreement with Dicerna that provides us with exclusive worldwide licenses and development and commercial rights for two preclinical RNA interference (RNAi) subcutaneously delivered molecules for complement-mediated diseases, as well as an exclusive option for other preclinical RNAi molecules for two additional targets within the complement pathway. In addition to the collaboration agreement, we made an equity investment in Dicerna. Under the terms of the agreements, we made an upfront payment of $37.0 for the exclusive licenses and the equity investment. In December 2019, we exercised our option for exclusive rights to two additional targets within the complement pathway under an existing agreement with Dicerna, which expands our existing research collaboration and license agreement with Dicerna to include a total of four targets within the complement pathway. In connection with the option exercise, we paid Dicerna $20.0, which we recorded as research and development expense in the fourth quarter 2019. As of September 30, 2020, excluding accrued milestones, we could be required to pay up
67
Alexion Pharmaceuticals, Inc.
(amounts in millions, except per share amounts)
to $604.1 for amounts due upon the achievement of specified research, development, regulatory and commercial milestones on the four licensed targets, as well as royalties on commercial sales.
In December 2017, we entered into a collaboration and license agreement with Halozyme Therapeutics, Inc. that allows us to use drug-delivery technology in the development of subcutaneous formulations for our portfolio of products for up to four targets. Under the terms of the agreement, we made an upfront payment of $40.0 for an exclusive license to two of the four potential targets and due to the early stage of the assets we are licensing, we recorded an expense for the upfront payment during the fourth quarter 2017. During the second quarter 2020, we forfeited our rights to one of the two targets we initially licensed. As of September 30, 2020, we could be required to pay up to $155.0 for the remaining licensed target upon achievement of specified development, regulatory and sales-based milestones, as well as royalties on commercial sales. Each of the two subsequent targets can be licensed for an option fee of $8.0, with contingent payments of up to $160.0 per target, subject to development, regulatory and commercial milestones, as well as royalties on commercial sales.
In connection with our prior acquisition of Syntimmune, Inc., a clinical-stage biotechnology company developing an antibody therapy targeting the FcRn, we could be required to pay up to $800.0 upon the achievement of specified development, regulatory and commercial milestones, of which $130.0 is specific to the subcutaneous formulation.
In addition, excluding accrued milestones, as of September 30, 2020, we have other license agreements under which we may be required to pay up to an additional $114.0 for currently licensed targets, if certain development, regulatory and commercial milestones are met, including up to $71.5 for the development of cerdulatinib in multiple indications pursuant to an in-licensing agreement with Astellas Pharma, Inc. which was assumed through the acquisition of Portola in the third quarter 2020. Additional amounts may be payable if we elect to acquire licenses to additional targets, as applicable, under the terms of these agreements.
We do not expect the payments associated with milestones under our asset acquisitions and licensing agreements to have a significant impact on our liquidity in the near-term. During the next 12 months, we may make milestone payments related to these arrangements of approximately $78.3, excluding milestones which were accrued as of September 30, 2020.
As additional future payments become probable, we will evaluate methods of funding payments, which could be made from available cash and marketable
securities, cash generated from operations or proceeds from the sale of equity securities or debt.
Operating and Financing Lease Liabilities
Operating and financing lease liabilities are recorded at lease commencement based on the present value of fixed, or in substance fixed, lease payments over the expected lease term. Lease liabilities are amortized over the lease term.
As of September 30, 2020, we have $275.5 of total financing and operating lease liabilities recorded on our condensed consolidated balance sheets. The total undiscounted lease commitments as of September 30, 2020 were $328.3, of which, $10.0 is payable during the remainder of 2020. We do not expect the payments associated with the maturity of lease liabilities to have a significant impact on our liquidity in the near-term.
Long-term Debt
On June 7, 2018, we entered into an Amended and Restated Credit Agreement (the Credit Agreement), with Bank of America, N.A. as Administrative Agent. The Credit Agreement amended and restated our credit agreement dated as of June 22, 2015 (the Prior Credit Agreement).
The Credit Agreement provides for a $1,000.0 revolving credit facility and a $2,612.5 term loan facility. The revolving credit facility and the term loan facility mature on June 7, 2023. Beginning with the quarter ending June 30, 2019, we are required to make payments of 5.00% of the original principal amount of the term loan facility annually, payable in equal quarterly installments.
As of September 30, 2020, we had $2,416.6 outstanding on the term loan. We had no outstanding borrowings under the revolving credit facility as of September 30, 2020. As of September 30, 2020, we had open letters of credit of $1.0 that offset our availability in the revolving credit facility.
In connection with our acquisition of Portola during the third quarter 2020, we assumed royalty-based debt relating to a royalty sales agreement Portola had entered into with HealthCare Royalty Partners (HCR) whereby HCR acquired a tiered royalty interest in future worldwide net sales of ANDEXXA. Portola received $50.0 upon closing of the agreement in February 2017 and an additional $100.0 following the U.S. regulatory approval of ANDEXXA in May 2018. Tiered royalties ranging from 4.2% to 8.5% are required to be paid to HCR based on net worldwide sales of ANDEXXA. The applicable rate decreases as worldwide net annual sales levels increase above defined thresholds. Total potential royalty payments are capped at 195% of the funding received less certain transaction expenses, or $290.6.
68
Alexion Pharmaceuticals, Inc.
(amounts in millions, except per share amounts)
As of September 30, 2020, the royalty-based debt carrying value of $185.2 includes accrued interest of $3.2, net of unamortized debt discount of $90.0. The maximum remaining royalty payments are capped at $275.2, as of September 30, 2020.
Manufacturing Obligations
We have supply agreements with Lonza relating to the manufacture of SOLIRIS, STRENSIQ, ULTOMIRIS and ANDEXXA which requires payments to Lonza at the inception of contract and upon the initiation and completion of product manufactured. On an ongoing basis, we evaluate our plans for future levels of manufacturing by Lonza, which depends upon our commercial requirements and the progress of our clinical development programs.
We have various agreements with Lonza, with remaining total non-cancellable commitments of approximately $1,432.3 through 2031. Certain commitments may be canceled only in limited circumstances. If we terminate certain supply agreements with Lonza without cause, we will be required to pay for product scheduled for manufacture under our arrangement. Under an existing arrangement with Lonza, we also pay Lonza a royalty on sales of SOLIRIS that was manufactured at Alexion Rhode Island Manufacturing Facility (ARIMF) prior to its sale and a payment with respect to sales of SOLIRIS manufactured at Lonza facilities. We also pay Lonza a royalty on the sales of ULTOMIRIS.
In addition to Lonza, we have non-cancellable commitments of approximately $78.6 through 2021 with other third party manufacturers.
Taxes
We have recorded tax on the undistributed earnings of our controlled foreign corporation (CFC) subsidiaries. To the extent CFC earnings may not be repatriated to the U.S. as a dividend distribution due to limitations imposed by law, we have not recorded the related potential withholding, foreign local, and U.S. state income taxes.

Common Stock Repurchase Program
In November 2012, our Board of Directors authorized a share repurchase program. In February
2017, our Board of Directors increased the amount that we are authorized to expend on future repurchases to $1,000.0 under our repurchase program, which superseded all prior repurchase programs. The entire amount authorized pursuant to this February 2017 Board approval has been utilized. On October 22, 2019, the Board of Directors approved a share repurchase authorization of up to $1,000.0. On July 28, 2020, the Board of Directors approved a new share repurchase authorization of up to an additional $1,500.0. The repurchase program does not have an expiration date and we are not obligated to acquire a particular number of shares. The repurchase program may be discontinued at any time at our discretion. Under the program, we repurchased 0.6 and 3.1 shares of our common stock at a cost of $73.5 and $334.6 during the three months ended September 30, 2020 and 2019, respectively. During the nine months ended September 30, 2020 and 2019, we repurchased 4.2 and 3.5 shares of our common stock at a cost of $434.3 and $383.5, respectively.
Subsequent to September 30, 2020, we repurchased 0.4 shares of common stock under our repurchase program at a cost of $45.2. As of October 27, 2020, there is a total of $2,055.9 remaining for repurchases under the repurchase program.

Cash Flows
The following summarizes our net change in cash and cash equivalents:
 Nine months ended September 30,$
 20202019Change
Net cash provided by operating activities$2,162.4 $1,567.8 $594.6 
Net cash used in investing activities(2,018.9)(46.6)(1,972.3)
Net cash used in financing activities(538.1)(679.4)141.3 
Effect of exchange rate changes on cash and restricted cash(0.5)(6.1)5.6 
Net change in cash and cash equivalents and restricted cash$(395.1)$835.7 $(1,230.8)
69
Alexion Pharmaceuticals, Inc.
(amounts in millions, except per share amounts)
Operating Activities
Cash flows provided by operations for the nine months ended September 30, 2020 was $2,162.4 compared to $1,567.8 for the nine months ended September 30, 2019. The increase in cash provided by operating activities was primarily due to cash generated from operations, including the timing of cash receipts, payments and other changes in working capital, during the nine months ended September 30, 2020 as compared to the same period in the prior year. Additionally, the same period in the prior year included upfront payments made in connection with agreements entered into with Zealand, Affibody and Eidos and a payment of a sales-based milestone to the former equity holders of Enobia Pharma Corp.
Investing Activities
Cash flows used in investing activities for the nine months ended September 30, 2020 was $2,018.9 compared to $46.6 for the nine months ended September 30, 2019. The increase in cash used in investing activities as compared to the prior year was primarily due to payments for the acquisition of Achillion and Portola, net of cash acquired, of $2,111.9. Partially offsetting these impacts were decreases in purchases of property, plant and equipment and purchases of strategic equity investments and options during the nine months ended September 30, 2020 as compared to the same period in the prior year.
Financing Activities
Cash flows used in financing activities for the nine months ended September 30, 2020 was $538.1 compared to $679.4 for the nine months ended September 30, 2019. The decrease in cash used for financing activities was primarily due to a decrease in payments on our revolving credit facility, partially offset by an increase of $50.8 in common stock repurchases and an increase of $32.5 in payments on term loan during the nine months ended September 30, 2020 as compared to the same period in the prior year.
Contractual Obligations
Other than potential contingent payments related to our acquisition of Achillion and obligations related to the acquisition of Portola, primarily consisting of $368.1 of manufacturing commitments with Lonza through 2028 and royalty-based debt assumed in connection with the acquisition, there have been no significant changes to the disclosure of payments we have committed to make under our contractual obligations as summarized in our Annual Report on Form 10-K for the twelve months ended December 31, 2019, in the section titled “Management's Discussion and Analysis of Financial Condition and Results of Operations” under the caption “Contractual Obligations.”

70

Item 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
        (amounts in millions, except
        percentages)
Interest Rate Risk
We have historically invested our cash in a variety of financial instruments, principally money market funds, bank deposits, corporate bonds, municipal bonds, commercial paper and government-related obligations which are subject to interest rate risk and could decline in value if interest rates fluctuate. Our investment portfolio has historically been comprised of marketable debt securities of highly rated financial institutions and investment-grade debt instruments, and we have guidelines to limit the term-to-maturity of our investments. During the second quarter of 2020, we liquidated all of our available-for-sale debt securities to fund the acquisition of Portola. As of September 30, 2020, our investment portfolio primarily consists of money market funds and mutual funds. Based on the type of securities we hold, we do not believe a change in interest rates would have a material impact on our financial statements. If interest rates were to increase or decrease by 1%, the fair value of our investment portfolio would increase (decrease) by an insignificant amount.
On June 7, 2018, we entered into an Amended and Restated Credit Agreement (the Credit Agreement), with Bank of America N.A. as administrative agent. The Credit Agreement amended and restated our credit agreement dated as of June 22, 2015 (the Prior Agreement). Loans under the Credit Agreement bear interest at our option, at either the base rate or a Eurodollar rate, in each case plus an applicable margin. Under the Credit Agreement, the applicable margins on base rate loans range from 0.25% to 1.00% and the applicable margins on Eurodollar loans range from 1.25% to 2.00%, in each case based on our consolidated net leverage ratio (as calculated in accordance with the Credit Agreement).
Changes in interest rates related to the Credit Agreement could have a material effect on our financial statements.
To achieve a desired mix of floating and fixed interest rates on our term loan, we entered into a number of interest rate swap agreements that qualified for and are designated as cash flow hedges. As of September 30, 2020 we had cash flow hedges with aggregate amounts of approximately 72.4% of our current outstanding term loan covering periods over the next twelve months. If interest rates were to increase or decrease by 1%, interest expense over the next year would increase or decrease by $6.1, based on the unhedged portion of our outstanding term loan as of September 30, 2020.
Foreign Exchange Market Risk
Our operations include activities in many countries outside the U.S. As a result, our financial results are impacted by factors such as changes in foreign currency exchange rates or weak economic conditions in the foreign markets where we operate. We have exposure to movements in foreign currency exchange rates, the most significant of which are the Euro, and Japanese Yen, against the U.S. dollar. We are a net receiver of many foreign currencies, and our consolidated financial results benefit from a weaker U.S. dollar and are adversely impacted by a stronger U.S. dollar relative to foreign currencies in which we sell our products.
Our monetary exposures on our balance sheet arise primarily from cash, accounts receivable, and payables denominated in foreign currencies. Approximately 39.6% and 39.2% of our net product sales were denominated in foreign currencies for the three and nine months ended September 30, 2020, and our revenues are also exposed to fluctuations in the foreign currency exchange rates over time. In certain foreign countries, we may sell in U.S. dollar, but our customers may be impacted adversely by fluctuations in foreign currency exchange rates which may also impact the timing and amount of our revenue.
Both positive and negative impacts to our international product sales from movements in foreign currency exchange rates are only partially mitigated by the natural, opposite impact that foreign currency exchange rates have on our international operating expenses. Additionally, we have operations based in Europe and accordingly, our expenses are impacted by fluctuations in the value of the Euro against the U.S. dollar.
We currently have a derivative program in place intended to achieve the following: (1) limit the foreign currency exposure of our monetary assets and liabilities on our balance sheet, using contracts with durations of up to 6 months and (2) hedge a portion of our forecasted product sales (in some currencies), including intercompany sales, and certain forecasted expenses using contracts with durations of up to 60 months. The objective of this program is to reduce the volatility of our operating results due to fluctuation of foreign exchange. This program utilizes foreign exchange forward contracts intended to reduce, not eliminate, the volatility of operating results due to fluctuations in foreign exchange rates.
As of September 30, 2020 and December 31, 2019, we held foreign exchange forward contracts with notional amounts totaling $2,292.0 and $3,078.5, respectively. As of September 30, 2020 and December 31, 2019, our outstanding foreign exchange forward contracts had a net fair value of $(13.0) and $2.8, respectively.
71

We do not use derivative financial instruments for speculative trading purposes. The counterparties to these foreign exchange forward contracts are large domestic and multinational commercial banks. We believe the risk of counterparty nonperformance is not material.
Based on our foreign currency exchange rate exposures as of September 30, 2020, a hypothetical 10% adverse fluctuation in exchange rates would decrease the fair value of our foreign exchange forward contracts that are designated as cash flow hedges by approximately $109.2. The resulting loss on these forward contracts would be offset by the gain on the underlying transactions and therefore would have minimal impact on future anticipated earnings and cash flows. Similarly, adverse fluctuations in exchange rates that would decrease the fair value of our foreign exchange forward contracts that are not designated as hedge instruments would be offset by a positive impact of the underlying monetary assets and liabilities.
Credit Risk
As a result of our foreign operations, we are exposed to changes in the general economic conditions in the countries in which we conduct business. The majority of our receivables are due from wholesale distributors, public hospitals and other government entities. We monitor the financial performance and creditworthiness of our large customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions, including the volatility associated with international economies, the COVID-19 pandemic and the relevant financial markets, and assess their possible impact on our business. Although collection of our accounts receivables from certain countries may extend beyond our standard credit terms and while we have begun to see an increase in requests for extended payment terms with certain customers as a result of the COVID-19 pandemic, we have not experienced any significant losses with respect to collection of our accounts receivable and we do not expect any such delays to have a material impact on our financial condition or results of operations.
72

Item 4.CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (Exchange Act), as of September 30, 2020. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2020, our disclosure controls and procedures were effective to provide reasonable assurance that information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure, and ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms.

Changes in Internal Control over Financial Reporting
Other than the item noted below, there has been no change in our internal control over financial reporting that occurred during the quarter ended September 30, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
In July 2020, the Company acquired Portola. Management is continuing to integrate the Portola internal controls over financial reporting with those of the Company and intends to exclude the internal controls of Portola from its annual assessment of the effectiveness of the Company’s internal control over financial reporting for 2020.
73


PART II. OTHER INFORMATION

Item 1.LEGAL PROCEEDINGS.

For a discussion of legal matters as of September 30, 2020, see Note 16, “Commitments and Contingencies,” Contingent Liabilities, within our notes to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q, which is incorporated into this item by reference.
74


Item 1A.Risk Factors.
(amounts in millions, except percentages)
You should carefully consider the following risk factors before you decide to invest in Alexion securities and our business, because the risks described below may have a material impact on our business, operating results, financial condition, and cash flows. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. If any of the following risks actually occurs, our business, financial condition and results of operations could be materially and adversely affected.
Risks Related to Revenue Concentration and Conversion
We depend on revenue from sales of our C5 complement inhibitors and, if we are unable to continue to increase revenues from sales of our C5 complement inhibitors, our business would be materially harmed and our future operating results may be adversely impacted.
Since 2007, our revenue has depended primarily on the sales of SOLIRIS, a C5 complement inhibitor with a 2-week dosing schedule. In December 2018, we obtained our first regulatory approval in the U.S. to sell ULTOMIRIS, a long-acting C5 complement inhibitor, with an 8-week dosing schedule (and we recently obtained approval in the US for a 100mg/mL formulation of ULTOMIRIS). Our C5 complement inhibitors accounted for 85.9% of our total revenues for the fiscal year ended December 31, 2019. Unless we are able to develop or acquire and commercialize new products beyond these C5 complement inhibitors, and/or materially increase sales of STRENSIQ and KANUMA (two additional currently approved products) and ANDEXXA®(another approved product that was obtained through the acquisition of Portola in July 2020), we will remain dependent on sales of SOLIRIS and ULTOMIRIS as a source of our revenue. We expect our revenues for 2020 will continue to depend on our ability to sell our C5 complement inhibitors.
    The commercial success of our C5 complement inhibitors and our ability to generate revenue depends on several factors, including: the safety and efficacy of our C5 complement inhibitors; coverage or reimbursement by government or third-party payers for our C5 complement inhibitors; pricing for our complement inhibitors; the analysis by doctors, payers and patients of the cost of our C5 complement inhibitors relative to the perceived benefits; manufacturing and uninterrupted supply; the introduction and success of competing products (including novel products and biosimilars to SOLIRIS); the size of patient populations and the number of
patients diagnosed who may be treated with our C5 complement inhibitors; the impact of legal, administrative, regulatory or legislative developments that impact the price or use of C5 complement inhibitors; and our ability to develop, obtain regulatory  approval for and commercialize our C5 complement inhibitors for new indications. Any of these or other factors may cause revenues from sales of our C5 complement inhibitors to decrease, which would harm our business results.
While SOLIRIS and ULTOMIRIS are studied for indications beyond those currently approved by regulatory authorities and ULTOMIRIS is being studied for subcutaneous administration, there is no guarantee that we can obtain regulatory approval or achieve any commercial sales of SOLIRIS or ULTOMIRIS for such other indications or for subcutaneous administration of ULTOMIRIS. Nor can we guarantee that, even if regulatory approval is obtained for such additional indications and routes of administration, physicians and patients will accept SOLIRIS or ULTOMIRIS as a treatment for such indications or means of administration, or that payers will pay for or reimburse the costs of these therapies.
If we are not able to maintain revenues from sales of SOLIRIS and ULTOMIRIS, or such revenues decrease, our operating results would be negatively impacted and our ability to fund research and development, commercialize or acquire new products would be harmed, which would limit our ability to diversify our revenue base and our stock price could be adversely affected. In addition, as a result of having our revenue concentrated in SOLIRIS and ULTOMIRIS, our future revenues and results of operations can be significantly harmed by, among other factors, the introduction of one or more biosimilar products or other competitive products that treat the same indications, adverse developments in the commercialization and sale of our C5 inhibitors or a change in reimbursement policies by payers for the C5 complement inhibitors. For example, a biosimilar has been introduced in Russia and a CD19-directed cytolytic antibody treatment and an IL-6R antibody, were both recently approved for NMOSD patients in the US and certain other jurisdictions.
We aim to facilitate the conversion of patients from SOLIRIS to ULTOMIRIS. If we are unable to achieve our conversion objectives, our business may be harmed. In addition, even if we are successful, due to the pricing of ULTOMIRIS, our revenues may decrease unless we are able to increase the number of patients using our C5 inhibitors.
ULTOMIRIS has been approved for patients with PNH and aHUS in certain jurisdictions, including in the U.S., Europe and Japan.
One of our principal business objectives is to facilitate the conversion of PNH and aHUS patients
75

from SOLIRIS to ULTOMIRIS. While clinical trials in PNH patients demonstrated that ULTOMIRIS is non-inferior to SOLIRIS at an 8 week dosing interval (compared to a 2 week dosing interval for SOLIRIS), existing patients taking SOLIRIS for PNH or aHUS and their physicians may decline to switch to ULTOMIRIS. If we are unable to facilitate conversion to ULTOMIRIS prior to the loss of intellectual property or regulatory exclusivities for SOLIRIS, our future revenues could be adversely impacted if we were to face biosimilar competition for SOLIRIS.
We have established what we believe is a globally sustainable and durable pricing strategy for ULTOMIRIS that is intended to facilitate such patient conversions (for example, in the U.S. the cost of current labeled maintenance therapy for ULTOMIRIS for adult PNH patients of average weight, represents on an annual basis an approximate 10% decrease relative to the cost of SOLIRIS). However, in the first year of PNH conversion to ULTOMIRIS, due to the loading doses required, there is an approximate 10% premium to the cost of SOLIRIS. We have also priced ULTOMIRIS for patients with aHUS in the U.S. at a cost relative to the cost of SOLIRIS for patients with aHUS in the U.S. that is approximately 30% less on an annual basis for an average adult patient on maintenance therapy (unlike PNH, the cost in the first year of aHUS conversion to ULTOMIRIS is approximately 20% less than the cost of SOLIRIS). If we achieve our goal of facilitating the conversion of patients from SOLIRIS (which accounted for approximately  $3,946.4, or 79.1%, of our revenues in 2019) to ULTOMIRIS, due to these discounts we anticipate that U.S. revenue attributable to each patient that converts from SOLIRIS to ULTOMIRIS will decrease. In addition, as a result of the decreased cost for ULTOMIRIS relative to SOLIRIS on a per patient basis, in order to maintain or increase C5 complement inhibitor revenues in the future as we succeed in converting patients from SOLIRIS to ULTOMIRIS, we must increase the total number of patients utilizing SOLIRIS, including gMG and NMOSD patients, and ULTOMIRIS.
Finally, as a result of patient conversion from SOLIRIS to ULTOMIRIS, we expect variability in our revenues in future quarters due to the extended ULTOMIRIS dosing interval and infusion timing which may result in either one or two infusions in a quarter.
Due to the decision to price ULTOMIRIS lower than SOLIRIS on an annual basis, we anticipate U.S. revenues will be unfavorably impacted by the lower annual cost per patient in maintenance years, with the impact more pronounced for aHUS due to the greater decrease in vials for aHUS ULTOMIRIS patients.
Risks Related to the COVID-19 Pandemic
Our business may be adversely affected by the ongoing COVID-19 pandemic.
Our business could be adversely affected by health epidemics in regions where we have operations, sales or other business activities, including regions where we have offices, manufacturing facilities, clinical trial sites and where our third party manufacturers, vendors and suppliers operate and where patients and potential patients are located. The outbreak of a novel strain of virus, which causes the disease called COVID-19, has evolved into a global pandemic. The ultimate impact of the COVID-19 pandemic on our business operations and financial results is highly uncertain and will depend on future developments, which cannot be accurately predicted, including the duration of the pandemic, the ultimate geographic spread of the disease, additional or modified government actions, new information that will emerge concerning the severity and impact of the coronavirus and the actions taken to address its impact, among others.
We have initiated a global Phase III study to investigate ULTOMIRIS in a subset of adults with COVID-19, who are hospitalized with severe pneumonia or acute respiratory distress syndrome (ARDS). The trial will evaluate the impact of ULTOMIRIS on survival, duration of mechanical ventilation, and duration of hospital stay compared to best supportive care. We cannot guarantee that the clinical trial will provide sufficient evidence that ULTOMIRIS is safe and effective for use as a treatment for adult COVID-19 patients hospitalized with severe pneumonia or ARDS. In addition, there can be no guarantee that the FDA or any other regulatory authority will approve ULTOMIRIS as a treatment for COVID-19.
As a result of the COVID-19 pandemic, we expect that we may experience disruptions that could severely impact our business and results of operations, including:
•Government and healthcare policies and federal, state, local or foreign regulations to address the COVID-19 pandemic may adversely affect our sales and revenue. Due to quarantines, travel restrictions, hospital policies and patient concerns regarding exposure to COVID-19, we have observed fewer patient/doctor interactions, we have also noted that the new patient productivity and initiation queue has decreased since the COVID-19 outbreak (particularly in our neurological indications) and our representatives are having fewer in-person visits with health care providers, including for infusion of our products which may affect our sales in the future. A decrease in the demand of our products could cause our cost of goods sold to increase due to expiration of inventory on hand, an increase in manufacturing
76

overhead allocated to inventory sold and other factors. Our net product sales could also be adversely impacted by the negative effects the COVID-19 pandemic has had on the global economy, which could result in (i) an increased number of patients utilizing our patient access programs to receive free drug due to loss of employer-based health insurance, or other factors impacting their ability to afford our medicines; and (ii) patients increasingly seeking Medicaid coverage for our products, which would lead to higher gross-to-net revenue reductions compared to commercial insurance providers. We are monitoring the impacts on our business of the growth in unemployment and loss of commercial insurance coverage and/or growth in Medicaid with higher discounts.
•Due to financial demands in addressing the COVID-19 pandemic, payors have requested and may continue to request extended credit terms, may extend payment dates beyond those experienced in the past, or may not be able to timely reimburse us for our products or at all, and such actions could have a material adverse impact on our cashflow from operations. Additionally, federal and state governments and foreign jurisdictions where we operate could increase tax rates to offset the economic impact and cost of addressing the COVID-19 pandemic. Any increase in such tax rates could have an adverse impact on our business.
•We believe that the COVID-19 pandemic has had, and will likely continue to have, an impact on various aspects of our clinical programs and trials. For example, our Phase I and Phase II trials for ALXN1830 had been paused due to COVID-19. Patient dosing and study monitoring may be paused, delayed or temporarily halted (and clinical trial re-start schedules may be delayed beyond the dates we anticipated) due to changes in policies at various clinical sites and federal, state, local or foreign laws, rules and regulations, including quarantines or other travel restrictions, prioritization of healthcare resources toward pandemic efforts, including diminished attention of physicians serving as our clinical trial investigators and reduced availability of site staff supporting the conduct of our clinical trials, or other reasons related to the COVID-19 pandemic. If the COVID-19 pandemic continues for an extended period of time, other aspects of our clinical trials may be adversely affected, delayed or interrupted, including, for example, site initiation, patient recruitment and enrollment, availability of
clinical trial materials, and data analysis. Some patients and clinical investigators may not be able to comply with clinical trial protocols and patients may choose to withdraw from our studies, or we may choose to or be required to pause enrollment and/or patient dosing in our ongoing clinical trials in order to preserve health resources and protect trial participants. Any such disruption could negatively impact the results generated in the trial, the development of our pipeline programs and the timing and probability of paying milestones associated with prior acquisitions and active license agreements (which may lead to litigation over milestone payments).
•We currently utilize third parties to, among other things, manufacture our products and product candidates, supply raw materials and consumables, perform quality testing and provide supply chain services. We also manufacture certain of our products and product candidates and perform various services at our manufacturing facilities. If any of these processes or services are adversely impacted by the COVID-19 outbreak, our ability to manufacture and supply our products to patients or manufacture product candidates for our clinical trials and conduct our research and development operations may be materially affected.
•The potential economic and financial impacts of the pandemic, including a deterioration in economic conditions that may negatively impact revenue and our liquidity, increase expenses and result in market capitalization declines, and disruption to our business, may result in the impairment of our long-lived and other assets, including goodwill, intangible assets and equity investments without readily determinable fair values. The impairment of significant assets could have a material impact on our deferred tax assets and liabilities. In addition, any impairment charge would have a negative impact on our financial results in the quarter that the charge is taken, and such charge may be material in amount.
•In accordance with business continuity plans and for the safety of our employees, we have directed most of our personnel to work remotely and we have generally restricted on-site staff to only those personnel and contractors who perform essential activities that must be completed on-site. Our increased reliance on personnel working from home may negatively impact productivity, or disrupt, delay, or otherwise adversely impact
77

our business. In addition, this could increase our cyber-security risk, create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could adversely impact our business operations.
•While our essential R&D employees have been able to access our laboratory space, if employees and contractors conducting such activities were exposed to or contracted COVID-19, we may be required to restrict access to our laboratory space for an extended period of time as a result. Governmental authorities may also impose restrictions limiting access to our lab space. As a result, this could delay timely completion of preclinical and other R&D activities.
•Health regulatory agencies globally may experience disruptions in their operations as a result of the COVID-19 pandemic. The FDA and other foreign regulatory agencies may have slower response times or be under-resourced to continue to authorize and monitor our clinical trials or review regulatory submissions (or authorize the use of facilities for manufacturing and related services) and, as a result, review, inspection, and other timelines may be materially delayed.
•In addition, a recession or other sustained adverse market event resulting from the spread of COVID-19 could materially and adversely affect our business, the value of our common shares and the availability of credit to operate our business and execute business development transactions. As a result, we may face difficulties raising capital through sales of our common shares, accessing credit to support our business development activities or other capital initiatives or such sales of common stock or credit may only be available on unfavorable terms.
•The trading prices for our common shares and other biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic and we expect this volatility may continue.
COVID-19, and the volatile regional and global economic conditions stemming from the pandemic, could also precipitate or aggravate the other risk factors discussed in this Quarterly Report on Form 10-Q, which could materially adversely affect our business, financial condition, results of operations, liquidity, and stock price.
Risks Related to Pricing and Reimbursement
Sales of our products depend on reimbursement by payers and these payers are subject to pressures to contain costs.
Our commercial success depends on setting a price for our products that will enable us to obtain reimbursement at anticipated levels. Our products are significantly more expensive than traditional drug treatments and almost all patients require governmental payers and/or private third-party payers to pay all or a portion of the cost of our products. There is a significant trend in the health care industry by public and private payers to contain or reduce their costs, including by taking the following steps, among others: decreasing the portion of costs payers will cover, ceasing to provide adequate payment for certain products or not covering certain products at all or requiring use of therapies that are less expensive. If payers implement any of the foregoing (or undertake similar measures) with respect to our products, it would have an adverse impact on our revenue and results of operations.
Our ability to set the price for our products varies significantly from country to country, including in those countries where pricing, coverage, reimbursement or funding of prescription drugs are subject to governmental control. We may be unable to timely or successfully negotiate coverage, pricing and reimbursement on terms that are favorable to us (or at all), or such coverage, pricing and reimbursement may differ in separate regions in the same country. In some countries, the proposed pricing for a drug must be approved before it may be lawfully marketed, which could delay market entry (or, if pricing is not approved, we may be unable to sell at all in a country where we have received regulatory approval for a product). In addition, authorities in some countries impose additional obligations, such as health technology assessments (HTAs), which assess how well a prescription drug works in relation to its cost. U.S. payers are increasingly considering new metrics, including HTAs, as the basis for reimbursement rates. If our products do not meet or surpass these metrics, these payers may not reimburse the use of our products or may reduce the rate of reimbursement for our products and as a result, revenue from such products may decrease. We have, in certain cases, voluntarily elected to reduce prices or establish price caps with payers. For example, in the past we have implemented strategic pricing decisions for STRENSIQ in the U.S. that limit annual treatment costs given weight-based dosing. In addition, in the future, we may implement further price caps on STRENSIQ or on our other products. And while we believe such price caps can provide value in the long term, they result in decreased revenue per patient and we may be unable to increase sales volume for such products in an amount sufficient to maintain revenues
78

commensurate with those prior to implementing the price cap.
In the United States, there have been, and we expect that there will continue to be, a number of federal and state proposals to implement governmental controls on pharmaceutical pricing. On July 24, 2020, the executive branch issued four executive orders intended to address the affordability and accessibility of medicines, including the “Executive Order on Lowering Drug Prices by Putting America First” that directs the US federal government to implement regulations that would require Medicare to benchmark its payments for Medicare Part B and Part D products to a set of "Most Favored Nations." The implementing regulations in connection with these executive orders are pending and, until issued, we are not able to determine the potential impact on our US business and results of operations in the future. Certain states have also proposed measures that are designed to control the costs of pharmaceuticals that they reimburse. If the U.S. (through the federal or state governments), which accounted for approximately  25%  of our revenue in 2019, were to move to a pricing system based on a "Most Favored Nations" model, negotiated prices with Medicare (that may apply to private payers as well) or to an international price index (or similar model) that were to apply to our products, we expect that our revenues for sales in the U.S. would be lower, and potentially materially lower than if the current pricing program remained in place.
Other countries, including many European countries and Canada, have established pricing and reimbursement policies that contain costs by referencing the price of the same or similar products in other countries. In these instances, if coverage or the level of reimbursement is reduced, limited or eliminated in one or more countries, we may be unable to obtain or maintain anticipated pricing or reimbursement in other countries or in new markets. This may create the opportunity for third-party cross-border trade or influence our decision whether to sell a product in one or more countries, thus adversely affecting our geographic expansion plans and revenues. See Note 16, Commitments and Contingencies, to the condensed consolidated financial statements for information about our lawsuit against the Patented Medicine Prices Review Board (PMPRB) to establish that Alexion did not excessively price SOLIRIS in Canada, which uses reference pricing.
Due to the cost of our therapies, any potential increase in the number of patients receiving our products (for example, we expect there may be increases in sales of SOLIRIS for patients with gMG and NMOSD as we continue the launch for those indications), may cause third-party payers to modify,
limit or eliminate coverage or reimbursement for our products because they may require an allocation of a greater percentage of the potential financial resources of any public or private payer for our products.
Further, health insurance programs may utilize coverage incentives and obstacles to discourage or prevent beneficiaries from using higher priced products such as ours, including:
•establishing formularies under which only selected drugs are covered (which may exclude one or more of our products);
•utilizing variable co-payments that make drugs that are not preferred by the payer more expensive for patients; and
•utilizing management controls, such as requirements for prior authorization or failure first on another treatment.
In countries where patients have access to insurance, their insurance co-payment amounts or other benefit limits may represent a barrier to obtaining or continuing use of our products or adoption of new treatment options, such as ULTOMIRIS and ANDEXXA. The imposition or continuation of the use of these types of limits or barriers by insurers or the imposition of similar limitations or barriers in the future may have an adverse impact on our revenue and results of operations. In some cases, we have financially supported non-profit organizations that assist patients in accessing treatments. Such organizations assist patients whose insurance coverage imposes high co-payment amounts or other expensive financial obligations. Such organizations’ ability to provide assistance to patients is dependent on funding from external sources, and we cannot guarantee that such funding will be provided at adequate levels, if at all. We have also provided our products without charge to patients who have no or limited insurance coverage for drugs. We are not able to predict the financial impact of the support we may provide for these and other charitable purposes; however, substantial support could have a material adverse effect on our profitability in the future.
As third-party payers attempt to contain health care costs, they are demanding price discounts or rebates and limiting both the types and variety of drugs that they may cover and the amounts that they will pay for drugs. As a result, they may not cover or provide adequate payment to patients for our products or they may demand discounts or rebates from us, which may be material.
In 2019, four customers accounted for 56.4% of our total revenues. If any one or more of these customers (or other customer who accounts for a significant percentage of revenue or accounts receivable) were to require significant discounts or
79

rebates, or were to discontinue purchasing our products (due to cost or otherwise), our results of operations may be materially and adversely impacted.
Risks Related to Intellectual Property
If we cannot obtain new patents, maintain our existing patents and protect the confidentiality and proprietary nature of our trade secrets and other intellectual property, our business and competitive position may be harmed.
Our success depends in part on our ability to obtain and maintain patent and regulatory protections for our products and investigational compounds, to preserve our trade secrets and other proprietary rights and to prevent third parties from infringing on our rights.
We have procured patent rights, through both ownership and license, that cover our products and investigational compounds, and will likely apply for additional patent protections in the future. However, our patent applications may not result in the issuance of patents in the U.S. or other countries. In addition, a patent may be issued in one country, but a counterpart patent may not be issued in another country. For example, the European Patent Office in September 2019 rejected a patent application relating to the composition of matter for SOLIRIS; related patents were granted in the U.S. and Japan.
Even if a patent is issued, that is not conclusive as to its inventorship, scope, validity or enforceability and therefore that patent may not afford adequate (or any) protection for our products. On the basis of such inconclusiveness, third parties may challenge our patents, have done so in the past and, in some cases, have been successful in such challenges. For example, on January 21, 2019, the Opposition Division of the European Patent Office determined, following multi-party opposition proceedings, to revoke one of our European patents that relates to the formulation of SOLIRIS. Further, on August 30, 2019, the U.S. Patent and Trademark Office instituted inter partes review (IPR) of three of our patents that relate to SOLIRIS. In May 2020, we entered into a Confidential Settlement and License Agreement with Amgen to settle the three IPRs (Settlement Agreement). Pursuant to the Settlement Agreement, Alexion and Amgen have terminated each of the pending IPRs and, effective March 1, 2025 (or an earlier date in certain circumstances), Alexion grants to Amgen (and its affiliates and certain partners) a non-exclusive, royalty-free, license under U.S. patents and patent applications related to eculizumab and various aspects of the eculizumab product that Alexion currently markets and sells under the tradename SOLIRIS. We may enter into similar agreements in the future to grant or clarify certain rights of third-parties in connection with our intellectual property rights in SOLIRIS or other
products or product candidates. In addition, under the settlement agreement with Amgen, if certain circumstances are satisfied, Amgen may have the right to market and sell an eculizumab product in the US prior to March 2025.
If any of our patents are narrowed, invalidated, revoked or become unenforceable, competitors may develop and market products similar to ours that do not conflict with or infringe our patents rights, which could have a material adverse effect on our financial condition. Even if we obtain and maintain patents, our business may be significantly harmed if the patents are not broad enough to protect our products from copycat products. In addition, we may in the future enter into agreements similar to the agreement with Amgen that provides certain intellectual property rights to our marketed products or products in our pipeline.
We may finance or collaborate in research and development projects conducted by third parties, including government organizations, hospitals, universities or other educational or research institutions, or other for-profit companies. Such third parties may be unwilling to grant us certain rights to technology or products developed through such projects. Disputes may also arise as to the rights to technology or products developed in collaboration with such third parties.
Significant legal questions exist concerning the extent and scope of patent protection for biopharmaceutical products and processes in the U.S. and elsewhere. Accordingly, there is no certainty that patent applications owned or licensed by us will issue as patents, or that our issued patents will afford meaningful protection against competitors. Once issued, patents are subject to challenge through both administrative and judicial proceedings in the U.S. and other countries. Such proceedings include re-examinations, inter partes reviews, post-grant reviews and interference proceedings before the U.S. Patent and Trademark Office, as well as opposition proceedings before the European Patent Office and other non-U.S. patent offices. Certain countries have laws that provide stronger bases for challenging third party patent rights than are available to challenge patents in other countries. Therefore, we may be able to defend our patents against a third-party claim in one country but counterpart patents may be invalidated in other countries and we may be able to invalidate a third-party patent in one country but not invalidate its counterpart patents in other countries. Litigation may be required to enforce, defend or obtain our patent and other intellectual property rights. Any administrative proceeding or litigation could require a significant commitment of our resources and, depending on outcome, could adversely affect the
80

scope, validity or enforceability of certain of our patent or other proprietary rights.
Some of the sensitive technology, techniques and proprietary compounds used in our business are protected as trade secrets. However, we may also rely on collaboration with, or discuss the potential for collaboration with, suppliers, outside scientists and other biopharmaceutical companies. Collaboration and discussion of potential collaboration or inadvertent disclosure of a trade secret present a strong risk of exposing our trade secrets. If our trade secrets were exposed, we may lose the protection and potential exclusive rights afforded by trade secret law, and such exposure may likely help our competitors and allow them to access technology without restriction and adversely affect our business prospects.
If we are found to be infringing third party patents, we may be forced to pay damages to the patent owner and/or obtain a license to continue the manufacture, sale or development of our products. If we cannot obtain a license, we may be prevented from the manufacture, sale or development of our products or product candidates, which may adversely affect our business.
Parts of our technology, techniques, proprietary compounds and potential product candidates, including those which are or may be in-licensed or developed in collaboration with third parties, may be found to infringe patents owned by or granted to others. We have, and may in the future, receive notices claiming our products infringe third party patents and third parties have and may in the future file civil lawsuits against us claiming infringement of their intellectual property rights. Chugai Pharmaceutical Co., Ltd. filed suits in the U.S. and Japan alleging that ULTOMIRIS infringes patents held by Chugai. See Note 16, Commitments and Contingencies to the footnotes to the condensed consolidated financial statements. Additional third parties may claim that the manufacture, use or sale of our products or product candidates infringes patents owned or granted to such third parties. We are aware of patents owned by third parties that might be claimed by such third parties to be infringed by the development and commercialization of our products or investigational compounds. In respect to some of these patents, we have invalidated patents or obtained licenses, or expect to obtain licenses. However, with regard to other patents, we have determined in our judgment that:
•our products and investigational compounds do not infringe the patents;
•the patents are not valid or enforceable; and/or
•we have identified and are testing various alternatives that should not infringe the patents and which should permit continued development and commercialization of our products and investigational compounds.
Any holder of these patents or other patents covering similar technology could sue us for damages, which may be material in amount, and seek to prevent us from manufacturing, selling or developing our products (and we may be, in certain cases, prevented from initiating product launches in certain jurisdictions or required to withdraw the product from the market after it has been launched). Intellectual property disputes, such as those initiated by Chugai, can be costly and time consuming to defend and there is no guarantee that we would prevail in such lawsuit. If we cannot successfully defend against any infringement claims, we may seek to invalidate the patent or seek a license to the technology prior to or during legal actions in order to reduce the risks in connection with the product launches (or at a later time after product introduction) and to reduce further costs and the risk of a court determination that our technology, techniques, proprietary compounds or potential product candidates infringe the third party’s patents. A required license may be costly or may not be available on acceptable terms, if at all. A costly license, or inability to obtain a necessary license, could have a material adverse effect on our business.
In some instances, we believe we may prevail in a patent infringement action. There can, however, be no assurance that the court will agree with our position or that it will decide any infringement case in our favor. Nor can we be certain, if we do not prevail in litigation, that we may be able to obtain a license to any third-party patent on commercially reasonable terms (or at all); successfully develop non-infringing alternatives on a timely basis (or at all); or license alternative non-infringing technology, if any exists, on commercially reasonable terms (or at all). Any impediment to our ability to manufacture, use or sell approved forms of our products or our product candidates could have a material adverse effect on our business and prospects.
It is possible that we could lose market exclusivity for a product earlier than expected, which may harm our competitive position.
In our industry, much of an innovative product’s commercial value is realized while it has market exclusivity.
Market exclusivity for our products depends in large part on patent rights and certain regulatory forms of protection. As noted above, patent protection can be uncertain as to the validity, scope and enforceability of many issued patents. Absent relevant patent protection for a product, once regulatory exclusivity periods expire, biosimilar or generic
81

versions of the product can be approved and marketed. For example, in 2019, a SOLIRIS biosimilar was approved in Russia for the treatment of patients with PNH and aHUS. We also believe that the manufacturer of a SOLIRIS biosimilar has commenced the process to obtain regulatory approval to market and sell a SOLIRIS biosimilar in Brazil and Turkey and, if approved, this biosimilar may compete with Soliris in Brazil and Turkey.
The market exclusivity of our products may be impacted by competitive products that are either innovative, biosimilar or generic copies. In our industry, the risk of biosimilar or generic challenges has been increasing. U.S. law includes an approval pathway for biosimilar versions of innovative biological products. Under the pathway, the FDA may approve products that are similar to (but not generic copies of) innovative  biologics (SOLIRIS, ULTOMIRIS and ANDEXXA are each innovative biologics) on the basis of less extensive data than is required for a full biologic license application (and there are similar pathways for generic copies of small molecule therapies (the Factor D therapies acquired in connection with the Achillion transaction are, for example, small molecules)). The law provides a mechanism to challenge the patents that protect an innovator’s products. Such litigation may begin as early as four years after the innovative biological product is first approved by the FDA. Pathways for biosimilar products also exist in many other markets, including Europe, Japan and Russia. Other companies are developing and advancing SOLIRIS biosimilar programs, including conducting clinical trials. Competition, including from biosimilars approved for marketing, would likely result in a decrease in volume of sales of our products, as well as a decrease in prices and lower margins for our products. In addition, approval of a biosimilar that is a substitute for one of our products may increase the risk of accelerated market penetration by that biosimilar. Further, if patients or healthcare providers do not believe that ULTOMIRIS provides a compelling profile for patient conversion from SOLIRIS, a SOLIRIS biosimilar may not only be expected to have a material and negative impact on our SOLIRIS revenues and margins (which accounted for a significant percentage of our revenue in 2019), it may also have a material impact on ULTOMIRIS revenue and margins and the ability of ULTOMIRIS to gain market acceptance.
Our other products and product candidates in development and trials are also at risk from biosimilars and generic drugs. Other than SOLIRIS for the treatment of gMG and NMOSD and SOLIRIS and ULTOMIRIS as a treatment for PNH and aHUS, each of our products is currently the only approved drug for the disease(s) the product treats. If a competitive product is approved for sale, including a biosimilar or generic product or other therapy (such as the two non-
C5 therapies approved by certain regulatory authorities, including the FDA, as a treatment for NMOSD), our market share and our revenues could decline, particularly if the competitive product is perceived to be more effective or is less expensive than our product.
Risks Related to Our Products and Product Candidates
Our future commercial success depends on gaining regulatory approval for new products and obtaining approvals for existing products for new indications.
We invest significant amounts in acquiring new products and technologies and advancing our existing product candidates and technologies. Our success and revenue growth and diversification will depend in part on our identification, acquisition (including licenses from or collaborations with third parties), development and commercialization of new products and technologies, and approval of additional indications for our existing products and products under development. Product development is very expensive, takes significant time and involves a high degree of risk. Only a small number of research and development programs result in the commercialization of a product. For example, we have recently terminated our agreement to co-develop ABY-039 with Affibody and determined not to exercise the co-development option agreement with Stealth BioTherapeutics Corp., in each case due to results of clinical trials. In addition, our recent business development activities have focused on new technologies with which we have very limited experience, including a Factor Xa reversal agent and antibody therapeutics targeting the neonatal Fc receptor, which may make the development, approval and commercialization of such potential products challenging for us.
Our ability to maintain or grow and diversify revenues may be adversely affected if we are delayed or unable to successfully develop the products in our pipeline, if we are unable to gain approval for SOLIRIS and ULTOMIRIS for additional indications, for new routes of administration (subcutaneous delivery) and in new jurisdictions, obtain marketing approval for STRENSIQ, KANUMA and ANDEXXA in additional territories, obtain approval for different dosing regimens (or expansion of indications included in the product label) or acquire or license products and technologies from third parties.
Even if we are successful in developing new products or addressing new indications, we cannot market any of those products unless and until we obtain all required regulatory approvals in each jurisdiction where we plan to sell these therapies. We must also maintain all such regulatory approvals for the period of time that we sell the product in each such jurisdiction. Our failure to obtain, or we have a delay in obtaining, approval or we fail to maintain
82

approvals once obtained, will prevent us from selling products and generating revenues for those products in such jurisdiction where we do not hold such approvals.
Our products and product candidates target diseases and conditions with small patient populations and we may not be effective at identifying patients.
The therapies that we have developed, acquired and that are in our product pipeline and in preclinical development target diseases and conditions that have small patient populations that have not been definitively determined. Further, in many cases there are either no or limited diagnostic tools for the indications we treat or may treat in the future. The lack of diagnostic tools, coupled with the fact that there is frequently limited awareness among certain health care providers concerning the rare diseases we treat, often means that a proper diagnosis can, and frequently does, take years to identify (or an appropriate diagnosis may never be made for certain patients). As a result, we may not be able to grow our revenues (even as we introduce new products or as existing products are approved for additional indications). There can be no guarantee that any of our programs will be effective at identifying patients that will benefit from our therapies, and even if we can identify patients that our therapies can help, the number of patients that our therapies treat may turn out to be lower than we expect, they may not be otherwise amenable to treatment with our products, or new patients may become increasingly difficult to identify, all of which may adversely affect our ability to grow and diversify revenue and adversely affect our results of operations and our business. In addition, even in instances where we do add patients, the number may be less than the number of patients that discontinue use of the applicable product in a given period resulting in a net loss of patients and potentially decreased revenue.
We may not be able to gain or maintain market acceptance of our products among the medical community, patients or payers, which could prevent us from maintaining profitability or growth.
Our products may not gain or maintain market acceptance among physicians, patients, payers and others. Although we have received regulatory approval for certain of our products in certain territories (and may receive approvals for additional products or in additional jurisdictions), such approvals do not guarantee future revenue. Physicians’ willingness to prescribe, and patients’ willingness to accept, our products, depends on many factors, including:
•prevalence and severity of adverse side effects in both clinical trials and commercial use;
•the timing of the market introduction of competitive drugs, biosimilars and generics;
•perceived safety of our products
•demonstrated clinical safety and efficacy compared to other drugs;
•perceived benefits relative to cost and/ or evaluations in HTAs (or similar assessments);
•pricing and availability of reimbursement from third-party payers, including governmental entities;
•convenience and ease of administration;
•effectiveness of our marketing strategy;
•publicity concerning our products and our other product candidates (and those of competitive products); and
•availability of alternative treatments.
The likelihood of physicians to prescribe SOLIRIS and ULTOMIRIS for patients with aHUS may also depend on how quickly SOLIRIS or ULTOMIRIS can be delivered to the hospital or clinic and our distribution methods may not be sufficient to satisfy this need. In addition, while SOLIRIS as a treatment for aHUS is recommended by some regulatory authorities to be used for the duration of a patient’s lifetime, we are aware that some healthcare providers prescribe SOLIRIS for aHUS for a shorter time period and, in some cases, may prescribe SOLIRIS for aHUS in emergency or acute situations only (and the same may occur in connection with the use of ULTOMIRIS for aHUS). Decisions such as this by aHUS patients and healthcare providers to use our products for a period that is less than the remaining lifetime of the patient or in only acute circumstances may cause our SOLIRIS or ULTOMIRIS revenues, and revenues for our other products, to fluctuate and past sales of our products may not be indicative of future sales for such products.
If our products fail to achieve or maintain market acceptance among the medical community or patients in a particular country, we may not be able to market and sell our products successfully in such country, which may limit our ability to generate revenue and could harm our overall business.
If our products harm patients, or are perceived to harm patients even when such harm is unrelated to our products, our regulatory approvals could be revoked or otherwise negatively impacted and we could be subject to costly and damaging product liability claims.
The testing, manufacturing, marketing and sale of biologics and small molecule therapies for use in humans may cause harm to patients, which exposes us to product liability risks and regulatory penalties.
83

Our products and our product candidates generally treat patients with rare diseases and, as a result, we generally are able to test our products in only a small number of patients. As more patients use our products, including more children and adolescents, new risks and side effects may be discovered, the rate of known risks or side effects may increase, and risks previously viewed as less significant could be determined to be significant.
Under pharmacovigilance guidelines, we are required to timely report any adverse events that any patient using our products experiences, as well as any clinical evaluations of outcomes in the post-marketing setting. This information is required to be reported to appropriate regulatory agencies in accordance with relevant regulations and, as a result, any potential adverse events will be promptly brought to the attention of regulators that may likely require prompt remedial action (and any failure to report these adverse events or report such events in a timely manner may result in penalties being imposed on Alexion by regulators). In the event any new risks or adverse effects are discovered as patients are treated for approved indications, or as our products are studied in or used by patients for other indications, regulatory authorities may delay or revoke their approvals or require changes to labeling or reformulation of the products (or take other actions that may adversely impact sales of such products).
If previously unknown side effects are discovered or if there is an increase in negative publicity regarding known side effects of any of our products, it could significantly reduce demand for the product, harm our reputation, result in product withdrawals, recalls, delays or revocations of regulatory approvals or require us to take actions that could negatively affect sales and operating results, including conducting additional clinical trials and safety studies, making changes in labeling, reformulating our products or making changes and obtaining new approvals for our and our suppliers’ manufacturing facilities. Further, any investigation into the circumstances surrounding an adverse event may be costly and time consuming (even if it is ultimately  determined that the adverse event is not the result of the use of our product).
There are also risks associated with our products; for example, use of C5 Inhibitors, such as SOLIRIS and ULTOMIRIS, is associated with an increased risk for certain types of infection, including meningococcal infection. In certain cases, a physician may not have the opportunity to timely vaccinate a patient in the event of an acute emergency episode, such as in a patient presenting with aHUS, which could result in the patient using SOLIRIS or ULTOMIRIS experiencing a life-threatening meningococcal infection (and even in certain cases in
which a vaccination can be delivered to the patient, it may not, eliminate all risk of meningococcal infection). In addition, ANDEXXA has been associated with thrombolic risks, ischemic risks, cardiac arrest and sudden death. Patients using our products and product candidates have died or suffered potentially life-threatening conditions either during or after ending their treatments, and these include patients who have died while participating in a clinical trial. In addition, many patients who use our products are already very ill and may suffer adverse events, including death, for reasons that may or may not be related to our products. We may be sued by patients who are harmed during the course of using our products, whether as a prescribed therapy, during a clinical trial, during an investigator-initiated study, or otherwise. Any such product liability lawsuit or injury claim, which could include class actions, could harm our reputation among patients, physicians, payers and others and require us to pay substantial amounts of money to injured patients, and even if successfully defended, could have a material adverse effect on our business, financial condition or results of operations due to the expense of defending any such claim. While we do have product liability insurance, it may not cover all potential types of liabilities or may not cover certain liabilities completely. Moreover, we may not be able to maintain our insurance on acceptable terms, or at all.
We anticipate that we will face increased competition from companies that will enter into the markets we currently serve and as our product pipeline expands into markets that are currently served by other companies.
We expect that the business environment in which we operate will become increasingly competitive. Currently, certain of our products are the only approved therapies for certain indications they treat. For example, SOLIRIS and ULTOMIRIS are the only approved treatments for PNH and aHUS in the U.S., Europe and Japan. In the future, we expect that SOLIRIS and ULTOMIRIS may compete with new drugs and biosimilars currently in development. Several companies are developing other therapies to treat PNH, aHUS, gMG and NMOSD, and other pharmaceutical companies have publicly stated that they are developing and intend to commercialize a SOLIRIS biosimilar. For example, the FDA and certain other foreign regulatory authorities recently approved a CD19-directed cytolytic antibody and an IL-6R antibody therapy indicated for the treatment of NMOSD in adult patients who are anti-aquaporin-4 antibody positive. The introduction of these and other competitive products may negatively impact our business, including our revenue and profitability. In addition, following the introduction of a SOLIRIS biosimilar in 2019 in Russia for the treatment of PNH and aHUS, we experienced a decrease in revenue from sales of SOLIRIS and expect that Russia will
84

account for a minor portion, if any, of future SOLIRIS revenue as a result of this competitive product. We also believe that the manufacturer of a SOLIRIS biosimilar has commenced the process to obtain regulatory approval to market and sell a SOLIRIS biosimilar in Brazil and Turkey and, if approved, this biosimilar may compete with Soliris in Brazil and Turkey and, like Russia, have an adverse impact on SOLIRIS revenues in Brazil and Turkey. STRENSIQ, KANUMA and ANDEXXA may also experience competition in the future. We are also aware of companies that have initiated or are planning to initiate studies for diseases and conditions that we are also targeting with our product pipeline. Our revenues could be negatively affected if patients or potential patients enroll in our clinical trials or clinical trials of other companies with respect to diseases and conditions that we also target with approved therapies.
Some of our competitors and future competitors may have significantly greater financial, technical and marketing resources than us and may commercialize competitive products that are cheaper, more effective, safer, have less frequent dosing schedules, or are easier and quicker to administer than our products. Our current and future competitors may develop products that are more broadly accepted or may receive patent protection that dominates, blocks or adversely affects our product development or business. These competitive products, including any biosimilars approved under alternative regulatory pathways (or generics that may be approved that compete with our small molecule therapies), may significantly reduce both the price that we receive for our marketed products and the volume of products that we sell, which may negatively impact our revenues and profitability. Given that a significant portion of our 2019 revenue was attributable to SOLIRIS, one or more competitive novel products or biosimilars could have a significant impact on our entire business.
In addition, we experience competition in drug development from universities and other research institutions, and pharmaceutical companies compete with us to attract universities and academic research institutions as drug development partners, including for licensing their proprietary technology. If our competitors successfully enter into such arrangements with academic institutions, we may be precluded from pursuing those unique opportunities and may not be able to find equivalent opportunities elsewhere.
If a company announces successful clinical trial results for a product that may be competitive with one of our products or product candidates, receives marketing approval of a competitive product, or gets to the market before we do with a competitive
product, our business may be harmed or our stock price may decline.
Risks Related to Business Operations
We rely on a limited number of facilities to produce our products and manufacturing issues at our facilities or the facilities of our third party service providers could cause product shortages, stop or delay commercialization of our products, disrupt or delay our clinical trials or regulatory approvals, and adversely affect our business.
The majority of our products and product candidates are biologics and the production of such biologic therapeutics that meet all product specification and regulatory requirements is particularly complex. Even slight deviations at any point in the production process may lead to production failures, product recalls and regulatory actions. For example, in 2013 and 2014 we undertook a voluntary recall of SOLIRIS due to the presence of visible particles in a limited number of vials. In addition, because the production process involves the use of materials that are derived from biological sources, the process can be affected by contaminants that could impact those biological micro-organisms. These manufacturing challenges are coupled with the fact that we have limited experience manufacturing commercial quantities of certain of our products (so we or our third party manufacturers may have limited previous experience resolving any issues in connection with the manufacture of certain of our products and any issues may take significant time to remediate or we may be unable to solve any manufacturing problems).  In addition, with our acquisition of Achillion, we also have small molecules in clinical trials and we are planning future clinical trials in new indications and we expect that manufacture of these therapies and compliance with cGMP will pose similar challenges and we have limited experience manufacturing small molecules for clinical trials and for commercial sales.
If we and/or our third party manufacturers and suppliers fail to meet the highly technical requirements/specifications of manufacturing our biologic and small molecule products and our strict quality and control specifications, we (or they) may be unable to manufacture or supply our products. We depend on our third party manufacturers to perform effectively on a timely basis and to comply with regulatory requirements and meet our product specifications. For example, we rely on Lonza owned and operated facilities for the production of a significant portion of our products, including ANDEXXA which we recently acquired, and Lonza has undertaken the construction and operation of new facilities to meet demand for certain of our products (including a new facility that is being qualified for manufacturing in New Hampshire) and these facilities
85

must meet our production requirements and new facilities must be qualified by regulatory authorities before product can be sold. Our failure or the failure of our third-party manufacturers (including the Lonza facility in New Hampshire) to produce sufficient quantities of our products and product candidates or to meet our specifications and quality standards or those standards imposed by regulatory authorities could result in lost revenue, diminish our profitability, delay the development of our product candidates, delay regulatory approval, result in the rejection of our product candidates or result in supply shortages for our patients, which may lead to lawsuits, harm to our reputation or could accelerate introduction of competing products to the market. For example, we experienced unexpected chemistry, manufacturing and control (or CMC) issues with our ALXN 1830 program that resulted in a delay in the clinical trial timeline for that program. We may experience similar CMC issues in the future that may impact marketed products or other clinical trials.
If we underestimate demand for ULTOMIRIS, SOLIRIS, ANDEXXA or any of our products, or experience product interruptions at Alexion’s internal manufacturing facilities or a facility of a third party provider, including as a result of risks and uncertainties described in this Quarterly Report on Form 10-Q, we may not be able to increase our revenues and alternative therapies may gain greater market acceptance.
We also face external factors, many of which are beyond our control, that could cause production interruptions at our facilities or at the facilities of our third party providers, including natural disasters, public health crises (such as COVID-19), labor disputes, acts of terrorism or war.
The risks to our business of any manufacturing stops or interruptions (whether the result of internal or external factors of the nature identified above) are amplified because we rely on a limited number of facilities to produce our products and product candidates. Further, we expect that we will continue to rely on a very limited number of manufacturing facilities in the future for all of our products, including our complement inhibitors. Although we have business continuity plans, including with respect to inventory, to reduce the potential for manufacturing disruptions or delays and reduce the severity of a disruptive event, there is no guarantee that these plans will be adequate, which could adversely affect our business and operations.
We and our third party providers are required to maintain compliance with cGMP and other stringent operation and manufacturing requirements and are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm such compliance. Governmental authorities will generally
not permit products manufactured at a facility that is not registered by the applicable government agency to enter into the country and such products may be returned for failure to comply with such regulation, which may decrease or delay sales and result in the loss of inventory. Any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging or storage of our products as a result of a failure of our facilities or the facilities or operations of third parties to pass any regulatory agency inspection or comply with ongoing operating regulations could significantly impair our ability to supply our products and product candidates. Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.
Our efforts to bring more of our manufacturing operations under our control present additional risks. We have made significant investments in biologics manufacturing facilities, warehousing, fill-finish and other facilities at our sites in Athlone and Dublin, Ireland and at dedicated sites owned by third parties. We have commenced manufacturing operations at certain of these sites prior to receiving regulatory approval and we have $117.2 of product produced at such sites in inventory as of September 30, 2020. Despite the significant investment we have made in these facilities and operations, we cannot guarantee that we will be able to successfully and timely complete the appropriate validation processes or obtain the necessary regulatory approvals for these and other facilities, that we will be able to perform the intended manufacturing and supply chain services at these facilities for commercial or clinical use or that we will be able to use the product manufactured at these sites. Prior to such time, we may continue to rely on third parties for these services.
If our products are subject to any manufacturing issues, we may be unable to timely identify alternative manufacturers, and if we are able to timely identify alternative manufacturers, such alternative manufactures may not be able to satisfy our requirements. No guarantee can be made that regulators will approve additional third party providers in a timely manner or at all, or that any third party providers will be able to perform manufacturing or related services for sufficient product volumes for any country or territory. Further, due to the nature of the current market for third-party commercial manufacturing, many arrangements require substantial penalty payments by the customer for failure to use the manufacturing capacity for which it contracted. The payment of a substantial penalty could harm our financial condition and may restrict our ability to transition to internal manufacturing or manufacturing by other third parties. In addition, the terms and conditions to engage an additional third-party manufacturer may not be as favorable to us as
86

our current arrangements and may likely reduce the profit on the sales of any products to which they relate.
Any adverse developments affecting our manufacturing operations or the operations of our third-party providers could result in a product shortage of clinical or commercial requirements, withdrawal of our product candidates or any approved products, shipment delays, lot failures or recalls. We may also have to write-off inventory and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Each of these could have an adverse material impact on our business individually or in the aggregate.
We rely on a limited number of providers for our raw materials and supply chain services, which could result in our being unable to continue to successfully commercialize our products and our product candidates (if approved) and to advance our clinical pipeline.
Certain of the raw materials required in the manufacture and the formulation of our products are derived from biological sources. Such raw materials are difficult to procure and may be subject to contamination or recall. Access to and supply of sufficient quantities of raw materials which meet the technical specifications for the production process is challenging, and often limited to single-source suppliers. If a raw material manufacturer were unable to supply such materials, our business may be impacted because we rely on one or a limited number of such manufacturers for certain materials for our products. Finding an alternative supplier could take a significant amount of time and involve significant expense due to the nature of the products and the need to obtain regulatory approvals. The failure of these single-source suppliers to supply adequate quantities of raw materials for the production process in a timely manner, or at all, may impact our ability to produce sufficient quantities of our products for clinical or commercial requirements. A material shortage, delay, contamination, recall, or restriction on the use of certain biologically derived substances or any raw material used in the manufacture of our products could adversely impact or disrupt manufacturing and materially limit our ability to generate revenues.
In addition, KANUMA is a transgenic product and the facilities on which we rely to produce raw material for KANUMA are the only animal facilities in the world that produce the necessary egg whites from transgenic chickens. Natural disasters, disease, such as exotic Newcastle disease or avian influenza, or other catastrophic events could have a significant impact on the supply of unpurified KANUMA, or destroy our animal operations altogether. If our animal
operations are disrupted, it may be extremely difficult to set up another animal facility to supply the unpurified KANUMA.
We also depend on a very limited number of third party providers for supply chain services with respect to our clinical and commercial product requirements, including product filling, finishing, packaging and labeling.
Our third-party raw material providers and supply chain service providers operate as independent entities and we do not exercise control over any such third-party provider’s operations or their compliance with our internal or external specifications or the rules and regulations of regulatory agencies. Any contractual remedies we may have under agreements with these parties may not protect us from the harm suffered by our business or our patients if they fail to provide material or perform services that meet our specifications. Due to the highly specialized nature of the services performed by these third parties, particularly the supply of raw materials and other drug product, as well as the delivery and supply chain operations regarding our products, we do not believe that we could quickly find replacement suppliers or service providers and, even if we were able to identify additional third parties, the terms of any such arrangement may not be favorable to us. In either of these cases, our revenue, results of operations, business and reputation may be harmed and we may not be able to provide the therapies that our patients require.
The success of our business may also depend on the security of our products while in the supply chain for delivery to patients, which, as noted above, is dependent on third-party providers. For example, if our products are not fully and adequately secured from unauthorized access by third parties, any of our products may be tampered with or contaminated. If our products were exposed to any tampering or contamination, or if they are not transported in accordance with the required specifications, our patients may be harmed through use of our products, and such harm may be severe. In addition, if the supply chain is not secure (or our distributors do not exercise control over our products while in their possession), we are also at risk for our products being diverted to patients other than those who are the intended recipient or to patients who do not have a prescription to receive our therapies (or it may be used for treatment by physicians who have not completed the necessary REMs protocols in order to treat patients) or it may be sold by distributors, channels or other entities that are not authorized by Alexion to sell our products. In addition, an unauthorized distributor may not properly store or ship our products, thereby exposing patients to potential harm from use of the product that was not handled in
87

accordance with our standards. If any of the foregoing were to happen, we could be subject to costly litigation, significant monetary penalties, harm to our reputation and investigation by regulatory authorities (and potentially subject to regulatory action, including recall, product withdrawals, suspensions and monetary penalties).
The sale and use of counterfeit versions of our products could result in significant harm to patients, reduced sales of our products and harm to our reputation.
We are aware that counterfeit versions of our products have been sold by entities that are not affiliated with Alexion using product packaging suggesting that the product was manufactured by Alexion. If unauthorized third parties illegally distribute and sell counterfeit versions of our products, those products may not meet our very stringent product specifications (or the manufacturing, handling and distribution requirements for our products) and any patient that takes any counterfeit product may suffer serious adverse health consequences, including death. Our reputation and business could suffer harm as a result of counterfeit drugs sold under our brand name and could result in lost sales for us and decreased revenues.
If we are unable to establish and maintain effective sales, marketing and distribution capabilities or to enter into agreements with third parties to do so, we may be unable to successfully commercialize our products.
We currently market and sell our products in the U.S., the EU, Japan and several other territories through a direct sales force. In addition, in order to gain greater efficiencies in our operations, we are implementing a plan pursuant to which certain portions of our international commercial operations have already or will transition to a new operating model in which sales, distribution, marketing and related efforts in designated countries will be conducted by third-parties, and our direct sales and marketing presence will decrease (or be eliminated) in these regions.
Due to the fact that some of our products are new to the market, we do not have lengthy experience in marketing and selling these products to patients, healthcare providers and payers (for example, we are relatively new to certain therapeutic areas, such as neurology (gMG and NMOSD), and our sales force has had limited exposure in educating and targeting sales to patients and physicians in neurology practices). In addition, ANDEXXA is also new to the market, having been authorized by the FDA to be marketed in the US in mid-2018. This challenge is coupled with the fact that many members of our sales and marketing team are new to working with Alexion products (and ANDEXXA) and we are transitioning to third parties to
market, distribute and sell our product in certain countries. If we are unable to successfully market and sell our new products (and expand our sales and commercial operations) and to successfully sell our products in new therapeutic areas, as well as successfully implement the transition to third parties to sell, distribute and market our products in certain countries, our business and sales may be harmed. We cannot guarantee that we will be able to establish, maintain and expand our own capabilities or enter into and maintain any sales, marketing or distribution agreements with third-party providers on acceptable terms, if at all, or that we will be able to manage the transition to third-party sales, marketing and distribution in the relevant jurisdictions that will not cause any interruption or disruption in our business and sales of our products. We will not exercise the same degree of control over such third parties that we do over our direct sales force and the ability to direct the third party and provide incentives for such third party to market and sell our products may not be as strong as in the case of a direct sales force. This transition and greater reliance on third party sales force, marketers and distributors may also increase the risk of litigation with or liability to third parties that we had previously engaged to perform services for us in jurisdictions where we are implementing these operational changes.
Even if we hire qualified sales and marketing personnel necessary to support our objectives and enter into distribution agreements with third parties on acceptable terms, we may not hire such employees or enter into such agreements in an efficient manner or on a timely basis. We may not be able to forecast accurately the size and experience of the sales and marketing force and the scale of distribution capabilities necessary to successfully market and sell our products, which could result in decreased revenues or margins. In addition, as we launch new products, such as ULTOMIRIS, and we move into other therapeutic areas (such as neurology and reversal of Factor Xa inhibitors), and, if and when, the products we acquire in connection with acquisitions and development agreements with third parties move closer to regulatory approval, we may have a larger product portfolio and address more therapeutic areas and the foregoing risks may continue to apply and may increase. Our expenses associated with building up and maintaining the sales force and distribution capabilities around the world, and in transitioning from direct sales force to third party sales, marketing and distribution, may be disproportionate compared to the revenues we may be able to generate on sales or any savings or efficiencies we gain through use of such third-parties. We cannot guarantee that we will be successful in commercializing any of our products for the above referenced or other reasons.
88

Our efforts to expand our business and product offerings through acquisitions of businesses and technologies may not be successful.
Building our product pipeline is a key strategic objective to address revenue concentration risk in C5 complement inhibitors and we expect to regularly evaluate and, when appropriate, purchase businesses and acquire, co-develop or license technologies and products from third parties in an effort to expand and diversify our pipeline, product offerings, and our technologies. For example, we recently completed the acquisitions of Portola and Achillion. Acquisitions of new businesses or products and in-licensing of new technologies and products may involve numerous risks, including:
•substantial cash expenditures;
•potentially dilutive issuance of equity securities and incurrence of debt;
•assumption of material liabilities in connection with the target or purchased technology, some of which may be difficult or impossible to identify at the time of acquisition;
•difficulties in integrating the operations of the acquired companies;
•failure of any acquired businesses or products or in-licensed products or technologies to achieve the scientific, medical, commercial or other results we anticipate;
•diverting our management's attention away from other business opportunities and on-going operations;
•the potential loss of our key employees or key employees of the acquired companies;
•risks of entering disease areas and indications or modalities in which we have limited or no direct experience; and
•significant investments in resources and personnel to evaluate, integrate and develop acquisition and in-license programs.
A substantial portion of our strategic efforts are focused on opportunities for rare disorders, but the availability of such opportunities may be limited. We may not be able to identify opportunities that satisfy our strategic criteria or are acceptable to us or our stockholders. Several companies have publicly announced intentions to establish or develop rare disease programs and we may compete with these companies (some of which may be larger and may be able to provide more consideration than we can) for the same opportunities. For these and other reasons, we may not be able to acquire the rights to additional product candidates or approved products on
acceptable terms, or at all. In such event, we may not be able to further rebuild our pipeline and any future revenue may remain largely dependent on our existing products, which are subject to the risks noted above.
In addition, through our business development initiatives we have acquired or obtained rights to new technologies, including a therapy to reverse Factor Xa inhibitors, Factor D small molecules and two FcRN platforms (in February 2020, based on data from our Phase I study, we terminated the agreement to co-develop ABY-039 with Affibody, which was the developer of one such FcRN platform), among others. These technologies are intended to diversify our pipeline and revenue base (if products based on these technologies are, where applicable, approved by regulatory authorities), but we have limited experience with these technologies, including developing these therapies, operating clinical trials with these therapies, obtaining regulatory approval and commercializing these assets. If we are unable to successfully bring these products to market and to increase sales of approved medicines in the case of ANDEXXA, we may not be able to diversify our revenue or generate a return on our investments.
Even if we are able to successfully identify and complete acquisitions and other strategic transactions, we may not be able to integrate or take full advantage of them. An acquisition or other strategic transaction may or may not result in short-term or long-term benefits to us (such as our transactions with Affibody and Stealth). A commercial stage product or near-commercial stage product acquired may not result in the revenues that we anticipate or we may be unable to realize expected profits on sales due to expenses related to the manufacturing and/or sales of the commercial product. We may also incorrectly judge the value or worth of an acquired company or business or an acquired or in-licensed product, particularly if the acquired technology is in preclinical trials or early-stage clinical trials. Any therapies we acquire that are pre-clinical or in clinical trials may not result in a commercialized product and any revenues, if the product is commercialized, may not meet our projections or result in generating an adequate return on our investment.
The acquired business of Portola may underperform relative to our expectations, and we may not be able to successfully integrate our existing business with the business of Portola and achieve anticipated synergies.
We completed the acquisition of Portola on July 2, 2020. Through the acquisition, we acquired ANDEXXA, a commercial-stage product that is intended, in part, to diversify our revenue from reliance on C5 inhibitors. The acquired business of Portola may underperform relative to our expectations, which may cause our financial results to differ from
89

our own or the investment community’s expectations, and it may not result in the revenue or generate the operating income in the future that we anticipate. The ultimate success of the acquisition will depend, in part, on Alexion’s ability to successfully combine and integrate the Portola business and realize the anticipated benefits, including synergies, innovation opportunities and operational manufacturing and sales efficiencies, from the acquisition. If we are unable to achieve our objectives within the anticipated time frame, or at all, the anticipated benefits may not be realized fully or at all, or may take longer to realize than expected, and the value of Alexion’s common stock may decline. In addition, if the results of the Phase IV post-marketing trial required by the FDA does not meet the safety and efficacy requirements of the FDA, ANDEXXA (the product that generated almost all of Portola’s revenues) may be withdrawn from the market or otherwise subject to regulatory restrictions which may limit the ability to realize expected value from the transaction. Andexanet alfa also received conditional approval in the EU.
The integration of the two companies may result in material challenges, including, without limitation:
•the diversion of management’s attention from ongoing business concerns;
•managing a larger combined business that includes a new therapeutic area for Alexion;
•maintaining employee morale and retaining key management and other employees;
•retaining existing business and operational relationships, including customers, suppliers and employees and other counterparties, and attracting new business and operational relationships; and
•coordinating geographically separate organizations.
The financial results of ANDEXXA, and our ability to generate returns on our investment in Portola, will require that we successfully commercialize this product (which received conditional approval from the FDA in early 2019). ANDEXXA utilization will depend, in large part, on access for the therapy at both the institutional level (where adoption will be driven by hospitals and emergency care facilities including ANDEXXA in the approved protocols for care and by ANDEXXA being qualified for adequate reimbursement by payers for use) and at the individual prescriber level (where adoption will be driven by immediate physical access to the product as it will be used in the acute care setting and by acceptance and endorsement of use by individual physicians who will need to be satisfied with, among other things, ANDEXXA's safety and efficacy). In addition, ANDEXXA may not gain expected market acceptance due to, among other reasons: pricing and
reimbursement decisions and lower than anticipated usage at facilities and dosing. While we do have experience with obtaining institutional approval for our therapies and promoting acute care products (SOLIRIS and ULTOMIRIS for aHUS) we will need to effectively address the needs of institutions and prescribers, as noted above, in order to increase sales of ANDEXXA.
In order to support potential growth of the business, we will be required to make significant investments in our business operations.
To effectively manage our current and future potential growth, we must continue to effectively enhance and develop our global employee base and our operational and financial processes. Supporting our growth strategy may require significant capital expenditures and management resources, including investments in research, development, sales and marketing, clinical trial capabilities, manufacturing and other areas of our operations. Efforts to advance our product pipeline, including the increased number of clinical trials that are under way or will commence in the future, will require significant expense in the remainder of 2020 and in 2021. The development or expansion of our business, any acquired business or any acquired or in-licensed products may require a substantial capital investment by us and we may likely incur substantial expenses in advancing acquired products through development, trials, regulatory approval and to commercialization. We may not have the necessary funds for these capital expenditures and expenses or these funds might not be available to us on acceptable terms, or at all. We may also seek to raise funds by incurring additional indebtedness and selling shares of our capital stock, which could dilute current stockholders’ ownership interest in our company, or securities convertible into our capital stock, which could dilute current stockholders’ ownership interest in us upon conversion.
Completion of proof of concept trials, biomarker studies, preclinical studies or clinical trials does not guarantee advancement to the next phase of development or regulatory approval or successful commercialization.
Conducting clinical trials is a complex, time-consuming and expensive process and there are no guarantees that any trial will meet its endpoints or objectives. Completion of preclinical studies or clinical trials does not guarantee that we will initiate additional studies or trials for our product candidates, if further studies or trials are initiated, what the scope and phase of the trial will be or that they will be completed, or if these further studies or trials are completed, that the design or results may provide a sufficient basis to apply for or receive regulatory approvals or to commercialize products. Results of clinical trials could be inconclusive, requiring
90

additional or repeat trials. Data obtained from preclinical studies and clinical trials are subject to varying interpretations that could delay, limit or prevent regulatory approval. Many companies have believed their product candidates performed satisfactorily in clinical trials but nonetheless failed to obtain marketing approval of their drug candidate. If the design or results achieved in our clinical trials are insufficient to proceed to further trials or to sustain regulatory approval of our product candidates, our business could be materially adversely affected. Failure of a clinical trial to achieve its pre-specified primary endpoint or objective generally increases the possibility that additional studies or trials may be required if we even determine to continue development of the product candidate, reduces the likelihood of timely development of and regulatory approval to market the product candidate, and may decrease the chances for successfully achieving the primary endpoint(s) or objective(s) in scientifically similar indications.
We are currently planning and conducting several clinical trials of products and product candidates that we anticipate may be important to our goal of expanding our business and diversifying our product portfolio. These trials may not yield the anticipated results for a number of reasons and may not result in a product that obtains regulatory approval.
ULTOMIRIS may not be approved as a treatment for additional indications or in other jurisdictions and any clinical trials may not achieve the designated endpoints and prove to be effective for use in patients with these additional indications. For example, we have initiated Phase III clinical trials for ULTOMIRIS as a treatment for: (i) Amyotrophic Lateral Sclerosis (ALS) and (ii) patients with COVID-19 and severe pneumonia or acute respiratory distress syndrome (and we plan to initiate studies of ULTOMIRIS for patients with HSCT-TMA, CM-TMA and a proof of concept basket study in renal indications, Lupus Nephritis (LN) and Immunoglobulin A Nephropathy (IgAN)). There is no guarantee that the Phase III clinical trial for ALS and COVID-19 (or the additional studies that we are planning for ULTOMIRIS) will provide sufficient evidence to advance our research beyond these stages. Drug development is very uncertain. We had, for example, conducted an exploratory clinical study in Primary Progressive Multiple Sclerosis (PPMS) that we have decided to no longer pursue based on biomarker analysis.
In addition, we are also conducting clinical trials in therapeutic areas with which we have limited experience (for example, ALXN1840 (WTX101), a therapy for Wilson’s disease), Factor D small molecules, and with technology platforms with which we also have limited experience (for example, humanized monoclonal antibody that inhibits the
interaction of FcRn with Immunoglobulin G (IgG) and IgG immune complexes). Further, we plan to initiate a Phase II clinical trial for ALXN2040 in Geographic Atrophy (GA), which is our first clinical trial in opthalmology, an indication with which we have limited experience at Alexion. In addition, we intend to also initiate a proof of concept trial using a Factor D molecule, ALXN2050, in patients with various renal diseases. And we are pursuing trials to expand the label for ANDEXXA to treat additional acute care indications. Each of these clinical trials, and any other trial we commence, require significant financial expenses and operational resources, is subject to the risks highlighted above and the investments we have made in these technologies may not generate the expected returns.
Our clinical studies may be costly and lengthy, and there are many reasons why drug testing could be delayed or terminated.
For human trials, patients must be recruited and each product candidate must generally be tested at various doses and formulations for each clinical indication. Many of our programs focus on diseases and conditions with small patient populations making patient enrollment difficult and requiring a relatively large number of trial sites to meet enrollment requirements to power our clinical trials to our desired levels for efficacy and, in certain cases, superiority. Additionally, we can have multiple clinical trials running for the same indication, further challenging clinical trial enrollment. Insufficient patient enrollment in our clinical trials could delay or cause us to abandon a product development program. We may decide to abandon development of a product candidate or a study at any time due to unfavorable results or other reasons, including if there are concerns about patient safety (as patients have, and may in the future, suffer injuries during clinical trials). If initial trials do not produce adequate results, we may have to spend considerable resources repeating clinical trials or conducting additional trials, either of which may increase costs and delay revenue from those product candidates, if any. We may open clinical sites and enroll patients in countries where or for indications in which we have little experience.
Even if we were to complete clinical trials for one or more of our therapies, we or regulatory authorities may determine that the results are not be sufficient for filing a BLA or NDA or granting approval to market the therapy.
We rely on a small number of clinical research organizations to carry out our clinical trial related activities, and one contract research organization (CRO) is responsible for many of our studies. We rely on such parties to enroll clinical sites and patients, operate trials and accurately report their results. Our reliance on CROs may impact our ability to control the
91

timing, conduct, expense and quality of our clinical trials. In addition, we may be responsible for any errors in clinical trials by a CRO as a result of the performance of services in connection with a clinical trial on our behalf. And regulatory agencies, in connection with a potential product approval or as part of ongoing monitoring, will review a CRO's compliance with regulatory requirements relating to clinical trials and we may be subject to findings and regulatory action (including denial or delay of product approval) if a CRO fails to comply with regulations.
Additional factors that can cause delay, impairment or termination of our clinical trials or our product development efforts include:
•delay or failure in obtaining institutional review board (IRB) approval or the approval of other reviewing entities to conduct a clinical trial at each site;
•delay or failure in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;
•withdrawal of clinical trial sites from our clinical trials as a result of changing standards of care or the ineligibility of a site to participate in our clinical trials;
•clinical sites and investigators deviating from trial protocol, failing to conduct the trial in accordance with regulatory requirements, or dropping out of a trial;
•delay or failure in having patients complete a trial or return for post-treatment follow-up;
•lack of sufficient supplies of the product candidate;
•disruption of operations at the clinical trial sites;
•adverse medical events or side effects in treated patients;
•failure of patients taking the placebo to continue to participate in our clinical trials;
•insufficient clinical trial data to support safety and effectiveness of the product candidates;
•lack of effectiveness or safety of the product candidate being tested;
•decisions by regulatory authorities, the IRB, ethics committee, or us, or recommendation by a data safety monitoring board, to suspend or terminate clinical trials at any time for safety issues or for any other reason;
•failure to obtain the necessary regulatory approvals for the product candidate or the
approvals for the facilities in which such product candidate is manufactured; and
•decisions by competent authorities, IRBs or ethics committees to demand variations in protocols or conduct of clinical trials
We expect our operating results to fluctuate.
Our quarterly revenues, expenses and net income (loss) may fluctuate, even significantly, due to certain risks, including those described in these “Risk Factors” as well as the timing of charges and expenses that we may take, acquisitions and business development transactions (such as the Portola Pharmaceuticals, Achillion Pharmaceuticals, Wilson Therapeutics and Syntimmune acquisitions) and the impact of converting patients from SOLIRIS to ULTOMIRIS (as noted above). We may not be able to sustain or increase profitability on a quarterly or annual basis. Since we have a limited sales and operating history with certain of our products and for new indications of existing products (such as SOLIRIS as a treatment for NMOSD, the 100mg/mL formulation of ULTOMIRIS and ANDEXXA), we may not be able to accurately forecast demand for our products or for new indications and formulations. Product demand and, in the case of conversion to ULTOMIRIS, product preference and conversion, is dependent on a number of factors, many of which are beyond our control. For these reasons, we may not be able to accurately forecast demand for our products. You should not consider our financial performance, including our revenue growth, in recent periods as indicative of our future performance.
We cannot guarantee that we will achieve our financial goals, including our ability to maintain profitability on a quarterly or annual basis in the future.
In the future, we may not generate sufficient revenues or control expenses to achieve our financial goals. Our investors and investment analysts may have widely varying expectations that may be materially higher or lower than actual revenues and profits and if our revenues and profits are different from these expectations, our stock price may experience significant volatility. Our revenues and profits are also subject to foreign exchange rate fluctuations due to the global nature of our operations and our results of operations could be adversely affected due to unfavorable foreign exchange rates. Although we use derivative instruments to manage foreign currency risk, our efforts to reduce currency exchange losses may not be successful.
In addition, we have in the past provided, and expect to continue to provide, financial guidance and anticipated customers for certain indications for future periods and if our actual operating results fail to meet or exceed the guidance that we have previously provided to our investors, our stock price could drop
92

suddenly and significantly. Financial guidance and anticipated customer levels are based on certain assumptions about future performance and such guidance is not a guarantee that the targets set forth will be achieved. In addition, due to the potential impact of COVID-19 on our business, operations and results of operations (including our revenues), the estimates, judgments and inputs required to generate guidance and customer levels are increasingly uncertain and therefore accurately forecasting performance is even more challenging in light of the current health crisis.
As we attempt to grow and expand our business, we may have substantial expenses as we continue our research and development efforts and our efforts to develop the assets we have acquired through acquisitions, collaborations and in-licenses, continue to undertake additional business development activities, continue to conduct clinical trials and continue to develop and expand manufacturing, sales, marketing and distribution capabilities worldwide, some of which could be delayed, scaled-back or eliminated to control expenses and/or achieve our financial objectives. Additionally, business development activities may include milestone and royalty obligations and may require substantial investment in research and development to achieve product approval. These expenses may increase and such increases may exceed analyst and investor expectations.
If we fail to attract and retain highly qualified personnel, we may not be able to successfully develop, manufacture or commercialize our products or products candidates.
The success of our business is dependent in large part on our continued ability to attract and retain our senior management, and other highly qualified personnel in our scientific, clinical, manufacturing, governmental regulations and commercial organizations and across the many geographies in which we operate. There is intense competition in the biopharmaceutical industry for these types of personnel.
Our business is specialized and global and we must attract and retain highly qualified individuals across many geographies and areas of expertise. We may not be able to continue to attract and retain the highly qualified personnel necessary to develop, manufacture and commercialize our products and product candidates. If we are unsuccessful in our recruitment and retention efforts, or if our recruitment efforts take longer than anticipated, our business may be harmed.
We may not achieve some or all of the expected benefits of our current and future restructuring plans and restructurings may adversely affect our business.
We initiated our most recent restructuring in the third quarter 2020, which is focused within our commercial organization as part of an initiative intended to redefine our operating model and reallocate resources necessary to align our organization with our diversifying portfolio of new products and strategic objectives. We may undertake additional restructurings in the future. Implementation of a restructuring plan may be costly and disruptive to our business, and we may not be able to obtain the estimated cost savings and benefits that were initially anticipated in connection with a restructuring in a timely manner, or at all. Additionally, as a result of any restructuring, we may experience a loss of continuity, loss of accumulated knowledge and/or inefficiency during transitional periods. Reorganization and restructuring can require a significant amount of management and other employees’ time and focus, which may divert attention from operating and growing our business. If we fail to achieve some or all of the expected benefits of restructuring, it could have an adverse effect on our business, financial condition, results of operations and cash flows.
If we fail to satisfy our debt service obligations or our contingent obligations, we may be unable to commercialize our products or continue or complete our product development.
We have significant debt service obligations. In addition to the obligations to make interest and principal payments under our credit facility throughout the term of the loans, any changes in interest rates related to this debt could significantly increase our annual interest expense and any hedging of this interest may not be effective to control expenses.
Our Amended and Restated Credit Agreement requires us to comply with certain financial covenants and negative covenants, restricting or limiting our ability and the ability of our subsidiaries to, among other things, incur additional indebtedness, grant liens, and engage in certain investment, acquisition and disposition transactions, subject to limited exceptions. If an event of default occurs (due to, for example, the failure to comply with certain covenants in the Amended and Restated Credit Agreement), the interest rate may increase and the administrative agent may be entitled to take various actions, including the acceleration of amounts due under the Amended and Restated Credit Agreement. If the interest rate imposed under our Amended and Restated Credit Agreement were to increase as a result of a default, our expenses may increase and we may need to allocate additional funds to this interest expense (which may limit the use of these funds for other purposes, including growing our business or responding to changes in our business and industry). If some or all of the amounts outstanding under the Amended and Restated Credit Agreement were to be
93

accelerated by the lenders, we may not have sufficient cash on hand to pay the amounts due, we may not be able to refinance such debt on terms acceptable to us (or at all) and we may be required to sell certain assets on terms that are unfavorable to us.
In addition, we have substantial contingent liabilities, including milestone and royalty obligations associated with acquisitions and strategic transactions, and we have been, and in the future may again be, engaged in disputes with certain counterparties regarding potential milestone and royalty obligations. Our increased indebtedness, including increased interest expense, together with our significant contingent liabilities, could, among other things:     
•make us more vulnerable to economic or industry downturns and competitive pressures;
•make it difficult for us to make payments on our credit facilities and require us to use cash flow from operations to satisfy our debt obligations, which may reduce the availability of our cash flow for other purposes, including business development efforts and research and development;
•limit our ability to incur additional debt or access the capital markets; and
•limit our flexibility in planning for, or reacting to changes in, our business.
Our ability to satisfy our obligations under the Amended and Restated Credit Agreement and meet our debt service obligations and our royalty and milestone obligations will depend upon our future performance, which will be subject to financial, business and other factors affecting our operations, many of which are beyond our control.
We may not be able to access the capital and credit markets on terms that are favorable to us or at all.
We may need to raise additional capital to supplement our existing funds and cash generated from operations for working capital, capital expenditure and debt service requirements, and other business activities (including business and technology acquisitions). The amount of capital we may need depends on many factors, including, the cost of any acquisition or any new collaborative, licensing or other commercial relationships that we may establish, the time and cost necessary to build new manufacturing facilities or enhance our manufacturing and related operations, amounts we may need to pay in connection with the resolution of any government investigation or litigation matter (including any securities class action matter or any product liability claim or any tax assessment), the cost of obtaining and maintaining the necessary regulatory approvals
for our manufacturing facilities, and the progress, timing and scope of our preclinical studies, clinical trials and product development and commercialization efforts. The capital and credit markets have experienced and may continue to experience extreme volatility and disruption. We may not receive additional funding when we need it or funding may only be available on unfavorable terms. If we cannot raise adequate funds to satisfy our working capital, capital requirements and debt repayment obligations (or royalty and milestone obligations) or business development activities, we may have to delay, scale-back or eliminate certain research, development, manufacturing, acquisition or commercial activities or sell certain assets and technologies.
We have incurred significant impairment charges, and may continue to incur such charges in the future for certain of our assets, including goodwill in connection with acquisitions, and such amounts may be material.
If the purchase price of a business acquisition exceeds the value of the assets (and liabilities) acquired, the acquirer must recognize goodwill in such amount. We may be required to recognize impairment charges for our goodwill and other intangible assets, and such charges may be material and have an adverse impact on our financial results in the period such charges are incurred and may also have an adverse impact on our reputation.
As of September 30, 2020, the net carrying value of our goodwill and other intangible assets, net totaled $8,157.3. As required by GAAP, we evaluate goodwill and intangible assets for impairment on an annual basis, or as facts and circumstances warrant. We have recorded charges that include inventory write-downs for failed quality specifications or recalls, impairments with respect to investments and acquisitions, fixed assets and long-lived assets, outcomes of litigation and other legal or administrative proceedings, regulatory matters and tax matters, and payments in connection with acquisitions and other business development activities, such as milestone payments. The impairment of tangible and intangible assets may be triggered by developments both within and outside our control. Deteriorating economic conditions, technological changes, disruptions to our business, inability to effectively integrate acquired businesses, unexpected significant changes or planned changes in the use of the assets, adverse clinical results, intensified competition, divestitures, market capitalization declines and other factors may impair our goodwill and other intangible assets.
As part of our standard quarterly procedures, we review facts and circumstances regarding our long-lived assets, including the KANUMA asset, to assess for potential indicators of impairment. During the quarter ended June 30, 2020, based on continued
94

challenges expanding patient growth and new alternative commercial opportunities, the Company revised its strategic view of KANUMA and determined that we have exhausted commercially viable initiatives related to KANUMA and will have difficulty expanding patient growth over the long term as we focus on promoting other commercial programs and growing our pipeline. While management is committed to continued access to KANUMA for existing patients and providing access to future patients diagnosed with LAL-D, as we grow our business and product offerings, including through the recent acquisition of Portola Pharmaceuticals, we will prioritize programs where the opportunity to find patients who can benefit from Alexion therapies is the greatest. Therefore, we no longer expect to increase the number of KANUMA patients at the rate we previously assumed in our cash flow projections for KANUMA. As a result of these developments during the second quarter 2020, management adjusted assumptions in our long term cash flow forecast model for KANUMA and recognized an impairment charge of $2,042.3 related to the associated intangible asset.
Cash flow models used in our assessments of intangible assets are based on the projected commercial sales of the underlying products which considers, where applicable, our commercial experience with the product to date. Cash flow models for products currently in development also include the likelihood of approval. These cash flow models require the use of significant estimates and judgements, which include, but are not limited to, probability of regulatory approval, market access assumptions, long-range pricing expectations and patient-related assumptions, including patient identification, conversion and retention rates. As we continue to develop and sell products that have a related intangible asset associated with it, new data may cause us to adjust the assumptions in our cash flow models. Changes to assumptions used in our net cash flow projections may result in material impairment charges in subsequent periods, similar to the impairment charge recognized in the second quarter 2020 related to KANUMA.
The efficiency of our corporate structure depends on the application of the tax laws and regulations in the countries where we operate and we may have exposure to additional tax liabilities or our effective tax rate could increase, which could have a material impact on our results of operations and financial position.
As a company with international operations, we are subject to income taxes, as well as non-income based taxes, in both the U.S. and various foreign jurisdictions. Significant judgment is required in determining our worldwide tax liabilities.  Although we believe our estimates are reasonable at the time made, the final taxes we owe may differ from the
amounts recorded in  our financial statements (and such differences may be material). If the IRS, or other taxing authority, disagrees with the positions we take (and such tax authorities have disagreed with certain positions we have taken for prior years, and may do so again the future), we could have additional tax liability, and this could have a material impact on our results of operations and financial position. Our effective tax rate could be adversely affected by changes in the mix of earnings in countries with different statutory tax rates, changes in the valuation of deferred tax assets and liabilities, changes in tax laws and regulations, changes in interpretations of tax laws, including pending tax law changes, changes in our manufacturing activities and changes in our future levels of research and development spending.
We have designed, and from time to time we modify, our corporate structure, the manner in which we develop and use our intellectual property, and our intercompany transactions between our affiliates in a way that is intended to enhance our operational and financial efficiency and increase our overall profitability. The application of the tax laws and regulations of various countries in which we operate and to our global operations is subject to interpretation. We also must operate our business in a manner consistent with our corporate structure to realize such efficiencies. The tax authorities of the countries in which we operate may challenge our methodologies for valuing developed technology or for transfer pricing or other operations. If tax authorities determine that the manner in which we operate results in our business not achieving the intended tax consequences, our effective tax rate could increase (and such increase may be material) and harm our financial position and results of operations. In addition, certain governments are considering and may adopt tax reform measures that significantly increase our worldwide tax liabilities. The Organization for Economic Co-operation and Development and other government bodies have focused on issues related to the taxation of multinational corporations, including, in the area of “base erosion and profit shifting,” where payments are made from affiliates in jurisdictions with high tax rates to affiliates in jurisdictions with lower tax rates. It is possible that these reform measures could increase our effective tax rate (and such increase may be material) and harm our financial position and results of operations over the next several years.
Our sales and operations are subject to a variety of risks relating to the conduct of our international business.
We have increased our international presence, including in emerging markets. Our operations in foreign countries subject us to a variety of risks, including:
95

•difficulties or the inability to obtain necessary foreign regulatory or reimbursement approvals of our products in a timely manner or at all;
•political or economic determinations or decisions that adversely impact pricing or reimbursement policies in foreign countries;
•economic problems or political instability;
•fluctuations in currency exchange rates;
•difficulties or inability to obtain financing in markets;
•unexpected changes in tariffs, trade barriers and regulatory requirements;
•customs and tax officials in foreign jurisdictions may disagree with the value we set when we or others import our products (including products that are donated for charitable purposes or used for clinical trials) and we may be required to pay additional duties or fines and such amounts may be substantial. For example, our offices in Brazil were visited by the Brazilian federal tax authorities and we received a written notice from such authorities requesting information with respect to the importation of SOLIRIS free of charge to patients in Brazil from 2014 to 2019. In connection with this matter, in August 2019, the Brazilian Federal Revenue Service provided a Notice of Tax and Description of the Facts to, among others, two Alexion subsidiaries. This notice focuses on: (i) the identity of the importer and (ii) the importation value of SOLIRIS vials in connection with Alexion’s free drug program in Brazil. See Note 16, Commitments and Contingencies to the condensed consolidated financial statements for more information on this matter);
•difficulties in establishing and enforcing contractual and intellectual property rights;
•compliance with complex import and export control laws;
•trade restrictions and restrictions on direct investments by foreign entities;
•compliance with local tax, employment and labor laws;
•costs and difficulties in recruiting and retaining qualified managers and employees to manage and operate the business in local jurisdictions;
•costs and difficulties in managing and monitoring international operations; and
•longer payment cycles
Additionally, our business and marketing methods are subject to the laws and regulations of the countries in which we operate, which may differ significantly from country to country and may conflict with U.S. laws and regulations. The FCPA and anti-bribery laws and regulations in the locations in which we operate our business are extensive and far-reaching, and we must maintain accurate records and control over the activities of our employees, distributors and third party service providers in countries where we operate. We have policies and procedures, and we are committed to continually focusing on our compliance program and we continue to enhance our comprehensive company-wide program and efforts, and these are designed to enhance our business processes, structures, controls, training, talent, and systems across Alexion’s global operations and to help us and our representatives, including our employees and our vendors and distributors, comply with such laws. We cannot, however, guarantee that these policies, programs and procedures will protect us against liability under the FCPA or other anti-bribery laws for actions taken by us, our employees or our representatives. Any determination that our operations or activities are not in compliance with existing laws or regulations, including the FCPA and the UK Anti-Bribery Act, could result in the imposition of fines, civil and criminal penalties, equitable remedies, including disgorgement, injunctive relief, and/or other sanctions against us, and remediation of such findings could have a material and adverse effect on our business operations. In addition, as our international operations expand, we are likely to become subject to new anti-corruption/anti-bribery laws or existing laws may govern our activities in new jurisdictions in which we commence operations. In addition, as we move from a direct sales force to third-party sales force, distributors and marketers in certain countries and regions, we may also have liability under the FCPA and anti-bribery laws and regulations for the actions of these third parties. Although we can impose contractual restrictions on what these third parties are authorized to do on our behalf, we will exercise only limited control over the actions of these third parties but may still face the same liabilities for their actions. Our failure, and the failure of others who we engage to act on our behalf, to comply, with the laws and regulations of the countries in which we operate, or will operate in the future, could materially harm our business.
Our business involves environmental risks and potential exposure to environmental liabilities.
As a biopharmaceutical company, our business involves the use of certain hazardous materials in our research, development, manufacturing and other activities. We and our third party providers are subject to various federal, state, local and foreign
96

environmental laws and regulations concerning the handling and disposal of non-hazardous and hazardous wastes, such as medical and biological wastes, and emissions and discharges into the environment (including air, soils and water sources). We also are subject to laws and regulations that impose liability and clean-up responsibility for releases of hazardous substances into the environment and a current or previous owner or operator of property may be liable for the costs of remediating its property or locations, without regard to whether the owner or operator knew of or caused the contamination. Although our safety procedures for handling and disposing of hazardous materials are designed to comply with the laws and regulations established by state, federal, local and foreign regulators, the risk of loss of, or accidental contamination or injury from, these materials cannot be eliminated. If an accident or environmental discharge occurs, or if we discover contamination caused by prior owners and operators of properties we acquire, we could be liable for remediation obligations, damages and fines that could exceed our insurance coverage and financial resources. Such obligations and liabilities, which to date have not been material, could have a material impact on our business and financial condition. Additionally, the cost of compliance with environmental and safety laws and regulations may increase in the future, and we may be required to dedicate more resources, including substantial financial resources, to comply with such laws and regulations or purchase supplemental insurance coverage, which may not be available on acceptable terms or at all.
Currency fluctuations and changes in exchange rates could adversely affect our revenue, increase our costs and negatively affect our profitability.
We conduct a substantial portion of our business in currencies other than the U.S. dollar. We are exposed to fluctuations in foreign currency exchange rates and such fluctuations affect our operating results. The exposures result from portions of our revenues, as well as the related receivables, and expenses that are denominated in currencies other than the U.S. dollar, including the Euro, Japanese Yen, British Pound, Canadian dollar and Turkish Lira. We cannot predict fluctuations in currency exchange rates and such fluctuations in exchange rates (and inflation) could negatively affect our business, cash flow, results of operations, financial position and prospects. We manage a portion of our foreign currency transaction risk within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes. While our hedging agreements may limit some of the exposure to exchange rate and interest rate fluctuations, such
attempts to mitigate these risks may be costly and not always successful and the results may have a material impact on our results of operations.
Risks Related to the Regulatory Environment
We operate in a highly regulated industry and if we or our third-party providers fail to comply with U.S. and foreign regulations, we or our third party providers could lose our approvals to market our products or our product candidates, and our business may be seriously harmed.
We and our current and future third-party vendors, including contract manufacturers, CROs, distributors and suppliers and logistic providers are subject to rigorous and extensive regulation by governmental authorities around the world, including the FDA, EMA, the competent authorities of the EU Member States and the MHLW. These regulations, many of which are complex, relate to almost all aspects of our business, including GCP, GLP, cGMP and pharmacovigilance rules (for additional information on the regulations relating to our business, see “Business - Government Regulation” in Item 1 in our Annual Report on Form 10-K for the year ended December 31, 2019). If we or a regulatory agency discover previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured (such as product contamination), or in the case of KANUMA, problems with animal operations, a regulatory agency may impose restrictions on that applicable product, the manufacturing facility or us. In 2013, we received a Warning Letter from the FDA relating to compliance with FDA’s cGMP requirements at one of our facilities, which was remediated. If we had failed to address the FDA’s concerns or if we (or one of our third-party contract manufacturers) were to receive another Warning Letter in the future relating to cGMP or other applicable regulations, the FDA or other regulatory authorities could take regulatory action, including fines, civil penalties, recalls, seizure of product, suspension of manufacturing operations, operating restrictions, injunctions, suspension of clinical trials, withdrawal of FDA (or other regulatory authority) approval and/or criminal prosecution.
If we or our third-party providers, including our product or raw material manufacturers, product fill-finish providers, packagers and labelers, fail to comply fully with applicable regulations, then we may be required to, among other things, initiate a recall or withdrawal of our products. In addition to our manufacturing operations and those of contract manufacturers’ manufacturing operations being subject to inspection and potential regulatory action for failure to comply with (among other regulations) cGMP, our animal operations may also be subject to FDA and U.S. Department of Agriculture, Animal and
97

Plant Health Inspection Service (USDA APHIS) inspection to evaluate whether our animal husbandry, containment, personnel, and record keeping practices are sufficient to ensure safety and security of our transgenic chickens and animal products (e.g., eggs, waste, etc.). Any failure to ensure safety and security of our transgenic chickens and/or animal products could result in regulatory action by the FDA or another regulatory body, including USDA APHIS.
Failure to comply with the laws and requirements that apply to our business, including statutes and regulations, administered by the FDA, the EC, the competent authorities of the EU Member States, the MHLW or other comparable agencies, could result in:
•a product recall;
•a product withdrawal;
•modification or revision to a product label;
•significant administrative and judicial sanctions, including, warning letters or untitled letters;
•significant fines and other civil penalties;
•suspension, variation or withdrawal of a previously granted approval for our products;
•interruption, suspension or termination of production;
•operating restrictions, such as a shutdown of production facilities or production lines, or new manufacturing requirements;
•suspension or termination of ongoing clinical trials;
•delays in approving or refusal to approve our products including pending BLAs, NDAs or BLA or NDA supplements for our products or a facility that manufactures our products;
•seizing or detaining product;
•requiring us or third-parties performing services for us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions and penalties for noncompliance;
•injunctions; and/or
•criminal prosecution.
In addition, we are subject to antitrust regulations with respect to our acquisitions, as well as our interactions with other participants in the markets we currently serve or may serve in the future. In addition, these antitrust laws are vigorously enforced in the U.S. and in other jurisdictions in which we operate. In connection with any business development transaction, acquisition, development agreement or collaboration that is reviewed by regulatory authorities, there can be no assurance that
these antitrust approvals will be obtained. In addition, the governmental entities from which these approvals are required may impose conditions on the completion of such business development transaction or require changes to the terms of the applicable transaction. Regulatory review process may cause a delay in the closing of a transaction beyond the time that we anticipate and communicate. Any conditions or unexpected delays in approval could have the effect of jeopardizing or delaying completion of the applicable transaction or reducing the anticipated benefits of the transaction (or, as noted above, may prohibit closing of the transaction).
Our product candidates require extensive clinical testing and regulatory approval and failure to satisfy regulatory requirements relating to safety and efficacy thresholds may prevent us from being able to market our products and limit our ability to grow our business and diversify our revenue.
We believe our future success may depend on our ability to develop and commercialize our product candidates and, to this end, we have recently acquired companies and technologies in an effort to expand our product pipeline. Our product candidates are in various stages of development and must satisfy the rigid safety and efficacy requirements of the FDA and other foreign regulatory agencies before they can be approved for sale to patients. To satisfy these standards, we must ensure, among other things, that we have appropriately established our protocol designs, obtained the necessary IRB approval, provide adequate patient enrollment rates, timely and appropriately report any adverse events and serious adverse events to the appropriate authorities and ensure compliance with cGCP. If we or our third-party clinical trial providers or third-party CROs do not successfully carry out these clinical activities, our clinical trials or the potential regulatory approval of a product candidate may be delayed or be unsuccessful.
If we discover safety or safety reporting issues with any of our approved products, or if we fail to comply with continuing U.S. and applicable foreign regulations as they relate to our products and operations, our revenue may decrease, an approved product could lose its marketing approval or sales could be suspended and our business could be materially harmed.
Following marketing approval of a pharmaceutical product, the safety profile of such product continues to be closely monitored by the FDA and other foreign regulatory authorities. Regulations continue to apply after product approval, and cover, among other things, testing, manufacturing, quality control, finishing, filling, labeling, advertising, promotion, risk mitigation, adverse event reporting requirements and export of biologics and small molecule compounds. Included in the post-approval marketing requirements are, for
98

example, the REMS program for both SOLIRIS and ULTOMIRIS in the U.S., and a REMS program can be updated from time to time by the FDA and such updates can be costly and burdensome to implement. In addition, continued approval for ANDEXXA for its currently approved indication in the US is contingent upon post-marketing study results that verify that clinical benefit is conferred to patients.
We are required to report any serious and unexpected adverse experiences and certain quality problems with our products to the FDA, the EMA, the MHLW and other health agencies. Adverse safety events involving our products may have a negative impact on our business. Discovery of safety issues with our products could result in product liability claims and could cause additional regulatory scrutiny and requirements for additional labeling or safety monitoring, withdrawal of products from the market and the imposition of fines or criminal penalties. In addition, governmental authorities are making greater amounts of safety information directly available to the public through periodic safety update reports, patient registries and other reporting requirements. The reporting of adverse safety events may also damage physician, patient and/or investor confidence in our products and our reputation. Any adverse events in connection with the use of our products could result in liabilities, loss of revenues, material write-offs of inventory, material impairments of intangible assets, goodwill and fixed assets, material restructuring charges, product liability claims and other adverse impacts on our results of operations.
Regulatory agencies periodically inspect our pharmacovigilance processes. If these regulatory agencies determine that we or other parties whom we do not control that perform pharmacovigilance-related services on our behalf, including clinical trial investigators, have not complied with the applicable reporting or other pharmacovigilance requirements, we may become subject to additional inspections, warning letters or other enforcement actions, including monetary fines, marketing authorization withdrawal and other penalties.
As a condition of approval for marketing our products, governmental authorities may require us to conduct additional studies. In connection with the approval of SOLIRIS we established a PNH Registry and an aHUS Registry to collect additional data on patients. Furthermore, in connection with the approval of STRENSIQ in the U.S., we agreed to conduct a prospective observational study in treated patients to assess the long-term safety of STRENSIQ therapy and to develop complementary assays. In the EU, in connection with the grant of authorization for STRENSIQ, we agreed to conduct a study of STRENSIQ in patients with HPP and to extend the studies ENB-008-10 and ENB-009-10 to provide
efficacy data in patients 13 to 18 years of age, and we completed this commitment to the EU. In the U.S., the FDA can also propose to withdraw approval for a product if it determines that such additional studies are inadequate or if new clinical data or information shows that a product is not safe for use in an approved indication.
In addition, similar or more stringent post-approval requirements and obligations may be imposed by the FDA and/or other regulatory agencies with respect to any of our future products that obtain regulatory approval. Compliance with these post-approval requirements could result in increased cost and expense and decrease our operating margins and, if we are unable to comply with these requirements, we may be subject to regulatory action by the applicable regulatory agency and the penalties may include fines and product withdrawals or restrictions in the use of a product.
If we fail to comply with applicable healthcare laws and regulations, including those related to healthcare fraud and abuse, we may be subject to investigations and civil or criminal penalties and our business could be adversely affected.
We are subject to healthcare “fraud and abuse” laws, such as the False Claims Act (FCA), the anti-kickback provisions of the federal Social Security Act, laws prohibiting off-label product promotion and other related federal and state laws and regulations.
The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, in cash or in kind to induce, or reward the purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid, or other federal healthcare programs. Liability may be established without a person or entity having actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it. A conviction for violation of the Anti-kickback Statute requires mandatory exclusion from participation in federal healthcare programs. The majority of states also have statutes similar to the federal Anti-Kickback Statute and false claims laws that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payer.
The FCA prohibits any person from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds, or knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim. Pharmaceutical companies have been investigated and have reached substantial financial settlements with the Federal government under the FCA for a variety of alleged promotional and
99

marketing activities, such as allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product; providing consulting fees and other benefits to physicians to induce them to prescribe products; engaging in promotion of pharmaceuticals for uses that the FDA has not approved, or “off-label” uses; and submitting inflated best price information to the Medicaid Rebate Program.
We seek to comply with the Anti-Kickback Statute and FCA laws, including operating within any available safe harbors, but we cannot assure that our compliance program, policies and procedures will always protect us from acts committed by employees or third-party distributors or service providers.
There is also enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third-party charities that provide such assistance. In 2019, we settled an investigation by the Department of Justice relating to our support for 501(c)(3) entities. If we, or our vendors or donation recipients, are deemed to fail to comply with relevant laws, regulations or government guidance in the operation of these programs again in the future, we could be subject to significant fines or penalties.
Other related federal and state laws and regulations that may affect our ability to operate include, among others, the federal False Statements Statute, the federal Civil Monetary Penalties Law, HIPAA, the federal Open Payments program, state anti-kickback and false claims acts, and state and local disclosure requirements and marketing restrictions. Additional information about the scope of these requirements and potential penalties is provided under “Government Regulation - Fraud and Abuse” included in Part I, Item 1 in our Annual Report on Form 10-K for the year ended December 31, 2019.
In recent years, legislation has been adopted at the federal, state and local level requiring pharmaceutical companies to establish marketing compliance programs, file periodic reports or make periodic public disclosures on sales, marketing, pricing, clinical trials, health care provider payments and other activities. For example, as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the PPACA), the federal government enacted the Open Payments (commonly known as the Sunshine Act) provisions. Open Payments requires pharmaceutical manufacturers to report annually to CMS payments or other transfers of value made by that entity to physicians and teaching hospitals. We also now have similar reporting obligations throughout the EU. Failure to comply with the reporting requirements may result in significant civil monetary penalties.
Violations of U.S. federal and state fraud and abuse laws (and comparable laws in foreign jurisdictions) may result in criminal, civil and administrative sanctions, including fines, damages, civil monetary penalties (which may be material in amount) and exclusion from federal healthcare programs (including Medicare and Medicaid). Any action initiated against us for violation of these laws, even if we successfully defend against it, could require the expenditure of significant resources and generate negative publicity, which could materially adversely affect our ability to operate our business and our financial results.
Finally, the FDA, the EU and EU Member States and the MHLW, among other regulatory agencies, impose restrictions on the promotion and marketing of drug products and prohibit pharmaceutical manufacturers from promoting products for indications other than those cleared or approved by regulatory authorities or for use in manner that is not consistent with the product label approved by regulatory agencies, or off-label promotion. In certain instances, physicians are, however, in their medical judgment permitted to use products for unapproved purposes and we are aware, for example, of such uses of SOLIRIS. Although we believe that our marketing materials and training programs for physicians do not constitute improper promotion, the FDA, the DOJ, other federal or state government agencies, the EU, EU Member States or the MHLW (or other foreign regulatory agencies) may disagree. If any governmental authority determines that our promotional materials, training or other activities constitute improper promotion of any of our products, it could request that we modify our training or promotional materials (which occurred in 2019 in Japan) or other activities or subject us to regulatory enforcement actions, including the issuance of a warning letter, product withdrawal or recall, injunction, seizure, civil fine and criminal penalties. It is also possible that other enforcement authorities might take action if they believe that the alleged improper promotion led to the submission and payment of claims for an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false or fraudulent claims for payment of government funds.
Our business and operations may be materially adversely affected by government investigations.
We are subject to the FCPA, the U.K. Bribery Act and other anti-corruption laws and regulations that generally prohibit companies and their intermediaries from making improper payments to government officials and/or other persons for the purpose of obtaining or retaining business and we operate in countries that are recognized as having a greater potential for governmental and commercial corruption.
100

While we have, and continue to, take steps that are intended to enhance our compliance and training programs, we cannot assure that our compliance program, policies and procedures will always protect us from acts committed by employees or third-parties acting on our behalf.
In May 2015, we received a subpoena in connection with an investigation by the Enforcement Division of the SEC requesting information related to our grant-making activities and compliance with the FCPA in various countries, including Brazil, Colombia, Japan, Russia and Turkey. In addition, in October 2015, we received a request from the DOJ for the voluntary production of documents and other information pertaining to our compliance with the FCPA. The SEC and DOJ also sought information related to our recalls of specific lots of SOLIRIS and related securities disclosures. DOJ informed us that it closed its inquiry into these matters. We settled the investigation with the SEC in July 2020, and made payment of approximately $21.5 in disgorgement, civil penalties, and pre-judgment interest in connection with the settlement. See Note 16, Commitments and Contingencies to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for additional information on this matter.
In May 2017, Brazilian authorities seized records and data from our Sao Paulo, Brazil offices as part of an investigation being conducted into our Brazilian operations. At this time, we are unable to predict the duration, scope or outcome of the open investigations. In addition, even though we have settled the DOJ investigation relating generally to our support of certain 501(c)(3) organizations that was initiated by the U.S. Attorney’s Office for the District of Massachusetts in December 2016 and the MHLW closed its 2018 investigation into our Japanese operations, we may be subject to similar investigations in the future by the same or other regulatory agencies and government authorities and the penalties imposed on us may be materially greater in amount or we may be subject to material limitations on our operations, activities and our business. In addition, any remedial actions that have been or will be taken with the intent to address the matters that were the subject of these or other governmental investigations may not prevent future investigations and potential liability as a result of such further investigations.
In addition, while we settled the SEC's investigation in July 2020 as described above (and the DOJ closed its inquiry into these matters), any future determination that our operations or activities are not, or were not, in compliance with existing U.S. or foreign laws or regulations could result in the imposition of a broad range of civil and criminal
sanctions against us and certain of our directors, officers and/or employees, including injunctive relief, disgorgement, substantial fines or penalties, imprisonment, and other legal or equitable sanctions, including exclusion from Medicare, Medicaid, and other governmental healthcare programs. In addition, settlement of investigations may lead to additional government actions. For example, following the settlement with the SEC in July 2020, the Ministry of Health in Turkey initiated an investigation regarding the matters referenced in the SEC Order as they relate to the Company’s operations in Turkey between 2010 and 2015. Any attempts to resolve some or all of any such matters in the future may not be successful. If we were to engage in settlement discussions with respect to any current or future investigation or litigation (and we may accrue amounts due to the nature of such discussions), but the matter is not settled, the ultimate resolution may result in monetary or other penalties materially greater or stricter than the amounts or terms that we proposed in discussions (or the amount that we accrued for such matter during negotiations). Additionally, remediation of any such findings resulting from any past or future investigations could have an adverse effect on our business operations, and we could experience interruptions of business, harm to our reputation, debarment from government contracts, loss of supplier, vendor or other third-party relationships, and necessary licenses and permits could be terminated. Other internal or government investigations or legal or regulatory proceedings, including lawsuits brought by private litigants, may also follow as a consequence. Cooperating with and responding to requests for information in connection with past and ongoing investigations, as well as responding to any future U.S., state or foreign governmental investigation or whistleblower lawsuit, has resulted and could continue to result in substantial expenses, and could divert management’s attention from other business concerns and could have a material adverse effect on our business and financial condition and growth prospects.
Our business could be adversely affected by litigation and regulatory enforcement actions.
We operate in many jurisdictions in a highly regulated industry and we could be subject to litigation, government investigations (as noted above) and enforcement and other legal actions on a variety of matters in the U.S. or foreign jurisdictions, including,  without limitation, intellectual property, regulatory, product liability, tax and custom/import duties, environmental, whistleblower, Qui Tam, false claims, privacy, anti-kickback, anti-bribery, securities, commercial, product pricing, employment and other claims and legal proceedings which may arise from conducting our business. We are involved in certain legal proceedings. See Note 16, Commitments and
101

Contingencies to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for information on certain of these legal proceedings. In addition, in connection with any acquisitions, we may assume potential liability related to pending legal proceedings of the acquired company. For example, securities class action complaints were filed against Portola and certain officers of Portola alleging violation of the antifraud provisions of the Exchange Act of 1934 and the Securities Act of 1933 due to misrepresentations and omissions in public disclosures concerning sales of andexanet alfa between January 8, 2019 and February 26, 2020. Legal proceedings are inherently unpredictable, and the outcome can result in costly verdicts, fines and penalties, exclusion from federal healthcare programs and/or injunctive relief that affect how we operate our business. Defense of litigation claims can be expensive, time consuming and distracting, and it is possible that we could incur judgments or enter into settlements of claims for monetary damages or change the way we operate our business, which could have a material adverse effect on our product sales, business and results of operations. In addition, product liability is a major risk in testing, selling, using and marketing biotechnology and pharmaceutical products. We may face potential product liability exposure in human clinical trials and for products we sell after regulatory approval. Product liability claims, regardless of their merits, could be costly and divert management’s attention and could adversely affect our reputation and the demand for our products and result in significant monetary liability.
Changes in healthcare laws and implementing regulations, as well as changes in healthcare policy, may affect coverage and reimbursement of our products in ways that we cannot currently predict and these changes could adversely affect our business and financial condition.
 In the U.S., there have been a number of legislative and regulatory initiatives focused on containing the cost of healthcare. The PPACA, for example, substantially changed the way healthcare is financed by both governmental and private insurers in the U.S., and significantly impacts the pharmaceutical industry. The PPACA contains a number of provisions that are expected to impact our business and operations, in some cases in ways we cannot currently predict. Changes that may affect our business include those governing enrollment in federal healthcare programs, reimbursement changes, rules regarding prescription drug benefits under health insurance exchanges, expansion of the 340B program, expansion of state Medicaid programs, fraud and abuse enforcement and rules governing the approval of biosimilar and generic products (and allowing biosimilars access to the market in
accordance with the FDA’s Biosimilars Action Plan). These changes may impact existing government healthcare programs, industry competition, formulary composition, and may result in the development of new programs, including Medicare payment for performance initiatives, health technology assessments and improvements to the physician quality reporting system and feedback program. In 2016, CMS implemented changes to the Medicaid Drug Rebate Program under the PPACA. Moreover, in the future, Congress could enact legislation that further increases Medicaid drug rebates or other costs and charges associated with participating in the Medicaid Drug Rebate Program. The issuance of regulations and coverage expansion by various governmental agencies relating to the Medicaid Drug Rebate Program has and may continue to decrease revenues, increase our costs and the complexity of compliance, has been and may be time-consuming to comply with, and could have a material adverse effect on our results of operations.
Similar efforts to those in the United States, and in some cases even more aggressive efforts, are being taken by governments to control the costs of pharmaceutical drugs and regulate the industry in countries outside the U.S. In these markets outside the U.S., the pricing and reimbursement of pharmaceutical products is subject to direct or indirect governmental control and such government authorities are increasingly attempting to limit or regulate the price of drug products and due to their control over pricing are able to move quickly to implement pricing changes. In certain cases, governments may challenge the price we charge for our products already delivered to patients under applicable regulations in those countries (and if these governments prevail, we could be required to return amounts to the government or the government may take steps in an attempt to claw-back amounts that were previously paid to us and such amounts may be material).
We may face uncertainties as a result of federal and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. There is no assurance that the PPACA, as currently enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot predict how future federal or state or foreign legislative or administrative changes relating to healthcare reform may affect our business. The recent COVID-19 pandemic may introduce temporary or permanent healthcare reform measures for which we cannot predict the financial implication on our business.
State governments have sought to put in place limits and caps on pharmaceutical prices and have also requested rebates for certain pharmaceuticals.
102

Attempts to decrease prices of pharmaceutical products may lead to increased use of managed care organizations by Medicaid programs which could lead to managed care organizations influencing prescription decisions for beneficiaries and a corresponding limitation on prices and reimbursement for our products.
Governments in countries where we operate have adopted or have also shown significant interest in pursuing legislative initiatives to reduce costs of healthcare. We expect that the implementation and enforcement of current laws and policies, the amendment of those laws and policies in the future, as well as the adoption of new laws and policies, could have a material adverse effect on our industry generally and on our ability to maintain or increase our product sales or revenues or successfully commercialize our product candidates, or could limit or eliminate our future spending on development projects and product candidates. The announcement or adoption of regulatory or legislative proposals could delay or prevent our entry into new markets, affect our reimbursement or sales in the markets where we are already selling our products and materially harm our business, financial condition and results of operations.
If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program, Medicare, or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions and fines which could have a material adverse effect on our business, financial condition, results of operations and prospects.
We participate in and have certain price reporting obligations to the Medicaid Drug Rebate Program and we have obligations to report the average sales price under the Medicare program. Under the Medicaid Drug Rebate Program, we are required to pay a rebate to each state Medicaid program for quantities of our products that are dispensed to Medicaid beneficiaries and paid for by a state Medicaid program as a condition of having federal funds being made available to the states for our products under Medicaid and Medicare Part B. Those rebates are based on pricing data reported by us on a monthly and quarterly basis to CMS. Any failure to comply with these price reporting and rebate payment obligations could negatively impact our financial results.
Pricing and rebate calculations vary among products and programs. The calculations are complex and are often subject to interpretation by us, governmental or regulatory agencies and the courts. We cannot assure you that our submissions will not be found by CMS or other applicable government authorities to be incomplete or incorrect. Governmental agencies may also make changes in
program interpretations, requirements or conditions of participation, some of which may have implications for amounts previously estimated or paid. Recalculations increase our costs for complying with the laws and regulations governing these programs, including the Medicaid Drug Rebate Program. Any corrections to our rebate calculations could result in an underage in our rebate liability for past quarters, and such amount may be material. Price recalculations also may affect the ceiling price at which we are required to offer our products to certain covered entities under the 340B pricing program.
We are liable for errors associated with our submission of pricing data. In addition to retroactive rebates and the potential for 340B program refunds, civil monetary penalties can be applied if we are found to have knowingly submitted any false pricing information to the government, if we are found to have made a misrepresentation in the reporting of our average sales price, or if we fail to submit the required pricing data on a timely basis. Such conduct also could be grounds for CMS to terminate our Medicaid drug rebate agreement, pursuant to which we participate in the Medicaid program. In the event that CMS terminates our rebate agreement, federal payments may not be available under Medicaid or Medicare Part B for our covered outpatient drugs and any such actions could negatively impact our business and results of operations.
The Public Health Service’s 340B drug pricing program, and other comparable government and payer regulations, may have a negative impact on the price we can charge for our products and result in a decrease in revenues.
Federal law requires that any company that participates in the Medicaid Drug Rebate Program also participate in the Public Health Service’s 340B drug pricing program in order for federal funds to be available for the manufacturer’s drugs under Medicaid and Medicare Part B. The 340B pricing program requires participating manufacturers to agree to charge statutorily-defined covered entities no more than the 340B “ceiling price” for the manufacturer’s covered outpatient drugs. The 340B pricing program is described in Pharmaceutical Pricing and Reimbursement in Item 1 Business in our Annual Report on Form 10-K for the year ended December 31, 2019. The 340B ceiling price is calculated using a statutory formula, which is based on, among other prices, the average manufacturer price and rebate amount for the covered outpatient drug as calculated under the Medicaid Drug Rebate Program. We are a participant in the 340B drug pricing program and are, for the applicable covered entities, subject to the price ceiling. Any changes to the 340B drug pricing program, including:
103

•the method of calculating the 340B ceiling price for our products;
•any expansion of the entities that qualify as covered entities; and
•any requirement that participating manufacturers agree to provide 340B discounted pricing on drugs used in an inpatient setting;
could have a material and negative impact our revenue and results of operations.
Pursuant to a final rule adopted on January 1, 2019, we could be subject to civil monetary penalties if the government finds that we knowingly and intentionally overcharged a 340B covered entity.
In addition, the agreement that manufacturers must sign to participate in the 340B pricing program obligates a manufacturer to offer the 340B price to covered entities if the manufacturer makes the drug available to any other purchaser at any price and to report to the government the ceiling prices for its drugs.
Beyond the Public Health Service’s 340B drug pricing program, federal law requires that a company must participate in the Department of Veterans Affairs Federal Supply Schedule (FFS) pricing program to be eligible to have its products paid for with federal funds. If we overcharge the government in connection with our FSS contract or Section 703 Agreement, whether due to a misstated FCP or otherwise, we are required to refund the difference to the government. Failure to make necessary disclosures and/or to identify contract overcharges can result in allegations against us under the FCA and other laws and regulations. Unexpected refunds to the government, and responding to a government investigation or enforcement action with respect to our pricing or participation in government health programs, may be expensive, and could have a material adverse effect on our business, financial condition, results of operations and growth prospects.
We may be subject to numerous and varying privacy and security laws, and our failure to comply could result in penalties and reputational damage.
We are subject to laws and regulations covering data privacy and the protection of personal information including health information. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues which have affected and may affect our business. In the U.S., numerous federal and state laws and regulations, including state security breach notification laws, state health information privacy laws, and federal and state consumer protection laws, govern the collection, use, disclosure, and protection of personal information. Each of these laws is subject
to varying interpretations by courts and government agencies, creating complex compliance issues for us. If we fail to comply with applicable laws and regulations, we could be subject to penalties or sanctions, including criminal penalties if we, our affiliates, or our agents knowingly obtain or disclose individually identifiable health information from a HIPAA covered entity in a manner that is not authorized or permitted by HIPAA.
Numerous other countries have, or are developing, laws governing the collection, use and transmission of personal information as well. Further, the EU's General Data Protection Regulation (GDPR) and implementing laws in the EU member states that govern the collection and processing of EU residents' personal data and among other requirements, imposes certain consent and data access rights. Such laws may impact, among other things, our ability to conduct clinical trials that involve EU personal data and engage in other activities that require the processing of EU personal data. These laws are complex, subject to interpretation by local authorities, and any determination that we breached such laws could lead to government enforcement actions, significant penalties, and these may adversely impact our operating results.
In May 2018, the GDPR, which applies in all EU Member States, went into effect. The regulation introduced comprehensive data protection requirements in the EU and substantial fines for breaches of the data protection rules. It increased our responsibility and liability in relation to personal data that we process and we may be required to put in place additional mechanisms ensuring compliance with the new EU data protection rules.    
Security breaches, cyber-attacks or other disruptions could expose us to liability and affect our business and reputation.
We are increasingly dependent on our information technology systems and infrastructure for our business. We collect, store and transmit sensitive information including intellectual property, proprietary business information and personal information in connection with business operations. The secure maintenance of this information is critical to our operations and business strategy. Some of this information could be an attractive target of criminal attack by third parties with a wide range of motives and expertise, including organized criminal groups, “hacktivists,” patient groups, disgruntled current or former employees and others. Cyber-attacks are of ever-increasing levels of sophistication, and despite our security measures, our information technology and infrastructure may be vulnerable to such attacks or may be breached, including due to employee error or malfeasance. We have implemented information security measures designed to protect patients’
104

personal information and other corporate information (including proprietary information) against the risk of inappropriate and unauthorized external use and disclosure. However, despite these measures, and due to the ever-changing information cyber-threat landscape, we may be subject to data breaches through cyber-attacks. Any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost or stolen. If our information technology systems become compromised, we may not promptly discover the intrusion. Like other companies in our industry, we have experienced attacks to our data and systems, including malware and computer viruses. If our systems failed or were breached or disrupted, we could lose product sales, and suffer reputational damage and loss of customer confidence. Such incidents may result in notification obligations to affected individuals and government agencies, legal claims or proceedings, and liability under foreign, federal and state laws that protect the privacy and security of personal information. Our proprietary and confidential information may also be accessed. Any one of these events could cause our business to be materially harmed and our results of operations may be adversely impacted.
Additionally, in response to the ongoing COVID-19 pandemic, we have generally required all employees who are able to work from home to do so until further notice. As a result of these measures, and as our employees continue to work from home and access our systems remotely, we may be subject to heightened information security risks, including the risk of cyber attacks.
Negative public opinion and increased regulatory scrutiny of recombinant and transgenic products, genetically modified products and genetically modified animals generally may damage public perception of our KANUMA product.
KANUMA is a transgenic product produced in the egg whites of genetically modified chickens who receive copies of the human lysosomal acid lipase gene to produce recombinant human lysosomal acid lipase. The success of KANUMA may depend, in part, on public attitudes of the use of genetic engineering. Public attitudes may be influenced by claims and perceptions that these types of activities or products are unsafe, and our products may not gain sufficient acceptance by, or fall out of favor with, the public or the medical community. Negative public attitudes to genetic engineering activities in general could result in more restrictive legislation or regulations and could impede our ability to conduct our business, delay preclinical or clinical studies, or otherwise prevent us from commercializing our product.
Risks Related to Our Common Stock
Our stock price is volatile.
The trading price of our common stock has been volatile and may continue to be volatile in the future. Many factors could have an impact on our stock price, including fluctuations in our or our competitors’ operating results, clinical trial results or adverse events associated with our products or our competitors' products, product development by us or our competitors, changes in laws, including healthcare, tax or intellectual property laws, intellectual property developments, changes in reimbursement or drug pricing, the existence or outcome of litigation or government proceedings, including the Chugai lawsuits alleging patent infringement, acquisitions or other strategic transactions, and the perceptions of our investors that we are not performing or meeting expectations. In addition, the sales of our common stock by our officers, directors, or by any entities that an officer or director may be affiliated with, may have caused our stock price to drop in the past and any future sales by such officer, director or affiliate (or the perception that such sales could occur) may have a negative impact on our stock price. The trading price of the common stock of many biopharmaceutical companies, including ours, has experienced price and volume fluctuations, which have at times been unrelated to the operating performance of the companies whose stocks were affected.
Anti-takeover provisions in our charter and bylaws and under Delaware law could make a third-party acquisition of us difficult and may frustrate any attempt to remove or replace our current management.
Our corporate charter and by-law provisions may discourage certain types of transactions involving an actual or potential change of control that might be beneficial to us or our stockholders. Our bylaws provide that special meetings of our stockholders may be called only by the Chairman of the Board of Directors, the President, the Secretary, or a majority of the Board of Directors, or upon the written request of stockholders who together own of record 25.0% of the outstanding stock of all classes entitled to vote at such meeting. Our bylaws also specify that the authorized number of directors may be changed only by resolution of the Board of Directors. Our charter does not include a provision for cumulative voting for directors, which may have enabled a minority stockholder holding a sufficient percentage of a class of shares to elect one or more directors. Under our charter, our Board of Directors has the authority, without further action by stockholders, to designate up to five million shares of preferred stock in one or more series. The rights of the holders of common stock will be subject to, and may be adversely affected by, the rights of the holders of any class or series of preferred stock that may be issued in the future.
105

Because we are a Delaware corporation, the anti-takeover provisions of Delaware law could make it more difficult for a third party to acquire control of us, even if the change in control may be beneficial to stockholders. We are subject to the provisions of Section 203 of the Delaware General Laws, which prohibits a person who owns in excess of 15.0% of our outstanding voting stock from merging or
combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15.0% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.


Item 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

ISSUER PURCHASE OF EQUITY SECURITIES (amounts in millions, except per share amounts)

The following table summarizes our common stock repurchase activity during the third quarter 2020:
PeriodTotal Number of Shares PurchasedAverage Price Paid per ShareTotal Number of Shares Purchased as Part of Publicly Announced ProgramsMaximum Dollar Value of Shares that May Yet Be Purchased Under the Program
July 1-31, 2020— $— — $2,174.7 
August 1-31, 20200.2 $102.63 0.2 $2,148.0 
September 1-30, 20200.4 $111.59 0.4 $2,101.1 
Total0.6 $108.16 0.6 
In November 2012, our Board of Directors authorized a share repurchase program. In February 2017, our Board of Directors increased the amount that we are authorized to expend on future repurchases to $1,000.0 under our repurchase program, which superseded all prior repurchase programs. The entire amount authorized pursuant to this February 2017 Board approval has been utilized. On October 22, 2019, the Board of Directors approved a share repurchase authorization of up to $1,000.0. On July 28, 2020, the Board of Directors approved a new share repurchase authorization of up to an additional $1,500.0. The repurchase program does not have an expiration date and we are not obligated to acquire a particular number of shares. The repurchase program may be discontinued at any time at our discretion.
Item 5.OTHER INFORMATION.
None.

106

Item 6.EXHIBITS.

(a)Exhibits:
Confidential Release and Separation Agreement by and between Anne-Marie Law and Alexion Pharmaceuticals, Inc. effective September 26, 2020.
Certificate of Chief Executive Officer pursuant to Exchange Act Rules 13a-14 and 15d-14, as adopted pursuant to Section 302 Sarbanes Oxley Act of 2002.
Certificate of Chief Financial Officer pursuant to Exchange Act Rules 13a-14 and 15d-14, as adopted pursuant to Section 302 of Sarbanes Oxley Act of 2002.
Certificate of Chief Executive Officer pursuant to Section 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act.
Certificate of Chief Financial Officer pursuant to Section 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act.
101 The following materials from the Alexion Pharmaceuticals, Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 formatted in Inline eXtensible Business Reporting Language (iXBRL): (i) the Condensed Consolidated Balance Sheets as of September 30, 2020 and December 31, 2019, (ii) the Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2020 and 2019, (iii) the Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended September 30, 2020 and 2019, (iv) the Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2020 and 2019, (v) the Condensed Consolidated Statements of Changes in Stockholders' Equity the three and nine months ended September 30, 2020 and 2019, and (vi) Notes to Condensed Consolidated Financial Statements.
104
The cover page from this Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, formatted in Inline XBRL.
107

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
ALEXION PHARMACEUTICALS, INC.
By:/s/    Ludwig N. Hantson, Ph.D.
Date: October 29, 2020Ludwig N. Hantson, Ph.D.
Chief Executive Officer
(principal executive officer)
By:/s/    Aradhana Sarin, M.D.
Date: October 29, 2020Aradhana Sarin, M.D.
Executive Vice President and Chief Financial Officer
(principal financial officer)



 EX-10.1 2 exhibitannemarielawsep.htm EX-10.1 Document

CONFIDENTIAL RELEASE AND SEPARATION AGREEMENT
This Confidential Release and Separation Agreement (“Agreement”) is made by and between Anne-Marie Law (“Employee” or “you”), on behalf of yourself and your agents, assignees, heirs, executors, administrators, beneficiaries, trustees, legal representatives and assigns (collectively “Employee Parties”), and Alexion Pharmaceuticals, Inc., its subsidiaries, parents, affiliates, divisions and related entities (“Alexion”), on behalf of its and their successors, predecessors, assigns, present or former directors, officers, executives, agents, attorneys, shareholders, fiduciaries or employees or any person acting on behalf of any of them (collectively, the “Alexion Released Parties”). Reference is made herein to the Employment Agreement by and between you and Alexion Pharmaceuticals, Inc., effective and dated as of June 5, 2017 (the “Employment Agreement”). Any capitalized term used but not defined herein shall have the same meaning as defined in the Employment Agreement.

WHEREAS, you are or were employed by Alexion Pharmaceuticals, Inc. or one of its subsidiaries, parents, affiliates, divisions and related entities; and

WHEREAS, you and Alexion wish to enter into this Agreement to fully resolve any actual or potential claims, including without limitation claims arising out of your employment with and/or separation from Alexion;

NOW, THEREFORE, in consideration of the promises and mutual covenants set forth herein, Employee and Alexion agree as follows:

1.End of Employment. Your employment with Alexion ends effective August 21, 2020 (the “Separation Date”). Regardless of whether you sign this agreement, you will be paid your base salary through the Separation Date and for all accrued unused vacation through the Separation Date. You acknowledge that (i) with the receipt of your final paycheck, you will have received all compensation and benefits that were due to you through the Separation Date as a result of services performed for Alexion, except as provided in this Agreement; (ii) you have reported to Alexion any and all work-related injuries incurred during your employment; (iii) you have reported to Alexion any and all business expenses; and (iv) Alexion has properly provided any leave of absence related to your own or a family member’s health condition, and you have not been subjected to any improper treatment, conduct or actions due to your request for or your taking of such leave.

2.Benefits Continuation. Regardless of whether you execute this Agreement, and assuming that you were enrolled in Alexion’s group health insurance plans prior to the Separation Date, you and your eligible dependents (if any) may continue to participate in Alexion’s group medical, dental, vision and/or employee assistance (EAP) plans for up to eighteen (18) months following the Separation Date (or longer if eligible), subject to the terms of the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”) and provided that you timely and properly elect COBRA continuation coverage and pay the premiums associated with such coverage. You may also continue to participate in Alexion’s Health Care Flexible Spending Account plan through the end of the calendar year if you have a balance in the plan as of the Separation Date. You will receive information regarding COBRA in a separate communication.



3.Consideration. In exchange for your execution of and compliance with this Agreement and your continued compliance with Section 5 of the Employment Agreement, and provided that you do not revoke this Agreement as set forth in Section 19, Alexion will provide you with the severance payments and benefits described in Section 9(c) of the Employment Agreement payable at the times set forth in, and subject to the terms and conditions of, the Employment Agreement. For the avoidance of doubt, such severance payments and benefits are set forth below in this Section 3 and are in full satisfaction of any rights you may have under the Employment Agreement. Any payments made under this Section 3 shall be offset by any amounts you owe to Alexion and any outstanding balance for your personal expenses on any Alexion-issued credit card that is not timely paid by you.

(a)Severance Pay. In accordance with Section 9(c)(i) of the Employment Agreement, Alexion will pay you a one-time, lump sum payment equal to $1,860,862.50, less applicable deductions and withholdings. This amount will be paid sixty (60) days following the Separation Date.

(c)COBRA Subsidy. In accordance with Section 9(c)(ii) of the Employment Agreement, and subject to your timely election to continue your participation and that of your eligible dependents in Alexion’s group medical, dental and/or vision plans under COBRA, Alexion will pay you an additional one-time, lump sum payment in the total gross amount of
$44,708.72 that, after all applicable taxes and withholdings are deducted, is the economic equivalent of the monthly health premiums paid by Alexion on behalf of you and your eligible dependents immediately prior to the Separation Date for a period of eighteen (18) months. This amount will be paid sixty (60) days following the Separation Date, provided that sufficient proof of COBRA enrollment is provided in advance.

(d)Outplacement. You will be eligible to participate in an outplacement assistance program though Essex Partners. All payments for outplacement shall be made by Alexion directly to the vendor. You must initiate contact with the vendor no later than three (3) months after the Separation Date in order to receive outplacement assistance.

(e)Equity Treatment.

(i)Time-Vesting RSUs Eligible for Vesting Acceleration. Any outstanding and unvested portion of the awards of time-vesting restricted stock units that were granted to you under the Alexion Pharmaceuticals, Inc. 2017 Incentive Plan (the “Incentive Plan”) on June 7, 2017 and February 28, 2018 (the “Eligible RSUs”) will accelerate and fully vest on the Separation Date. The Eligible RSUs will be settled and released to you as soon as reasonably practicable following the Effective Date (defined in Section 19), and in no event later than thirty (30) days following the Effective Date.

(ii)PSUs Eligible to Be Earned. The number of shares underlying the awards of performance stock units granted to you under the Incentive Plan on February 28, 2018, February 28, 2019 and February 28, 2020 will be pro-rated to the end of the month of the Separation Date and the pro-rated portion of such awards (the “Continuing PSUs”) will remain outstanding and will vest, if at all, upon certification of the performance criteria for each such award, with such certification (if any) to be completed at the time and as provided for in the
Page 2


Incentive Plan and the applicable award agreement evidencing such Continuing PSUs. The Continuing PSUs that are earned and become payable under this subsection (e)(ii), if any, will be settled and released to you as soon as reasonably practicable following the certification of the performance criteria for the applicable award, but in no event later than the March 15 following the end of the applicable Performance Period (as defined in the applicable award agreement). Except as may be specifically provided in this Agreement, the Continuing PSUs will be governed by the terms of the Incentive Plan and the applicable award agreement evidencing such awards.

(iii)All Other Awards. All other equity awards other than the Eligible RSUs and the Continuing PSUs and not otherwise described in this Section 3(e), including the awards of restricted stock units granted to you under the Incentive Plan on February 28, 2019 and February 28, 2020, shall be canceled without consideration upon the Separation Date. For the avoidance of any doubt, your equity awards outstanding as of the Separation Date and the treatment provided for in this Agreement for each award is outlined in Exhibit A attached hereto.

4.Non-Admission. Alexion’s offer of this Agreement to you and any payments made under this Agreement do not constitute an admission by Alexion that you have any claim of any kind against Alexion or that Alexion admits to any liability. Further, by signing this Agreement, you are not admitting any wrongdoing.

5.Release. In exchange for the consideration described in Section 3 of this Agreement, and provided that you do not revoke this Agreement as set forth in Section 19, you and the Employee Parties, unless specifically excluded by this Agreement, agree to release Alexion and the Alexion Released Parties from all known and unknown claims of any type to date, including without limitation, any known or unknown claims arising out of anything having to do with your employment with Alexion or the end of your employment. This means that you and the Employee Parties give up these claims to the fullest extent permitted by law, including without limitation:

(a)claims for any pay, compensation or benefits, bonuses, commissions, incentive pay, paid or unpaid leave or time off, salary, separation or severance pay or benefits, wages, unpaid accrued vacation or other paid time off, overtime, unvested equity, or any other form of compensation whatsoever (including penalties for non-payment), costs, damages, interest, expenses or insurance;

(b)claims concerning any express or implied employment contracts, covenants or duties;

(c)claims for defamation; detrimental reliance; fraud; impairment/loss of business/economic opportunity; insufficiency of termination notice; intentional/negligent infliction of emotional distress; interference with contractual or legal rights; invasion of privacy; loss of consortium; misrepresentation; negligence including negligent hiring/retention/ supervision; personal injury; premises liability; promissory estoppel; public policy violation; retaliatory discharge; tortious interference; posting requirement violations; records access violations; wrongful termination; or any other federal, state, local or common law claims;

Page 3


(d)claims of discrimination based on age, ancestry, benefit entitlement, color, concerted activity, disability, failure to accommodate, gender, gender identity or expression, genetics, harassment, income source, leave rights, marital status, military status, national origin, parental status, perception of a protected characteristic, political affiliation, race, religion, retaliation, sex, sexual orientation, union activity, veteran status or other legally protected status; claims that any payment under this Agreement was affected by any such discrimination; or any other claims under Title VII of the Civil Rights Act of 1964; the Civil Rights Act of 1866; the Civil Rights Act of 1991; the Equal Pay Act of 1963; the Age Discrimination in Employment Act (“ADEA”) and the Older Workers Benefit Protection Act; the Americans with Disabilities Act; the Family and Medical Leave Act; the Employee Retirement Income Security Act; the Sarbanes-Oxley Act of 2002; or the False Claims Act; each as amended;

(e)claims arising under state or local law, including, but not limited to, the Connecticut Fair Employment Practices Act, Conn. Gen. Stat. §§ 46a-51 et seq.; the Connecticut Human Rights and Opportunities Act, Conn. Gen. Stat. § 46a-60; the Connecticut Equal Pay Law, Conn. Gen. Stat. § 31-75; the Connecticut Family and Medical Leave Law, Conn. Gen. Stat. §§ 31-51kk et seq.; the Massachusetts Law Prohibiting Unlawful Discrimination, Mass. Gen. Laws. ch. 151B, §§ 1 et seq.; the Massachusetts Equal Pay Law, Mass. Gen. Laws ch. 149, §§ 105A et seq.; the Massachusetts Right to be Free from Sexual Harassment Law, Mass. Gen. Laws ch. 214 § 1C et seq.; the Massachusetts Discrimination Against Certain Persons on Account of Age Law, Mass. Gen. Laws ch. 149, §§ 24B et seq.; the Massachusetts Equal Rights Law, Mass. Gen. Laws ch. 93, §§ 102 et seq.; the Massachusetts Family and Medical Leave Law, Mass. Gen. Laws ch. 149, § 52D et seq.; the Massachusetts Payment of Wages Act, Mass. Gen. Laws ch. 149; the Massachusetts Minimum Fair Wages Act, Mass. Gen. Laws ch. 151; the Massachusetts Paid Family and Medical Leave law, Mass. Gen. Laws ch. 175M; the District of Columbia Human Rights Act, D.C. Code 2-1401.01 et seq.; and the Georgia Equal Pay Act,
O.C.G.A. §§ 34-5-1 et seq., each as amended; and

(f)any right to be or remain a member of any class, representative or collective action against Alexion or the Alexion Released Parties.

You acknowledge and agree that, as a condition of this Agreement, you and the Employee Parties expressly release all rights and claims against Alexion or the Alexion Released Parties that you know about, as well as those you may not know about. For the purpose of implementing a full and complete release and discharge of Alexion, the Alexion Released Parties, and others released herein, you expressly acknowledge that this Agreement is intended to include and does include in its effect, without limitation, all claims which you do not know or suspect to exist, and that this Agreement contemplates the extinguishment of any such claim or claims, except to the extent precluded by federal, state or local statutes.

6.Disclosure. In addition to the foregoing, and in further exchange for the consideration described in Section 3 of this Agreement, you specifically represent and warrant that as of the date that you execute this Agreement, either you (i) have disclosed to Alexion’s General Counsel or to another member of Alexion’s internal Legal Department in writing any matter that you know, suspect or have reason to know or suspect could constitute an actual or potential violation of the Alexion Code of Conduct, or similar code of business conduct and ethics, or of any internal or external legal, regulatory or compliance requirement applicable to
Page 4


Alexion in any jurisdiction in which it does business, or (ii) have no information concerning any such matter.

7.Promise Not to Sue. Without limiting your rights under Section 13 of this Agreement, you promise not to sue Alexion or any Alexion Released Party for any claims covered by Section 5 of this Agreement and not excluded by any other section of this Agreement. This promise not to sue is separate from and in addition to your promises in Section 5 of this Agreement.

8.Confidential Terms. You agree that, except as required by applicable federal, state, or local law, you will keep all of the terms of this Agreement strictly confidential, including the amount of the payment provided to you under this Agreement and the fact of this Agreement (“Confidential Terms”). Subject to the second and third sentences of Section 13 of this Agreement, you will not disclose these Confidential Terms to anyone except your immediate family members and your legal/financial advisors, except to the extent required to comply with or enforce this Agreement, or as required to comply with: a valid subpoena, a court order, the submission of information to bank personnel in connection with a personal loan, outplacement personnel, tax or unemployment authorities, or another similar legal process. You further represent that prior to executing this Agreement, you have not disclosed its terms in a manner inconsistent with this confidentiality provision.

9.Reference. If the Company is asked to provide you and oral reference, such references are to be directed to Alexion’s HR Central department which will confirm only dates of employment and positions held. The Company agrees to provide you with the written letter of reference attached hereto as Exhibit B.

10.Continuing Obligations. You acknowledge and agree that you must abide by all of the obligations set out in your Employment Agreement, including without limitation nondisclosure, assignment of inventions, non-competition, non-solicitation, non- disparagement,and that these obligations survive your separation from Alexion and remain in full force and effect You also agree to comply with the covenants listed below following the Separation Date. In the event of any conflict between this Agreement and the Employment Agreement, the agreements will be interpreted to provide Alexion with cumulative rights and remedies such that the terms most protective of Alexion are enforced.

(a)Non-Disclosure of Confidential Information. You agree that, during your employment with Alexion, you had access to a variety of trade secret and/or confidential and proprietary information relating to Alexion’s business that is not generally available to the public through legitimate means, including but not limited to information relating to business opportunities, operations, cost and pricing data, strategies, forecasts, customer lists, improvements, technologies, techniques, processes, research, methods, procedures, testing systems, assays, compounds, molecules, organisms, gene sequences, cell lines, other reagents, uses of any of the foregoing, manufacture of any of the foregoing, computer software and programs (including source code and related documentation), test and/or experimental data and results, specifications, laboratory notebooks and drawings, and/or other information which has not been made available to the general public by senior management (all of which information in this Section 10(a) is collectively referenced as “Confidential Information”). You acknowledge
Page 5


and agree that such Confidential Information is Alexion property, and you shall not, directly or indirectly, use or disclose it for your own or a third party’s benefit.

(b)Assignment of Inventions. You acknowledge and agree that during the course of your employment with Alexion you may have participated in conceiving ideas or making discoveries and inventions, which Alexion considers to be proprietary and confidential, and includes all information and materials that you create, discover, develop, make, or which are made known by you or to you in connection with your employment with Alexion (“Proprietary Information”). Alexion (or its assigns) solely own all Proprietary Information and related patents, copyrights, trade secrets, trademarks and other intellectual property rights. You hereby assign and transfer to Alexion, and to the extent any such assignment cannot be made at present, will assign and transfer to Alexion, any and all right, title and interest that you may have or acquire in Proprietary Information, including intellectual property rights therein. Also, you agree to cooperate with Alexion’s reasonable requests for assistance in perfecting its ownership of Proprietary Information, such as by signing necessary documents, without additional compensation (but at Alexion’s expense). Notwithstanding the above, this assignment of rights does not apply to any inventions, ideas, discoveries, know-how, trade secrets, and other intellectual property for which no equipment, supplies, facility, or trade secret information of Alexion was used and which you developed entirely on your own time, unless (a) the invention relates (i) to Alexion’s business; or (ii) to Alexion’s actual or demonstrably anticipated research or development; or (b) the invention results from your work for Alexion. You do not have any right, title or interest in or to, or any license under, any patent, copyright, trademark or other intellectual property right of Alexion, and this Agreement does not grant you any right, title or interest in or to, or any license under, Proprietary Information. You will not seek any patent or any other form of intellectual property protection with respect to Proprietary Information, nor use Proprietary Information to obtain or seek to obtain a commercial advantage over Alexion. Alexion will have the sole right (but not any obligation) to use, assert and/or apply for patent, copyright, trademark and other intellectual property protections for Proprietary Information. You agree to assist Alexion in every reasonable way, without additional compensation (but at Alexion’s expense), to apply for, prosecute, maintain, enforce, defend and protect patent, copyright, trademark and other protection for Proprietary Information. You will, whether during or following your employment with Alexion, execute any and all assignments, transfers, applications and other papers that are necessary or helpful to Alexion in furtherance of the foregoing. If Alexion is unable for any reason to secure your signature to a document that is lawful and necessary to apply for, prosecute or maintain any patent or patent application concerning Proprietary Information, you hereby irrevocably designate and appoint Alexion and its duly authorized officers and agents as your agents and attorneys-in-fact to act for you in such matter with the same legal force and effect as if done by you.

(c)Non-Competition. You agree that for twelve (12) months following the Separation Date, you shall not, directly or indirectly, (a) own, operate, finance, control, or participate in the formation of, any Competing Organization in the Restricted Territory other than as a passive owner of not more than two percent (2%) of the outstanding shares of capital stock of any publicly traded corporation; or (b) render services to, give advice to, consult with, or be employed by a Competing Organization in the Restricted Territory if such services, advice, consultation, or employment involve (i) research, development, production, distribution, marketing, providing, selling or commercialization of Competing Products, (ii) assisting others
Page 6


in the research, development, production, distribution, marketing, providing, selling or commercialization of Competing Products; (iii) developing or implementing strategies to compete with Alexion with respect to Competing Products; (iv) directly or indirectly supervising or managing employees or other personnel who compete with Alexion with respect to Competing Products; or (iv) utilizing or disclosing Confidential Information. A “Competing Organization” means any person or entity that is engaged in, or about to become engaged in, the research, development, production, distribution, marketing, providing, selling or commercialization of a Competing Product. A “Competing Product” is a product, product candidate, process or service that is or would be directly or indirectly competitive with a product, product candidate, process or service with which you worked or about which you acquired Confidential Information through your work with Alexion within in the twenty-four month period prior to the Separation Date. The “Restricted Territory” means the United States or America, and any other country (or political subdivision thereof) in which Alexion conducts business and, within the twelve-month period prior to the Separation Date (i) in which you performed services for Alexion; (ii) over which you had sales or management responsibilities for Alexion; (iii) in which Alexion employed or engaged Restricted Employees whom you directly or indirectly supervised or managed or with whom you collaborated; or (iv) about which you had access to Confidential Information. A “Restricted Employee” means a person who is employed or engaged by Alexion as an employee or independent contractor (and has not received advance notice of Alexion’s termination of his or her employment or engagement by Alexion) and (i) with whom you had business-related contact within the twelve-month period prior to the Separation Date or (ii) about whom you had access to Confidential Information within the twelve-month period prior to the Separation Date.

(d)Remedies. You acknowledge that you have read and considered the restraints imposed upon you pursuant to this Section 10. You agree without reservation that these restraints are necessary for the reasonable and proper protection of Alexion, and are reasonable in respect to subject matter, length of time, and geographic area. If you commit a breach, or threaten to commit a breach, of any provision of this Section 10, Alexion shall have the right and remedy to have the provisions of this Agreement specifically enforced by any court having equity jurisdiction, it being acknowledged and agreed that any such breach or threatened breach will cause irreparable injury to Alexion and that money damages may not provide an adequate remedy to Alexion. You therefore agree that Alexion, in addition to any other remedies available to it, shall be entitled to preliminary and permanent injunctive relief against any breach or threatened breach by Alexion of any of the provisions of this Section 10, without having to post bond. So that Alexion may enjoy the full benefit of the covenants contained above, you agree that periods of time set forth in each of the covenants in this Section 10 shall be tolled, and shall not run, during the period of any breach by you of such covenants.

(e)Severability; Modification. If any of the covenants contained in this Section 10, or any part thereof, is hereafter construed to be invalid or unenforceable, the same shall not affect the remainder of the covenant or covenants, which shall be given full effect without regard to the invalid portions. Moreover, if any of the covenants contained in this Section 10, or any part thereof, are held to be unenforceable because of the duration or scope of such provision or the area covered thereby, you and Alexion agree that the court making such determination shall have the power to reduce the duration and/or area of such provision, and you and Alexion intend for the court to modify the duration and/or area of such provision to the
Page 7


maximum extent permitted by law. You and Alexion agree that in its reduced form, such provision shall then be enforceable. In the event that the courts of any state of the United States shall hold any such covenant wholly unenforceable by reason of the breadth of such scope or otherwise, it is the intention of the parties hereto that such determination not bar or in any way affect Alexion’s right to the relief provided above in the courts of any other states within the geographical scope of such other covenants, as to breaches of such covenants in such other respective jurisdictions, the above covenants as they relate to each state being, for this purpose, severable into diverse and independent covenants.

11.Return of Alexion Property. You agree that you have returned or will return immediately, and no later than the Effective Date, all Alexion property or assets that you had or controlled during your employment, including without limitation: your Alexion identification badge; key fob; lab notebooks; laptop, desktop and handheld computers; mobile phones; tablets; personal digital assistants; secure ID cards; P-cards and corporate credit cards; keys; tools and tool boxes; personal protective equipment; external hard drives; flash drives; power and sync cables; all originals and soft or hard copies of documents such as e-mails, facsimiles, handbooks, letters, manuals, or memoranda; and any other Alexion-related communications, material, hardware, equipment or property. You acknowledge and agree that this obligation to return Alexion property includes, but is not limited to, all Confidential Information and other Alexion property within your possession, custody, or control, regardless of the form in which you held or acquired it, and includes all Alexion property contained on your personal electronic document storage accounts or electronic devices, including computers, computer equipment, mobile devices, external storage devices, smart phones, tablets, USB devices, and internet or cloud- based accounts. By your signature below, you warrant and representation that you have conducted a thorough search for Alexion property in all such electronic document storage accounts and electronic devices, as well as all files and hard copy documents in your possession, custody, or control.

12.Cooperation. You agree to cooperate with, and assist, Alexion to ensure a smooth transition of your work responsibilities. At any time following the Separation Date, you will provide such information as Alexion may reasonably request with respect to any Alexion- related transaction or other matter in which you were involved in any way while employed by Alexion. You further agree to assist and cooperate with Alexion in connection with the defense, prosecution, government investigation, or internal investigation of any claim or matter that may be made against, concerning, or by Alexion. Such assistance and cooperation shall include timely, comprehensive, and truthful disclosure of all relevant facts known to you, including through in-person interview(s) with Alexion’s internal Legal Department or outside counsel for Alexion. You shall be entitled to reimbursement for all properly documented expenses incurred in connection with rendering services under this Section, including, but not limited to, reimbursement for all reasonable travel, lodging, and meal expenses.

13.Non-Interference with Rights. Nothwithstanding anything to the contrary in this Agreement, the Release set forth in Section 5 of this Agreement excludes: (i) any claims for breach of this Agreement, (ii) claims challenging the enforceability of this Agreement under the ADEA, (iii) claims which cannot be waived by law, such as claims for unemployment or worker’s compensation benefits, (iv) claims for vested/earned benefits under ERISA-covered employee benefit plans, and (v) claims and rights to indemnification and/or defense to the fullest
Page 8


extent permitted under applicable law, Alexion's then current articles of incorporation and by- laws, and any Alexion liability insurance policies and paragraph 11 of the Employment Agreement. Further, you understand, agree and acknowledge that nothing contained in this Agreement, including but not limited to Sections 5 (Release), 6 (Disclosure), 7 (Promise Not to Sue), 8 (Confidential Terms), 10 (Continuing Obligations), 11 (Return of Alexion Property), 12 (Cooperation), will prevent, prohibit or restrict you from reporting possible violations of any law or regulation to, making disclosures to, and/or participating or cooperating in any investigation or proceeding conducted by the National Labor Relations Board, the Equal Employment Opportunity Commission, the U.S. Department of Labor, the Securities and Exchange Commission (SEC), and/or any other governmental agency or entity charged with the enforcement of any laws, or from exercising rights under Section 7 of the National Labor Relations Act to engage in joint activity with other employees. Notwithstanding any other provision in this Agreement, you are not required to seek authorization from Alexion or to notify Alexion before making any such report or disclosure, or before participating or cooperating in any investigation or proceeding. You acknowledge that you are waiving any right you may have to benefit in any manner from any relief (whether monetary or otherwise) arising out of any proceeding, including any proceeding conducted by the Equal Employment Opportunity Commission or comparable state or local agency, except as may be required by law (for example, you may recover money properly awarded by the U.S. Securities and Exchange Commission as a reward for providing information to that agency). You acknowledge that you have been notified in accordance with the Defend Trade Secrets Act of 2016, 18 U.S.C. § 1833(b), that you will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (a) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made in a complaint or other document that is filed under seal in a lawsuit or other proceeding. You further acknowledge that you have been notified that if you file a lawsuit for retaliation against Alexion for reporting a suspected violation of law, you may disclose Alexion’s trade secrets with your attorney and use the trade secret information related to that suspected violation of law in the court proceeding if you: (a) file any document containing the trade secret under seal; and (b) do not disclose the trade secret, except pursuant to court order.

14.Remedies. You agree that if you are found to have violated this Agreement by a court of competent jurisdiction, you will pay Alexion’s reasonable attorneys’ fees, court costs and other expenses to enforce this Agreement, in addition to any other available relief. Without limiting the foregoing, you further acknowledge and agree that, if you violate the terms of this Agreement by, without limitation, violating the covenants in Sections 5 (Release), 6 (Disclosure), 7 (Promise Not to Sue), 8 (Confidential Terms), 10 (Continuing Obligations), 11 (Return of Alexion Property), or 12 (Cooperation), Alexion may (a) recapture the value of any proceeds from the exercise or sale of equity awards that were unvested as of the Separation Date, (b) require you to return all but $100.00 of the payments and benefits provided to you under this Agreement, and (c) suspend payment of any further payments and benefits provided to you under this Agreement. Nothing herein shall limit your rights under Section 13 of this Agreement.

Page 9


15.Choice of Law and Forum. This Agreement shall be governed by and construed under the laws of the Commonwealth of Massachusetts, without regard to its conflicts of law rules. You and Alexion hereby consent to the jurisdiction of the federal and state courts located in the Commonwealth of Massachusetts to resolve any disputes arising out of the interpretation or administration of this Agreement.

16.Successors. This Agreement shall be binding upon and inure to the benefit of you and the Employee Parties, Alexion, the Alexion Released Parties, and their respective heirs, representatives, executors, administrators, successors, insurers, and assigns, and shall inure to the benefit of each and all of them.

17.Severability. The provisions of this Agreement are severable, and if any part of it is found to be unenforceable or invalid, the other Sections shall remain fully valid and enforceable.

18.Representations. You acknowledge and agree that:

(a)you are advised, and by being given a copy of this Agreement, have been advised to consult with an attorney of your own choice, and you have been given the opportunity to do so prior to signing this Agreement;

(b)you have not been promised anything besides what is in this Agreement;

(c)the payments and benefits described in this Agreement exceeds the amount that you otherwise would receive at the end of your employment with Alexion and provides adequate and sufficient consideration to support this Agreement;

(d)you have reviewed this Agreement and are signing this Agreement knowingly and voluntarily;

(e)you have not been coerced or threatened into signing this Agreement;

(f)you do not have any pending court or administrative complaint or action against Alexion;

(g)you were not required to waive any attorneys’ fees as a condition of this Agreement; and

(h)this Agreement can only be modified in a written document signed by both you and Alexion.

19.Time Periods. You are given twenty-one (21) days from the date you receive this Agreement or until September 18, 2020 to consider it before executing it (“Consideration Period”). You may sign this agreement any time after your Separation Date and before the close of business on the final day of the Consideration Period. If you sign this Agreement prior to the end of the Consideration Period, your signature constitutes a voluntary waiver of this
Page 10


Consideration Period. You agree with Alexion that changes to this Agreement, whether material or immaterial, do not restart the running of the Consideration Period.

You will have seven (7) calendar days after you sign this Agreement to revoke it (“Revocation Period”) by providing written notice to Alexion during the Revocation Period. Any revocation must be made both: a) via email sent to Ellen.Chiniara@alexion.com no later than 5:00pm EST on final day of the Revocation Period; and b) via writing postmarked no later than the close of business on the final day of the Revocation Period and addressed to:

Ellen Chiniara
Executive Vice President, Chief Legal Officer, and Corporate Secretary Alexion Pharmaceuticals, Inc.
121 Seaport Blvd.
Boston, MA 02210

This Agreement will not become effective or enforceable until the Revocation Period has expired (“Effective Date”). If you do not revoke this Agreement, you will receive the consideration described in Section 3 of this Agreement.

Notwithstanding anything to the contrary in this Agreement, if the Consideration Period or the Revocation Period spans two calendar years, any payments to which you become entitled under this Agreement following the Effective Date will be paid in the second calendar year to the extent such payments constitute “nonqualified deferred compensation” within the meaning of IRC §409A (as defined below).
20.Section 409A. This Agreement is intended to comply with the applicable requirements of Internal Revenue Code Section 409A (“IRC §409A”) and shall be construed accordingly. All references in this Agreement to termination of employment, a termination, retirement, cessation of employment, separation from service, and correlative terms, that result in the payment or vesting of any amounts or benefits that constitute “nonqualified deferred compensation” within the meaning of IRC §409A shall be construed to require a Separation from Service (as defined below), and the date of such termination in any such case shall be construed to mean the date of the Separation from Service. Each of the payments required to be made under this Agreement shall be treated as a separate payment and the right to a series of installment payments under this Agreement shall be treated as a right to a series of separate payments for purposes of IRC §409A. If you are a Specified Employee (as defined below) on the Separation Date, if any payment hereunder that is payable by reason of the termination of your employment constitutes “nonqualified deferred compensation” subject to IRC §409A and would otherwise have been required to be paid during the six (6)-month period following such termination of employment, it shall instead be delayed and paid, without interest, in a lump sum on the date that is six (6) months and one (1) day after your termination of employment (or, if earlier, the date of your death). You are solely responsible for any tax penalties that may be imposed on you as a result of IRC §409A. In no event shall Alexion have any liability relating to the failure or alleged failure of any payment or benefit under this Agreement to comply with, or be exempt from, the requirements of IRC §409A. For purposes of the foregoing:

“Separation from Service” shall mean a “separation from service” (as that term is defined at Section 1.409A-1(h) of the Treasury Regulations under IRC §409A after giving effect
Page 11


to the presumptions contained therein) from Alexion and from all other corporations and trades or businesses, if any, that would be treated as a single “service recipient” with Alexion under Section 1.409A-1(h)(3) of such Treasury Regulations. The Board of Directors of Alexion Pharmaceuticals, Inc. (the “Board”) or the Leadership and Compensation Committee thereof (the “Committee”) may, but need not, elect in writing, subject to the applicable limitations under IRC §409A, any of the special elective rules prescribed in Section 1.409A-1(h) of the Treasury Regulations for purposes of determining whether a “separation from service” has occurred. Any such written election shall be deemed part of this Agreement; and

“Specified Employee” shall mean an individual determined by the Board, the Committee, or their delegate, to be a specified employee as defined in subsection (a)(2)(B)(i) of IRC §409A. The Committee may, but need not, elect in writing, subject to the applicable limitations under IRC §409A, any of the special elective rules prescribed in Section 1.409A-1(i) of the Treasury Regulations for purposes of determining “specified employee” status. Any such written election shall be deemed part of this Agreement.

21.Medicare. Employee acknowledges and agrees that Employee is not Medicare eligible, is not a Medicare beneficiary, and is not within thirty (30) months of becoming Medicare eligible, and, therefore, that Employee is not aware of any medical expenses that Medicare has paid and for which any of Released Party is or could be liable now or in the future. If any person, entity, or governmental agency seeks damages (including multiple damages) and/or other relief from Alexion or any Alexion Released Party relating to any alleged injuries or claims of Employee, Employee will indemnify, defend, and hold Alexion and the Alexion Released Parties harmless from any and all such damages (including multiple damages) and/or other relief, claims, liens, Medicare conditional payments, and rights to payment, including any attorneys’ fees sought by such entities.

22.Entire Agreement. This Agreement, the Employment Agreement and the equity agreements referenced herein, as well as Exhibits A and B of this Agreement set forth the entire agreement between the parties. You are not relying on any other agreements or oral representations not fully addressed in this Agreement. Any prior agreements between or directly involving you and Alexion are superseded by this Agreement. In the event of any conflict between this Agreement and the Employment Agreement and equity agreements referenced herein, , the agreements will be interpreted to provide Alexion with cumulative rights and remedies such that the terms most protective of Alexion are enforced. Further, and for the avoidance of doubt, to the extent of any conflict between the terms of this Agreement and any other document concerning severance benefits, the provisions of this Agreement shall prevail. The headings in this Agreement are provided for reference only and shall not affect the substance of this Agreement. Further, for the avoidance of doubt, your rights to indemnification in your Employment Agreement survive your separation from Alexion.

23.Execution. This Agreement may be executed in two or more counterparts, including by electronic delivery through DocuSign, each of which shall be deemed an original, and together, all of which shall constitute one original document. Original signatures that are transmitted by fax or electronic mail shall be considered original signatures under this Agreement. This Agreement is and shall be deemed to be executed under seal.

Page 12



INTENDING TO BE BOUND, the undersigned have executed this Agreement under seal as of the date written below.


ANNE-MARIE LAW


/s/ Anne-Marie Law Date:18-Sep-2020 Employee Signature

ALEXION PHARMACEUTICALS, INC.

/s/ Ludwig Hantson Date: 18-Sep-2020
By: Ludwig Hantson
Chief Executive Officer


Page 13

 EX-31.1 3 alxnex311q320.htm EX-31.1 Document

Exhibit 31.1
I, Ludwig N. Hantson, Ph.D., certify that:
1I have reviewed this quarterly report on Form 10-Q of Alexion Pharmaceuticals, Inc.;
2Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
 
Dated:October 29, 2020 /s/    LUDWIG N. HANTSON, Ph.D.
 Chief Executive Officer


 EX-31.2 4 alxnex312q320.htm EX-31.2 Document

Exhibit 31.2
I, Aradhana Sarin, certify that:
1I have reviewed this quarterly report on Form 10-Q of Alexion Pharmaceuticals, Inc.;
2Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
Dated:October 29, 2020 /s/     ARADHANA SARIN, M.D.
 Executive Vice President and Chief Financial Officer


 EX-32.1 5 alxnex321q320.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the quarterly report on Form 10-Q of Alexion Pharmaceuticals, Inc. (the “Company”) for the fiscal quarter ended September 30, 2020 as filed with the Securities and Exchange Commission (the “Report”), I, Ludwig N. Hantson, Ph.D., Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, to my knowledge, that:
(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Dated:October 29, 2020 
/s/    LUDWIG N. HANTSON, Ph.D.
 Chief Executive Officer
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.


EX-32.2 6 alxnex322q320.htm EX-32.2 Document

Exhibit 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the quarterly report on Form 10-Q of Alexion Pharmaceuticals, Inc. (the “Company”) for the fiscal quarter ended September 30, 2020 as filed with the Securities and Exchange Commission (the “Report”), I, Aradhana Sarin, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, to my knowledge, that:
(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
Dated:October 29, 2020 
/s/     ARADHANA SARIN, M.D.
 Executive Vice President and Chief Financial Officer
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.


EX-101.SCH 7 alxn-20200930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income Statement link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - Condensed Consolidated Statements of Changes in Stockholder's Equity Statement link:presentationLink link:calculationLink link:definitionLink 1007008 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Business link:presentationLink link:calculationLink link:definitionLink 2102102 - Disclosure - Basis of Presentation and Principles Of Consolidation link:presentationLink link:calculationLink link:definitionLink 2203201 - Disclosure - Basis of Presentation and Principles Of Consolidation (Policies) link:presentationLink link:calculationLink link:definitionLink 2104103 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 2406401 - Disclosure - Acquisitions (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Acquisitions (Summary of Total Consideration) (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Acquisitions (Pro Forma Information) (Details) link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - Acquisitions (Acquisition-Related Costs) (Details) link:presentationLink link:calculationLink link:definitionLink 2110104 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2311302 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2412405 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2113105 - Disclosure - Intangible Assets and Goodwill link:presentationLink link:calculationLink link:definitionLink 2314303 - Disclosure - Intangible Assets and Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 2415406 - Disclosure - Intangible Assets and Goodwill (Schedule of Intangible Assets and Goodwill) (Details) link:presentationLink link:calculationLink link:definitionLink 2415406 - Disclosure - Intangible Assets and Goodwill (Schedule of Intangible Assets and Goodwill) (Details) link:presentationLink link:calculationLink link:definitionLink 2416407 - Disclosure - Intangible Assets and Goodwill (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2417408 - Disclosure - Intangible Assets and Goodwill (Changes in Goodwill) (Details) link:presentationLink link:calculationLink link:definitionLink 2118106 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2319304 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2420409 - Disclosure - Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2421410 - Disclosure - Debt (Schedule of Debt) (Details) link:presentationLink link:calculationLink link:definitionLink 2122107 - Disclosure - Earnings Per Common Share link:presentationLink link:calculationLink link:definitionLink 2323305 - Disclosure - Earnings Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2424411 - Disclosure - Earnings Per Common Share (Summary Of Calculation Of Basic And Diluted Earnings Per Share) (Details) link:presentationLink link:calculationLink link:definitionLink 2425412 - Disclosure - Earnings Per Common Share (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2126108 - Disclosure - Marketable Securities link:presentationLink link:calculationLink link:definitionLink 2327306 - Disclosure - Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 2428413 - Disclosure - Marketable Securities (Proceeds from Sale) (Details) link:presentationLink link:calculationLink link:definitionLink 2429414 - Disclosure - Marketable Securities (Available-for-sale Investments by Classification in Balance Sheet) (Details) link:presentationLink link:calculationLink link:definitionLink 2430415 - Disclosure - Marketable Securities (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2131109 - Disclosure - Derivative Instruments and Hedging Activities link:presentationLink link:calculationLink link:definitionLink 2332307 - Disclosure - Derivative Instruments and Hedging Activities (Tables) link:presentationLink link:calculationLink link:definitionLink 2433416 - Disclosure - Derivative Instruments and Hedging Activities (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2434417 - Disclosure - Derivative Instruments and Hedging Activities (Schedule of Interest Rate Contracts) (Details) link:presentationLink link:calculationLink link:definitionLink 2435418 - Disclosure - Derivative Instruments and Hedging Activities (Schedule Of Other Comprehensive Income And Earnings From Foreign Exchange Contracts) (Details) link:presentationLink link:calculationLink link:definitionLink 2436419 - Disclosure - Derivative Instruments and Hedging Activities (Schedule Of Fair Value Of Outstanding Derivatives) (Details) link:presentationLink link:calculationLink link:definitionLink 2437420 - Disclosure - Derivative Instruments and Hedging Activities (Offsetting Assets and Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 2138110 - Disclosure - Other Investments link:presentationLink link:calculationLink link:definitionLink 2439421 - Disclosure - Other Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2140111 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2441422 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 2142112 - Disclosure - Other Comprehensive Income and Accumulated Other Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 2343308 - Disclosure - Other Comprehensive Income and Accumulated Other Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 2444423 - Disclosure - Other Comprehensive Income and Accumulated Other Comprehensive Income (Changes in AOCI) (Details) link:presentationLink link:calculationLink link:definitionLink 2445424 - Disclosure - Other Comprehensive Income and Accumulated Other Comprehensive Income (Significant Reclassifications from AOCI) (Details) link:presentationLink link:calculationLink link:definitionLink 2146113 - Disclosure - Fair Value Measurement link:presentationLink link:calculationLink link:definitionLink 2347309 - Disclosure - Fair Value Measurement (Tables) link:presentationLink link:calculationLink link:definitionLink 2448425 - Disclosure - Fair Value Measurement (Schedule Of Assets And Liabilites Measured At Fair Value) (Details) link:presentationLink link:calculationLink link:definitionLink 2449426 - Disclosure - Fair Value Measurement (Schedule Of Acquisition-Related Contingent Consideration) (Details) link:presentationLink link:calculationLink link:definitionLink 2450427 - Disclosure - Fair Value Measurement (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2151114 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 2352310 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 2453428 - Disclosure - Revenue Recognition (Disaggregation of Revenue by Product and Geographical Region) (Details) link:presentationLink link:calculationLink link:definitionLink 2454429 - Disclosure - Revenue Recognition (Summary of Receivables and Contract Liabilities from Contracts) (Details) link:presentationLink link:calculationLink link:definitionLink 2155115 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2356311 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2457430 - Disclosure - Income Taxes (Schedule of Income Tax Provision and Effective Tax Rate) (Details) link:presentationLink link:calculationLink link:definitionLink 2458431 - Disclosure - Income Taxes (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2159116 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2460432 - Disclosure - Commitments and Contingencies (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2161117 - Disclosure - Restructuring and Related Expenses link:presentationLink link:calculationLink link:definitionLink 2362312 - Disclosure - Restructuring and Related Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 2463433 - Disclosure - Restructuring and Related Expenses (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2464434 - Disclosure - Restructuring and Related Expenses (Schedule of Restructuring and related Costs) (Details) link:presentationLink link:calculationLink link:definitionLink 2465435 - Disclosure - Restructuring and Related Expenses (Restructuring Reserve Roll Forward) (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 alxn-20200930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 alxn-20200930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 alxn-20200930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Issuance of restricted common stock Stock Issued During Period, Value, Restricted Stock Award, Gross Foreign currency translation Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Research and Development Arrangement, Potential Payment, Maximum Research and Development Arrangement, Potential Payment, Maximum Research and Development Arrangement, Potential Payment, Maximum Other assets Other Assets [Member] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Level 3 Fair Value, Inputs, Level 3 [Member] Change in fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Proceeds from maturity or sale of available-for-sale debt securities Proceeds from Sale and Maturity of Debt Securities, Available-for-sale Share-based compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition Total current liabilities Liabilities, Current Derivative Asset, Fair Value, Amount Offset Against Collateral [Abstract] Derivative Asset, Fair Value, Amount Offset Against Collateral [Abstract] Goodwill [Line Items] Goodwill [Line Items] Derivative Financial Instruments Derivative, Collateral, Right to Reclaim Securities Indefinite-lived Intangible Assets (Excluding Goodwill) Indefinite-lived Intangible Assets (Excluding Goodwill) Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Asset Class [Axis] Asset Class [Axis] Goodwill resulting from the acquisitions of Achillion and Portola Goodwill, Acquired During Period Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Other comprehensive (loss) income, net of tax: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Payments on revolving credit facility Repayments of Lines of Credit Treasury Stock, Shares Balances, treasury shares Balances, treasury shares Treasury Stock, Shares Litigation Settlement, Amount Awarded to Other Party Litigation Settlement, Amount Awarded to Other Party New Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Cost of sales (exclusive of amortization of purchased intangible assets) Cost of Goods and Services Sold Collaborative Agreement, Amendment Collaborative Agreement, Amendment [Member] Collaborative Agreement, Amendment [Member] Escrow Deposit Escrow Deposit Current Fiscal Year End Date Current Fiscal Year End Date Type of Restructuring [Domain] Type of Restructuring [Domain] Collaboration and License Agreement Collaboration and License Agreement [Member] Collaboration and License Agreement [Member] Derivative [Line Items] Derivative [Line Items] Marketable securities Marketable Securities, Current Diluted Shares used in computing earnings per common share-diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Entity Address, Postal Zip Code Entity Address, Postal Zip Code Intellectual Property Election Intellectual Property Election [Member] Intellectual Property Election [Member] Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Upfront payment, fair value of equity compensation attributable to the post-combination service period Fair value of equity compensation attributable to the post-combination service period Share-based Payment Arrangement, Accelerated Cost Property, plant and equipment, net Property, Plant and Equipment, Net Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Gain on derecognition of Portola strategic equity investment Gain on Sale of Investments Total assets Assets Entity Shell Company Entity Shell Company Option To Acquire Remaining Equity, Amount Option To Acquire Remaining Equity, Amount Option To Acquire Remaining Equity, Amount Document Type Document Type Debt Instrument, Interest Rate, Effective Percentage Debt Instrument, Interest Rate, Effective Percentage Gross Unrealized Holding Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Subsequent Event Subsequent Event [Member] KANUMA Kanuma Product Line [Member] Kanuma Product Line[Member] Derivative Financial Instruments Derivative, Collateral, Obligation to Return Securities Unrealized Gains (Losses) from Hedging Activities Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] Payments on term loan Repayments of Long-term Debt Estimated gains (losses) to be reclassified from other comprehenisve income in next 12 months Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred Royalty Agreement, Maximum Potential Royalty Payments As A Percentage Of Funding Received Royalty Agreement, Maximum Potential Royalty Payments As A Percentage Of Funding Received Royalty Agreement, Maximum Potential Royalty Payments As A Percentage Of Funding Received Repurchase of common stock, shares Treasury Stock, Shares, Acquired Treasury Stock, Shares, Acquired Scenario [Domain] Scenario [Domain] Fair Value Inputs, Weighted Average Cost of Capital Fair Value Inputs, Weighted Average Cost of Capital Fair Value Inputs, Weighted Average Cost of Capital Business Combination, Contingent Consideration, Liability Business Combination, Contingent Consideration, Liability Other revenue Other Revenue [Member] Other Revenue [Member] Work-in-process Inventory, Work in Process, Gross Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Acquisition costs adjustment Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Acquisition Costs Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Acquisition Costs Accounts receivable Increase (Decrease) in Accounts Receivable Credit Facility [Axis] Credit Facility [Axis] Lonza Group AG Lonza Group AG [Member] Lonza Group AG [Member] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Less: interest to be accreted in future periods Royalty Agreement, Interest To Be Accrued Royalty Agreement, Interest To Be Accrued Financial Instrument [Axis] Financial Instrument [Axis] Debt Instrument, Unamortized Discount Debt Instrument, Unamortized Discount Effect of exchange rate changes on cash and cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Equity [Abstract] Equity [Abstract] Foreign exchange forward contracts Foreign Exchange Forward [Member] Document Quarterly Report Document Quarterly Report Commitments and contingencies (Note 16) Commitments and Contingencies Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Marketable securities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities Cash and cash equivalents and restricted cash at beginning of period Cash and cash equivalents and restricted cash at end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Collaboration Agreement, Payment For Additional Equity Interest Collaboration Agreement, Payment For Additional Equity Interest Collaboration Agreement, Payment For Additional Equity Interest Debt Instrument [Line Items] Debt Instrument [Line Items] Equity Method Investment, Aggregate Cost Equity Method Investment, Aggregate Cost Remaining authorized repurchase amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Class of Stock [Domain] Class of Stock [Domain] Money market funds Money Market Funds [Member] Collaboration Agreement, Potential Future Payments, Milestone Achievement Collaboration Agreement, Potential Future Payments, Milestone Achievement Collaboration Agreement, Potential Future Payments, Milestone Achievement Issuance of restricted common stock, shares Stock Issued During Period, Shares, Restricted Stock Award, Gross Fair Value by Asset Class [Domain] Asset Class [Domain] Proceeds from Sale of Equity Method Investments Proceeds from Sale of Equity Method Investments Debt Instrument, Periodic Payment Debt Instrument, Periodic Payment Other Commitments [Line Items] Other Commitments [Line Items] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Entity File Number Entity File Number Deferred tax assets, net Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets Other Proceeds from (Payments for) Other Financing Activities Impairment Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Treasury Stock at Cost Treasury Stock [Member] Segments [Axis] Segments [Axis] Document Fiscal Period Focus Document Fiscal Period Focus Financial Instruments [Domain] Financial Instruments [Domain] Other comprehensive (loss) income, net of tax Other comprehensive income Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other liabilities Other Liabilities [Member] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Treasury stock, at cost, 20.7 and 16.5 shares at September 30, 2020 and December 31, 2019, respectively Treasury Stock, Value Goodwill [Roll Forward] Goodwill [Roll Forward] Product and Service [Domain] Product and Service [Domain] Subcutaneous Formulation Subcutaneous Formulation [Member] Subcutaneous Formulation Prepaid expenses and other current assets Prepaid Expenses and Other Current Assets [Member] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Commercial paper Commercial Paper [Member] Purchases of mutual funds related to nonqualified deferred compensation plan Payments to Acquire Trading Securities Held-for-investment Asset Acquisition, Contingent Consideration, Milestone Payments Asset Acquisition, Contingent Consideration, Milestone Payments Asset Acquisition, Contingent Consideration, Milestone Payments Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Operating income Operating Income (Loss) Charges Restructuring and Related Cost, Incurred Cost Contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Intangible Assets, Accumulated Amortization Intangible Assets, Accumulated Amortization Intangible Assets, Accumulated Amortization Goodwill Goodwill Balance at December 31, 2019 Balance at September 30, 2020 Goodwill Schedule of Fair Value of Outstanding Derivatives Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block] Segments [Domain] Segments [Domain] Caelum Caelum Biosciences [Member] Caelum Biosciences [Member] Statement [Line Items] Statement [Line Items] Hedging Designation [Domain] Hedging Designation [Domain] Total revenues Total Net Product Sales Revenue from Contract with Customer, Excluding Assessed Tax Disaggregation of revenue from contracts with customer Disaggregation of Revenue [Table Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Research and development Research and Development Expense (Excluding Acquired in Process Cost) Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Basic (in dollars per share) Earnings Per Share, Basic Inventories Inventory Disclosure [Text Block] Restructuring and Related Costs Restructuring and Related Costs [Table Text Block] Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Noncurrent inventory Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Noncurrent Assets, Inventory Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Noncurrent Assets, Inventory Subsequent Event Type [Axis] Subsequent Event Type [Axis] Acquisition-Related Contingent Consideration [Roll Forward] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Effective Income Tax Rate Reconciliation, Deduction, Percent Effective Income Tax Rate Reconciliation, Deduction, Percent Revenue since acquisition Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual Gross Amounts Offset in the Condensed Consolidated Balance Sheet Derivative Asset, Fair Value, Gross Liability Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Earnings Per Common Share [Abstract] Earnings Per Common Share [Abstract] Earnings Per Common Share [Abstract] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Amendment Flag Amendment Flag Collaboration Agreement, Potential Future Payments, Option Fee Collaboration Agreement, Potential Future Payments, Option Fee Collaboration Agreement, Potential Future Payments, Option Fee Royalty Agreement, Milestone Payment Based On Regulatory Approval Royalty Agreement, Milestone Payment Based On Regulatory Approval Royalty Agreement, Milestone Payment Based On Regulatory Approval Licensing rights Licensing Agreements [Member] Accumulated Other Comprehensive Income [Abstract] Accumulated Other Comprehensive Income [Abstract] Accumulated Other Comprehensive Income [Abstract] Inventory, Current [Table] Inventory, Current [Table] Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Changes in operating assets and liabilities, excluding the effect of acquisitions: Increase (Decrease) in Operating Capital [Abstract] Balances, common shares Balances, common shares Common Stock, Shares, Outstanding Income (loss) before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Level 1 Fair Value, Inputs, Level 1 [Member] Contingent consideration issued in acquisitions Noncash Or Part Noncash Acquisition, Contingent Consideration Issued Noncash Or Part Noncash Acquisition, Contingent Consideration Issued Interest expense Interest expense Interest Expense Class of Stock [Axis] Class of Stock [Axis] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Interest Expense Interest Expense [Member] Use of Estimates Use of Estimates, Policy [Policy Text Block] Basis of Presentation and Principles of Consolidation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Inventory obsolescence charge Inventory Write-down Gain on sale of asset Gain (Loss) on Disposition of Assets Gain (Loss) on Disposition of Assets Raw materials Inventory, Raw Materials, Gross Local Phone Number Local Phone Number Cost of goods sold adjustment Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Cost Of Goods sold Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Cost Of Goods sold Other intangibles Other Intangible Assets [Member] Portola Pharmaceuticals, Inc. Portola Pharmaceuticals, Inc. [Member] Portola Pharmaceuticals, Inc. Senior Secured Term Loan Senior Secured Term Loan [Member] Senior Secured Term Loan [Member] DOJ And OIG DOJ And OIG [Member] DOJ And OIG [Member] Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Liability Class [Axis] Liability Class [Axis] Trade accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Restructuring expenses Restructuring Charges And Accrual Adjustment Restructuring Charges And Accrual Adjustment Exchange of intellectual property rights for equity shares in Inozyme Contribution of Property Fair Value Inputs, Liabilities, Quantitative Information [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Equity securities Equity Securities [Member] Issuance of common stock under stock option and stock purchase plans, shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Moderna LLC Moderna LLC [Member] Moderna LLC [Member] Letters of credit, amount outstanding Letters of Credit Outstanding, Amount Total current assets Assets, Current Entity Current Reporting Status Entity Current Reporting Status Purchased techonology Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Employee Separation Costs Employee Severance [Member] Net change in cash and cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net income Net income Net income used for basic and diluted calculation Net Income (Loss) Attributable to Parent Research and Development Arrangement, Potential Contingent Payment, Maximum Research and Development Arrangement, Potential Contingent Payment, Maximum Research and Development Arrangement, Potential Contingent Payment, Maximum Net proceeds from issuance of common stock under share-based compensation arrangements Proceeds from Stock Options Exercised Common Stock Common Stock [Member] Realized Gain (Loss) on Investments Realized Gain (Loss) on Investments [Table Text Block] 2024 Finite-Lived Intangible Assets, Amortization Expense, Year Five Indefinite-Lived Intangible Assets, Gross (Excluding Goodwill) Indefinite-Lived Intangible Assets, Gross (Excluding Goodwill) Indefinite-Lived Intangible Assets, Gross (Excluding Goodwill) Business [Abstract] Business [Abstract] Business [Abstract] Debt Instrument [Axis] Debt Instrument [Axis] Fair value of equity shares held by Alexion at closing Equity Securities, FV-NI Equity Securities, FV-NI Product and Service [Axis] Product and Service [Axis] Investment income, net Investment Income, Net Entity Small Business Entity Small Business Astellas Pharam [Member] Astellas Pharam [Member] Astellas Pharam Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Scenario [Axis] Scenario [Axis] Entity Filer Category Entity Filer Category Business Combination, Contingent Consideration, Arrangements, Range of Outcomes, Value, High Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Other assets Other Noncurrent Assets [Member] Accumulated Other Comprehensive Income (Loss) [Roll Forward] Accumulated Other Comprehensive Income (Loss) [Roll Forward] Accumulated Other Comprehensive Income (Loss) [Roll Forward] Total liabilities and stockholders' equity Liabilities and Equity Entity Address, City or Town Entity Address, City or Town Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Bank certificates of deposit Certificates of Deposit [Member] Contingent value rights per share (in dollars per share) Business Combination, Contingent Consideration, Liability, Per Share Business Combination, Contingent Consideration, Liability, Per Share Derivative Instruments and Hedging Activities [Abstract] Derivative Instruments and Hedging Activities [Abstract] Derivative Instruments and Hedging Activities [Abstract] Foreign exchange forward contracts, asset Foreign Currency Contract, Asset, Fair Value Disclosure Collaboration Agreement, Milestone Payment Collaboration Agreement, Milestone Payment Collaboration Agreement, Milestone Payment Cash and Cash Equivalents Cash and Cash Equivalents [Member] Current portion of long-term debt Long-term Debt, Current Maturities Noncurrent operating lease liabilities Operating Lease, Liability, Noncurrent Costs and expenses: Operating Expenses [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Restricted cash included in other current assets Restricted Cash and Cash Equivalents, Current Total consideration to acquire outstanding equity, net Business Combination, Consideration Transferred, Net Business Combination, Consideration Transferred, Net Stockholders' Equity: Stockholders' Equity Attributable to Parent [Abstract] Contingent consideration, fair value of equity compensation attributable to the post-combination service period Contingent consideration, fair value of equity compensation attributable to the post-combination service period Business Combination, Contingent Consideration, Liability, Post-Combination Service Period Compensation Business Combination, Contingent Consideration, Liability, Post-Combination Service Period Compensation Document Fiscal Year Focus Document Fiscal Year Focus Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Derivative Liability Derivative Liability Finite-Lived Intangible Asset, Useful Life Finite-Lived Intangible Asset, Useful Life Litigation Case [Domain] Litigation Case [Domain] Schedule of Debt Schedule of Debt [Table Text Block] Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax Deferred tax liabilities, intangible assetes Deferred Tax Liabilities, Intangible Assets Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Amortization expense adjustment Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangible Asset Amortization Expense Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangible Asset Amortization Expense Assets Acquired and Liabilities Assumed Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest [Abstract] Remaining total commitments Unrecorded Unconditional Purchase Obligation Gross Amounts Offset in the Condensed Consolidated Balance Sheet Derivative Liability, Fair Value, Gross Asset Other income and (expense) Other Nonoperating Income (Expense) Class of Stock [Line Items] Class of Stock [Line Items] Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Loss Contingency, Estimate of Possible Loss Loss Contingency, Estimate of Possible Loss Accumulated other comprehensive loss Beginning Balance Ending Balance Accumulated Other Comprehensive Income (Loss), Net of Tax Contingent consideration Contingent Consideration [Member] Contingent Consideration [Member] Net Amount Derivative Asset, Fair Value, Amount Offset Against Collateral Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Geographical [Axis] Geographical [Axis] Deferred tax liabilities, inventory Deferred Tax Liabilities, Inventory Inventory [Line Items] Inventory [Line Items] Retained Earnings Retained Earnings [Member] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Amounts of Liabilities Presented in the Condensed Consolidated Balance Sheet Derivative Liability, Fair Value, Amount Not Offset Against Collateral Amortization of deferred financing costs Amortization of Debt Issuance Costs Schedule of Interest Rate Contracts Schedule of Interest Rate Derivatives [Table Text Block] Accounts payable and accrued expenses for purchases of property, plant and equipment and intangible assets Capital Expenditures Incurred but Not yet Paid Document Period End Date Document Period End Date Prepaid expenses and other current assets Other Assets, Current Statement [Table] Statement [Table] Entity Registrant Name Entity Registrant Name Investment, Name [Domain] Investment, Name [Domain] Royalty-Based Financing Agreement Royalty-Based Financing Agreement [Member] Royalty-Based Financing Agreement Purchases of available-for-sale debt securities Payments to Acquire Debt Securities, Available-for-sale License Agreement 1 License Agreement 1 [Member] License Agreement 1 [Member] Intangible Assets and Goodwill Goodwill and Intangible Assets Disclosure [Text Block] Property, Plant and Equipment, Useful Life Property, Plant and Equipment, Useful Life Schedule Of Assets And Liabilites Measured At Fair Value Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Maximum Maximum [Member] Change in fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Designated as Hedging Instrument Designated as Hedging Instrument [Member] Goodwill adjustments Goodwill, Purchase Accounting Adjustments Collaboration Agreement, Potential Future Payments Collaboration Agreement, Potential Future Payments Collaboration Agreement, Potential Future Payments Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Fair Value Debt Securities, Available-for-sale Pre Approval Inventory Pre Approval Inventory [Member] Pre Approval Inventory [Member] Fair Value Inputs, Cost of Debt Fair Value Inputs, Cost of Debt Fair Value Inputs, Cost of Debt Restricted cash included in other noncurrent assets Restricted Cash and Cash Equivalents, Noncurrent Long-term debt, including current portion of $7.7 Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Long-Term Debt Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Long-Term Debt Portola Pharmaceuticals Portola Pharmaceuticals [Member] Portola Pharmaceuticals [Member] Corporate bonds Corporate Bond Securities [Member] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Cash equivalents Cash Equivalents [Member] Retained earnings Retained Earnings (Accumulated Deficit) Repurchases of common stock Payments for Repurchase of Common Stock Revenue Sales Sales [Member] Entity Tax Identification Number Entity Tax Identification Number Document and Entity Information [Abstract] Document and Entity Information [Abstract] Document and Entity Information [Abstract] Debt instrument, principal amount Debt Instrument, Face Amount Diluted (in dollars per share) Earnings Per Share, Diluted STRENSIQ Strensiq Product Line [Member] Strensiq Product Line [Member] Zealand Zealand [Member] Zealand [Member] Trading Symbol Trading Symbol Minimum Minimum [Member] Dicerna Pharmaceutical Collaboration Agreement Dicerna Pharmaceutical Collaboration Agreement [Member] Dicerna Pharmaceutical Collaboration Agreement [Member] Loss Contingency Accrual, Payments Loss Contingency Accrual, Payments Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] 2021 Finite-Lived Intangible Assets, Amortization Expense, Year Two Equity Method Investment, Realized Gain (Loss) on Disposal Equity Method Investment, Realized Gain (Loss) on Disposal Proceeds from maturities and sales Proceeds from Sale and Maturity of Debt Securities, Available-for-sale And Cash Equivalents Proceeds from Sale and Maturity of Debt Securities, Available-for-sale And Cash Equivalents Restructuring Type [Axis] Restructuring Type [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Legal Entity [Axis] Legal Entity [Axis] Adjustments to previous estimates Restructuring Reserve, Accrual Adjustment Deferred Income Tax Expense (Benefit) Deferred Income Tax Expense (Benefit) Statistical Measurement [Domain] Statistical Measurement [Domain] Adjustments to reconcile net income to net cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Total repayment obligation as of the acquisition date Royalty Agreement, Remaining Royalty Payments To Be Paid Royalty Agreement, Remaining Royalty Payments To Be Paid Collaboration Agreement, Upfront Payment Collaboration Agreement, Upfront Payment Collaboration Agreement, Upfront Payment Accounts payable and accrued expenses Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Foreign Exchange Forward, Open Expense Foreign Exchange Forward, Open Expense [Member] Foreign Exchange Forward, Open Expense [Member] 2025 Finite-Lived Intangible Assets, Amortization Expense, after Year Five Entity [Domain] Entity [Domain] Income tax expense (benefit) Income tax provision Provision for income taxes Income Tax Expense (Benefit) Portola replacement equity awards attributable to the pre-combination period Stock Issued During Period, Value, Acquisitions Fair value of replacement equity awards attributable to the pre-combination period Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value Amounts reclassified from other comprehensive income Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Acquisition-related contingent consideration Acquisition Related Contingent Consideration [Member] Acquisition-Related Contingent Consideration [Member] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Liability Derivatives, Fair Value Gross Amounts of Recognized Liabilities Derivative Liability, Fair Value, Gross Liability Other liabilities Other Liabilities, Noncurrent Total consideration Business Combination, Total Consideration Business Combination, Total Consideration Other Commitments [Table] Other Commitments [Table] City Area Code City Area Code Schedule Of Asset Acquisition, By Acquisition [Table] Schedule Of Asset Acquisition, By Acquisition [Table] Schedule Of Asset Acquisition, By Acquisition [Table] Prepaid expenses, right of use operating assets and other assets Increase (Decrease) in Prepaid Expense and Other Assets Intangible assets, net Intangible assets Intangible Assets, Net (Excluding Goodwill) Title of 12(b) Security Title of 12(b) Security Unrealized foreign currency loss (gain) Foreign Currency Transaction Gain (Loss), before Tax Schedule Of Asset Acquisition, By Acquisition [Line Items] Schedule Of Asset Acquisition, By Acquisition [Line Items] [Line Items] for Schedule Of Asset Acquisition, By Acquisition [Table] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Unrealized loss on hedge, tax effect Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax Counterparty Name [Axis] Counterparty Name [Axis] Earnings per common share Earnings Per Share [Abstract] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Debt Instrument, quarterly payment as a percent of total borrowings Debt Instrument, Quarterly Payment, Percentage of Total Borrowings Debt Instrument, Quarterly Payment, Percentage of Total Borrowings Other Other Noncash Income (Expense) Unrealized Gains (Losses) from Debt Securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] Deferred tax assets Deferred Income Tax Assets, Net Purchases of strategic equity investments and options Payments to Acquire Other Investments Payments to Acquire Other Investments Defined Benefit Pension Plans Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Assets Assets [Abstract] Gross Unrealized Holding Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax SOLIRIS Soliris [Member] Soliris [Member] Deferred tax assets, income tax credits Deferred Tax Assets, Tax Credit Carryforwards Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Zealand Zealand Pharma [Member] Zealand Pharma [Member] Canadian Patented Medicine Prices Review Board Canadian Patented Medicine Prices Review Board [Member] Canadian Patented Medicine Prices Review Board [Member] Syntimmune, Inc Syntimmune, Inc [Member] Syntimmune, Inc [Member] Net Amount Derivative Liability, Fair Value, Amount Offset Against Collateral Rest of World Other Non-Us, Excluding Europe And Asia Pacific [Member] Other Non-Us, Excluding Europe And Asia Pacific [Member] Credit Agreement Credit Agreement [Member] Credit Agreement [Member] Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] 2022 Finite-Lived Intangible Assets, Amortization Expense, Year Three Royalty Agreement, Closing Day Payment Royalty Agreement, Closing Day Payment Royalty Agreement, Closing Day Payment Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Business Nature of Operations [Text Block] Marketable securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Danicopan Danicopan [Member] Danicopan [Member] Cash Collateral Received Derivative, Collateral, Obligation to Return Cash Other income and expense: Nonoperating Income (Expense) [Abstract] Europe Europe [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Other Third Party Manufacturers Other Third Party Manufacturers [Member] Other Third Party Manufacturers [Member] Deferred Tax Expense (Benefit) By Type [Axis] Deferred Tax Expense (Benefit) By Type [Axis] Deferred Tax Expense (Benefit) By Type [Axis] Repayments of debt Less: payments made Repayments of Debt Supplemental cash flow disclosures from investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Fair value of strategic investment and purchase option acquired, less upfront cash paid Other Significant Noncash Transaction, Value of Consideration Given Issuance of common stock under stock option and stock purchase plans Stock Issued During Period, Value, Stock Options Exercised Net Net Finite-Lived Intangible Assets, Net Other Other Restructuring [Member] Debt Disclosure [Abstract] Restructuring and Related Expenses Restructuring and Related Activities Disclosure [Text Block] Other government-related obligations Other Government Obligations [Member] Other Government Obligations [Member] Schedule of Inventory, Current Schedule of Inventory, Current [Table Text Block] Derivative Instrument [Axis] Derivative Instrument [Axis] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Income Statement Location [Domain] Income Statement Location [Domain] Statistical Measurement [Axis] Statistical Measurement [Axis] Consideration Business Combination, Consideration Transferred [Abstract] Gain on sale of asset Gain (Loss) on Disposition of Property Plant Equipment Dicerna Dicerna [Member] Dicerna [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Total net assets acquired Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Other Comprehensive Income and Accumulated Other Comprehensive Income Comprehensive Income (Loss) Note [Text Block] Acquired in-process research and development Research and Development Asset Acquired Other than Through Business Combination, Written-off Derivative Fair Value, Discounted Cost Of Debt Derivative Fair Value, Discounted Cost Of Debt Derivative Fair Value, Discounted Cost Of Debt Summary of Pro Forma Information Business Acquisition, Pro Forma Information [Table Text Block] Inventory [Axis] Inventory [Axis] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Total acquisition value, per share (in dollars per share) Business Combination, Consideration Transferred, Per Share Business Combination, Consideration Transferred, Per Share Weighted average cost of capital Intangible Assets, Impairment, Weighted Average Cost Of Capital Intangible Assets, Impairment, Weighted Average Cost Of Capital Unrealized gain on forward contracts Gain (Loss) on Derivative Instruments, Net, Pretax Restructuring Reserve Beginning Balance Ending Balance Restructuring Reserve Unrealized (gains) losses on hedging activities, net of tax of $(2.8), $3.5, $(14.3) and $(10.8), respectively Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Other Investments Investment [Text Block] Impairment of intangible assets Impairment of Intangible Assets (Excluding Goodwill) SEC SEC [Member] SEC Debt Debt Disclosure [Text Block] Derivative, fixed interest rate Derivative, Fixed Interest Rate Purchased technology Purchased Technology [Member] Purchased Technology [Member] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Intangible Assets and Goodwill Schedule of Intangible Assets and Goodwill [Table Text Block] Net product sales Net Product Sales [Member] Net Product Sales [Member] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Business Acquisition, Pro Forma Net Income (Loss) Business Acquisition, Pro Forma Net Income (Loss) Investment, Name [Axis] Investment, Name [Axis] Adoption of new accounting standards Cumulative Effect, Period Of Adoption, Adjustment [Member] Cumulative Effect, Period Of Adoption, Adjustment Common stock, shares authorized Common Stock, Shares Authorized Finite-Lived Intangible Assets, Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Central Index Key Entity Central Index Key Operating ROU lease assets obtained in exchange for operating lease liabilities Operating Right-Of-Use Assets Exchanged For Operating Lease Liability Operating Right-Of-Use Assets Exchanged For Operating Lease Liability Entity Emerging Growth Company Entity Emerging Growth Company Selling, general and administrative Selling, General and Administrative Expense Amortization of purchased intangible assets Amortization of Intangible Assets Acquired Amortization of Intangible Assets Acquired Integration costs Business Combination, Integration Related Costs Shares used in computing earnings per common share Shares Used In Computing Net Income Per Share Shares used in computing net income per share. Share-based compensation expense Share-based Payment Arrangement, Noncash Expense Schedule Of Basic And Diluted Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Derivative Instruments and Hedging Activities Derivative Instruments and Hedging Activities Disclosure [Text Block] Long-term debt, less current portion Long-term Debt, Excluding Current Maturities Derivative [Table] Derivative [Table] Realized gains Debt Securities, Available-for-sale, Realized Gain Deferred tax assets, other differences Deferred Tax Assets, Other Collaboration Agreement, Potential Future Payments, Additional Milestone Achievement Collaboration Agreement, Potential Future Payments, Additional Milestone Achievement Collaboration Agreement, Potential Future Payments, Additional Milestone Achievement Balance at beginning of period Balance at end of period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Reclassification out of Accumulated Other Comprehensive Income [Line Items] Reclassification out of Accumulated Other Comprehensive Income [Line Items] [Line Items] for Reclassification out of Accumulated Other Comprehensive Income [Table] Credit Facility [Domain] Credit Facility [Domain] Current debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt Level 2 Fair Value, Inputs, Level 2 [Member] Income Taxes Income Tax Disclosure [Text Block] Purchase of intangible assets Payments to Acquire Intangible Assets Payments To Acquire Licenses And Equity Investment Payments To Acquire Licenses And Equity Investment Payments To Acquire Licenses And Equity Investment Schedule of Income Tax Provision and Effective Tax Rate Schedule of Income Tax Provision and Effective Tax Rate [Table Text Block] Schedule of Income Tax Provision and Effective Tax Rate Foreign Exchange Forward Contracts Term Foreign Exchange Forward Contracts Term Foreign Exchange Forward Contracts Term Offsetting Assets and Liabilities Offsetting Assets and Liabilities [Table Text Block] Offsetting Assets and Liabilities [Table Text Block] Fair value of equity shares in Portola settled at closing of the acquisition Fair Value Of Equity Shares Of Business Combination Fair Value Of Equity Shares Of Business Combination Other assets and liabilities, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other, Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other, Net Schedule of Other Comprehensive Income and Earnings from Foreign Exchange Contracts Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Product Product [Member] U.S. US Government Agencies Debt Securities [Member] Liabilities and Stockholders' Equity Liabilities and Equity [Abstract] Unrealized gains on debt securities Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Other assets Other Assets, Noncurrent Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Total available-for-sale debt securities Debt Securities [Member] Inventory [Domain] Inventory [Domain] Derivative Contract [Domain] Derivative Contract [Domain] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Accounts payable, accrued expenses, lease liabilities and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Outstanding debt Long-term Debt Estimated additional charges Restructuring Charges, Estimated Additional Charge Restructuring Charges, Estimated Additional Charge 2020 (remainder) Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year 2023 Finite-Lived Intangible Assets, Amortization Expense, Year Four Collaboration Agreement, Acquisition Option, Maximum Potential Future Payment Collaboration Agreement, Potential Future Payments, Acquisition Option Exercise Collaboration Agreement, Potential Future Payments, Acquisition Option Exercise Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Operating loss since acquisition Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual Inozyme Inozyme [Member] Inozyme Marketable securities Marketable Securities [Member] Marketable Securities [Member] Effective Income Tax Rate Reconciliation, Intangible Asset Impairment, Percent Effective Income Tax Rate Reconciliation, Intangible Asset Impairment, Percent Effective Income Tax Rate Reconciliation, Intangible Asset Impairment, Percent Summary of receivables and contract liabilities from contracts Contract with Customer, Asset and Liability [Table Text Block] Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Inventories, including noncurrent portion of $169.1 and validation batches of $60.9 Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Unrealized gain on strategic equity investments Unrealized Gain (Loss) on Investments Unrealized Gain (Loss) on Investments Other current liabilities Other Liabilities, Current Additional Paid-In Capital Additional Paid-in Capital [Member] Revenue Recognition Revenue from Contract with Customer [Text Block] Other liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Liabilities Inventory, Net [Abstract] Inventory, Net [Abstract] Interest Rate Swap Interest Rate Swap Two [Member] Interest Rate Swap Two [Member] Valuation Allowance Release Valuation Allowance Release [Member] Valuation Allowance Release [Member] Revenue, Initial Application Period Cumulative Effect Transition [Table] Revenue, Initial Application Period Cumulative Effect Transition [Table] Realized losses Debt Securities, Available-for-sale, Realized Loss Deferred tax assets, net operating loss carryforward Deferred Tax Assets, Operating Loss Carryforwards Achillion Achillion [Member] Achillion [Member] Deferred tax liabilities Deferred Income Tax Liabilities, Net United States UNITED STATES Summary of Acquisition-Related Costs Business Combination, Separately Recognized Transactions [Table Text Block] Payment for acquisition of businesses, net of cash and restricted cash acquired Payments to Acquire Businesses, Net of Cash Acquired Payments of contingent consideration Payment for Contingent Consideration Liability, Operating Activities Marketable securities Investments, Fair Value Disclosure Payments of financing costs Payments of Financing Costs Finished goods Inventory, Finished Goods, Gross Entity Address, Address Line One Entity Address, Address Line One Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Business Combinations [Abstract] Business Combinations [Abstract] Available-for-sale Securities by Balance Sheet Location Classification Available-for-sale Securities by Balance Sheet Location Classification [Table Text Block] Available-for-sale Securities by Balance Sheet Location Classification [Table Text Block] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Geographical [Domain] Geographical [Domain] Estimated milestone payments Business Combination, Estimated Milestone Payments Business Combination, Estimated Milestone Payments Other liabilities Other Noncurrent Liabilities [Member] Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Upfront payment to shareholders and equity holders Payments to Acquire Businesses, Gross Payments to Acquire Businesses, Gross Entity Address, State or Province Entity Address, State or Province Income Statement Location [Axis] Income Statement Location [Axis] Business Acquisition [Axis] Business Acquisition [Axis] Restructuring expenses Restructuring Charges Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Prepaid Research And Development Expense Prepaid Research And Development Expense Prepaid Research And Development Expense Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Deferred tax assets, royalty debt Deferred Tax Assets, Long-Term Debt Deferred Tax Assets, Long-Term Debt Eidos Eidos [Member] [Member] Eidos [Member] Validation batches Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Validation Batches Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Validation Batches Stealth Stealth [Member] Stealth [Member] Upfront cash paid, net Upfront cash paid, net Business Combination, Consideration Transferred Investments, All Other Investments [Abstract] Investments, All Other Investments [Abstract] Offsetting Assets and Liabilities [Line Items] Offsetting Assets and Liabilities [Line Items] [Line Items] for Offsetting Assets and Liabilities [Table] Business Acquisition [Line Items] Business Acquisition [Line Items] Accounts payable Accounts Payable, Current Gain (Loss) on Fair Value Hedges Recognized in Earnings Gain (Loss) on Fair Value Hedges Recognized in Earnings Other comprehensive income (loss) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Affibody Affibody [Member] Affibody [Member] Royalty Agreement, Maximum Potential Royalty Payments Royalty Agreement, Maximum Potential Royalty Payments Royalty Agreement, Maximum Potential Royalty Payments Cumulative Effect, Period Of Adoption [Domain] Cumulative Effect, Period Of Adoption [Domain] Cumulative Effect, Period Of Adoption Accrued expenses Accrued Liabilities, Current Inventories Inventories [Member] Entity Interactive Data Current Entity Interactive Data Current Common stock, shares issued Common Stock, Shares, Issued Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Total costs and expenses Costs and Expenses Common stock, par value Common Stock, Par or Stated Value Per Share Notional amount of derivative instruments Derivative, notional amount Derivative, Notional Amount1 Derivative, Notional Amount1 Settlements Payments for Restructuring Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] ACH-5528, Phase 3 ACH-5528, Phase 3 [Member] ACH-5528, Phase 3 [Member] Inventory, Net Inventory, Net Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Interest Expense, Debt Interest Expense, Debt ULTOMIRIS Ultomiris [Member] Ultomiris [Member] Schedule Of Acquisition-Related Contingent Consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] In-process research & development assets (IPR&D) Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Earnings Per Common Share Earnings Per Share [Text Block] Interest Rate Derivative Assets, at Fair Value Interest Rate Derivative Assets, at Fair Value Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Revolving Credit Facility Revolving Credit Facility [Member] Foreign exchange forward contracts, liability Foreign Currency Contracts, Liability, Fair Value Disclosure Amounts of Assets Presented in the Condensed Consolidated Balance Sheet Derivative Asset, Fair Value, Amount Not Offset Against Collateral Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Derivative Liability, Fair Value, Amount Offset Against Collateral [Abstract] Derivative Liability, Fair Value, Amount Offset Against Collateral [Abstract] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Hedging Designation [Axis] Hedging Designation [Axis] Unrecorded Unconditional Purchase Obligation, Undiscounted Fixed Payment Amount Unrecorded Unconditional Purchase Obligation, Undiscounted Fixed Payment Amount Unrecorded Unconditional Purchase Obligation, Undiscounted Fixed Payment Amount Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Effective tax rate Effective Income Tax Rate Reconciliation, Percent Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] Investments [Domain] Investments [Domain] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Total liabilities Liabilities Acquisitions Business Combination Disclosure [Text Block] Fair Value Inputs, Discount Rate Fair Value Input, Discount Rate Fair Value Input, Discount Rate Common stock, $0.0001 par value; 290.0 shares authorized; 239.7 and 237.8 shares issued at September 30, 2020 and December 31, 2019, respectively Common Stock, Value, Issued In-process research & development assets (IPR&D) Acquired IPRD [Member] Acquired IPR&D [Member] Deferred taxes (benefit) Deferred Income Taxes and Tax Credits Deferred Tax Expense (Benefit) By Type [Domain] Deferred Tax Expense (Benefit) By Type [Domain] [Domain] for Deferred Tax Expense (Benefit) By Type [Axis] Research and development Research and Development Expense Acquisition costs not included in net income Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Not Expensed Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Not Expensed Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Counterparty Name [Domain] Counterparty Name [Domain] Intangible Assets, Cost Intangible Assets, Cost Intangible Assets, Cost Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Inventories Increase (Decrease) in Inventories Halozyme Therapeutics, Inc Halozyme Therapeutics, Inc [Member] Halozyme Therapeutics, Inc [Member] HealthCare Royalty Partners HealthCare Royalty Partners [Member] HealthCare Royalty Partners Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Royalty Agreement, Tiered Royalty, Percent Royalty Agreement, Tiered Royalty, Percent Royalty Agreement, Tiered Royalty, Percent Acquisition-related costs Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed Stock awards (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Restructuring and Related Cost, Expected Cost Restructuring and Related Cost, Expected Cost Summary of Changes in Goodwill Schedule of Goodwill [Table Text Block] Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months Basic Shares used in computing earnings per common share—basic (in shares) Weighted Average Number of Shares Outstanding, Basic Effective Income Tax Rate Reconciliation Deduction, Foreign-Derived Intangible Income, Percent Effective Income Tax Rate Reconciliation Deduction, Foreign-Derived Intangible Income, Percent Effective Income Tax Rate Reconciliation Deduction, Foreign-Derived Intangible Income, Percent Right of use operating assets Operating Lease, Right-of-Use Asset Cumulative Effect, Period Of Adoption [Axis] Cumulative Effect, Period Of Adoption [Axis] Cumulative Effect, Period Of Adoption Income Tax Expense (Benefit), Foreign-Derived Intangible Income Income Tax Expense (Benefit), Foreign-Derived Intangible Income Income Tax Expense (Benefit), Foreign-Derived Intangible Income Equity Components [Axis] Equity Components [Axis] Payments to Acquire Equity Method Investments Payments to Acquire Equity Method Investments Acquisition-related costs Business Combination, Acquisition Related Costs Total stockholders' equity Balances, value Balances, value Stockholders' Equity Attributable to Parent Amortization of purchased intangible assets Amortization of Intangible Assets Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Intangible Asset Impairment Intangible Asset Impairment [Member] Intangible Asset Impairment Contract liabilities, which are included in Other current liabilities Contract with Customer, Liability, Current Asia Pacific Asia Pacific [Member] Interest Rate Swap Interest Rate Swap Four [Member] Interest Rate Swap Four [Member] Fair Value Measurement Fair Value Disclosures [Text Block] Offsetting Assets and Liabilities [Table] Offsetting Assets and Liabilities [Table] Offsetting Assets and Liabilities [Table] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Trading securities. fair value Debt Securities, Trading, and Equity Securities, FV-NI Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Foreign Currency Translation Adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Mutual funds Mutual Funds [Member] Mutual Funds [Member] Total net assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Receivables, which are included in Trade accounts receivable, net Contract with Customer, Asset, Net, Current Restructuring-related costs Restructuring Costs Depreciation and amortization Depreciation, Depletion and Amortization Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Investment Type [Axis] Investment Type [Axis] Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Gross Affibody AB Affibody AB [Domain] Affibody AB [Domain] Caelum Biosciences, Option Caelum Biosciences, Option [Member] Caelum Biosciences, Option Forecast [Member] Forecast [Member] Goodwill, Accumulated Amortization Goodwill, Accumulated Amortization Goodwill, Accumulated Amortization Fair value of replacement equity awards issued to Portola employees attributable to the pre-combination period Stock Issued Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Repurchase of common stock Treasury Stock, Value, Acquired, Cost Method Treasury Stock, Value, Acquired, Cost Method Security Exchange Name Security Exchange Name Net deferred tax liability Deferred tax liabilities, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Schedule of Business Acquisitions, by Acquisition [Table Text Block] Schedule of Business Acquisitions, by Acquisition [Table Text Block] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Other contingent payments Other Contingent Payments [Member] Other Contingent Payments [Member] Litigation Case [Axis] Litigation Case [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Additional paid-in capital Additional Paid in Capital, Common Stock Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Schedule of Available-for-sale Securities Reconciliation Schedule of Available-for-sale Securities Reconciliation [Table Text Block] Equity Component [Domain] Equity Component [Domain] Hedging Relationship [Domain] Hedging Relationship [Domain] Document Transition Report Document Transition Report Other current liabilities Other Current Liabilities [Member] Cash Collateral Pledged Derivative, Collateral, Right to Reclaim Cash Cash Flow Hedging Cash Flow Hedging [Member] Remaining unamortized deferred financing costs Debt Issuance Costs, Net Transaction costs Business Combination, Separately Recognized Transactions, Additional Disclosures, Transaction Costs Business Combination, Separately Recognized Transactions, Additional Disclosures, Transaction Costs Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low ANDEXXA Andexxa Product Line [Member] Andexxa Product Line Repurchase authorization amount Stock Repurchase Program, Authorized Amount Intangible asset amortization expense since acquisition Business Combination, Intangible Asset Amortization Of Acquiree Since Acquisition Date, Actual Business Combination, Intangible Asset Amortization Of Acquiree Since Acquisition Date, Actual Line of Credit Line of Credit [Member] Proceeds from sale of mutual funds related to nonqualified deferred compensation plan Proceeds from Sale and Maturity of Marketable Securities Hedging Relationship [Axis] Hedging Relationship [Axis] Inventories Inventory, Current Inventory, Current Patents Patents [Member] Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Business Acquisition, Pro Forma Revenue Business Acquisition, Pro Forma Revenue Collaborative Arrangement Collaborative Arrangement [Member] Income Statement [Abstract] Income Statement [Abstract] Research and Development Agreement, Option Fee Research and Development Agreement, Option Fee Research and Development Agreement, Option Fee Interest Rate Derivative Liabilities, at Fair Value Interest Rate Derivative Liabilities, at Fair Value Asset Derivatives, Fair Value Gross Amounts of Recognized Assets Derivative Asset, Fair Value, Gross Asset Balance Sheet Location [Axis] Balance Sheet Location [Axis] Interest rate contracts Interest Rate Contract [Member] Goodwill, Gross Goodwill, Gross EX-101.PRE 11 alxn-20200930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 12 alxn-20200930_g1.jpg begin 644 alxn-20200930_g1.jpg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end GRAPHIC 13 alxn-20200930_g10.jpg begin 644 alxn-20200930_g10.jpg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end GRAPHIC 14 alxn-20200930_g11.jpg begin 644 alxn-20200930_g11.jpg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end GRAPHIC 15 alxn-20200930_g12.jpg begin 644 alxn-20200930_g12.jpg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end GRAPHIC 16 alxn-20200930_g13.jpg begin 644 alxn-20200930_g13.jpg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end GRAPHIC 17 alxn-20200930_g14.jpg begin 644 alxn-20200930_g14.jpg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end GRAPHIC 18 alxn-20200930_g15.jpg begin 644 alxn-20200930_g15.jpg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end GRAPHIC 19 alxn-20200930_g16.jpg begin 644 alxn-20200930_g16.jpg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end GRAPHIC 20 alxn-20200930_g17.jpg begin 644 alxn-20200930_g17.jpg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end GRAPHIC 21 alxn-20200930_g18.jpg begin 644 alxn-20200930_g18.jpg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�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alxn-20200930_g19.jpg begin 644 alxn-20200930_g19.jpg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end GRAPHIC 23 alxn-20200930_g2.jpg begin 644 alxn-20200930_g2.jpg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alxn-20200930_g20.jpg begin 644 alxn-20200930_g20.jpg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end GRAPHIC 25 alxn-20200930_g21.jpg begin 644 alxn-20200930_g21.jpg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alxn-20200930_g22.jpg begin 644 alxn-20200930_g22.jpg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alxn-20200930_g23.jpg begin 644 alxn-20200930_g23.jpg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end GRAPHIC 28 alxn-20200930_g24.jpg begin 644 alxn-20200930_g24.jpg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

B_\ 2HG9E_\ OL/7]#]PJ***_E\^P"BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***_*/X_?\'/'_"C?COX MV^"?_#$/]J?\(=XNU+0_[3_X65Y'VO[)=20>=Y?]FOY>_P O=MW-MSC)QFO7 MRG(LUSVI*&!I\[BKO6*LO^WFC"OB:.'2=1VOZ_H?JY17XZ_\197_ %8)_P"9 M4_\ O71_Q%E?]6"?^94_^]=>Y_Q#[B__ *!O_)Z?_P F<_\ :>!_G_!_Y'ZM M?&CX ?!W]HC0])\-_&KP':>(+'0O$EEK^DVUXSA;;4K23S+:Y78RG=&_(SD> MH-=A7XZ_\197_5@G_F5/_O71_P 197_5@G_F5/\ [UT?\0^XO_Z!O_)Z?_R8 M?VG@?Y_P?^1^Q5%?CK_Q%E?]6"?^94_^]='_ !%E?]6"?^94_P#O71_Q#[B_ M_H&_\GI__)A_:>!_G_!_Y'[%45^.O_$65_U8)_YE3_[UT?\ $65_U8)_YE3_ M .]='_$/N+_^@;_R>G_\F']IX'^?\'_D?L517XZ_\197_5@G_F5/_O71_P 1 M97_5@G_F5/\ [UT?\0^XO_Z!O_)Z?_R8?VG@?Y_P?^1^Q5%?CK_Q%E?]6"?^ M94_^]='_ !%E?]6"?^94_P#O71_Q#[B__H&_\GI__)A_:>!_G_!_Y'[%45^= MO_!.'_@OE_P\#_:?L/V;_P#AE#_A$OMVE7E[_;/_ G7V_9Y$>_9Y/V&'.[I MG>,>AK]$J^>S3*,PR7$_5\;#DG:]KIZ._6+:Z'51KTL1#FINZ"BBBO--0HHH MH *X#X)_M/\ P5_:'\2>//"7PE\5R:E?_#3Q?+X8\90OIT\ L=3CBCE>$-*B MB4!)4.^,LASC.0:_++_@[J_;?_:N_9;^'/P6^%7P)^+/B3X>>$_B'K>J)X\\ M9^$VECOHX[;[%Y5LDT3(\89+BXE,:NC3>2%SM5P?B3_@F'^QY^S#^TM\3OBY MHW[-G_!?;XA?##QQ_P +0EMOAEJREFM+BZGDE:1&4. M&Q'@H<'(!_2%\6/C+\(?@-X,G^(WQQ^*GASP;X?MG5+C7/%6MP:?9QLV=JM- M.ZH"<' SDXKQ_P"!'_!5_P#X)Q_M/_%VV^ W[/?[8/@SQ?XNO$G>TT30[]II M)UAC:25D8+L8*BLV0V,#C-=3^VI^PW^S=_P4'^#L7P"_:K\%W/B#PFFMVVJR M:5;:O<67G3P!Q'NEMG20+^\;(5AGUK\!O^"5/P:^&?[/'_!V_P"(_@?\&O"L M6A^%?"VN>+M/T'2(9Y)5M+:/2K@)&'E9G; [LQ)[DT ?T>?$'XC?#WX2^#K[ MXB?%7QWHWAGP_IB*^I:[XAU2*RL[16=45I9IF5(P695!8C)8#J17A/PR_P"" MO?\ P3)^-/QBTWX _"+]MCP'XG\7ZQ>&UTG1M"U?[4UY,$9RL4D8,;_*K'(8 MC@\UZ-^UU^R;\$_VX_V>]?\ V7?VB_#]SJO@SQ,]DVM:?::C+:23BUO(+R)1 M+$RN@\VWC)VD$@$9YK^>S2OV7O@/^QI_P=^^ _V=/V:?A_%X7\&:!X@T?^R= M%AO;BY$!F\,)/*?,N)))7+2R.Q+,3EJ /Z7***^:O^"QWBSXP^!O^"6?QX\6 M_ 2>]A\56/PVU&33[G32PN+:/R\7$T17YEDCMS,ZLO*E01@@4 9GQ7_X+>?\ M$FO@A\3I_@[\2_V[O =AXBM+MK6^LH+^2Z2SG4X:*>:W1XH74@AE=U*D$'!% M?2?@;QWX)^)_@_3OB#\-_%^F>(-!UBT2ZTG6M%OX[JTO(6&5DBEC)213V921 M7\SO_!&#P#_P18\1?\$9OV@O$/[;<_PU_P"%KV\^M"RF\67]O'KUK;+I<)TY MM)61A+N:Z,P7R 6>7*/N7:M?3O\ P9(_M+>/_%'PQ^-/[*/B36;B[T#PG?Z5 MKWAB":3<+%KW[5'>1IG[J,UO!(%'RAVE;&7)(!^[5%%% !1110 4444 %%%% M !4&J_\ (+N?^O=__034]0:K_P @NY_Z]W_]!--;@?QY4445_99\&%%%% !1 M110 4444 %%%% !1110 5^J7_!JI_P G*?%'_L1K;_TL6ORMK]4O^#53_DY3 MXH_]B-;?^EBU\GQS_P DIBO1?^E1.S+_ /?8>OZ'[A4445_+Y]@%%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 5_*-^W[_R?=\:_^RM^)/\ TZ7% M?U*/_)21_Z]Q_.1]/D_^Z/U?Z!1117Y MP>J%%%% 'PQ_P6K_ &]?V8_V1/#?A#X=?MM_L&>)?C'\*/'$.H2:_J>C^%(- M8M- N+4VXA,\-R%B5G%Q(R2>:DB^0Q0,TR>2VM?!CV@5;.6W665A.+L[E*J=JAMTFT*M?V7 MUXG^R1^Q;H7[)OCWXR^/-&\=7>LR?&/XGW/C.^M[JS6)=-EFMX(#;1E6/F*! M"#N.#\QXH \P^+W[<.F_\$BO^"6_PY^.7[>6F^*_$NK^&_"?AGP_XW/A2*VO M;ZYUM[**&XFS<7$,;J9TD9G\S)SD YK^=_\ 9K_X+!_LT?!S_@X"\4_\%6/$ M_@?QU/\ #S7->\07MIHUAIEDVM)'?6%[M8 P9P6Q.0 #@L>*_K;HH ^ M6-<_X*Z_LV^'_P#@EPG_ 5MO/!/CAOAQ)H]OJ0T2+3;,ZWY4VHIIZKY)NQ! MN$L@8CS\; 2"3\M?SJ_%;_@LC^S'XY_X.(M)_P""MVD^!?'D?PXL-4TRYFT2 MYTRR&ME+;0X]/<"%;LP9,J%AF<93!.#\M?UHT4 ?$5U_P6D^'?Q6_P""/_CC M_@J_^R_\,-:FTWPUIM_+IGASQ[##9SW$UI+?^"DG_ 3G\5_MK_%+X,Z;HD_A_6M9L9?#>@74EPEW!96<-Q@& M89+OYK+@\<"ON&B@#^9+]H7]NG_@UB\2>&]9^.OP(_X)C>+[WXOZG#+)X?\ M!6HPW5EHD&KN"(GN;2#4FM/LZR$$PPQ,KA=OEC<2/OK_ (-(_P#@F/\ &?\ M8F_9D\;?M%_M%>#+WPWXE^+EWI_]D>'-5MVBN[+1[)9S%+-&P#0O/)H-5_P"07<_]>[_^@FFMP/X\J*** M_LL^#"BBB@ HHHH **** "BBB@ HHHH *_5+_@U4_P"3E/BC_P!B-;?^EBU^ M5M?JE_P:J?\ )RGQ1_[$:V_]+%KY/CG_ ))3%>B_]*B=F7_[[#U_0_<*BBBO MY?/L HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OY1OV_?^3[OC M7_V5OQ)_Z=+BOZN:_E&_;]_Y/N^-?_96_$G_ *=+BOUKPF_Y&&)_PQ_,\3.O MX4/4\DHHHK]R/G@HHHH **** "BBB@ HHHH **** /N__@W$_P"4G^@_]BKK M'_I/7]$M?SM?\&XG_*3_ $'_ +%76/\ TGK^B6OYZ\4?^2DC_P!>X_G(^GR? M_='ZO] KD/C=\>?A1^SEX';XD?&;Q5_8VBK=QVS7OV&>XQ*^=J[($=^<'G&/ M6NOKY#_X+[?\$\?^C@__+3U;_Y$H_X>[?\ !/'_ *.#_P#+3U;_ .1* M_$FBC_B$W#G_ #]J_P#@4/\ Y6'_ !,'QG_T#X?_ , J?_+3]MO^'NW_ 3Q M_P"C@_\ RT]6_P#D2C_A[M_P3Q_Z.#_\M/5O_D2OQ)HH_P"(3<.?\_:O_@4/ M_E8?\3!\9_\ 0/A__ *G_P M/VV_X>[?\$\?^C@__+3U;_Y$H_X>[?\ !/'_ M *.#_P#+3U;_ .1*_$FBC_B$W#G_ #]J_P#@4/\ Y6'_ !,'QG_T#X?_ , J M?_+3]MO^'NW_ 3Q_P"C@_\ RT]6_P#D2C_A[M_P3Q_Z.#_\M/5O_D2OQ)HH M_P"(3<.?\_:O_@4/_E8?\3!\9_\ 0/A__ *G_P M/VV_X>[?\$\?^C@__+3U M;_Y$H_X>[?\ !/'_ *.#_P#+3U;_ .1*_$FBC_B$W#G_ #]J_P#@4/\ Y6'_ M !,'QG_T#X?_ , J?_+3]MO^'NW_ 3Q_P"C@_\ RT]6_P#D2O;/@_\ &'X< M_'OX>V'Q5^$_B+^UM!U,RBRO_LDT'F&*5XG^29$<8=&'*C.,C((-?SNU^V/_ M 2 _P"4>_@7_KMJO_ITNJ^-XWX'RGAK*88K"SG*3FH^\XM6<9/I%:Z+J?I' MA=XI<0<;<05,#CJ5*,(TI33A&:=U*$?M3DK6D^E]M3Z7HHHK\L/WL**** "B MBB@ J#5?^07<_P#7N_\ Z":GJ#5?^07<_P#7N_\ Z"::W _CRHHHK^RSX,** M** "BBB@ HHHH **** "BBB@ K]4O^#53_DY3XH_]B-;?^EBU^5M?JE_P:J? M\G*?%'_L1K;_ -+%KY/CG_DE,5Z+_P!*B=F7_P"^P]?T/W"HHHK^7S[ **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^4;]OW_D^[XU_P#96_$G M_ITN*_JYK^4;]OW_ )/N^-?_ &5OQ)_Z=+BOUKPF_P"1AB?\,?S/$SK^%#U/ M)****_O%'_ )*2/_7N/YR/I\G_ -T? MJ_T"OD/_ (+_@7_ *[:K_Z=+JOQ.K]L?^"0'_*/?P+_ -=M5_\ M3I=5^8^+'_).4O\ K['_ -(F?N?T?O\ DM*__8//_P!.4CZ7HHHK^>3^Q0HH MHH **** "H-5_P"07<_]>[_^@FIZ@U7_ )!=S_U[O_Z"::W _CRHHHK^RSX, M**** "BBB@ HHHH **** "BBB@ K]4O^#53_ ).4^*/_ &(UM_Z6+7Y6U^J7 M_!JI_P G*?%'_L1K;_TL6OD^.?\ DE,5Z+_TJ)V9?_OL/7]#]PJ***_E\^P" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_E&_;]_Y/N^-?_96_ M$G_ITN*_JYK^4;]OW_D^[XU_]E;\2?\ ITN*_6O";_D88G_#'\SQ,Z_A0]3R M2BBBOW(^>"BBB@ HHHH **** "BBB@ HHHH ^[_^#<3_ )2?Z#_V*NL?^D]? MT2U_.U_P;B?\I/\ 0?\ L5=8_P#2>OZ):_GKQ1_Y*2/_ %[C^BBBOYY/[%"BBB@ HHHH *@U M7_D%W/\ U[O_ .@FIZ@U7_D%W/\ U[O_ .@FFMP/X\J***_LL^#"BBB@ HHH MH **** "BBB@ HHHH *_5+_@U4_Y.4^*/_8C6W_I8M?E;7ZI?\&JG_)RGQ1_ M[$:V_P#2Q:^3XY_Y)3%>B_\ 2HG9E_\ OL/7]#]PJ***_E\^P"BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH *_E&_;]_Y/N^-?\ V5OQ)_Z=+BOZ MN:_E&_;]_P"3[OC7_P!E;\2?^G2XK]:\)O\ D88G_#'\SQ,Z_A0]3R2BBBOW M(^>"BBB@ HHHH **** "BBB@ HHHH ^[_P#@W$_Y2?Z#_P!BKK'_ *3U_1+7 M\[7_ ;B?\I/]!_[%76/_2>OZ):_GKQ1_P"2DC_U[C^9_D?CG1117]9'^?04444 %%%% !1110 4444 %%%% M!7[8_P#!(#_E'OX%_P"NVJ_^G2ZK\3J_;'_@D!_RCW\"_P#7;5?_ $Z75?F/ MBQ_R3E+_ *^Q_P#2)G[G]'[_ )+2O_V#S_\ 3E(^EZ***_GD_L4**** "BBB M@ J#5?\ D%W/_7N__H)J>H-5_P"07<_]>[_^@FFMP/X\J***_LL^#"BBB@ H MHHH **** "BBB@ HHHH *_5+_@U4_P"3E/BC_P!B-;?^EBU^5M?JE_P:J?\ M)RGQ1_[$:V_]+%KY/CG_ ))3%>B_]*B=F7_[[#U_0_<*BBBOY?/L HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "OY1OV_?^3[OC7_V5OQ)_Z=+B MOZN:_E&_;]_Y/N^-?_96_$G_ *=+BOUKPF_Y&&)_PQ_,\3.OX4/4\DHHHK]R M/G@HHHH **** "BBB@ HHHH **** /N__@W$_P"4G^@_]BKK'_I/7]$M?SM? M\&XG_*3_ $'_ +%76/\ TGK^B6OYZ\4?^2DC_P!>X_G(^GR?_='ZO] KY#_X M+3^Q0HHHH **** "H-5_Y!=S_ M ->[_P#H)J>H-5_Y!=S_ ->[_P#H)IK<#^/*BBBO[+/@PHHHH **** "BBB@ M HHHH **** "OU2_X-5/^3E/BC_V(UM_Z6+7Y6U^J7_!JI_RX_G(^GR?\ W1^K_0*^0_\ @MQ_ MR8_ M#XB?\D-F/_7F?Y'XYT445_61_GT%%%% !1110 4444 %%%% !1110 5^V/\ MP2 _Y1[^!?\ KMJO_ITNJ_$ZOVQ_X) ?\H]_ O\ UVU7_P!.EU7YCXL?\DY2 M_P"OL?\ TB9^Y_1^_P"2TK_]@\__ $Y2/I>BBBOYY/[%"BBB@ HHHH *@U7_ M )!=S_U[O_Z":GJ#5?\ D%W/_7N__H)IK<#^/*BBBO[+/@PHHHH **** "BB MB@ HHHH **** "OU2_X-5/\ DY3XH_\ 8C6W_I8M?E;7ZI?\&JG_ "O%'_DI(_\ 7N/YR/I\G_W1^K_0*^0_^"W'_)C] MQ_V-6G_^U*^O*^0_^"W'_)C]Q_V-6G_^U*^:X1_Y*?!_]?(_F>#XB?\ )#9C M_P!>9_D?CG1117]9'^?04444 %%%% !1110 4444 %%%% !7[8_\$@/^4>_@ M7_KMJO\ Z=+JOQ.K]L?^"0'_ "CW\"_]=M5_].EU7YCXL?\ ).4O^OL?_2)G M[G]'[_DM*_\ V#S_ /3E(^EZ***_GD_L4**** "BBB@ J#5?^07<_P#7N_\ MZ":GJ#5?^07<_P#7N_\ Z"::W _CRHHHK^RSX,**** "BBB@ HHHH **** " MBBB@ K]4O^#53_DY3XH_]B-;?^EBU^5M?JE_P:J?\G*?%'_L1K;_ -+%KY/C MG_DE,5Z+_P!*B=F7_P"^P]?T/W"HHHK^7S[ **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ K^4;]OW_D^[XU_P#96_$G_ITN*_JYK^4;]OW_ )/N M^-?_ &5OQ)_Z=+BOUKPF_P"1AB?\,?S/$SK^%#U/)****_O%'_ )*2/_7N/YR/I\G_ -T?J_T"OD/_ (+ M_@7_ *[:K_Z=+JOQ.K]L?^"0'_*/?P+_ -=M5_\ 3I=5^8^+'_).4O\ K['_ M -(F?N?T?O\ DM*__8//_P!.4CZ7HHHK^>3^Q0HHHH **** "H-5_P"07<_] M>[_^@FIZ@U7_ )!=S_U[O_Z"::W _CRHHHK^RSX,**** "BBB@ HHHH **** M "BBB@ K]4O^#53_ ).4^*/_ &(UM_Z6+7Y6U^J7_!JI_P G*?%'_L1K;_TL M6OD^.?\ DE,5Z+_TJ)V9?_OL/7]#]PJ***_E\^P"BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH *_E&_;]_Y/N^-?_96_$G_ITN*_JYK^4;]OW_D^ M[XU_]E;\2?\ ITN*_6O";_D88G_#'\SQ,Z_A0]3R2BBBOW(^>"BBB@ HHHH M**** "BBB@ HHHH ^[_^#<3_ )2?Z#_V*NL?^D]?T2U_.U_P;B?\I/\ 0?\ ML5=8_P#2>OZ):_GKQ1_Y*2/_ %[C^BBBOYY/[%"BBB@ HHHH *@U7_D%W/\ U[O_ .@FIZ@U M7_D%W/\ U[O_ .@FFMP/X\J***_LL^#"BBB@ HHHH **** "BBB@ HHHH *_ M5+_@U4_Y.4^*/_8C6W_I8M?E;7ZI?\&JG_)RGQ1_[$:V_P#2Q:^3XY_Y)3%> MB_\ 2HG9E_\ OL/7]#]PJ***_E\^P"BBB@ HHHH **RO'?C7PY\-O!&L_$7Q MC?&UTC0-*N-2U6Y6%I##;01-+*^U 6;"*QPH)., $UE? WXU?#C]H_X.^&?C MU\']=?5/"WB_1H-5T#47M);-S'*JNF5(.UE!'<"@#JJ*\]_:4_:Q_ M9J_8Z^'Y^*7[47QM\.^!M!,WDPW_ (@U%8?M,V"?*A0_//)@$[(U9L G& :X M?]DO_@J#_P $_OVZ=8NO#7[*'[5?A3QCJUG 9[C1+2Z>"_$(.&E%K<+',T8) M +A"HR,GD9 />J**\[_:8_:U_9I_8V\ 1?%+]J7XU^'_ -H%Q?+96NI>(+X M0K<7+(\@@B'+2R%(Y&V*"<(QQ@&@#T2BOD[X._\ !='_ ()'?'KQS:?#;X9? MMX>![G6K^Y6WL+/4IY].^TS,=JQQO>1Q)([$@*JL2Q( !)KZQH **** "BBB M@ K^4;]OW_D^[XU_]E;\2?\ ITN*_JYK^4;]OW_D^[XU_P#96_$G_ITN*_6O M";_D88G_ Q_,\3.OX4/4\DHHHK]R/G@HHHH **** "BBB@ HHHH **** /N M_P#X-Q/^4G^@_P#8JZQ_Z3U_1+7\[7_!N)_RD_T'_L5=8_\ 2>OZ):_GKQ1_ MY*2/_7N/YR/I\G_W1^K_ $"OD/\ X+#XB?\D-F/_7F?Y'XYT445_61_GT%% M%% !1110 4444 %%%% !1110 5^V/_!(#_E'OX%_Z[:K_P"G2ZK\3J_;'_@D M!_RCW\"_]=M5_P#3I=5^8^+'_).4O^OL?_2)G[G]'[_DM*__ &#S_P#3E(^E MZ***_GD_L4**** "BBB@ J#5?^07<_\ 7N__ *":GJ#5?^07<_\ 7N__ *": M:W _CRHHHK^RSX,**** "BBB@ HHHH **** "BBB@ K]4O\ @U4_Y.4^*/\ MV(UM_P"EBU^5M?JE_P &JG_)RGQ1_P"Q&MO_ $L6OD^.?^24Q7HO_2HG9E_^ M^P]?T/W"HHHK^7S[ **** "BBB@#^;W_ (+_ /[:OQ>^('_!7_Q[^Q7^TW^V M#X\^#_P0\*^!6;PSIWA'[3';Z]>2Z$MW +I8/^/A;B]D:V,KK(D2J4PG[R0? M27_!N/\ LB_#%HO@M^T5^SO_ ,%C_%7B*;2?!S77Q4_9JN/&27EE!-<:9-!Y M/V*.X0VJ6]S-%*AD@DY@"A@3N&W_ ,%U?^"C_P#P39@\>_$_]DG_ (*)_P#! M.#Q9?:[X=\/2V?PJ^+YTQ)X9+>^9H)[=4N9MC)$98RT+%CD;1^ M9W_!(_X'6OQO_P""G?[)_CK_ ()E?"+XAZ:O@FR\/W?[07BJ_CE_LQ;^&5VU MIXIR[B*">T)@$;,GF/(52, C(!]&?\%1Y5_X*9?\'5?@;]AGXU7%UJ7PW\&Z MWI&AQ>'UN7CBEM1IL>K:@N$(*-.[/"\BD.8XX^1L7',_\'%/P ^$7_!&'_@I MC\ _VJ?^"?O@:T^'MPVEC5Y=#T"1XK5[NPO DAV$D*EQ;S+!+&/D=0V5)=RW MI/\ P7.^$'Q4_P""7W_!>3P!_P %G8_A=J_B+X6ZQK>CZAXBO='MMXLKJVM$ MTZ\LV8_)%++:QK-"9"JR.[J"-C$>6?\ !0?XWM_P=&?\%1OA#\(_V'?A7XQC M\ ^$](BLO%'B77M*6 Z;;3W?G7]]-Y3R)#&D*1I&'<-+*I51EER ?TQZ9J%M MJVFV^JV3;H;J!)8F]58 CI[&O#?^"B?[-G[%/Q__ &?+OQ7^WG\+8/%O@;X7 M"Z\:SV%S)#B)L*^3@ _GO\ ^"N7BS_@D=^W7\!?%WPO^ '@;X9^ M/_%)US7O#O@[3-,UO6R[-_:%W;VD<4UQEN3YDB,^3S\W-?S%?\%Q?V\OV /^ M"M>O?#7X0_\ !+7]AG7%^(4&L2_;]Q:22Z ?#[I M/+V83(D@#URBBB@ HHHH *_E&_;]_P"3[OC7_P!E;\2?^G2X MK^KFOY1OV_?^3[OC7_V5OQ)_Z=+BOUKPF_Y&&)_PQ_,\3.OX4/4\DHHHK]R/ MG@HHHH **** "BBB@ HHHH **** /N__ (-Q/^4G^@_]BKK'_I/7]$M?SM?\ M&XG_ "D_T'_L5=8_])Z_HEK^>O%'_DI(_P#7N/YR/I\G_P!T?J_T"OD/_@MQ M_P F/W'_ &-6G_\ M2OKROD/_@MQ_P F/W'_ &-6G_\ M2OFN$?^2GP?_7R/ MYG@^(G_)#9C_ ->9_D?CG1117]9'^?04444 %%%% !1110 4444 %%%% !7[ M8_\ !(#_ )1[^!?^NVJ_^G2ZK\3J_;'_ () ?\H]_ O_ %VU7_TZ75?F/BQ_ MR3E+_K['_P!(F?N?T?O^2TK_ /8//_TY2/I>BBBOYY/[%"BBB@ HHHH *@U7 M_D%W/_7N_P#Z":GJ#5?^07<_]>[_ /H)IK<#^/*BBBO[+/@PHHHH **** "B MBB@ HHHH **** "OU2_X-5/^3E/BC_V(UM_Z6+7Y6U^J7_!JI_RB_P#2HG9E_P#OL/7]#]PJ***_E\^P"BO/OV@/VI_@-^RW MI>G:U\=O'?\ 85MJUP\&GR_V7=77FR(H9ABWBD*X!') %>7?\/=O^">/_1P? M_EIZM_\ (E>GALDSG&T55P^&J3@]G&$FM/-)H\/&\3\-9;B7A\9C:-.HK7C. MI",E?573DGJM4?25%?-O_#W;_@GC_P!'!_\ EIZM_P#(E'_#W;_@GC_T<'_Y M:>K?_(E='^K7$?\ T!U?_!<_\CD_UVX,_P"AEA__ =3_P#DCV[XR?#FU^,/ MPA\5?"2^U.2RA\4^&[[2)KV*,.UNMS;O"9 I(#%0^0"><5S?['O[.>E_LA?L ML?#_ /9=T7Q/<:U:> ?"EEH=MJUU;K%)>);Q+&)6120I;&< G%>:_P##W;_@ MGC_T<'_Y:>K?_(E'_#W;_@GC_P!'!_\ EIZM_P#(E'^K7$?_ $!U?_!<_P#( M/]=N#/\ H98?_P '4_\ Y(^C;ZQL=4LY=.U*SBN+>>,I/!/&'212,%64\$$= MC5/PSX0\)>"K Z5X.\+Z=I-JTA=K;3+*.",L>K;4 &>!S7S]_P /=O\ @GC_ M -'!_P#EIZM_\B4?\/=O^">/_1P?_EIZM_\ (E'^K7$?_0'5_P#!<_\ (/\ M7;@S_H98?_P=3_\ DCZ2J#4]+TS6K"72M9TZ"[M9UVS6US"LD<@]&5@01]:^ M=/\ A[M_P3Q_Z.#_ /+3U;_Y$H_X>[?\$\?^C@__ "T]6_\ D2C_ %:XC_Z MZO\ X+G_ )!_KMP9_P!#+#_^#J?_ ,D>\^%OAU\/O SRR>"? NC:.TXQ,VE: M9%;F0?[7EJ,_C6S7S;_P]V_X)X_]'!_^6GJW_P B4?\ #W;_ ()X_P#1P?\ MY:>K?_(E'^K7$?\ T!U?_!<_\@_UVX,_Z&6'_P#!U/\ ^2/I*BOFW_A[M_P3 MQ_Z.#_\ +3U;_P"1*/\ A[M_P3Q_Z.#_ /+3U;_Y$H_U:XC_ .@.K_X+G_D' M^NW!G_0RP_\ X.I__)'TE167X)\9>&_B+X.TKQ_X-U+[9I&MZ=#?:7=^2\?G M6\J!XWVN%9$W_ M ",,3_AC^9X^=?PH>IY)1117[D?/!1110 4444 %%%% !1110 4444 ?=_\ MP;B?\I/]!_[%76/_ $GK^B6OYVO^#<3_ )2?Z#_V*NL?^D]?T2U_/7BC_P E M)'_KW'\Y'T^3_P"Z/U?Z!7R'_P %N/\ DQ^X_P"QJT__ -J5]>5\A_\ !;C_ M ),?N/\ L:M/_P#:E?-<(_\ )3X/_KY'\SP?$3_DALQ_Z\S_ "/QSHHHK^LC M_/H**** "BBB@ HHHH **** "BBB@ K]L?\ @D!_RCW\"_\ 7;5?_3I=5^)U M?MC_ ,$@/^4>_@7_ *[:K_Z=+JOS'Q8_Y)RE_P!?8_\ I$S]S^C]_P EI7_[ M!Y_^G*1]+T445_/)_8H4444 %%%% 'FW[2/[+?P\_:DT33= ^(>N>)+&'2KI M[BW?PWK\U@[,R[2':(Y<8['O7D7_ Z'_9F_Z'_XI_\ AQ[W_&OJ:B@#Y9_X M=#_LS?\ 0_\ Q3_\./>_XT?\.A_V9O\ H?\ XI_^''O?\:^IJ* /EG_AT/\ MLS?]#_\ %/\ \./>_P"-'_#H?]F;_H?_ (I_^''O?\:^IJ* /EG_ (=#_LS? M]#_\4_\ PX][_C1_PZ'_ &9O^A_^*?\ X<>]_P :^IJ* /EG_AT/^S-_T/\ M\4__ X][_C1_P .A_V9O^A_^*?_ (<>]_QKZFHH ^6?^'0_[,W_ $/_ ,4_ M_#CWO^-'_#H?]F;_ *'_ .*?_AQ[W_&OJ:B@#Y9_X=#_ +,W_0__ !3_ /#C MWO\ C1_PZ'_9F_Z'_P"*?_AQ[W_&OJ:B@#Y9_P"'0_[,W_0__%/_ ,./>_XT M?\.A_P!F;_H?_BG_ .''O?\ &OJ:B@#Y9_X=#_LS?]#_ /%/_P ./>_XT?\ M#H?]F;_H?_BG_P"''O?\:^IJ* /EG_AT/^S-_P!#_P#%/_PX][_C1_PZ'_9F M_P"A_P#BG_X<>]_QKZFHH ^6?^'0_P"S-_T/_P 4_P#PX][_ (T?\.A_V9O^ MA_\ BG_X<>]_QKZFHH ^6?\ AT/^S-_T/_Q3_P##CWO^-'_#H?\ 9F_Z'_XI M_P#AQ[W_ !KZFHH ^6?^'0_[,W_0_P#Q3_\ #CWO^-'_ Z'_9F_Z'_XI_\ MAQ[W_&OJ:B@#Y9_X=#_LS?\ 0_\ Q3_\./>_XT?\.A_V9O\ H?\ XI_^''O? M\:^IJ* /EG_AT/\ LS?]#_\ %/\ \./>_P"-'_#H?]F;_H?_ (I_^''O?\:^ MIJ* /EG_ (=#_LS?]#_\4_\ PX][_C1_PZ'_ &9O^A_^*?\ X<>]_P :^IJ* M /EG_AT/^S-_T/\ \4__ X][_C1_P .A_V9O^A_^*?_ (<>]_QKZFHH ^6? M^'0_[,W_ $/_ ,4__#CWO^-'_#H?]F;_ *'_ .*?_AQ[W_&OJ:B@#Y9_X=#_ M +,W_0__ !3_ /#CWO\ C1_PZ'_9F_Z'_P"*?_AQ[W_&OJ:B@#Y9_P"'0_[, MW_0__%/_ ,./>_XT?\.A_P!F;_H?_BG_ .''O?\ &OJ:B@#Y9_X=#_LS?]#_ M /%/_P ./>_XT?\ #H?]F;_H?_BG_P"''O?\:^IJ* /EG_AT/^S-_P!#_P#% M/_PX][_C1_PZ'_9F_P"A_P#BG_X<>]_QKZFHH ^6?^'0_P"S-_T/_P 4_P#P MX][_ (T?\.A_V9O^A_\ BG_X<>]_QKZFHH ^6?\ AT/^S-_T/_Q3_P##CWO^ M-'_#H?\ 9F_Z'_XI_P#AQ[W_ !KZFHH ^6?^'0_[,W_0_P#Q3_\ #CWO^-'_ M Z'_9F_Z'_XI_\ AQ[W_&OJ:B@#Y9_X=#_LS?\ 0_\ Q3_\./>_XT?\.A_V M9O\ H?\ XI_^''O?\:^IJ* /EG_AT/\ LS?]#_\ %/\ \./>_P"-'_#H?]F; M_H?_ (I_^''O?\:^IJ* /EG_ (=#_LS?]#_\4_\ PX][_C1_PZ'_ &9O^A_^ M*?\ X<>]_P :^IJ* /EG_AT/^S-_T/\ \4__ X][_C1_P .A_V9O^A_^*?_ M (<>]_QKZFHH ^6?^'0_[,W_ $/_ ,4__#CWO^-'_#H?]F;_ *'_ .*?_AQ[ MW_&OJ:B@#Y9_X=#_ +,W_0__ !3_ /#CWO\ C1_PZ'_9F_Z'_P"*?_AQ[W_& MOJ:B@#Y9_P"'0_[,W_0__%/_ ,./>_XT?\.A_P!F;_H?_BG_ .''O?\ &OJ: MB@#Y9_X=#_LS?]#_ /%/_P ./>_XT?\ #H?]F;_H?_BG_P"''O?\:^IJ* /G MCX6_\$SO@%\(OB#I/Q*\,^-/B'<7^CW0N+6'5?'5U$_#S^T_/\GS_P"T9/L&[./^ M/[9]EVY_B\W;WS7@O_!POJGC/XZ_%;]E+_@EOIOB:_T?PG^T1\4+I?B/FVOB#0+[08_%5EKEG-IO, M(EGBN9Y+,,3C)NUB-N%_VC)MQSG%>#?\&^6I^(/@W\2OVK?^"3OB/7[O7?"? M[/\ \2XH_A\VM2^?+#X?U874D5BQ;[R1BWW'(P6N7QQ@#;_X*._\%"?^",O[ M W@[Q=^R!\;/V6;2]%IH20R>!=!^$:PZ3>"ZMU:&%;PPQV4.0Z OY@\H\\%< M4 ??GB'XP_"WPM\(K_X^ZUX^TM/!6F>')=?O/%$-VLUDFEQ0&X>\$L>Y7B$* MF3NZ;:7^B^+]']3\8^/O M@_XLT_P[#O$'BBX9ELM#^T2VEQ M>LH)*VZW,,=,\/>']%LWN]7 MUO6;Y+:ULX$&6DEED(5%'J2*_+'_ (.6?AE\"O%'PU^#7[+W[.GPXT2#]IGQ M7\3]*;X+?\(MIL-OJFC0P2E[F_:2%0T%E&JC<6(0,HDP?(9D[;_@X-6;XW?% MK]CO_@GQXCNI&\(_&/X\0S^/=/AD:-=5TO2A!++9O@_ZM_M(;&>&CC89*B@# MZG_9@_X*U?\ !-[]LWXBS?"+]F;]K[PEXJ\3PI(ZZ%;W$D%S%_'?[/'C_P[K'@ M;5]$TV*TDM+=KZ*T:P!B4?Z,WG1EH?N'REXQD5^FGA_6;7Q'H-CXAL@PAO[. M*XA##D*Z!AG\#0!;HHHH **** "BBB@ KRC]JG]N?]D#]B#PY:^*OVLOVB/" M_@6UOV8:;'KFHA;B]*XW^1;KNEGVY&[8C;%=#TU(GC^RQ2 I%*Z7,2M(% M#;DF88,\FX ^\?V3/^"E_P"P5^W3>7>E?LG?M3>%/&>HV,/G7>CV%ZT5_%$# M@RFUG5)O+!(!?9M!(&>16]^U3^V_^R1^Q!X9L/%_[67Q_P##G@2QU662+2FU MV]V27SQA3(L$2@R3%0REMBG&Y_ALIK&\\L+]I@/VE6*OGY%D0?+*X;[;^) M/C']E_QA^S;HO[:WQZ^$FD:UH_A[P8/%.GW-_P"%$UB]TFVN+6*XE^RH(GE\ MQD5 1$-S[%&#@4 9?[)?_!4O_@GO^W1X@N?"'[*7[5WA7Q?K5I T\VAVUQ); MWWDJ<-*MM&I'/VF\LK=@LTZ#&"J$@'GO7Y">,/VAOV/_\ @JY_P6._9G'_ 3H\+6W MA;Q3\'_$EQXD^)7C76]'A\,WU_HB(F=*@M)S'>ZB9 DR-B(I DQ.0LCD?H1\ M5_V,/BQXW_X*V?";]N?2-4T-/!W@?X6Z]X)HHQ$4:,!3 MN)D4CLIH [_]H_\ X*'?L+?L@ZA_8G[37[6W@#P5J9A69=%UWQ/;Q:@\3?=D M6UW&9D/]X(1[UZ9\/?'_ (-^*_@'0_BE\.?$-OJ_A[Q+H]MJN@ZM:,3%>V5Q M$LT$Z$@$J\;JP]F%?#W_ 7G_8W_ &3]?_X)]?M"_M3>(OV'[#GBVU\ _M4_M8^%?".O7D"S1:' @C(->??M5_LQ_"/]LO\ 9Y\6?LQ_'3P^ MNI>%_&&DR6.HPC DA)PT=Q$Q!V312*DL;X.UXU/:OQZC_:T_X*4Z%\/6_P"# M;"*PU9_C\VLKX8T[XV>0WV+_ (5DT1?_ (2$R;MPN$M0;7&=P/ D-RN" ?HQ MXC_X+D_\$D?"5Y)9>(?V\O ELT=U/;>8;R5HI)(7V2A)%C*2!6&"5)'O6=_P M_P!_^"-O_20GX?\ _@9-_P#&Z]2_9\_X)V_L??LX_ #P;^SEX0^!/AG4=#\$ MZ(FG:7<:]H-M=W,OS-)+-)))&^'+66&Q1K;42RPHT96($J,A0 <#TH ^T MO%/_ 5J_P"";W@GX)>%OVC_ !7^U]X1L? WC:\O+3PIXFGN9!;:G-:R&.X2 M(A,DQNI4Y Y%+\'/^"MG_!,C]H#Q-:^"OA%^W=\+]8UF^=4L-(7Q=;0W5T[= M$BBF9'D?_94$^U?'W_!<7X:_#G2?VO\ _@GQ\.-+\ :);>'I/VBVBDT&WTJ% M+)DD:T+J8 NPABS$C&"2<]:^O/VK/^"3'_!/;]L/X4:K\*OBO^RIX)C&H64D M-EK^B^&K6RU/2I2IV3VUS#&LD;HQ#8SL;&'5E)4@'N7Q)^(_@;X/?#W6_BM\ M3?$MMHWASPWI4^I:[J]XQ$-E:0QF269R 2%5%+'CH*Y#XA_MC_LJ_"/X$:5^ MT[\5/V@?"GAKP!KMG:W6B^*]>UB*TM+^.YA\^W$+2E3*\D0+K&H+LH)"\&OS MD_X)1:K^TE_P4&_X(/\ QW_88\;^.X-9^(G@R[\9?!W3?$?B.[D"792Q1;.6 MXE59'V(+M8=V'?9 "0QY/W5\)?V&/A9JO[&'P2_9J_:V^%/A+QU<_"GPMX?C M6SU6P74-.BUK3])%@;J))T DP))PC.@(#AMJL!@ Q_V:/^"P7_!,O]L+XB+\ M)/V<_P!LKP?XC\3REQ::$+B6TNKPH"S"WCN4C-P0H+$1;OE!/0$U[Q\2/B7\ M//@YX$U3XH?%CQQI7AKPYHEHUSJ^NZY?QVMI9PCJ\DLA"H,D#D\D@=37Y:_\ M'&?PR^"7C"\_9Y_9B_9E^'>B6_[3.N_%O2;WX7W'A?3(H-2T+3+5W>ZOY9(5 M#16495&(8A-T1< ^0Q7L_P#@OG;1?'K]JO\ 8F_X)\^,':;P-\5OC)>ZOXXT MDL1%J]IHD5K,+*;'WHI/M;97H2%;JJD 'U;^RQ_P5>_X)T?ML>/+GX6_LN_M M;^$_%OB2UB>5M"M9Y(+J:-.7DABN$C:=%'+-&& ')(%?0M?EW_P\<_L__%/P_J/AW5M#TZ*VE73GG^SS:<2@ -LY>+,1 M^7Y,=&8']0XY$E02Q.&5@"K*<@CUH 6BBB@ HHHH *X+X=_M0? #XL_%CQC\ M"?AY\5-+U/QE\/Y8(_&7AF*1DO-*,REH6DC< ['495QE2""#AAGO:_.[_@L5 M^S_\4_V:?BMX8_X+;_L:^&9+WQS\)]/:Q^,'A*Q^3_A-O Y(:[B?'#3VJ@S1 MN0<*FX[C!$A /L_]HK]J[]G/]DKPYI7BO]H_XNZ1X2L==UF+2-%DU25M]_?2 M*S);PQH&>20A&(50>E>!?\/]_P#@C;_TD)^'_P#X&3?_ !NOG[_@G]I&K?\ M!:3]MJ3_ (*]?&'PI?6OP6^&[76@?LN>#M>M@OVR;/EZAXEGA)*^8TBF*+KM M,>.'MU=M'_@YE_9[^ 7@?_@B+\;/%/@KX'^#]'U.U_X1O[-J.E^&K6WGAW>) M=+1MLD<89+-$^!7@VSU M6#POID\&IVOABTCN(Y?LL9\Q9%C#!L\[@-OVUM1^)? MPC\,>(KB']LCQ=!%/KN@6]VZ1>8IV!I48AM?EM_P5]_9Q^$ M?_!)?]I_]GK_ (*D?L2>"-/^'-UJOQDTWP-\6?#7A"U6QTSQ-HVH)+(YFM(@ M(1(JVTH#JF3))'(_MXZ=JFAKX,\*_!G5O"F MI6^N;U9XWCC$11H@H.6,@8'HIZT =W^T;_P %&?V#/V1M5?P[^TK^ MU[\/?!NK(B.VAZUXHMTU (X!5_L@8S[2"#NV8P0"[SXER_#_ .7QW?\ AVWGU6'R?)AC\JXD5GA*QJ$S&5XKZM_X M)[?\F"_ _P#[(_X9_P#35;4 _X)T?L1^-K?X:_M2?M;^%/"?B*X MA24:%<3R7%Y%&_*22PVZ2/"C#E6D"@CD$BO8?A'\8?A5\?/AWI?Q<^"?Q$T? MQ7X8UJ#SM*U[0=0CNK6Y0$J=LB$@D,"K#JK*5(!!%?F?_P &YWACX5^/_$/[ M67B[XYZ%I&J?'N7]HWQ!9?$;^W;>.;4K?3 8UM( ) 62RWB[5 $)C9<810, MG_@@)\:OA=I7_!3']M_]C[]F_5K&7X3Z1X\MO$?@C3M&=?[/T^YD:6VU-;0) M\@@:9(E0)\@6!=@VF@#]:J*** "BBB@ HHHH **** "BBB@ HHHH _/;_@O9 M^S1^T)XAA^!G_!0[]E/X?W7C+QK^S%\0'\0S^"; $W.N:'9^[W;_)W<^9M^:OORO$?VV/^">/[*7[?GP8U_X+_M!?#"PN8==B4KXA MT^TAAU;3;E/]3=VUT4+1S1G[I.Y2,HRLC,I /DS_ ((O?!SXS_ 'X7_M(?\ M!57]M'X:ZKX1\4_'CQ3=>-[WP)]F:74-%\.Z?%,=9UWPEX0U MH.MSH6B74X>VMG1_FCR1+,%(!Q."0"2!ZQ_P6!_X*=>!O^"37[&U]^TWXK\( M7/B#5+[5XM \&Z%"2D=]J\\$\T23R#_4P+';32._7$>UDJ;#]Q:Q9 9EP967)X S]1?\%__ (>?$/1]"_9Z_P""D?PF\#ZEXJ3]F_XM MVGB;Q5HNBVS2WP JEX> M\$^#/"4UU<>%/"6F:9)>R>9>R:?81PMZT MB&XO55;C2;N2!',$R+% @RH_U#2-M25&K]>ZK:OH^D>(--FT;7M+MKVSN$V7 M%I=P++%*OHRL"&'L10!^1/\ P5*_;A^'W_!<3P;IW_!)/_@EMK=U\0_^$U\2 MZ5<_ :7I-PNA>#M!MKM+HO-WBD$4@1T(\S M:& ;G(Q4>G?\$LO@!X&_;KM?V_?@1XB\0?#GQ-A:)XETR71?$>C6NH6\6YWI"1/' T";FBD'SR+C;SC(SV'_!";_@I5 M^Q'^TU^R)\'OV0O@=\=+?7OB-\._@'X;3QEX:CT6_@;36L["QLKD&::!(9-E MPZQ_NW;.:^\Z* /RG_X*7>-_^#8;QW^U+XM/_!0C5-(TCXN>#%BL?% ? OB?4[;6_$O@K2=1O;/'V.[OM-BFE@P%O"GQYEU/7] M6>VEF%I:0K:/)(4B5G?"@G"J2>P->A?$[_@Y9_8$USPI>Z%^P8/&G[0?Q*N; M9H_#7@;P%\.]8)GNV!$7VB:>VB6*'?@NREW"Y(0\5^B5% 'Q9_P05_80^+O[ M!'[!J>%?VBVA7XE?$'QCJ/CCQ_:03+(MEJ-]Y2_9]Z$JS)#!"'VDJ)#(%+* MQZ;_ (+'_P#!4?P9_P $EOV/+G]HK7O!\WB'7=6U9-"\%:&I*076JRPS2QFY MD'^J@1())'(^9@@5<%@1]6T4 ?B7_P $P_\ @IQ_P18_9GU37?VPOVP_^"D& MD_$']ICXEQB7Q[XVD\$Z^\&D0$ADT72U.GC[/90@(OR@>88P3A5C1/IG_@O[ MX$^(/PV\4?LU_P#!3KP+X%U/Q+8_LU_%"34?'>DZ+;&:[C\-:@D$6H7<<8Y? MREMH\]@)-[81&8?HW10!^//_ 5;_;A_9H_X+<>!_AA_P3%_X)U_$$_$S4_B M+\0M(U?X@ZGHNE726GA7PQ:2>;'/!7 M@WP>;@^$?"6F:7]LE\R[_LZPC@\]_P"\^Q1N/)Y/-:= !1110 4444 %>8?M MN_\ )E_Q>_[)?K__ *;IZ]/HH ^(/^#;W_E"5\ _^Q?U#_T[7M<__P '1W_* M"CXY_P#-U MVDAOEZ8(K]OJ* /R$_:/^+/BK_@X5_:@^!_P8_93^#'C2V_9S^%OQ+L_'GQ& M^+GC#PU<:38ZY/9JXM[#34N5628LDLT;':&4W"LR*L>Y_P!>Z** /S,_X../ M^"E7[$?PL_8E^,W["/C[XZ6^G_%CQ/\ #M7T+PBVBW\CW2SR@Q$3I T"[O+? M[T@QMYQD5[!_P1F_X*5?L1_M=?LX^ /V=?V=OCI;^)/&?P_^$>@IXOT2+1;^ MW;3FAL[>UD!DN((XY-LP*?NV;/49'-?:=% 'Y-?\%%_B#_P:Y?$;]ISQGJO[ M>6HZ5IGQ9\'7!TSQDEFGB32=1U$)&I6*3^S/+345:,1A6S(=H5=R@8'6_P#! MO?\ LGR:/X_^.7_!1&T_9WE^$_@_XOZEI>E?!OX?76FBRN-/\)Z5;F"VNY8! MS$]U\DA#$LS1M+EQ*LC_ *1:SX!\"^(]8MO$/B'P5I-_?V6/L=]>:;%+-!@Y M&QV4LO//!'-:U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 B4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$! end GRAPHIC 29 alxn-20200930_g25.jpg begin 644 alxn-20200930_g25.jpg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end GRAPHIC 30 alxn-20200930_g26.jpg begin 644 alxn-20200930_g26.jpg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end GRAPHIC 31 alxn-20200930_g3.jpg begin 644 alxn-20200930_g3.jpg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alxn-20200930_g4.jpg begin 644 alxn-20200930_g4.jpg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alxn-20200930_g5.jpg begin 644 alxn-20200930_g5.jpg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alxn-20200930_g6.jpg begin 644 alxn-20200930_g6.jpg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end GRAPHIC 35 alxn-20200930_g7.jpg begin 644 alxn-20200930_g7.jpg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

XML 40 R2.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2020
Dec. 31, 2019
Assets    
Cash and cash equivalents $ 2,268.0 $ 2,685.5
Marketable securities 28.9 64.0
Trade accounts receivable, net 1,437.1 1,243.2
Inventories 729.0 627.6
Prepaid expenses and other current assets 604.8 456.1
Total current assets 5,067.8 5,076.4
Property, plant and equipment, net 1,214.5 1,163.3
Intangible assets, net 3,056.6 3,344.3
Goodwill 5,100.7 5,037.4
Right of use operating assets 220.1 204.0
Deferred tax assets 2,270.5 2,290.2
Other assets 618.2 429.0
Total assets 17,548.4 17,544.6
Liabilities and Stockholders' Equity    
Accounts payable 89.2 74.0
Accrued expenses 978.4 892.7
Current portion of long-term debt 138.6 126.7
Other current liabilities 124.8 100.9
Total current liabilities 1,331.0 1,194.3
Long-term debt, less current portion 2,453.3 2,375.0
Contingent consideration 398.1 192.4
Deferred tax liabilities 1,818.2 2,081.4
Noncurrent operating lease liabilities 175.8 164.1
Other liabilities 297.1 265.6
Total liabilities 6,473.5 6,272.8
Commitments and contingencies (Note 16)
Stockholders' Equity:    
Common stock, $0.0001 par value; 290.0 shares authorized; 239.7 and 237.8 shares issued at September 30, 2020 and December 31, 2019, respectively 0.0 0.0
Additional paid-in capital 9,030.4 8,804.7
Treasury stock, at cost, 20.7 and 16.5 shares at September 30, 2020 and December 31, 2019, respectively (2,543.7) (2,105.9)
Accumulated other comprehensive loss (119.2) (66.8)
Retained earnings 4,707.4 4,639.8
Total stockholders' equity 11,074.9 11,271.8
Total liabilities and stockholders' equity $ 17,548.4 $ 17,544.6
XML 41 R3.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
shares in Millions
Sep. 30, 2020
Dec. 31, 2019
Statement of Financial Position [Abstract]    
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 290.0 290.0
Common stock, shares issued 239.7 237.8
Treasury Stock, Shares 20.7 16.5
XML 42 R4.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Total revenues $ 1,588.7 $ 1,263.1 $ 4,478.1 $ 3,606.8
Costs and expenses:        
Cost of sales (exclusive of amortization of purchased intangible assets) 144.7 95.2 401.3 280.2
Research and development 285.9 232.9 707.9 616.4
Selling, general and administrative 334.2 299.3 955.5 880.1
Acquired in-process research and development 0.0 0.0 0.0 (4.1)
Amortization of purchased intangible assets 53.1 75.6 200.5 235.7
Change in fair value of contingent consideration 23.4 29.8 45.0 7.2
Acquisition-related costs 63.0 0.0 105.7 0.0
Restructuring expenses 14.3 0.3 13.5 11.9
Impairment of intangible assets 0.0 0.0 2,053.3 0.0
Gain on sale of asset (14.8) 0.0 (14.8) 0.0
Total costs and expenses 903.8 733.1 4,467.9 2,027.4
Operating income 684.9 530.0 10.2 1,579.4
Other income and expense:        
Investment income, net 11.5 23.0 47.8 50.6
Interest expense (27.6) (17.9) (77.0) (56.1)
Other income and (expense) (1.9) 0.4 (2.6) 2.9
Income (loss) before income taxes 666.9 535.5 (21.6) 1,576.8
Income tax expense (benefit) 88.8 67.9 (89.2) 61.5
Net income $ 578.1 $ 467.6 $ 67.6 $ 1,515.3
Earnings per common share        
Basic (in dollars per share) $ 2.64 $ 2.09 $ 0.31 $ 6.77
Diluted (in dollars per share) $ 2.62 $ 2.08 $ 0.30 $ 6.72
Shares used in computing earnings per common share        
Basic 219.1 223.3 220.4 223.8
Diluted 220.6 224.5 221.9 225.4
Net product sales        
Total revenues $ 1,588.3 $ 1,263.1 $ 4,477.4 $ 3,605.8
Other revenue        
Total revenues $ 0.4 $ 0.0 $ 0.7 $ 1.0
XML 43 R5.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Comprehensive Income Statement - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Statement of Comprehensive Income [Abstract]        
Net income $ 578.1 $ 467.6 $ 67.6 $ 1,515.3
Other comprehensive (loss) income, net of tax:        
Foreign currency translation 1.2 (2.5) (5.3) (3.0)
Unrealized gains on debt securities 0.0 0.0 0.1 0.2
Unrealized (gains) losses on hedging activities, net of tax of $(2.8), $3.5, $(14.3) and $(10.8), respectively (9.5) 12.2 (47.2) (35.7)
Other comprehensive (loss) income, net of tax (8.3) 9.7 (52.4) (38.5)
Comprehensive income $ 569.8 $ 477.3 $ 15.2 $ 1,476.8
XML 44 R6.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Unrealized loss on hedge, tax effect $ (2.8) $ 3.5 $ (14.3) $ (10.8)
XML 45 R7.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Changes in Stockholder's Equity Statement - USD ($)
shares in Millions, $ in Millions
Total
Adoption of new accounting standards
Common Stock
Additional Paid-In Capital
Treasury Stock at Cost
Accumulated Other Comprehensive Income (Loss)
Retained Earnings
Retained Earnings
Adoption of new accounting standards
Balances, common shares at Dec. 31, 2018     236.2          
Balances, value at Dec. 31, 2018 $ 9,165.3 $ (90.3) $ 0.0 $ 8,539.1 $ (1,689.9) $ (9.7) $ 2,325.8 $ (90.3)
Balances, treasury shares at Dec. 31, 2018         12.7      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Repurchase of common stock, shares 3.5       3.5      
Repurchase of common stock $ (383.5)       $ (383.5)      
Issuance of common stock under stock option and stock purchase plans, shares     0.3          
Issuance of common stock under stock option and stock purchase plans 23.2     23.2        
Issuance of restricted common stock, shares     1.0          
Issuance of restricted common stock 0.0              
Share-based compensation expense 175.7     175.7        
Net income 1,515.3           1,515.3  
Other comprehensive income (38.5)         (38.5)    
Balances, treasury shares at Sep. 30, 2019         16.2      
Balances, value at Sep. 30, 2019 10,367.2   $ 0.0 8,738.0 $ (2,073.4) (48.2) 3,750.8  
Balances, common shares at Sep. 30, 2019     237.5          
Balances, common shares at Jun. 30, 2019     237.3          
Balances, value at Jun. 30, 2019 $ 10,163.5   $ 0.0 8,677.0 $ (1,738.8) (57.9) 3,283.2  
Balances, treasury shares at Jun. 30, 2019         13.1      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Repurchase of common stock, shares 3.1       3.1      
Repurchase of common stock $ (334.6)       $ (334.6)      
Issuance of common stock under stock option and stock purchase plans, shares     0.1          
Issuance of common stock under stock option and stock purchase plans 1.9     1.9        
Issuance of restricted common stock, shares     0.1          
Issuance of restricted common stock 0.0              
Share-based compensation expense 59.1     59.1        
Net income 467.6           467.6  
Other comprehensive income 9.7         9.7    
Balances, treasury shares at Sep. 30, 2019         16.2      
Balances, value at Sep. 30, 2019 10,367.2   $ 0.0 8,738.0 $ (2,073.4) (48.2) 3,750.8  
Balances, common shares at Sep. 30, 2019     237.5          
Balances, common shares at Dec. 31, 2019     237.8          
Balances, value at Dec. 31, 2019 $ 11,271.8   $ 0.0 8,804.7 $ (2,105.9) (66.8) 4,639.8  
Balances, treasury shares at Dec. 31, 2019 16.5       16.5      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Repurchase of common stock, shares 4.2       4.2      
Repurchase of common stock $ (434.3)       $ (434.3)      
Issuance of common stock under stock option and stock purchase plans, shares     0.4          
Issuance of common stock under stock option and stock purchase plans 23.4     23.4        
Issuance of restricted common stock, shares     1.5          
Issuance of restricted common stock 0.0              
Share-based compensation expense 191.6     195.1 $ (3.5)      
Portola replacement equity awards attributable to the pre-combination period 7.2     7.2        
Net income 67.6           67.6  
Other comprehensive income $ (52.4)         (52.4)    
Balances, treasury shares at Sep. 30, 2020 20.7       20.7      
Balances, value at Sep. 30, 2020 $ 11,074.9   $ 0.0 9,030.4 $ (2,543.7) (119.2) 4,707.4  
Balances, common shares at Sep. 30, 2020     239.7          
Balances, common shares at Jun. 30, 2020     239.2          
Balances, value at Jun. 30, 2020 $ 10,490.8   $ 0.0 8,942.4 $ (2,470.0) (110.9) 4,129.3  
Balances, treasury shares at Jun. 30, 2020         20.1      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Repurchase of common stock, shares 0.6       0.6      
Repurchase of common stock $ (73.5)       $ (73.5)      
Issuance of common stock under stock option and stock purchase plans, shares     0.2          
Issuance of common stock under stock option and stock purchase plans 10.5     10.5        
Issuance of restricted common stock, shares     0.3          
Issuance of restricted common stock 0.0              
Share-based compensation expense 70.1     70.3 $ (0.2)      
Portola replacement equity awards attributable to the pre-combination period 7.2     7.2        
Net income 578.1           578.1  
Other comprehensive income $ (8.3)         (8.3)    
Balances, treasury shares at Sep. 30, 2020 20.7       20.7      
Balances, value at Sep. 30, 2020 $ 11,074.9   $ 0.0 $ 9,030.4 $ (2,543.7) $ (119.2) $ 4,707.4  
Balances, common shares at Sep. 30, 2020     239.7          
XML 46 R8.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Cash flows from operating activities:          
Net income $ 578.1 $ 467.6 $ 67.6 $ 1,515.3  
Adjustments to reconcile net income to net cash flows from operating activities:          
Depreciation and amortization     254.3 286.2  
Change in fair value of contingent consideration 23.4 29.8 45.0 7.2  
Payments of contingent consideration     0.0 (100.0)  
Share-based compensation expense     195.6 176.8  
Deferred taxes (benefit)     (174.2) (136.1)  
Unrealized foreign currency loss (gain)     0.9 (3.3)  
Unrealized gain on forward contracts     (3.9) (15.3)  
Unrealized gain on strategic equity investments     (4.6) (20.6)  
Gain on sale of asset     (14.8) 0.0  
Gain on derecognition of Portola strategic equity investment     (29.7) 0.0  
Inventory obsolescence charge     24.6 0.0  
Impairment of intangible assets 0.0 0.0 2,053.3 0.0  
Other     10.7 (2.3)  
Changes in operating assets and liabilities, excluding the effect of acquisitions:          
Accounts receivable     (183.5) (199.1)  
Inventories     (10.3) (105.9)  
Prepaid expenses, right of use operating assets and other assets     (92.3) (42.2)  
Accounts payable, accrued expenses, lease liabilities and other liabilities     23.7 207.1  
Net cash provided by operating activities     2,162.4 1,567.8  
Cash flows from investing activities:          
Purchases of available-for-sale debt securities     (19.4) (51.2)  
Proceeds from maturity or sale of available-for-sale debt securities     184.2 211.0  
Purchases of mutual funds related to nonqualified deferred compensation plan     (14.1) (13.4)  
Proceeds from sale of mutual funds related to nonqualified deferred compensation plan     9.6 11.4  
Purchases of property, plant and equipment     (29.2) (124.7)  
Payment for acquisition of businesses, net of cash and restricted cash acquired     (2,111.9) 0.0  
Purchases of strategic equity investments and options     (38.1) (63.7)  
Purchase of intangible assets     0.0 (16.0)  
Net cash used in investing activities     (2,018.9) (46.6)  
Cash flows from financing activities:          
Payments on term loan     (97.9) (65.4)  
Payments on revolving credit facility     0.0 (250.0)  
Repurchases of common stock     (434.3) (383.5)  
Net proceeds from issuance of common stock under share-based compensation arrangements     22.1 23.2  
Other     (28.0) (3.7)  
Net cash used in financing activities     (538.1) (679.4)  
Effect of exchange rate changes on cash and cash equivalents and restricted cash     (0.5) (6.1)  
Net change in cash and cash equivalents and restricted cash     (395.1) 835.7  
Cash and cash equivalents and restricted cash at beginning of period     2,723.6 1,367.4 $ 1,367.4
Cash and cash equivalents and restricted cash at end of period 2,328.5 2,203.1 2,328.5 2,203.1 2,723.6
Supplemental cash flow disclosures from investing and financing activities:          
Contingent consideration issued in acquisitions     155.0 0.0  
Fair value of equity shares in Portola settled at closing of the acquisition     47.8 0.0  
Fair value of replacement equity awards issued to Portola employees attributable to the pre-combination period     7.2 0.0  
Exchange of intellectual property rights for equity shares in Inozyme     14.8 0.0  
Fair value of strategic investment and purchase option acquired, less upfront cash paid     0.0 27.6  
Operating ROU lease assets obtained in exchange for operating lease liabilities     21.2 23.9  
Accounts payable and accrued expenses for purchases of property, plant and equipment and intangible assets     14.3 3.1  
Cash and cash equivalents 2,268.0 2,171.3 2,268.0 2,171.3 $ 2,685.5
Restricted cash included in other current assets 60.4 31.5 60.4 31.5  
Restricted cash included in other noncurrent assets $ 0.1 $ 0.3 $ 0.1 $ 0.3  
XML 47 R9.htm IDEA: XBRL DOCUMENT v3.20.2
Business
 9 Months Ended
Sep. 30, 2020
Business [Abstract]  
Business Business
Alexion Pharmaceuticals, Inc. (Alexion, the Company, we, our or us) is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines.
As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD) in patients who are anti-aquaporin-4 (AQP4) antibody positive. Alexion also has two highly innovative enzyme replacement therapies and the first and only approved therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). With the acquisition of Portola Pharmaceuticals, Inc. (Portola) in July 2020, we added the first and only approved Factor Xa inhibitor reversal agent for patients treated with rivaroxaban or apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
In addition to our marketed therapies, we have a diverse pipeline resulting from internal innovation and business development. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. We were incorporated in 1992 under the laws of the State of Delaware.
XML 48 R10.htm IDEA: XBRL DOCUMENT v3.20.2
Basis of Presentation and Principles Of Consolidation
 9 Months Ended
Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation and Principles of Consolidation Basis of Presentation and Principles of Consolidation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. These accounting principles were applied on a basis consistent with those of the consolidated financial statements contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2019. In our opinion, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of our financial statements for interim periods presented in accordance with accounting principles generally accepted in the United States. The condensed consolidated balance sheet as of December 31, 2019 was derived from audited annual financial statements but does not include all disclosures required by accounting principles generally accepted in the United States. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2019 included in our Annual Report on Form 10-K for the year ended December 31, 2019. The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the results to be expected for the full year or any other future periods.
The financial statements of our subsidiaries with functional currencies other than the U.S. dollar are translated into U.S. dollars using period-end exchange rates for assets and liabilities, historical exchange rates for stockholders' equity and weighted average exchange rates for operating results. Translation gains and losses are included in accumulated other comprehensive income (loss), net of tax, in stockholders' equity. Foreign currency transaction gains and losses are included in the results of operations in other income and expense.
The accompanying unaudited condensed consolidated financial statements include the accounts of Alexion Pharmaceuticals, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Our significant accounting policies are described in Note 1 of the notes to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2019. Updates to our accounting policies, including impacts from the adoption of new accounting standards, are discussed below in this Note 2.
Reclassifications
Certain items in the prior period’s condensed consolidated financial statements have been reclassified to conform to the current presentation.
Use of Estimates
Preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues, expenses and disclosure of contingent liabilities in our condensed consolidated financial statements.
Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain. We are not aware of any specific event or circumstance that would require an update to our estimates, judgments and assumptions or a revision of the carrying value of our assets or liabilities as of October 29, 2020, the date of issuance of this Quarterly Report on Form 10-Q. These estimates may change, as new events occur and additional information is obtained. Actual results may differ from these estimates under different assumptions or conditions and such differences may be material.
New Accounting Pronouncements
Accounting Standards Update (ASU) 2019-12, “Income Taxes: Simplifying the Accounting for Income Taxes”: In December 2019, the Financial Accounting Standards Board (FASB) issued a new standard intended to simplify the accounting for income taxes by eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new standard also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for annual periods beginning after December 15, 2020 and interim periods within, with early adoption permitted. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. We do not expect the adoption of this standard to have a material impact on our financial condition and results of operations.
ASU 2020-01, “Investments - Equity Securities, Investments - Equity Method and Joint Ventures, and Derivatives and Hedging - Clarifying the Interactions Between Topic 321, Topic 323, and Topic 815”: In January 2020, the FASB issued a new standard intended to clarify the interactions between Accounting Standards Codification (ASC) 321, ASC 323 and ASC 815. The new standard addresses accounting for the transition into and out of the equity method and measurement of certain purchased options and forward contracts to acquire investments. The standard is effective for annual and interim periods beginning after December 15, 2020, with early adoption permitted. Adoption of the standard requires changes to be made prospectively. We do not expect the adoption of this standard to have a material impact on our financial condition and results of operations.
ASU 2020-04, “Reference Rate Reform, Facilitation of the Effects of Reference Rate Reform on Financial Reporting": In response to concerns about structural risks of interbank offered rates, and, particularly, the risk of cessation of the London Interbank Offered Rate (LIBOR), regulators around the world have undertaken reference rate reform initiatives to identify alternative reference rates that are more observable or transaction-based and less susceptible to manipulation. In March 2020, the FASB issued a new standard that provides optional guidance for a limited time to ease the potential burden in accounting for the effects of reference rate reform, including optional expedients and exceptions for the accounting implications of contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met.
The amendments in this new standard only apply to contracts and hedging relationships that reference LIBOR or another reference rate expected to be discontinued due to reference rate reform. The expedients and exceptions provided by the standard do not apply to contract modifications made and hedging relationships entered into or evaluated after December 31, 2022. We are currently reviewing our contracts impacted by reference rate reform and are assessing the impact of this standard on our financial condition and results of operations.
Recently Adopted Accounting Pronouncements
ASU 2018-15, "Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract": In August 2018, the FASB issued a new standard on a customer's accounting for implementation, set-up, and other upfront costs incurred in a cloud computing arrangement (CCA) that aligns the requirements for capitalizing implementation costs in a CCA service contract with existing internal-use software guidance. The standard also provides classification guidance on these implementation costs as well as additional
quantitative and qualitative disclosures. The standard is effective for interim and annual periods beginning after December 15, 2019, with early adoption permitted, and can be adopted prospectively or retrospectively.
We adopted the new standard on January 1, 2020 on a prospective basis. The adoption of this standard had no impact on our financial statements at the date of adoption; however, we anticipate the adoption of this standard will result in an increase in capitalized assets related to qualifying CCA implementation costs in future periods.
Qualifying CCA implementation, set-up and other upfront costs incurred after January 1, 2020 are capitalized as other assets in our condensed consolidated balance sheets. These assets will be expensed over the term of the hosting arrangement and such expense will be presented within the same line item in our condensed consolidated statements of operations as the expense for fees for the associated hosting arrangement. These capitalized costs will be evaluated for impairment when events or changes in circumstances indicate that the carrying value of the capitalized implementation costs is not recoverable. For the nine months ended September 30, 2020, capitalized CCA implementation costs were not material.
ASU 2016-13, "Measurement of Credit Losses on Financial Instruments": In June 2016, the FASB issued a new standard intended to improve reporting requirements specific to loans, receivables and other financial instruments. The new standard requires that credit losses on financial assets measured at amortized cost be determined using an expected loss model, instead of the current incurred loss model, and requires that credit losses related to available-for-sale debt securities be recorded through an allowance for credit losses and limited to the amount by which carrying value exceeds fair value. The new standard also requires enhanced disclosure of credit risk associated with financial assets. The standard is effective for interim and annual periods beginning after December 15, 2019 with early adoption permitted.
We adopted the new standard on January 1, 2020 and have completed our assessment of the standard based on the composition of our portfolio of financial instruments and current and forecasted economic conditions at that date. Our significant financial assets that are within the scope of the new standard consist of trade accounts receivable and available for sale debt securities. We have not historically experienced any material credit losses associated with our trade accounts receivable or available for debt securities.
We monitor economic conditions, including volatility associated with international economies and the associated impacts on the financial markets and our business. We disaggregate our trade accounts receivable population into pools of similar risk characteristics based on underlying customer type and geographical location. Current expected credit loss allowances are estimated for each risk pool based on available information, including i) historical credit loss experience, ii) current economic conditions and, iii) reasonable and supportable forecasts of future economic conditions that may affect the collectibility of the recorded amounts. Based on the relevant facts and economic conditions as of the date of adoption, we concluded that the expected credit losses on our trade accounts receivable were immaterial. Additionally, unrealized losses on our available for sale investment portfolio were immaterial.
As of September 30, 2020, we reassessed our estimated credit losses on our trade accounts receivable, including consideration of the potential impacts of the COVID-19 global pandemic. Based on the relevant facts and economic conditions as of September 30, 2020, we concluded that the expected credit losses on our trade accounts receivable continued to be immaterial.
XML 49 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Acquisitions
 9 Months Ended
Sep. 30, 2020
Business Combinations [Abstract]  
Acquisitions Acquisitions
Business Combinations
Achillion Pharmaceuticals, Inc.
In October 2019, Alexion entered into a definitive agreement to acquire Achillion Pharmaceuticals, Inc. (Achillion), a clinical-stage biopharmaceutical company focused on the development of oral Factor D inhibitors. Achillion was developing oral small molecule Factor D inhibitors to treat people with complement alternative pathway-mediated rare diseases, such as PNH and C3 glomerulopathy (C3G). Achillion had two clinical stage medicines in development, including danicopan (ACH-4471/ALXN2040) and ACH-5228 (ALXN2050).
The acquisition of Achillion closed on January 28, 2020. Under the terms of the agreement, we acquired all outstanding common stock of Achillion for $6.30 per share, or an aggregate of $926.2, inclusive of the settlement of Achillion's outstanding equity awards. The acquisition was funded with cash on hand. The transaction includes the potential for additional consideration in the form of non-tradeable contingent value rights (CVRs), which will be paid to Achillion shareholders if certain clinical and regulatory milestones are achieved within specified periods. These
include $1.00 per share for the U.S. Food and Drug Administration (FDA) approval of danicopan and $1.00 per share for the initiation of a Phase III clinical trial in ACH-5228.
The transaction was accounted for as a business combination. The following table summarizes the total consideration transferred to acquire Achillion and the estimated fair value of the identified assets acquired and liabilities assumed at the acquisition date:
Consideration
Upfront payment to shareholders and option holders$926.2 
Upfront payment, fair value of equity compensation attributable to the post-combination service period(20.0)
Upfront cash paid, net906.2 
Contingent consideration160.7 
Contingent consideration, fair value of equity compensation attributable to the post-combination service period(5.7)
Total consideration$1,061.2 
Assets Acquired and Liabilities Assumed
Cash and cash equivalents$68.5 
Marketable securities106.1 
In-process research & development assets (IPR&D)918.0 
Goodwill37.8 
Deferred tax liabilities, net(62.9)
Other assets and liabilities, net(6.3)
Total net assets acquired$1,061.2 

Our accounting for this acquisition was finalized during the second quarter of 2020. Measurement period adjustments increased goodwill by $3.1 during the second quarter of 2020 due to purchase price allocation increases to deferred tax liabilities, net. Measurement period adjustments were recorded as a result of studies completed during the second quarter of 2020 to determine the tax deductibility of certain acquisition-related costs and the valuation of historical net operating loss and income tax credit carryforwards.
The initial fair value estimate of the contingent consideration in the form of non-tradeable CVRs was $160.7, which was recorded as a noncurrent liability in our condensed consolidated balance sheet, including $5.7 related to compensation attributable to the post-combination service period. We determined the fair value of these milestone-related payment obligations using various estimates, including probabilities of success prior to expiration of the specified period, discount rates and the amount of time until the conditions of the milestone payments are expected to be met. This fair value measurement was based on significant inputs not observable in the market, representing Level 3 measurements within the fair value hierarchy. The resulting probability-weighted cash flows were discounted using a cost of debt rate ranging from 2.1% to 2.3%. The range of estimated milestone payments upon closing of the acquisition is from zero, if no milestones are achieved for any product, to $306.3 if certain development and regulatory milestones are achieved.
Subsequent to the acquisition date, we have adjusted the contingent consideration to fair value with changes in fair value recognized in operating earnings. Changes in fair values reflect new information about the probability and timing of meeting the conditions of the milestone payments. In the absence of new information, changes in fair value will only reflect the interest component of contingent consideration related to the passage of time as development work progresses towards the potential achievement of the milestones. At September 30, 2020, the fair value of the contingent consideration for the Achillion acquisition was $209.4 based on the probability-weighted cash flows, discounted using a cost of debt ranging from 3.9% to 4.3%. Changes in fair value of the contingent consideration associated with the Achillion acquisition for the three and nine months ended September 30, 2020 was $19.3 and $48.6, respectively.
The aggregate fair value of equity compensation attributable to the post-combination service period was $25.7. This amount was excluded from the total consideration transferred and was recognized as a charge to acquisition-related costs in our condensed consolidated statements of operations. These amounts were associated with the
accelerated vesting of stock options previously granted to Achillion employees. Excluding the $5.7 of contingent consideration related to equity compensation attributable to the post-combination service period, such amounts were paid during the first quarter 2020.
Intangible assets associated with IPR&D relate to two development-stage programs, ACH-4471 (ALXN2040) and ACH-5228 (ALXN2050). The estimated fair value of $918.0 was determined using the excess earnings valuation method, a variation of the income valuation approach. The excess earnings valuation method estimates the value of an intangible asset equal to the present value of the incremental after-tax cash flows attributable to that intangible asset. Some of the more significant assumptions utilized in our asset valuations included the estimated net cash flows for each asset, including net revenues, cost of sales, research and development and other operating expenses, the potential regulatory and commercial success rates, competitive trends impacting the assets, and tax rates. The fair value using the excess earnings valuation method was determined using an estimated weighted average cost of capital for Achillion of 11.5%, which represents a rate of return that a market participant would expect for these assets. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements. In the second quarter 2020, we recognized an impairment charge of $11.0 to write off our ACHN-4471 (ALXN2040) IPR&D asset due to clinical results received during the quarter.
The excess of purchase price over the fair value of the assets acquired and liabilities assumed represents the goodwill resulting from the acquisition. The goodwill, which is not tax-deductible, has been recorded as a noncurrent asset and is not amortized, but is subject to an annual review for impairment. The factors that contributed to the recognition of goodwill include the value of the acquired workforce, synergies that are specific to our business and not available to market participants, and early research in preclinical Factor D inhibitors, as well as the effects of the establishment of a deferred tax liability for the acquired IPR&D intangible assets, which has no tax basis.
We recorded a net deferred tax liability of $62.9, inclusive of measurement period adjustments recorded during the second quarter 2020. This amount was primarily comprised of $205.3 of deferred tax liabilities relating to the IPR&D acquired, offset by $142.4 of deferred tax assets related to net operating loss carryforwards (NOLs), income tax credits, and other temporary differences.
Achillion's results of operations are included in the condensed consolidated financial statements from the date of acquisition. For the three and nine months ended September 30, 2020 we recorded $24.6 and $51.4 of pre-tax operating losses exclusive of transaction costs, $19.3 and $48.6, respectively, of changes in contingent consideration and zero and $11.0, respectively, of impairment charges, associated with the operations of Achillion in our condensed consolidated statements of operations. We also recorded acquisition-related costs in connection with the acquisition during the three and nine months ended September 30, 2020 as presented below. No revenues were recorded in the results of operations during the three and nine months ended September 30, 2020 as neither ALXN2040 nor ALXN2050 has been approved for commercial sale by any regulatory agency.
Portola Pharmaceuticals, Inc.
In May 2020, Alexion entered into a definitive merger agreement to acquire Portola Pharmaceuticals, Inc. (Portola), a commercial-stage biopharmaceutical company focused on life-threatening blood-related disorders. Portola’s commercialized medicine, ANDEXXA®, marketed as ONDEXXYA® in Europe, is the first and only approved Factor Xa inhibitor reversal agent, and has demonstrated transformative clinical value by rapidly reversing the anticoagulant effects of Factor Xa inhibitors rivaroxaban and apixaban in severe and uncontrolled bleeding. The acquisition provides the opportunity to grow Alexion's commercial portfolio and is a strategic fit with our existing expertise in acute care, hematology and neurology.
Alexion completed the acquisition through a tender offer and subsequent merger of Portola which closed on July 2, 2020. Under the terms of the tender offer and merger agreement, Alexion purchased all outstanding common stock of Portola for $18.00 per share, or an aggregate of approximately $1,380.8, including the settlement of certain of Portola's outstanding equity awards but excluding shares of Portola stock held by Alexion at closing. The acquisition was funded by cash on hand.
Prior to the acquisition of Portola, in March 2020 and April 2020, we purchased $14.5 and $3.6, respectively, of common stock of Portola, which we recorded at fair value. Upon the closing of the acquisition of Portola, the fair value of the equity investment of $47.8 was derecognized and included in the fair value of consideration transferred. For additional information on our Portola equity investment, please see Note 10, Other Investments.
The aggregate fair value of equity compensation attributable to the post-combination service period was $11.1. This amount was excluded from the total consideration transferred and was recognized as a charge to acquisition-related costs in our condensed consolidated statements of operations. These amounts were primarily associated with the accelerated vesting of stock options previously granted to Portola employees and were paid during the third quarter 2020.
We issued $41.5 of equity compensation replacement awards, of which the portion attributable to services performed prior to the acquisition date, or $7.2, was allocated to purchase consideration. The remaining fair value is attributable to future services and will be expensed as share-based compensation over the remaining service periods. Expense associated with the accelerated-vesting of the replacement awards in connection with employee terminations will be recognized as acquisition-related employee separation costs.
In connection with the acquisition, Alexion also paid $196.9 to settle certain debt held by Portola that was subject to preexisting change of control provisions.
The transaction was accounted for as a business combination. The following table summarizes the total consideration transferred to acquire Portola and the estimated fair value of the identified assets acquired and liabilities assumed at the acquisition date:
Consideration
Upfront payment to shareholders and equity holders$1,380.8 
Upfront payment, fair value of equity compensation attributable to the post-combination service period(11.1)
Upfront cash paid, net1,369.7 
Fair value of equity shares held by Alexion at closing 47.8 
Fair value of replacement equity awards attributable to the pre-combination period7.2 
Total consideration to acquire outstanding equity, net1,424.7 
Total consideration to settle preexisting debt196.9 
Total consideration$1,621.6 
Assets Acquired and Liabilities Assumed
Cash and cash equivalents$288.5 
Marketable securities17.8 
Inventories, including noncurrent portion of $169.1 and validation batches of $60.9
362.5 
Intangible assets1,051.0 
Goodwill25.5 
Deferred tax assets, net116.0 
Other assets41.9 
Accounts payable and accrued expenses(75.6)
Long-term debt, including current portion of $7.7
(182.0)
Other liabilities(24.0)
Total net assets acquired$1,621.6 

Our accounting for this acquisition is preliminary. The fair value estimates for the assets acquired and liabilities assumed were based on preliminary calculations, and our estimates and assumptions are subject to change as we obtain additional information for our estimates during the measurement period. The areas that rely on preliminary estimates that are not yet finalized relate to the valuation of acquired intangible assets, an ongoing assessment of the condition of certain inventory and deferred taxes, net, as a result of ongoing studies to determine the tax deductibility of certain acquisition-related costs and the valuation of historical net operating loss and income tax credit carryforwards.
We acquired $362.5 of ANDEXXA inventory, inclusive of $60.9 of validation batches manufactured under processes which are subject to regulatory approval and expected to be commercially saleable following approval. The estimated fair value of raw material inventory was valued at replacement cost, which is equal to the value a market participant would pay to acquire the inventory. The estimated fair value of work-in-process and finished goods inventory was based on the expected selling price of the inventory, adjusted for incremental costs to complete the manufacturing process, for direct selling efforts, and for a normal profit on the remaining manufacturing and selling costs. Additionally, as the inventory acquired, inclusive of validation batches, is expected to be realized over a period of approximately 3.0 years, the fair value of the inventory was determined using a discount rate of 17.5%, representing the rate of return that a market participant would expect for the inventory, which shares risk that is similar to the underlying intellectual property. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements. The acquired inventory, inclusive of the acquisition-date fair value step-up, will be expensed within cost of sales as the inventory is sold to customers. We classified the ANDEXXA inventory that is expected to be utilized beyond our normal operating cycle as a long-term asset. The fair value of the non-current portion of inventory, in addition to the validation batches, are classified within other assets in our condensed consolidated balance sheet.
Intangible assets consist of purchased technology of $1,036.0 and IPR&D of $15.0. The purchased technology intangible asset relates to Portola's lead product ANDEXXA. The estimated fair value was determined using the excess earnings valuation method, a variation of the income valuation approach. The excess earnings valuation method estimates the value of an intangible asset equal to the present value of the incremental after-tax cash flows attributable to that intangible asset. Some of the more significant assumptions utilized in our asset valuation included the estimated net cash flows for ANDEXXA, including net revenues, cost of sales, research and development and other operating expenses, the potential regulatory and commercial success rates associated with ANDEXXA's current conditional approval status and planned extension into the urgent surgery setting, competitive trends impacting the assets, and tax rates. The fair value using the excess earnings valuation method was determined using a discount rate commensurate with the risks of ANDEXXA of 17.5%, which represents a rate of return that a market participant would expect for the asset. The acquired purchased technology intangible asset is being amortized over an estimated useful life of approximately 10 years. IPR&D relates to the cerdulatinib development-stage asset. The estimated fair value of the IPR&D asset was determined using a relief from royalty (RFR) method, a variation of the income approach that is based on the cost savings that accrue to the owner of an intangible asset who would otherwise have to pay royalties on revenues earned through the use of the asset. The RFR method was modified to reflect the cash flow forecast of Portola's pre-existing in-license of cerdulatinib from Astellas Pharma, Inc. The acquired fair value of $15.0 represents an increase in the value of the asset relative to when it was initially in-licensed by Portola. Some of the more significant assumptions utilized in the IPR&D asset valuation included the estimated net revenue, royalty rate, and tax rates. The fair value using the RFR method was determined using an estimated discount rate commensurate with the risks of cerdulatinib of 17.5%, which represents a rate of return that a market participant would expect for the asset. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements.
In connection with the acquisition, we assumed royalty-based debt which requires repayment through tiered royalties on future net worldwide sales of ANDEXXA. Total potential royalty payments are capped at $290.6, of which $13.7 were paid by Portola prior to the acquisition. The fair value of the remaining $276.9 in royalty-based payments as of the date of acquisition was $182.0. The estimated fair value was measured using Level 3 inputs and was calculated using a real options method, which runs simulations using various estimates, including probability-weighted net sales of ANDEXXA and volatility. Using the simulation results, the fair value was calculated based on the expected probability-weighted risk-neutral royalties, discounted at our estimated cost of debt, ranging from 3.3% to 7.1%, commensurate with the cost of debt at each period in which the royalty-based payments are estimated to be made.
We recorded net deferred tax assets of $116.0. This amount was primarily comprised of $301.0, $42.0, $42.4 and $39.1 of deferred tax assets relating to net operating loss carryforwards (NOLs), income tax credits, royalty-based debt, and other temporary differences, respectively, offset by $245.1 and $63.4 of deferred tax liabilities relating to intangible assets acquired and inventory fair value adjustments, respectively.
The excess of purchase price over the fair value of the assets acquired and liabilities assumed represents the goodwill resulting from the acquisition. The goodwill, which is not tax-deductible, has been recorded as a noncurrent asset and is not amortized, but is subject to an annual review for impairment. The factors that contributed to the recognition of goodwill primarily include the value of the acquired workforce and the effects of the establishment of a deferred tax liability for the fair value step-up of acquired inventory and intangible assets which exceed the incremental book value of acquired deferred tax assets over their fair value.
Portola's results of operations are included in the condensed consolidated financial statements from the date of acquisition. For the three and nine months ended September 30, 2020, we recorded $38.9 of revenue associated with ANDEXXA in our condensed consolidated statements of operations. For the three and nine months ended September 30, 2020, we recorded $35.4 of pre-tax operating losses excluding transaction costs and $25.9 of intangible asset amortization, associated with the operations of Portola in our condensed consolidated statements of operations. We also recorded acquisition-related costs in connection with the acquisition during the three and nine months ended September 30, 2020 as presented below.
Pro forma financial information (unaudited)
The following unaudited pro forma information presents the combined results of Alexion, Achillion, and Portola as if the acquisitions of Achillion and Portola had been completed on January 1, 2019, with adjustments to give effect to pro forma events that are directly attributable to the acquisitions. The unaudited pro forma results do not reflect operating efficiencies or potential cost savings that may have resulted from the consolidation of operations. Accordingly, the unaudited pro forma financial information is not necessarily indicative of the results of operations had we completed the transaction on January 1, 2019.
 Three months ended September 30Nine months ended September 30
 2020201920202019
Pro forma revenue$1,589.5 $1,299.9 $4,526.5 $3,694.2 
Pro forma net income (loss)$625.4 $372.0 $(23.2)$1,063.7 

The unaudited pro forma consolidated results for the three and nine months ended September 30, 2020 and 2019 primarily include the following pro forma adjustments related to non-recurring activity, net of tax:
•Reclassification of Alexion, Achillion and Portola acquisition-related costs. Acquisition-related costs of $72.2 and $143.5, respectively, were excluded from net income for the three and nine months ended September 30, 2020. Expenses of $129.3 were included in net income for the nine months ended September 30, 2020.
•Incremental amortization expense related to Portola purchased technology intangible assets for the three and nine months ended September 30, 2019 was $19.9 and $59.6, respectively, and for the nine months ended September 30, 2020 was $39.7.
•Incremental cost of goods sold related to Portola inventory fair value step-up adjustments calculated based on the fair value of finished goods inventory for the three and nine months ended September 30, 2019 was $10.1 and $16.7, respectively, and for the nine months ended September 30, 2020 was $10.9.
Acquisition-Related Costs
Acquisition-related costs recorded within the condensed consolidated statement of operations associated with our acquisitions of Achillion and Portola for the three and nine months ended September 30, 2020 and 2019 include the following:
 Three months ended September 30,Nine months ended September 30,
 2020201920202019
Transaction costs (1)
$1.8 $— $7.4 $— 
Integration costs4.6 — 5.6 — 
Fair value of equity compensation attributable to the post-combination service period11.1 — 36.8 — 
Employee separation costs (2)
45.5 — 55.9 — 
$63.0 $— $105.7 $— 
(1) Transaction costs primarily include legal fees related to the acquisition of Portola as well as costs incurred to effectuate the settlement of the Achillion outstanding options
(2) Employee separation costs include liabilities recognized, and subsequent changes in estimates recorded for, severance payments, one-time short-term retention awards agreed to in connection with the acquisition of Achillion and share-based compensation expense relating to awards accelerated in connection with terminations of Portola employees.
Acquisition-related costs attributable to the Achillion acquisition for the nine months ended September 30, 2020 were $38.0. There were immaterial acquisition-related costs attributable to the Achillion acquisition for the three months ended September 30, 2020. Acquisition-related costs attributable to the Portola acquisition for three and nine months ended September 30, 2020 were $63.0 and $67.7, respectively.
XML 50 R12.htm IDEA: XBRL DOCUMENT v3.20.2
Inventories
 9 Months Ended
Sep. 30, 2020
Inventory, Net [Abstract]  
Inventories Inventories
The components of inventory are as follows:
 September 30,December 31,
 20202019
Raw materials$94.2 $41.2 
Work-in-process256.6 180.8 
Finished goods510.5 405.6 
Total inventories$861.3 $627.6 
Balance Sheet Classification:
Inventories$729.0 $627.6 
Other assets$132.3 $— 

Total inventories include ANDEXXA inventory acquired in connection with the July 2, 2020 Portola acquisition, but exclude acquired ANDEXXA validation batches of $60.9 that were manufactured under processes which are subject to regulatory approval. The acquired ANDEXXA inventory includes the acquisition-date fair value step-up, which is expensed within cost of sales as the inventory is sold to customers. For additional information on our acquisition of Portola, please see Note 3, Acquisitions.
We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in other assets in our condensed consolidated balance sheets. Inventories classified as long-term relate to ANDEXXA inventory acquired in connection with the Portola acquisition.
As of September 30, 2020 and December 31, 2019, the carrying value of capitalized inventory manufactured at production facilities that have not yet received regulatory approval was $117.2 and $60.5, respectively.
XML 51 R13.htm IDEA: XBRL DOCUMENT v3.20.2
Intangible Assets and Goodwill
 9 Months Ended
Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets and Goodwill Intangible Assets and Goodwill
The following table summarizes the carrying amount of our intangible assets and goodwill, net of accumulated amortization and impairment charges: 
September 30, 2020December 31, 2019
Estimated
Life (years)		CostAccumulated
Amortization 		NetCostAccumulated
Amortization 		Net
Licensing rights
3-8
$57.0 $(37.5)$19.5 $57.0 $(34.7)$22.3 
Patents710.5 (10.5)— 10.5 (10.5)— 
Purchased technology
6-16
5,746.5 (3,631.5)(a)2,115.0 4,710.5 (1,388.7)3,321.8 
Other intangibles50.4 (0.3)0.1 0.4 (0.2)0.2 
Acquired IPR&DIndefinite922.0 — 922.0 — — — 
Total$6,736.4 $(3,679.8)$3,056.6 $4,778.4 $(1,434.1)$3,344.3 
GoodwillIndefinite$5,103.6 $(2.9)$5,100.7 $5,040.3 $(2.9)$5,037.4 
(a) Includes an impairment charge of $2,042.3 recognized during the second quarter 2020 related to the KANUMA intangible asset
In connection with our acquisition of Achillion during the first quarter 2020, we acquired IPR&D programs with a fair value of $918.0 and recorded goodwill of $37.8. For additional information on our acquisition of Achillion, please see Note 3, Acquisitions. In the second quarter 2020, we recognized an impairment charge of $11.0 to write off the cost basis of our ACHN-4471 (ALXN2040) acquired in-process research and development asset due to clinical results received during the quarter.
In connection with our acquisition of Portola during the third quarter 2020, we acquired purchased technology and IPR&D programs with a fair value of $1,036.0 and $15.0, respectively and recorded goodwill of $25.5. For additional information on our acquisition of Portola, please see Note 3, Acquisitions.
Amortization expense for the three months ended September 30, 2020 and 2019 was $54.1 and $77.5, respectively. Amortization expense for the nine months ended September 30, 2020 and 2019 was $203.4 and $239.2, respectively. As of September 30, 2020, assuming no changes in the gross cost basis of intangible assets, the total estimated amortization expense for finite-lived intangible assets is $54.1 for the three months ending December 31, 2020, and approximately $216.0 for each of the years ending December 31, 2021 through December 31, 2025.
During the quarter ended June 30, 2020, based on continued challenges expanding patient growth and new alternative commercial opportunities, the Company revised its strategic view of KANUMA and determined that we have exhausted commercially viable initiatives related to KANUMA and will have difficulty expanding patient growth over the long term as we focus on promoting other commercial programs and growing our pipeline. As a result, we no longer expect to increase the number of KANUMA patients in the long term at the rate previously assumed. This determination resulted in reduced cash flow projections for KANUMA, which indicated that the related intangible asset value was not fully recoverable on an undiscounted cash flows basis. On June 30, 2020, the Company utilized market participant assumptions to determine its best estimate of the fair value of the intangible asset related to KANUMA that, when compared with its related carrying value, resulted in an impairment charge of $2,042.3.
The estimated fair value of the KANUMA asset as of June 30, 2020 was determined using the excess earnings method, a variation of the income approach. The excess earnings method estimates the value of an intangible asset equal to the present value of the incremental after-tax cash flows attributable to that intangible asset over its remaining economic life. Long term cash flow projections for the asset require the use of significant estimates and judgements, including discount rates and revenue growth rates, and were based on the Company’s most recent strategic plan. The fair value of the asset was determined using an estimated weighted average cost of capital of 10.0%, which reflects the risks inherent in future cash flow projections and represents a rate of return that a market participant would expect for this asset. The estimated revenue growth rates fluctuate over the life of the asset, with a weighted average growth rate in the low single digits. The Company believes its assumptions are consistent with the plans and estimates that a market participant would use to manage the business. The estimated fair value of the KANUMA intangible asset as of June 30, 2020 was $820.0 and will continue to be amortized over its remaining estimated useful life. This fair value measurement was based on significant inputs not observable in the market and thus represents a Level 3 fair value measurement.
The following summarizes the changes in the carrying amount of goodwill:
September 30, 2020
Balance at December 31, 2019$5,037.4 
Goodwill resulting from the acquisitions of Achillion and Portola63.3 
Balance at September 30, 2020$5,100.7 
XML 52 R14.htm IDEA: XBRL DOCUMENT v3.20.2
Debt
 9 Months Ended
Sep. 30, 2020
Debt Disclosure [Abstract]  
Debt Debt
Credit Agreement
On June 7, 2018, we entered into an Amended and Restated Credit Agreement (the Credit Agreement), with Bank of America, N.A. as Administrative Agent. The Credit Agreement amended and restated our credit agreement dated as of June 22, 2015 (the Prior Credit Agreement).
The Credit Agreement provides for a $1,000.0 revolving credit facility and a $2,612.5 term loan facility. The revolving credit facility and the term loan facility mature on June 7, 2023. Beginning with the quarter ending June 30, 2019, we are required to make payments of 5.00% of the original principal amount of the term loan facility annually, payable in equal quarterly installments.
In connection with entering into the Credit Agreement and the Prior Credit Agreement, we paid an aggregate of $53.1 in financing costs in 2018. Financing costs are amortized as interest expense over the life of the debt. Amortization expense associated with deferred financing costs for the three months ended September 30, 2020 and 2019 was $1.2 and $1.3, respectively. Amortization expense associated with deferred financing costs for the nine months ended September 30, 2020 and 2019 was $3.6 and $3.8, respectively. Remaining unamortized deferred financing costs as of September 30, 2020 and December 31, 2019 were $12.2 and $15.8, respectively.
We made principal payments of $32.6 and $97.9 on the term loan during the three and nine months ended September 30, 2020, respectively, and as of September 30, 2020, we had $2,416.6 outstanding on the term loan. We had no outstanding borrowings under the revolving credit facility as of September 30, 2020. As of September 30, 2020, we had open letters of credit of $1.0 that offset our availability in the revolving credit facility.
The amount outstanding under the term loan of $2,416.6 as of September 30, 2020 is subject to variable interest rates, which are based on current market rates, and as such, the Company believes the carrying amount of the obligation approximates fair value.
We were in compliance with all applicable covenants under the Credit Agreement as of September 30, 2020.
Royalty-based Financing
In connection with our acquisition of Portola during the third quarter 2020, we assumed royalty-based debt relating to a royalty sales agreement Portola had entered into with HealthCare Royalty Partners (HCR) whereby HCR acquired a tiered royalty interest in future worldwide net sales of ANDEXXA. Portola received $50.0 upon closing of the agreement in February 2017 and an additional $100.0 following the U.S. regulatory approval of ANDEXXA in May 2018. Tiered royalties ranging from 4.2% to 8.5% are required to be paid to HCR based on net worldwide sales of ANDEXXA. The applicable rate decreases as worldwide net annual sales levels increase above defined thresholds. Total potential royalty payments are capped at 195% of the funding received less certain transaction expenses, or $290.6. As of the date of acquisition, the remaining due to HCR was $276.9 in royalty-based payments.
We recorded the HCR debt at its fair value of $182.0 upon closing of the acquisition, representing an initial debt discount of $94.9. We have also recognized a deferred tax asset of $42.4 related to the royalty-based debt as of the acquisition date. For additional information on our acquisition of Portola, please see Note 3, Acquisitions. Interest expense is recognized using the effective interest rate method over the estimated period the related debt will be paid. This requires estimation of the timing and amount of future royalty payments to be generated from future sales of ANDEXXA. We reassess the expected royalty payments each reporting period and account for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt require that we make estimates that could impact the short and long term classification of the debt carrying values.
Each period, we amortize the initial debt discount using the effective interest rate implied from the projected timing of royalty payments to HCR. The effective interest rate for the HCR royalty-based debt as of September 30, 2020 was 11.4%. During the three and nine months ended September 30, 2020, we recognized interest expense
associated with the amortization of the debt discount of $4.9. We made royalty-based debt payments of $1.7 during the three and nine months ended September 30, 2020. As of September 30, 2020, the carrying value of the royalty-based debt includes approximately $3.0 of royalty payments on third quarter sales of ANDEXXA which will be paid during the fourth quarter 2020.
As of September 30, 2020, the carrying value of the HCR royalty-based debt was $185.2, of which $11.7 was recorded within current portion of long-term debt and $173.5 was recorded within long-term debt, less current portion on our condensed consolidated balance sheet. Our payment obligations for HCR royalty-based debt are as follows:
Nine Months Ended September 30, 2020
Total repayment obligation as of the acquisition date$276.9 
Less: interest to be accreted in future periods(90.0)
Less: payments made(1.7)
Carrying value as of September 30, 2020$185.2 
The carrying value of the royalty based debt as of September 30, 2020 approximates fair value due to the proximity to the acquisition date.
XML 53 R15.htm IDEA: XBRL DOCUMENT v3.20.2
Earnings Per Common Share
 9 Months Ended
Sep. 30, 2020
Earnings Per Common Share [Abstract]  
Earnings Per Common Share Earnings Per Common Share
Basic earnings per common share (EPS) is computed by dividing net income by the weighted-average number of shares of common stock outstanding. For purposes of calculating diluted EPS, the denominator reflects the potential dilution that could occur if stock options, unvested restricted stock units or other contracts to issue common stock were exercised or converted into common stock, using the treasury stock method.
The following table summarizes the calculation of basic and diluted EPS for the three and nine months ended September 30, 2020 and 2019:
Three months endedNine months ended
 September 30,September 30,
 2020201920202019
Net income used for basic and diluted calculation$578.1 $467.6 $67.6 $1,515.3 
Shares used in computing earnings per common share—basic219.1 223.3 220.4 223.8 
Weighted-average effect of dilutive securities:
Stock awards1.5 1.2 1.5 1.6 
Shares used in computing earnings per common share—diluted220.6 224.5 221.9 225.4 
Earnings per common share:
Basic$2.64 $2.09 $0.31 $6.77 
Diluted$2.62 $2.08 $0.30 $6.72 

We exclude from diluted EPS the weighted-average number of securities whose effect is anti-dilutive. Excluded from the calculation of EPS for the three and nine months ended September 30, 2020 were 2.5 and 1.8 shares of common stock, respectively, because their effect is anti-dilutive. Excluded from the calculation of EPS for the three and nine months ended September 30, 2019 were 3.3 and 3.1 shares of common stock, respectively, because their effect is anti-dilutive.
XML 54 R16.htm IDEA: XBRL DOCUMENT v3.20.2
Marketable Securities
 9 Months Ended
Sep. 30, 2020
Investments, Debt and Equity Securities [Abstract]  
Marketable securities Marketable SecuritiesThe proceeds from maturities and sales of available-for-sale debt securities and resulting realized gains and losses are summarized below. In the second quarter of 2020, we liquidated all of our available-for-sale debt securities to fund the acquisition of Portola. Additionally, we liquidated all available-for-sale debt securities acquired in connection with the Portola acquisition.
Three months endedNine months ended
September 30,September 30,
2020201920202019
Proceeds from maturities and sales (1)
$25.5 $645.4 $1,042.4 $2,271.7 
Realized gains$— $— $— $— 
Realized losses$— $— $— $— 
 (1) Proceeds from maturities and sales of available-for-sale debt securities include securities previously classified as cash and cash equivalents and marketable securities in the condensed consolidated balance sheet.
We utilize the specific identification method in computing realized gains and losses.
As a result of our liquidation of all available-for-sale debt securities during the second and third quarters of 2020, we have no remaining available-for-sale debt securities as of September 30, 2020. The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of available-for-sale debt securities by type of security as of December 31, 2019 were as follows:
December 31, 2019
Amortized CostGross Unrealized Holding GainsGross Unrealized Holding LossesFair Value
Commercial paper$246.9 $— $— $246.9 
Corporate bonds24.3 — — 24.3 
Other government-related obligations:
U.S.70.4 — — 70.4 
Bank certificates of deposit27.4 — — 27.4 
Total available-for-sale debt securities$369.0 $— $— $369.0 

The aggregate fair value of available-for-sale debt securities in an unrealized loss position as of December 31, 2019 was $21.5. We did not have any investments in a continuous unrealized loss position for more than twelve months as of December 31, 2019.
The fair values of available-for-sale debt securities by classification in the condensed consolidated balance sheets were as follows:
September 30, 2020December 31, 2019
Cash and cash equivalents$— $328.1 
Marketable securities— 40.9 
$— $369.0 

We sponsor a nonqualified deferred compensation plan which allows certain highly-compensated employees to elect to defer income to future periods. Participants in the plan earn a return on their deferrals based on several investment options, which mirror returns on underlying mutual fund investments. We choose to invest in the underlying mutual fund investments to offset the liability associated with our nonqualified deferred compensation plan. These mutual fund investments are valued at net asset value per share and are carried at fair value with gains and losses included in investment income. The changes in the underlying liability to the employee are recorded in operating expenses. As of September 30, 2020 and December 31, 2019, the fair value of these investments was $28.9 and $23.1, respectively.
XML 55 R17.htm IDEA: XBRL DOCUMENT v3.20.2
Derivative Instruments and Hedging Activities
 9 Months Ended
Sep. 30, 2020
Derivative Instruments and Hedging Activities [Abstract]  
Derivative Instruments and Hedging Activities Derivative Instruments and Hedging Activities
We operate internationally and, in the normal course of business, are exposed to fluctuations in foreign currency exchange rates. The exposures result from portions of our revenues, as well as the related receivables, and expenses that are denominated in currencies other than the U.S. dollar, primarily the Euro and Japanese Yen. We are also exposed to fluctuations in interest rates on outstanding borrowings under our revolving credit facility, if any, and term loan facility. We manage these exposures within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes.
We enter into foreign exchange forward contracts, with durations of up to 60 months, to hedge exposures resulting from portions of our forecasted revenues, including intercompany revenues, and certain forecasted expenses that are denominated in currencies other than the U.S. dollar. The purpose of these hedges is to reduce the volatility of exchange rate fluctuations on our operating results. These hedges are designated as cash flow hedges upon contract inception. As of September 30, 2020, we had open revenue related foreign exchange forward contracts with notional amounts totaling $1,029.0 that qualified for hedge accounting with current contract maturities through June 2022. As of September 30, 2020, we had open expense related foreign exchange forward contracts with notional amounts totaling $10.0 that qualified for hedge accounting with contract maturities through September 2022.
To achieve a desired mix of floating and fixed interest rates on our term loan, we enter into interest rate swap agreements that qualify for and are designated as cash flow hedges. These contracts convert the floating interest rate on a portion of our debt to a fixed rate, plus a borrowing spread.
The following table summarizes the total interest rate swap contracts executed as of September 30, 2020:
Type of Interest Rate Swap ContractNotional AmountEffective DateTermination DateFixed Interest Rate or Rate Range
Floating to Fixed$450.0December 2018December 2022
2.60% - 2.79%
Floating to Fixed$1,300.0December 2019December 2022
2.37% - 2.83%

The amount of gains and (losses) recognized in the condensed consolidated statements of operations for the three and nine months ended September 30, 2020 and 2019 from foreign exchange and interest rate swap contracts that qualified as cash flow hedges were as follows:
Three months endedThree months ended
 September 30, 2020September 30, 2019
Financial Statement Line Item in which the Effects of Cash Flow Hedges are RecordedNet Product SalesInterest ExpenseNet Product SalesInterest Expense
Total amount presented in the Condensed Consolidated Statements of Operations$1,588.3 $(27.6)$1,263.1 $(17.9)
Impact of cash flow hedging relationships:
Foreign exchange forward contracts$(5.0)$— $11.0 $— 
Interest rate swap contracts$— $(11.3)$— $3.4 
Nine months endedNine months ended
 September 30, 2020September 30, 2019
Financial Statement Line Item in which the Effects of Cash Flow Hedges are RecordedNet Product SalesInterest ExpenseNet Product SalesInterest Expense
Total amount presented in the Condensed Consolidated Statements of Operations$4,477.4 $(77.0)$3,605.8 $(56.1)
Impact of cash flow hedging relationships:
Foreign exchange forward contracts$15.9 $— $27.1 $— 
Interest rate swap contracts$— $(25.9)$— $12.5 
The impact on accumulated other comprehensive income (AOCI) and earnings from foreign exchange and interest rate swap contracts that qualified as cash flow hedges, for the three and nine months ended September 30, 2020 and 2019 were as follows:
Three months endedNine months ended
 September 30,September 30,
 2020201920202019
Foreign Exchange Forward Contracts:
(Loss) gain recognized in AOCI, net of tax$(22.9)$30.5 $(3.0)$40.8 
(Loss) gain reclassified from AOCI to net product sales, net of tax$(4.0)$8.6 $12.2 $21.0 
Interest Rate Swap Contracts:
Gain (loss) recognized in AOCI, net of tax$0.1 $(7.1)$(52.6)$(45.9)
(Loss) gain reclassified from AOCI to interest expense, net of tax$(8.8)$2.6 $(20.1)$9.6 

Assuming no change in foreign exchange rates from market rates at September 30, 2020, $13.6 of losses recognized in AOCI will be reclassified to revenue over the next 12 months. Assuming no change in LIBOR-based interest rates from market rates at September 30, 2020, $45.6 of losses recognized in AOCI will be reclassified to interest expense over the next 12 months. Amounts recognized in AOCI for expense related foreign exchange forward contracts were immaterial as of September 30, 2020.
We enter into foreign exchange forward contracts, with durations of up to 6 months, designed to limit the balance sheet exposure of monetary assets and liabilities. We enter into these hedges to reduce the impact of fluctuating exchange rates on our operating results. Hedge accounting is not applied to these derivative instruments as gains and losses on these hedge transactions are designed to offset gains and losses on underlying balance sheet exposures. As of September 30, 2020, the notional amount of foreign exchange contracts where hedge accounting is not applied was $1,253.0.
We recognized a (loss) gain of $(6.2) and $1.4, in other income and (expense) for the three months ended September 30, 2020 and 2019, respectively, associated with the foreign exchange contracts not designated as hedging instruments. We recognized a gain (loss) of $6.8 and $(1.2), in other income and (expense) for the nine months ended September 30, 2020 and 2019, respectively, associated with the foreign exchange contracts not designated as hedging instruments. These amounts were partially offset by gains or losses on monetary assets and liabilities.
The following tables summarize the fair value of outstanding derivatives as of September 30, 2020 and December 31, 2019: 
September 30, 2020
 Derivative AssetsDerivative Liabilities
Balance Sheet
Location		Fair
Value		Balance Sheet
Location		Fair
Value
Derivatives designated as hedging instruments:
Foreign exchange forward contractsPrepaid expenses and other current assets$3.0 Other current liabilities$16.8 
Foreign exchange forward contractsOther assets0.4 Other liabilities0.3 
Interest rate swap contractsPrepaid expenses and other current assets— Other current liabilities45.6 
Interest rate swap contractsOther assets— Other liabilities57.6 
Derivatives not designated as hedging instruments:
Foreign exchange forward contractsPrepaid expenses and other current assets8.7 Other current liabilities8.0 
Total fair value of derivative instruments$12.1 $128.3 
December 31, 2019
 Derivative AssetsDerivative Liabilities
Balance Sheet
Location		Fair
Value		Balance Sheet
Location		Fair
Value
Derivatives designated as hedging instruments:
Foreign exchange forward contractsPrepaid expenses and other current assets$12.7 Other current liabilities$6.2 
Foreign exchange forward contractsOther assets0.6 Other liabilities1.1 
Interest rate swap contractsPrepaid expenses and other current assets— Other current liabilities19.5 
Interest rate swap contractsOther assets— Other liabilities41.9 
Derivatives not designated as hedging instruments:
Foreign exchange forward contractsPrepaid expenses and other current assets17.2 Other current liabilities20.4 
Total fair value of derivative instruments$30.5 $89.1 
Although we do not offset derivative assets and liabilities within our condensed consolidated balance sheets, our International Swap and Derivatives Association agreements provide for net settlement of transactions that are due to or from the same counterparty upon early termination of the agreement due to an event of default or other termination event. The following tables summarize the potential effect on our condensed consolidated balance sheets of offsetting our foreign exchange forward contracts and interest rate contracts subject to such provisions:
September 30, 2020
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet
DescriptionGross Amounts of Recognized Assets/LiabilitiesGross Amounts Offset in the Condensed Consolidated Balance SheetNet Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance SheetDerivative Financial InstrumentsCash Collateral Received (Pledged)Net Amount
Derivative assets$12.1 $— $12.1 $(11.4)$— $0.7 
Derivative liabilities$(128.3)$— $(128.3)$11.4 $— $(116.9)
December 31, 2019
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet
DescriptionGross Amounts of Recognized Assets/LiabilitiesGross Amounts Offset in the Condensed Consolidated Balance SheetNet Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance SheetDerivative Financial InstrumentsCash Collateral Received (Pledged)Net Amount
Derivative assets$30.5 $— $30.5 $(21.4)$— $9.1 
Derivative liabilities$(89.1)$— $(89.1)$21.4 $— $(67.7)
XML 56 R18.htm IDEA: XBRL DOCUMENT v3.20.2
Other Investments
 9 Months Ended
Sep. 30, 2020
Investments, All Other Investments [Abstract]  
Other Investments Other Investments    
Other investments include strategic investments in equity securities of certain biotechnology companies which we acquired in connection with strategic business development transactions, including license and option agreements. These investments are included in other assets in our condensed consolidated balance sheets.
Moderna
During 2014, we purchased $37.5 of preferred stock of Moderna Therapeutics, Inc. (Moderna), a privately held biotechnology company, which was initially recorded at cost. We began recording the investment at fair value, with the effects of a holding period restriction estimated using an option pricing valuation model, upon Moderna's completion of its initial public offering (IPO) in 2018. During the three and nine months ended September 30, 2019, we recognized an unrealized gain of $12.3 and $13.1, respectively, in investment income to adjust our investment in Moderna to fair value. On December 9, 2019, we sold our investment in Moderna for $114.7 in net proceeds, resulting in a realized gain of $77.2 on our initial investment.
Dicerna
In October 2018, we purchased $10.3 of Dicerna Pharmaceuticals Inc. (Dicerna) common stock in connection with an agreement that we entered into with Dicerna, a publicly-traded biopharmaceutical company. As our equity investment in Dicerna common stock has a readily determinable fair value, we are recording the investment at fair value. During the three and nine months ended September 30, 2020, we recognized an unrealized loss of $6.2 and $3.4, respectively, in investment income to adjust our equity investment in Dicerna to fair value. During the three and nine months ended September 30, 2019, we recognized an unrealized loss of $1.1 and unrealized gain of $3.1, respectively, in investment income to adjust our equity investment in Dicerna to fair value.
The fair value of this investment was $15.0 and $18.4 as of September 30, 2020 and December 31, 2019, respectively.
Caelum
In January 2019, we purchased $41.0 of preferred stock of Caelum Biosciences (Caelum), a privately-held biotechnology company, and a $16.1 option to acquire the remaining equity in Caelum, based on Phase II data, in connection with an agreement that we entered into with Caelum. Following discussions with the FDA, Caelum changed its clinical development plan for CAEL-101 in the fourth quarter 2019. A Phase II trial for CAEL-101 subsequently commenced during the first quarter of 2020 and met its primary objectives, supporting the safety and tolerability of CAEL-101 and confirmed the dose and regimen to be adopted for the Phase III studies. In December 2019, we amended the terms of the agreement with respect to the option to acquire the remaining equity in Caelum based on data from the modified Phase II/III trials. We accounted for the amendment as an exchange transaction as the terms of the modified option were determined to be substantially different than the terms of the original option. In conjunction with this amendment, we recognized a gain of $32.0 during the fourth quarter 2019 in other income and (expense), which reflects an increase in the fair value of the option, less $20.0 in incremental upfront funding which we accrued as of December 31, 2019 and paid during the first quarter 2020, and $4.1 associated with the change in the fair value of contingent payments which we also modified as part of the amendment. See Note 16, Commitments and Contingencies, for additional information on the agreement. As our equity investment in Caelum and the option to acquire the remaining equity in Caelum do not have a readily determinable fair value, we only adjust the carrying value of the assets for impairment and any subsequent changes resulting from an observable price change in an orderly transaction for identical or similar equity securities of the same issuer.
There were no observable price changes associated with these assets during the three and nine months ended September 30, 2020 and 2019. As of September 30, 2020, the carrying value of the investment and option, respectively, was $41.0 and $64.0. As of December 31, 2019, the carrying value of the investment and option, respectively, was $41.0 and $64.0. The investment and option were not impaired as of September 30, 2020.
Zealand
In March 2019, we purchased $13.8 of Zealand Pharma A/S (Zealand) common stock in connection with an agreement that we entered into with Zealand, a publicly-traded biopharmaceutical company based in Copenhagen, Denmark. See Note 16, Commitments and Contingencies, for additional information on the agreement. As our equity investment in Zealand common stock has a readily determinable fair value, we are recording the investment at fair value. During the three and nine months ended September 30, 2020, we recognized an unrealized gain of $1.8 and $0.8, respectively, in investment income to adjust our equity investment in Zealand to fair value. During the three and nine months ended September 30, 2019, we recognized an unrealized gain of $3.7 and $7.3, respectively, in investment income to adjust our equity investment in Zealand to fair value.
The fair value of this investment was $30.5 and $28.5 as of September 30, 2020 and December 31, 2019, respectively.
Eidos
In September 2019, we purchased $19.9 of Eidos Therapeutics, Inc. (Eidos) common stock, in connection with an agreement that we entered into with Eidos, a publicly-traded biopharmaceutical company and subsidiary of BridgeBio Pharma, Inc. See Note 16, Commitments and Contingencies, for additional information on the agreement. As our equity investment in Eidos common stock has a readily determinable fair value, we are recording the investment at fair value. During the three and nine months ended September 30, 2020, we recognized an unrealized gain of $3.4 and $0.3, respectively, in investment income to adjust our equity investment in Eidos to fair value. During the three and nine months ended September 30, 2019, we recognized an unrealized loss of $2.9, in investment income to adjust our equity investment in Eidos to fair value.
The fair value of this investment was $28.1 and $27.8 as of September 30, 2020 and December 31, 2019, respectively.
Stealth
In October 2019, we purchased $9.6 of Stealth BioTherapeutics Corp. (Stealth) common stock, in connection with an agreement that we entered into with Stealth, a publicly traded clinical-stage biotechnology company. As our equity investment in Stealth common stock has a readily determinable fair value, we are recording the investment at fair value. During the three and nine months ended September 30, 2020, we recognized an unrealized loss of $0.7 and $2.6, respectively, in investment income to adjust our equity investment in Stealth to fair value.
The fair value of this investment was $1.8 and $4.4 as of September 30, 2020 and December 31, 2019, respectively.
Portola
In March 2020 and April 2020, we purchased $14.5 and $3.6, respectively, of common stock of Portola Pharmaceuticals, Inc., a publicly traded commercial-stage biological company which we acquired on July 2, 2020. As our equity investment in Portola common stock had a readily determinable fair value, we recorded the investment at fair value. During the three and nine months ended September 30, 2020, we recognized a net gain of $0.1 and $29.7 in investment income, respectively, relating to our Portola investment. Upon the closing of the acquisition of Portola on July 2, 2020, the fair value of the equity investment of $47.8 was derecognized and included in the fair value of consideration transferred, resulting in a realized gain of $29.7 on our initial investment.
Inozyme
On July 17, 2020, we sold certain intellectual property rights and assets focusing on ENPP1 gene deficiencies to Inozyme Pharma (Inozyme), a publicly traded biopharmaceutical company, in exchange for $14.8 of Inozyme Pharma common stock, which was initially recorded at its IPO offering price, net of the effects of a nine month holding period restriction. We recognized the $14.8 of consideration received as a gain within gain on sale of asset in our condensed consolidated statement of operations. As our equity investment in Inozyme common stock has a readily determinable fair value, we are recording the investment at fair value, with the effects of a nine month holding period restriction estimated using an option pricing valuation model. During the three and nine months ended September 30, 2020, we recognized an unrealized gain of $10.2, in investment income to adjust our investment to fair value.
The fair value of this investment was $25.0 as of September 30, 2020.
XML 57 R19.htm IDEA: XBRL DOCUMENT v3.20.2
Stockholders' Equity
 9 Months Ended
Sep. 30, 2020
Equity [Abstract]  
Stockholders' Equity Stockholders' Equity
Share Repurchases
In November 2012, our Board of Directors authorized a share repurchase program. In February 2017, our Board of Directors increased the amount that we are authorized to expend on future repurchases to $1,000.0 under our repurchase program, which superseded all prior repurchase programs. The entire amount authorized pursuant to this February 2017 Board approval has been utilized. On October 22, 2019, the Board of Directors approved a share repurchase authorization of up to $1,000.0. On July 28, 2020, the Board of Directors approved a new share repurchase authorization of up to an additional $1,500.0. The repurchase program does not have an expiration date and we are not obligated to acquire a particular number of shares. The repurchase program may be discontinued at any time at our discretion. Under the program, we repurchased 0.6 and 3.1 shares of our common stock at a cost of $73.5 and $334.6 during the three months ended September 30, 2020 and 2019, respectively. During the nine months ended September 30, 2020 and 2019, we repurchased 4.2 and 3.5 shares of our common stock at a cost of $434.3 and $383.5, respectively.
Subsequent to September 30, 2020, we repurchased 0.4 shares of common stock under our repurchase program at a cost of $45.2. As of October 27, 2020, there is a total of $2,055.9 remaining for repurchases under the repurchase program.
XML 58 R20.htm IDEA: XBRL DOCUMENT v3.20.2
Other Comprehensive Income and Accumulated Other Comprehensive Income
 9 Months Ended
Sep. 30, 2020
Accumulated Other Comprehensive Income [Abstract]  
Other Comprehensive Income and Accumulated Other Comprehensive Income Other Comprehensive Income and Accumulated Other Comprehensive Income
The following tables summarize the changes in AOCI, by component, for the nine months ended September 30, 2020 and 2019:
Defined Benefit Pension PlansUnrealized Gains (Losses) from Debt SecuritiesUnrealized Gains (Losses) from Hedging ActivitiesForeign Currency Translation AdjustmentTotal Accumulated Other Comprehensive Income (Loss)
Balances, December 31, 2019$(9.2)$(0.1)$(40.1)$(17.4)$(66.8)
Other comprehensive income (loss) before reclassifications— 0.1 (55.1)(5.3)(60.3)
Amounts reclassified from other comprehensive income— — 7.9 — 7.9 
Net other comprehensive income (loss)— 0.1 (47.2)(5.3)(52.4)
Balances, September 30, 2020$(9.2)$— $(87.3)$(22.7)$(119.2)
Defined Benefit Pension PlansUnrealized Gains (Losses) from Debt SecuritiesUnrealized Gains (Losses) from Hedging ActivitiesForeign Currency Translation AdjustmentTotal Accumulated Other Comprehensive Income (Loss)
Balances, December 31, 2018$(2.6)$(0.3)$9.6 $(16.4)$(9.7)
Other comprehensive income (loss) before reclassifications— 0.2 (5.1)(3.0)(7.9)
Amounts reclassified from other comprehensive income— — (30.6)— (30.6)
Net other comprehensive income (loss)— 0.2 (35.7)(3.0)(38.5)
Balances, September 30, 2019$(2.6)$(0.1)$(26.1)$(19.4)$(48.2)

The table below provides details regarding significant reclassifications from AOCI during the three and nine months ended September 30, 2020 and 2019:
Details about Accumulated Other Comprehensive Income ComponentsAmount Reclassified From Accumulated Other Comprehensive Income during the three months ended September 30,Amount Reclassified From Accumulated Other Comprehensive Income during the nine months ended September 30,Affected Line Item in the Condensed Consolidated Statements of Operations
2020201920202019
Unrealized Gains (Losses) on Hedging Activity
Foreign exchange forward contracts$(5.0)$11.0 $15.9 $27.1 Net product sales
Interest rate swap contracts(11.3)3.4 (25.9)12.5 Interest expense
(16.3)14.4 (10.0)39.6 
3.5 (3.2)2.1 (9.0)Income tax (benefit) expense
$(12.8)$11.2 $(7.9)$30.6 
XML 59 R21.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurement
 9 Months Ended
Sep. 30, 2020
Fair Value Disclosures [Abstract]  
Fair Value Measurement Fair Value MeasurementAuthoritative guidance establishes a valuation hierarchy for disclosure of the inputs to the valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value.
The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2020 and December 31, 2019, and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair value.
  Fair Value Measurement at
September 30, 2020
Balance Sheet
Classification		Type of InstrumentTotalLevel 1Level 2Level 3
Cash equivalentsMoney market funds$424.9 $— $424.9 $— 
Marketable securitiesMutual funds$28.9 $28.9 $— $— 
Other assetsEquity securities$100.4 $75.4 $25.0 $— 
Prepaid expenses and other current assetsForeign exchange forward contracts$11.7 $— $11.7 $— 
Other assetsForeign exchange forward contracts$0.4 $— $0.4 $— 
Other current liabilitiesForeign exchange forward contracts$24.8 $— $24.8 $— 
Other liabilitiesForeign exchange forward contracts$0.3 $— $0.3 $— 
Other current liabilitiesInterest rate contracts$45.6 $— $45.6 $— 
Other liabilitiesInterest rate contracts$57.6 $— $57.6 $— 
Contingent considerationAcquisition-related contingent consideration$398.1 $— $— $398.1 
 
  Fair Value Measurement at
December 31, 2019
Balance Sheet
Classification		Type of InstrumentTotalLevel 1Level 2Level 3
Cash equivalentsMoney market funds$635.9 $— $635.9 $— 
Cash equivalentsCommercial paper$227.9 $— $227.9 $— 
Cash equivalentsCorporate bonds$20.6 $— $20.6 $— 
Cash equivalentsBank certificates of deposit$19.2 $— $19.2 $— 
Cash equivalentsOther government-related obligations$60.4 $— $60.4 $— 
Marketable securitiesMutual funds$23.1 $23.1 $— $— 
Marketable securitiesCommercial paper$19.0 $— $19.0 $— 
Marketable securitiesCorporate bonds$3.7 $— $3.7 $— 
Marketable securitiesOther government-related obligations$10.0 $— $10.0 $— 
Marketable securitiesBank certificates of deposit$8.2 $— $8.2 $— 
Other assetsEquity securities$79.0 $51.2 $27.8 $— 
Prepaid expenses and other current assetsForeign exchange forward contracts$29.9 $— $29.9 $— 
Other assetsForeign exchange forward contracts$0.6 $— $0.6 $— 
Other current liabilitiesForeign exchange forward contracts$26.6 $— $26.6 $— 
Other liabilitiesForeign exchange forward contracts$1.1 $— $1.1 $— 
Other current liabilitiesInterest rate contracts$19.5 $— $19.5 $— 
Other liabilitiesInterest rate contracts$41.9 $— $41.9 $— 
Contingent considerationAcquisition-related contingent consideration$192.4 $— $— $192.4 
Other current liabilitiesOther contingent payments$24.0 $— $— $24.0 

There were no securities transferred between Level 1, 2 and 3 during the nine months ended September 30, 2020.
Valuation Techniques
We classify mutual fund investments and equity securities, which are valued based on quoted market prices in active markets with no valuation adjustment, as Level 1 assets within the fair value hierarchy.
Cash equivalents and marketable securities classified as Level 2 within the valuation hierarchy include money market funds, commercial paper, U.S. and foreign government-related debt, corporate debt securities and certificates of deposit. We estimate the fair values of these marketable securities by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for similar securities, issuer credit spreads, benchmark yields, and other observable inputs. We validate the prices provided by our third-party pricing sources by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances.
Other investments in equity securities of publicly traded companies which are subject to holding period restrictions are carried at fair value using an option pricing valuation model and classified as Level 2 equity securities within the fair value hierarchy. The most significant assumptions within the option pricing valuation model are the term of the restrictions and the stock price volatility, which is based upon the historical volatility of the applicable company or similar companies. We also use a constant maturity risk-free interest rate to match the remaining term of the restrictions on such investments.
Our derivative assets and liabilities include foreign exchange and interest rate derivatives that are measured at fair value using observable market inputs such as forward rates, interest rates, our own credit risk as well as an evaluation of our counterparties’ credit risks. Based on these inputs, the derivative assets and liabilities are classified within Level 2 of the valuation hierarchy.
Contingent consideration liabilities related to business acquisitions and derivative liabilities associated with other contingent payments are classified as Level 3 within the valuation hierarchy and are valued based on various estimates, including probability of success, discount rates and amount of time until the conditions of the milestone payments are anticipated to be met.
As of September 30, 2020, there has not been any impact to the fair value of our derivative liabilities due to our own credit risk. Similarly, there has not been any significant adverse impact to our derivative assets based on our evaluation of our counterparties’ credit risks.
Acquisition-Related Contingent Consideration
In connection with our prior business combinations, we may be required to pay future consideration that is contingent upon the achievement of specified development, regulatory approvals or sales-based milestone events. We determine the fair value of these obligations using various estimates that are not observable in the market and represent a Level 3 measurement within the fair value hierarchy. As of September 30, 2020, the resulting probability-weighted cash flows were discounted using a cost of debt ranging from 3.9% to 4.3% for developmental and regulatory milestones and a weighted average cost of capital of 9.0% for sales-based milestones. As of December 31, 2019, the resulting probability-weighted cash flows were discounted using a weighted average cost of capital of 9.0% for sales-based milestones.
Each reporting period, we adjust the contingent consideration to fair value with changes in fair value recognized in operating earnings. Changes in fair values reflect new information about the probability and anticipated timing of meeting the conditions of the milestone payments. In the absence of new information, changes in fair value will only reflect the interest component of contingent consideration related to the passage of time.
As of September 30, 2020, estimated future contingent milestone payments related to our business combinations range from zero if no milestone events are achieved, to a maximum of $905.6 if all development, regulatory and sales-based milestones are reached.
As of September 30, 2020, the fair value of acquisition-related contingent consideration was $398.1. Amounts issued during the nine months ended September 30, 2020, represent the fair value of the non-tradeable CVRs recorded in connection with the acquisition of Achillion. See Note 3, Acquisitions. The following table represents a roll-forward of our acquisition-related contingent consideration:
Nine Months Ended September 30, 2020
Balance as of December 31, 2019$192.4 
Amounts issued160.7 
Changes in fair value45.0 
Balance as of September 30, 2020$398.1 
Other Contingent Payments
In January 2019, we entered into an agreement with Caelum, a biotechnology company that is developing CAEL-101 for light chain (AL) amyloidosis.  Under the terms of the agreement, we acquired a minority equity interest in preferred stock of Caelum and an exclusive option to acquire the remaining equity in Caelum based on Phase II data, for pre-negotiated economics. We paid $30.0 during the first quarter 2019 and agreed to pay up to an additional $30.0 in contingent development milestones prior to our exercise of the option to acquire the remaining equity in Caelum. These contingent payments met the definition of a derivative liability and were initially recorded at fair value of $27.1, based on the probability-weighted cash flows, discounted using a cost of debt ranging from 3.3% to 3.5%.
In December 2019, following FDA feedback which resulted in the redesign and expansion of Caelum's planned clinical development program for CAEL-101, we amended the terms of our existing option agreement with Caelum. The amendment modified the terms of the option to acquire the remaining equity in Caelum based on data from the expanded Phase II/III trials. The amendment also modified the development-related milestone events associated with the initial $30.0 in contingent payments, provided for an additional $20.0 in upfront funding, which we accrued as of December 31, 2019 and paid during the first quarter 2020, as well as funding of $60.0 in exchange for an additional equity interest at fair value upon achievement of a specific development-related milestone event. During the second quarter 2020, we paid an aggregate of $15.0 of contingent payments to Caelum related to two development-based milestones and during the third quarter 2020, we paid a $15.0 contingent payment to Caelum related to another development-based milestone.
Each reporting period, we adjust the derivative liability associated with the contingent payments to fair value with changes in fair value recognized in other income and (expense). Changes in fair values reflect new information about the probability and anticipated timing of meeting the conditions of the milestone payments. In the absence of new information, changes in fair value will only reflect the interest component of the liability related to the passage of time. The aggregate $30.0 milestone payments made during the second and third quarter 2020 settled the derivative liability and reduced the derivative liability balance to zero. We recorded $3.6 and $6.0 of expense in other income and (expense) during the three and nine months ended September 30, 2020, respectively, related to the change in the fair value of the liability. We recorded $0.2 and $0.5 of expense in other income and (expense) during the three and nine months ended September 30, 2019, respectively, related to the change in the fair value of the liability.
XML 60 R22.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue Recognition
 9 Months Ended
Sep. 30, 2020
Revenue from Contract with Customer [Abstract]  
Revenue Recognition Revenue Recognition
Disaggregation of Revenue
The Company disaggregates revenue from contracts with customers into product and geographical regions as summarized below.
Three months ended September 30,Nine months ended September 30,
2020201920202019
SOLIRIS
United States$562.8 $496.8 $1,672.3 $1,456.8 
Europe254.3 255.5 765.7 800.2 
Asia Pacific86.0 118.0 255.5 329.2 
Rest of World139.2 120.2 347.2 347.1 
Total$1,042.3 $990.5 $3,040.7 $2,933.3 
ULTOMIRIS
United States$170.7 $65.1 $460.3 $143.9 
Europe46.6 21.1 112.4 21.1 
Asia Pacific69.6 3.7 186.3 3.7 
Rest of World2.4 — 4.2 — 
Total$289.3 $89.9 $763.2 $168.7 
STRENSIQ
United States$149.3 $118.0 $418.1 $323.7 
Europe19.3 19.0 61.6 56.0 
Asia Pacific16.1 14.0 44.7 36.0 
Rest of World4.7 3.3 21.5 10.0 
Total$189.4 $154.3 $545.9 $425.7 
ANDEXXA
United States$36.2 $— $36.2 $— 
Europe2.7 — 2.7 — 
Asia Pacific— — — — 
Rest of World— — — — 
Total$38.9 $— $38.9 $— 
KANUMA
United States$15.8 $16.0 $47.6 $45.1 
Europe9.5 6.3 25.4 19.4 
Asia Pacific1.1 1.3 2.9 3.4 
Rest of World2.0 4.8 12.8 10.2 
Total$28.4 $28.4 $88.7 $78.1 
Total Net Product Sales$1,588.3 $1,263.1 $4,477.4 $3,605.8 
Contract Balances and Receivables
Contract liabilities primarily relate to consideration received and/or billed for goods that have not been delivered to the customer and for which the performance obligation has not yet been completed. These amounts are included within other current liabilities in the condensed consolidated balance sheets.
The following table provides information about receivables and contract liabilities from our contracts with customers.
September 30, 2020December 31, 2019
Receivables, which are included in "Trade accounts receivable, net"$1,437.1 $1,243.2 
Contract liabilities, which are included in "Other current liabilities"$22.7 $6.8 
Contract balances and receivables associated with collaboration agreements assumed through the acquisition of Portola in the third quarter 2020, which were included in the table above, were not material as of September 30, 2020.
XML 61 R23.htm IDEA: XBRL DOCUMENT v3.20.2
Income Taxes
 9 Months Ended
Sep. 30, 2020
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
Coronavirus Aid, Relief and Economic Security Act
In response to the market volatility and instability resulting from the COVID-19 pandemic, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was signed into law on March 27, 2020. The CARES Act lifts certain deduction limitations originally imposed by the Tax Cuts and Jobs Act of 2017 (2017 Tax Act). Under the 2017 Tax Act, federal net operating losses (NOLs) generated after 2017 could not be carried back and utilization was limited to 80% of taxable income. The CARES Act allows for a five-year carryback of federal NOLs generated in 2018 through 2020 and eliminates the 80% taxable income limitation by allowing corporate entities to fully utilize NOL carryforwards to offset taxable income in 2018 through 2020. In addition, the CARES Act generally allows taxpayers to deduct interest up to 50% of adjusted taxable income (30% limit under the 2017 Tax Act) for tax years 2019 and 2020. The CARES Act also allows taxpayers with prior year alternative minimum tax (repealed by the 2017 Tax Act) (AMT) credits to accelerate refund claims to tax years beginning in 2018 and 2019 instead of recovering the credits over a period of years, as originally enacted by the 2017 Tax Act.
Additionally, the CARES Act raises the corporate charitable deduction limit to 25% of taxable income and provides a technical correction to the 2017 Tax Act to generally provide qualified improvement property a 15-year cost-recovery period and allow 100% bonus depreciation. The enactment of the CARES Act did not result in any material adjustments to our income tax provision for the three and nine months ended September 30, 2020, or to our U.S. federal and state net deferred tax liabilities as of September 30, 2020.
Tax Rate
The following table provides a comparative summary of our income tax expense and effective income tax rate for the three and nine months ended September 30, 2020:
Three months endedNine months ended
September 30,September 30,
2020201920202019
Income tax expense (benefit)$88.8$67.9 $(89.2)$61.5 
Effective income tax rate13.3 %12.7 %413.0 %3.9 %

Income tax expense (benefit) is attributable to the U.S. federal, state and foreign income taxes on our profitable operations.
During the second quarter 2020, we recognized an impairment charge of $2,042.3 related to the KANUMA intangible asset, resulting in a deferred tax benefit of $377.3. See Note 5, Intangible Assets and Goodwill, for additional information on the impairment charge. These deferred tax benefits increased the effective tax rate for the nine months ended September 30, 2020 by approximately 399.6%.
The income tax expense for the nine months ended September 30, 2019 includes one-time tax benefits recorded during the first quarter 2019, in connection with the future integration of intellectual property of Wilson
Therapeutics into the Alexion corporate structure. The deferred tax benefits included $95.7 and $30.3 associated with a tax election made with respect to intellectual property of Wilson Therapeutics and a valuation allowance release and corresponding recognition of net operating losses, respectively. These deferred tax benefits decreased the effective tax rate for the nine months ended September 30, 2019 by approximately 8.0%. Additionally, during the third quarter 2019, we completed a comprehensive analysis of our current and prior year estimates related to our foreign-derived intangible income based on additional guidance provided in the proposed regulations issued by the U.S. Treasury Department in 2019. The analysis resulted in income tax benefits of approximately $29.9, including $17.0 related to prior year estimated tax benefits, which were recorded as a change in estimate in income tax expense in our consolidated statements of operations during the three and nine months ended September 30, 2019. These tax benefits decreased the effective tax rate for the three and nine months ended September 30, 2019 by approximately 5.6% and 1.9%, respectively.
In April 2020 we became aware of a European withholding tax regulation that could be interpreted to apply to certain of our previous intra-group transactions. We continue to evaluate whether the interpretation of this regulation applies to our facts and circumstances, and, based on our preliminary analysis, we recorded an immaterial reserve related to this matter during the second quarter of 2020.
In August 2020, we received a notice of examination from the Dutch Tax Authorities (“DTA”) regarding certain matters relating to our 2014 through 2017 tax years. Discussions with the DTA are currently ongoing and, at Alexion’s request, we have expanded these discussions to include the 2018 and 2019 tax years as well. We have not received any final findings on any of these tax years, nor have we received any proposed adjustments or any tax assessments related to any of the tax years under discussion with the DTA. Accordingly, we have not recorded any related reserves and an estimate of the possible loss or range of loss, if any, cannot be made at this time.
During the third quarter of 2020, the U.S. Treasury Department released certain proposed and final regulations which were originally enacted under the 2017 Tax Act. The impact of these regulations did not have a material impact on our financial condition and results of operations.
In 2017, the Internal Revenue Service (IRS) commenced an examination of our U.S. income tax returns for 2015. During the second quarter of 2020 we received a Revenue Agent Report (RAR) and held discussions with the IRS regarding a proposed adjustment related to the valuation of certain intellectual property that was contributed into our captive partnership during 2015. The Company agreed with the adjustment outlined in the RAR and recognized a previously unrecognized tax benefit in the second quarter of 2020 that did not result in a significant impact to the financial statements. The IRS concluded its examination during the third quarter 2020 without additional adjustments.
We have recorded tax on the undistributed earnings of our controlled foreign corporation (CFC) subsidiaries. To the extent CFC earnings may not be repatriated to the U.S. as a dividend distribution due to limitations imposed by law, we have not recorded the related potential withholding, foreign, local, and U.S. state income taxes.
We continue to maintain a valuation allowance against certain deferred tax assets where realization is not certain.
XML 62 R24.htm IDEA: XBRL DOCUMENT v3.20.2
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Asset Acquisition and In-License Agreements
We have entered into asset purchase agreements, license agreements, and option arrangements in order to advance and obtain technologies and services related to our business. These agreements generally require us to pay an initial fee and certain agreements call for future payments upon the attainment of agreed upon development, regulatory and/or commercial milestones. These agreements may also require minimum royalty payments based on sales of products developed from the applicable technologies, if any.
In January 2019, we entered into an agreement with Caelum, a biotechnology company that is developing CAEL101 for light chain (AL) amyloidosis. Under the terms of the agreement, we acquired a minority equity interest in preferred stock of Caelum and an exclusive option to acquire the remaining equity in Caelum based on Phase II data, for pre-negotiated economics. We paid $30.0 in the first quarter 2019 and agreed to pay up to an additional $30.0 in contingent development milestones prior to the exercise the option to acquire the remaining equity in Caelum. These contingent payments meet the definition of a derivative liability and were initially recorded at fair value of $27.1. We allocated the total consideration of $57.1, inclusive of the fair value of the contingent payments, to the equity investment in Caelum and the option to acquire the remaining equity in Caelum based on the relative fair values of the assets. Following discussions with the FDA, Caelum changed its clinical development plan for
CAEL-101 in the fourth quarter 2019. A Phase II trial for CAEL-101 subsequently commenced during the first quarter of 2020 and met its primary objectives, supporting the safety and tolerability of CAEL-101 and confirmed the dose and regimen to be adopted for the Phase III studies. In September 2020, Alexion and Caelum announced the initiation of the Cardiac Amyloid Reaching for Extended Survival (CARES) program. This includes two parallel Phase III trials to evaluate the survival benefits of CAEL-101. In December 2019, we amended the terms of the agreement with Caelum to modify the option to acquire the remaining equity in Caelum based on data from the modified Phase II/III trials. The amendment also modified the development-related milestone events associated with the initial $30.0 in contingent payments, provided for an additional $20.0 in upfront funding, which we accrued as of December 31, 2019 and paid during the first quarter 2020, as well as funding of $60.0 in exchange for an additional equity interest at fair value upon achievement of a specific development-related milestone event. The agreement with Caelum also provides for additional payments, in the event Alexion exercises the purchase option, for up to $500.0, which includes an upfront option exercise payment and potential regulatory and commercial milestone payments. During the second quarter 2020, we paid an aggregate of $15.0 of contingent payments to Caelum related to two development-based milestones and during the third quarter 2020, we paid a $15.0 contingent payment to Caelum related to another development-based milestone.
In March 2019, we entered into an agreement with Zealand which provides us with exclusive worldwide licenses, as well as development and commercial rights, for subcutaneously delivered preclinical peptide therapies directed at up to four complement pathway targets. Pursuant to the agreement, Zealand will lead joint discovery and research efforts through the preclinical stage, and Alexion will lead development efforts beginning with the investigational new drug filing and Phase I studies. In addition to the agreement, we made an equity investment in Zealand (see Note 10, Other Investments). Under the terms of the agreement, we made an upfront payment of $40.0 for an exclusive license to the lead target and the equity investment, as well as for preclinical research services to be performed by Zealand in relation to the lead target. The market value of the equity investment was $13.8 as of the date of acquisition, which we recorded in other assets in our condensed consolidated balance sheets. We also recognized prepaid research and development expense of $5.0 within the condensed consolidated balance sheets associated with the research activities to be performed by Zealand. Due to the early stage of the asset we are licensing, we recorded the upfront license payment of $21.2 as research and development expense during the first quarter 2019. As of September 30, 2020, we could be required to pay up to $610.0, for the lead target, upon the achievement of specified development, regulatory and commercial milestones, as well as royalties on commercial sales. In addition, we could be required to pay up to an additional $115.0 in development and regulatory milestones if both a long-acting and short-acting product are developed with respect to the lead target. Each of the three subsequent targets can be selected for an option fee of $15.0 and has the potential for additional development, regulatory and commercial milestones, as well as royalty payments, at a reduced price to the lead target.
In April 2019, we entered into an agreement with Affibody AB (Affibody), through which Alexion obtained an exclusive worldwide license, as well as development and commercial rights, to ABY-039, a bivalent antibody-mimetic that targets the neonatal Fc receptor (FcRn). Under the terms of the agreement, we made an upfront payment of $25.0 for the exclusive license to ABY-039. Due to the early stage of the asset we licensed, we recorded the upfront license payment as research and development expense during the second quarter 2019. In February 2020, based on data from our Phase I study, we terminated the agreement to co-develop ABY-039 with Affibody.
In September 2019, we entered into an agreement with Eidos through which Alexion obtained an exclusive license to develop and commercialize AG10 in Japan. AG10 is a small molecule designed to treat the root cause of transthyretin amyloidosis (ATTR) and is currently in a Phase III study in the U.S. and Europe for ATTR cardiomyopathy (ATTR-CM). In addition, we made an equity investment in Eidos (see Note 10, Other Investments). Under the terms of the agreement, we made an upfront payment of $50.0 for the exclusive license to AG10 in Japan and the equity investment. The market value of the equity investment was $19.9 as of the date of acquisition, which we recorded in other assets in our condensed consolidated balance sheets. Due to the early stage of the asset we are licensing, we recorded the upfront license payment of $30.1 as research and development expense during the third quarter 2019. As of September 30, 2020, we could also be required to pay $30.0 upon achievement of a Japanese-based regulatory milestone as well as royalties on commercial sales.
In October 2018, we entered into a collaboration agreement with Dicerna that provides us with exclusive worldwide licenses and development and commercial rights for two preclinical RNA interference (RNAi) subcutaneously delivered molecules for complement-mediated diseases, as well as an exclusive option for other preclinical RNAi molecules for two additional targets within the complement pathway. In addition to the collaboration agreement, we made an equity investment in Dicerna. Under the terms of the agreements, we made an upfront payment of $37.0 for the exclusive licenses and the equity investment. The market value of the equity investment
was $10.3 as of the date of acquisition, which we recorded in other assets in our condensed consolidated balance sheets. Due to the early stage of the assets we are licensing, we recorded the upfront license payment of $26.7 as research and development expense during the fourth quarter 2018. In December 2019, we exercised our option for exclusive rights to two additional targets within the complement pathway under an existing agreement with Dicerna, which expands our existing research collaboration and license agreement with Dicerna to include a total of four targets within the complement pathway. In connection with the option exercise, we paid Dicerna $20.0, which we recorded as research and development expense in the fourth quarter 2019. As of September 30, 2020, excluding accrued milestones, we could be required to pay up to $604.1 for amounts due upon the achievement of specified research, development, regulatory and commercial milestones on the four licensed targets, as well as royalties on commercial sales.
In December 2017, we entered into a collaboration and license agreement with Halozyme Therapeutics, Inc. that allows us to use drug-delivery technology in the development of subcutaneous formulations for our portfolio of products for up to four targets. Under the terms of the agreement, we made an upfront payment of $40.0 for an exclusive license to two of the four potential targets and due to the early stage of the assets we are licensing, we recorded an expense for the upfront payment during the fourth quarter 2017. During the second quarter 2020, we forfeited our rights to one of the two targets we initially licensed. As of September 30, 2020, we could be required to pay up to $155.0 for the remaining licensed target upon achievement of specified development, regulatory and sales-based milestones, as well as royalties on commercial sales. Each of the two subsequent targets can be licensed for an option fee of $8.0, with contingent payments of up to $160.0 per target, subject to development, regulatory and commercial milestones, as well as royalties on commercial sales.
In connection with our prior acquisition of Syntimmune, Inc., a clinical-stage biotechnology company developing an antibody therapy targeting the FcRn, we could be required to pay up to $800.0 upon the achievement of specified development, regulatory and commercial milestones, of which $130.0 is specific to the subcutaneous formulation.
In addition, excluding accrued milestones, as of September 30, 2020, we have other license agreements under which we may be required to pay up to an additional $114.0 for currently licensed targets, if certain development, regulatory and commercial milestones are met, including up to $71.5 for the development of cerdulatinib in multiple indications pursuant to an in-licensing agreement with Astellas Pharma, Inc. which was assumed through the acquisition of Portola in the third quarter 2020. Additional amounts may be payable if we elect to acquire licenses to additional targets, as applicable, under the terms of these agreements.
Asset Sale and Out-License Arrangements
In connection with prior asset sale and out-license arrangements, including those assumed by Alexion through the acquisition of Portola in the third quarter 2020, Alexion is entitled to receive contingent payments upon the achievement of various regulatory and commercial milestones and other events, as well as royalties on commercial sales. The amount of contingent consideration related to these agreements is fully constrained and therefore has not been recognized as of September 30, 2020.
Manufacturing Agreements
We have various manufacturing development and license agreements to support our clinical and commercial product needs.
We rely on Lonza, a third party manufacturer, to produce a portion of commercial and clinical quantities of our commercial products and product candidates. We have various manufacturing and license agreements with Lonza, with remaining total non-cancellable future commitments of approximately $1,432.3 through 2031. This amount includes $105.5 of undiscounted, fixed payments applicable to our Contract Manufacturing Organization (CMO) embedded lease arrangement with Lonza. If we terminate certain supply agreements with Lonza without cause, we will be required to pay for product scheduled for manufacture under our arrangement. Under an existing arrangement with Lonza, we also pay Lonza a royalty on sales of SOLIRIS that was manufactured at the Alexion Rhode Island Manufacturing Facility (ARIMF facility) prior to the sale of the facility and a payment with respect to sales of SOLIRIS manufactured at Lonza facilities. We also pay Lonza a royalty on the sales of ULTOMIRIS.
In addition to our commitments with Lonza, as of September 30, 2020 we have non-cancellable commitments of approximately $78.6 through 2021 with other third party manufacturers.
Contingent Liabilities
We are currently involved in various claims, disputes, lawsuits, investigations, administrative proceedings and legal proceedings. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure. In accordance with generally accepted accounting principles, if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, we accrue a liability for the estimated loss. Because of uncertainties related to claims, proceedings and litigation, accruals are based on our best estimates based on information available at the time of the assessment. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation, court decisions or settlement of claims (and offers of settlement), we may reassess the potential liability related to these matters and may revise these estimates, which could result in a material adverse adjustment to our operating results. Costs associated with our involvement in legal proceedings are expensed as incurred. The outcome of any such proceedings, regardless of the merits, is inherently uncertain. If we were unable to prevail in any such proceedings, our consolidated financial position, results of operations, and future cash flows may be materially impacted.
We have received, and may in the future receive, notices from third parties claiming that their patents may be infringed by the use, development, manufacture, importation or sale of our products or product candidates. Under the guidance of ASC 450, Contingencies, we record a royalty accrual based on our best estimate of the fair value percent of net sales of our products that we could be required to pay the owners of patents for technology used in the manufacture and sale of our products. A costly license, or inability to obtain a necessary license, could have a material adverse effect on our financial results.
In May 2015, we received a subpoena in connection with an investigation by the Enforcement Division of the Securities and Exchange Commission (SEC) requesting information related to our grant-making activities and compliance with the Foreign Corrupt Practices Act (FCPA) in various countries. In addition, in October 2015, we received a request from the Department of Justice (DOJ) for the voluntary production of documents and other information pertaining to Alexion’s compliance with the FCPA. The SEC and DOJ also sought information related to Alexion’s recalls of specific lots of SOLIRIS and related securities disclosures.
The investigations focused on operations in various countries, including Brazil, Colombia, Japan, Russia and Turkey, and Alexion's compliance with the FCPA and other applicable laws.
In May 2020, DOJ informed us that it has closed its inquiry into these matters.
On July 2, 2020, we reached a civil settlement with the SEC fully resolving the SEC’s investigation into possible violations of the FCPA. Alexion neither admitted nor denied any wrongdoing in connection with the settlement but agreed to pay $21.5 to the SEC, consisting of amounts attributable to disgorgement, civil penalties, and pre-judgment interest. In connection with this settlement, in July 2020, we paid $21.5 to the SEC.
Following the settlement with the SEC, the Ministry of Health in Turkey initiated an investigation regarding the matters referenced in the SEC Order as they relate to the Company’s operations in Turkey between 2010 and 2015. We are cooperating with this investigation.
Alexion is committed to continually focusing on its compliance program and continues to enhance its comprehensive company-wide program that is designed to enhance our business processes, structures, controls, training, talent, and systems across Alexion’s global operations.
As previously reported, on December 29, 2016, a shareholder filed a putative class action against the Company and certain former employees in the U.S. District Court for the District of Connecticut, alleging that defendants made misrepresentations and omissions about SOLIRIS. On April 12, 2017, the court appointed a lead plaintiff. On July 14, 2017, the lead plaintiff filed an amended putative class action complaint against the Company and seven current or former employees. Defendants moved to dismiss the amended complaint on September 12, 2017. Plaintiffs filed an opposition to defendants’ motion to dismiss on November 13, 2017, and defendants filed a reply brief in further support of their motion on December 28, 2017. On March 26, 2019, the court held a telephonic status conference.  During that conference, the court informed counsel that it was preparing a ruling granting the defendants’ pending motion to dismiss.  The court inquired of plaintiffs’ counsel whether they intended to seek leave to amend their complaint, and indicated that if they wished to file a second amended complaint, they would be allowed to do so.  On April 2, 2019, the court granted plaintiffs until May 31, 2019 to file a second amended complaint, thereby rendering moot defendants’ pending motion to dismiss. On June 2, 2019, plaintiffs filed a second amended complaint against the same defendants. The complaint alleges that defendants engaged in securities
fraud, including by making misrepresentations and omissions in its public disclosures concerning the Company’s SOLIRIS sales practices, management changes, and related investigations, between January 30, 2014 and May 26, 2017, and that the Company's stock price dropped upon the purported disclosure of the alleged fraud. The plaintiffs seek to recover unspecified monetary relief, unspecified equitable and injunctive relief, interest, and attorneys’ fees and costs. Defendants’ filed a motion to dismiss the amended complaint on August 2, 2019; plaintiffs’ filed their opposition to that motion on October 2, 2019; and defendants’ filed their reply in further support of their motion on November 15, 2019. Given the early stage of these proceedings, we cannot presently predict the likelihood of obtaining dismissal of the case (or the ultimate outcome of the case if the motion to dismiss is denied by the court), nor can we estimate the possible loss or range of loss at this time.
In December 2016, we received a subpoena from the U.S. Attorney's Office for the District of Massachusetts requesting documents relating generally to our support of Patient Services, Inc. (PSI) and National Organization for Rare Disorders (NORD), 501(c)(3) organizations that provide financial assistance to Medicare patients taking drugs sold by Alexion; Alexion’s provision of free drug to Medicare patients; and Alexion compliance policies and training materials concerning the anti-kickback statute and information on donations to PSI and NORD from 2010 through 2016. In April 2019, we entered into a civil settlement agreement with the DOJ and the Office of Inspector General (OIG) of the U.S. Department of Health and Human Services to resolve this matter. As part of the settlement agreement, Alexion paid $13.1 to the DOJ and OIG. OIG did not require a Corporate Integrity Agreement with Alexion because it made fundamental organizational changes, including hiring a new executive leadership team, replacing half of the members of its Board of Directors, and effecting a significant change in the workforce.
In May 2017, Brazilian authorities seized records and data from our São Paulo, Brazil offices as part of an investigation being conducted into Alexion’s Brazilian operations. We are cooperating with this inquiry.
In June 2017, we received a demand to inspect certain of our books and records pursuant to Section 220 of the General Corporation Law of the State of Delaware on behalf of a purported stockholder. Among other things, the demand sought to determine whether to institute a derivative lawsuit against certain of the Company’s directors and officers in relation to the investigation by our Audit and Finance Committee announced in November 2016 and the investigations instituted by the SEC, DOJ, U.S. Attorney’s Office for the District of Massachusetts, and Brazilian law enforcement officials that are described above. We have responded to the demand. Given the early stages of this matter, an estimate of the possible loss or range of loss cannot be made at this time.
On September 27, 2017, a hearing panel of the Canadian Patented Medicine Prices Review Board (PMPRB) issued a decision in a previously pending administrative pricing matter that we had excessively priced SOLIRIS in a manner inconsistent with the Canadian pricing rules and guidelines. In its decision, the PMPRB ordered Alexion to decrease the price of SOLIRIS to an upper limit based upon pricing in certain other countries, and to forfeit excess revenues for the period between 2009 and 2017. The amount of excess revenues for the period between 2009 and 2017 was not determined to be a material amount and was paid in 2018. In October 2017, Alexion filed an application for judicial review of the PMPRB’s decision in the Federal Court of Canada. On May 23, 2019, the Federal Court of Canada dismissed Alexion's application for judicial review and, as a consequence, affirmed the decision of the PMPRB that we had excessively priced SOLIRIS. On June 21, 2019, Alexion filed a notice of appeal of the Federal Court of Canada's ruling, and, on October 17, 2019, Alexion filed a memorandum of fact and law in support of the appeal. On December 3, 2019, the Attorney General of Canada filed its memorandum of fact and law in support of the Federal Court of Canada's dismissal of Alexion's appeal of the PMPRB's decision. On December 19, 2019, the intervenor, the Minister of Health for the Province of British Columbia, filed a separate memorandum of fact and law in support of the Federal Court of Canada's decision. The Canadian Federal Court of Appeal heard the appeal on October 21 and 22, 2020, but has not issued a decision as of the date of this filing. Pursuant to an order made by the Federal Court of Canada, as of October 27, 2020, we have placed approximately $61.5 in escrow to secure our obligations pending the final resolution of all appeals in this matter. This amount reflects the difference between the list price for SOLIRIS and the price determined by the PMPRB to be non-excessive for sales of SOLIRIS in Canada for the period beginning September 2017 through September 30, 2020. In addition, on a quarterly basis, until the appeals process has concluded, Alexion will be required to place amounts into escrow for each vial of SOLIRIS sold in the applicable quarter equal to the list price for SOLIRIS and the price determined by the PMPRB to be non-excessive. Our revenues in Canada have been reduced by $42.2 cumulatively to date, which is our current best estimate of our liability through September 30, 2020 if we lose the appeal of this matter (the amount of our ultimate liability, however, may be greater than this estimate when the appeal process for this matter is concluded).
Chugai Pharmaceutical Co., Ltd. has filed three lawsuits against Alexion.  The first was filed in November 2018 in the United States District Court for the District of Delaware against Alexion Pharmaceuticals, Inc. alleging that
ULTOMIRIS infringes one U.S. patent held by Chugai Pharmaceutical Co., Ltd.  Upon issuance of a new U.S. patent on November 12, 2019, Chugai filed a second lawsuit in the United States alleging that ULTOMIRIS infringes the new patent. The parties have agreed to consolidate the November 2018 and November 2019 lawsuits. Chugai filed a third lawsuit in December 2018 in the Tokyo District Court against Alexion Pharma GK (a wholly-owned subsidiary of Alexion) in Japan, and alleges that ULTOMIRIS infringes two Japanese patents held by Chugai Pharmaceutical Co., Ltd.  Chugai’s complaints seek unspecified damages and certain injunctive relief. On March 5, 2020, the Supreme Court of Japan dismissed Chugai's appeal against an earlier IP High Court of Japan decision which held that one of the Chugai patents-in-suit is invalid. Subsequently Chugai filed a correction to the claims of this patents-in-suit and Alexion has countered that the corrected claims are still invalid and not infringed. In all cases, Alexion has denied the charges and countered that the patents are neither valid nor infringed. A trial date for the U.S. case which was initially set for July 2021 has been re-scheduled for October 2021. The case is still at the briefing stage in Japan.  Given the early stages of these litigations, an estimate of the possible loss or range of loss cannot be made at this time.
On February 28, 2019, Amgen Inc. (Amgen) petitioned the U.S. Patent and Trademark Office (PTO) to institute Inter Partes Review (IPR) of three patents owned by Alexion that relate to SOLIRIS:  U.S. Patent Nos. 9,725,504; 9,718,880; and 9,732,149. In each case, Amgen alleged the patented subject matter was anticipated and/or obvious in view of prior art, and that the patent claims are therefore invalid. On August 30, 2019, the PTO instituted IPRs of each of the three patents. On May 28, 2020, we entered into a Confidential Settlement and License Agreement (the “Settlement Agreement”) with Amgen to settle the three IPRs at the Patent Trial and Appeal Board (“PTAB”) of the PTO. Pursuant to the Settlement Agreement, Alexion and Amgen have terminated each of the pending IPRs. In addition, effective March 1, 2025 (or an earlier date in certain circumstances), the Company grants to Amgen (and its affiliates and certain partners) a non-exclusive, royalty-free, license under U.S. patents and patent applications related to eculizumab and various aspects of the eculizumab product that Alexion currently markets and sells under the tradename SOLIRIS. This license will allow Amgen (and its affiliates and certain partners), effective March 1, 2025, the right to make, have made, use, import, have imported, sell, have sold, offer for sale, have offered for sale, distribute, and have distributed in, or for, the U.S., an eculizumab product.
In connection with an ongoing matter, in August 2019, the Brazilian Federal Revenue Service provided a Notice of Tax and Description of the Facts (the “Tax Assessment”) to two Alexion subsidiaries (the "Brazil Subsidiaries"), as well as to two additional entities, a logistics provider utilized by Alexion and a distributor. The Tax Assessment focuses on the importation of SOLIRIS vials pursuant to Alexion’s free drug supply to patients program (referred to as Global Access to Medicines, or GATM) in Brazil. In September 2019, the Brazil Subsidiaries filed defenses to the Tax Assessment disputing the basis for liability under the Tax Assessment, based on, among others, the following: in connection with the operation of GATM, during the period from September 2014 to June 2019: (i) the importers responsible for the importation of the GATM SOLIRIS vials into Brazil were correctly identified and (ii) the correct customs value was utilized for the purpose of importing the GATM SOLIRIS vials provided to the patients free of charge. The defenses filed by Alexion are pending judgment at the first level of administrative appeals within the Brazilian federal administrative proceeding system. There are three separate levels of administrative appeals within the Brazilian federal administrative proceeding system and, if the outcome of these administrative appeals is unfavorable, the final decision of the federal administrative proceeding system can be disputed to the federal court systems in Brazil (at this time, Alexion intends to appeal the Tax Assessment if it is not overturned in the course of administrative appeals). Given the early stage of these proceedings, Alexion is unable to predict the duration, scope or outcome of this matter, but we expect that a final resolution will take three years or more. While it is possible that a loss related to the Tax Assessment may be incurred, given its ongoing nature, we cannot reasonably estimate the potential magnitude of any such possible loss or range of loss, or the cost of the ongoing administrative appeals (and potential appeals to the federal court system) of the Tax Assessment. Any determination that any aspects of the importation of free of charge medications into Brazil as set forth in the Tax Assessment are not, or were not, in compliance with existing laws or regulations could result in the imposition of fines, civil penalties and, potentially criminal penalties, and/or other sanctions against us, and could have an adverse impact on our Brazilian operations.
In connection with Alexion’s acquisition of Portola, we have assumed litigation to which Portola was a party. Among the litigation assumed is a securities fraud class action filed against Portola and certain of its officers, directors and underwriters (“Defendants”) under the Securities Act of 1933 and the Securities Exchange Act of 1934. Specifically, on January 16, 2020, February 7, 2020, and February 28, 2020, stockholders filed three putative class actions in the U.S. District Court for the Northern District of California, captioned Hayden v. Portola Pharmaceuticals, Inc., et al., No. 3:20-cv-00367-VC (N.D. Cal.); McCutcheon v. Portola Pharmaceuticals, Inc., et al., No. 3:20-cv-00949 (N.D. Cal.); and Southeastern Pennsylvania Transportation Authority v. Portola Pharmaceuticals, Inc., et
al., No. 3:20-cv-01501 (N.D. Cal.). These cases have since been consolidated, and on April 22, 2020, the Court issued an Order appointing the Alameda County Employees’ Retirement Association (“ACERA”) as Lead Plaintiff in the litigation. ACERA filed its amended consolidated complaint on May 20, 2020, asserting that Defendants made misrepresentations and omissions in public disclosures (including in materials issued in connection with the August 7, 2019 securities offering) concerning Portola’s sales of andexanet alfa, marketed as ANDEXXA in the United States and ONDEXXYA in Europe, between January 8, 2019 and February 26, 2020. Specifically, plaintiffs allege that Defendants made materially false and/or misleading statements about the demand for ANDEXXA, usage of ANDEXXA by hospitals and healthcare organizations, and about Portola’s accounting for its return reserves. Plaintiffs contend that the alleged fraud was revealed on January 9, 2020, when Portola announced its preliminary unaudited financial results for the fourth quarter of 2019, and again on February 26, 2020, when Portola issued its fourth quarter 2019 financial results. In July 2020, Portola and the Portola Defendants filed a motion to dismiss with the Court. The court heard oral argument on September 24, 2020 and granted defendants’ pending motion to dismiss, but with leave for plaintiffs to amend further their complaint. Plaintiffs have until November 5, 2020 to file a second amended complaint. Plaintiffs seek to recover unspecified monetary relief, interest, and attorneys’ fees and costs. Given the early stage of these proceedings, we cannot presently predict the likelihood of obtaining dismissal of the case which the Company intends to submit following the filing of the second amended complaint (or the ultimate outcome of the case if that motion to dismiss is denied by the court), nor can we estimate the possible loss or range of loss at this time.
XML 63 R25.htm IDEA: XBRL DOCUMENT v3.20.2
Restructuring and Related Expenses
 9 Months Ended
Sep. 30, 2020
Restructuring and Related Activities [Abstract]  
Restructuring and Related Expenses Restructuring and Related Expenses
During the third quarter 2020, we initiated restructuring activities primarily within our commercial organization as part of an initiative intended to redefine our operating model. The actions are intended to reallocate resources necessary to align our organization with our diversifying portfolio of new products and strategic objectives, and will include investments in digital capabilities, technologies and solutions to support a more virtual and digital customer experience and tailored to the markets in which we operate.
The actions are expected to be substantially completed by the end of 2021, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $25.0. We expect that the pretax costs will primarily result in cash outlays, as the costs primarily relate to employee separation expenses.
In the first quarter 2019, we initiated corporate restructuring activities to re-align our international commercial organization through re-prioritization of certain geographical markets and to implement operational excellence through strategic reallocation of resources. Actions under the previous restructuring programs have been completed.
The following table summarizes the total expenses recorded related to the restructuring activities by type of activity and the locations recognized within the consolidated statements of operations:
Three months ended September 30,Three months ended September 30,
20202019
Employee Separation CostsOtherTotalEmployee Separation CostsOtherTotal
Restructuring expenses$14.3 $— $14.3 $(2.8)$3.1 $0.3 
Nine months ended September 30,Nine months ended September 30,
20202019
Employee Separation CostsOtherTotalEmployee Separation CostsOtherTotal
Restructuring expenses$14.0 $(0.5)$13.5 $8.7 $3.2 $11.9 
The following table presents a reconciliation of the restructuring reserve recorded within accounts payable and accrued expenses on the Company's consolidated balance sheets as of September 30, 2020
Three months ended September 30,Nine months ended September 30,
20202020
Employee Separation CostsOtherTotalEmployee Separation CostsOtherTotal
Liability, beginning of period$1.6 $— $1.6 $3.3 $3.5 $6.8 
Charges14.3 — 14.3 14.3 — 14.3 
Settlements— — — (1.4)(3.0)(4.4)
Adjustments to previous estimates— — — (0.3)(0.5)(0.8)
Liability, end of period$15.9 $— $15.9 $15.9 $— $15.9 
The restructuring reserve of $15.9 and $6.8 is recorded in accounts payable and accrued expenses on the Company's condensed consolidated balance sheet as of September 30, 2020 and December 31, 2019, respectively. The accrued amounts are expected to be paid in the next twelve months. We currently estimate incurring up to an additional $11.0 in restructuring expenses related to the third quarter 2020 action.
XML 64 R26.htm IDEA: XBRL DOCUMENT v3.20.2
Basis of Presentation and Principles Of Consolidation (Policies)
 9 Months Ended
Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Use of Estimates
Use of Estimates
Preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues, expenses and disclosure of contingent liabilities in our condensed consolidated financial statements.
Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain. We are not aware of any specific event or circumstance that would require an update to our estimates, judgments and assumptions or a revision of the carrying value of our assets or liabilities as of October 29, 2020, the date of issuance of this Quarterly Report on Form 10-Q. These estimates may change, as new events occur and additional information is obtained. Actual results may differ from these estimates under different assumptions or conditions and such differences may be material.
New Accounting Pronouncements
New Accounting Pronouncements
Accounting Standards Update (ASU) 2019-12, “Income Taxes: Simplifying the Accounting for Income Taxes”: In December 2019, the Financial Accounting Standards Board (FASB) issued a new standard intended to simplify the accounting for income taxes by eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new standard also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for annual periods beginning after December 15, 2020 and interim periods within, with early adoption permitted. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. We do not expect the adoption of this standard to have a material impact on our financial condition and results of operations.
ASU 2020-01, “Investments - Equity Securities, Investments - Equity Method and Joint Ventures, and Derivatives and Hedging - Clarifying the Interactions Between Topic 321, Topic 323, and Topic 815”: In January 2020, the FASB issued a new standard intended to clarify the interactions between Accounting Standards Codification (ASC) 321, ASC 323 and ASC 815. The new standard addresses accounting for the transition into and out of the equity method and measurement of certain purchased options and forward contracts to acquire investments. The standard is effective for annual and interim periods beginning after December 15, 2020, with early adoption permitted. Adoption of the standard requires changes to be made prospectively. We do not expect the adoption of this standard to have a material impact on our financial condition and results of operations.
ASU 2020-04, “Reference Rate Reform, Facilitation of the Effects of Reference Rate Reform on Financial Reporting": In response to concerns about structural risks of interbank offered rates, and, particularly, the risk of cessation of the London Interbank Offered Rate (LIBOR), regulators around the world have undertaken reference rate reform initiatives to identify alternative reference rates that are more observable or transaction-based and less susceptible to manipulation. In March 2020, the FASB issued a new standard that provides optional guidance for a limited time to ease the potential burden in accounting for the effects of reference rate reform, including optional expedients and exceptions for the accounting implications of contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met.
The amendments in this new standard only apply to contracts and hedging relationships that reference LIBOR or another reference rate expected to be discontinued due to reference rate reform. The expedients and exceptions provided by the standard do not apply to contract modifications made and hedging relationships entered into or evaluated after December 31, 2022. We are currently reviewing our contracts impacted by reference rate reform and are assessing the impact of this standard on our financial condition and results of operations.
Recently Adopted Accounting Pronouncements
ASU 2018-15, "Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract": In August 2018, the FASB issued a new standard on a customer's accounting for implementation, set-up, and other upfront costs incurred in a cloud computing arrangement (CCA) that aligns the requirements for capitalizing implementation costs in a CCA service contract with existing internal-use software guidance. The standard also provides classification guidance on these implementation costs as well as additional
quantitative and qualitative disclosures. The standard is effective for interim and annual periods beginning after December 15, 2019, with early adoption permitted, and can be adopted prospectively or retrospectively.
We adopted the new standard on January 1, 2020 on a prospective basis. The adoption of this standard had no impact on our financial statements at the date of adoption; however, we anticipate the adoption of this standard will result in an increase in capitalized assets related to qualifying CCA implementation costs in future periods.
Qualifying CCA implementation, set-up and other upfront costs incurred after January 1, 2020 are capitalized as other assets in our condensed consolidated balance sheets. These assets will be expensed over the term of the hosting arrangement and such expense will be presented within the same line item in our condensed consolidated statements of operations as the expense for fees for the associated hosting arrangement. These capitalized costs will be evaluated for impairment when events or changes in circumstances indicate that the carrying value of the capitalized implementation costs is not recoverable. For the nine months ended September 30, 2020, capitalized CCA implementation costs were not material.
ASU 2016-13, "Measurement of Credit Losses on Financial Instruments": In June 2016, the FASB issued a new standard intended to improve reporting requirements specific to loans, receivables and other financial instruments. The new standard requires that credit losses on financial assets measured at amortized cost be determined using an expected loss model, instead of the current incurred loss model, and requires that credit losses related to available-for-sale debt securities be recorded through an allowance for credit losses and limited to the amount by which carrying value exceeds fair value. The new standard also requires enhanced disclosure of credit risk associated with financial assets. The standard is effective for interim and annual periods beginning after December 15, 2019 with early adoption permitted.
We adopted the new standard on January 1, 2020 and have completed our assessment of the standard based on the composition of our portfolio of financial instruments and current and forecasted economic conditions at that date. Our significant financial assets that are within the scope of the new standard consist of trade accounts receivable and available for sale debt securities. We have not historically experienced any material credit losses associated with our trade accounts receivable or available for debt securities.
We monitor economic conditions, including volatility associated with international economies and the associated impacts on the financial markets and our business. We disaggregate our trade accounts receivable population into pools of similar risk characteristics based on underlying customer type and geographical location. Current expected credit loss allowances are estimated for each risk pool based on available information, including i) historical credit loss experience, ii) current economic conditions and, iii) reasonable and supportable forecasts of future economic conditions that may affect the collectibility of the recorded amounts. Based on the relevant facts and economic conditions as of the date of adoption, we concluded that the expected credit losses on our trade accounts receivable were immaterial. Additionally, unrealized losses on our available for sale investment portfolio were immaterial.
As of September 30, 2020, we reassessed our estimated credit losses on our trade accounts receivable, including consideration of the potential impacts of the COVID-19 global pandemic. Based on the relevant facts and economic conditions as of September 30, 2020, we concluded that the expected credit losses on our trade accounts receivable continued to be immaterial.
XML 65 R27.htm IDEA: XBRL DOCUMENT v3.20.2
Acquisitions (Tables)
 9 Months Ended
Sep. 30, 2020
Business Combinations [Abstract]  
Schedule of Business Acquisitions, by Acquisition [Table Text Block] The following table summarizes the total consideration transferred to acquire Achillion and the estimated fair value of the identified assets acquired and liabilities assumed at the acquisition date:
Consideration
Upfront payment to shareholders and option holders$926.2 
Upfront payment, fair value of equity compensation attributable to the post-combination service period(20.0)
Upfront cash paid, net906.2 
Contingent consideration160.7 
Contingent consideration, fair value of equity compensation attributable to the post-combination service period(5.7)
Total consideration$1,061.2 
Assets Acquired and Liabilities Assumed
Cash and cash equivalents$68.5 
Marketable securities106.1 
In-process research & development assets (IPR&D)918.0 
Goodwill37.8 
Deferred tax liabilities, net(62.9)
Other assets and liabilities, net(6.3)
Total net assets acquired$1,061.2 
The following table summarizes the total consideration transferred to acquire Portola and the estimated fair value of the identified assets acquired and liabilities assumed at the acquisition date:
Consideration
Upfront payment to shareholders and equity holders$1,380.8 
Upfront payment, fair value of equity compensation attributable to the post-combination service period(11.1)
Upfront cash paid, net1,369.7 
Fair value of equity shares held by Alexion at closing 47.8 
Fair value of replacement equity awards attributable to the pre-combination period7.2 
Total consideration to acquire outstanding equity, net1,424.7 
Total consideration to settle preexisting debt196.9 
Total consideration$1,621.6 
Assets Acquired and Liabilities Assumed
Cash and cash equivalents$288.5 
Marketable securities17.8 
Inventories, including noncurrent portion of $169.1 and validation batches of $60.9
362.5 
Intangible assets1,051.0 
Goodwill25.5 
Deferred tax assets, net116.0 
Other assets41.9 
Accounts payable and accrued expenses(75.6)
Long-term debt, including current portion of $7.7
(182.0)
Other liabilities(24.0)
Total net assets acquired$1,621.6 
Summary of Pro Forma Information
The following unaudited pro forma information presents the combined results of Alexion, Achillion, and Portola as if the acquisitions of Achillion and Portola had been completed on January 1, 2019, with adjustments to give effect to pro forma events that are directly attributable to the acquisitions. The unaudited pro forma results do not reflect operating efficiencies or potential cost savings that may have resulted from the consolidation of operations. Accordingly, the unaudited pro forma financial information is not necessarily indicative of the results of operations had we completed the transaction on January 1, 2019.
 Three months ended September 30Nine months ended September 30
 2020201920202019
Pro forma revenue$1,589.5 $1,299.9 $4,526.5 $3,694.2 
Pro forma net income (loss)$625.4 $372.0 $(23.2)$1,063.7 
Summary of Acquisition-Related Costs
Acquisition-related costs recorded within the condensed consolidated statement of operations associated with our acquisitions of Achillion and Portola for the three and nine months ended September 30, 2020 and 2019 include the following:
 Three months ended September 30,Nine months ended September 30,
 2020201920202019
Transaction costs (1)
$1.8 $— $7.4 $— 
Integration costs4.6 — 5.6 — 
Fair value of equity compensation attributable to the post-combination service period11.1 — 36.8 — 
Employee separation costs (2)
45.5 — 55.9 — 
$63.0 $— $105.7 $— 
(1) Transaction costs primarily include legal fees related to the acquisition of Portola as well as costs incurred to effectuate the settlement of the Achillion outstanding options
(2) Employee separation costs include liabilities recognized, and subsequent changes in estimates recorded for, severance payments, one-time short-term retention awards agreed to in connection with the acquisition of Achillion and share-based compensation expense relating to awards accelerated in connection with terminations of Portola employees.
XML 66 R28.htm IDEA: XBRL DOCUMENT v3.20.2
Inventories (Tables)
 9 Months Ended
Sep. 30, 2020
Inventory, Net [Abstract]  
Schedule of Inventory, Current
The components of inventory are as follows:
 September 30,December 31,
 20202019
Raw materials$94.2 $41.2 
Work-in-process256.6 180.8 
Finished goods510.5 405.6 
Total inventories$861.3 $627.6 
Balance Sheet Classification:
Inventories$729.0 $627.6 
Other assets$132.3 $— 
XML 67 R29.htm IDEA: XBRL DOCUMENT v3.20.2
Intangible Assets and Goodwill (Tables)
 9 Months Ended
Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets and Goodwill
The following table summarizes the carrying amount of our intangible assets and goodwill, net of accumulated amortization and impairment charges: 
September 30, 2020December 31, 2019
Estimated
Life (years)		CostAccumulated
Amortization 		NetCostAccumulated
Amortization 		Net
Licensing rights
3-8
$57.0 $(37.5)$19.5 $57.0 $(34.7)$22.3 
Patents710.5 (10.5)— 10.5 (10.5)— 
Purchased technology
6-16
5,746.5 (3,631.5)(a)2,115.0 4,710.5 (1,388.7)3,321.8 
Other intangibles50.4 (0.3)0.1 0.4 (0.2)0.2 
Acquired IPR&DIndefinite922.0 — 922.0 — — — 
Total$6,736.4 $(3,679.8)$3,056.6 $4,778.4 $(1,434.1)$3,344.3 
GoodwillIndefinite$5,103.6 $(2.9)$5,100.7 $5,040.3 $(2.9)$5,037.4 
(a) Includes an impairment charge of $2,042.3 recognized during the second quarter 2020 related to the KANUMA intangible asset
Summary of Changes in Goodwill
The following summarizes the changes in the carrying amount of goodwill:
September 30, 2020
Balance at December 31, 2019$5,037.4 
Goodwill resulting from the acquisitions of Achillion and Portola63.3 
Balance at September 30, 2020$5,100.7 
XML 68 R30.htm IDEA: XBRL DOCUMENT v3.20.2
Debt (Tables)
 9 Months Ended
Sep. 30, 2020
Debt Disclosure [Abstract]  
Schedule of Debt Our payment obligations for HCR royalty-based debt are as follows:
Nine Months Ended September 30, 2020
Total repayment obligation as of the acquisition date$276.9 
Less: interest to be accreted in future periods(90.0)
Less: payments made(1.7)
Carrying value as of September 30, 2020$185.2 
XML 69 R31.htm IDEA: XBRL DOCUMENT v3.20.2
Earnings Per Common Share (Tables)
 9 Months Ended
Sep. 30, 2020
Earnings Per Common Share [Abstract]  
Schedule Of Basic And Diluted Earnings Per Share
The following table summarizes the calculation of basic and diluted EPS for the three and nine months ended September 30, 2020 and 2019:
Three months endedNine months ended
 September 30,September 30,
 2020201920202019
Net income used for basic and diluted calculation$578.1 $467.6 $67.6 $1,515.3 
Shares used in computing earnings per common share—basic219.1 223.3 220.4 223.8 
Weighted-average effect of dilutive securities:
Stock awards1.5 1.2 1.5 1.6 
Shares used in computing earnings per common share—diluted220.6 224.5 221.9 225.4 
Earnings per common share:
Basic$2.64 $2.09 $0.31 $6.77 
Diluted$2.62 $2.08 $0.30 $6.72 
XML 70 R32.htm IDEA: XBRL DOCUMENT v3.20.2
Marketable Securities (Tables)
 9 Months Ended
Sep. 30, 2020
Investments, Debt and Equity Securities [Abstract]  
Realized Gain (Loss) on Investments The proceeds from maturities and sales of available-for-sale debt securities and resulting realized gains and losses are summarized below. In the second quarter of 2020, we liquidated all of our available-for-sale debt securities to fund the acquisition of Portola. Additionally, we liquidated all available-for-sale debt securities acquired in connection with the Portola acquisition.
Three months endedNine months ended
September 30,September 30,
2020201920202019
Proceeds from maturities and sales (1)
$25.5 $645.4 $1,042.4 $2,271.7 
Realized gains$— $— $— $— 
Realized losses$— $— $— $— 
 (1) Proceeds from maturities and sales of available-for-sale debt securities include securities previously classified as cash and cash equivalents and marketable securities in the condensed consolidated balance sheet.
Schedule of Available-for-sale Securities Reconciliation The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of available-for-sale debt securities by type of security as of December 31, 2019 were as follows:
December 31, 2019
Amortized CostGross Unrealized Holding GainsGross Unrealized Holding LossesFair Value
Commercial paper$246.9 $— $— $246.9 
Corporate bonds24.3 — — 24.3 
Other government-related obligations:
U.S.70.4 — — 70.4 
Bank certificates of deposit27.4 — — 27.4 
Total available-for-sale debt securities$369.0 $— $— $369.0 
Available-for-sale Securities by Balance Sheet Location Classification
The fair values of available-for-sale debt securities by classification in the condensed consolidated balance sheets were as follows:
September 30, 2020December 31, 2019
Cash and cash equivalents$— $328.1 
Marketable securities— 40.9 
$— $369.0 
XML 71 R33.htm IDEA: XBRL DOCUMENT v3.20.2
Derivative Instruments and Hedging Activities (Tables)
 9 Months Ended
Sep. 30, 2020
Derivative Instruments and Hedging Activities [Abstract]  
Schedule of Interest Rate Contracts
The following table summarizes the total interest rate swap contracts executed as of September 30, 2020:
Type of Interest Rate Swap ContractNotional AmountEffective DateTermination DateFixed Interest Rate or Rate Range
Floating to Fixed$450.0December 2018December 2022
2.60% - 2.79%
Floating to Fixed$1,300.0December 2019December 2022
2.37% - 2.83%
Schedule of Other Comprehensive Income and Earnings from Foreign Exchange Contracts
The amount of gains and (losses) recognized in the condensed consolidated statements of operations for the three and nine months ended September 30, 2020 and 2019 from foreign exchange and interest rate swap contracts that qualified as cash flow hedges were as follows:
Three months endedThree months ended
 September 30, 2020September 30, 2019
Financial Statement Line Item in which the Effects of Cash Flow Hedges are RecordedNet Product SalesInterest ExpenseNet Product SalesInterest Expense
Total amount presented in the Condensed Consolidated Statements of Operations$1,588.3 $(27.6)$1,263.1 $(17.9)
Impact of cash flow hedging relationships:
Foreign exchange forward contracts$(5.0)$— $11.0 $— 
Interest rate swap contracts$— $(11.3)$— $3.4 
Nine months endedNine months ended
 September 30, 2020September 30, 2019
Financial Statement Line Item in which the Effects of Cash Flow Hedges are RecordedNet Product SalesInterest ExpenseNet Product SalesInterest Expense
Total amount presented in the Condensed Consolidated Statements of Operations$4,477.4 $(77.0)$3,605.8 $(56.1)
Impact of cash flow hedging relationships:
Foreign exchange forward contracts$15.9 $— $27.1 $— 
Interest rate swap contracts$— $(25.9)$— $12.5 
The impact on accumulated other comprehensive income (AOCI) and earnings from foreign exchange and interest rate swap contracts that qualified as cash flow hedges, for the three and nine months ended September 30, 2020 and 2019 were as follows:
Three months endedNine months ended
 September 30,September 30,
 2020201920202019
Foreign Exchange Forward Contracts:
(Loss) gain recognized in AOCI, net of tax$(22.9)$30.5 $(3.0)$40.8 
(Loss) gain reclassified from AOCI to net product sales, net of tax$(4.0)$8.6 $12.2 $21.0 
Interest Rate Swap Contracts:
Gain (loss) recognized in AOCI, net of tax$0.1 $(7.1)$(52.6)$(45.9)
(Loss) gain reclassified from AOCI to interest expense, net of tax$(8.8)$2.6 $(20.1)$9.6 
Schedule of Fair Value of Outstanding Derivatives
The following tables summarize the fair value of outstanding derivatives as of September 30, 2020 and December 31, 2019: 
September 30, 2020
 Derivative AssetsDerivative Liabilities
Balance Sheet
Location		Fair
Value		Balance Sheet
Location		Fair
Value
Derivatives designated as hedging instruments:
Foreign exchange forward contractsPrepaid expenses and other current assets$3.0 Other current liabilities$16.8 
Foreign exchange forward contractsOther assets0.4 Other liabilities0.3 
Interest rate swap contractsPrepaid expenses and other current assets— Other current liabilities45.6 
Interest rate swap contractsOther assets— Other liabilities57.6 
Derivatives not designated as hedging instruments:
Foreign exchange forward contractsPrepaid expenses and other current assets8.7 Other current liabilities8.0 
Total fair value of derivative instruments$12.1 $128.3 
December 31, 2019
 Derivative AssetsDerivative Liabilities
Balance Sheet
Location		Fair
Value		Balance Sheet
Location		Fair
Value
Derivatives designated as hedging instruments:
Foreign exchange forward contractsPrepaid expenses and other current assets$12.7 Other current liabilities$6.2 
Foreign exchange forward contractsOther assets0.6 Other liabilities1.1 
Interest rate swap contractsPrepaid expenses and other current assets— Other current liabilities19.5 
Interest rate swap contractsOther assets— Other liabilities41.9 
Derivatives not designated as hedging instruments:
Foreign exchange forward contractsPrepaid expenses and other current assets17.2 Other current liabilities20.4 
Total fair value of derivative instruments$30.5 $89.1 
Offsetting Assets and Liabilities The following tables summarize the potential effect on our condensed consolidated balance sheets of offsetting our foreign exchange forward contracts and interest rate contracts subject to such provisions:
September 30, 2020
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet
DescriptionGross Amounts of Recognized Assets/LiabilitiesGross Amounts Offset in the Condensed Consolidated Balance SheetNet Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance SheetDerivative Financial InstrumentsCash Collateral Received (Pledged)Net Amount
Derivative assets$12.1 $— $12.1 $(11.4)$— $0.7 
Derivative liabilities$(128.3)$— $(128.3)$11.4 $— $(116.9)
December 31, 2019
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet
DescriptionGross Amounts of Recognized Assets/LiabilitiesGross Amounts Offset in the Condensed Consolidated Balance SheetNet Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance SheetDerivative Financial InstrumentsCash Collateral Received (Pledged)Net Amount
Derivative assets$30.5 $— $30.5 $(21.4)$— $9.1 
Derivative liabilities$(89.1)$— $(89.1)$21.4 $— $(67.7)
XML 72 R34.htm IDEA: XBRL DOCUMENT v3.20.2
Other Comprehensive Income and Accumulated Other Comprehensive Income (Tables)
 9 Months Ended
Sep. 30, 2020
Accumulated Other Comprehensive Income [Abstract]  
Schedule of Accumulated Other Comprehensive Income (Loss)
The following tables summarize the changes in AOCI, by component, for the nine months ended September 30, 2020 and 2019:
Defined Benefit Pension PlansUnrealized Gains (Losses) from Debt SecuritiesUnrealized Gains (Losses) from Hedging ActivitiesForeign Currency Translation AdjustmentTotal Accumulated Other Comprehensive Income (Loss)
Balances, December 31, 2019$(9.2)$(0.1)$(40.1)$(17.4)$(66.8)
Other comprehensive income (loss) before reclassifications— 0.1 (55.1)(5.3)(60.3)
Amounts reclassified from other comprehensive income— — 7.9 — 7.9 
Net other comprehensive income (loss)— 0.1 (47.2)(5.3)(52.4)
Balances, September 30, 2020$(9.2)$— $(87.3)$(22.7)$(119.2)
Defined Benefit Pension PlansUnrealized Gains (Losses) from Debt SecuritiesUnrealized Gains (Losses) from Hedging ActivitiesForeign Currency Translation AdjustmentTotal Accumulated Other Comprehensive Income (Loss)
Balances, December 31, 2018$(2.6)$(0.3)$9.6 $(16.4)$(9.7)
Other comprehensive income (loss) before reclassifications— 0.2 (5.1)(3.0)(7.9)
Amounts reclassified from other comprehensive income— — (30.6)— (30.6)
Net other comprehensive income (loss)— 0.2 (35.7)(3.0)(38.5)
Balances, September 30, 2019$(2.6)$(0.1)$(26.1)$(19.4)$(48.2)
Reclassification out of Accumulated Other Comprehensive Income
The table below provides details regarding significant reclassifications from AOCI during the three and nine months ended September 30, 2020 and 2019:
Details about Accumulated Other Comprehensive Income ComponentsAmount Reclassified From Accumulated Other Comprehensive Income during the three months ended September 30,Amount Reclassified From Accumulated Other Comprehensive Income during the nine months ended September 30,Affected Line Item in the Condensed Consolidated Statements of Operations
2020201920202019
Unrealized Gains (Losses) on Hedging Activity
Foreign exchange forward contracts$(5.0)$11.0 $15.9 $27.1 Net product sales
Interest rate swap contracts(11.3)3.4 (25.9)12.5 Interest expense
(16.3)14.4 (10.0)39.6 
3.5 (3.2)2.1 (9.0)Income tax (benefit) expense
$(12.8)$11.2 $(7.9)$30.6 
XML 73 R35.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurement (Tables)
 9 Months Ended
Sep. 30, 2020
Fair Value Disclosures [Abstract]  
Schedule Of Assets And Liabilites Measured At Fair Value
The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2020 and December 31, 2019, and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair value.
  Fair Value Measurement at
September 30, 2020
Balance Sheet
Classification		Type of InstrumentTotalLevel 1Level 2Level 3
Cash equivalentsMoney market funds$424.9 $— $424.9 $— 
Marketable securitiesMutual funds$28.9 $28.9 $— $— 
Other assetsEquity securities$100.4 $75.4 $25.0 $— 
Prepaid expenses and other current assetsForeign exchange forward contracts$11.7 $— $11.7 $— 
Other assetsForeign exchange forward contracts$0.4 $— $0.4 $— 
Other current liabilitiesForeign exchange forward contracts$24.8 $— $24.8 $— 
Other liabilitiesForeign exchange forward contracts$0.3 $— $0.3 $— 
Other current liabilitiesInterest rate contracts$45.6 $— $45.6 $— 
Other liabilitiesInterest rate contracts$57.6 $— $57.6 $— 
Contingent considerationAcquisition-related contingent consideration$398.1 $— $— $398.1 
 
  Fair Value Measurement at
December 31, 2019
Balance Sheet
Classification		Type of InstrumentTotalLevel 1Level 2Level 3
Cash equivalentsMoney market funds$635.9 $— $635.9 $— 
Cash equivalentsCommercial paper$227.9 $— $227.9 $— 
Cash equivalentsCorporate bonds$20.6 $— $20.6 $— 
Cash equivalentsBank certificates of deposit$19.2 $— $19.2 $— 
Cash equivalentsOther government-related obligations$60.4 $— $60.4 $— 
Marketable securitiesMutual funds$23.1 $23.1 $— $— 
Marketable securitiesCommercial paper$19.0 $— $19.0 $— 
Marketable securitiesCorporate bonds$3.7 $— $3.7 $— 
Marketable securitiesOther government-related obligations$10.0 $— $10.0 $— 
Marketable securitiesBank certificates of deposit$8.2 $— $8.2 $— 
Other assetsEquity securities$79.0 $51.2 $27.8 $— 
Prepaid expenses and other current assetsForeign exchange forward contracts$29.9 $— $29.9 $— 
Other assetsForeign exchange forward contracts$0.6 $— $0.6 $— 
Other current liabilitiesForeign exchange forward contracts$26.6 $— $26.6 $— 
Other liabilitiesForeign exchange forward contracts$1.1 $— $1.1 $— 
Other current liabilitiesInterest rate contracts$19.5 $— $19.5 $— 
Other liabilitiesInterest rate contracts$41.9 $— $41.9 $— 
Contingent considerationAcquisition-related contingent consideration$192.4 $— $— $192.4 
Other current liabilitiesOther contingent payments$24.0 $— $— $24.0 
Schedule Of Acquisition-Related Contingent Consideration The following table represents a roll-forward of our acquisition-related contingent consideration:
Nine Months Ended September 30, 2020
Balance as of December 31, 2019$192.4 
Amounts issued160.7 
Changes in fair value45.0 
Balance as of September 30, 2020$398.1 
XML 74 R36.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue Recognition (Tables)
 9 Months Ended
Sep. 30, 2020
Revenue from Contract with Customer [Abstract]  
Disaggregation of revenue from contracts with customer
The Company disaggregates revenue from contracts with customers into product and geographical regions as summarized below.
Three months ended September 30,Nine months ended September 30,
2020201920202019
SOLIRIS
United States$562.8 $496.8 $1,672.3 $1,456.8 
Europe254.3 255.5 765.7 800.2 
Asia Pacific86.0 118.0 255.5 329.2 
Rest of World139.2 120.2 347.2 347.1 
Total$1,042.3 $990.5 $3,040.7 $2,933.3 
ULTOMIRIS
United States$170.7 $65.1 $460.3 $143.9 
Europe46.6 21.1 112.4 21.1 
Asia Pacific69.6 3.7 186.3 3.7 
Rest of World2.4 — 4.2 — 
Total$289.3 $89.9 $763.2 $168.7 
STRENSIQ
United States$149.3 $118.0 $418.1 $323.7 
Europe19.3 19.0 61.6 56.0 
Asia Pacific16.1 14.0 44.7 36.0 
Rest of World4.7 3.3 21.5 10.0 
Total$189.4 $154.3 $545.9 $425.7 
ANDEXXA
United States$36.2 $— $36.2 $— 
Europe2.7 — 2.7 — 
Asia Pacific— — — — 
Rest of World— — — — 
Total$38.9 $— $38.9 $— 
KANUMA
United States$15.8 $16.0 $47.6 $45.1 
Europe9.5 6.3 25.4 19.4 
Asia Pacific1.1 1.3 2.9 3.4 
Rest of World2.0 4.8 12.8 10.2 
Total$28.4 $28.4 $88.7 $78.1 
Total Net Product Sales$1,588.3 $1,263.1 $4,477.4 $3,605.8 
Summary of receivables and contract liabilities from contracts
September 30, 2020December 31, 2019
Receivables, which are included in "Trade accounts receivable, net"$1,437.1 $1,243.2 
Contract liabilities, which are included in "Other current liabilities"$22.7 $6.8 
XML 75 R37.htm IDEA: XBRL DOCUMENT v3.20.2
Income Taxes (Tables)
 9 Months Ended
Sep. 30, 2020
Income Tax Disclosure [Abstract]  
Schedule of Income Tax Provision and Effective Tax Rate
The following table provides a comparative summary of our income tax expense and effective income tax rate for the three and nine months ended September 30, 2020:
Three months endedNine months ended
September 30,September 30,
2020201920202019
Income tax expense (benefit)$88.8$67.9 $(89.2)$61.5 
Effective income tax rate13.3 %12.7 %413.0 %3.9 %
XML 76 R38.htm IDEA: XBRL DOCUMENT v3.20.2
Restructuring and Related Expenses (Tables)
 9 Months Ended
Sep. 30, 2020
Restructuring and Related Activities [Abstract]  
Restructuring and Related Costs
The following table summarizes the total expenses recorded related to the restructuring activities by type of activity and the locations recognized within the consolidated statements of operations:
Three months ended September 30,Three months ended September 30,
20202019
Employee Separation CostsOtherTotalEmployee Separation CostsOtherTotal
Restructuring expenses$14.3 $— $14.3 $(2.8)$3.1 $0.3 
Nine months ended September 30,Nine months ended September 30,
20202019
Employee Separation CostsOtherTotalEmployee Separation CostsOtherTotal
Restructuring expenses$14.0 $(0.5)$13.5 $8.7 $3.2 $11.9 
The following table presents a reconciliation of the restructuring reserve recorded within accounts payable and accrued expenses on the Company's consolidated balance sheets as of September 30, 2020
Three months ended September 30,Nine months ended September 30,
20202020
Employee Separation CostsOtherTotalEmployee Separation CostsOtherTotal
Liability, beginning of period$1.6 $— $1.6 $3.3 $3.5 $6.8 
Charges14.3 — 14.3 14.3 — 14.3 
Settlements— — — (1.4)(3.0)(4.4)
Adjustments to previous estimates— — — (0.3)(0.5)(0.8)
Liability, end of period$15.9 $— $15.9 $15.9 $— $15.9 
XML 77 R39.htm IDEA: XBRL DOCUMENT v3.20.2
Acquisitions (Narrative) (Details) - USD ($)
 3 Months Ended 9 Months Ended
Jul. 02, 2020
Jan. 28, 2020
Sep. 30, 2020
Sep. 30, 2020
Jun. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Feb. 28, 2017
Schedule Of Asset Acquisition, By Acquisition [Line Items]                    
Contingent consideration     $ 398,100,000 $ 398,100,000     $ 398,100,000   $ 192,400,000  
Change in fair value of contingent consideration     23,400,000     $ 29,800,000 45,000,000.0 $ 7,200,000    
Upfront payment, fair value of equity compensation attributable to the post-combination service period     (11,100,000)     0 $ (36,800,000) 0    
Fair Value Inputs, Weighted Average Cost of Capital             11.50%      
Acquisition costs not included in net income     72,200,000       $ 143,500,000      
Acquisition costs adjustment               129,300,000    
HealthCare Royalty Partners | Royalty-Based Financing Agreement                    
Schedule Of Asset Acquisition, By Acquisition [Line Items]                    
Repayments of debt     1,700,000 1,700,000     1,700,000      
Outstanding debt     185,200,000 185,200,000     185,200,000      
HealthCare Royalty Partners | Royalty-Based Financing Agreement | Portola Pharmaceuticals, Inc.                    
Schedule Of Asset Acquisition, By Acquisition [Line Items]                    
Repayments of debt $ 13,700,000                  
Royalty Agreement, Maximum Potential Royalty Payments                   $ 290,600,000
Purchased technology                    
Schedule Of Asset Acquisition, By Acquisition [Line Items]                    
Impairment         $ 2,042,300,000          
Achillion                    
Schedule Of Asset Acquisition, By Acquisition [Line Items]                    
Total acquisition value, per share (in dollars per share)   $ 6.30                
Upfront cash paid, net   $ 906,200,000                
Goodwill adjustments         3,100,000          
Contingent consideration   160,700,000 209,400,000 209,400,000     209,400,000      
Contingent consideration, fair value of equity compensation attributable to the post-combination service period   5,700,000                
Change in fair value of contingent consideration     19,300,000       48,600,000      
Upfront payment, fair value of equity compensation attributable to the post-combination service period   (20,000,000.0)         (25,700,000)      
Net deferred tax liability   (62,900,000)                
Deferred tax assets, net   $ 142,400,000                
Operating loss since acquisition     (24,600,000)       (51,400,000)      
Portola Pharmaceuticals, Inc.                    
Schedule Of Asset Acquisition, By Acquisition [Line Items]                    
Total acquisition value, per share (in dollars per share) $ 18.00                  
Upfront cash paid, net $ 1,369,700,000                  
Upfront payment, fair value of equity compensation attributable to the post-combination service period (11,100,000)                  
Deferred tax assets, net 116,000,000.0                  
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 41,500,000                  
Fair value of replacement equity awards attributable to the pre-combination period 7,200,000                  
Repayments of debt 196,900,000                  
Inventories, including noncurrent portion of $169.1 and validation batches of $60.9 362,500,000                  
Validation batches $ 60,900,000                  
Fair Value Inputs, Discount Rate 17.50%                  
Deferred tax assets, net operating loss carryforward $ 301,000.0                  
Deferred tax assets, income tax credits 42,000.0                  
Deferred tax assets, other differences 39,100                  
Deferred tax assets, royalty debt 42,400                  
Deferred tax liabilities, intangible assetes 245,100                  
Deferred tax liabilities, inventory 63,400                  
Revenue since acquisition     38,900,000       38,900,000      
Operating loss since acquisition     35,400,000       35,400,000      
Intangible asset amortization expense since acquisition     25,900,000       25,900,000      
Amortization expense adjustment           19,900,000 39,700,000 59,600,000    
Cost of goods sold adjustment           $ 10,100,000 $ 10,900,000 $ 16,700,000    
Portola Pharmaceuticals, Inc. | HealthCare Royalty Partners | Royalty-Based Financing Agreement                    
Schedule Of Asset Acquisition, By Acquisition [Line Items]                    
Total repayment obligation as of the acquisition date 276,900,000                  
Outstanding debt 182,000,000.0                  
Portola Pharmaceuticals, Inc. | Purchased technology                    
Schedule Of Asset Acquisition, By Acquisition [Line Items]                    
Purchased techonology $ 1,036,000,000.0                  
Finite-Lived Intangible Asset, Useful Life 10 years                  
Portola Pharmaceuticals, Inc. | ANDEXXA                    
Schedule Of Asset Acquisition, By Acquisition [Line Items]                    
Property, Plant and Equipment, Useful Life 3 years                  
Fair Value Inputs, Discount Rate 17.50%                  
Danicopan | Achillion                    
Schedule Of Asset Acquisition, By Acquisition [Line Items]                    
Contingent value rights per share (in dollars per share)   $ 1.00                
ACH-5528, Phase 3 | Achillion                    
Schedule Of Asset Acquisition, By Acquisition [Line Items]                    
Contingent value rights per share (in dollars per share)   $ 1.00                
Minimum | Purchased technology                    
Schedule Of Asset Acquisition, By Acquisition [Line Items]                    
Finite-Lived Intangible Asset, Useful Life             6 years      
Minimum | Achillion                    
Schedule Of Asset Acquisition, By Acquisition [Line Items]                    
Estimated milestone payments   $ 0                
Minimum | Portola Pharmaceuticals, Inc.                    
Schedule Of Asset Acquisition, By Acquisition [Line Items]                    
Fair Value Inputs, Discount Rate 3.30%                  
Maximum | Purchased technology                    
Schedule Of Asset Acquisition, By Acquisition [Line Items]                    
Finite-Lived Intangible Asset, Useful Life             16 years      
Maximum | Achillion                    
Schedule Of Asset Acquisition, By Acquisition [Line Items]                    
Estimated milestone payments   $ 306,300,000                
Maximum | Portola Pharmaceuticals, Inc.                    
Schedule Of Asset Acquisition, By Acquisition [Line Items]                    
Fair Value Inputs, Discount Rate 7.10%                  
Acquisition-related contingent consideration | Minimum | Level 3                    
Schedule Of Asset Acquisition, By Acquisition [Line Items]                    
Fair Value Inputs, Cost of Debt   2.10%         3.90%      
Fair Value Inputs, Weighted Average Cost of Capital             9.00%      
Acquisition-related contingent consideration | Maximum | Level 3                    
Schedule Of Asset Acquisition, By Acquisition [Line Items]                    
Fair Value Inputs, Cost of Debt   2.30%         4.30%      
In-process research & development assets (IPR&D)                    
Schedule Of Asset Acquisition, By Acquisition [Line Items]                    
Impairment         $ 11,000,000.0          
In-process research & development assets (IPR&D) | Achillion                    
Schedule Of Asset Acquisition, By Acquisition [Line Items]                    
In-process research & development assets (IPR&D)   $ 918,000,000.0                
Net deferred tax liability   $ (205,300,000)                
In-process research & development assets (IPR&D) | Portola Pharmaceuticals, Inc.                    
Schedule Of Asset Acquisition, By Acquisition [Line Items]                    
In-process research & development assets (IPR&D)     $ 15,000,000.0 $ 15,000,000.0     $ 15,000,000.0      
XML 78 R40.htm IDEA: XBRL DOCUMENT v3.20.2
Acquisitions (Summary of Total Consideration) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Jul. 02, 2020
Jan. 28, 2020
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Consideration              
Upfront payment, fair value of equity compensation attributable to the post-combination service period     $ (11.1) $ 0.0 $ (36.8) $ 0.0  
Contingent consideration     398.1   398.1   $ 192.4
Assets Acquired and Liabilities Assumed              
Goodwill     5,100.7   5,100.7   $ 5,037.4
Portola Pharmaceuticals              
Consideration              
Fair value of equity shares held by Alexion at closing $ 47.8            
Achillion              
Consideration              
Upfront payment to shareholders and equity holders   $ 926.2          
Upfront payment, fair value of equity compensation attributable to the post-combination service period   (20.0)     (25.7)    
Upfront cash paid, net   906.2          
Contingent consideration   160.7 209.4   209.4    
Contingent consideration, fair value of equity compensation attributable to the post-combination service period   (5.7)          
Total consideration   1,061.2          
Assets Acquired and Liabilities Assumed              
Cash and cash equivalents   68.5          
Marketable securities   106.1          
Deferred tax assets, net   142.4          
Goodwill   37.8          
Deferred tax liabilities, net   (62.9)          
Other assets and liabilities, net   (6.3)          
Total net assets acquired   1,061.2          
Portola Pharmaceuticals, Inc.              
Consideration              
Upfront payment to shareholders and equity holders 1,380.8            
Upfront payment, fair value of equity compensation attributable to the post-combination service period (11.1)            
Upfront cash paid, net 1,369.7            
Fair value of replacement equity awards attributable to the pre-combination period 7.2            
Total consideration to acquire outstanding equity, net 1,424.7            
Repayments of debt 196.9            
Total consideration 1,621.6            
Assets Acquired and Liabilities Assumed              
Cash and cash equivalents 288.5            
Marketable securities 17.8            
Inventories, including noncurrent portion of $169.1 and validation batches of $60.9 362.5            
Noncurrent inventory 169.1            
Validation batches 60.9            
Intangible assets 1,051.0            
Deferred tax assets, net 116.0            
Other assets 41.9            
Goodwill 25.5            
Accounts payable and accrued expenses (75.6)            
Long-term debt, including current portion of $7.7 (182.0)            
Current debt 7.7            
Other liabilities (24.0)            
Total net assets acquired $ 1,621.6            
In-process research & development assets (IPR&D) | Achillion              
Assets Acquired and Liabilities Assumed              
In-process research & development assets (IPR&D)   918.0          
Deferred tax liabilities, net   $ (205.3)          
In-process research & development assets (IPR&D) | Portola Pharmaceuticals, Inc.              
Assets Acquired and Liabilities Assumed              
In-process research & development assets (IPR&D)     $ 15.0   $ 15.0    
XML 79 R41.htm IDEA: XBRL DOCUMENT v3.20.2
Acquisitions (Pro Forma Information) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Business Combinations [Abstract]        
Business Acquisition, Pro Forma Revenue $ 1,589.5 $ 1,299.9 $ 4,526.5 $ 3,694.2
Business Acquisition, Pro Forma Net Income (Loss) $ 625.4 $ 372.0 $ (23.2) $ 1,063.7
XML 80 R42.htm IDEA: XBRL DOCUMENT v3.20.2
Acquisitions (Acquisition-Related Costs) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Jul. 02, 2020
Jan. 28, 2020
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Business Acquisition [Line Items]            
Transaction costs     $ 1.8 $ 0.0 $ 7.4 $ 0.0
Integration costs     4.6 0.0 5.6 0.0
Fair value of equity compensation attributable to the post-combination service period     11.1 0.0 36.8 0.0
Restructuring-related costs     45.5 0.0 55.9 0.0
Acquisition-related costs     63.0 $ 0.0 105.7 $ 0.0
Achillion            
Business Acquisition [Line Items]            
Fair value of equity compensation attributable to the post-combination service period   $ 20.0     25.7  
Acquisition-related costs         38.0  
Portola Pharmaceuticals, Inc.            
Business Acquisition [Line Items]            
Fair value of equity compensation attributable to the post-combination service period $ 11.1          
Acquisition-related costs     $ 63.0   $ 67.7  
XML 81 R43.htm IDEA: XBRL DOCUMENT v3.20.2
Inventories (Details) - USD ($)
$ in Millions
Sep. 30, 2020
Jul. 02, 2020
Dec. 31, 2019
Inventory [Line Items]      
Raw materials $ 94.2   $ 41.2
Work-in-process 256.6   180.8
Finished goods 510.5   405.6
Inventory, Net 861.3   627.6
Portola Pharmaceuticals, Inc.      
Inventory [Line Items]      
Validation batches   $ 60.9  
Inventories      
Inventory [Line Items]      
Inventory, Net 729.0   627.6
Other assets      
Inventory [Line Items]      
Inventory, Net 132.3   0.0
Pre Approval Inventory      
Inventory [Line Items]      
Inventory, Net $ 117.2   $ 60.5
XML 82 R44.htm IDEA: XBRL DOCUMENT v3.20.2
Intangible Assets and Goodwill (Schedule of Intangible Assets and Goodwill) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Jun. 30, 2020
Sep. 30, 2020
Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]      
Intangible Assets, Cost   $ 6,736.4 $ 4,778.4
Intangible Assets, Accumulated Amortization   (3,679.8) (1,434.1)
Intangible assets   3,056.6 3,344.3
Goodwill, Gross   5,103.6 5,040.3
Goodwill, Accumulated Amortization   (2.9) (2.9)
Goodwill   5,100.7 5,037.4
Licensing rights      
Finite-Lived Intangible Assets [Line Items]      
Finite-Lived Intangible Assets, Gross   57.0 57.0
Finite-Lived Intangible Assets, Accumulated Amortization   (37.5) (34.7)
Net   $ 19.5 22.3
Patents      
Finite-Lived Intangible Assets [Line Items]      
Finite-Lived Intangible Asset, Useful Life   7 years  
Finite-Lived Intangible Assets, Gross   $ 10.5 10.5
Finite-Lived Intangible Assets, Accumulated Amortization   (10.5) (10.5)
Net   0.0 0.0
Purchased technology      
Finite-Lived Intangible Assets [Line Items]      
Finite-Lived Intangible Assets, Gross   5,746.5 4,710.5
Finite-Lived Intangible Assets, Accumulated Amortization   (3,631.5) (1,388.7)
Net   $ 2,115.0 3,321.8
Impairment $ 2,042.3    
Other intangibles      
Finite-Lived Intangible Assets [Line Items]      
Finite-Lived Intangible Asset, Useful Life   5 years  
Finite-Lived Intangible Assets, Gross   $ 0.4 0.4
Finite-Lived Intangible Assets, Accumulated Amortization   (0.3) (0.2)
Net   $ 0.1 0.2
Minimum | Licensing rights      
Finite-Lived Intangible Assets [Line Items]      
Finite-Lived Intangible Asset, Useful Life   3 years  
Minimum | Purchased technology      
Finite-Lived Intangible Assets [Line Items]      
Finite-Lived Intangible Asset, Useful Life   6 years  
Maximum | Licensing rights      
Finite-Lived Intangible Assets [Line Items]      
Finite-Lived Intangible Asset, Useful Life   8 years  
Maximum | Purchased technology      
Finite-Lived Intangible Assets [Line Items]      
Finite-Lived Intangible Asset, Useful Life   16 years  
In-process research & development assets (IPR&D)      
Finite-Lived Intangible Assets [Line Items]      
Indefinite-Lived Intangible Assets, Gross (Excluding Goodwill)   $ 922.0 0.0
Indefinite-lived Intangible Assets (Excluding Goodwill)   $ 922.0 $ 0.0
Impairment $ 11.0    
XML 83 R45.htm IDEA: XBRL DOCUMENT v3.20.2
Intangible Assets and Goodwill (Narrative) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Jun. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Jul. 02, 2020
Jan. 28, 2020
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]                
Amortization of purchased intangible assets $ 54.1   $ 77.5 $ 203.4 $ 239.2      
2020 (remainder) 54.1     54.1        
2021 216.0     216.0        
2022 216.0     216.0        
2023 216.0     216.0        
2024 216.0     216.0        
2025 216.0     216.0        
Goodwill [Line Items]                
Goodwill 5,100.7     5,100.7       $ 5,037.4
Purchased technology                
Goodwill [Line Items]                
Impairment   $ 2,042.3            
Net 2,115.0     2,115.0       $ 3,321.8
KANUMA                
Goodwill [Line Items]                
Weighted average cost of capital   10.00%            
Net   $ 820.0            
In-process research & development assets (IPR&D)                
Goodwill [Line Items]                
Impairment   $ 11.0            
Achillion                
Goodwill [Line Items]                
Goodwill             $ 37.8  
Achillion | In-process research & development assets (IPR&D)                
Goodwill [Line Items]                
In-process research & development assets (IPR&D)             $ 918.0  
Portola Pharmaceuticals, Inc.                
Goodwill [Line Items]                
Goodwill           $ 25.5    
Portola Pharmaceuticals, Inc. | Purchased technology                
Goodwill [Line Items]                
Purchased techonology           $ 1,036.0    
Portola Pharmaceuticals, Inc. | In-process research & development assets (IPR&D)                
Goodwill [Line Items]                
In-process research & development assets (IPR&D) $ 15.0     $ 15.0        
XML 84 R46.htm IDEA: XBRL DOCUMENT v3.20.2
Intangible Assets and Goodwill (Changes in Goodwill) (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2020
USD ($)
Goodwill [Roll Forward]  
Balance at December 31, 2019 $ 5,037.4
Goodwill resulting from the acquisitions of Achillion and Portola 63.3
Balance at September 30, 2020 $ 5,100.7
XML 85 R47.htm IDEA: XBRL DOCUMENT v3.20.2
Debt (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Jul. 02, 2020
Feb. 28, 2017
Dec. 31, 2020
Sep. 30, 2020
Sep. 30, 2020
Sep. 30, 2019
Mar. 31, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Jun. 07, 2018
May 31, 2018
Debt Instrument [Line Items]                        
Amortization of deferred financing costs       $ 1,200,000   $ 1,300,000   $ 3,600,000 $ 3,800,000      
Remaining unamortized deferred financing costs       12,200,000 $ 12,200,000     12,200,000   $ 15,800,000    
Current portion of long-term debt       138,600,000 138,600,000     138,600,000   126,700,000    
Long-term debt, less current portion       2,453,300,000 2,453,300,000     2,453,300,000   $ 2,375,000,000.0    
Portola Pharmaceuticals, Inc.                        
Debt Instrument [Line Items]                        
Deferred tax assets, royalty debt $ 42,400                      
Repayments of debt 196,900,000                      
Credit Agreement                        
Debt Instrument [Line Items]                        
Payments of financing costs             $ 53,100,000          
Credit Agreement | Revolving Credit Facility                        
Debt Instrument [Line Items]                        
Line of credit facility, maximum borrowing capacity                     $ 1,000,000,000.0  
Letters of credit, amount outstanding       1,000,000.0 1,000,000.0     1,000,000.0        
Credit Agreement | Senior Secured Term Loan | Line of Credit                        
Debt Instrument [Line Items]                        
Debt instrument, principal amount                     $ 2,612,500,000  
Debt Instrument, quarterly payment as a percent of total borrowings                     5.00%  
Debt Instrument, Periodic Payment       (32,600,000)       (97,900,000)        
Outstanding debt       2,416,600,000 2,416,600,000     2,416,600,000        
Royalty-Based Financing Agreement | HealthCare Royalty Partners                        
Debt Instrument [Line Items]                        
Outstanding debt       $ 185,200,000 $ 185,200,000     $ 185,200,000        
Debt Instrument, Interest Rate, Effective Percentage       11.40% 11.40%     11.40%        
Interest Expense, Debt       $ 4,900,000       $ 4,900,000        
Repayments of debt       1,700,000 $ 1,700,000     1,700,000        
Current portion of long-term debt       11,700,000 11,700,000     11,700,000        
Long-term debt, less current portion       $ 173,500,000 $ 173,500,000     $ 173,500,000        
Royalty-Based Financing Agreement | HealthCare Royalty Partners | Portola Pharmaceuticals, Inc.                        
Debt Instrument [Line Items]                        
Outstanding debt 182,000,000.0                      
Total repayment obligation as of the acquisition date 276,900,000                      
Debt Instrument, Unamortized Discount 94,900,000                      
Royalty-Based Financing Agreement | HealthCare Royalty Partners | Portola Pharmaceuticals, Inc.                        
Debt Instrument [Line Items]                        
Royalty Agreement, Closing Day Payment   $ 50,000,000.0                    
Royalty Agreement, Milestone Payment Based On Regulatory Approval                       $ 100,000,000.0
Royalty Agreement, Maximum Potential Royalty Payments As A Percentage Of Funding Received   195.00%                    
Royalty Agreement, Maximum Potential Royalty Payments   $ 290,600,000                    
Repayments of debt $ 13,700,000                      
Royalty-Based Financing Agreement | HealthCare Royalty Partners | Portola Pharmaceuticals, Inc. | Minimum                        
Debt Instrument [Line Items]                        
Royalty Agreement, Tiered Royalty, Percent   4.20%                    
Royalty-Based Financing Agreement | HealthCare Royalty Partners | Portola Pharmaceuticals, Inc. | Maximum                        
Debt Instrument [Line Items]                        
Royalty Agreement, Tiered Royalty, Percent   8.50%                    
Royalty-Based Financing Agreement | Forecast [Member] | HealthCare Royalty Partners                        
Debt Instrument [Line Items]                        
Repayments of debt     $ 3,000,000.0                  
XML 86 R48.htm IDEA: XBRL DOCUMENT v3.20.2
Debt (Schedule of Debt) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Jul. 02, 2020
Sep. 30, 2020
Sep. 30, 2020
Sep. 30, 2020
Debt Instrument [Line Items]        
Less: interest to be accreted in future periods     $ (90.0)  
Portola Pharmaceuticals, Inc.        
Debt Instrument [Line Items]        
Less: payments made $ (196.9)      
HealthCare Royalty Partners | Royalty-Based Financing Agreement        
Debt Instrument [Line Items]        
Less: payments made   $ (1.7) (1.7) $ (1.7)
Outstanding debt   $ 185.2 $ 185.2 $ 185.2
HealthCare Royalty Partners | Portola Pharmaceuticals, Inc. | Royalty-Based Financing Agreement        
Debt Instrument [Line Items]        
Total repayment obligation as of the acquisition date 276.9      
Outstanding debt $ 182.0      
XML 87 R49.htm IDEA: XBRL DOCUMENT v3.20.2
Earnings Per Common Share (Summary Of Calculation Of Basic And Diluted Earnings Per Share) (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Earnings Per Common Share [Abstract]        
Net income used for basic and diluted calculation $ 578.1 $ 467.6 $ 67.6 $ 1,515.3
Shares used in computing earnings per common share—basic (in shares) 219.1 223.3 220.4 223.8
Stock awards (in shares) 1.5 1.2 1.5 1.6
Shares used in computing earnings per common share-diluted (in shares) 220.6 224.5 221.9 225.4
Earnings per common share        
Basic (in dollars per share) $ 2.64 $ 2.09 $ 0.31 $ 6.77
Diluted (in dollars per share) $ 2.62 $ 2.08 $ 0.30 $ 6.72
XML 88 R50.htm IDEA: XBRL DOCUMENT v3.20.2
Earnings Per Common Share (Narrative) (Details) - shares
shares in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Earnings Per Share [Abstract]        
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 2.5 3.3 1.8 3.1
XML 89 R51.htm IDEA: XBRL DOCUMENT v3.20.2
Marketable Securities (Proceeds from Sale) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Investments, Debt and Equity Securities [Abstract]        
Proceeds from maturities and sales $ 25.5 $ 645.4 $ 1,042.4 $ 2,271.7
Realized gains 0.0 0.0 0.0 0.0
Realized losses $ 0.0 $ 0.0 $ 0.0 $ 0.0
XML 90 R52.htm IDEA: XBRL DOCUMENT v3.20.2
Marketable Securities (Available-for-sale Investments by Classification in Balance Sheet) (Details) - USD ($)
$ in Millions
Sep. 30, 2020
Dec. 31, 2019
Debt Securities, Available-for-sale [Line Items]    
Fair Value $ 0.0 $ 369.0
Cash and Cash Equivalents    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 0.0 328.1
Marketable securities    
Debt Securities, Available-for-sale [Line Items]    
Fair Value $ 0.0 40.9
Commercial paper    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost   246.9
Gross Unrealized Holding Gains   0.0
Gross Unrealized Holding Losses   0.0
Fair Value   246.9
Corporate bonds    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost   24.3
Gross Unrealized Holding Gains   0.0
Gross Unrealized Holding Losses   0.0
Fair Value   24.3
U.S.    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost   70.4
Gross Unrealized Holding Gains   0.0
Gross Unrealized Holding Losses   0.0
Fair Value   70.4
Bank certificates of deposit    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost   27.4
Gross Unrealized Holding Gains   0.0
Gross Unrealized Holding Losses   0.0
Fair Value   27.4
Total available-for-sale debt securities    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost   369.0
Gross Unrealized Holding Gains   0.0
Gross Unrealized Holding Losses   0.0
Fair Value   $ 369.0
XML 91 R53.htm IDEA: XBRL DOCUMENT v3.20.2
Marketable Securities (Narrative) (Details) - USD ($)
$ in Millions
Sep. 30, 2020
Dec. 31, 2019
Investments, Debt and Equity Securities [Abstract]    
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value   $ 21.5
Trading securities. fair value $ 28.9 $ 23.1
XML 92 R54.htm IDEA: XBRL DOCUMENT v3.20.2
Derivative Instruments and Hedging Activities (Narrative) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Designated as Hedging Instrument        
Derivative [Line Items]        
Foreign Exchange Forward Contracts Term     60 months  
Not Designated as Hedging Instrument        
Derivative [Line Items]        
Foreign Exchange Forward Contracts Term 6 months      
Gain (Loss) on Fair Value Hedges Recognized in Earnings $ (6.2) $ 1.4 $ 6.8 $ (1.2)
Foreign exchange forward contracts | Designated as Hedging Instrument        
Derivative [Line Items]        
Notional amount of derivative instruments 1,029.0   1,029.0  
Foreign exchange forward contracts | Designated as Hedging Instrument | Revenue        
Derivative [Line Items]        
Estimated gains (losses) to be reclassified from other comprehenisve income in next 12 months 13.6      
Foreign exchange forward contracts | Not Designated as Hedging Instrument        
Derivative [Line Items]        
Notional amount of derivative instruments 1,253.0   1,253.0  
Foreign Exchange Forward, Open Expense | Designated as Hedging Instrument        
Derivative [Line Items]        
Notional amount of derivative instruments 10.0   $ 10.0  
Interest rate contracts | Designated as Hedging Instrument        
Derivative [Line Items]        
Estimated gains (losses) to be reclassified from other comprehenisve income in next 12 months $ 45.6      
XML 93 R55.htm IDEA: XBRL DOCUMENT v3.20.2
Derivative Instruments and Hedging Activities (Schedule of Interest Rate Contracts) (Details) - Designated as Hedging Instrument - Interest Rate Swap
$ in Millions
Sep. 30, 2020
USD ($)
Derivative [Line Items]  
Derivative, notional amount $ 450.0
Derivative, notional amount $ 1,300.0
Minimum  
Derivative [Line Items]  
Derivative, fixed interest rate 2.60%
Minimum  
Derivative [Line Items]  
Derivative, fixed interest rate 2.37%
Maximum  
Derivative [Line Items]  
Derivative, fixed interest rate 2.79%
Maximum  
Derivative [Line Items]  
Derivative, fixed interest rate 2.83%
XML 94 R56.htm IDEA: XBRL DOCUMENT v3.20.2
Derivative Instruments and Hedging Activities (Schedule Of Other Comprehensive Income And Earnings From Foreign Exchange Contracts) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Derivative Instruments, Gain (Loss) [Line Items]        
Total revenues $ 1,588.7 $ 1,263.1 $ 4,478.1 $ 3,606.8
Interest expense (27.6) (17.9) (77.0) (56.1)
Foreign exchange forward contracts | Cash Flow Hedging        
Derivative Instruments, Gain (Loss) [Line Items]        
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax (22.9) 30.5 (3.0) 40.8
Foreign exchange forward contracts | Sales | Cash Flow Hedging        
Derivative Instruments, Gain (Loss) [Line Items]        
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax (4.0) 8.6 12.2 21.0
Interest rate contracts | Cash Flow Hedging        
Derivative Instruments, Gain (Loss) [Line Items]        
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax 0.1 (7.1) (52.6) (45.9)
Interest rate contracts | Interest Expense | Cash Flow Hedging        
Derivative Instruments, Gain (Loss) [Line Items]        
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax (8.8) 2.6 (20.1) 9.6
Reclassification out of Accumulated Other Comprehensive Income | Unrealized Gains (Losses) from Hedging Activities        
Derivative Instruments, Gain (Loss) [Line Items]        
Total revenues (5.0) 11.0 15.9 27.1
Interest expense 11.3 (3.4) 25.9 (12.5)
Reclassification out of Accumulated Other Comprehensive Income | Unrealized Gains (Losses) from Hedging Activities | Foreign exchange forward contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Total revenues (5.0) 11.0 15.9 27.1
Interest expense 0.0 0.0 0.0 0.0
Reclassification out of Accumulated Other Comprehensive Income | Unrealized Gains (Losses) from Hedging Activities | Interest rate contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Total revenues 0.0 0.0 0.0 0.0
Interest expense $ 11.3 $ (3.4) $ 25.9 $ (12.5)
XML 95 R57.htm IDEA: XBRL DOCUMENT v3.20.2
Derivative Instruments and Hedging Activities (Schedule Of Fair Value Of Outstanding Derivatives) (Details) - USD ($)
$ in Millions
Sep. 30, 2020
Dec. 31, 2019
Derivatives, Fair Value [Line Items]    
Asset Derivatives, Fair Value $ 12.1 $ 30.5
Liability Derivatives, Fair Value 128.3 89.1
Interest rate contracts | Other current liabilities | Designated as Hedging Instrument    
Derivatives, Fair Value [Line Items]    
Liability Derivatives, Fair Value 45.6 19.5
Interest rate contracts | Other liabilities | Designated as Hedging Instrument    
Derivatives, Fair Value [Line Items]    
Liability Derivatives, Fair Value 57.6 41.9
Foreign exchange forward contracts    
Derivatives, Fair Value [Line Items]    
Asset Derivatives, Fair Value 12.1 30.5
Liability Derivatives, Fair Value 128.3 89.1
Foreign exchange forward contracts | Other current liabilities | Designated as Hedging Instrument    
Derivatives, Fair Value [Line Items]    
Liability Derivatives, Fair Value 16.8 6.2
Foreign exchange forward contracts | Other assets | Designated as Hedging Instrument    
Derivatives, Fair Value [Line Items]    
Asset Derivatives, Fair Value 0.4 0.6
Foreign exchange forward contracts | Other liabilities | Designated as Hedging Instrument    
Derivatives, Fair Value [Line Items]    
Liability Derivatives, Fair Value 0.3 1.1
Foreign exchange forward contracts | Prepaid expenses and other current assets | Designated as Hedging Instrument    
Derivatives, Fair Value [Line Items]    
Asset Derivatives, Fair Value 3.0 12.7
Foreign exchange forward contracts | Foreign exchange forward contracts | Other current liabilities | Not Designated as Hedging Instrument    
Derivatives, Fair Value [Line Items]    
Liability Derivatives, Fair Value 8.0 20.4
Foreign exchange forward contracts | Foreign exchange forward contracts | Prepaid expenses and other current assets | Not Designated as Hedging Instrument    
Derivatives, Fair Value [Line Items]    
Asset Derivatives, Fair Value 8.7 17.2
Interest rate contracts | Interest rate contracts | Other assets | Designated as Hedging Instrument    
Derivatives, Fair Value [Line Items]    
Interest Rate Derivative Assets, at Fair Value 0.0 0.0
Interest rate contracts | Interest rate contracts | Prepaid expenses and other current assets | Designated as Hedging Instrument    
Derivatives, Fair Value [Line Items]    
Interest Rate Derivative Assets, at Fair Value $ 0.0 $ 0.0
XML 96 R58.htm IDEA: XBRL DOCUMENT v3.20.2
Derivative Instruments and Hedging Activities (Offsetting Assets and Liabilities) (Details) - USD ($)
$ in Millions
Sep. 30, 2020
Dec. 31, 2019
Derivative Asset, Fair Value, Amount Offset Against Collateral [Abstract]    
Gross Amounts of Recognized Assets $ 12.1 $ 30.5
Derivative Liability, Fair Value, Amount Offset Against Collateral [Abstract]    
Gross Amounts of Recognized Liabilities (128.3) (89.1)
Foreign exchange forward contracts    
Derivative Asset, Fair Value, Amount Offset Against Collateral [Abstract]    
Gross Amounts of Recognized Assets 12.1 30.5
Gross Amounts Offset in the Condensed Consolidated Balance Sheet 0.0 0.0
Amounts of Assets Presented in the Condensed Consolidated Balance Sheet 12.1 30.5
Derivative Financial Instruments (11.4) (21.4)
Cash Collateral Received 0.0 0.0
Net Amount 0.7 9.1
Derivative Liability, Fair Value, Amount Offset Against Collateral [Abstract]    
Gross Amounts of Recognized Liabilities (128.3) (89.1)
Gross Amounts Offset in the Condensed Consolidated Balance Sheet 0.0 0.0
Amounts of Liabilities Presented in the Condensed Consolidated Balance Sheet (128.3) (89.1)
Derivative Financial Instruments 11.4 21.4
Cash Collateral Pledged 0.0 0.0
Net Amount $ (116.9) $ (67.7)
XML 97 R59.htm IDEA: XBRL DOCUMENT v3.20.2
Other Investments (Details) - USD ($)
$ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jul. 17, 2020
Jul. 02, 2020
Dec. 09, 2019
Apr. 30, 2020
Mar. 31, 2020
Oct. 31, 2019
Sep. 30, 2019
Mar. 31, 2019
Jan. 31, 2019
Oct. 31, 2018
Sep. 30, 2020
Dec. 31, 2019
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Dec. 31, 2014
Schedule of Equity Method Investments [Line Items]                                  
Payments to Acquire Other Investments                           $ 38.1 $ 63.7    
Other income and (expense)                     $ (1.9)   $ 0.4 (2.6) 2.9    
Unrealized Gain (Loss) on Investments                           4.6 20.6    
Gain (Loss) on Disposition of Assets                     14.8   0.0 14.8 0.0    
Zealand                                  
Schedule of Equity Method Investments [Line Items]                                  
Unrealized Gain (Loss) on Investments                     1.8   3.7 0.8 7.3    
Equity Securities, FV-NI                     30.5 $ 28.5   30.5   $ 28.5  
Payments to Acquire Equity Method Investments               $ 13.8                  
Moderna LLC                                  
Schedule of Equity Method Investments [Line Items]                                  
Payments to Acquire Other Investments                                 $ 37.5
Unrealized Gain (Loss) on Investments                         12.3   13.1    
Proceeds from Sale of Equity Method Investments     $ 114.7                            
Equity Method Investment, Realized Gain (Loss) on Disposal     $ 77.2                            
Dicerna                                  
Schedule of Equity Method Investments [Line Items]                                  
Unrealized Gain (Loss) on Investments                     (6.2)   (1.1) (3.4) 3.1    
Equity Securities, FV-NI                     15.0 18.4   15.0   18.4  
Payments to Acquire Equity Method Investments                   $ 10.3              
Caelum                                  
Schedule of Equity Method Investments [Line Items]                                  
Payments to Acquire Other Investments                 $ 41.0         41.0   41.0  
Option To Acquire Remaining Equity, Amount                 $ 16.1                
Other income and (expense)                       32.0          
Caelum Biosciences, Option                                  
Schedule of Equity Method Investments [Line Items]                                  
Payments to Acquire Other Investments                           64.0   64.0  
Eidos                                  
Schedule of Equity Method Investments [Line Items]                                  
Unrealized Gain (Loss) on Investments                     3.4   (2.9) 0.3 (2.9)    
Equity Securities, FV-NI                     28.1 27.8   28.1   27.8  
Payments to Acquire Equity Method Investments             $ 19.9                    
Stealth                                  
Schedule of Equity Method Investments [Line Items]                                  
Unrealized Gain (Loss) on Investments                     (0.7)     (2.6)      
Equity Securities, FV-NI                     1.8 4.4   1.8   $ 4.4  
Payments to Acquire Equity Method Investments           $ 9.6                      
Portola Pharmaceuticals                                  
Schedule of Equity Method Investments [Line Items]                                  
Payments to Acquire Other Investments       $ 3.6 $ 14.5                        
Unrealized Gain (Loss) on Investments                     (0.1)     (29.7)      
Equity Method Investment, Realized Gain (Loss) on Disposal   $ 29.7                              
Equity Securities, FV-NI   $ 47.8                              
Inozyme                                  
Schedule of Equity Method Investments [Line Items]                                  
Unrealized Gain (Loss) on Investments                     10.2     10.2      
Equity Securities, FV-NI                     25.0     25.0      
Gain (Loss) on Disposition of Assets $ 14.8                                
Collaborative Arrangement | Caelum                                  
Schedule of Equity Method Investments [Line Items]                                  
Collaboration Agreement, Potential Future Payments                       20.0          
Research and development                     $ 3.6   $ 0.2 $ 6.0 $ 0.5    
Collaborative Agreement, Amendment | Caelum                                  
Schedule of Equity Method Investments [Line Items]                                  
Research and development                       $ 4.1          
XML 98 R60.htm IDEA: XBRL DOCUMENT v3.20.2
Stockholders' Equity (Details) - USD ($)
shares in Millions, $ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
Oct. 29, 2020
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Oct. 27, 2020
Jul. 28, 2020
Oct. 22, 2019
Feb. 28, 2017
Class of Stock [Line Items]                  
Treasury Stock, Shares, Acquired   0.6 3.1 4.2 3.5        
Treasury Stock, Value, Acquired, Cost Method   $ 73.5 $ 334.6 $ 434.3 $ 383.5        
Common Stock                  
Class of Stock [Line Items]                  
Repurchase authorization amount             $ 1,500.0 $ 1,000.0 $ 1,000.0
Subsequent Event | Common Stock                  
Class of Stock [Line Items]                  
Treasury Stock, Shares, Acquired 0.4                
Treasury Stock, Value, Acquired, Cost Method $ 45.2                
Remaining authorized repurchase amount           $ 2,055.9      
XML 99 R61.htm IDEA: XBRL DOCUMENT v3.20.2
Other Comprehensive Income and Accumulated Other Comprehensive Income (Changes in AOCI) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Beginning Balance     $ (66.8) $ (9.7)
Other comprehensive income (loss) before reclassifications     (60.3) (7.9)
Amounts reclassified from other comprehensive income     7.9 (30.6)
Other comprehensive (loss) income, net of tax $ (8.3) $ 9.7 (52.4) (38.5)
Ending Balance (119.2) (48.2) (119.2) (48.2)
Defined Benefit Pension Plans        
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Beginning Balance     (9.2) (2.6)
Other comprehensive income (loss) before reclassifications     0.0 0.0
Amounts reclassified from other comprehensive income     0.0 0.0
Other comprehensive (loss) income, net of tax     0.0 0.0
Ending Balance (9.2) (2.6) (9.2) (2.6)
Unrealized Gains (Losses) from Debt Securities        
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Beginning Balance     (0.1) (0.3)
Other comprehensive income (loss) before reclassifications     0.1 0.2
Amounts reclassified from other comprehensive income     0.0 0.0
Other comprehensive (loss) income, net of tax     0.1 0.2
Ending Balance 0.0 (0.1) 0.0 (0.1)
Unrealized Gains (Losses) from Hedging Activities        
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Beginning Balance     (40.1) 9.6
Other comprehensive income (loss) before reclassifications     (55.1) (5.1)
Amounts reclassified from other comprehensive income     7.9 (30.6)
Other comprehensive (loss) income, net of tax     (47.2) (35.7)
Ending Balance (87.3) (26.1) (87.3) (26.1)
Foreign Currency Translation Adjustment        
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Beginning Balance     (17.4) (16.4)
Other comprehensive income (loss) before reclassifications     (5.3) (3.0)
Amounts reclassified from other comprehensive income     0.0 0.0
Other comprehensive (loss) income, net of tax     (5.3) (3.0)
Ending Balance $ (22.7) $ (19.4) $ (22.7) $ (19.4)
XML 100 R62.htm IDEA: XBRL DOCUMENT v3.20.2
Other Comprehensive Income and Accumulated Other Comprehensive Income (Significant Reclassifications from AOCI) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Reclassification out of Accumulated Other Comprehensive Income [Line Items]        
Total revenues $ 1,588.7 $ 1,263.1 $ 4,478.1 $ 3,606.8
Interest expense 27.6 17.9 77.0 56.1
Income (loss) before income taxes 666.9 535.5 (21.6) 1,576.8
Income tax provision (88.8) (67.9) 89.2 (61.5)
Net income 578.1 467.6 67.6 1,515.3
Unrealized Gains (Losses) from Hedging Activities | Reclassification out of Accumulated Other Comprehensive Income        
Reclassification out of Accumulated Other Comprehensive Income [Line Items]        
Total revenues (5.0) 11.0 15.9 27.1
Interest expense (11.3) 3.4 (25.9) 12.5
Income (loss) before income taxes (16.3) 14.4 (10.0) 39.6
Income tax provision 3.5 (3.2) 2.1 (9.0)
Net income $ (12.8) $ 11.2 $ (7.9) $ 30.6
XML 101 R63.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurement (Schedule Of Assets And Liabilites Measured At Fair Value) (Details) - USD ($)
$ in Millions
Sep. 30, 2020
Dec. 31, 2019
Other assets    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities  
Foreign exchange forward contracts | Other current liabilities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Foreign exchange forward contracts, liability 24.8 $ 26.6
Foreign exchange forward contracts | Other current liabilities | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Foreign exchange forward contracts, liability 0.0 0.0
Foreign exchange forward contracts | Other current liabilities | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Foreign exchange forward contracts, liability 24.8 26.6
Foreign exchange forward contracts | Other current liabilities | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Foreign exchange forward contracts, liability 0.0 0.0
Foreign exchange forward contracts | Other liabilities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Foreign exchange forward contracts, liability 0.3 1.1
Foreign exchange forward contracts | Other liabilities | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Foreign exchange forward contracts, liability 0.0 0.0
Foreign exchange forward contracts | Other liabilities | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Foreign exchange forward contracts, liability 0.3 1.1
Foreign exchange forward contracts | Other liabilities | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Foreign exchange forward contracts, liability 0.0 0.0
Acquisition-related contingent consideration | Contingent consideration    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Business Combination, Contingent Consideration, Liability 398.1 192.4
Acquisition-related contingent consideration | Contingent consideration | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Business Combination, Contingent Consideration, Liability 0.0 0.0
Acquisition-related contingent consideration | Contingent consideration | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Business Combination, Contingent Consideration, Liability 0.0 0.0
Acquisition-related contingent consideration | Contingent consideration | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Business Combination, Contingent Consideration, Liability 398.1 192.4
Other contingent payments | Other current liabilities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Business Combination, Contingent Consideration, Liability   24.0
Other contingent payments | Other current liabilities | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Business Combination, Contingent Consideration, Liability   0.0
Other contingent payments | Other current liabilities | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Business Combination, Contingent Consideration, Liability   0.0
Other contingent payments | Other current liabilities | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Business Combination, Contingent Consideration, Liability   24.0
Money market funds | Cash equivalents    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 424.9 635.9
Money market funds | Cash equivalents | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0.0 0.0
Money market funds | Cash equivalents | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 424.9 635.9
Money market funds | Cash equivalents | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0.0 0.0
Mutual funds | Marketable securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities 28.9 23.1
Mutual funds | Marketable securities | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities 28.9 23.1
Mutual funds | Marketable securities | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities 0.0 0.0
Mutual funds | Marketable securities | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities 0.0 0.0
Equity securities | Other assets    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities 100.4 79.0
Equity securities | Other assets | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities 75.4 51.2
Equity securities | Other assets | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities 25.0 27.8
Equity securities | Other assets | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities 0.0 0.0
Foreign exchange forward contracts | Prepaid expenses and other current assets    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Foreign exchange forward contracts, asset 11.7 29.9
Foreign exchange forward contracts | Prepaid expenses and other current assets | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Foreign exchange forward contracts, asset 0.0 0.0
Foreign exchange forward contracts | Prepaid expenses and other current assets | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Foreign exchange forward contracts, asset 11.7 29.9
Foreign exchange forward contracts | Prepaid expenses and other current assets | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Foreign exchange forward contracts, asset 0.0 0.0
Foreign exchange forward contracts | Other assets    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Foreign exchange forward contracts, asset 0.4 0.6
Foreign exchange forward contracts | Other assets | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Foreign exchange forward contracts, asset 0.0 0.0
Foreign exchange forward contracts | Other assets | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Foreign exchange forward contracts, asset 0.4 0.6
Foreign exchange forward contracts | Other assets | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Foreign exchange forward contracts, asset 0.0 0.0
Interest rate contracts | Other current liabilities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Interest Rate Derivative Liabilities, at Fair Value 45.6 19.5
Interest rate contracts | Other current liabilities | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Interest Rate Derivative Assets, at Fair Value   0.0
Interest Rate Derivative Liabilities, at Fair Value 0.0  
Interest rate contracts | Other current liabilities | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Interest Rate Derivative Liabilities, at Fair Value 45.6 19.5
Interest rate contracts | Other current liabilities | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Interest Rate Derivative Assets, at Fair Value   0.0
Interest Rate Derivative Liabilities, at Fair Value 0.0  
Interest rate contracts | Other liabilities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Interest Rate Derivative Assets, at Fair Value 57.6 41.9
Interest rate contracts | Other liabilities | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Interest Rate Derivative Assets, at Fair Value 0.0 0.0
Interest rate contracts | Other liabilities | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Interest Rate Derivative Assets, at Fair Value 57.6 41.9
Interest rate contracts | Other liabilities | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Interest Rate Derivative Assets, at Fair Value $ 0.0 0.0
Commercial paper | Cash equivalents    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents   227.9
Commercial paper | Cash equivalents | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents   0.0
Commercial paper | Cash equivalents | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents   227.9
Commercial paper | Cash equivalents | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents   0.0
Commercial paper | Marketable securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities   19.0
Commercial paper | Marketable securities | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities   0.0
Commercial paper | Marketable securities | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities   19.0
Commercial paper | Marketable securities | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities   0.0
Corporate bonds | Cash equivalents    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents   20.6
Corporate bonds | Cash equivalents | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents   0.0
Corporate bonds | Cash equivalents | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents   20.6
Corporate bonds | Cash equivalents | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents   0.0
Corporate bonds | Marketable securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities   3.7
Corporate bonds | Marketable securities | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities   0.0
Corporate bonds | Marketable securities | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities   3.7
Corporate bonds | Marketable securities | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities   0.0
Bank certificates of deposit | Cash equivalents    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents   19.2
Bank certificates of deposit | Cash equivalents | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents   0.0
Bank certificates of deposit | Cash equivalents | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents   19.2
Bank certificates of deposit | Cash equivalents | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents   0.0
Bank certificates of deposit | Marketable securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities   8.2
Bank certificates of deposit | Marketable securities | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities   0.0
Bank certificates of deposit | Marketable securities | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities   8.2
Bank certificates of deposit | Marketable securities | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities   0.0
Other government-related obligations | Cash equivalents    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents   60.4
Other government-related obligations | Cash equivalents | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents   0.0
Other government-related obligations | Cash equivalents | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents   60.4
Other government-related obligations | Cash equivalents | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents   0.0
Other government-related obligations | Marketable securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities   10.0
Other government-related obligations | Marketable securities | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities   0.0
Other government-related obligations | Marketable securities | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities   10.0
Other government-related obligations | Marketable securities | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities   $ 0.0
XML 102 R64.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurement (Schedule Of Acquisition-Related Contingent Consideration) (Details)
$ in Millions
 9 Months Ended
Jan. 28, 2020
Sep. 30, 2020
USD ($)
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]    
Fair Value Inputs, Weighted Average Cost of Capital   11.50%
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low   $ 0.0
Business Combination, Contingent Consideration, Arrangements, Range of Outcomes, Value, High   905.6
Acquisition-Related Contingent Consideration [Roll Forward]    
Asset Acquisition, Contingent Consideration, Milestone Payments   160.7
Acquisition-related contingent consideration | Level 3    
Acquisition-Related Contingent Consideration [Roll Forward]    
Balance at beginning of period   192.4
Change in fair value   45.0
Balance at end of period   $ 398.1
Acquisition-related contingent consideration | Minimum | Level 3    
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]    
Fair Value Inputs, Cost of Debt 2.10% 3.90%
Fair Value Inputs, Weighted Average Cost of Capital   9.00%
Acquisition-related contingent consideration | Maximum | Level 3    
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]    
Fair Value Inputs, Cost of Debt 2.30% 4.30%
XML 103 R65.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurement (Narrative) (Details) - Caelum - Collaborative Arrangement - USD ($)
$ in Millions
 1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended
Dec. 31, 2019
Jan. 31, 2019
Sep. 30, 2020
Jun. 30, 2020
Dec. 31, 2019
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2020
Sep. 30, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                  
Collaboration Agreement, Upfront Payment   $ 30.0              
Collaboration Agreement, Potential Future Payments, Milestone Achievement   $ 30.0 $ 15.0            
Derivative Liability $ 27.1       $ 27.1        
Collaboration Agreement, Potential Future Payments         $ 20.0        
Collaboration Agreement, Payment For Additional Equity Interest $ 60.0                
Collaboration Agreement, Milestone Payment       $ 15.0     $ 30.0    
Research and development     $ 3.6     $ 0.2   $ 6.0 $ 0.5
Minimum                  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                  
Derivative Fair Value, Discounted Cost Of Debt   3.30%              
Maximum                  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                  
Derivative Fair Value, Discounted Cost Of Debt   3.50%              
XML 104 R66.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue Recognition (Disaggregation of Revenue by Product and Geographical Region) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Total Net Product Sales $ 1,588.7 $ 1,263.1 $ 4,478.1 $ 3,606.8
SOLIRIS        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Total Net Product Sales 1,042.3 990.5 3,040.7 2,933.3
ULTOMIRIS        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Total Net Product Sales 289.3 89.9 763.2 168.7
STRENSIQ        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Total Net Product Sales 189.4 154.3 545.9 425.7
ANDEXXA        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Total Net Product Sales 38.9 0.0 38.9 0.0
KANUMA        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Total Net Product Sales 28.4 28.4 88.7 78.1
United States | SOLIRIS        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Total Net Product Sales 562.8 496.8 1,672.3 1,456.8
United States | ULTOMIRIS        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Total Net Product Sales 170.7 65.1 460.3 143.9
United States | STRENSIQ        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Total Net Product Sales 149.3 118.0 418.1 323.7
United States | ANDEXXA        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Total Net Product Sales 36.2 0.0 36.2 0.0
United States | KANUMA        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Total Net Product Sales 15.8 16.0 47.6 45.1
Europe | SOLIRIS        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Total Net Product Sales 254.3 255.5 765.7 800.2
Europe | ULTOMIRIS        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Total Net Product Sales 46.6 21.1 112.4 21.1
Europe | STRENSIQ        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Total Net Product Sales 19.3 19.0 61.6 56.0
Europe | ANDEXXA        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Total Net Product Sales 2.7 0.0 2.7 0.0
Europe | KANUMA        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Total Net Product Sales 9.5 6.3 25.4 19.4
Asia Pacific | SOLIRIS        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Total Net Product Sales 86.0 118.0 255.5 329.2
Asia Pacific | ULTOMIRIS        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Total Net Product Sales 69.6 3.7 186.3 3.7
Asia Pacific | STRENSIQ        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Total Net Product Sales 16.1 14.0 44.7 36.0
Asia Pacific | ANDEXXA        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Total Net Product Sales 0.0 0.0 0.0 0.0
Asia Pacific | KANUMA        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Total Net Product Sales 1.1 1.3 2.9 3.4
Rest of World | SOLIRIS        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Total Net Product Sales 139.2 120.2 347.2 347.1
Rest of World | ULTOMIRIS        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Total Net Product Sales 2.4 0.0 4.2 0.0
Rest of World | STRENSIQ        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Total Net Product Sales 4.7 3.3 21.5 10.0
Rest of World | ANDEXXA        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Total Net Product Sales 0.0 0.0 0.0 0.0
Rest of World | KANUMA        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Total Net Product Sales 2.0 4.8 12.8 10.2
Product        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Total Net Product Sales $ 1,588.3 $ 1,263.1 $ 4,477.4 $ 3,605.8
XML 105 R67.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue Recognition (Summary of Receivables and Contract Liabilities from Contracts) (Details) - USD ($)
$ in Millions
Sep. 30, 2020
Dec. 31, 2019
Revenue from Contract with Customer [Abstract]    
Receivables, which are included in Trade accounts receivable, net $ 1,437.1 $ 1,243.2
Contract liabilities, which are included in Other current liabilities $ 22.7 $ 6.8
XML 106 R68.htm IDEA: XBRL DOCUMENT v3.20.2
Income Taxes (Schedule of Income Tax Provision and Effective Tax Rate) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Income Tax Disclosure [Abstract]        
Provision for income taxes $ 88.8 $ 67.9 $ (89.2) $ 61.5
Effective tax rate 13.30% 12.70% 413.00% 3.90%
XML 107 R69.htm IDEA: XBRL DOCUMENT v3.20.2
Income Taxes (Narrative) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended 12 Months Ended
Jun. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2018
Schedule Of Asset Acquisition, By Acquisition [Line Items]          
Effective Income Tax Rate Reconciliation, Intangible Asset Impairment, Percent     399.60%    
Effective Income Tax Rate Reconciliation, Deduction, Percent       8.00%  
Income Tax Expense (Benefit), Foreign-Derived Intangible Income   $ 29.9     $ 17.0
Effective Income Tax Rate Reconciliation Deduction, Foreign-Derived Intangible Income, Percent   5.60%   1.90%  
Purchased technology          
Schedule Of Asset Acquisition, By Acquisition [Line Items]          
Impairment $ 2,042.3        
Intangible Asset Impairment          
Schedule Of Asset Acquisition, By Acquisition [Line Items]          
Deferred Income Tax Expense (Benefit) $ (377.3)        
Intellectual Property Election          
Schedule Of Asset Acquisition, By Acquisition [Line Items]          
Deferred Income Tax Expense (Benefit)       $ (95.7)  
Valuation Allowance Release          
Schedule Of Asset Acquisition, By Acquisition [Line Items]          
Deferred Income Tax Expense (Benefit)       $ (30.3)  
XML 108 R70.htm IDEA: XBRL DOCUMENT v3.20.2
Commitments and Contingencies (Narrative) (Details) - USD ($)
$ in Millions
 1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended
Jul. 02, 2020
Dec. 31, 2019
Sep. 30, 2019
Apr. 30, 2019
Mar. 31, 2019
Jan. 31, 2019
Nov. 30, 2018
Oct. 31, 2018
Sep. 30, 2020
Jun. 30, 2020
Dec. 31, 2019
Sep. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Sep. 30, 2020
Sep. 30, 2020
Sep. 30, 2019
Oct. 27, 2020
Other Commitments [Line Items]                                      
Asset Acquisition, Contingent Consideration, Milestone Payments                                 $ 160.7    
Research and development                 $ 285.9     $ 232.9         707.9 $ 616.4  
Lonza Group AG                                      
Other Commitments [Line Items]                                      
Remaining total commitments                 1,432.3             $ 1,432.3 1,432.3    
Unrecorded Unconditional Purchase Obligation, Undiscounted Fixed Payment Amount                 105.5             105.5 105.5    
Other Third Party Manufacturers                                      
Other Commitments [Line Items]                                      
Remaining total commitments                 78.6             78.6 78.6    
Collaborative Arrangement | Caelum                                      
Other Commitments [Line Items]                                      
Collaboration Agreement, Upfront Payment           $ 30.0                          
Research and development                 3.6     0.2         6.0 $ 0.5  
Collaboration Agreement, Potential Future Payments, Milestone Achievement           30.0     15.0                    
Derivative Liability   $ 27.1                 $ 27.1                
Collaboration Agreement, Acquisition Option, Maximum Potential Future Payment           500.0                          
Collaboration Agreement, Milestone Payment                   $ 15.0           30.0      
Collaboration Agreement, Potential Future Payments                     20.0                
Collaboration Agreement, Payment For Additional Equity Interest   $ 60.0                                  
Zealand | Zealand                                      
Other Commitments [Line Items]                                      
Payments To Acquire Licenses And Equity Investment         $ 40.0                            
Prepaid Research And Development Expense         5.0               $ 5.0            
Research and development                         $ 21.2            
Collaboration Agreement, Potential Future Payments, Milestone Achievement                                 610.0    
Collaboration Agreement, Potential Future Payments, Additional Milestone Achievement                                 115.0    
Collaboration Agreement, Potential Future Payments, Option Fee                                 15.0    
Affibody AB | Affibody                                      
Other Commitments [Line Items]                                      
Payments To Acquire Licenses And Equity Investment       $ 25.0                              
Affibody AB | Eidos                                      
Other Commitments [Line Items]                                      
Payments To Acquire Licenses And Equity Investment     $ 50.0                                
Research and development                       $ 30.1              
Collaboration Agreement, Potential Future Payments, Milestone Achievement                                 30.0    
Dicerna Pharmaceutical Collaboration Agreement | Dicerna                                      
Other Commitments [Line Items]                                      
Payments To Acquire Licenses And Equity Investment               $ 37.0                      
Research and development                     $ 20.0     $ 26.7          
Research and Development Arrangement, Potential Payment, Maximum                 604.1             604.1 604.1    
License Agreement 1 | Halozyme Therapeutics, Inc                                      
Other Commitments [Line Items]                                      
Research and Development Arrangement, Potential Payment, Maximum                 155.0             155.0 155.0    
Research and development                             $ 40.0        
Research and Development Agreement, Option Fee                 8.0             8.0 8.0    
Research and Development Arrangement, Potential Contingent Payment, Maximum                 160.0             160.0 160.0    
Collaboration and License Agreement                                      
Other Commitments [Line Items]                                      
Collaboration Agreement, Potential Future Payments, Milestone Achievement                                 114.0    
Eidos                                      
Other Commitments [Line Items]                                      
Payments to Acquire Equity Method Investments     $ 19.9                                
Caelum | Collaborative Arrangement                                      
Other Commitments [Line Items]                                      
Equity Method Investment, Aggregate Cost           $ 57.1                          
Zealand                                      
Other Commitments [Line Items]                                      
Payments to Acquire Equity Method Investments         $ 13.8                            
Dicerna                                      
Other Commitments [Line Items]                                      
Payments to Acquire Equity Method Investments               $ 10.3                      
SEC                                      
Other Commitments [Line Items]                                      
Litigation Settlement, Amount Awarded to Other Party $ 21.5                                    
DOJ And OIG                                      
Other Commitments [Line Items]                                      
Loss Contingency Accrual, Payments       $ 13.1                              
Canadian Patented Medicine Prices Review Board                                      
Other Commitments [Line Items]                                      
Loss Contingency, Estimate of Possible Loss                 42.2             $ 42.2 $ 42.2    
Syntimmune, Inc                                      
Other Commitments [Line Items]                                      
Asset Acquisition, Contingent Consideration, Milestone Payments             $ 800.0                        
Syntimmune, Inc | Subcutaneous Formulation                                      
Other Commitments [Line Items]                                      
Asset Acquisition, Contingent Consideration, Milestone Payments             $ 130.0                        
Astellas Pharam [Member]                                      
Other Commitments [Line Items]                                      
Asset Acquisition, Contingent Consideration, Milestone Payments                 $ 71.5                    
Subsequent Event | Canadian Patented Medicine Prices Review Board                                      
Other Commitments [Line Items]                                      
Escrow Deposit                                     $ 61.5
XML 109 R71.htm IDEA: XBRL DOCUMENT v3.20.2
Restructuring and Related Expenses (Narrative) (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2020
Jun. 30, 2020
Dec. 31, 2019
Restructuring and Related Activities [Abstract]      
Restructuring and Related Cost, Expected Cost $ 25.0    
Restructuring Reserve 15.9 $ 1.6 $ 6.8
Estimated additional charges $ 11.0    
XML 110 R72.htm IDEA: XBRL DOCUMENT v3.20.2
Restructuring and Related Expenses (Schedule of Restructuring and related Costs) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Restructuring Cost and Reserve [Line Items]        
Restructuring expenses $ 14.3 $ 0.3 $ 13.5 $ 11.9
Employee Separation Costs        
Restructuring Cost and Reserve [Line Items]        
Restructuring expenses 14.3 (2.8) 14.0 8.7
Other        
Restructuring Cost and Reserve [Line Items]        
Restructuring expenses $ 0.0 $ 3.1 $ (0.5) $ 3.2
XML 111 R73.htm IDEA: XBRL DOCUMENT v3.20.2
Restructuring and Related Expenses (Restructuring Reserve Roll Forward) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2020
Restructuring Reserve [Roll Forward]    
Beginning Balance $ 1.6 $ 6.8
Charges 14.3 14.3
Settlements 0.0 (4.4)
Adjustments to previous estimates 0.0 (0.8)
Ending Balance 15.9 15.9
Employee Separation Costs    
Restructuring Reserve [Roll Forward]    
Beginning Balance 1.6 3.3
Charges 14.3 14.3
Settlements 0.0 (1.4)
Adjustments to previous estimates 0.0 (0.3)
Ending Balance 15.9 15.9
Other    
Restructuring Reserve [Roll Forward]    
Beginning Balance 0.0 3.5
Charges 0.0 0.0
Settlements 0.0 (3.0)
Adjustments to previous estimates 0.0 (0.5)
Ending Balance $ 0.0 $ 0.0
EXCEL 112 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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c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end XML 113 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 114 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 115 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 572 440 1 false 124 0 false 4 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.alxn.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.alxn.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.alxn.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income Statement Sheet http://www.alxn.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeStatement Condensed Consolidated Statements of Comprehensive Income Statement Statements 5 false false R6.htm 1005006 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical) Sheet http://www.alxn.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical Condensed Consolidated Statements of Comprehensive Income (Parenthetical) Statements 6 false false R7.htm 1006007 - Statement - Condensed Consolidated Statements of Changes in Stockholder's Equity Statement Sheet http://www.alxn.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityStatement Condensed Consolidated Statements of Changes in Stockholder's Equity Statement Statements 7 false false R8.htm 1007008 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 8 false false R9.htm 2101101 - Disclosure - Business Sheet http://www.alxn.com/role/Business Business Notes 9 false false R10.htm 2102102 - Disclosure - Basis of Presentation and Principles Of Consolidation Sheet http://www.alxn.com/role/BasisofPresentationandPrinciplesOfConsolidation Basis of Presentation and Principles Of Consolidation Notes 10 false false R11.htm 2104103 - Disclosure - Acquisitions Sheet http://www.alxn.com/role/Acquisitions Acquisitions Notes 11 false false R12.htm 2110104 - Disclosure - Inventories Sheet http://www.alxn.com/role/Inventories Inventories Notes 12 false false R13.htm 2113105 - Disclosure - Intangible Assets and Goodwill Sheet http://www.alxn.com/role/IntangibleAssetsandGoodwill Intangible Assets and Goodwill Notes 13 false false R14.htm 2118106 - Disclosure - Debt Sheet http://www.alxn.com/role/Debt Debt Notes 14 false false R15.htm 2122107 - Disclosure - Earnings Per Common Share Sheet http://www.alxn.com/role/EarningsPerCommonShare Earnings Per Common Share Notes 15 false false R16.htm 2126108 - Disclosure - Marketable Securities Sheet http://www.alxn.com/role/MarketableSecurities Marketable Securities Notes 16 false false R17.htm 2131109 - Disclosure - Derivative Instruments and Hedging Activities Sheet http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivities Derivative Instruments and Hedging Activities Notes 17 false false R18.htm 2138110 - Disclosure - Other Investments Sheet http://www.alxn.com/role/OtherInvestments Other Investments Notes 18 false false R19.htm 2140111 - Disclosure - Stockholders' Equity Sheet http://www.alxn.com/role/StockholdersEquity Stockholders' Equity Notes 19 false false R20.htm 2142112 - Disclosure - Other Comprehensive Income and Accumulated Other Comprehensive Income Sheet http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncome Other Comprehensive Income and Accumulated Other Comprehensive Income Notes 20 false false R21.htm 2146113 - Disclosure - Fair Value Measurement Sheet http://www.alxn.com/role/FairValueMeasurement Fair Value Measurement Notes 21 false false R22.htm 2151114 - Disclosure - Revenue Recognition Sheet http://www.alxn.com/role/RevenueRecognition Revenue Recognition Notes 22 false false R23.htm 2155115 - Disclosure - Income Taxes Sheet http://www.alxn.com/role/IncomeTaxes Income Taxes Notes 23 false false R24.htm 2159116 - Disclosure - Commitments and Contingencies Sheet http://www.alxn.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 24 false false R25.htm 2161117 - Disclosure - Restructuring and Related Expenses Sheet http://www.alxn.com/role/RestructuringandRelatedExpenses Restructuring and Related Expenses Notes 25 false false R26.htm 2203201 - Disclosure - Basis of Presentation and Principles Of Consolidation (Policies) Sheet http://www.alxn.com/role/BasisofPresentationandPrinciplesOfConsolidationPolicies Basis of Presentation and Principles Of Consolidation (Policies) Policies 26 false false R27.htm 2305301 - Disclosure - Acquisitions (Tables) Sheet http://www.alxn.com/role/AcquisitionsTables Acquisitions (Tables) Tables http://www.alxn.com/role/Acquisitions 27 false false R28.htm 2311302 - Disclosure - Inventories (Tables) Sheet http://www.alxn.com/role/InventoriesTables Inventories (Tables) Tables http://www.alxn.com/role/Inventories 28 false false R29.htm 2314303 - Disclosure - Intangible Assets and Goodwill (Tables) Sheet http://www.alxn.com/role/IntangibleAssetsandGoodwillTables Intangible Assets and Goodwill (Tables) Tables http://www.alxn.com/role/IntangibleAssetsandGoodwill 29 false false R30.htm 2319304 - Disclosure - Debt (Tables) Sheet http://www.alxn.com/role/DebtTables Debt (Tables) Tables http://www.alxn.com/role/Debt 30 false false R31.htm 2323305 - Disclosure - Earnings Per Common Share (Tables) Sheet http://www.alxn.com/role/EarningsPerCommonShareTables Earnings Per Common Share (Tables) Tables http://www.alxn.com/role/EarningsPerCommonShare 31 false false R32.htm 2327306 - Disclosure - Marketable Securities (Tables) Sheet http://www.alxn.com/role/MarketableSecuritiesTables Marketable Securities (Tables) Tables http://www.alxn.com/role/MarketableSecurities 32 false false R33.htm 2332307 - Disclosure - Derivative Instruments and Hedging Activities (Tables) Sheet http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesTables Derivative Instruments and Hedging Activities (Tables) Tables http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivities 33 false false R34.htm 2343308 - Disclosure - Other Comprehensive Income and Accumulated Other Comprehensive Income (Tables) Sheet http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeTables Other Comprehensive Income and Accumulated Other Comprehensive Income (Tables) Tables http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncome 34 false false R35.htm 2347309 - Disclosure - Fair Value Measurement (Tables) Sheet http://www.alxn.com/role/FairValueMeasurementTables Fair Value Measurement (Tables) Tables http://www.alxn.com/role/FairValueMeasurement 35 false false R36.htm 2352310 - Disclosure - Revenue Recognition (Tables) Sheet http://www.alxn.com/role/RevenueRecognitionTables Revenue Recognition (Tables) Tables http://www.alxn.com/role/RevenueRecognition 36 false false R37.htm 2356311 - Disclosure - Income Taxes (Tables) Sheet http://www.alxn.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.alxn.com/role/IncomeTaxes 37 false false R38.htm 2362312 - Disclosure - Restructuring and Related Expenses (Tables) Sheet http://www.alxn.com/role/RestructuringandRelatedExpensesTables Restructuring and Related Expenses (Tables) Tables http://www.alxn.com/role/RestructuringandRelatedExpenses 38 false false R39.htm 2406401 - Disclosure - Acquisitions (Narrative) (Details) Sheet http://www.alxn.com/role/AcquisitionsNarrativeDetails Acquisitions (Narrative) (Details) Details http://www.alxn.com/role/AcquisitionsTables 39 false false R40.htm 2407402 - Disclosure - Acquisitions (Summary of Total Consideration) (Details) Sheet http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails Acquisitions (Summary of Total Consideration) (Details) Details http://www.alxn.com/role/AcquisitionsTables 40 false false R41.htm 2408403 - Disclosure - Acquisitions (Pro Forma Information) (Details) Sheet http://www.alxn.com/role/AcquisitionsProFormaInformationDetails Acquisitions (Pro Forma Information) (Details) Details http://www.alxn.com/role/AcquisitionsTables 41 false false R42.htm 2409404 - Disclosure - Acquisitions (Acquisition-Related Costs) (Details) Sheet http://www.alxn.com/role/AcquisitionsAcquisitionRelatedCostsDetails Acquisitions (Acquisition-Related Costs) (Details) Details http://www.alxn.com/role/AcquisitionsTables 42 false false R43.htm 2412405 - Disclosure - Inventories (Details) Sheet http://www.alxn.com/role/InventoriesDetails Inventories (Details) Details http://www.alxn.com/role/InventoriesTables 43 false false R44.htm 2415406 - Disclosure - Intangible Assets and Goodwill (Schedule of Intangible Assets and Goodwill) (Details) Sheet http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails Intangible Assets and Goodwill (Schedule of Intangible Assets and Goodwill) (Details) Details http://www.alxn.com/role/IntangibleAssetsandGoodwillTables 44 false false R45.htm 2416407 - Disclosure - Intangible Assets and Goodwill (Narrative) (Details) Sheet http://www.alxn.com/role/IntangibleAssetsandGoodwillNarrativeDetails Intangible Assets and Goodwill (Narrative) (Details) Details http://www.alxn.com/role/IntangibleAssetsandGoodwillTables 45 false false R46.htm 2417408 - Disclosure - Intangible Assets and Goodwill (Changes in Goodwill) (Details) Sheet http://www.alxn.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails Intangible Assets and Goodwill (Changes in Goodwill) (Details) Details http://www.alxn.com/role/IntangibleAssetsandGoodwillTables 46 false false R47.htm 2420409 - Disclosure - Debt (Details) Sheet http://www.alxn.com/role/DebtDetails Debt (Details) Details http://www.alxn.com/role/DebtTables 47 false false R48.htm 2421410 - Disclosure - Debt (Schedule of Debt) (Details) Sheet http://www.alxn.com/role/DebtScheduleofDebtDetails Debt (Schedule of Debt) (Details) Details http://www.alxn.com/role/DebtTables 48 false false R49.htm 2424411 - Disclosure - Earnings Per Common Share (Summary Of Calculation Of Basic And Diluted Earnings Per Share) (Details) Sheet http://www.alxn.com/role/EarningsPerCommonShareSummaryOfCalculationOfBasicAndDilutedEarningsPerShareDetails Earnings Per Common Share (Summary Of Calculation Of Basic And Diluted Earnings Per Share) (Details) Details http://www.alxn.com/role/EarningsPerCommonShareTables 49 false false R50.htm 2425412 - Disclosure - Earnings Per Common Share (Narrative) (Details) Sheet http://www.alxn.com/role/EarningsPerCommonShareNarrativeDetails Earnings Per Common Share (Narrative) (Details) Details http://www.alxn.com/role/EarningsPerCommonShareTables 50 false false R51.htm 2428413 - Disclosure - Marketable Securities (Proceeds from Sale) (Details) Sheet http://www.alxn.com/role/MarketableSecuritiesProceedsfromSaleDetails Marketable Securities (Proceeds from Sale) (Details) Details http://www.alxn.com/role/MarketableSecuritiesTables 51 false false R52.htm 2429414 - Disclosure - Marketable Securities (Available-for-sale Investments by Classification in Balance Sheet) (Details) Sheet http://www.alxn.com/role/MarketableSecuritiesAvailableforsaleInvestmentsbyClassificationinBalanceSheetDetails Marketable Securities (Available-for-sale Investments by Classification in Balance Sheet) (Details) Details http://www.alxn.com/role/MarketableSecuritiesTables 52 false false R53.htm 2430415 - Disclosure - Marketable Securities (Narrative) (Details) Sheet http://www.alxn.com/role/MarketableSecuritiesNarrativeDetails Marketable Securities (Narrative) (Details) Details http://www.alxn.com/role/MarketableSecuritiesTables 53 false false R54.htm 2433416 - Disclosure - Derivative Instruments and Hedging Activities (Narrative) (Details) Sheet http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails Derivative Instruments and Hedging Activities (Narrative) (Details) Details http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesTables 54 false false R55.htm 2434417 - Disclosure - Derivative Instruments and Hedging Activities (Schedule of Interest Rate Contracts) (Details) Sheet http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofInterestRateContractsDetails Derivative Instruments and Hedging Activities (Schedule of Interest Rate Contracts) (Details) Details http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesTables 55 false false R56.htm 2435418 - Disclosure - Derivative Instruments and Hedging Activities (Schedule Of Other Comprehensive Income And Earnings From Foreign Exchange Contracts) (Details) Sheet http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails Derivative Instruments and Hedging Activities (Schedule Of Other Comprehensive Income And Earnings From Foreign Exchange Contracts) (Details) Details http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesTables 56 false false R57.htm 2436419 - Disclosure - Derivative Instruments and Hedging Activities (Schedule Of Fair Value Of Outstanding Derivatives) (Details) Sheet http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails Derivative Instruments and Hedging Activities (Schedule Of Fair Value Of Outstanding Derivatives) (Details) Details http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesTables 57 false false R58.htm 2437420 - Disclosure - Derivative Instruments and Hedging Activities (Offsetting Assets and Liabilities) (Details) Sheet http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesOffsettingAssetsandLiabilitiesDetails Derivative Instruments and Hedging Activities (Offsetting Assets and Liabilities) (Details) Details http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesTables 58 false false R59.htm 2439421 - Disclosure - Other Investments (Details) Sheet http://www.alxn.com/role/OtherInvestmentsDetails Other Investments (Details) Details http://www.alxn.com/role/OtherInvestments 59 false false R60.htm 2441422 - Disclosure - Stockholders' Equity (Details) Sheet http://www.alxn.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://www.alxn.com/role/StockholdersEquity 60 false false R61.htm 2444423 - Disclosure - Other Comprehensive Income and Accumulated Other Comprehensive Income (Changes in AOCI) (Details) Sheet http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeChangesinAOCIDetails Other Comprehensive Income and Accumulated Other Comprehensive Income (Changes in AOCI) (Details) Details http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeTables 61 false false R62.htm 2445424 - Disclosure - Other Comprehensive Income and Accumulated Other Comprehensive Income (Significant Reclassifications from AOCI) (Details) Sheet http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeSignificantReclassificationsfromAOCIDetails Other Comprehensive Income and Accumulated Other Comprehensive Income (Significant Reclassifications from AOCI) (Details) Details http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeTables 62 false false R63.htm 2448425 - Disclosure - Fair Value Measurement (Schedule Of Assets And Liabilites Measured At Fair Value) (Details) Sheet http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails Fair Value Measurement (Schedule Of Assets And Liabilites Measured At Fair Value) (Details) Details http://www.alxn.com/role/FairValueMeasurementTables 63 false false R64.htm 2449426 - Disclosure - Fair Value Measurement (Schedule Of Acquisition-Related Contingent Consideration) (Details) Sheet http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails Fair Value Measurement (Schedule Of Acquisition-Related Contingent Consideration) (Details) Details http://www.alxn.com/role/FairValueMeasurementTables 64 false false R65.htm 2450427 - Disclosure - Fair Value Measurement (Narrative) (Details) Sheet http://www.alxn.com/role/FairValueMeasurementNarrativeDetails Fair Value Measurement (Narrative) (Details) Details http://www.alxn.com/role/FairValueMeasurementTables 65 false false R66.htm 2453428 - Disclosure - Revenue Recognition (Disaggregation of Revenue by Product and Geographical Region) (Details) Sheet http://www.alxn.com/role/RevenueRecognitionDisaggregationofRevenuebyProductandGeographicalRegionDetails Revenue Recognition (Disaggregation of Revenue by Product and Geographical Region) (Details) Details http://www.alxn.com/role/RevenueRecognitionTables 66 false false R67.htm 2454429 - Disclosure - Revenue Recognition (Summary of Receivables and Contract Liabilities from Contracts) (Details) Sheet http://www.alxn.com/role/RevenueRecognitionSummaryofReceivablesandContractLiabilitiesfromContractsDetails Revenue Recognition (Summary of Receivables and Contract Liabilities from Contracts) (Details) Details http://www.alxn.com/role/RevenueRecognitionTables 67 false false R68.htm 2457430 - Disclosure - Income Taxes (Schedule of Income Tax Provision and Effective Tax Rate) (Details) Sheet http://www.alxn.com/role/IncomeTaxesScheduleofIncomeTaxProvisionandEffectiveTaxRateDetails Income Taxes (Schedule of Income Tax Provision and Effective Tax Rate) (Details) Details http://www.alxn.com/role/IncomeTaxesTables 68 false false R69.htm 2458431 - Disclosure - Income Taxes (Narrative) (Details) Sheet http://www.alxn.com/role/IncomeTaxesNarrativeDetails Income Taxes (Narrative) (Details) Details http://www.alxn.com/role/IncomeTaxesTables 69 false false R70.htm 2460432 - Disclosure - Commitments and Contingencies (Narrative) (Details) Sheet http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails Commitments and Contingencies (Narrative) (Details) Details http://www.alxn.com/role/CommitmentsandContingencies 70 false false R71.htm 2463433 - Disclosure - Restructuring and Related Expenses (Narrative) (Details) Sheet http://www.alxn.com/role/RestructuringandRelatedExpensesNarrativeDetails Restructuring and Related Expenses (Narrative) (Details) Details http://www.alxn.com/role/RestructuringandRelatedExpensesTables 71 false false R72.htm 2464434 - Disclosure - Restructuring and Related Expenses (Schedule of Restructuring and related Costs) (Details) Sheet http://www.alxn.com/role/RestructuringandRelatedExpensesScheduleofRestructuringandrelatedCostsDetails Restructuring and Related Expenses (Schedule of Restructuring and related Costs) (Details) Details http://www.alxn.com/role/RestructuringandRelatedExpensesTables 72 false false R73.htm 2465435 - Disclosure - Restructuring and Related Expenses (Restructuring Reserve Roll Forward) (Details) Sheet http://www.alxn.com/role/RestructuringandRelatedExpensesRestructuringReserveRollForwardDetails Restructuring and Related Expenses (Restructuring Reserve Roll Forward) (Details) Details http://www.alxn.com/role/RestructuringandRelatedExpensesTables 73 false false All Reports Book All Reports alxn-20200930.htm alxn-20200930.xsd alxn-20200930_cal.xml alxn-20200930_def.xml alxn-20200930_lab.xml alxn-20200930_pre.xml alxnex311q320.htm alxnex312q320.htm alxnex321q320.htm alxnex322q320.htm exhibitannemarielawsep.htm alxn-20200930_g1.jpg alxn-20200930_g10.jpg alxn-20200930_g11.jpg alxn-20200930_g12.jpg alxn-20200930_g13.jpg alxn-20200930_g14.jpg alxn-20200930_g15.jpg alxn-20200930_g16.jpg alxn-20200930_g17.jpg alxn-20200930_g18.jpg alxn-20200930_g19.jpg alxn-20200930_g2.jpg alxn-20200930_g20.jpg alxn-20200930_g21.jpg alxn-20200930_g22.jpg alxn-20200930_g23.jpg alxn-20200930_g24.jpg alxn-20200930_g25.jpg alxn-20200930_g26.jpg alxn-20200930_g3.jpg alxn-20200930_g4.jpg alxn-20200930_g5.jpg alxn-20200930_g6.jpg alxn-20200930_g7.jpg alxn-20200930_g8.jpg alxn-20200930_g9.jpg http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/us-gaap/2019-01-31 true true JSON 117 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "alxn-20200930.htm": { "axisCustom": 2, "axisStandard": 34, "contextCount": 572, "dts": { "calculationLink": { "local": [ "alxn-20200930_cal.xml" ] }, "definitionLink": { "local": [ "alxn-20200930_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "alxn-20200930.htm" ] }, "labelLink": { "local": [ "alxn-20200930_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "alxn-20200930_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml" ] }, "schema": { "local": [ "alxn-20200930.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 646, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 5 }, "keyCustom": 67, "keyStandard": 373, "memberCustom": 57, "memberStandard": 52, "nsprefix": "alxn", "nsuri": "http://www.alxn.com/20200930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.alxn.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102102 - Disclosure - Basis of Presentation and Principles Of Consolidation", "role": "http://www.alxn.com/role/BasisofPresentationandPrinciplesOfConsolidation", "shortName": "Basis of Presentation and Principles Of Consolidation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104103 - Disclosure - Acquisitions", "role": "http://www.alxn.com/role/Acquisitions", "shortName": "Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110104 - Disclosure - Inventories", "role": "http://www.alxn.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113105 - Disclosure - Intangible Assets and Goodwill", "role": "http://www.alxn.com/role/IntangibleAssetsandGoodwill", "shortName": "Intangible Assets and Goodwill", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118106 - Disclosure - Debt", "role": "http://www.alxn.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2122107 - Disclosure - Earnings Per Common Share", "role": "http://www.alxn.com/role/EarningsPerCommonShare", "shortName": "Earnings Per Common Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2126108 - Disclosure - Marketable Securities", "role": "http://www.alxn.com/role/MarketableSecurities", "shortName": "Marketable Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2131109 - Disclosure - Derivative Instruments and Hedging Activities", "role": "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivities", "shortName": "Derivative Instruments and Hedging Activities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2138110 - Disclosure - Other Investments", "role": "http://www.alxn.com/role/OtherInvestments", "shortName": "Other Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2140111 - Disclosure - Stockholders' Equity", "role": "http://www.alxn.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "iabc3bc8d9e92459180d4124b6f00c7e6_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "iabc3bc8d9e92459180d4124b6f00c7e6_I20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2142112 - Disclosure - Other Comprehensive Income and Accumulated Other Comprehensive Income", "role": "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncome", "shortName": "Other Comprehensive Income and Accumulated Other Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2146113 - Disclosure - Fair Value Measurement", "role": "http://www.alxn.com/role/FairValueMeasurement", "shortName": "Fair Value Measurement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2151114 - Disclosure - Revenue Recognition", "role": "http://www.alxn.com/role/RevenueRecognition", "shortName": "Revenue Recognition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2155115 - Disclosure - Income Taxes", "role": "http://www.alxn.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2159116 - Disclosure - Commitments and Contingencies", "role": "http://www.alxn.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2161117 - Disclosure - Restructuring and Related Expenses", "role": "http://www.alxn.com/role/RestructuringandRelatedExpenses", "shortName": "Restructuring and Related Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2203201 - Disclosure - Basis of Presentation and Principles Of Consolidation (Policies)", "role": "http://www.alxn.com/role/BasisofPresentationandPrinciplesOfConsolidationPolicies", "shortName": "Basis of Presentation and Principles Of Consolidation (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Acquisitions (Tables)", "role": "http://www.alxn.com/role/AcquisitionsTables", "shortName": "Acquisitions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311302 - Disclosure - Inventories (Tables)", "role": "http://www.alxn.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314303 - Disclosure - Intangible Assets and Goodwill (Tables)", "role": "http://www.alxn.com/role/IntangibleAssetsandGoodwillTables", "shortName": "Intangible Assets and Goodwill (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "iabc3bc8d9e92459180d4124b6f00c7e6_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.alxn.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "iabc3bc8d9e92459180d4124b6f00c7e6_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2319304 - Disclosure - Debt (Tables)", "role": "http://www.alxn.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2323305 - Disclosure - Earnings Per Common Share (Tables)", "role": "http://www.alxn.com/role/EarningsPerCommonShareTables", "shortName": "Earnings Per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2327306 - Disclosure - Marketable Securities (Tables)", "role": "http://www.alxn.com/role/MarketableSecuritiesTables", "shortName": "Marketable Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2332307 - Disclosure - Derivative Instruments and Hedging Activities (Tables)", "role": "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesTables", "shortName": "Derivative Instruments and Hedging Activities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2343308 - Disclosure - Other Comprehensive Income and Accumulated Other Comprehensive Income (Tables)", "role": "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeTables", "shortName": "Other Comprehensive Income and Accumulated Other Comprehensive Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2347309 - Disclosure - Fair Value Measurement (Tables)", "role": "http://www.alxn.com/role/FairValueMeasurementTables", "shortName": "Fair Value Measurement (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2352310 - Disclosure - Revenue Recognition (Tables)", "role": "http://www.alxn.com/role/RevenueRecognitionTables", "shortName": "Revenue Recognition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "alxn:ScheduleOfIncomeTaxProvisionAndEffectiveTaxRateTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2356311 - Disclosure - Income Taxes (Tables)", "role": "http://www.alxn.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "alxn:ScheduleOfIncomeTaxProvisionAndEffectiveTaxRateTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2362312 - Disclosure - Restructuring and Related Expenses (Tables)", "role": "http://www.alxn.com/role/RestructuringandRelatedExpensesTables", "shortName": "Restructuring and Related Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "iabc3bc8d9e92459180d4124b6f00c7e6_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406401 - Disclosure - Acquisitions (Narrative) (Details)", "role": "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "shortName": "Acquisitions (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i9465f7e3f9a943e6bbc2a606ca5cde15_D20200701-20200930", "decimals": "-5", "lang": "en-US", "name": "alxn:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostNotExpensed", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i9465f7e3f9a943e6bbc2a606ca5cde15_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations", "role": "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations", "shortName": "Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i9465f7e3f9a943e6bbc2a606ca5cde15_D20200701-20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i9465f7e3f9a943e6bbc2a606ca5cde15_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Acquisitions (Summary of Total Consideration) (Details)", "role": "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails", "shortName": "Acquisitions (Summary of Total Consideration) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i67b13e4c0f6b45408acb8ce4242354d6_D20200128-20200128", "decimals": "-5", "lang": "en-US", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i9465f7e3f9a943e6bbc2a606ca5cde15_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Acquisitions (Pro Forma Information) (Details)", "role": "http://www.alxn.com/role/AcquisitionsProFormaInformationDetails", "shortName": "Acquisitions (Pro Forma Information) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i9465f7e3f9a943e6bbc2a606ca5cde15_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i9465f7e3f9a943e6bbc2a606ca5cde15_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "alxn:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresTransactionCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409404 - Disclosure - Acquisitions (Acquisition-Related Costs) (Details)", "role": "http://www.alxn.com/role/AcquisitionsAcquisitionRelatedCostsDetails", "shortName": "Acquisitions (Acquisition-Related Costs) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i9465f7e3f9a943e6bbc2a606ca5cde15_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "alxn:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresTransactionCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "iabc3bc8d9e92459180d4124b6f00c7e6_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412405 - Disclosure - Inventories (Details)", "role": "http://www.alxn.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "iabc3bc8d9e92459180d4124b6f00c7e6_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "iabc3bc8d9e92459180d4124b6f00c7e6_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "alxn:IntangibleAssetsCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415406 - Disclosure - Intangible Assets and Goodwill (Schedule of Intangible Assets and Goodwill) (Details)", "role": "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails", "shortName": "Intangible Assets and Goodwill (Schedule of Intangible Assets and Goodwill) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "iabc3bc8d9e92459180d4124b6f00c7e6_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "alxn:IntangibleAssetsCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i9465f7e3f9a943e6bbc2a606ca5cde15_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416407 - Disclosure - Intangible Assets and Goodwill (Narrative) (Details)", "role": "http://www.alxn.com/role/IntangibleAssetsandGoodwillNarrativeDetails", "shortName": "Intangible Assets and Goodwill (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i9465f7e3f9a943e6bbc2a606ca5cde15_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i682018b266884ac38f4fc74b83bcc956_I20191231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417408 - Disclosure - Intangible Assets and Goodwill (Changes in Goodwill) (Details)", "role": "http://www.alxn.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails", "shortName": "Intangible Assets and Goodwill (Changes in Goodwill) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i9465f7e3f9a943e6bbc2a606ca5cde15_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfFinancingCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420409 - Disclosure - Debt (Details)", "role": "http://www.alxn.com/role/DebtDetails", "shortName": "Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i9465f7e3f9a943e6bbc2a606ca5cde15_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfFinancingCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i44fc8317380a426babb03e3a523e4b92_D20200703-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "alxn:RoyaltyAgreementInterestToBeAccrued", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421410 - Disclosure - Debt (Schedule of Debt) (Details)", "role": "http://www.alxn.com/role/DebtScheduleofDebtDetails", "shortName": "Debt (Schedule of Debt) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i44fc8317380a426babb03e3a523e4b92_D20200703-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "alxn:RoyaltyAgreementInterestToBeAccrued", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i9465f7e3f9a943e6bbc2a606ca5cde15_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424411 - Disclosure - Earnings Per Common Share (Summary Of Calculation Of Basic And Diluted Earnings Per Share) (Details)", "role": "http://www.alxn.com/role/EarningsPerCommonShareSummaryOfCalculationOfBasicAndDilutedEarningsPerShareDetails", "shortName": "Earnings Per Common Share (Summary Of Calculation Of Basic And Diluted Earnings Per Share) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i9465f7e3f9a943e6bbc2a606ca5cde15_D20200701-20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i9465f7e3f9a943e6bbc2a606ca5cde15_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income Statement", "role": "http://www.alxn.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeStatement", "shortName": "Condensed Consolidated Statements of Comprehensive Income Statement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i9465f7e3f9a943e6bbc2a606ca5cde15_D20200701-20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i9465f7e3f9a943e6bbc2a606ca5cde15_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425412 - Disclosure - Earnings Per Common Share (Narrative) (Details)", "role": "http://www.alxn.com/role/EarningsPerCommonShareNarrativeDetails", "shortName": "Earnings Per Common Share (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i9465f7e3f9a943e6bbc2a606ca5cde15_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i9465f7e3f9a943e6bbc2a606ca5cde15_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "alxn:ProceedsFromSaleAndMaturityOfDebtSecuritiesAvailableForSaleAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428413 - Disclosure - Marketable Securities (Proceeds from Sale) (Details)", "role": "http://www.alxn.com/role/MarketableSecuritiesProceedsfromSaleDetails", "shortName": "Marketable Securities (Proceeds from Sale) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i9465f7e3f9a943e6bbc2a606ca5cde15_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "alxn:ProceedsFromSaleAndMaturityOfDebtSecuritiesAvailableForSaleAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "alxn:AvailableForSaleSecuritiesByBalanceSheetLocationClassificationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "iabc3bc8d9e92459180d4124b6f00c7e6_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429414 - Disclosure - Marketable Securities (Available-for-sale Investments by Classification in Balance Sheet) (Details)", "role": "http://www.alxn.com/role/MarketableSecuritiesAvailableforsaleInvestmentsbyClassificationinBalanceSheetDetails", "shortName": "Marketable Securities (Available-for-sale Investments by Classification in Balance Sheet) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "alxn:AvailableForSaleSecuritiesByBalanceSheetLocationClassificationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "iabc3bc8d9e92459180d4124b6f00c7e6_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i682018b266884ac38f4fc74b83bcc956_I20191231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430415 - Disclosure - Marketable Securities (Narrative) (Details)", "role": "http://www.alxn.com/role/MarketableSecuritiesNarrativeDetails", "shortName": "Marketable Securities (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i682018b266884ac38f4fc74b83bcc956_I20191231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i7e16e27af2c14d84a59fc75f111b6b1d_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "alxn:ForeignExchangeForwardContractsTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433416 - Disclosure - Derivative Instruments and Hedging Activities (Narrative) (Details)", "role": "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "shortName": "Derivative Instruments and Hedging Activities (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i7e16e27af2c14d84a59fc75f111b6b1d_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "alxn:ForeignExchangeForwardContractsTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "icdb4196e867b41d7806759f1117646f4_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "alxn:DerivativeNotionalAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434417 - Disclosure - Derivative Instruments and Hedging Activities (Schedule of Interest Rate Contracts) (Details)", "role": "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofInterestRateContractsDetails", "shortName": "Derivative Instruments and Hedging Activities (Schedule of Interest Rate Contracts) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "icdb4196e867b41d7806759f1117646f4_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "alxn:DerivativeNotionalAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i9465f7e3f9a943e6bbc2a606ca5cde15_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435418 - Disclosure - Derivative Instruments and Hedging Activities (Schedule Of Other Comprehensive Income And Earnings From Foreign Exchange Contracts) (Details)", "role": "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails", "shortName": "Derivative Instruments and Hedging Activities (Schedule Of Other Comprehensive Income And Earnings From Foreign Exchange Contracts) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i4d79336515694486ace86c55e08e463f_D20200701-20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "iabc3bc8d9e92459180d4124b6f00c7e6_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436419 - Disclosure - Derivative Instruments and Hedging Activities (Schedule Of Fair Value Of Outstanding Derivatives) (Details)", "role": "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "shortName": "Derivative Instruments and Hedging Activities (Schedule Of Fair Value Of Outstanding Derivatives) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "id9729345fad74cad9d7a517799af3506_I20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "iabc3bc8d9e92459180d4124b6f00c7e6_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437420 - Disclosure - Derivative Instruments and Hedging Activities (Offsetting Assets and Liabilities) (Details)", "role": "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesOffsettingAssetsandLiabilitiesDetails", "shortName": "Derivative Instruments and Hedging Activities (Offsetting Assets and Liabilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i26ea9358003146e894260470d82d5171_I20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DerivativeAssetFairValueGrossLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquireOtherInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439421 - Disclosure - Other Investments (Details)", "role": "http://www.alxn.com/role/OtherInvestmentsDetails", "shortName": "Other Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i4464f6d559f643f2b28b809767acf81e_D20200701-20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:UnrealizedGainLossOnInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i9465f7e3f9a943e6bbc2a606ca5cde15_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)", "role": "http://www.alxn.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i9465f7e3f9a943e6bbc2a606ca5cde15_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i9465f7e3f9a943e6bbc2a606ca5cde15_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:TreasuryStockSharesAcquired", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441422 - Disclosure - Stockholders' Equity (Details)", "role": "http://www.alxn.com/role/StockholdersEquityDetails", "shortName": "Stockholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "iee9c2bffb63a43268cd46007b1900e2c_I20200728", "decimals": "-5", "lang": "en-US", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i682018b266884ac38f4fc74b83bcc956_I20191231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2444423 - Disclosure - Other Comprehensive Income and Accumulated Other Comprehensive Income (Changes in AOCI) (Details)", "role": "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeChangesinAOCIDetails", "shortName": "Other Comprehensive Income and Accumulated Other Comprehensive Income (Changes in AOCI) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i479cd66fb77c446eb5d2f2a99835732a_I20181231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i9465f7e3f9a943e6bbc2a606ca5cde15_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445424 - Disclosure - Other Comprehensive Income and Accumulated Other Comprehensive Income (Significant Reclassifications from AOCI) (Details)", "role": "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeSignificantReclassificationsfromAOCIDetails", "shortName": "Other Comprehensive Income and Accumulated Other Comprehensive Income (Significant Reclassifications from AOCI) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i93e8a8e7b3024b2d8424c421e24e62e9_D20200701-20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i636b7c12cf7a48ea8c546d15d8f1ef55_I20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "true" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448425 - Disclosure - Fair Value Measurement (Schedule Of Assets And Liabilites Measured At Fair Value) (Details)", "role": "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails", "shortName": "Fair Value Measurement (Schedule Of Assets And Liabilites Measured At Fair Value) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i636b7c12cf7a48ea8c546d15d8f1ef55_I20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "true" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": "3", "first": true, "lang": "en-US", "name": "alxn:FairValueInputsWeightedAverageCostOfCapital", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2449426 - Disclosure - Fair Value Measurement (Schedule Of Acquisition-Related Contingent Consideration) (Details)", "role": "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails", "shortName": "Fair Value Measurement (Schedule Of Acquisition-Related Contingent Consideration) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "iabc3bc8d9e92459180d4124b6f00c7e6_I20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i42c3b548f32c499ba54ad5f663e4c9e8_D20190101-20190131", "decimals": "-5", "first": true, "lang": "en-US", "name": "alxn:CollaborationAgreementUpfrontPayment", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2450427 - Disclosure - Fair Value Measurement (Narrative) (Details)", "role": "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails", "shortName": "Fair Value Measurement (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i7221b50ba14b4b0a8c430d8dbbc600e7_D20190101-20190131", "decimals": "3", "lang": "en-US", "name": "alxn:DerivativeFairValueDiscountedCostOfDebt", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i9465f7e3f9a943e6bbc2a606ca5cde15_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2453428 - Disclosure - Revenue Recognition (Disaggregation of Revenue by Product and Geographical Region) (Details)", "role": "http://www.alxn.com/role/RevenueRecognitionDisaggregationofRevenuebyProductandGeographicalRegionDetails", "shortName": "Revenue Recognition (Disaggregation of Revenue by Product and Geographical Region) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i48ec4741946d4d1e91f16980fa270163_D20200701-20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "iabc3bc8d9e92459180d4124b6f00c7e6_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2454429 - Disclosure - Revenue Recognition (Summary of Receivables and Contract Liabilities from Contracts) (Details)", "role": "http://www.alxn.com/role/RevenueRecognitionSummaryofReceivablesandContractLiabilitiesfromContractsDetails", "shortName": "Revenue Recognition (Summary of Receivables and Contract Liabilities from Contracts) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "iabc3bc8d9e92459180d4124b6f00c7e6_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i9465f7e3f9a943e6bbc2a606ca5cde15_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2457430 - Disclosure - Income Taxes (Schedule of Income Tax Provision and Effective Tax Rate) (Details)", "role": "http://www.alxn.com/role/IncomeTaxesScheduleofIncomeTaxProvisionandEffectiveTaxRateDetails", "shortName": "Income Taxes (Schedule of Income Tax Provision and Effective Tax Rate) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "alxn:ScheduleOfIncomeTaxProvisionAndEffectiveTaxRateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i9465f7e3f9a943e6bbc2a606ca5cde15_D20200701-20200930", "decimals": "3", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": "3", "first": true, "lang": "en-US", "name": "alxn:EffectiveIncomeTaxRateReconciliationIntangibleAssetImpairmentPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2458431 - Disclosure - Income Taxes (Narrative) (Details)", "role": "http://www.alxn.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": "3", "first": true, "lang": "en-US", "name": "alxn:EffectiveIncomeTaxRateReconciliationIntangibleAssetImpairmentPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i3a3f6ae67337473dadfb57b3206402e9_I20181231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - Condensed Consolidated Statements of Changes in Stockholder's Equity Statement", "role": "http://www.alxn.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityStatement", "shortName": "Condensed Consolidated Statements of Changes in Stockholder's Equity Statement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i3a3f6ae67337473dadfb57b3206402e9_I20181231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "alxn:AssetAcquisitionContingentConsiderationMilestonePayments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2460432 - Disclosure - Commitments and Contingencies (Narrative) (Details)", "role": "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails", "shortName": "Commitments and Contingencies (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i42c3b548f32c499ba54ad5f663e4c9e8_D20190101-20190131", "decimals": "-5", "lang": "en-US", "name": "alxn:CollaborationAgreementPotentialFuturePaymentsAcquisitionOptionExercise", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "iabc3bc8d9e92459180d4124b6f00c7e6_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2463433 - Disclosure - Restructuring and Related Expenses (Narrative) (Details)", "role": "http://www.alxn.com/role/RestructuringandRelatedExpensesNarrativeDetails", "shortName": "Restructuring and Related Expenses (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "iabc3bc8d9e92459180d4124b6f00c7e6_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i9465f7e3f9a943e6bbc2a606ca5cde15_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringCharges", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2464434 - Disclosure - Restructuring and Related Expenses (Schedule of Restructuring and related Costs) (Details)", "role": "http://www.alxn.com/role/RestructuringandRelatedExpensesScheduleofRestructuringandrelatedCostsDetails", "shortName": "Restructuring and Related Expenses (Schedule of Restructuring and related Costs) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i9465f7e3f9a943e6bbc2a606ca5cde15_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringCharges", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "ic632f1d818e1459c89f4e0545bd08671_I20200630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2465435 - Disclosure - Restructuring and Related Expenses (Restructuring Reserve Roll Forward) (Details)", "role": "http://www.alxn.com/role/RestructuringandRelatedExpensesRestructuringReserveRollForwardDetails", "shortName": "Restructuring and Related Expenses (Restructuring Reserve Roll Forward) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i9465f7e3f9a943e6bbc2a606ca5cde15_D20200701-20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i9465f7e3f9a943e6bbc2a606ca5cde15_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1007008 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Business", "role": "http://www.alxn.com/role/Business", "shortName": "Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn-20200930.htm", "contextRef": "i58b52482952342e0b204de451aaac3d0_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 124, "tag": { "alxn_ACH5528Phase3Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ACH-5528, Phase 3 [Member]", "label": "ACH-5528, Phase 3 [Member]", "terseLabel": "ACH-5528, Phase 3" } } }, "localname": "ACH5528Phase3Member", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_AccumulatedOtherComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accumulated Other Comprehensive Income [Abstract]", "label": "Accumulated Other Comprehensive Income [Abstract]", "terseLabel": "Accumulated Other Comprehensive Income [Abstract]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeAbstract", "nsuri": "http://www.alxn.com/20200930", "xbrltype": "stringItemType" }, "alxn_AccumulatedOtherComprehensiveIncomeLossRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accumulated Other Comprehensive Income (Loss) [Roll Forward]", "label": "Accumulated Other Comprehensive Income (Loss) [Roll Forward]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Roll Forward]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossRollForward", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeChangesinAOCIDetails" ], "xbrltype": "stringItemType" }, "alxn_AchillionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Achillion [Member]", "label": "Achillion [Member]", "terseLabel": "Achillion" } } }, "localname": "AchillionMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsAcquisitionRelatedCostsDetails", "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails", "http://www.alxn.com/role/IntangibleAssetsandGoodwillNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_AcquiredIprdMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Acquired IPR&D [Member]", "label": "Acquired IPRD [Member]", "terseLabel": "In-process research & development assets (IPR&D)" } } }, "localname": "AcquiredIprdMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails", "http://www.alxn.com/role/IntangibleAssetsandGoodwillNarrativeDetails", "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" ], "xbrltype": "domainItemType" }, "alxn_AcquisitionRelatedContingentConsiderationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Acquisition-Related Contingent Consideration [Member]", "label": "Acquisition Related Contingent Consideration [Member]", "terseLabel": "Acquisition-related contingent consideration" } } }, "localname": "AcquisitionRelatedContingentConsiderationMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "alxn_AffibodyABDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Affibody AB [Domain]", "label": "Affibody AB [Domain]", "terseLabel": "Affibody AB" } } }, "localname": "AffibodyABDomain", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_AffibodyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Affibody [Member]", "label": "Affibody [Member]", "terseLabel": "Affibody" } } }, "localname": "AffibodyMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_AmortizationofIntangibleAssetsAcquired": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortization of Intangible Assets Acquired", "label": "Amortization of Intangible Assets Acquired", "terseLabel": "Amortization of purchased intangible assets" } } }, "localname": "AmortizationofIntangibleAssetsAcquired", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "alxn_AndexxaProductLineMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Andexxa Product Line", "label": "Andexxa Product Line [Member]", "terseLabel": "ANDEXXA" } } }, "localname": "AndexxaProductLineMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/RevenueRecognitionDisaggregationofRevenuebyProductandGeographicalRegionDetails" ], "xbrltype": "domainItemType" }, "alxn_AssetAcquisitionContingentConsiderationMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Contingent Consideration, Milestone Payments", "label": "Asset Acquisition, Contingent Consideration, Milestone Payments", "terseLabel": "Asset Acquisition, Contingent Consideration, Milestone Payments" } } }, "localname": "AssetAcquisitionContingentConsiderationMilestonePayments", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "alxn_AstellasPharamMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Astellas Pharam", "label": "Astellas Pharam [Member]", "terseLabel": "Astellas Pharam [Member]" } } }, "localname": "AstellasPharamMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_AvailableForSaleSecuritiesByBalanceSheetLocationClassificationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Available-for-sale Securities by Balance Sheet Location Classification [Table Text Block]", "label": "Available-for-sale Securities by Balance Sheet Location Classification [Table Text Block]", "terseLabel": "Available-for-sale Securities by Balance Sheet Location Classification" } } }, "localname": "AvailableForSaleSecuritiesByBalanceSheetLocationClassificationTableTextBlock", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "alxn_BusinessAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business [Abstract]", "label": "Business [Abstract]", "terseLabel": "Business [Abstract]" } } }, "localname": "BusinessAbstract", "nsuri": "http://www.alxn.com/20200930", "xbrltype": "stringItemType" }, "alxn_BusinessCombinationConsiderationTransferredNet": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails": { "order": 1.0, "parentTag": "alxn_BusinessCombinationTotalConsideration", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Consideration Transferred, Net", "label": "Business Combination, Consideration Transferred, Net", "terseLabel": "Total consideration to acquire outstanding equity, net" } } }, "localname": "BusinessCombinationConsiderationTransferredNet", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "alxn_BusinessCombinationConsiderationTransferredPerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Combination, Consideration Transferred, Per Share", "label": "Business Combination, Consideration Transferred, Per Share", "terseLabel": "Total acquisition value, per share (in dollars per share)" } } }, "localname": "BusinessCombinationConsiderationTransferredPerShare", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "alxn_BusinessCombinationContingentConsiderationLiabilityPerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Combination, Contingent Consideration, Liability, Per Share", "label": "Business Combination, Contingent Consideration, Liability, Per Share", "terseLabel": "Contingent value rights per share (in dollars per share)" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityPerShare", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "alxn_BusinessCombinationContingentConsiderationLiabilityPostCombinationServicePeriodCompensation": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Contingent Consideration, Liability, Post-Combination Service Period Compensation", "label": "Business Combination, Contingent Consideration, Liability, Post-Combination Service Period Compensation", "negatedTerseLabel": "Contingent consideration, fair value of equity compensation attributable to the post-combination service period", "terseLabel": "Contingent consideration, fair value of equity compensation attributable to the post-combination service period" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityPostCombinationServicePeriodCompensation", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "alxn_BusinessCombinationEstimatedMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Estimated Milestone Payments", "label": "Business Combination, Estimated Milestone Payments", "terseLabel": "Estimated milestone payments" } } }, "localname": "BusinessCombinationEstimatedMilestonePayments", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_BusinessCombinationIntangibleAssetAmortizationOfAcquireeSinceAcquisitionDateActual": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Intangible Asset Amortization Of Acquiree Since Acquisition Date, Actual", "label": "Business Combination, Intangible Asset Amortization Of Acquiree Since Acquisition Date, Actual", "terseLabel": "Intangible asset amortization expense since acquisition" } } }, "localname": "BusinessCombinationIntangibleAssetAmortizationOfAcquireeSinceAcquisitionDateActual", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAcquisitionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Acquisition Costs", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Acquisition Costs", "terseLabel": "Acquisition costs adjustment" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAcquisitionCosts", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCostOfGoodsSold": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Cost Of Goods sold", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Cost Of Goods sold", "terseLabel": "Cost of goods sold adjustment" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCostOfGoodsSold", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibleAssetAmortizationExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangible Asset Amortization Expense", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangible Asset Amortization Expense", "terseLabel": "Amortization expense adjustment" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibleAssetAmortizationExpense", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermDebt": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails": { "order": 7.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Long-Term Debt", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Long-Term Debt", "negatedTerseLabel": "Long-term debt, including current portion of $7.7" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermDebt", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "alxn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsInventory": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Noncurrent Assets, Inventory", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Noncurrent Assets, Inventory", "terseLabel": "Noncurrent inventory" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsInventory", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "alxn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Liabilities", "negatedTerseLabel": "Other liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "alxn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedValidationBatches": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Validation Batches", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Validation Batches", "terseLabel": "Validation batches" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedValidationBatches", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails", "http://www.alxn.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "alxn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherNet": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other, Net", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other, Net", "terseLabel": "Other assets and liabilities, net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherNet", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "alxn_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostNotExpensed": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Not Expensed", "label": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Not Expensed", "terseLabel": "Acquisition costs not included in net income" } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostNotExpensed", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresTransactionCosts": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/AcquisitionsAcquisitionRelatedCostsDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Transaction Costs", "label": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Transaction Costs", "terseLabel": "Transaction costs" } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresTransactionCosts", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsAcquisitionRelatedCostsDetails" ], "xbrltype": "monetaryItemType" }, "alxn_BusinessCombinationTotalConsideration": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Total Consideration", "label": "Business Combination, Total Consideration", "totalLabel": "Total consideration" } } }, "localname": "BusinessCombinationTotalConsideration", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "alxn_CaelumBiosciencesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Caelum Biosciences [Member]", "label": "Caelum Biosciences [Member]", "terseLabel": "Caelum" } } }, "localname": "CaelumBiosciencesMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails", "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "domainItemType" }, "alxn_CaelumBiosciencesOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Caelum Biosciences, Option", "label": "Caelum Biosciences, Option [Member]", "terseLabel": "Caelum Biosciences, Option" } } }, "localname": "CaelumBiosciencesOptionMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "domainItemType" }, "alxn_CanadianPatentedMedicinePricesReviewBoardMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Canadian Patented Medicine Prices Review Board [Member]", "label": "Canadian Patented Medicine Prices Review Board [Member]", "terseLabel": "Canadian Patented Medicine Prices Review Board" } } }, "localname": "CanadianPatentedMedicinePricesReviewBoardMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_CollaborationAgreementMilestonePayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Collaboration Agreement, Milestone Payment", "label": "Collaboration Agreement, Milestone Payment", "terseLabel": "Collaboration Agreement, Milestone Payment" } } }, "localname": "CollaborationAgreementMilestonePayment", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_CollaborationAgreementPaymentForAdditionalEquityInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Collaboration Agreement, Payment For Additional Equity Interest", "label": "Collaboration Agreement, Payment For Additional Equity Interest", "terseLabel": "Collaboration Agreement, Payment For Additional Equity Interest" } } }, "localname": "CollaborationAgreementPaymentForAdditionalEquityInterest", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_CollaborationAgreementPotentialFuturePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Collaboration Agreement, Potential Future Payments", "label": "Collaboration Agreement, Potential Future Payments", "terseLabel": "Collaboration Agreement, Potential Future Payments" } } }, "localname": "CollaborationAgreementPotentialFuturePayments", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails", "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "alxn_CollaborationAgreementPotentialFuturePaymentsAcquisitionOptionExercise": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Collaboration Agreement, Potential Future Payments, Acquisition Option Exercise", "label": "Collaboration Agreement, Potential Future Payments, Acquisition Option Exercise", "terseLabel": "Collaboration Agreement, Acquisition Option, Maximum Potential Future Payment" } } }, "localname": "CollaborationAgreementPotentialFuturePaymentsAcquisitionOptionExercise", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_CollaborationAgreementPotentialFuturePaymentsAdditionalMilestoneAchievement": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Collaboration Agreement, Potential Future Payments, Additional Milestone Achievement", "label": "Collaboration Agreement, Potential Future Payments, Additional Milestone Achievement", "terseLabel": "Collaboration Agreement, Potential Future Payments, Additional Milestone Achievement" } } }, "localname": "CollaborationAgreementPotentialFuturePaymentsAdditionalMilestoneAchievement", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_CollaborationAgreementPotentialFuturePaymentsMilestoneAchievement": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Collaboration Agreement, Potential Future Payments, Milestone Achievement", "label": "Collaboration Agreement, Potential Future Payments, Milestone Achievement", "terseLabel": "Collaboration Agreement, Potential Future Payments, Milestone Achievement" } } }, "localname": "CollaborationAgreementPotentialFuturePaymentsMilestoneAchievement", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_CollaborationAgreementPotentialFuturePaymentsOptionFee": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Collaboration Agreement, Potential Future Payments, Option Fee", "label": "Collaboration Agreement, Potential Future Payments, Option Fee", "terseLabel": "Collaboration Agreement, Potential Future Payments, Option Fee" } } }, "localname": "CollaborationAgreementPotentialFuturePaymentsOptionFee", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_CollaborationAgreementUpfrontPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Collaboration Agreement, Upfront Payment", "label": "Collaboration Agreement, Upfront Payment", "terseLabel": "Collaboration Agreement, Upfront Payment" } } }, "localname": "CollaborationAgreementUpfrontPayment", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_CollaborationandLicenseAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaboration and License Agreement [Member]", "label": "Collaboration and License Agreement [Member]", "terseLabel": "Collaboration and License Agreement" } } }, "localname": "CollaborationandLicenseAgreementMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_CollaborativeAgreementAmendmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Agreement, Amendment [Member]", "label": "Collaborative Agreement, Amendment [Member]", "terseLabel": "Collaborative Agreement, Amendment" } } }, "localname": "CollaborativeAgreementAmendmentMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "domainItemType" }, "alxn_ContingentConsiderationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contingent Consideration [Member]", "label": "Contingent Consideration [Member]", "terseLabel": "Contingent consideration" } } }, "localname": "ContingentConsiderationMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "alxn_CreditAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Credit Agreement [Member]", "label": "Credit Agreement [Member]", "terseLabel": "Credit Agreement" } } }, "localname": "CreditAgreementMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "alxn_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cumulative Effect, Period Of Adoption, Adjustment", "label": "Cumulative Effect, Period Of Adoption, Adjustment [Member]", "terseLabel": "Adoption of new accounting standards" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "alxn_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cumulative Effect, Period Of Adoption", "label": "Cumulative Effect, Period Of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period Of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityStatement" ], "xbrltype": "stringItemType" }, "alxn_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cumulative Effect, Period Of Adoption", "label": "Cumulative Effect, Period Of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period Of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "alxn_DOJAndOIGMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "DOJ And OIG [Member]", "label": "DOJ And OIG [Member]", "terseLabel": "DOJ And OIG" } } }, "localname": "DOJAndOIGMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_DanicopanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Danicopan [Member]", "label": "Danicopan [Member]", "terseLabel": "Danicopan" } } }, "localname": "DanicopanMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_DebtInstrumentQuarterlyPaymentPercentageofTotalBorrowings": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Quarterly Payment, Percentage of Total Borrowings", "label": "Debt Instrument, Quarterly Payment, Percentage of Total Borrowings", "terseLabel": "Debt Instrument, quarterly payment as a percent of total borrowings" } } }, "localname": "DebtInstrumentQuarterlyPaymentPercentageofTotalBorrowings", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "percentItemType" }, "alxn_DeferredTaxAssetsLongTermDebt": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred Tax Assets, Long-Term Debt", "label": "Deferred Tax Assets, Long-Term Debt", "terseLabel": "Deferred tax assets, royalty debt" } } }, "localname": "DeferredTaxAssetsLongTermDebt", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "alxn_DeferredTaxExpenseBenefitByTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Deferred Tax Expense (Benefit) By Type [Axis]", "label": "Deferred Tax Expense (Benefit) By Type [Axis]", "terseLabel": "Deferred Tax Expense (Benefit) By Type [Axis]" } } }, "localname": "DeferredTaxExpenseBenefitByTypeAxis", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "alxn_DeferredTaxExpenseBenefitByTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Deferred Tax Expense (Benefit) By Type [Axis]", "label": "Deferred Tax Expense (Benefit) By Type [Domain]", "terseLabel": "Deferred Tax Expense (Benefit) By Type [Domain]" } } }, "localname": "DeferredTaxExpenseBenefitByTypeDomain", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_DerivativeFairValueDiscountedCostOfDebt": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Derivative Fair Value, Discounted Cost Of Debt", "label": "Derivative Fair Value, Discounted Cost Of Debt", "terseLabel": "Derivative Fair Value, Discounted Cost Of Debt" } } }, "localname": "DerivativeFairValueDiscountedCostOfDebt", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails" ], "xbrltype": "percentItemType" }, "alxn_DerivativeInstrumentsAndHedgingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Derivative Instruments and Hedging Activities [Abstract]", "label": "Derivative Instruments and Hedging Activities [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesAbstract", "nsuri": "http://www.alxn.com/20200930", "xbrltype": "stringItemType" }, "alxn_DerivativeNotionalAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Derivative, Notional Amount1", "label": "Derivative, Notional Amount1", "terseLabel": "Notional amount of derivative instruments", "verboseLabel": "Derivative, notional amount" } } }, "localname": "DerivativeNotionalAmount1", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofInterestRateContractsDetails" ], "xbrltype": "monetaryItemType" }, "alxn_DicernaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Dicerna [Member]", "label": "Dicerna [Member]", "terseLabel": "Dicerna" } } }, "localname": "DicernaMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "domainItemType" }, "alxn_DicernaPharmaceuticalCollaborationAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Dicerna Pharmaceutical Collaboration Agreement [Member]", "label": "Dicerna Pharmaceutical Collaboration Agreement [Member]", "terseLabel": "Dicerna Pharmaceutical Collaboration Agreement" } } }, "localname": "DicernaPharmaceuticalCollaborationAgreementMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_DocumentAndEntityInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Document and Entity Information [Abstract]", "label": "Document and Entity Information [Abstract]", "terseLabel": "Document and Entity Information [Abstract]" } } }, "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.alxn.com/20200930", "xbrltype": "stringItemType" }, "alxn_EarningsPerCommonShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Earnings Per Common Share [Abstract]", "label": "Earnings Per Common Share [Abstract]", "terseLabel": "Earnings Per Common Share [Abstract]" } } }, "localname": "EarningsPerCommonShareAbstract", "nsuri": "http://www.alxn.com/20200930", "xbrltype": "stringItemType" }, "alxn_EffectiveIncomeTaxRateReconciliationDeductionForeignDerivedIntangibleIncomePercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation Deduction, Foreign-Derived Intangible Income, Percent", "label": "Effective Income Tax Rate Reconciliation Deduction, Foreign-Derived Intangible Income, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation Deduction, Foreign-Derived Intangible Income, Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationDeductionForeignDerivedIntangibleIncomePercent", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "percentItemType" }, "alxn_EffectiveIncomeTaxRateReconciliationIntangibleAssetImpairmentPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Intangible Asset Impairment, Percent", "label": "Effective Income Tax Rate Reconciliation, Intangible Asset Impairment, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Intangible Asset Impairment, Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationIntangibleAssetImpairmentPercent", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "percentItemType" }, "alxn_EidosMemberMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Eidos [Member]", "label": "Eidos [Member] [Member]", "terseLabel": "Eidos" } } }, "localname": "EidosMemberMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "domainItemType" }, "alxn_FairValueInputDiscountRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fair Value Input, Discount Rate", "label": "Fair Value Input, Discount Rate", "terseLabel": "Fair Value Inputs, Discount Rate" } } }, "localname": "FairValueInputDiscountRate", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "percentItemType" }, "alxn_FairValueInputsCostOfDebt": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fair Value Inputs, Cost of Debt", "label": "Fair Value Inputs, Cost of Debt", "terseLabel": "Fair Value Inputs, Cost of Debt" } } }, "localname": "FairValueInputsCostOfDebt", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails" ], "xbrltype": "percentItemType" }, "alxn_FairValueInputsWeightedAverageCostOfCapital": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fair Value Inputs, Weighted Average Cost of Capital", "label": "Fair Value Inputs, Weighted Average Cost of Capital", "terseLabel": "Fair Value Inputs, Weighted Average Cost of Capital" } } }, "localname": "FairValueInputsWeightedAverageCostOfCapital", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails" ], "xbrltype": "percentItemType" }, "alxn_FairValueOfEquitySharesOfBusinessCombination": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair Value Of Equity Shares Of Business Combination", "label": "Fair Value Of Equity Shares Of Business Combination", "terseLabel": "Fair value of equity shares in Portola settled at closing of the acquisition" } } }, "localname": "FairValueOfEquitySharesOfBusinessCombination", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "alxn_ForeignExchangeForwardContractsTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Foreign Exchange Forward Contracts Term", "label": "Foreign Exchange Forward Contracts Term", "terseLabel": "Foreign Exchange Forward Contracts Term" } } }, "localname": "ForeignExchangeForwardContractsTerm", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails" ], "xbrltype": "durationItemType" }, "alxn_ForeignExchangeForwardOpenExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Foreign Exchange Forward, Open Expense [Member]", "label": "Foreign Exchange Forward, Open Expense [Member]", "terseLabel": "Foreign Exchange Forward, Open Expense" } } }, "localname": "ForeignExchangeForwardOpenExpenseMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_GoodwillAccumulatedAmortization": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Goodwill, Accumulated Amortization", "label": "Goodwill, Accumulated Amortization", "negatedTerseLabel": "Goodwill, Accumulated Amortization" } } }, "localname": "GoodwillAccumulatedAmortization", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "alxn_HalozymeTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Halozyme Therapeutics, Inc [Member]", "label": "Halozyme Therapeutics, Inc [Member]", "terseLabel": "Halozyme Therapeutics, Inc" } } }, "localname": "HalozymeTherapeuticsIncMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_HealthCareRoyaltyPartnersMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "HealthCare Royalty Partners", "label": "HealthCare Royalty Partners [Member]", "terseLabel": "HealthCare Royalty Partners" } } }, "localname": "HealthCareRoyaltyPartnersMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/DebtDetails", "http://www.alxn.com/role/DebtScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "alxn_IncomeTaxExpenseBenefitForeignDerivedIntangibleIncome": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Income Tax Expense (Benefit), Foreign-Derived Intangible Income", "label": "Income Tax Expense (Benefit), Foreign-Derived Intangible Income", "negatedTerseLabel": "Income Tax Expense (Benefit), Foreign-Derived Intangible Income" } } }, "localname": "IncomeTaxExpenseBenefitForeignDerivedIntangibleIncome", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails": { "order": 1.0, "parentTag": "alxn_IntangibleAssetsCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Indefinite-Lived Intangible Assets, Gross (Excluding Goodwill)", "label": "Indefinite-Lived Intangible Assets, Gross (Excluding Goodwill)", "terseLabel": "Indefinite-Lived Intangible Assets, Gross (Excluding Goodwill)" } } }, "localname": "IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "alxn_InozymeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Inozyme", "label": "Inozyme [Member]", "terseLabel": "Inozyme" } } }, "localname": "InozymeMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "domainItemType" }, "alxn_IntangibleAssetImpairmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Intangible Asset Impairment", "label": "Intangible Asset Impairment [Member]", "terseLabel": "Intangible Asset Impairment" } } }, "localname": "IntangibleAssetImpairmentMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_IntangibleAssetsAccumulatedAmortization": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Intangible Assets, Accumulated Amortization", "label": "Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Intangible Assets, Accumulated Amortization" } } }, "localname": "IntangibleAssetsAccumulatedAmortization", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "alxn_IntangibleAssetsCost": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Intangible Assets, Cost", "label": "Intangible Assets, Cost", "totalLabel": "Intangible Assets, Cost" } } }, "localname": "IntangibleAssetsCost", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "alxn_IntangibleAssetsImpairmentWeightedAverageCostOfCapital": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Intangible Assets, Impairment, Weighted Average Cost Of Capital", "label": "Intangible Assets, Impairment, Weighted Average Cost Of Capital", "terseLabel": "Weighted average cost of capital" } } }, "localname": "IntangibleAssetsImpairmentWeightedAverageCostOfCapital", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsandGoodwillNarrativeDetails" ], "xbrltype": "percentItemType" }, "alxn_IntellectualPropertyElectionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Intellectual Property Election [Member]", "label": "Intellectual Property Election [Member]", "terseLabel": "Intellectual Property Election" } } }, "localname": "IntellectualPropertyElectionMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_InterestRateSwapFourMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest Rate Swap Four [Member]", "label": "Interest Rate Swap Four [Member]", "terseLabel": "Interest Rate Swap" } } }, "localname": "InterestRateSwapFourMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofInterestRateContractsDetails" ], "xbrltype": "domainItemType" }, "alxn_InterestRateSwapTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest Rate Swap Two [Member]", "label": "Interest Rate Swap Two [Member]", "verboseLabel": "Interest Rate Swap" } } }, "localname": "InterestRateSwapTwoMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofInterestRateContractsDetails" ], "xbrltype": "domainItemType" }, "alxn_InventoryCurrent": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Inventory, Current", "label": "Inventory, Current", "verboseLabel": "Inventories" } } }, "localname": "InventoryCurrent", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "alxn_KanumaProductLineMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Kanuma Product Line[Member]", "label": "Kanuma Product Line [Member]", "terseLabel": "KANUMA" } } }, "localname": "KanumaProductLineMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsandGoodwillNarrativeDetails", "http://www.alxn.com/role/RevenueRecognitionDisaggregationofRevenuebyProductandGeographicalRegionDetails" ], "xbrltype": "domainItemType" }, "alxn_LicenseAgreement1Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "License Agreement 1 [Member]", "label": "License Agreement 1 [Member]", "terseLabel": "License Agreement 1" } } }, "localname": "LicenseAgreement1Member", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_LonzaGroupAGMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lonza Group AG [Member]", "label": "Lonza Group AG [Member]", "terseLabel": "Lonza Group AG" } } }, "localname": "LonzaGroupAGMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "domainItemType" }, "alxn_MarketableSecuritiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Marketable Securities [Member]", "label": "Marketable Securities [Member]", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails", "http://www.alxn.com/role/MarketableSecuritiesAvailableforsaleInvestmentsbyClassificationinBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "alxn_ModernaLLCMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Moderna LLC [Member]", "label": "Moderna LLC [Member]", "terseLabel": "Moderna LLC" } } }, "localname": "ModernaLLCMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "domainItemType" }, "alxn_MutualFundsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Mutual Funds [Member]", "label": "Mutual Funds [Member]", "terseLabel": "Mutual funds" } } }, "localname": "MutualFundsMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "alxn_NetProductSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Net Product Sales [Member]", "label": "Net Product Sales [Member]", "terseLabel": "Net product sales" } } }, "localname": "NetProductSalesMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "domainItemType" }, "alxn_NoncashOrPartNoncashAcquisitionContingentConsiderationIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Noncash Or Part Noncash Acquisition, Contingent Consideration Issued", "label": "Noncash Or Part Noncash Acquisition, Contingent Consideration Issued", "terseLabel": "Contingent consideration issued in acquisitions" } } }, "localname": "NoncashOrPartNoncashAcquisitionContingentConsiderationIssued", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "alxn_OffsettingAssetsandLiabilitiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Offsetting Assets and Liabilities [Table]", "label": "Offsetting Assets and Liabilities [Line Items]", "terseLabel": "Offsetting Assets and Liabilities [Line Items]" } } }, "localname": "OffsettingAssetsandLiabilitiesLineItems", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesOffsettingAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "alxn_OffsettingAssetsandLiabilitiesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Offsetting Assets and Liabilities [Table]", "label": "Offsetting Assets and Liabilities [Table]", "terseLabel": "Offsetting Assets and Liabilities [Table]" } } }, "localname": "OffsettingAssetsandLiabilitiesTable", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesOffsettingAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "alxn_OffsettingAssetsandLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Offsetting Assets and Liabilities [Table Text Block]", "label": "Offsetting Assets and Liabilities [Table Text Block]", "terseLabel": "Offsetting Assets and Liabilities" } } }, "localname": "OffsettingAssetsandLiabilitiesTableTextBlock", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "alxn_OperatingRightOfUseAssetsExchangedForOperatingLeaseLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating Right-Of-Use Assets Exchanged For Operating Lease Liability", "label": "Operating Right-Of-Use Assets Exchanged For Operating Lease Liability", "terseLabel": "Operating ROU lease assets obtained in exchange for operating lease liabilities" } } }, "localname": "OperatingRightOfUseAssetsExchangedForOperatingLeaseLiability", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "alxn_OptionToAcquireRemainingEquityAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Option To Acquire Remaining Equity, Amount", "label": "Option To Acquire Remaining Equity, Amount", "terseLabel": "Option To Acquire Remaining Equity, Amount" } } }, "localname": "OptionToAcquireRemainingEquityAmount", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "alxn_OtherContingentPaymentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Contingent Payments [Member]", "label": "Other Contingent Payments [Member]", "terseLabel": "Other contingent payments" } } }, "localname": "OtherContingentPaymentsMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "alxn_OtherGovernmentObligationsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Government Obligations [Member]", "label": "Other Government Obligations [Member]", "terseLabel": "Other government-related obligations" } } }, "localname": "OtherGovernmentObligationsMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "alxn_OtherNonUsExcludingEuropeAndAsiaPacificMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Non-Us, Excluding Europe And Asia Pacific [Member]", "label": "Other Non-Us, Excluding Europe And Asia Pacific [Member]", "terseLabel": "Rest of World" } } }, "localname": "OtherNonUsExcludingEuropeAndAsiaPacificMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionDisaggregationofRevenuebyProductandGeographicalRegionDetails" ], "xbrltype": "domainItemType" }, "alxn_OtherRevenueMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Revenue [Member]", "label": "Other Revenue [Member]", "terseLabel": "Other revenue" } } }, "localname": "OtherRevenueMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "domainItemType" }, "alxn_OtherThirdPartyManufacturersMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Third Party Manufacturers [Member]", "label": "Other Third Party Manufacturers [Member]", "terseLabel": "Other Third Party Manufacturers" } } }, "localname": "OtherThirdPartyManufacturersMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_PaymentsToAcquireLicensesAndEquityInvestment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments To Acquire Licenses And Equity Investment", "label": "Payments To Acquire Licenses And Equity Investment", "terseLabel": "Payments To Acquire Licenses And Equity Investment" } } }, "localname": "PaymentsToAcquireLicensesAndEquityInvestment", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_PortolaPharmaceuticalsIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Portola Pharmaceuticals, Inc.", "label": "Portola Pharmaceuticals, Inc. [Member]", "terseLabel": "Portola Pharmaceuticals, Inc." } } }, "localname": "PortolaPharmaceuticalsIncMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsAcquisitionRelatedCostsDetails", "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails", "http://www.alxn.com/role/DebtDetails", "http://www.alxn.com/role/DebtScheduleofDebtDetails", "http://www.alxn.com/role/IntangibleAssetsandGoodwillNarrativeDetails", "http://www.alxn.com/role/InventoriesDetails" ], "xbrltype": "domainItemType" }, "alxn_PortolaPharmaceuticalsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Portola Pharmaceuticals [Member]", "label": "Portola Pharmaceuticals [Member]", "terseLabel": "Portola Pharmaceuticals" } } }, "localname": "PortolaPharmaceuticalsMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails", "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "domainItemType" }, "alxn_PreApprovalInventoryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pre Approval Inventory [Member]", "label": "Pre Approval Inventory [Member]", "terseLabel": "Pre Approval Inventory" } } }, "localname": "PreApprovalInventoryMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/InventoriesDetails" ], "xbrltype": "domainItemType" }, "alxn_PrepaidResearchAndDevelopmentExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Prepaid Research And Development Expense", "label": "Prepaid Research And Development Expense", "terseLabel": "Prepaid Research And Development Expense" } } }, "localname": "PrepaidResearchAndDevelopmentExpense", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_ProceedsFromSaleAndMaturityOfDebtSecuritiesAvailableForSaleAndCashEquivalents": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale And Cash Equivalents", "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale And Cash Equivalents", "terseLabel": "Proceeds from maturities and sales" } } }, "localname": "ProceedsFromSaleAndMaturityOfDebtSecuritiesAvailableForSaleAndCashEquivalents", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesProceedsfromSaleDetails" ], "xbrltype": "monetaryItemType" }, "alxn_PurchasedTechnologyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Purchased Technology [Member]", "label": "Purchased Technology [Member]", "terseLabel": "Purchased technology" } } }, "localname": "PurchasedTechnologyMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/IncomeTaxesNarrativeDetails", "http://www.alxn.com/role/IntangibleAssetsandGoodwillNarrativeDetails", "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" ], "xbrltype": "domainItemType" }, "alxn_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Reclassification out of Accumulated Other Comprehensive Income [Table]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Line Items]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Line Items]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLineItems", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeSignificantReclassificationsfromAOCIDetails" ], "xbrltype": "stringItemType" }, "alxn_ResearchAndDevelopmentAgreementOptionFee": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Research and Development Agreement, Option Fee", "label": "Research and Development Agreement, Option Fee", "terseLabel": "Research and Development Agreement, Option Fee" } } }, "localname": "ResearchAndDevelopmentAgreementOptionFee", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_ResearchAndDevelopmentArrangementPotentialContingentPaymentMaximum": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Research and Development Arrangement, Potential Contingent Payment, Maximum", "label": "Research and Development Arrangement, Potential Contingent Payment, Maximum", "terseLabel": "Research and Development Arrangement, Potential Contingent Payment, Maximum" } } }, "localname": "ResearchAndDevelopmentArrangementPotentialContingentPaymentMaximum", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_ResearchandDevelopmentArrangementPotentialPaymentMaximum": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Research and Development Arrangement, Potential Payment, Maximum", "label": "Research and Development Arrangement, Potential Payment, Maximum", "terseLabel": "Research and Development Arrangement, Potential Payment, Maximum" } } }, "localname": "ResearchandDevelopmentArrangementPotentialPaymentMaximum", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_RestructuringChargesAndAccrualAdjustment": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations": { "order": 6.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Restructuring Charges And Accrual Adjustment", "label": "Restructuring Charges And Accrual Adjustment", "terseLabel": "Restructuring expenses" } } }, "localname": "RestructuringChargesAndAccrualAdjustment", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "alxn_RestructuringChargesEstimatedAdditionalCharge": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Restructuring Charges, Estimated Additional Charge", "label": "Restructuring Charges, Estimated Additional Charge", "terseLabel": "Estimated additional charges" } } }, "localname": "RestructuringChargesEstimatedAdditionalCharge", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/RestructuringandRelatedExpensesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_RoyaltyAgreementClosingDayPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Royalty Agreement, Closing Day Payment", "label": "Royalty Agreement, Closing Day Payment", "terseLabel": "Royalty Agreement, Closing Day Payment" } } }, "localname": "RoyaltyAgreementClosingDayPayment", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "alxn_RoyaltyAgreementInterestToBeAccrued": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Royalty Agreement, Interest To Be Accrued", "label": "Royalty Agreement, Interest To Be Accrued", "negatedTerseLabel": "Less: interest to be accreted in future periods" } } }, "localname": "RoyaltyAgreementInterestToBeAccrued", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/DebtScheduleofDebtDetails" ], "xbrltype": "monetaryItemType" }, "alxn_RoyaltyAgreementMaximumPotentialRoyaltyPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Royalty Agreement, Maximum Potential Royalty Payments", "label": "Royalty Agreement, Maximum Potential Royalty Payments", "terseLabel": "Royalty Agreement, Maximum Potential Royalty Payments" } } }, "localname": "RoyaltyAgreementMaximumPotentialRoyaltyPayments", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "alxn_RoyaltyAgreementMaximumPotentialRoyaltyPaymentsAsAPercentageOfFundingReceived": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Royalty Agreement, Maximum Potential Royalty Payments As A Percentage Of Funding Received", "label": "Royalty Agreement, Maximum Potential Royalty Payments As A Percentage Of Funding Received", "terseLabel": "Royalty Agreement, Maximum Potential Royalty Payments As A Percentage Of Funding Received" } } }, "localname": "RoyaltyAgreementMaximumPotentialRoyaltyPaymentsAsAPercentageOfFundingReceived", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "percentItemType" }, "alxn_RoyaltyAgreementMilestonePaymentBasedOnRegulatoryApproval": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Royalty Agreement, Milestone Payment Based On Regulatory Approval", "label": "Royalty Agreement, Milestone Payment Based On Regulatory Approval", "terseLabel": "Royalty Agreement, Milestone Payment Based On Regulatory Approval" } } }, "localname": "RoyaltyAgreementMilestonePaymentBasedOnRegulatoryApproval", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "alxn_RoyaltyAgreementRemainingRoyaltyPaymentsToBePaid": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Royalty Agreement, Remaining Royalty Payments To Be Paid", "label": "Royalty Agreement, Remaining Royalty Payments To Be Paid", "terseLabel": "Total repayment obligation as of the acquisition date" } } }, "localname": "RoyaltyAgreementRemainingRoyaltyPaymentsToBePaid", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/DebtDetails", "http://www.alxn.com/role/DebtScheduleofDebtDetails" ], "xbrltype": "monetaryItemType" }, "alxn_RoyaltyAgreementTieredRoyaltyPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Royalty Agreement, Tiered Royalty, Percent", "label": "Royalty Agreement, Tiered Royalty, Percent", "terseLabel": "Royalty Agreement, Tiered Royalty, Percent" } } }, "localname": "RoyaltyAgreementTieredRoyaltyPercent", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "percentItemType" }, "alxn_RoyaltyBasedFinancingAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Royalty-Based Financing Agreement", "label": "Royalty-Based Financing Agreement [Member]", "terseLabel": "Royalty-Based Financing Agreement" } } }, "localname": "RoyaltyBasedFinancingAgreementMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/DebtDetails", "http://www.alxn.com/role/DebtScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "alxn_SECMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "SEC", "label": "SEC [Member]", "terseLabel": "SEC" } } }, "localname": "SECMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_ScheduleOfAssetAcquisitionByAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Schedule Of Asset Acquisition, By Acquisition [Table]", "label": "Schedule Of Asset Acquisition, By Acquisition [Line Items]", "terseLabel": "Schedule Of Asset Acquisition, By Acquisition [Line Items]" } } }, "localname": "ScheduleOfAssetAcquisitionByAcquisitionLineItems", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails", "http://www.alxn.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "alxn_ScheduleOfAssetAcquisitionByAcquisitionTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule Of Asset Acquisition, By Acquisition [Table]", "label": "Schedule Of Asset Acquisition, By Acquisition [Table]", "terseLabel": "Schedule Of Asset Acquisition, By Acquisition [Table]" } } }, "localname": "ScheduleOfAssetAcquisitionByAcquisitionTable", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails", "http://www.alxn.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "alxn_ScheduleOfIncomeTaxProvisionAndEffectiveTaxRateTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Income Tax Provision and Effective Tax Rate", "label": "Schedule of Income Tax Provision and Effective Tax Rate [Table Text Block]", "terseLabel": "Schedule of Income Tax Provision and Effective Tax Rate" } } }, "localname": "ScheduleOfIncomeTaxProvisionAndEffectiveTaxRateTableTextBlock", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "alxn_SeniorSecuredTermLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Secured Term Loan [Member]", "label": "Senior Secured Term Loan [Member]", "terseLabel": "Senior Secured Term Loan" } } }, "localname": "SeniorSecuredTermLoanMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "alxn_SharesUsedInComputingNetIncomePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Shares used in computing net income per share.", "label": "Shares Used In Computing Net Income Per Share", "terseLabel": "Shares used in computing earnings per common share" } } }, "localname": "SharesUsedInComputingNetIncomePerShare", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "alxn_SolirisMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Soliris [Member]", "label": "Soliris [Member]", "terseLabel": "SOLIRIS" } } }, "localname": "SolirisMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionDisaggregationofRevenuebyProductandGeographicalRegionDetails" ], "xbrltype": "domainItemType" }, "alxn_StealthMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stealth [Member]", "label": "Stealth [Member]", "terseLabel": "Stealth" } } }, "localname": "StealthMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "domainItemType" }, "alxn_StrensiqProductLineMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Strensiq Product Line [Member]", "label": "Strensiq Product Line [Member]", "terseLabel": "STRENSIQ" } } }, "localname": "StrensiqProductLineMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionDisaggregationofRevenuebyProductandGeographicalRegionDetails" ], "xbrltype": "domainItemType" }, "alxn_SubcutaneousFormulationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Subcutaneous Formulation", "label": "Subcutaneous Formulation [Member]", "terseLabel": "Subcutaneous Formulation" } } }, "localname": "SubcutaneousFormulationMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_SyntimmuneIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Syntimmune, Inc [Member]", "label": "Syntimmune, Inc [Member]", "terseLabel": "Syntimmune, Inc" } } }, "localname": "SyntimmuneIncMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_UltomirisMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Ultomiris [Member]", "label": "Ultomiris [Member]", "terseLabel": "ULTOMIRIS" } } }, "localname": "UltomirisMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionDisaggregationofRevenuebyProductandGeographicalRegionDetails" ], "xbrltype": "domainItemType" }, "alxn_UnrecordedUnconditionalPurchaseObligationUndiscountedFixedPaymentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Unrecorded Unconditional Purchase Obligation, Undiscounted Fixed Payment Amount", "label": "Unrecorded Unconditional Purchase Obligation, Undiscounted Fixed Payment Amount", "terseLabel": "Unrecorded Unconditional Purchase Obligation, Undiscounted Fixed Payment Amount" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationUndiscountedFixedPaymentAmount", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_ValuationAllowanceReleaseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Valuation Allowance Release [Member]", "label": "Valuation Allowance Release [Member]", "terseLabel": "Valuation Allowance Release" } } }, "localname": "ValuationAllowanceReleaseMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_ZealandMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Zealand [Member]", "label": "Zealand [Member]", "terseLabel": "Zealand" } } }, "localname": "ZealandMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "domainItemType" }, "alxn_ZealandPharmaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Zealand Pharma [Member]", "label": "Zealand Pharma [Member]", "terseLabel": "Zealand" } } }, "localname": "ZealandPharmaMember", "nsuri": "http://www.alxn.com/20200930", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionDisaggregationofRevenuebyProductandGeographicalRegionDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r446" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r447" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r448" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets", "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r448" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r448" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r449" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r448" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r448" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r448" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r448" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets", "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r444" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r445" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Asia Pacific [Member]", "terseLabel": "Asia Pacific" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionDisaggregationofRevenuebyProductandGeographicalRegionDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r75", "r137" ], "lang": { "en-US": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.alxn.com/role/DebtDetails", "http://www.alxn.com/role/DebtScheduleofDebtDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails", "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails", "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Europe [Member]", "terseLabel": "Europe" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionDisaggregationofRevenuebyProductandGeographicalRegionDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/DebtDetails", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofInterestRateContractsDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails", "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/DebtDetails", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofInterestRateContractsDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails", "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r170", "r280", "r282", "r431", "r432" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations", "http://www.alxn.com/role/RevenueRecognitionDisaggregationofRevenuebyProductandGeographicalRegionDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations", "http://www.alxn.com/role/RevenueRecognitionDisaggregationofRevenuebyProductandGeographicalRegionDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/DebtDetails", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofInterestRateContractsDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails", "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/DebtDetails", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofInterestRateContractsDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails", "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.alxn.com/role/DebtDetails", "http://www.alxn.com/role/DebtScheduleofDebtDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails", "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical", "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r185" ], "lang": { "en-US": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails", "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionDisaggregationofRevenuebyProductandGeographicalRegionDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r171", "r280", "r283", "r433", "r440", "r442" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionDisaggregationofRevenuebyProductandGeographicalRegionDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r250", "r394" ], "lang": { "en-US": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical", "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r15", "r35", "r172", "r173", "r281" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Trade accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r84", "r89", "r91", "r287", "r341" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Defined Benefit Pension Plans" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeChangesinAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": { "auth_ref": [ "r89", "r340" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.", "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]", "terseLabel": "Unrealized Gains (Losses) from Hedging Activities" } } }, "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails", "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeChangesinAOCIDetails", "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeSignificantReclassificationsfromAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r81", "r82", "r83", "r89", "r91" ], "lang": { "en-US": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]", "terseLabel": "Unrealized Gains (Losses) from Debt Securities" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeChangesinAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeChangesinAOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r86", "r88", "r89" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets", "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeChangesinAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeChangesinAOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r85", "r89", "r91", "r341" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r79", "r89", "r91", "r341" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign Currency Translation Adjustment" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeChangesinAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r36" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r289", "r290", "r293", "r294" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash flows from operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r102", "r129", "r389" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of deferred financing costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r129", "r213", "r221" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of purchased intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsandGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r153" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/EarningsPerCommonShareNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails", "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r169", "r403", "r422" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r17", "r18", "r67" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r179" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Holding Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesAvailableforsaleInvestmentsbyClassificationinBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r180" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "terseLabel": "Gross Unrealized Holding Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesAvailableforsaleInvestmentsbyClassificationinBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r177", "r194" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "terseLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesAvailableforsaleInvestmentsbyClassificationinBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r175", "r178", "r194" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesAvailableforsaleInvestmentsbyClassificationinBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails", "http://www.alxn.com/role/InventoriesDetails", "http://www.alxn.com/role/MarketableSecuritiesAvailableforsaleInvestmentsbyClassificationinBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r349", "r353" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails", "http://www.alxn.com/role/InventoriesDetails", "http://www.alxn.com/role/MarketableSecuritiesAvailableforsaleInvestmentsbyClassificationinBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsAcquisitionRelatedCostsDetails", "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails", "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.alxn.com/role/DebtDetails", "http://www.alxn.com/role/DebtScheduleofDebtDetails", "http://www.alxn.com/role/IntangibleAssetsandGoodwillNarrativeDetails", "http://www.alxn.com/role/InventoriesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r320", "r321" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsAcquisitionRelatedCostsDetails", "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails", "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.alxn.com/role/DebtDetails", "http://www.alxn.com/role/DebtScheduleofDebtDetails", "http://www.alxn.com/role/IntangibleAssetsandGoodwillNarrativeDetails", "http://www.alxn.com/role/InventoriesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsAcquisitionRelatedCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r318", "r319" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Summary of Pro Forma Information" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r318", "r319" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Business Acquisition, Pro Forma Net Income (Loss)" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsProFormaInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r318", "r319" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Business Acquisition, Pro Forma Revenue" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsProFormaInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r313" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "terseLabel": "Acquisition-related costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r327", "r328", "r331" ], "calculation": { "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Upfront cash paid, net", "totalLabel": "Upfront cash paid, net" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails", "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combination, Consideration Transferred [Abstract]", "terseLabel": "Consideration" } } }, "localname": "BusinessCombinationConsiderationTransferredAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r327", "r328" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "terseLabel": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r128", "r335" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Change in fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [ "r334" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "terseLabel": "Business Combination, Contingent Consideration, Arrangements, Range of Outcomes, Value, High" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow": { "auth_ref": [ "r334" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For contingent consideration arrangements and indemnification assets recognized in connection with a business combination, this element represents an estimate of the low-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r326", "r329", "r333" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Business Combination, Contingent Consideration, Liability" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r326", "r330" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails", "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r336" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisitions" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/Acquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationIntegrationRelatedCosts": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/AcquisitionsAcquisitionRelatedCostsDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.", "label": "Business Combination, Integration Related Costs", "terseLabel": "Integration costs" } } }, "localname": "BusinessCombinationIntegrationRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsAcquisitionRelatedCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": { "auth_ref": [ "r317" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.", "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual", "negatedTerseLabel": "Operating loss since acquisition" } } }, "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": { "auth_ref": [ "r317" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.", "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual", "terseLabel": "Revenue since acquisition" } } }, "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r323" ], "calculation": { "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": { "auth_ref": [ "r323" ], "calculation": { "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities", "terseLabel": "Marketable securities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r323" ], "calculation": { "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails": { "order": 8.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "negatedTerseLabel": "Accounts payable and accrued expenses" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": { "auth_ref": [ "r323" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt", "terseLabel": "Current debt" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": { "auth_ref": [ "r299", "r323" ], "calculation": { "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.", "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets", "terseLabel": "Deferred tax assets, net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r299", "r323" ], "calculation": { "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "negatedLabel": "Net deferred tax liability", "negatedTerseLabel": "Deferred tax liabilities, net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": { "auth_ref": [ "r323" ], "calculation": { "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets", "terseLabel": "In-process research & development assets (IPR&D)" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails", "http://www.alxn.com/role/IntangibleAssetsandGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r323" ], "calculation": { "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r322", "r323" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Purchased techonology" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/IntangibleAssetsandGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r322", "r323" ], "calculation": { "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventories, including noncurrent portion of $169.1 and validation batches of $60.9" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r322", "r323" ], "calculation": { "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Total net assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r323" ], "calculation": { "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails": { "order": 9.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Other assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest [Abstract]", "terseLabel": "Assets Acquired and Liabilities Assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r323" ], "calculation": { "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Total net assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed": { "auth_ref": [ "r315" ], "calculation": { "http://www.alxn.com/role/AcquisitionsAcquisitionRelatedCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs which have been expensed.", "label": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed", "totalLabel": "Acquisition-related costs" } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsAcquisitionRelatedCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock": { "auth_ref": [ "r314" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.", "label": "Business Combination, Separately Recognized Transactions [Table Text Block]", "terseLabel": "Summary of Acquisition-Related Costs" } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": { "auth_ref": [ "r316" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value", "terseLabel": "Fair value of replacement equity awards attributable to the pre-combination period" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]", "terseLabel": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r132", "r133", "r134" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Accounts payable and accrued expenses for purchases of property, plant and equipment and intangible assets" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r13", "r44", "r131" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets", "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesAvailableforsaleInvestmentsbyClassificationinBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r126", "r131", "r135" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash and cash equivalents and restricted cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r126", "r385" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash and cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r23" ], "lang": { "en-US": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]", "terseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r346" ], "lang": { "en-US": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental cash flow disclosures from investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r417" ], "lang": { "en-US": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates of Deposit [Member]", "terseLabel": "Bank certificates of deposit" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails", "http://www.alxn.com/role/MarketableSecuritiesAvailableforsaleInvestmentsbyClassificationinBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementMember": { "auth_ref": [ "r337" ], "lang": { "en-US": { "role": { "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.", "label": "Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement" } } }, "localname": "CollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails", "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r255" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails", "http://www.alxn.com/role/MarketableSecuritiesAvailableforsaleInvestmentsbyClassificationinBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r58", "r249", "r410", "r427" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 16)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r248", "r253" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common\u00a0Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityStatement", "http://www.alxn.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r34" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r34" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r34" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r34", "r264" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Balances, common shares", "periodStartLabel": "Balances, common shares" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r34" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.0001 par value; 290.0 shares authorized; 239.7 and 237.8 shares issued at September 30, 2020 and December 31, 2019, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r94", "r96", "r97" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r111" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Other Comprehensive Income and Accumulated Other Comprehensive Income" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncome" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r278" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of contract balances and changes in contract balances.", "label": "Contract with Customer, Asset and Liability [Table Text Block]", "terseLabel": "Summary of receivables and contract liabilities from contracts" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "auth_ref": [ "r275", "r277", "r281" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.", "label": "Contract with Customer, Asset, Net, Current", "terseLabel": "Receivables, which are included in Trade accounts receivable, net" } } }, "localname": "ContractWithCustomerAssetNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionSummaryofReceivablesandContractLiabilitiesfromContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r275", "r276", "r281" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Contract liabilities, which are included in Other current liabilities" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionSummaryofReceivablesandContractLiabilitiesfromContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContributionOfProperty": { "auth_ref": [ "r132", "r133", "r134" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Value of property contributed in noncash investing and financing activities.", "label": "Contribution of Property", "terseLabel": "Exchange of intellectual property rights for equity shares in Inozyme" } } }, "localname": "ContributionOfProperty", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateBondSecuritiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).", "label": "Corporate Bond Securities [Member]", "terseLabel": "Corporate bonds" } } }, "localname": "CorporateBondSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails", "http://www.alxn.com/role/MarketableSecuritiesAvailableforsaleInvestmentsbyClassificationinBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r106" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales (exclusive of amortization of purchased intangible assets)" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r105" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r260" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r28", "r30", "r31", "r404", "r405", "r420" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/DebtDetails", "http://www.alxn.com/role/DebtScheduleofDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r388", "r390" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument, principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r55", "r258", "r388" ], "lang": { "en-US": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Debt Instrument, Interest Rate, Effective Percentage" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails", "http://www.alxn.com/role/DebtScheduleofDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r56" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/DebtDetails", "http://www.alxn.com/role/DebtScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r56", "r418" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Debt Instrument, Periodic Payment", "negatedTerseLabel": "Debt Instrument, Periodic Payment" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r56", "r139", "r265", "r268", "r269", "r270", "r387", "r388", "r390", "r419" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails", "http://www.alxn.com/role/DebtScheduleofDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r387", "r390" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "terseLabel": "Debt Instrument, Unamortized Discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "auth_ref": [ "r181", "r196", "r199" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months", "terseLabel": "Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": { "auth_ref": [ "r182" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Realized Gain", "terseLabel": "Realized gains" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesProceedsfromSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": { "auth_ref": [ "r182" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Realized Loss", "negatedTerseLabel": "Realized losses" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesProceedsfromSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r183" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesAvailableforsaleInvestmentsbyClassificationinBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesMember": { "auth_ref": [ "r183" ], "lang": { "en-US": { "role": { "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.", "label": "Debt Securities [Member]", "terseLabel": "Total available-for-sale debt securities" } } }, "localname": "DebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesAvailableforsaleInvestmentsbyClassificationinBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r47", "r389" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Remaining unamortized deferred financing costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r303" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r129", "r136", "r307", "r309" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred Income Tax Expense (Benefit)" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r300", "r303" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "auth_ref": [ "r130" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.", "label": "Deferred Income Taxes and Tax Credits", "terseLabel": "Deferred taxes (benefit)" } } }, "localname": "DeferredIncomeTaxesAndTaxCredits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r296", "r305", "r306" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Deferred tax assets, net operating loss carryforward" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r298", "r305", "r306" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Deferred tax assets, other differences" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r304", "r305", "r306" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Deferred tax assets, income tax credits" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts": { "auth_ref": [ "r297", "r305", "r306" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from inventory.", "label": "Deferred Tax Liabilities, Inventory", "terseLabel": "Deferred tax liabilities, inventory" } } }, "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "auth_ref": [ "r298", "r305", "r306" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.", "label": "Deferred Tax Liabilities, Intangible Assets", "terseLabel": "Deferred tax liabilities, intangible assetes" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r129", "r167" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetFairValueAmountOffsetAgainstCollateralAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Asset, Fair Value, Amount Offset Against Collateral [Abstract]", "terseLabel": "Derivative Asset, Fair Value, Amount Offset Against Collateral [Abstract]" } } }, "localname": "DerivativeAssetFairValueAmountOffsetAgainstCollateralAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesOffsettingAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeAssetFairValueGrossLiability": { "auth_ref": [ "r69", "r77", "r351" ], "calculation": { "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesOffsettingAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Asset, Fair Value, Gross Liability", "terseLabel": "Gross Amounts Offset in the Condensed Consolidated Balance Sheet" } } }, "localname": "DerivativeAssetFairValueGrossLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesOffsettingAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeCollateralObligationToReturnCash": { "auth_ref": [ "r71", "r74", "r364" ], "calculation": { "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesOffsettingAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.", "label": "Derivative, Collateral, Obligation to Return Cash", "negatedTerseLabel": "Cash Collateral Received" } } }, "localname": "DerivativeCollateralObligationToReturnCash", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesOffsettingAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeCollateralObligationToReturnSecurities": { "auth_ref": [ "r71", "r74" ], "calculation": { "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesOffsettingAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to return securities collateral under master netting arrangements that have not been offset against derivative assets.", "label": "Derivative, Collateral, Obligation to Return Securities", "negatedTerseLabel": "Derivative Financial Instruments" } } }, "localname": "DerivativeCollateralObligationToReturnSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesOffsettingAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeCollateralRightToReclaimCash": { "auth_ref": [ "r71", "r74", "r364" ], "calculation": { "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesOffsettingAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.", "label": "Derivative, Collateral, Right to Reclaim Cash", "terseLabel": "Cash Collateral Pledged" } } }, "localname": "DerivativeCollateralRightToReclaimCash", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesOffsettingAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeCollateralRightToReclaimSecurities": { "auth_ref": [ "r71", "r74" ], "calculation": { "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesOffsettingAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of right to receive securities collateral under master netting arrangements that have not been offset against derivative liabilities.", "label": "Derivative, Collateral, Right to Reclaim Securities", "terseLabel": "Derivative Financial Instruments" } } }, "localname": "DerivativeCollateralRightToReclaimSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesOffsettingAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesOffsettingAssetsandLiabilitiesDetails", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofInterestRateContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r68", "r76", "r351", "r399" ], "calculation": { "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesOffsettingAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Gross Asset", "terseLabel": "Gross Amounts of Recognized Assets", "verboseLabel": "Asset Derivatives, Fair Value" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesOffsettingAssetsandLiabilitiesDetails", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral": { "auth_ref": [ "r70", "r73", "r78", "r365" ], "calculation": { "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesOffsettingAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, after offset of derivative liability, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, before offset against an obligation to return collateral under a master netting arrangement. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Amount Not Offset Against Collateral", "totalLabel": "Amounts of Assets Presented in the Condensed Consolidated Balance Sheet" } } }, "localname": "DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesOffsettingAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral": { "auth_ref": [ "r72", "r74", "r363" ], "calculation": { "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesOffsettingAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, after effects of master netting arrangements, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset offset against an obligation to return collateral. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset, Fair Value, Amount Offset Against Collateral", "totalLabel": "Net Amount" } } }, "localname": "DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesOffsettingAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r68", "r76", "r351", "r399" ], "calculation": { "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesOffsettingAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "negatedTerseLabel": "Gross Amounts of Recognized Liabilities", "terseLabel": "Liability Derivatives, Fair Value" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesOffsettingAssetsandLiabilitiesDetails", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral": { "auth_ref": [ "r70", "r73", "r78", "r365" ], "calculation": { "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesOffsettingAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after offset of derivative asset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be and before offset against a right to receive collateral under a master netting arrangement. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Amount Not Offset Against Collateral", "negatedTotalLabel": "Amounts of Liabilities Presented in the Condensed Consolidated Balance Sheet" } } }, "localname": "DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesOffsettingAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral": { "auth_ref": [ "r72", "r74", "r363" ], "calculation": { "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesOffsettingAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after effects of master netting arrangements, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset offset against the right to receive collateral. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Fair Value, Amount Offset Against Collateral", "negatedTotalLabel": "Net Amount" } } }, "localname": "DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesOffsettingAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFixedInterestRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fixed interest rate related to the interest rate derivative.", "label": "Derivative, Fixed Interest Rate", "verboseLabel": "Derivative, fixed interest rate" } } }, "localname": "DerivativeFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofInterestRateContractsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r350", "r352", "r357", "r360" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesOffsettingAssetsandLiabilitiesDetails", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofInterestRateContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r371" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Derivative Instruments and Hedging Activities" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivities" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r347", "r350", "r357" ], "lang": { "en-US": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r347", "r350", "r357", "r360", "r361", "r367", "r368" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred": { "auth_ref": [ "r370" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.", "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred", "terseLabel": "Estimated gains (losses) to be reclassified from other comprehenisve income in next 12 months" } } }, "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r70", "r73", "r381" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Derivative Liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityFairValueAmountOffsetAgainstCollateralAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Liability, Fair Value, Amount Offset Against Collateral [Abstract]", "terseLabel": "Derivative Liability, Fair Value, Amount Offset Against Collateral [Abstract]" } } }, "localname": "DerivativeLiabilityFairValueAmountOffsetAgainstCollateralAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesOffsettingAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilityFairValueGrossAsset": { "auth_ref": [ "r69", "r77", "r351" ], "calculation": { "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesOffsettingAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Liability, Fair Value, Gross Asset", "terseLabel": "Gross Amounts Offset in the Condensed Consolidated Balance Sheet" } } }, "localname": "DerivativeLiabilityFairValueGrossAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesOffsettingAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofInterestRateContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r143", "r343", "r344", "r345", "r347", "r348", "r354", "r357", "r362", "r366", "r368" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofInterestRateContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]", "terseLabel": "Derivatives, Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r347" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofInterestRateContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r280" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of revenue from contracts with customer" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings per common share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations", "http://www.alxn.com/role/EarningsPerCommonShareSummaryOfCalculationOfBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r101", "r145", "r148", "r150", "r151", "r152", "r155", "r414", "r429" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations", "http://www.alxn.com/role/EarningsPerCommonShareSummaryOfCalculationOfBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r101", "r145", "r148", "r150", "r151", "r152", "r155", "r414", "r429" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations", "http://www.alxn.com/role/EarningsPerCommonShareSummaryOfCalculationOfBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r156" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Common Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/EarningsPerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r385" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r142", "r301", "r302" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/IncomeTaxesScheduleofIncomeTaxProvisionandEffectiveTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions": { "auth_ref": [ "r301", "r302", "r308" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deductions. Including, but not limited to, extraterritorial income exclusion deduction, qualified production activity deduction, dividend deduction, deduction for dividend paid to employee stock ownership plan, Medicare prescription drug benefit subsidy deduction, and other deductions.", "label": "Effective Income Tax Rate Reconciliation, Deduction, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Deduction, Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationDeductions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]", "terseLabel": "Employee Separation Costs" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringandRelatedExpensesRestructuringReserveRollForwardDetails", "http://www.alxn.com/role/RestructuringandRelatedExpensesScheduleofRestructuringandrelatedCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r264" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityStatement", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails", "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeChangesinAOCIDetails", "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeSignificantReclassificationsfromAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentAggregateCost": { "auth_ref": [ "r45" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.", "label": "Equity Method Investment, Aggregate Cost", "terseLabel": "Equity Method Investment, Aggregate Cost" } } }, "localname": "EquityMethodInvestmentAggregateCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": { "auth_ref": [ "r103", "r104", "r129" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment.", "label": "Equity Method Investment, Realized Gain (Loss) on Disposal", "terseLabel": "Equity Method Investment, Realized Gain (Loss) on Disposal" } } }, "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r380" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI", "terseLabel": "Equity Securities, FV-NI", "verboseLabel": "Fair value of equity shares held by Alexion at closing" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails", "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r24", "r29", "r183", "r408", "r421", "r438" ], "lang": { "en-US": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Equity securities" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EscrowDeposit": { "auth_ref": [ "r409" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.", "label": "Escrow Deposit", "terseLabel": "Escrow Deposit" } } }, "localname": "EscrowDeposit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r372", "r373", "r374", "r379" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Fair Value Inputs, Liabilities, Quantitative Information [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r375" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r376" ], "lang": { "en-US": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Fair Value by Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Acquisition-Related Contingent Consideration [Roll Forward]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r372", "r379" ], "lang": { "en-US": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r285", "r286", "r288", "r373", "r395" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r378", "r379" ], "lang": { "en-US": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r378" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurement" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurement" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r285", "r286", "r288", "r373", "r396" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level\u00a01" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r285", "r286", "r288", "r373", "r397" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "verboseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r285", "r286", "r288", "r373", "r398" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level\u00a03" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r376" ], "lang": { "en-US": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r376", "r379" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule Of Acquisition-Related Contingent Consideration" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r377" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "negatedTerseLabel": "Change in fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r376" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "negatedPeriodEndLabel": "Balance at end of period", "negatedPeriodStartLabel": "Balance at beginning of period" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "auth_ref": [ "r349", "r354", "r367" ], "lang": { "en-US": { "role": { "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]" } } }, "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r189", "r190", "r191", "r192", "r193", "r195", "r197", "r198", "r199" ], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesAvailableforsaleInvestmentsbyClassificationinBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Finite-Lived Intangible Asset, Useful Life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r220" ], "calculation": { "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Finite-Lived Intangible Assets, Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsandGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year", "terseLabel": "2020 (remainder)" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsandGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r222" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsandGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r222" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsandGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r222" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsandGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r222" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsandGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r214", "r217", "r220", "r224", "r401" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/IncomeTaxesNarrativeDetails", "http://www.alxn.com/role/IntangibleAssetsandGoodwillNarrativeDetails", "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r220", "r401" ], "calculation": { "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails": { "order": 2.0, "parentTag": "alxn_IntangibleAssetsCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Finite-Lived Intangible Assets, Gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r214", "r219" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/IncomeTaxesNarrativeDetails", "http://www.alxn.com/role/IntangibleAssetsandGoodwillNarrativeDetails", "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r220" ], "calculation": { "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails_1": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Net", "totalLabel": "Net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsandGoodwillNarrativeDetails", "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.", "label": "Foreign Currency Contract, Asset, Fair Value Disclosure", "terseLabel": "Foreign exchange forward contracts, asset" } } }, "localname": "ForeignCurrencyContractAssetFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.", "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure", "terseLabel": "Foreign exchange forward contracts, liability" } } }, "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r382", "r383", "r384" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedTerseLabel": "Unrealized foreign currency loss (gain)" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "terseLabel": "Foreign exchange forward contracts" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesOffsettingAssetsandLiabilitiesDetails", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "auth_ref": [ "r350" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.", "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "negatedTerseLabel": "Unrealized gain on forward contracts" } } }, "localname": "GainLossOnDerivativeInstrumentsNetPretax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r129" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations": { "order": 10.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedTerseLabel": "Gain on sale of asset", "terseLabel": "Gain (Loss) on Disposition of Assets" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations", "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings": { "auth_ref": [ "r355" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total amount of gain (loss) derived from fair value hedges recognized in earnings in the period.", "label": "Gain (Loss) on Fair Value Hedges Recognized in Earnings", "terseLabel": "Gain (Loss) on Fair Value Hedges Recognized in Earnings" } } }, "localname": "GainLossOnFairValueHedgesRecognizedInEarnings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r129" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedTerseLabel": "Gain on sale of asset" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainOnSaleOfInvestments": { "auth_ref": [ "r103", "r104", "r129", "r412", "r430" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The difference between the carrying value and the sale price of an investment. A gain would be recognized when the sale price of the investment is greater than the carrying value of the investment. This element refers to the Gain included in earnings and not to the cash proceeds of the sale.", "label": "Gain on Sale of Investments", "negatedTerseLabel": "Gain on derecognition of Portola strategic equity investment" } } }, "localname": "GainOnSaleOfInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r204", "r205" ], "calculation": { "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Balance at September 30, 2020", "periodStartLabel": "Balance at December 31, 2019", "terseLabel": "Goodwill", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails", "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets", "http://www.alxn.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails", "http://www.alxn.com/role/IntangibleAssetsandGoodwillNarrativeDetails", "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r207" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill resulting from the acquisitions of Achillion and Portola" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r226" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets and Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsandGoodwill" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillGross": { "auth_ref": [ "r206", "r209" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Gross", "terseLabel": "Goodwill, Gross" } } }, "localname": "GoodwillGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsandGoodwillNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "auth_ref": [ "r208", "r312" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Purchase Accounting Adjustments", "terseLabel": "Goodwill adjustments" } } }, "localname": "GoodwillPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r347", "r361" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofInterestRateContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r347" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofInterestRateContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r347" ], "lang": { "en-US": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r129", "r225" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations": { "order": 8.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "terseLabel": "Impairment of intangible assets" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r129", "r225" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)", "terseLabel": "Impairment" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/IncomeTaxesNarrativeDetails", "http://www.alxn.com/role/IntangibleAssetsandGoodwillNarrativeDetails", "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r141" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations", "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeSignificantReclassificationsfromAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r0", "r2", "r3", "r4", "r5", "r6", "r7", "r8", "r9", "r10", "r11", "r231", "r232" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r229" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r311" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r136", "r168", "r310" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedTerseLabel": "Income tax provision", "terseLabel": "Income tax expense (benefit)", "verboseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations", "http://www.alxn.com/role/IncomeTaxesScheduleofIncomeTaxProvisionandEffectiveTaxRateDetails", "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeSignificantReclassificationsfromAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r128" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable, accrued expenses, lease liabilities and other liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r128" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r128" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities, excluding the effect of acquisitions:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r128" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses, right of use operating assets and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityStatement" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r149", "r154" ], "calculation": { "http://www.alxn.com/role/EarningsPerCommonShareSummaryOfCalculationOfBasicAndDilutedEarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "verboseLabel": "Stock awards (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/EarningsPerCommonShareSummaryOfCalculationOfBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r215", "r223" ], "lang": { "en-US": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails", "http://www.alxn.com/role/IntangibleAssetsandGoodwillNarrativeDetails", "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r223" ], "calculation": { "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails_1": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "totalLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill)" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r215", "r223" ], "lang": { "en-US": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails", "http://www.alxn.com/role/IntangibleAssetsandGoodwillNarrativeDetails", "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r212", "r218" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "totalLabel": "Intangible assets" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets", "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r99", "r166", "r386", "r389", "r415" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails", "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeSignificantReclassificationsfromAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r109", "r259" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "terseLabel": "Interest Expense, Debt" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r359" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest Expense" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateContractMember": { "auth_ref": [ "r285", "r358" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.", "label": "Interest Rate Contract [Member]", "terseLabel": "Interest rate contracts" } } }, "localname": "InterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateDerivativeAssetsAtFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value as of the balance sheet date of interest rate derivative assets, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as assets.", "label": "Interest Rate Derivative Assets, at Fair Value", "terseLabel": "Interest Rate Derivative Assets, at Fair Value" } } }, "localname": "InterestRateDerivativeAssetsAtFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateDerivativeLiabilitiesAtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value as of the balance sheet date of interest rate derivative liabilities, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as liabilities.", "label": "Interest Rate Derivative Liabilities, at Fair Value", "terseLabel": "Interest Rate Derivative Liabilities, at Fair Value" } } }, "localname": "InterestRateDerivativeLiabilitiesAtFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoriesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.", "label": "Inventories [Member]", "terseLabel": "Inventories" } } }, "localname": "InventoriesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/InventoriesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryCurrentTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.", "label": "Inventory, Current [Table]", "terseLabel": "Inventory, Current [Table]" } } }, "localname": "InventoryCurrentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/InventoriesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r203" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r62" ], "calculation": { "http://www.alxn.com/role/InventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Inventory [Line Items]", "terseLabel": "Inventory [Line Items]" } } }, "localname": "InventoryLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/InventoriesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r14", "r65", "r201" ], "calculation": { "http://www.alxn.com/role/InventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Inventory, Net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory, Net [Abstract]", "terseLabel": "Inventory, Net [Abstract]" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r64" ], "calculation": { "http://www.alxn.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r63" ], "calculation": { "http://www.alxn.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r202" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Inventory Write-down", "terseLabel": "Inventory obsolescence charge" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNet": { "auth_ref": [ "r108", "r109", "r110" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Net", "terseLabel": "Investment income, net" } } }, "localname": "InvestmentIncomeNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTextBlock": { "auth_ref": [ "r183", "r184", "r187", "r188" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for investment.", "label": "Investment [Text Block]", "terseLabel": "Other Investments" } } }, "localname": "InvestmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/OtherInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r434", "r435", "r436", "r437" ], "lang": { "en-US": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r434", "r435", "r436", "r437" ], "lang": { "en-US": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsAllOtherInvestmentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investments, All Other Investments [Abstract]", "terseLabel": "Investments, All Other Investments [Abstract]" } } }, "localname": "InvestmentsAllOtherInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]", "terseLabel": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r372" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Marketable securities" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r183", "r402", "r416", "r439" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Marketable securities" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letters of credit, amount outstanding" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r51" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r40", "r406", "r425" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r54" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r324" ], "lang": { "en-US": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "Licensing rights" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r49" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit facility, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded to Other Party", "terseLabel": "Litigation Settlement, Amount Awarded to Other Party" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r31", "r257", "r405", "r423" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Outstanding debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/DebtDetails", "http://www.alxn.com/role/DebtScheduleofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets", "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r56" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt, less current portion" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets", "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r56" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r56", "r256" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyAccrualPayments": { "auth_ref": [ "r249" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow reducing loss contingency liability.", "label": "Loss Contingency Accrual, Payments", "terseLabel": "Loss Contingency Accrual, Payments" } } }, "localname": "LossContingencyAccrualPayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyEstimateOfPossibleLoss": { "auth_ref": [ "r251", "r252", "r254" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.", "label": "Loss Contingency, Estimate of Possible Loss", "terseLabel": "Loss Contingency, Estimate of Possible Loss" } } }, "localname": "LossContingencyEstimateOfPossibleLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r16", "r52" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r285" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r157", "r165" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Business" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/Business" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r126" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r126" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r126", "r127", "r130" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r92", "r95", "r100", "r130", "r154", "r413", "r428" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.alxn.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income", "totalLabel": "Net income", "verboseLabel": "Net income used for basic and diluted calculation" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.alxn.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityStatement", "http://www.alxn.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeStatement", "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations", "http://www.alxn.com/role/EarningsPerCommonShareSummaryOfCalculationOfBasicAndDilutedEarningsPerShareDetails", "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeSignificantReclassificationsfromAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/BasisofPresentationandPrinciplesOfConsolidationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r347" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not Designated as Hedging Instrument" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income and expense:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Costs and expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r392" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Noncurrent operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r391" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right of use operating assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r12", "r342" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Basis of Presentation and Principles of Consolidation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/BasisofPresentationandPrinciplesOfConsolidation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r66" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsMember": { "auth_ref": [ "r349", "r367" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other assets.", "label": "Other Assets [Member]", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails", "http://www.alxn.com/role/InventoriesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r47" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Commitments [Line Items]", "terseLabel": "Other Commitments [Line Items]" } } }, "localname": "OtherCommitmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about obligations resulting from other commitments.", "label": "Other Commitments [Table]", "terseLabel": "Other Commitments [Table]" } } }, "localname": "OtherCommitmentsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r338", "r339", "r340" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Unrealized gains on debt securities" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r338", "r339", "r340" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r89", "r98" ], "calculation": { "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeChangesinAOCIDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "terseLabel": "Other comprehensive income (loss) before reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeChangesinAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "auth_ref": [ "r80", "r86" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "terseLabel": "Unrealized (gains) losses on hedging activities, net of tax of $(2.8), $3.5, $(14.3) and $(10.8), respectively" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": { "auth_ref": [ "r87" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax", "terseLabel": "Unrealized loss on hedge, tax effect" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "auth_ref": [ "r86", "r90" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r93", "r96", "r338", "r339", "r340" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeChangesinAOCIDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive income", "totalLabel": "Other comprehensive (loss) income, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityStatement", "http://www.alxn.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeStatement", "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeChangesinAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive (loss) income, net of tax:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax": { "auth_ref": [ "r80", "r86", "r369" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax", "terseLabel": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other current liabilities" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other intangibles" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r20", "r21", "r53" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesMember": { "auth_ref": [ "r349", "r367" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other liabilities.", "label": "Other Liabilities [Member]", "terseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r57" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r130" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other assets" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r110" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income and (expense)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations", "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherRestructuringMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restructuring and related activities classified as other.", "label": "Other Restructuring [Member]", "terseLabel": "Other" } } }, "localname": "OtherRestructuringMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringandRelatedExpensesRestructuringReserveRollForwardDetails", "http://www.alxn.com/role/RestructuringandRelatedExpensesScheduleofRestructuringandrelatedCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1": { "auth_ref": [ "r132", "r133", "r134" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The value of the noncash (or part noncash) consideration given (for example, liability, equity) in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.", "label": "Other Significant Noncash Transaction, Value of Consideration Given", "terseLabel": "Fair value of strategic investment and purchase option acquired, less upfront cash paid" } } }, "localname": "OtherSignificantNoncashTransactionValueOfConsiderationGiven1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r325" ], "lang": { "en-US": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]", "terseLabel": "Patents" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities": { "auth_ref": [ "r124" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Operating Activities", "negatedTerseLabel": "Payments of contingent consideration" } } }, "localname": "PaymentForContingentConsiderationLiabilityOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r121" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Repurchases of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r125", "r235" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedTerseLabel": "Settlements" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringandRelatedExpensesRestructuringReserveRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r123" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "terseLabel": "Payments of financing costs" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r112", "r115", "r176" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-sale", "negatedTerseLabel": "Purchases of available-for-sale debt securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r116", "r332" ], "calculation": { "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Upfront payment to shareholders and equity holders", "verboseLabel": "Payments to Acquire Businesses, Gross" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails", "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r116" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedTerseLabel": "Payment for acquisition of businesses, net of cash and restricted cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireEquityMethodInvestments": { "auth_ref": [ "r116" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.", "label": "Payments to Acquire Equity Method Investments", "verboseLabel": "Payments to Acquire Equity Method Investments" } } }, "localname": "PaymentsToAcquireEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r117" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Purchase of intangible assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherInvestments": { "auth_ref": [ "r118" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to acquire investments classified as other.", "label": "Payments to Acquire Other Investments", "negatedTerseLabel": "Purchases of strategic equity investments and options", "terseLabel": "Payments to Acquire Other Investments" } } }, "localname": "PaymentsToAcquireOtherInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r117" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchases of property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireTradingSecuritiesHeldforinvestment": { "auth_ref": [ "r118" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire securities classified as trading securities and held for investment purposes. Excludes payments for trading securities purchased and held principally for the purpose of selling them in the near term (thus held for only a short period of time).", "label": "Payments to Acquire Trading Securities Held-for-investment", "negatedTerseLabel": "Purchases of mutual funds related to nonqualified deferred compensation plan" } } }, "localname": "PaymentsToAcquireTradingSecuritiesHeldforinvestment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r120", "r123", "r144" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "auth_ref": [ "r112", "r113", "r176" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale", "terseLabel": "Proceeds from maturity or sale of available-for-sale debt securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from sale of mutual funds related to nonqualified deferred compensation plan" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": { "auth_ref": [ "r114" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.", "label": "Proceeds from Sale of Equity Method Investments", "terseLabel": "Proceeds from Sale of Equity Method Investments" } } }, "localname": "ProceedsFromSaleOfEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r119", "r292" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Net proceeds from issuance of common stock under share-based compensation arrangements" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionDisaggregationofRevenuebyProductandGeographicalRegionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r46", "r228" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r25", "r26", "r228", "r426" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r25", "r227" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property, Plant and Equipment, Useful Life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_PublicUtilitiesInventoryAxis": { "auth_ref": [ "r41" ], "lang": { "en-US": { "role": { "documentation": "Information by type of inventory held.", "label": "Inventory [Axis]", "terseLabel": "Inventory [Axis]" } } }, "localname": "PublicUtilitiesInventoryAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/InventoriesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PublicUtilitiesInventoryTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.", "label": "Inventory [Domain]", "terseLabel": "Inventory [Domain]" } } }, "localname": "PublicUtilitiesInventoryTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/InventoriesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RealizedGainLossOnInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of realized gains and losses on investments reported in the statement of income.", "label": "Realized Gain (Loss) on Investments [Table Text Block]", "terseLabel": "Realized Gain (Loss) on Investments" } } }, "localname": "RealizedGainLossOnInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r89", "r91", "r98" ], "calculation": { "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeChangesinAOCIDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "negatedTerseLabel": "Amounts reclassified from other comprehensive income" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeChangesinAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails", "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeSignificantReclassificationsfromAOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails", "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeSignificantReclassificationsfromAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails", "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeSignificantReclassificationsfromAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeSignificantReclassificationsfromAOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r122" ], "calculation": { "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails": { "order": 2.0, "parentTag": "alxn_BusinessCombinationTotalConsideration", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "negatedTerseLabel": "Less: payments made", "terseLabel": "Repayments of debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails", "http://www.alxn.com/role/DebtDetails", "http://www.alxn.com/role/DebtScheduleofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r122", "r140" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Repayments of Lines of Credit", "negatedTerseLabel": "Payments on revolving credit facility" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r122" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedTerseLabel": "Payments on term loan" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": { "auth_ref": [ "r216" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations": { "order": 7.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.", "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off", "negatedTerseLabel": "Acquired in-process research and development" } } }, "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r295", "r443" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails", "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r295" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations": { "order": 9.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r13", "r23", "r131", "r135" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Current", "terseLabel": "Restricted cash included in other current assets" } } }, "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "auth_ref": [ "r19", "r27", "r131", "r135", "r441" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Noncurrent", "terseLabel": "Restricted cash included in other noncurrent assets" } } }, "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restructuring and Related Activities [Abstract]", "terseLabel": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r246" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring and Related Expenses" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringandRelatedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "auth_ref": [ "r234", "r236", "r243", "r245" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.", "label": "Restructuring and Related Cost, Expected Cost", "terseLabel": "Restructuring and Related Cost, Expected Cost" } } }, "localname": "RestructuringAndRelatedCostExpectedCost1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringandRelatedExpensesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "auth_ref": [ "r234", "r236", "r243", "r245" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.", "label": "Restructuring and Related Cost, Incurred Cost", "terseLabel": "Charges" } } }, "localname": "RestructuringAndRelatedCostIncurredCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringandRelatedExpensesRestructuringReserveRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r129", "r233", "r239", "r244" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring expenses" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringandRelatedExpensesScheduleofRestructuringandrelatedCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringandRelatedExpensesRestructuringReserveRollForwardDetails", "http://www.alxn.com/role/RestructuringandRelatedExpensesScheduleofRestructuringandrelatedCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringandRelatedExpensesRestructuringReserveRollForwardDetails", "http://www.alxn.com/role/RestructuringandRelatedExpensesScheduleofRestructuringandrelatedCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCosts": { "auth_ref": [ "r129" ], "calculation": { "http://www.alxn.com/role/AcquisitionsAcquisitionRelatedCostsDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Costs", "terseLabel": "Restructuring-related costs" } } }, "localname": "RestructuringCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsAcquisitionRelatedCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r235", "r241" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "terseLabel": "Restructuring Reserve" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringandRelatedExpensesNarrativeDetails", "http://www.alxn.com/role/RestructuringandRelatedExpensesRestructuringReserveRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveAccrualAdjustment1": { "auth_ref": [ "r233", "r240" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.", "label": "Restructuring Reserve, Accrual Adjustment", "terseLabel": "Adjustments to previous estimates" } } }, "localname": "RestructuringReserveAccrualAdjustment1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringandRelatedExpensesRestructuringReserveRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring Reserve [Roll Forward]" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringandRelatedExpensesRestructuringReserveRollForwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r37", "r271", "r424" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r279", "r280" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total revenues", "verboseLabel": "Total Net Product Sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails", "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeSignificantReclassificationsfromAOCIDetails", "http://www.alxn.com/role/RevenueRecognitionDisaggregationofRevenuebyProductandGeographicalRegionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r284" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/RevenueRecognition" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]", "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]" } } }, "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionDisaggregationofRevenuebyProductandGeographicalRegionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information when using transition method for cumulative effect in initial period of application for revenue from contract with customer.", "label": "Revenue, Initial Application Period Cumulative Effect Transition [Table]", "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Table]" } } }, "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionDisaggregationofRevenuebyProductandGeographicalRegionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesMember": { "auth_ref": [ "r359" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.", "label": "Sales [Member]", "terseLabel": "Sales", "verboseLabel": "Revenue" } } }, "localname": "SalesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r89" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesAvailableforsaleInvestmentsbyClassificationinBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]", "terseLabel": "Schedule of Available-for-sale Securities Reconciliation" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r320", "r321" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsAcquisitionRelatedCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r320", "r321" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r356" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.", "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Other Comprehensive Income and Earnings from Foreign Exchange Contracts" } } }, "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Debt" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r154" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule Of Basic And Diluted Earnings Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/EarningsPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Equity Method Investments [Line Items]", "terseLabel": "Schedule of Equity Method Investments [Line Items]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "auth_ref": [ "r186" ], "lang": { "en-US": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.", "label": "Schedule of Equity Method Investments [Table]", "terseLabel": "Schedule of Equity Method Investments [Table]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r372", "r373" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule Of Assets And Liabilites Measured At Fair Value" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r214", "r219" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock": { "auth_ref": [ "r352" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts.", "label": "Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]", "terseLabel": "Schedule of Fair Value of Outstanding Derivatives" } } }, "localname": "ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r210", "r211" ], "lang": { "en-US": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsandGoodwillNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r210", "r211" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Summary of Changes in Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsandGoodwillTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "auth_ref": [ "r210" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "terseLabel": "Schedule of Intangible Assets and Goodwill" } } }, "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsandGoodwillTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock": { "auth_ref": [ "r357" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.", "label": "Schedule of Interest Rate Derivatives [Table Text Block]", "terseLabel": "Schedule of Interest Rate Contracts" } } }, "localname": "ScheduleOfInterestRateDerivativesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r22", "r41", "r42", "r43" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "verboseLabel": "Schedule of Inventory, Current" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r237", "r238", "r242" ], "lang": { "en-US": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringandRelatedExpensesRestructuringReserveRollForwardDetails", "http://www.alxn.com/role/RestructuringandRelatedExpensesScheduleofRestructuringandrelatedCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r237", "r238", "r242" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Restructuring and Related Costs" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringandRelatedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r59", "r138", "r261", "r262", "r263", "r265", "r266", "r267", "r268", "r269", "r270", "r271" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionDisaggregationofRevenuebyProductandGeographicalRegionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r107", "r200" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r128" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/AcquisitionsAcquisitionRelatedCostsDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed", "weight": 1.0 }, "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.", "label": "Share-based Payment Arrangement, Accelerated Cost", "negatedTerseLabel": "Upfront payment, fair value of equity compensation attributable to the post-combination service period", "verboseLabel": "Fair value of equity compensation attributable to the post-combination service period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsAcquisitionRelatedCostsDetails", "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryofTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r1", "r169", "r210", "r230", "r236", "r245", "r431" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionDisaggregationofRevenuebyProductandGeographicalRegionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r32", "r33", "r34", "r264" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r61", "r264" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityStatement", "http://www.alxn.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails", "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeChangesinAOCIDetails", "http://www.alxn.com/role/OtherComprehensiveIncomeandAccumulatedOtherComprehensiveIncomeSignificantReclassificationsfromAOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets", "http://www.alxn.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityStatement", "http://www.alxn.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical", "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets", "http://www.alxn.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityStatement", "http://www.alxn.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical", "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r132", "r133", "r134" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "terseLabel": "Fair value of replacement equity awards issued to Portola employees attributable to the pre-combination period" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r264", "r271" ], "lang": { "en-US": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Issuance of restricted common stock, shares" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r33", "r34", "r264", "r271", "r291" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "terseLabel": "Issuance of common stock under stock option and stock purchase plans, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r61", "r264", "r271" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Portola replacement equity awards attributable to the pre-combination period" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r33", "r34", "r264", "r271" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Issuance of restricted common stock" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r61", "r264", "r271" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock under stock option and stock purchase plans" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Repurchase authorization amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Remaining authorized repurchase amount" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r34", "r38", "r39", "r174" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balances, value", "periodStartLabel": "Balances, value", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets", "http://www.alxn.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' Equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r274" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.alxn.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r393" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.alxn.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r393" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.alxn.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradingSecurities": { "auth_ref": [ "r411" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Debt Securities, Trading, and Equity Securities, FV-NI", "terseLabel": "Trading securities. fair value" } } }, "localname": "TradingSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r400" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesAvailableforsaleInvestmentsbyClassificationinBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r60", "r272" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury\u00a0Stock at Cost" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r60", "r272" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "periodEndLabel": "Balances, treasury shares", "periodStartLabel": "Balances, treasury shares", "terseLabel": "Treasury Stock, Shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.alxn.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r34", "r264", "r271" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Repurchase of common stock, shares", "verboseLabel": "Treasury Stock, Shares, Acquired" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityStatement", "http://www.alxn.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r60", "r272", "r273" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, at cost, 20.7 and 16.5 shares at September 30, 2020 and December 31, 2019, respectively" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r264", "r271", "r272" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedTerseLabel": "Repurchase of common stock", "terseLabel": "Treasury Stock, Value, Acquired, Cost Method" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityStatement", "http://www.alxn.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r337" ], "lang": { "en-US": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails", "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringandRelatedExpensesRestructuringReserveRollForwardDetails", "http://www.alxn.com/role/RestructuringandRelatedExpensesScheduleofRestructuringandrelatedCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r285", "r407" ], "lang": { "en-US": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S." } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesAvailableforsaleInvestmentsbyClassificationinBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r129" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.", "label": "Unrealized Gain (Loss) on Investments", "negatedTerseLabel": "Unrealized gain on strategic equity investments", "terseLabel": "Unrealized Gain (Loss) on Investments" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount": { "auth_ref": [ "r247" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the unrecorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).", "label": "Unrecorded Unconditional Purchase Obligation", "terseLabel": "Remaining total commitments" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r158", "r159", "r160", "r161", "r162", "r163", "r164" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/BasisofPresentationandPrinciplesOfConsolidationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r147", "r152" ], "calculation": { "http://www.alxn.com/role/EarningsPerCommonShareSummaryOfCalculationOfBasicAndDilutedEarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Shares used in computing earnings per common share-diluted (in shares)", "verboseLabel": "Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations", "http://www.alxn.com/role/EarningsPerCommonShareSummaryOfCalculationOfBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r146", "r152" ], "calculation": { "http://www.alxn.com/role/EarningsPerCommonShareSummaryOfCalculationOfBasicAndDilutedEarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic", "verboseLabel": "Shares used in computing earnings per common share\u2014basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsofOperations", "http://www.alxn.com/role/EarningsPerCommonShareSummaryOfCalculationOfBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r111": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r12": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(ee)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(d),(e))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r156": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r165": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563" }, "r183": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r184": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "321", "URI": "http://asc.fasb.org/topic&trid=75115024" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(b)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r187": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "http://asc.fasb.org/topic&trid=2196965" }, "r188": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "325", "URI": "http://asc.fasb.org/topic&trid=2197064" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922890-210455" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314" }, "r203": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r226": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r246": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=77896938&loc=d3e25336-109308" }, "r248": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349" }, "r253": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r274": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130533-203044" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r284": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31917-109318" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r311": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e961-128460" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5419-128473" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r336": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r342": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=116861445&loc=SL5629052-113961" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109978405&loc=d3e80720-113993" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80845-113994" }, "r371": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=SL51823488-111719" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r402": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6)(a)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r416": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(2)(i))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12C(1)(a))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010" }, "r439": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=116631420&loc=SL116631458-115580" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r444": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r445": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r446": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r447": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r448": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r449": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226006-175313" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e689-108580" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" } }, "version": "2.1" } ZIP 118 0000899866-20-000088-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000899866-20-000088-xbrl.zip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󝣈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end GRAPHIC 36 alxn-20200930_g8.jpg begin 644 alxn-20200930_g8.jpg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end GRAPHIC 37 alxn-20200930_g9.jpg begin 644 alxn-20200930_g9.jpg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end XML 38 alxn-20200930_htm.xml IDEA: XBRL DOCUMENT 0000899866 2020-01-01 2020-09-30 0000899866 2020-10-27 0000899866 2020-09-30 0000899866 2019-12-31 0000899866 alxn:NetProductSalesMember 2020-07-01 2020-09-30 0000899866 alxn:NetProductSalesMember 2019-07-01 2019-09-30 0000899866 alxn:NetProductSalesMember 2020-01-01 2020-09-30 0000899866 alxn:NetProductSalesMember 2019-01-01 2019-09-30 0000899866 alxn:OtherRevenueMember 2020-07-01 2020-09-30 0000899866 alxn:OtherRevenueMember 2019-07-01 2019-09-30 0000899866 alxn:OtherRevenueMember 2020-01-01 2020-09-30 0000899866 alxn:OtherRevenueMember 2019-01-01 2019-09-30 0000899866 2020-07-01 2020-09-30 0000899866 2019-07-01 2019-09-30 0000899866 2019-01-01 2019-09-30 0000899866 us-gaap:CommonStockMember 2020-06-30 0000899866 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000899866 us-gaap:TreasuryStockMember 2020-06-30 0000899866 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000899866 us-gaap:RetainedEarningsMember 2020-06-30 0000899866 2020-06-30 0000899866 us-gaap:TreasuryStockMember 2020-07-01 2020-09-30 0000899866 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000899866 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000899866 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000899866 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000899866 us-gaap:CommonStockMember 2020-09-30 0000899866 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000899866 us-gaap:TreasuryStockMember 2020-09-30 0000899866 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0000899866 us-gaap:RetainedEarningsMember 2020-09-30 0000899866 us-gaap:CommonStockMember 2019-06-30 0000899866 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000899866 us-gaap:TreasuryStockMember 2019-06-30 0000899866 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000899866 us-gaap:RetainedEarningsMember 2019-06-30 0000899866 2019-06-30 0000899866 us-gaap:TreasuryStockMember 2019-07-01 2019-09-30 0000899866 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0000899866 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000899866 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0000899866 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000899866 us-gaap:CommonStockMember 2019-09-30 0000899866 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000899866 us-gaap:TreasuryStockMember 2019-09-30 0000899866 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000899866 us-gaap:RetainedEarningsMember 2019-09-30 0000899866 2019-09-30 0000899866 us-gaap:CommonStockMember 2019-12-31 0000899866 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000899866 us-gaap:TreasuryStockMember 2019-12-31 0000899866 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000899866 us-gaap:RetainedEarningsMember 2019-12-31 0000899866 us-gaap:TreasuryStockMember 2020-01-01 2020-09-30 0000899866 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0000899866 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0000899866 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0000899866 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0000899866 us-gaap:CommonStockMember 2018-12-31 0000899866 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000899866 us-gaap:TreasuryStockMember 2018-12-31 0000899866 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000899866 us-gaap:RetainedEarningsMember 2018-12-31 0000899866 2018-12-31 0000899866 us-gaap:TreasuryStockMember 2019-01-01 2019-09-30 0000899866 us-gaap:CommonStockMember 2019-01-01 2019-09-30 0000899866 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0000899866 us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 0000899866 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0000899866 us-gaap:RetainedEarningsMember alxn:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2018-12-31 0000899866 alxn:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2018-12-31 0000899866 alxn:AchillionMember 2020-01-28 2020-01-28 0000899866 alxn:AchillionMember alxn:DanicopanMember 2020-01-28 2020-01-28 0000899866 alxn:AchillionMember alxn:ACH5528Phase3Member 2020-01-28 2020-01-28 0000899866 alxn:AchillionMember 2020-01-28 0000899866 alxn:AchillionMember alxn:AcquiredIprdMember 2020-01-28 0000899866 alxn:AchillionMember 2020-04-01 2020-06-30 0000899866 srt:MinimumMember us-gaap:FairValueInputsLevel3Member alxn:AcquisitionRelatedContingentConsiderationMember 2020-01-28 2020-01-28 0000899866 srt:MaximumMember us-gaap:FairValueInputsLevel3Member alxn:AcquisitionRelatedContingentConsiderationMember 2020-01-28 2020-01-28 0000899866 srt:MinimumMember alxn:AchillionMember 2020-01-28 0000899866 srt:MaximumMember alxn:AchillionMember 2020-01-28 0000899866 alxn:AchillionMember 2020-09-30 0000899866 srt:MinimumMember us-gaap:FairValueInputsLevel3Member alxn:AcquisitionRelatedContingentConsiderationMember 2020-01-01 2020-09-30 0000899866 srt:MaximumMember us-gaap:FairValueInputsLevel3Member alxn:AcquisitionRelatedContingentConsiderationMember 2020-01-01 2020-09-30 0000899866 alxn:AchillionMember 2020-07-01 2020-09-30 0000899866 alxn:AchillionMember 2020-01-01 2020-09-30 0000899866 alxn:AcquiredIprdMember 2020-04-01 2020-06-30 0000899866 alxn:PortolaPharmaceuticalsIncMember 2020-07-02 2020-07-02 0000899866 alxn:PortolaPharmaceuticalsMember 2020-03-01 2020-03-31 0000899866 alxn:PortolaPharmaceuticalsMember 2020-04-01 2020-04-30 0000899866 alxn:PortolaPharmaceuticalsMember 2020-07-02 0000899866 alxn:PortolaPharmaceuticalsIncMember 2020-07-02 0000899866 alxn:PortolaPharmaceuticalsIncMember alxn:AndexxaProductLineMember 2020-07-02 2020-07-02 0000899866 alxn:PortolaPharmaceuticalsIncMember alxn:PurchasedTechnologyMember 2020-07-02 0000899866 alxn:PortolaPharmaceuticalsIncMember alxn:AcquiredIprdMember 2020-09-30 0000899866 alxn:PortolaPharmaceuticalsIncMember alxn:PurchasedTechnologyMember 2020-07-02 2020-07-02 0000899866 alxn:HealthCareRoyaltyPartnersMember alxn:RoyaltyBasedFinancingAgreementMember alxn:PortolaPharmaceuticalsIncMember 2017-02-28 0000899866 alxn:HealthCareRoyaltyPartnersMember alxn:RoyaltyBasedFinancingAgreementMember alxn:PortolaPharmaceuticalsIncMember 2020-07-02 2020-07-02 0000899866 alxn:HealthCareRoyaltyPartnersMember alxn:PortolaPharmaceuticalsIncMember alxn:RoyaltyBasedFinancingAgreementMember 2020-07-02 0000899866 srt:MinimumMember alxn:PortolaPharmaceuticalsIncMember 2020-07-02 2020-07-02 0000899866 srt:MaximumMember alxn:PortolaPharmaceuticalsIncMember 2020-07-02 2020-07-02 0000899866 alxn:PortolaPharmaceuticalsIncMember 2020-01-01 2020-09-30 0000899866 alxn:PortolaPharmaceuticalsIncMember 2020-07-01 2020-09-30 0000899866 alxn:PortolaPharmaceuticalsIncMember 2019-07-01 2019-09-30 0000899866 alxn:PortolaPharmaceuticalsIncMember 2019-01-01 2019-09-30 0000899866 us-gaap:InventoriesMember 2020-09-30 0000899866 us-gaap:InventoriesMember 2019-12-31 0000899866 us-gaap:OtherAssetsMember 2020-09-30 0000899866 us-gaap:OtherAssetsMember 2019-12-31 0000899866 alxn:PreApprovalInventoryMember 2020-09-30 0000899866 alxn:PreApprovalInventoryMember 2019-12-31 0000899866 srt:MinimumMember us-gaap:LicensingAgreementsMember 2020-01-01 2020-09-30 0000899866 srt:MaximumMember us-gaap:LicensingAgreementsMember 2020-01-01 2020-09-30 0000899866 us-gaap:LicensingAgreementsMember 2020-09-30 0000899866 us-gaap:LicensingAgreementsMember 2019-12-31 0000899866 us-gaap:PatentsMember 2020-01-01 2020-09-30 0000899866 us-gaap:PatentsMember 2020-09-30 0000899866 us-gaap:PatentsMember 2019-12-31 0000899866 srt:MinimumMember alxn:PurchasedTechnologyMember 2020-01-01 2020-09-30 0000899866 srt:MaximumMember alxn:PurchasedTechnologyMember 2020-01-01 2020-09-30 0000899866 alxn:PurchasedTechnologyMember 2020-09-30 0000899866 alxn:PurchasedTechnologyMember 2019-12-31 0000899866 us-gaap:OtherIntangibleAssetsMember 2020-01-01 2020-09-30 0000899866 us-gaap:OtherIntangibleAssetsMember 2020-09-30 0000899866 us-gaap:OtherIntangibleAssetsMember 2019-12-31 0000899866 alxn:AcquiredIprdMember 2020-09-30 0000899866 alxn:AcquiredIprdMember 2019-12-31 0000899866 alxn:PurchasedTechnologyMember 2020-04-01 2020-06-30 0000899866 alxn:KanumaProductLineMember 2020-06-30 0000899866 us-gaap:RevolvingCreditFacilityMember alxn:CreditAgreementMember 2018-06-07 0000899866 alxn:SeniorSecuredTermLoanMember alxn:CreditAgreementMember us-gaap:LineOfCreditMember 2018-06-07 0000899866 alxn:CreditAgreementMember 2019-01-01 2019-03-31 0000899866 alxn:SeniorSecuredTermLoanMember alxn:CreditAgreementMember us-gaap:LineOfCreditMember 2020-07-01 2020-09-30 0000899866 alxn:SeniorSecuredTermLoanMember alxn:CreditAgreementMember us-gaap:LineOfCreditMember 2020-01-01 2020-09-30 0000899866 alxn:SeniorSecuredTermLoanMember alxn:CreditAgreementMember us-gaap:LineOfCreditMember 2020-09-30 0000899866 us-gaap:RevolvingCreditFacilityMember alxn:CreditAgreementMember 2020-09-30 0000899866 alxn:HealthCareRoyaltyPartnersMember alxn:RoyaltyBasedFinancingAgreementMember alxn:PortolaPharmaceuticalsIncMember 2017-02-01 2017-02-28 0000899866 alxn:HealthCareRoyaltyPartnersMember alxn:RoyaltyBasedFinancingAgreementMember alxn:PortolaPharmaceuticalsIncMember 2018-05-31 0000899866 alxn:HealthCareRoyaltyPartnersMember srt:MinimumMember alxn:RoyaltyBasedFinancingAgreementMember alxn:PortolaPharmaceuticalsIncMember 2017-02-28 0000899866 alxn:HealthCareRoyaltyPartnersMember srt:MaximumMember alxn:RoyaltyBasedFinancingAgreementMember alxn:PortolaPharmaceuticalsIncMember 2017-02-28 0000899866 alxn:HealthCareRoyaltyPartnersMember alxn:RoyaltyBasedFinancingAgreementMember 2020-09-30 0000899866 alxn:HealthCareRoyaltyPartnersMember alxn:RoyaltyBasedFinancingAgreementMember 2020-07-01 2020-09-30 0000899866 alxn:HealthCareRoyaltyPartnersMember alxn:RoyaltyBasedFinancingAgreementMember 2020-01-01 2020-09-30 0000899866 alxn:HealthCareRoyaltyPartnersMember srt:ScenarioForecastMember alxn:RoyaltyBasedFinancingAgreementMember 2020-10-01 2020-12-31 0000899866 2020-07-03 2020-09-30 0000899866 alxn:HealthCareRoyaltyPartnersMember alxn:RoyaltyBasedFinancingAgreementMember 2020-07-03 2020-09-30 0000899866 us-gaap:CommercialPaperMember 2019-12-31 0000899866 us-gaap:CorporateBondSecuritiesMember 2019-12-31 0000899866 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0000899866 us-gaap:CertificatesOfDepositMember 2019-12-31 0000899866 us-gaap:DebtSecuritiesMember 2019-12-31 0000899866 us-gaap:CashAndCashEquivalentsMember 2020-09-30 0000899866 us-gaap:CashAndCashEquivalentsMember 2019-12-31 0000899866 alxn:MarketableSecuritiesMember 2020-09-30 0000899866 alxn:MarketableSecuritiesMember 2019-12-31 0000899866 us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-09-30 0000899866 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000899866 alxn:ForeignExchangeForwardOpenExpenseMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000899866 alxn:InterestRateSwapTwoMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000899866 srt:MinimumMember alxn:InterestRateSwapTwoMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000899866 srt:MaximumMember alxn:InterestRateSwapTwoMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000899866 alxn:InterestRateSwapFourMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000899866 srt:MinimumMember alxn:InterestRateSwapFourMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000899866 srt:MaximumMember alxn:InterestRateSwapFourMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000899866 us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2020-07-01 2020-09-30 0000899866 us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2019-07-01 2019-09-30 0000899866 us-gaap:InterestRateContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2020-07-01 2020-09-30 0000899866 us-gaap:InterestRateContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2019-07-01 2019-09-30 0000899866 us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2020-01-01 2020-09-30 0000899866 us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2019-01-01 2019-09-30 0000899866 us-gaap:InterestRateContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2020-01-01 2020-09-30 0000899866 us-gaap:InterestRateContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2019-01-01 2019-09-30 0000899866 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2020-07-01 2020-09-30 0000899866 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2019-07-01 2019-09-30 0000899866 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2020-01-01 2020-09-30 0000899866 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2019-01-01 2019-09-30 0000899866 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2020-07-01 2020-09-30 0000899866 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2019-07-01 2019-09-30 0000899866 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2020-01-01 2020-09-30 0000899866 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2019-01-01 2019-09-30 0000899866 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2020-07-01 2020-09-30 0000899866 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2019-07-01 2019-09-30 0000899866 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2020-01-01 2020-09-30 0000899866 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2019-01-01 2019-09-30 0000899866 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2020-07-01 2020-09-30 0000899866 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2019-07-01 2019-09-30 0000899866 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2020-01-01 2020-09-30 0000899866 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2019-01-01 2019-09-30 0000899866 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SalesMember 2020-07-01 2020-09-30 0000899866 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-07-01 2020-09-30 0000899866 us-gaap:NondesignatedMember 2020-07-01 2020-09-30 0000899866 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2020-09-30 0000899866 us-gaap:NondesignatedMember 2019-07-01 2019-09-30 0000899866 us-gaap:NondesignatedMember 2020-01-01 2020-09-30 0000899866 us-gaap:NondesignatedMember 2019-01-01 2019-09-30 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000899866 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000899866 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000899866 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000899866 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ForeignExchangeForwardMember 2020-09-30 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ForeignExchangeForwardMember 2020-09-30 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000899866 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000899866 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000899866 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000899866 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ForeignExchangeForwardMember 2019-12-31 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ForeignExchangeForwardMember 2019-12-31 0000899866 us-gaap:ForeignExchangeForwardMember 2020-09-30 0000899866 us-gaap:ForeignExchangeForwardMember 2019-12-31 0000899866 alxn:ModernaLLCMember 2014-01-01 2014-12-31 0000899866 alxn:ModernaLLCMember 2019-07-01 2019-09-30 0000899866 alxn:ModernaLLCMember 2019-01-01 2019-09-30 0000899866 alxn:ModernaLLCMember 2019-12-09 2019-12-09 0000899866 alxn:DicernaMember 2018-10-01 2018-10-31 0000899866 alxn:DicernaMember 2020-07-01 2020-09-30 0000899866 alxn:DicernaMember 2020-01-01 2020-09-30 0000899866 alxn:DicernaMember 2019-07-01 2019-09-30 0000899866 alxn:DicernaMember 2019-01-01 2019-09-30 0000899866 alxn:DicernaMember 2020-09-30 0000899866 alxn:DicernaMember 2019-12-31 0000899866 alxn:CaelumBiosciencesMember 2019-01-01 2019-01-31 0000899866 alxn:CaelumBiosciencesMember 2019-10-01 2019-12-31 0000899866 alxn:CaelumBiosciencesMember us-gaap:CollaborativeArrangementMember 2019-10-01 2019-12-31 0000899866 alxn:CaelumBiosciencesMember alxn:CollaborativeAgreementAmendmentMember 2019-10-01 2019-12-31 0000899866 alxn:CaelumBiosciencesMember 2019-01-01 2019-12-31 0000899866 alxn:CaelumBiosciencesMember 2020-01-01 2020-09-30 0000899866 alxn:CaelumBiosciencesOptionMember 2020-01-01 2020-09-30 0000899866 alxn:CaelumBiosciencesOptionMember 2019-01-01 2019-12-31 0000899866 alxn:ZealandMember 2019-03-01 2019-03-31 0000899866 alxn:ZealandMember 2020-07-01 2020-09-30 0000899866 alxn:ZealandMember 2020-01-01 2020-09-30 0000899866 alxn:ZealandMember 2019-07-01 2019-09-30 0000899866 alxn:ZealandMember 2019-01-01 2019-09-30 0000899866 alxn:ZealandMember 2020-09-30 0000899866 alxn:ZealandMember 2019-12-31 0000899866 alxn:EidosMemberMember 2019-09-01 2019-09-30 0000899866 alxn:EidosMemberMember 2020-07-01 2020-09-30 0000899866 alxn:EidosMemberMember 2020-01-01 2020-09-30 0000899866 alxn:EidosMemberMember 2019-07-01 2019-09-30 0000899866 alxn:EidosMemberMember 2019-01-01 2019-09-30 0000899866 alxn:EidosMemberMember 2020-09-30 0000899866 alxn:EidosMemberMember 2019-12-31 0000899866 alxn:StealthMember 2019-10-01 2019-10-31 0000899866 alxn:StealthMember 2020-07-01 2020-09-30 0000899866 alxn:StealthMember 2020-01-01 2020-09-30 0000899866 alxn:StealthMember 2020-09-30 0000899866 alxn:StealthMember 2019-12-31 0000899866 alxn:PortolaPharmaceuticalsMember 2020-07-01 2020-09-30 0000899866 alxn:PortolaPharmaceuticalsMember 2020-01-01 2020-09-30 0000899866 alxn:PortolaPharmaceuticalsMember 2020-07-02 2020-07-02 0000899866 alxn:InozymeMember 2020-07-17 2020-07-17 0000899866 alxn:InozymeMember 2020-01-01 2020-09-30 0000899866 alxn:InozymeMember 2020-07-01 2020-09-30 0000899866 alxn:InozymeMember 2020-09-30 0000899866 us-gaap:CommonStockMember 2017-02-28 0000899866 us-gaap:CommonStockMember 2019-10-22 0000899866 us-gaap:CommonStockMember 2020-07-28 0000899866 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2020-10-01 2020-10-29 0000899866 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2020-10-27 0000899866 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0000899866 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-31 0000899866 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2019-12-31 0000899866 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000899866 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-09-30 0000899866 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-01-01 2020-09-30 0000899866 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2020-01-01 2020-09-30 0000899866 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-09-30 0000899866 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-09-30 0000899866 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-09-30 0000899866 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2020-09-30 0000899866 us-gaap:AccumulatedTranslationAdjustmentMember 2020-09-30 0000899866 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0000899866 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0000899866 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2018-12-31 0000899866 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000899866 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-09-30 0000899866 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-09-30 0000899866 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2019-01-01 2019-09-30 0000899866 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-09-30 0000899866 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-09-30 0000899866 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-09-30 0000899866 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2019-09-30 0000899866 us-gaap:AccumulatedTranslationAdjustmentMember 2019-09-30 0000899866 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2020-07-01 2020-09-30 0000899866 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2019-07-01 2019-09-30 0000899866 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2020-01-01 2020-09-30 0000899866 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2019-01-01 2019-09-30 0000899866 us-gaap:CashEquivalentsMember us-gaap:MoneyMarketFundsMember 2020-09-30 0000899866 us-gaap:CashEquivalentsMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2020-09-30 0000899866 us-gaap:CashEquivalentsMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2020-09-30 0000899866 us-gaap:CashEquivalentsMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2020-09-30 0000899866 alxn:MarketableSecuritiesMember alxn:MutualFundsMember 2020-09-30 0000899866 alxn:MarketableSecuritiesMember alxn:MutualFundsMember us-gaap:FairValueInputsLevel1Member 2020-09-30 0000899866 alxn:MarketableSecuritiesMember alxn:MutualFundsMember us-gaap:FairValueInputsLevel2Member 2020-09-30 0000899866 alxn:MarketableSecuritiesMember alxn:MutualFundsMember us-gaap:FairValueInputsLevel3Member 2020-09-30 0000899866 us-gaap:OtherAssetsMember us-gaap:EquitySecuritiesMember 2020-09-30 0000899866 us-gaap:OtherAssetsMember us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2020-09-30 0000899866 us-gaap:OtherAssetsMember us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-09-30 0000899866 us-gaap:OtherAssetsMember us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2020-09-30 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember 2020-09-30 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel1Member 2020-09-30 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel2Member 2020-09-30 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel3Member 2020-09-30 0000899866 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeForwardMember 2020-09-30 0000899866 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel1Member 2020-09-30 0000899866 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel2Member 2020-09-30 0000899866 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel3Member 2020-09-30 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember 2020-09-30 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignExchangeForwardMember 2020-09-30 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeForwardMember 2020-09-30 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignExchangeForwardMember 2020-09-30 0000899866 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember 2020-09-30 0000899866 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignExchangeForwardMember 2020-09-30 0000899866 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeForwardMember 2020-09-30 0000899866 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignExchangeForwardMember 2020-09-30 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateContractMember 2020-09-30 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member 2020-09-30 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member 2020-09-30 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member 2020-09-30 0000899866 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateContractMember 2020-09-30 0000899866 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member 2020-09-30 0000899866 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member 2020-09-30 0000899866 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member 2020-09-30 0000899866 alxn:ContingentConsiderationMember alxn:AcquisitionRelatedContingentConsiderationMember 2020-09-30 0000899866 alxn:ContingentConsiderationMember us-gaap:FairValueInputsLevel1Member alxn:AcquisitionRelatedContingentConsiderationMember 2020-09-30 0000899866 alxn:ContingentConsiderationMember us-gaap:FairValueInputsLevel2Member alxn:AcquisitionRelatedContingentConsiderationMember 2020-09-30 0000899866 alxn:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member alxn:AcquisitionRelatedContingentConsiderationMember 2020-09-30 0000899866 us-gaap:CashEquivalentsMember us-gaap:MoneyMarketFundsMember 2019-12-31 0000899866 us-gaap:CashEquivalentsMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000899866 us-gaap:CashEquivalentsMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000899866 us-gaap:CashEquivalentsMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000899866 us-gaap:CashEquivalentsMember us-gaap:CommercialPaperMember 2019-12-31 0000899866 us-gaap:CashEquivalentsMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000899866 us-gaap:CashEquivalentsMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000899866 us-gaap:CashEquivalentsMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000899866 us-gaap:CashEquivalentsMember us-gaap:CorporateBondSecuritiesMember 2019-12-31 0000899866 us-gaap:CashEquivalentsMember us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000899866 us-gaap:CashEquivalentsMember us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000899866 us-gaap:CashEquivalentsMember us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000899866 us-gaap:CashEquivalentsMember us-gaap:CertificatesOfDepositMember 2019-12-31 0000899866 us-gaap:CashEquivalentsMember us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000899866 us-gaap:CashEquivalentsMember us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000899866 us-gaap:CashEquivalentsMember us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000899866 us-gaap:CashEquivalentsMember alxn:OtherGovernmentObligationsMember 2019-12-31 0000899866 us-gaap:CashEquivalentsMember alxn:OtherGovernmentObligationsMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000899866 us-gaap:CashEquivalentsMember alxn:OtherGovernmentObligationsMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000899866 us-gaap:CashEquivalentsMember alxn:OtherGovernmentObligationsMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000899866 alxn:MarketableSecuritiesMember alxn:MutualFundsMember 2019-12-31 0000899866 alxn:MarketableSecuritiesMember alxn:MutualFundsMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000899866 alxn:MarketableSecuritiesMember alxn:MutualFundsMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000899866 alxn:MarketableSecuritiesMember alxn:MutualFundsMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000899866 alxn:MarketableSecuritiesMember us-gaap:CommercialPaperMember 2019-12-31 0000899866 alxn:MarketableSecuritiesMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000899866 alxn:MarketableSecuritiesMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000899866 alxn:MarketableSecuritiesMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000899866 alxn:MarketableSecuritiesMember us-gaap:CorporateBondSecuritiesMember 2019-12-31 0000899866 alxn:MarketableSecuritiesMember us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000899866 alxn:MarketableSecuritiesMember us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000899866 alxn:MarketableSecuritiesMember us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000899866 alxn:MarketableSecuritiesMember alxn:OtherGovernmentObligationsMember 2019-12-31 0000899866 alxn:MarketableSecuritiesMember alxn:OtherGovernmentObligationsMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000899866 alxn:MarketableSecuritiesMember alxn:OtherGovernmentObligationsMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000899866 alxn:MarketableSecuritiesMember alxn:OtherGovernmentObligationsMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000899866 alxn:MarketableSecuritiesMember us-gaap:CertificatesOfDepositMember 2019-12-31 0000899866 alxn:MarketableSecuritiesMember us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000899866 alxn:MarketableSecuritiesMember us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000899866 alxn:MarketableSecuritiesMember us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000899866 us-gaap:OtherAssetsMember us-gaap:EquitySecuritiesMember 2019-12-31 0000899866 us-gaap:OtherAssetsMember us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000899866 us-gaap:OtherAssetsMember us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000899866 us-gaap:OtherAssetsMember us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember 2019-12-31 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000899866 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeForwardMember 2019-12-31 0000899866 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000899866 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000899866 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember 2019-12-31 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignExchangeForwardMember 2019-12-31 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeForwardMember 2019-12-31 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignExchangeForwardMember 2019-12-31 0000899866 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember 2019-12-31 0000899866 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignExchangeForwardMember 2019-12-31 0000899866 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeForwardMember 2019-12-31 0000899866 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignExchangeForwardMember 2019-12-31 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateContractMember 2019-12-31 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000899866 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateContractMember 2019-12-31 0000899866 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000899866 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000899866 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000899866 alxn:ContingentConsiderationMember alxn:AcquisitionRelatedContingentConsiderationMember 2019-12-31 0000899866 alxn:ContingentConsiderationMember us-gaap:FairValueInputsLevel1Member alxn:AcquisitionRelatedContingentConsiderationMember 2019-12-31 0000899866 alxn:ContingentConsiderationMember us-gaap:FairValueInputsLevel2Member alxn:AcquisitionRelatedContingentConsiderationMember 2019-12-31 0000899866 alxn:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member alxn:AcquisitionRelatedContingentConsiderationMember 2019-12-31 0000899866 us-gaap:OtherCurrentLiabilitiesMember alxn:OtherContingentPaymentsMember 2019-12-31 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member alxn:OtherContingentPaymentsMember 2019-12-31 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member alxn:OtherContingentPaymentsMember 2019-12-31 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member alxn:OtherContingentPaymentsMember 2019-12-31 0000899866 us-gaap:FairValueInputsLevel3Member alxn:AcquisitionRelatedContingentConsiderationMember 2019-12-31 0000899866 us-gaap:FairValueInputsLevel3Member alxn:AcquisitionRelatedContingentConsiderationMember 2020-01-01 2020-09-30 0000899866 us-gaap:FairValueInputsLevel3Member alxn:AcquisitionRelatedContingentConsiderationMember 2020-09-30 0000899866 alxn:CaelumBiosciencesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-01-31 0000899866 alxn:CaelumBiosciencesMember us-gaap:CollaborativeArrangementMember 2019-12-31 0000899866 alxn:CaelumBiosciencesMember srt:MinimumMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-01-31 0000899866 alxn:CaelumBiosciencesMember srt:MaximumMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-01-31 0000899866 alxn:CaelumBiosciencesMember us-gaap:CollaborativeArrangementMember 2019-12-01 2019-12-31 0000899866 alxn:CaelumBiosciencesMember us-gaap:CollaborativeArrangementMember 2020-04-01 2020-06-30 0000899866 alxn:CaelumBiosciencesMember us-gaap:CollaborativeArrangementMember 2020-07-01 2020-09-30 0000899866 alxn:CaelumBiosciencesMember us-gaap:CollaborativeArrangementMember 2020-04-01 2020-09-30 0000899866 alxn:CaelumBiosciencesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-09-30 0000899866 alxn:CaelumBiosciencesMember us-gaap:CollaborativeArrangementMember 2019-07-01 2019-09-30 0000899866 alxn:CaelumBiosciencesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-09-30 0000899866 country:US alxn:SolirisMember 2020-07-01 2020-09-30 0000899866 country:US alxn:SolirisMember 2019-07-01 2019-09-30 0000899866 country:US alxn:SolirisMember 2020-01-01 2020-09-30 0000899866 country:US alxn:SolirisMember 2019-01-01 2019-09-30 0000899866 srt:EuropeMember alxn:SolirisMember 2020-07-01 2020-09-30 0000899866 srt:EuropeMember alxn:SolirisMember 2019-07-01 2019-09-30 0000899866 srt:EuropeMember alxn:SolirisMember 2020-01-01 2020-09-30 0000899866 srt:EuropeMember alxn:SolirisMember 2019-01-01 2019-09-30 0000899866 srt:AsiaPacificMember alxn:SolirisMember 2020-07-01 2020-09-30 0000899866 srt:AsiaPacificMember alxn:SolirisMember 2019-07-01 2019-09-30 0000899866 srt:AsiaPacificMember alxn:SolirisMember 2020-01-01 2020-09-30 0000899866 srt:AsiaPacificMember alxn:SolirisMember 2019-01-01 2019-09-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:SolirisMember 2020-07-01 2020-09-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:SolirisMember 2019-07-01 2019-09-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:SolirisMember 2020-01-01 2020-09-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:SolirisMember 2019-01-01 2019-09-30 0000899866 alxn:SolirisMember 2020-07-01 2020-09-30 0000899866 alxn:SolirisMember 2019-07-01 2019-09-30 0000899866 alxn:SolirisMember 2020-01-01 2020-09-30 0000899866 alxn:SolirisMember 2019-01-01 2019-09-30 0000899866 country:US alxn:UltomirisMember 2020-07-01 2020-09-30 0000899866 country:US alxn:UltomirisMember 2019-07-01 2019-09-30 0000899866 country:US alxn:UltomirisMember 2020-01-01 2020-09-30 0000899866 country:US alxn:UltomirisMember 2019-01-01 2019-09-30 0000899866 srt:EuropeMember alxn:UltomirisMember 2020-07-01 2020-09-30 0000899866 srt:EuropeMember alxn:UltomirisMember 2019-07-01 2019-09-30 0000899866 srt:EuropeMember alxn:UltomirisMember 2020-01-01 2020-09-30 0000899866 srt:EuropeMember alxn:UltomirisMember 2019-01-01 2019-09-30 0000899866 srt:AsiaPacificMember alxn:UltomirisMember 2020-07-01 2020-09-30 0000899866 srt:AsiaPacificMember alxn:UltomirisMember 2019-07-01 2019-09-30 0000899866 srt:AsiaPacificMember alxn:UltomirisMember 2020-01-01 2020-09-30 0000899866 srt:AsiaPacificMember alxn:UltomirisMember 2019-01-01 2019-09-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:UltomirisMember 2020-07-01 2020-09-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:UltomirisMember 2019-07-01 2019-09-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:UltomirisMember 2020-01-01 2020-09-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:UltomirisMember 2019-01-01 2019-09-30 0000899866 alxn:UltomirisMember 2020-07-01 2020-09-30 0000899866 alxn:UltomirisMember 2019-07-01 2019-09-30 0000899866 alxn:UltomirisMember 2020-01-01 2020-09-30 0000899866 alxn:UltomirisMember 2019-01-01 2019-09-30 0000899866 country:US alxn:StrensiqProductLineMember 2020-07-01 2020-09-30 0000899866 country:US alxn:StrensiqProductLineMember 2019-07-01 2019-09-30 0000899866 country:US alxn:StrensiqProductLineMember 2020-01-01 2020-09-30 0000899866 country:US alxn:StrensiqProductLineMember 2019-01-01 2019-09-30 0000899866 srt:EuropeMember alxn:StrensiqProductLineMember 2020-07-01 2020-09-30 0000899866 srt:EuropeMember alxn:StrensiqProductLineMember 2019-07-01 2019-09-30 0000899866 srt:EuropeMember alxn:StrensiqProductLineMember 2020-01-01 2020-09-30 0000899866 srt:EuropeMember alxn:StrensiqProductLineMember 2019-01-01 2019-09-30 0000899866 srt:AsiaPacificMember alxn:StrensiqProductLineMember 2020-07-01 2020-09-30 0000899866 srt:AsiaPacificMember alxn:StrensiqProductLineMember 2019-07-01 2019-09-30 0000899866 srt:AsiaPacificMember alxn:StrensiqProductLineMember 2020-01-01 2020-09-30 0000899866 srt:AsiaPacificMember alxn:StrensiqProductLineMember 2019-01-01 2019-09-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:StrensiqProductLineMember 2020-07-01 2020-09-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:StrensiqProductLineMember 2019-07-01 2019-09-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:StrensiqProductLineMember 2020-01-01 2020-09-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:StrensiqProductLineMember 2019-01-01 2019-09-30 0000899866 alxn:StrensiqProductLineMember 2020-07-01 2020-09-30 0000899866 alxn:StrensiqProductLineMember 2019-07-01 2019-09-30 0000899866 alxn:StrensiqProductLineMember 2020-01-01 2020-09-30 0000899866 alxn:StrensiqProductLineMember 2019-01-01 2019-09-30 0000899866 country:US alxn:AndexxaProductLineMember 2020-07-01 2020-09-30 0000899866 country:US alxn:AndexxaProductLineMember 2019-07-01 2019-09-30 0000899866 country:US alxn:AndexxaProductLineMember 2020-01-01 2020-09-30 0000899866 country:US alxn:AndexxaProductLineMember 2019-01-01 2019-09-30 0000899866 srt:EuropeMember alxn:AndexxaProductLineMember 2020-07-01 2020-09-30 0000899866 srt:EuropeMember alxn:AndexxaProductLineMember 2019-07-01 2019-09-30 0000899866 srt:EuropeMember alxn:AndexxaProductLineMember 2020-01-01 2020-09-30 0000899866 srt:EuropeMember alxn:AndexxaProductLineMember 2019-01-01 2019-09-30 0000899866 srt:AsiaPacificMember alxn:AndexxaProductLineMember 2020-07-01 2020-09-30 0000899866 srt:AsiaPacificMember alxn:AndexxaProductLineMember 2019-07-01 2019-09-30 0000899866 srt:AsiaPacificMember alxn:AndexxaProductLineMember 2020-01-01 2020-09-30 0000899866 srt:AsiaPacificMember alxn:AndexxaProductLineMember 2019-01-01 2019-09-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:AndexxaProductLineMember 2020-07-01 2020-09-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:AndexxaProductLineMember 2019-07-01 2019-09-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:AndexxaProductLineMember 2020-01-01 2020-09-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:AndexxaProductLineMember 2019-01-01 2019-09-30 0000899866 alxn:AndexxaProductLineMember 2020-07-01 2020-09-30 0000899866 alxn:AndexxaProductLineMember 2019-07-01 2019-09-30 0000899866 alxn:AndexxaProductLineMember 2020-01-01 2020-09-30 0000899866 alxn:AndexxaProductLineMember 2019-01-01 2019-09-30 0000899866 country:US alxn:KanumaProductLineMember 2020-07-01 2020-09-30 0000899866 country:US alxn:KanumaProductLineMember 2019-07-01 2019-09-30 0000899866 country:US alxn:KanumaProductLineMember 2020-01-01 2020-09-30 0000899866 country:US alxn:KanumaProductLineMember 2019-01-01 2019-09-30 0000899866 srt:EuropeMember alxn:KanumaProductLineMember 2020-07-01 2020-09-30 0000899866 srt:EuropeMember alxn:KanumaProductLineMember 2019-07-01 2019-09-30 0000899866 srt:EuropeMember alxn:KanumaProductLineMember 2020-01-01 2020-09-30 0000899866 srt:EuropeMember alxn:KanumaProductLineMember 2019-01-01 2019-09-30 0000899866 srt:AsiaPacificMember alxn:KanumaProductLineMember 2020-07-01 2020-09-30 0000899866 srt:AsiaPacificMember alxn:KanumaProductLineMember 2019-07-01 2019-09-30 0000899866 srt:AsiaPacificMember alxn:KanumaProductLineMember 2020-01-01 2020-09-30 0000899866 srt:AsiaPacificMember alxn:KanumaProductLineMember 2019-01-01 2019-09-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:KanumaProductLineMember 2020-07-01 2020-09-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:KanumaProductLineMember 2019-07-01 2019-09-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:KanumaProductLineMember 2020-01-01 2020-09-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:KanumaProductLineMember 2019-01-01 2019-09-30 0000899866 alxn:KanumaProductLineMember 2020-07-01 2020-09-30 0000899866 alxn:KanumaProductLineMember 2019-07-01 2019-09-30 0000899866 alxn:KanumaProductLineMember 2020-01-01 2020-09-30 0000899866 alxn:KanumaProductLineMember 2019-01-01 2019-09-30 0000899866 us-gaap:ProductMember 2020-07-01 2020-09-30 0000899866 us-gaap:ProductMember 2019-07-01 2019-09-30 0000899866 us-gaap:ProductMember 2020-01-01 2020-09-30 0000899866 us-gaap:ProductMember 2019-01-01 2019-09-30 0000899866 alxn:IntangibleAssetImpairmentMember 2020-04-01 2020-06-30 0000899866 alxn:IntellectualPropertyElectionMember 2019-01-01 2019-09-30 0000899866 alxn:ValuationAllowanceReleaseMember 2019-01-01 2019-09-30 0000899866 2018-01-01 2018-12-31 0000899866 alxn:CaelumBiosciencesMember us-gaap:CollaborativeArrangementMember 2019-01-31 0000899866 alxn:ZealandMember alxn:ZealandPharmaMember 2019-03-01 2019-03-31 0000899866 alxn:ZealandMember alxn:ZealandPharmaMember 2019-03-31 0000899866 alxn:ZealandMember alxn:ZealandPharmaMember 2019-01-01 2019-03-31 0000899866 alxn:ZealandMember alxn:ZealandPharmaMember 2020-01-01 2020-09-30 0000899866 alxn:AffibodyMember alxn:AffibodyABDomain 2019-04-01 2019-04-30 0000899866 alxn:EidosMemberMember alxn:AffibodyABDomain 2019-09-01 2019-09-30 0000899866 alxn:EidosMemberMember alxn:AffibodyABDomain 2019-07-01 2019-09-30 0000899866 alxn:EidosMemberMember alxn:AffibodyABDomain 2020-01-01 2020-09-30 0000899866 alxn:DicernaMember alxn:DicernaPharmaceuticalCollaborationAgreementMember 2018-10-01 2018-10-31 0000899866 alxn:DicernaMember alxn:DicernaPharmaceuticalCollaborationAgreementMember 2018-10-01 2018-12-31 0000899866 alxn:DicernaMember alxn:DicernaPharmaceuticalCollaborationAgreementMember 2019-10-01 2019-12-31 0000899866 alxn:DicernaMember alxn:DicernaPharmaceuticalCollaborationAgreementMember 2020-09-30 0000899866 alxn:HalozymeTherapeuticsIncMember alxn:LicenseAgreement1Member 2017-10-01 2017-12-31 0000899866 alxn:HalozymeTherapeuticsIncMember alxn:LicenseAgreement1Member 2020-09-30 0000899866 alxn:SyntimmuneIncMember 2018-11-01 2018-11-30 0000899866 alxn:SyntimmuneIncMember alxn:SubcutaneousFormulationMember 2018-11-01 2018-11-30 0000899866 alxn:CollaborationandLicenseAgreementMember 2020-01-01 2020-09-30 0000899866 alxn:AstellasPharamMember 2020-07-01 2020-09-30 0000899866 alxn:LonzaGroupAGMember 2020-09-30 0000899866 alxn:OtherThirdPartyManufacturersMember 2020-09-30 0000899866 alxn:SECMember 2020-07-02 2020-07-02 0000899866 alxn:DOJAndOIGMember 2019-04-01 2019-04-30 0000899866 alxn:CanadianPatentedMedicinePricesReviewBoardMember us-gaap:SubsequentEventMember 2020-10-27 0000899866 alxn:CanadianPatentedMedicinePricesReviewBoardMember 2020-09-30 0000899866 us-gaap:EmployeeSeveranceMember 2020-07-01 2020-09-30 0000899866 us-gaap:OtherRestructuringMember 2020-07-01 2020-09-30 0000899866 us-gaap:EmployeeSeveranceMember 2019-07-01 2019-09-30 0000899866 us-gaap:OtherRestructuringMember 2019-07-01 2019-09-30 0000899866 us-gaap:EmployeeSeveranceMember 2020-01-01 2020-09-30 0000899866 us-gaap:OtherRestructuringMember 2020-01-01 2020-09-30 0000899866 us-gaap:EmployeeSeveranceMember 2019-01-01 2019-09-30 0000899866 us-gaap:OtherRestructuringMember 2019-01-01 2019-09-30 0000899866 us-gaap:EmployeeSeveranceMember 2020-06-30 0000899866 us-gaap:OtherRestructuringMember 2020-06-30 0000899866 us-gaap:EmployeeSeveranceMember 2019-12-31 0000899866 us-gaap:OtherRestructuringMember 2019-12-31 0000899866 us-gaap:EmployeeSeveranceMember 2020-09-30 0000899866 us-gaap:OtherRestructuringMember 2020-09-30 shares iso4217:USD iso4217:USD shares pure 0000899866 --12-31 2020 Q3 false 10-Q true 2020-09-30 false 0-27756 ALEXION PHARMACEUTICALS, INC. DE 13-3648318 121 Seaport Boulevard Boston MA 02210 475 230-2596 Common Stock $0.0001 par value ALXN NASDAQ Yes Yes Large Accelerated Filer false false false 218845432 2268000000.0 2685500000 28900000 64000000.0 1437100000 1243200000 729000000.0 627600000 604800000 456100000 5067800000 5076400000 1214500000 1163300000 3056600000 3344300000 5100700000 5037400000 220100000 204000000.0 2270500000 2290200000 618200000 429000000.0 17548400000 17544600000 89200000 74000000.0 978400000 892700000 138600000 126700000 124800000 100900000 1331000000.0 1194300000 2453300000 2375000000.0 398100000 192400000 1818200000 2081400000 175800000 164100000 297100000 265600000 6473500000 6272800000 0.0001 0.0001 290000000.0 290000000.0 239700000 237800000 0 0 9030400000 8804700000 20700000 16500000 2543700000 2105900000 -119200000 -66800000 4707400000 4639800000 11074900000 11271800000 17548400000 17544600000 1588300000 1263100000 4477400000 3605800000 400000 0 700000 1000000.0 1588700000 1263100000 4478100000 3606800000 144700000 95200000 401300000 280200000 285900000 232900000 707900000 616400000 334200000 299300000 955500000 880100000 0 0 0 4100000 53100000 75600000 200500000 235700000 23400000 29800000 45000000.0 7200000 63000000.0 0 105700000 0 14300000 300000 13500000 11900000 0 0 2053300000 0 14800000 0 14800000 0 903800000 733100000 4467900000 2027400000 684900000 530000000.0 10200000 1579400000 11500000 23000000.0 47800000 50600000 27600000 17900000 77000000.0 56100000 -1900000 400000 -2600000 2900000 666900000 535500000 -21600000 1576800000 88800000 67900000 -89200000 61500000 578100000 467600000 67600000 1515300000 2.64 2.09 0.31 6.77 2.62 2.08 0.30 6.72 219100000 223300000 220400000 223800000 220600000 224500000 221900000 225400000 578100000 467600000 67600000 1515300000 1200000 -2500000 -5300000 -3000000.0 0 0 100000 200000 -2800000 3500000 -14300000 -10800000 -9500000 12200000 -47200000 -35700000 -8300000 9700000 -52400000 -38500000 569800000 477300000 15200000 1476800000 239200000 0 8942400000 20100000 -2470000000.0 -110900000 4129300000 10490800000 600000 73500000 73500000 200000 10500000 10500000 300000 0 70300000 -200000 70100000 7200000 7200000 578100000 578100000 -8300000 -8300000 239700000 0 9030400000 20700000 -2543700000 -119200000 4707400000 11074900000 237300000 0 8677000000.0 13100000 -1738800000 -57900000 3283200000 10163500000 3100000 334600000 334600000 100000 1900000 1900000 100000 0 59100000 59100000 467600000 467600000 9700000 9700000 237500000 0 8738000000.0 16200000 -2073400000 -48200000 3750800000 10367200000 237800000 0 8804700000 16500000 -2105900000 -66800000 4639800000 11271800000 4200000 434300000 434300000 400000 23400000 23400000 1500000 0 195100000 -3500000 191600000 7200000 7200000 67600000 67600000 -52400000 -52400000 239700000 0 9030400000 20700000 -2543700000 -119200000 4707400000 11074900000 236200000 0 8539100000 12700000 -1689900000 -9700000 2325800000 9165300000 3500000 383500000 383500000 300000 23200000 23200000 1000000.0 0 175700000 175700000 1515300000 1515300000 -38500000 -38500000 -90300000 -90300000 237500000 0 8738000000.0 16200000 -2073400000 -48200000 3750800000 10367200000 67600000 1515300000 254300000 286200000 45000000.0 7200000 0 100000000.0 195600000 176800000 -174200000 -136100000 -900000 3300000 3900000 15300000 4600000 20600000 14800000 0 29700000 0 24600000 0 2053300000 0 -10700000 2300000 183500000 199100000 10300000 105900000 92300000 42200000 23700000 207100000 2162400000 1567800000 19400000 51200000 184200000 211000000.0 14100000 13400000 9600000 11400000 29200000 124700000 2111900000 0 38100000 63700000 0 16000000.0 -2018900000 -46600000 97900000 65400000 0 250000000.0 434300000 383500000 22100000 23200000 -28000000.0 -3700000 -538100000 -679400000 -500000 -6100000 -395100000 835700000 2723600000 1367400000 2328500000 2203100000 155000000.0 0 47800000 0 7200000 0 14800000 0 0 27600000 21200000 23900000 14300000 3100000 2268000000.0 2171300000 60400000 31500000 100000 300000 2328500000 2203100000 Business<div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alexion Pharmaceuticals, Inc. (Alexion, the Company, we, our or us) is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD) in patients who are anti-aquaporin-4 (AQP4) antibody positive. Alexion also has two highly innovative enzyme replacement therapies and the first and only approved therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). With the acquisition of Portola Pharmaceuticals, Inc. (Portola) in July 2020, we added the first and only approved Factor Xa inhibitor reversal agent for patients treated with rivaroxaban or apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our marketed therapies, we have a diverse pipeline resulting from internal innovation and business development. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. We were incorporated in 1992 under the laws of the State of Delaware.</span></div> Basis of Presentation and Principles of Consolidation<div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. These accounting principles were applied on a basis consistent with those of the consolidated financial statements contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2019. In our opinion, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of our financial statements for interim periods presented in accordance with accounting principles generally accepted in the United States. The condensed consolidated balance sheet as of December 31, 2019 was derived from audited annual financial statements but does not include all disclosures required by accounting principles generally accepted in the United States. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2019 included in our Annual Report on Form 10-K for the year ended December 31, 2019. The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the results to be expected for the full year or any other future periods. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements of our subsidiaries with functional currencies other than the U.S. dollar are translated into U.S. dollars using period-end exchange rates for assets and liabilities, historical exchange rates for stockholders' equity and weighted average exchange rates for operating results. Translation gains and losses are included in accumulated other comprehensive income (loss), net of tax, in stockholders' equity. Foreign currency transaction gains and losses are included in the results of operations in other income and expense.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include the accounts of Alexion Pharmaceuticals, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies are described in Note 1 of the notes to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2019. Updates to our accounting policies, including impacts from the adoption of new accounting standards, are discussed below in this Note 2</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain items in the prior period’s condensed consolidated financial statements have been reclassified to conform to the current presentation.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues, expenses and disclosure of contingent liabilities in our condensed consolidated financial statements.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain. We are not aware of any specific event or circumstance that would require an update to our estimates, judgments and assumptions or a revision of the carrying value of our assets or liabilities as of October 29, 2020, the date of issuance of this Quarterly Report on Form 10-Q. These estimates may change, as new events occur and additional information is obtained. Actual results may differ from these estimates under different assumptions or conditions and such differences may be material.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New Accounting Pronouncements</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Accounting Standards Update (ASU) 2019-12, “Income Taxes: Simplifying the Accounting for Income Taxes”:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In December 2019, the Financial Accounting Standards Board (FASB) issued a new standard intended to simplify the accounting for income taxes by eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new standard also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for annual periods beginning after December 15, 2020 and interim periods within, with early adoption permitted. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. We do not expect the adoption of this standard to have a material impact on our financial condition and results of operations.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ASU 2020-01, “Investments - Equity Securities, Investments - Equity Method and Joint Ventures, and Derivatives and Hedging - Clarifying the Interactions Between Topic 321, Topic 323, and Topic 815”</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In January 2020, the FASB issued a new standard intended to clarify the interactions between Accounting Standards Codification (ASC) 321, ASC 323 and ASC 815. The new standard addresses accounting for the transition into and out of the equity method and measurement of certain purchased options and forward contracts to acquire investments. The standard is effective for annual and interim periods beginning after December 15, 2020, with early adoption permitted. Adoption of the standard requires changes to be made prospectively. We do not expect the adoption of this standard to have a material impact on our financial condition and results of operations.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ASU 2020-04, “Reference Rate Reform, Facilitation of the Effects of Reference Rate Reform on Financial Reporting"</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to concerns about structural risks of interbank offered rates, and, particularly, the risk of cessation of the London Interbank Offered Rate (LIBOR), regulators around the world have undertaken reference rate reform initiatives to identify alternative reference rates that are more observable or transaction-based and less susceptible to manipulation. In March 2020, the FASB issued a new standard that provides optional guidance for a limited time to ease the potential burden in accounting for the effects of reference rate reform, including optional expedients and exceptions for the accounting implications of contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendments in this new standard only apply to contracts and hedging relationships that reference LIBOR or another reference rate expected to be discontinued due to reference rate reform. The expedients and exceptions provided by the standard do not apply to contract modifications made and hedging relationships entered into or evaluated after December 31, 2022. We are currently reviewing our contracts impacted by reference rate reform and are assessing the impact of this standard on our financial condition and results of operations.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ASU 2018-15, "Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract"</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">: </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued a new standard on a customer's accounting for implementation, set-up, and other upfront costs incurred in a cloud computing arrangement (CCA) that aligns the requirements for capitalizing implementation costs in a CCA service contract with existing internal-use software guidance. The standard also provides classification guidance on these implementation costs as well as additional </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">quantitative and qualitative disclosures. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The standard is effective for interim and annual periods beginning after December 15, 2019, with early adoption permitted, and can be adopted prospectively or retrospectively.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted the new standard on January 1, 2020 on a prospective basis. The adoption of this stand</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ard had no impact on our financial statements at the date of adoption; however, we anticipate the adoption of this standard will result in an increase in capitalized assets related to qualifying CCA implementation costs in future periods. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Qualifying CCA implementation, set-up and other upfront costs incurred after January 1, 2020 are capitalized as other assets in our condensed consolidated balance sheets. These assets will be expensed over the term of the hosting arrangement and such expense will be presented within the same line item in our condensed consolidated statements of operations as the expense for fees for the associated hosting arrangement. These capitalized costs will be evaluated for impairment when events or changes in circumstances indicate that the carrying value of the capitalized implementation costs is not recoverable. For the nine months ended September 30, 2020, capitalized CCA implementation costs were not material.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ASU 2016-13, "Measurement of Credit Losses on Financial Instruments"</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">: </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued a new standard intended to improve reporting requirements specific to loans, receivables and other financial instruments. The new standard requires that credit losses on financial assets measured at amortized cost be determined using an expected loss model, instead of the current incurred loss model, and requires that credit losses related to available-for-sale debt securities be recorded through an allowance for credit losses and limited to the amount by which carrying value exceeds fair value. The new standard also requires enhanced disclosure of credit risk associated with financial assets.</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The standard is effective for interim and annual periods beginning after December 15, 2019 with early adoption permitted.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted the new standard on January 1, 2020 and have completed our assessment of the standard based on the composition of our portfolio of financial instruments and current and forecasted economic conditions at that date. Our significant financial assets that are within the scope of the new standard consist of trade accounts receivable and available for sale debt securities. We have not historically experienced any material credit losses associated with our trade accounts receivable or available for debt securities. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor economic conditions, including volatility associated with international economies and the associated impacts on the financial markets and our business. We disaggregate our trade accounts receivable population into pools of similar risk characteristics based on underlying customer type and geographical location. Current expected credit loss allowances are estimated for each risk pool based on available information, including i) historical credit loss experience, ii) current economic conditions and, iii) reasonable and supportable forecasts of future economic conditions that may affect the collectibility of the recorded amounts. Based on the relevant facts and economic conditions as of the date of adoption, we concluded that the expected credit losses on our trade accounts receivable were immaterial. Additionally, unrealized losses on our available for sale investment portfolio were immaterial. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, we reassessed our estimated credit losses on our trade accounts receivable, including consideration of the potential impacts of the COVID-19 global pandemic. Based on the relevant facts and economic conditions as of September 30, 2020, we concluded that the expected credit losses on our trade accounts receivable continued to be immaterial.</span></div> <div style="margin-top:5pt;text-align:justify"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues, expenses and disclosure of contingent liabilities in our condensed consolidated financial statements.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain. We are not aware of any specific event or circumstance that would require an update to our estimates, judgments and assumptions or a revision of the carrying value of our assets or liabilities as of October 29, 2020, the date of issuance of this Quarterly Report on Form 10-Q. These estimates may change, as new events occur and additional information is obtained. Actual results may differ from these estimates under different assumptions or conditions and such differences may be material.</span></div> <div style="margin-top:5pt;text-align:justify"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New Accounting Pronouncements</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Accounting Standards Update (ASU) 2019-12, “Income Taxes: Simplifying the Accounting for Income Taxes”:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In December 2019, the Financial Accounting Standards Board (FASB) issued a new standard intended to simplify the accounting for income taxes by eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new standard also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for annual periods beginning after December 15, 2020 and interim periods within, with early adoption permitted. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. We do not expect the adoption of this standard to have a material impact on our financial condition and results of operations.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ASU 2020-01, “Investments - Equity Securities, Investments - Equity Method and Joint Ventures, and Derivatives and Hedging - Clarifying the Interactions Between Topic 321, Topic 323, and Topic 815”</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In January 2020, the FASB issued a new standard intended to clarify the interactions between Accounting Standards Codification (ASC) 321, ASC 323 and ASC 815. The new standard addresses accounting for the transition into and out of the equity method and measurement of certain purchased options and forward contracts to acquire investments. The standard is effective for annual and interim periods beginning after December 15, 2020, with early adoption permitted. Adoption of the standard requires changes to be made prospectively. We do not expect the adoption of this standard to have a material impact on our financial condition and results of operations.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ASU 2020-04, “Reference Rate Reform, Facilitation of the Effects of Reference Rate Reform on Financial Reporting"</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to concerns about structural risks of interbank offered rates, and, particularly, the risk of cessation of the London Interbank Offered Rate (LIBOR), regulators around the world have undertaken reference rate reform initiatives to identify alternative reference rates that are more observable or transaction-based and less susceptible to manipulation. In March 2020, the FASB issued a new standard that provides optional guidance for a limited time to ease the potential burden in accounting for the effects of reference rate reform, including optional expedients and exceptions for the accounting implications of contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendments in this new standard only apply to contracts and hedging relationships that reference LIBOR or another reference rate expected to be discontinued due to reference rate reform. The expedients and exceptions provided by the standard do not apply to contract modifications made and hedging relationships entered into or evaluated after December 31, 2022. We are currently reviewing our contracts impacted by reference rate reform and are assessing the impact of this standard on our financial condition and results of operations.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ASU 2018-15, "Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract"</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">: </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued a new standard on a customer's accounting for implementation, set-up, and other upfront costs incurred in a cloud computing arrangement (CCA) that aligns the requirements for capitalizing implementation costs in a CCA service contract with existing internal-use software guidance. The standard also provides classification guidance on these implementation costs as well as additional </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">quantitative and qualitative disclosures. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The standard is effective for interim and annual periods beginning after December 15, 2019, with early adoption permitted, and can be adopted prospectively or retrospectively.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted the new standard on January 1, 2020 on a prospective basis. The adoption of this stand</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ard had no impact on our financial statements at the date of adoption; however, we anticipate the adoption of this standard will result in an increase in capitalized assets related to qualifying CCA implementation costs in future periods. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Qualifying CCA implementation, set-up and other upfront costs incurred after January 1, 2020 are capitalized as other assets in our condensed consolidated balance sheets. These assets will be expensed over the term of the hosting arrangement and such expense will be presented within the same line item in our condensed consolidated statements of operations as the expense for fees for the associated hosting arrangement. These capitalized costs will be evaluated for impairment when events or changes in circumstances indicate that the carrying value of the capitalized implementation costs is not recoverable. For the nine months ended September 30, 2020, capitalized CCA implementation costs were not material.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ASU 2016-13, "Measurement of Credit Losses on Financial Instruments"</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">: </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued a new standard intended to improve reporting requirements specific to loans, receivables and other financial instruments. The new standard requires that credit losses on financial assets measured at amortized cost be determined using an expected loss model, instead of the current incurred loss model, and requires that credit losses related to available-for-sale debt securities be recorded through an allowance for credit losses and limited to the amount by which carrying value exceeds fair value. The new standard also requires enhanced disclosure of credit risk associated with financial assets.</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The standard is effective for interim and annual periods beginning after December 15, 2019 with early adoption permitted.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted the new standard on January 1, 2020 and have completed our assessment of the standard based on the composition of our portfolio of financial instruments and current and forecasted economic conditions at that date. Our significant financial assets that are within the scope of the new standard consist of trade accounts receivable and available for sale debt securities. We have not historically experienced any material credit losses associated with our trade accounts receivable or available for debt securities. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor economic conditions, including volatility associated with international economies and the associated impacts on the financial markets and our business. We disaggregate our trade accounts receivable population into pools of similar risk characteristics based on underlying customer type and geographical location. Current expected credit loss allowances are estimated for each risk pool based on available information, including i) historical credit loss experience, ii) current economic conditions and, iii) reasonable and supportable forecasts of future economic conditions that may affect the collectibility of the recorded amounts. Based on the relevant facts and economic conditions as of the date of adoption, we concluded that the expected credit losses on our trade accounts receivable were immaterial. Additionally, unrealized losses on our available for sale investment portfolio were immaterial. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, we reassessed our estimated credit losses on our trade accounts receivable, including consideration of the potential impacts of the COVID-19 global pandemic. Based on the relevant facts and economic conditions as of September 30, 2020, we concluded that the expected credit losses on our trade accounts receivable continued to be immaterial.</span></div> Acquisitions<div style="margin-top:5pt"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Achillion Pharmaceuticals, Inc.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, Alexion entered into a definitive agreement to acquire Achillion Pharmaceuticals, Inc. (Achillion), a clinical-stage biopharmaceutical company focused on the development of oral Factor D inhibitors. Achillion was developing oral small molecule Factor D inhibitors to treat people with complement alternative pathway-mediated rare diseases, such as PNH and C3 glomerulopathy (C3G). Achillion had two clinical stage medicines in development, including danicopan (ACH-4471/ALXN2040) and ACH-5228 (ALXN2050).</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Achillion closed on January 28, 2020. Under the terms of the agreement, we acquired all outstanding common stock of Achillion for $6.30 per share, or an aggregate of $926.2, inclusive of the settlement of Achillion's outstanding equity awards. The acquisition was funded with cash on hand. The transaction includes the potential for additional consideration in the form of non-tradeable contingent value rights (CVRs), which will be paid to Achillion shareholders if certain clinical and regulatory milestones are achieved within specified periods. These </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">include $1.00 per share for the U.S. Food and Drug Administration (FDA) approval of danicopan and $1.00 per share for the initiation of a Phase III clinical trial in ACH-5228.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The transaction was accounted for as a business combination. The following table summarizes the total consideration transferred to acquire Achillion and the estimated fair value of the identified assets acquired and liabilities assumed at the acquisition date:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0868ac;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consideration</span></td><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront payment to shareholders and option holders</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926.2 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront payment, fair value of equity compensation attributable to the post-combination service period</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.0)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront cash paid, net</span></td><td colspan="2" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906.2 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.7 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, fair value of equity compensation attributable to the post-combination service period</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,061.2 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0868ac;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets Acquired and Liabilities Assumed</span></td><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.1 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research &amp; development assets (IPR&amp;D)</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">918.0 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.8 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.9)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total net assets acquired</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,061.2 </span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting for this acquisition was finalized during the second quarter of 2020. Measurement period adjustments increased goodwill by $3.1 during the second quarter of 2020 due to purchase price allocation increases to deferred tax liabilities, net. Measurement period adjustments were recorded as a result of studies completed during the second quarter of 2020 to determine the tax deductibility of certain acquisition-related costs and the valuation of historical net operating loss and income tax credit carryforwards.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial fair value estimate of the contingent consideration in the form of non-tradeable CVRs was $160.7, which was recorded as a noncurrent liability in our condensed consolidated balance sheet, including $5.7 related to compensation attributable to the post-combination service period. We determined the fair value of these milestone-related payment obligations using various estimates, including probabilities of success prior to expiration of the specified period, discount rates and the amount of time until the conditions of the milestone payments are expected to be met. This fair value measurement was based on significant inputs not observable in the market, representing Level 3 measurements within the fair value hierarchy. The resulting probability-weighted cash flows were discounted using a cost of debt rate ranging from 2.1% to 2.3%. The range of estimated milestone payments upon closing of the acquisition is from zero, if no milestones are achieved for any product, to $306.3 if certain development and regulatory milestones are achieved.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the acquisition date, we have adjusted the contingent consideration to fair value with changes in fair value recognized in operating earnings. Changes in fair values reflect new information about the probability and timing of meeting the conditions of the milestone payments. In the absence of new information, changes in fair value will only reflect the interest component of contingent consideration related to the passage of time as development work progresses towards the potential achievement of the milestones. At September 30, 2020, the fair value of the contingent consideration for the Achillion acquisition was</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $209.4 b</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ased on the probability-weighted cash flows, discounted using a cost of debt ranging f</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rom 3.9% to 4.3%. Cha</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nges in fair value of the contingent consideration associated with the Achillion acquisition for the three and nine months ended September 30, 2020 was </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$19.3 and $48.6, respectively</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate fair value of equity compensation attributable to the post-combination service period was $25.7. This amount was excluded from the total consideration transferred and was recognized as a charge to acquisition-related costs in our condensed consolidated statements of operations. These amounts were associated with the </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accelerated vesting of stock options previously granted to Achillion employees. Excluding the $5.7 of contingent consideration related to equity compensation attributable to the post-combination service period, such amounts were paid during the first quarter 2020.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets associated with IPR&amp;D relate to two development-stage programs, ACH-4471 (ALXN2040) and ACH-5228 (ALXN2050). The estimated fair value of $918.0 was determined using the excess earnings valuation method, a variation of the income valuation approach. The excess earnings valuation method estimates the value of an intangible asset equal to the present value of the incremental after-tax cash flows attributable to that intangible asset. Some of the more significant assumptions utilized in our asset valuations included the estimated net cash flows for each asset, including net revenues, cost of sales, research and development and other operating expenses, the potential regulatory and commercial success rates, competitive trends impacting the assets, and tax rates. The fair value using the excess earnings valuation method was determined using an estimated weighted average cost of capital for Achillion of 11.5%, which represents a rate of return that a market participant would expect for these assets. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements. In the second quarter 2020, we recognized an impairment charge of $11.0 to write off our ACHN-4471 (ALXN2040) IPR&amp;D asset due to clinical results received during the quarter.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of purchase price over the fair value of the assets acquired and liabilities assumed represents the goodwill resulting from the acquisition. The goodwill, which is not tax-deductible, has been recorded as a noncurrent asset and is not amortized, but is subject to an annual review for impairment. The factors that contributed to the recognition of goodwill include the value of the acquired workforce, synergies that are specific to our business and not available to market participants, and early research in preclinical Factor D inhibitors, as well as the effects of the establishment of a deferred tax liability for the acquired IPR&amp;D intangible assets, which has no tax basis. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded a net deferred tax liabilit</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y of $62.9,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> inclusive of measurement period adjustments recorded during the second quarter 2020. This amount was pr</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">imarily comprised of $205.3 of deferred tax liabilities relating to the IPR&amp;D acquired, offset by $142.4 of deferred tax assets related to net operating loss carryforwards (NOLs), income tax credits, and other temporary differences. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Achillion's results of operations are included in the condensed consolidated financial statements from the date of acquisition. For the three and nine months ended September 30, 2020 we recorded $24.6 and $51.4 of pre-tax operating losses exclusive of transaction costs, $19.3 and $48.6, respectively, of changes in contingent consideration and zero and $11.0, respectively, of impairment charges, associated with the operations of Achillion in our condensed consolidated statements of operations. We also recorded acquisition-related costs in connection with the acquisition during the three and nine months ended September 30, 2020 as presented below. No revenues were recorded in the results of operations during the three and nine months ended September 30, 2020 as neither ALXN2040 nor ALXN2050 has been approved for commercial sale by any regulatory agency.</span></div><div style="margin-top:5pt;text-align:justify"><span style="background-color:#ffffff;color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Portola Pharmaceuticals, Inc.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Alexion entered into a definitive merger agreement to acquire Portola Pharmaceuticals, Inc. (Portola), a commercial-stage biopharmaceutical company focused on life-threatening blood-related disorders. Portola’s commercialized medicine, ANDEXXA®, marketed as ONDEXXYA® in Europe, is the first and only approved Factor Xa inhibitor reversal agent, and has demonstrated transformative clinical value by rapidly reversing the anticoagulant effects of Factor Xa inhibitors rivaroxaban and apixaban in severe and uncontrolled bleeding. The acquisition provides the opportunity to grow Alexion's commercial portfolio and is a strategic fit with our existing expertise in</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> acute care, h</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ematology and neurology.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alexion completed the acquisition through a tender offer and subsequent merger of Portola which closed on July 2, 2020. Under the terms of the tender offer and merger agreement, Alexion purchased all outstanding common stock of Portola for $18.00 per share, or an aggregate of approximately $1,380.8, including the settlement of certain of Portola's outstanding equity awards but excluding shares of Portola stock held by Alexion at closing. The acquisition was funded by cash on hand.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the acquisition of Portola, in March 2020 and April 2020, we purchased $14.5 and $3.6, respectively, of common stock of Portola, which we recorded at fair value. Upon the closing of the acquisition of Portola, the fair value of the equity investment of $47.8 was derecognized and included in the fair value of consideration transferred. For additional information on our Portola equity investment, please see Note 10, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Investments.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate fair value of equity compensation attributable to the post-combination service period was $11.1. This amount was excluded from the total consideration transferred and was recognized as a charge to acquisition-related costs in our condensed consolidated statements of operations. These amounts were primarily associated with the accelerated vesting of stock options previously granted to Portola employees and were paid during the third quarter 2020.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued $41.5 of equity compensation replacement awards, of which the portion attributable to services performed prior to the acquisition date, or $7.2, was allocated to purchase consideration. The remaining fair value is attributable to future services and will be expensed as share-based compensation over the remaining service periods. Expense associated with the accelerated-vesting of the replacement awards in connection with employee terminations will be recognized as acquisition-related employee separation costs.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition, Alexion also paid $196.9 to settle certain debt held by Portola that was subject to preexisting change of control provisions. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction was accounted for as a business combination. The following table summarizes the total consideration transferred to acquire Portola and the estimated fair value of the identified assets acquired and liabilities assumed at the acquisition date:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0868ac;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consideration</span></td><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront payment to shareholders and equity holders</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,380.8 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront payment, fair value of equity compensation attributable to the post-combination service period</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.1)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront cash paid, net</span></td><td colspan="2" style="background-color:#eaeaea;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,369.7 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of equity shares held by Alexion at closing </span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.8 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of replacement equity awards attributable to the pre-combination period</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration to acquire outstanding equity, net</span></td><td colspan="2" style="background-color:#eaeaea;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424.7 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration to settle preexisting debt</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.9 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,621.6 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0868ac;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets Acquired and Liabilities Assumed</span></td><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, including noncurrent portion of $169.1 and validation batches of $60.9</span></div></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051.0 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.0 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.9 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75.6)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including current portion of $7.7</span></div></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182.0)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.0)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total net assets acquired</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,621.6 </span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting for this acquisition is preliminary. The fair value estimates for the assets acquired and liabilities assumed were based on preliminary calculations, and our estimates and assumptions are subject to change as we obtain additional information for our estimates during the measurement period. The areas that rely on preliminary estimates that are not yet finalized relate to the valuation of acquired intangible assets, an ongoing assessment of the condition of certain inventory and deferred taxes, net, as a result of ongoing studies to determine the tax deductibility of certain acquisition-related costs and the valuation of historical net operating loss and income tax credit carryforwards.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired $362.5 of ANDEXXA inventory, inclusive of $60.9 of validation batches manufactured under processes which are subject to regulatory approval and expected to be commercially saleable following approval. The estimated fair value of raw material inventory was valued at replacement cost, which is equal to the value a market participant would pay to acquire the inventory. The estimated fair value of work-in-process and finished goods inventory was based on the expected selling price of the inventory, adjusted for incremental costs to complete the manufacturing process, for direct selling efforts, and for a normal profit on the remaining manufacturing and selling costs. Additionally, as the inventory acquired, inclusive of validation batches, is expected to be realized over a period of approximately 3.0 years, the fair value of the inventory was determined using a discount rate of 17.5%, representing the rate of return that a market participant would expect for the inventory, which shares risk that is similar to the underlying intellectual property. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements. The acquired inventory, inclusive of the acquisition-date fair value step-up, will be expensed within cost of sales as the inventory is sold to customers. We classified the ANDEXXA inventory that is expected to be utilized beyond our normal operating cycle as a long-term asset. The fair value of the non-current portion of inventory, in addition to the validation batches, are classified within other assets in our condensed consolidated balance sheet.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consist of purchased technology of $1,036.0 and IPR&amp;D of $15.0. The purchased technology intangible asset relates to Portola's lead product ANDEXXA. The estimated fair value was determined using the excess earnings valuation method, a variation of the income valuation approach. The excess earnings valuation method estimates the value of an intangible asset equal to the present value of the incremental after-tax cash flows attributable to that intangible asset. Some of the more significant assumptions utilized in our asset valuation included the estimated net cash flows for ANDEXXA, including net revenues, cost of sales, research and development and other operating expenses, the potential regulatory and commercial success rates associated with ANDEXXA's current conditional approval status and planned extension into the urgent surgery setting, competitive trends impacting the assets, and tax rates. The fair value using the excess earnings valuation method was determined using a discount rate commensurate with the risks of ANDEXXA of 17.5%, which represents a rate of return that a market participant would expect for the asset. The acquired purchased technology intangible asset is being amortized over an estimated useful life of approximately 10 years. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D relates to the cerdulatinib development-stage asset. The estimated fair value of the IPR&amp;D asset was determined using a relief from royalty (RFR) method, a variation of the income approach that is based on the cost savings that accrue to the owner of an intangible asset who would otherwise have to pay royalties on revenues earned through the use of the asset. The RFR method was modified to reflect the cash flow forecast of Portola's pre-existing in-license of cerdulatinib from Astellas Pharma, Inc. The acquired fair value of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$15.0 represents an increase in the value of the asset relative to when it was initially in-licensed by Portola.</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Some of the more significant assumptions utilized in the IPR&amp;D asset valuation included the estimated net revenue, royalty rate, and tax rates. The fair value using the RFR method was determined using an estimated </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discount rate commensurate with the risks of cerdulatinib </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of 17.5%, which represents a rate of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">return that a market participant would expect for the asset. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In connection with the acquisition, we assumed royalty-based debt which requires repayment through tiered royalties on future net worldwide sales of ANDEXXA. Total potential royalty payments are capped at $290.6, of which $13.7 were paid by Portola prior to the acquisition. The fair value of the remaining $276.9 in royalty-based payments as of the date of acquisition was $182.0. The estimated fair value was measured using Level 3 inputs and was calculated using a real options method, which runs simulations using various estimates, including probability-weighted net sales of ANDEXXA and volatility. Using the simulation results, the fair value was calculated based on the expected probability-weighted risk-neutral royalties, discounted at our estimated cost of debt, ranging from 3.3% to 7.1%, commensurate with the cost of debt at each period in which the royalty-based payments are estimated to be made. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded net deferred tax assets of $116.0. This amount was primarily comprised of $301.0, $42.0, $42.4 and $39.1 of deferred tax assets relating to net operating loss carryforwards (NOLs), income tax credits, royalty-based debt, and other temporary differences, respectively, offset by $245.1 and $63.4 of deferred tax liabilities relating to intangible assets acquired and inventory fair value adjustments, respectively.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of purchase price over the fair value of the assets acquired and liabilities assumed represents the goodwill resulting from the acquisition. The goodwill, which is not tax-deductible, has been recorded as a noncurrent asset and is not amortized, but is subject to an annual review for impairment. The factors that contributed to the recognition of goodwill primarily include the value of the acquired workforce and the effects of the establishment of a deferred tax liability for the fair value step-up of acquired inventory and intangible assets which exceed the incremental book value of acquired deferred tax assets over their fair value.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portola's results of operations are included in the condensed consolidated financial statements from the date of acquisition. For the three and nine months ended September 30, 2020, we recorded $38.9 of revenue associated with ANDEXXA in </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our condensed consolidated statements of operations. For the three and nine months ended September 30, 2020, we recorded $35.4 of pre-tax operating losses excluding transaction costs and $25.9 of intangible asset amortization, associated with the operations of Portola in our condensed consolidated statements of operations. We also recorded acqu</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">isition-related costs in connection with the acquisition during the three and nine months ended September 30, 2020 as presented below.</span></div><div style="margin-top:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pro forma financial information (unaudited)</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma information presents the combined results of Alexion, Achillion, and Portola as if the acquisitions of Achillion and Portola had been completed on January 1, 2019, with adjustments to give effect to pro forma events that are directly attributable to the acquisitions. The unaudited pro forma results do not reflect operating efficiencies or potential cost savings that may have resulted from the consolidation of operations. Accordingly, the unaudited pro forma financial information is not necessarily indicative of the results of operations had we completed the transaction on January 1, 2019.</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.434%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.434%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.439%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma revenue</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,589.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,299.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,526.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,694.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma net income (loss)</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625.4 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.2)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,063.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma consolidated results for the three and nine months ended September 30, 2020 and 2019 primarily include the following pro forma adjustments related to non-recurring activity, net of tax:</span></div><div style="margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.5pt">Reclassification of Alexion, Achillion and Portola acquisition-related costs. Acquisition-related costs of $72.2 and $143.5, respectively, were excluded from net income for the three and nine months ended September 30, 2020. Expenses of $129.3 were included in net income for the nine months ended September 30, 2020.</span></div><div style="margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:4.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.5pt">Incremental amortization expense related to Portola purchased technology intangible assets for the three and nine months ended September 30, 2019 was $19.9 and $59.6, respectively, and for the nine months ended September 30, 2020 was $39.7.</span></div><div style="margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:4.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.5pt">Incremental cost of goods sold related to Portola inventory fair value step-up adjustments calculated based on the fair value of finished goods inventory for the three and nine months ended September 30, 2019 was $10.1 and $16.7, respectively, and for the nine months ended September 30, 2020 was $10.9.</span></div><div style="margin-top:5pt;text-align:justify"><span style="background-color:#ffffff;color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition-Related Costs</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related costs recorded within the condensed consolidated statement of operations associated with our acquisitions of Achillion and Portola for the three and nine months ended September 30, 2020 and 2019 include the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.491%"><tr><td style="width:1.0%"/><td style="width:41.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.839%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.839%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.839%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integration costs</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of equity compensation attributable to the post-combination service period</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.8 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee separation costs</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.9 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.0 </span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.7 </span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:110%">(1) Transaction costs primarily include legal fees related to the acquisition of Portola as well as costs incurred to effectuate the settlement of the Achillion outstanding options</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:110%">(2) Employee separation costs include liabilities recognized, and subsequent changes in estimates recorded for, severance payments, one-time short-term retention awards agreed to in connection with the acquisition of Achillion and share-based compensation expense relating to awards accelerated in connection with terminations of Portola employees.</span></div><div style="margin-bottom:3pt;margin-top:5pt;padding-right:2.25pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Acquisition-related costs attributable to the Achillion acquisition for the nine months ended September 30, 2020 were $38.0. There were immaterial acquisition-related costs attributable to the Achillion acquisition for the three months ended September 30, 2020. Acquisition-related costs attributable to the Portola acquisition for three and nine months ended September 30, 2020 were $63.0 and $67.7, respectively.</span></div> 6.30 926200000 1.00 1.00 The following table summarizes the total consideration transferred to acquire Achillion and the estimated fair value of the identified assets acquired and liabilities assumed at the acquisition date:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0868ac;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consideration</span></td><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront payment to shareholders and option holders</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926.2 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront payment, fair value of equity compensation attributable to the post-combination service period</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.0)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront cash paid, net</span></td><td colspan="2" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906.2 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.7 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, fair value of equity compensation attributable to the post-combination service period</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,061.2 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0868ac;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets Acquired and Liabilities Assumed</span></td><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.1 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research &amp; development assets (IPR&amp;D)</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">918.0 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.8 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.9)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total net assets acquired</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,061.2 </span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>The following table summarizes the total consideration transferred to acquire Portola and the estimated fair value of the identified assets acquired and liabilities assumed at the acquisition date:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0868ac;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consideration</span></td><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront payment to shareholders and equity holders</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,380.8 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront payment, fair value of equity compensation attributable to the post-combination service period</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.1)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront cash paid, net</span></td><td colspan="2" style="background-color:#eaeaea;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,369.7 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of equity shares held by Alexion at closing </span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.8 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of replacement equity awards attributable to the pre-combination period</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration to acquire outstanding equity, net</span></td><td colspan="2" style="background-color:#eaeaea;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424.7 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration to settle preexisting debt</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.9 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,621.6 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0868ac;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets Acquired and Liabilities Assumed</span></td><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, including noncurrent portion of $169.1 and validation batches of $60.9</span></div></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051.0 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.0 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.9 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75.6)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including current portion of $7.7</span></div></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182.0)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.0)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total net assets acquired</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,621.6 </span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 926200000 20000000.0 906200000 160700000 5700000 1061200000 68500000 106100000 918000000.0 37800000 62900000 -6300000 1061200000 3100000 160700000 5700000 0.021 0.023 0 306300000 209400000 0.039 0.043 19300000 48600000 25700000 5700000 918000000.0 0.115 11000000.0 62900000 205300000 142400000 24600000 51400000 19300000 48600000 11000000.0 18.00 1380800000 14500000 3600000 47800000 11100000 41500000 7200000 196900000 1380800000 11100000 1369700000 47800000 7200000 1424700000 196900000 1621600000 288500000 17800000 169100000 60900000 362500000 1051000000.0 25500000 116000000.0 41900000 75600000 7700000 182000000.0 24000000.0 1621600000 362500000 60900000 P3Y 0.175 1036000000.0 15000000.0 0.175 P10Y 15000000.0 0.175 290600000 13700000 276900000 182000000.0 0.033 0.071 116000000.0 301000.0 42000.0 42400 39100 245100 63400 38900000 38900000 -35400000 -35400000 25900000 25900000 <div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma information presents the combined results of Alexion, Achillion, and Portola as if the acquisitions of Achillion and Portola had been completed on January 1, 2019, with adjustments to give effect to pro forma events that are directly attributable to the acquisitions. The unaudited pro forma results do not reflect operating efficiencies or potential cost savings that may have resulted from the consolidation of operations. Accordingly, the unaudited pro forma financial information is not necessarily indicative of the results of operations had we completed the transaction on January 1, 2019.</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.434%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.434%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.439%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma revenue</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,589.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,299.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,526.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,694.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma net income (loss)</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625.4 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.2)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,063.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div> 1589500000 1299900000 4526500000 3694200000 625400000 372000000.0 -23200000 1063700000 72200000 143500000 129300000 19900000 59600000 39700000 10100000 16700000 10900000 <div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related costs recorded within the condensed consolidated statement of operations associated with our acquisitions of Achillion and Portola for the three and nine months ended September 30, 2020 and 2019 include the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.491%"><tr><td style="width:1.0%"/><td style="width:41.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.839%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.839%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.839%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integration costs</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of equity compensation attributable to the post-combination service period</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.8 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee separation costs</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.9 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.0 </span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.7 </span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:110%">(1) Transaction costs primarily include legal fees related to the acquisition of Portola as well as costs incurred to effectuate the settlement of the Achillion outstanding options</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:110%">(2) Employee separation costs include liabilities recognized, and subsequent changes in estimates recorded for, severance payments, one-time short-term retention awards agreed to in connection with the acquisition of Achillion and share-based compensation expense relating to awards accelerated in connection with terminations of Portola employees.</span></div> 1800000 0 7400000 0 4600000 0 5600000 0 11100000 0 36800000 0 45500000 0 55900000 0 63000000.0 0 105700000 0 38000000.0 63000000.0 67700000 Inventories<div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.2 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256.6 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861.3 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627.6 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification:</span></td><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729.0 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total inventories include ANDEXXA inventory acquired in connection with the July 2, 2020 Portola acquisition, but exclude acquired ANDEXXA validation batches of $60.9 that were manufactured under processes which are subject to regulatory approval. The acquired ANDEXXA inventory includes the acquisition-date fair value step-up, which is expensed within cost of sales as the inventory is sold to customers. For additional information on our acquisition of Portola, please see Note 3, </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in other assets in our condensed consolidated balance sheets. Inventories classified as long-term relate to ANDEXXA inventory acquired in connection with the Portola acquisition.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020 and December 31, 2019, the carrying value of capitalized inventory manufactured at production facilities that have not yet received regulatory approval was</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $117.2</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $60.5, respectively.</span></div> <div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.2 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256.6 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861.3 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627.6 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification:</span></td><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729.0 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 94200000 41200000 256600000 180800000 510500000 405600000 861300000 627600000 729000000.0 627600000 132300000 0 60900000 117200000 60500000 Intangible Assets and Goodwill<div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of our intangible assets and goodwill, net of accumulated amortization and impairment charges:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:19.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="15" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="15" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated<br/>Life (years)</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization </span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization </span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing rights</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-8</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.0 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.5)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.5)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased technology</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6-16</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,746.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,631.5)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,115.0 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,710.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,388.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,321.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922.0 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922.0 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,736.4 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,679.8)</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,056.6 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,778.4 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,434.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,344.3 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,103.6 </span></td><td style="background-color:#eaeaea;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#eaeaea;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100.7 </span></td><td style="background-color:#eaeaea;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,040.3 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,037.4 </span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="42" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a) Includes an impairment charge of $2,042.3 recognized during the second quarter 2020 related to the KANUMA intangible asset</span></div></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-right:2.25pt;text-indent:36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In connection with our acquisition of Achillion during the first quarter 2020, we acquired IPR&amp;D programs with a fair value of $918.0 and recorded goodwill of $37.8. For additional information on our acquisition of Achillion, please see Note 3, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. In the second quarter 2020, we recognized an impairment charge of $11.0 to write off the cost basis of our ACHN-4471 (ALXN2040) acquired in-process research and development asset due to clinical results received during the quarter.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Portola during the third quarter 2020, we acquired purchased technology and IPR&amp;D programs with a fair value of $1,036.0 and $15.0, respectively and recorded goodwill of $25.5. For additional information on our acquisition of Portola, please see Note 3, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for the three months ended September 30, 2020 and 2019 was $54.1 and $77.5, respectively. Amortization expense for the nine months ended September 30, 2020 and 2019 was $203.4 and $239.2, respectively. As of September 30, 2020, assuming no changes in the gross cost basis of intangible assets, the</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> total estimated amortization expense for finite-lived intangible assets is $54.1 for the three months ending</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020, and approximate</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ly $216.0 for</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> each of the years ending December 31, 2021 through December 31, 2025.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended June 30, 2020, based on continued challenges expanding patient growth and new alternative commercial opportunities, the Company revised its strategic view of KANUMA and determined that we have exhausted commercially viable initiatives related to KANUMA and will have difficulty expanding patient growth over the long term as we focus on promoting other commercial programs and growing our pipeline. As a result, we no longer expect to increase the number of KANUMA patients in the long term at the rate previously assumed. This determination resulted in reduced cash flow projections for KANUMA, which indicated that the related intangible asset value was not fully recoverable on an undiscounted cash flows basis. On June 30, 2020, the Company utilized market participant assumptions to determine its best estimate of the fair value of the intangible asset related to KANUMA that, when compared with its related carrying value, resulted in an impairment charge of $2,042.3.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the KANUMA asset as of June 30, 2020 was determined using the excess earnings method, a variation of the income approach. The excess earnings method estimates the value of an intangible asset equal to the present value of the incremental after-tax cash flows attributable to that intangible asset over its remaining economic life. Long term cash flow projections for the asset require the use of significant estimates and judgements, including discount rates and revenue growth rates, and were based on the Company’s most recent strategic plan. The fair value of the asset was determined using an estimated weighted average cost of capital of 10.0%, which reflects the risks inherent in future cash flow projections and represents a rate of return that a market participant would expect for this asset. The estimated revenue growth rates fluctuate over the life of the asset, with a weighted average growth rate in the low single digits. The Company believes its assumptions are consistent with the plans and estimates that a market participant would use to manage the business. The estimated fair value of the KANUMA intangible asset as of June 30, 2020 was $820.0 and will continue to be amortized over its remaining estimated useful life. This fair value measurement was based on significant inputs not observable in the market and thus represents a Level 3 fair value measurement.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the changes in the carrying amount of goodwill:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.321%"><tr><td style="width:1.0%"/><td style="width:79.881%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.919%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,037.4 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill resulting from the acquisitions of Achillion and Portola</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100.7 </span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of our intangible assets and goodwill, net of accumulated amortization and impairment charges:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:19.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="15" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="15" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated<br/>Life (years)</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization </span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization </span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing rights</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-8</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.0 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.5)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.5)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased technology</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6-16</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,746.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,631.5)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,115.0 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,710.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,388.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,321.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922.0 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922.0 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,736.4 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,679.8)</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,056.6 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,778.4 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,434.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,344.3 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,103.6 </span></td><td style="background-color:#eaeaea;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#eaeaea;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100.7 </span></td><td style="background-color:#eaeaea;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,040.3 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,037.4 </span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="42" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a) Includes an impairment charge of $2,042.3 recognized during the second quarter 2020 related to the KANUMA intangible asset</span></div></td></tr></table></div> P3Y P8Y 57000000.0 37500000 19500000 57000000.0 34700000 22300000 P7Y 10500000 10500000 0 10500000 10500000 0 P6Y P16Y 5746500000 3631500000 2115000000.0 4710500000 1388700000 3321800000 P5Y 400000 300000 100000 400000 200000 200000 922000000.0 922000000.0 0 0 6736400000 3679800000 3056600000 4778400000 1434100000 3344300000 5103600000 2900000 5100700000 5040300000 2900000 5037400000 2042300000 918000000.0 37800000 11000000.0 1036000000.0 15000000.0 25500000 54100000 77500000 203400000 239200000 54100000 216000000.0 216000000.0 216000000.0 216000000.0 216000000.0 2042300000 0.100 820000000.0 <div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the changes in the carrying amount of goodwill:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.321%"><tr><td style="width:1.0%"/><td style="width:79.881%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.919%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,037.4 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill resulting from the acquisitions of Achillion and Portola</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100.7 </span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5037400000 63300000 5100700000 Debt<div style="margin-top:5pt;text-align:justify"><span style="background-color:#ffffff;color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 7, 2018, we entered into an Amended and Restated Credit Agreement (the Credit Agreement), with Bank of America, N.A. as Administrative Agent. The Credit Agreement amended and restated our credit agreement dated as of June 22, 2015 (the Prior Credit Agreement).</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement provides for a $1,000.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revolving credit facility and a $2,612.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">term loan facility. The revolving credit facility and the term loan facility mature on June 7, 2023. Beginning with the quarter ending June 30, 2019, we are required to make payments of 5.00%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the original principal amount of the term loan facility annually, payable in equal quarterly installments.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with entering into the Credit Agreement and the Prior Credit Agreement, we paid an aggregate of $53.1 in financing costs in 2018. Financing costs are amortized as interest expense over the life of the debt. Amortization expense associated with deferred financing costs for the three months ended September 30, 2020 and 2019 was $1.2 and $1.3, respectively. Amortization expense associated with deferred financing costs for the nine months ended September 30, 2020 and 2019 was $3.6 and $3.8, respectively. Remaining unamortized deferred financing costs as of September 30, 2020 and December 31, 2019 were $12.2 and $15.8, respectively.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We made principal payments of $32.6 and $97.9 on the term loan during the three and nine months ended September 30, 2020, respectively, and as of September 30, 2020, we had $2,416.6 outstanding on the term loan. We had no outstanding borrowings under the revolving credit facility as of September 30, 2020. As of September 30, 2020, we had open letters of credit of $1.0 that offset our availability in the revolving credit facility.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount outstanding under the term loan of $2,416.6 as of September 30, 2020 is subject to variable interest rates, which are based on current market rates, and as such, the Company believes the carrying amount of the obligation approximates fair value.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were in compliance with all applicable covenants under the Credit Agreement as of September 30, 2020.</span></div><div style="margin-top:5pt;text-align:justify"><span style="background-color:#ffffff;color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty-based Financing</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisiti</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on of Portola during the third quarter 2020, we assumed royalty-based debt relating to a royalty sales agreement Portola had entered into with HealthCare Royalty Partners (HCR) whereby HCR acquired a tiered royalty interest in future worldwide net sales of ANDEXXA. Portola received $50.0 upon closing of the agreement in February 2017 and an additional $100.0 following the U.S. regulatory approval of ANDEXXA in May 2018. Tiered royalties ranging from 4.2% to 8.5% are required to be paid to HCR based on net worldwide sales of ANDEXXA. The applicable rate decreases as worldwide net annual sales levels increase above defined thresholds. Total potential royalty payments are capped at 195% of the funding received less certain transaction expenses, or $290.6. As of the date of acquisition, the remaining due to HCR was $276.9 in royalty-based payments.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded the HCR debt at its fair value of $182.0 upon closing of the acquisition, representing an initial debt discount of $94.9. We have also recognized a deferred tax asset of $42.4 related to the royalty-based debt as of the acquisition date. For additional information on our acquisition of Portola, please see Note 3, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Interest expense is recognized using the effective interest rate method over the estimated period the related debt will be paid. This requires estimation of the timing and amount of future royalty payments to be generated from future sales of ANDEXXA. We reassess the expected royalty payments each reporting period and account for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt require that we make estimates that could impact the short and long term</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> classification of the debt carrying values.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each period, we amortize the initial debt discount using the effective interest rate implied from the projected timing of royalty payments to HCR. The effective interest rate for the HCR royalty-based debt as of September 30, 2020 was 11.4%. During the three and nine months ended September 30, 2020, we recognized interest expense </span></div><div style="margin-top:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">associated with the amortization of the debt discount of $4.9. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We made royalty-based debt payments of $1.7 during the three and nine months ended September 30, 2020. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, the carrying value of the royalty-based debt includes approximately $3.0 of royalty payments on third quarter sales of ANDEXXA which will be paid during the fourth quarter 2020.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, the carrying value of the HCR royalty-based debt was $185.2, of which $11.7 was recorded within current portion of long-term debt and $173.5 was recorded within long-term debt, less current portion on our condensed consolidated balance sheet. Our payment obligations for HCR royalty-based debt are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total repayment obligation as of the acquisition date</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276.9 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest to be accreted in future periods</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90.0)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: payments made</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value as of September 30, 2020</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.2 </span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the royalty based debt as of September 30, 2020 approximates fair value due to the proximity to the acquisition date.</span></div> 1000000000.0 2612500000 0.0500 53100000 1200000 1300000 3600000 3800000 12200000 15800000 32600000 97900000 2416600000 1000000.0 2416600000 50000000.0 100000000.0 0.042 0.085 1.95 290600000 276900000 182000000.0 94900000 42400 0.114 4900000 4900000 1700000 1700000 3000000.0 185200000 11700000 173500000 Our payment obligations for HCR royalty-based debt are as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total repayment obligation as of the acquisition date</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276.9 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest to be accreted in future periods</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90.0)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: payments made</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value as of September 30, 2020</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.2 </span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 276900000 90000000.0 1700000 185200000 Earnings Per Common Share<div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per common share (EPS) is computed by dividing net income by the weighted-average number of shares of common stock outstanding. For purposes of calculating diluted EPS, the denominator reflects the potential dilution that could occur if stock options, unvested restricted stock units or other contracts to issue common stock were exercised or converted into common stock, using the treasury stock method.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the calculation of basic and diluted EPS for the three and nine months ended September 30, 2020 and 2019:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income used for basic and diluted calculation</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578.1 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.6 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,515.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing earnings per common share—basic</span></td><td colspan="2" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219.1 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.3 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220.4 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.8 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average effect of dilutive securities:</span></td><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock awards</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing earnings per common share—diluted</span></td><td colspan="2" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220.6 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.5 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221.9 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225.4 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per common share:</span></td><td colspan="3" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 29.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.64 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.09 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.77 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 29.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.62 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.08 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.72 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We exclude from diluted EPS the weighted-average number of securities whose effect is anti-dilutive. Excluded from the calculation of EPS for the three and nine months ended September 30, 2020 were 2.5 and 1.8 shares of common stock, respectively, because their effect is anti-dilutive. Excluded from the calculation of EPS for the three and nine months ended September 30, 2019 were 3.3 and 3.1 shares of common stock, respectively, because their effect is anti-dilutive.</span></div> <div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the calculation of basic and diluted EPS for the three and nine months ended September 30, 2020 and 2019:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income used for basic and diluted calculation</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578.1 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.6 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,515.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing earnings per common share—basic</span></td><td colspan="2" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219.1 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.3 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220.4 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.8 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average effect of dilutive securities:</span></td><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock awards</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing earnings per common share—diluted</span></td><td colspan="2" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220.6 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.5 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221.9 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225.4 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per common share:</span></td><td colspan="3" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 29.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.64 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.09 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.77 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 29.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.62 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.08 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.72 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 578100000 467600000 67600000 1515300000 219100000 223300000 220400000 223800000 1500000 1200000 1500000 1600000 220600000 224500000 221900000 225400000 2.64 2.09 0.31 6.77 2.62 2.08 0.30 6.72 2500000 1800000 3300000 3100000 Marketable SecuritiesThe proceeds from maturities and sales of available-for-sale debt securities and resulting realized gains and losses are summarized below. In the second quarter of 2020, we liquidated all of our available-for-sale debt securities to fund the acquisition of Portola. Additionally, we liquidated all available-for-sale debt securities acquired in connection with the Portola acquisition.<div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.963%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities and sales </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042.4 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,271.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gains</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized losses</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:110%"> (1) Proceeds from maturities and sales of available-for-sale debt securities include securities previously classified as cash and cash equivalents and marketable securities in the condensed consolidated balance sheet.</span></div></td></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize the specific identification method in computing realized gains and losses.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our liquidation of all available-for-sale debt securities during the second and third quarters of 2020, we have no remaining available-for-sale debt securities as of September 30, 2020. The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of available-for-sale debt securities by type of security as of December 31, 2019 were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:37.553%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.543%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="21" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Holding Gains</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Holding Losses</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government-related obligations:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bank certificates of deposit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369.0 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369.0 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate fair value of available-for-sale debt securities in an unrealized loss position as of December 31, 2019 was $21.5. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have any investments in a continuous unrealized loss position for more than twelve months as of December 31, 2019.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of available-for-sale debt securities by classification in the condensed consolidated balance sheets were as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369.0 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sponsor a nonqualified deferred compensation plan which allows certain highly-compensated employees to elect to defer income to future periods. Participants in the plan earn a return on their deferrals based on several investment options, which mirror returns on underlying mutual fund investments. We choose to invest in the underlying mutual fund investments to offset the liability associated with our nonqualified deferred compensation plan. These mutual fund investments are valued at net asset value per share and are carried at fair value with gains and losses included in investment income. The changes in the underlying liability to the employee are recorded in operating expenses. As of September 30, 2020 and December 31, 2019, the fair value of these investments was $28.9 and $23.1, respectively.</span></div> The proceeds from maturities and sales of available-for-sale debt securities and resulting realized gains and losses are summarized below. In the second quarter of 2020, we liquidated all of our available-for-sale debt securities to fund the acquisition of Portola. Additionally, we liquidated all available-for-sale debt securities acquired in connection with the Portola acquisition.<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.963%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities and sales </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042.4 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,271.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gains</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized losses</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:110%"> (1) Proceeds from maturities and sales of available-for-sale debt securities include securities previously classified as cash and cash equivalents and marketable securities in the condensed consolidated balance sheet.</span></div></td></tr></table> 25500000 645400000 1042400000 2271700000 0 0 0 0 0 0 0 0 The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of available-for-sale debt securities by type of security as of December 31, 2019 were as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:37.553%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.543%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="21" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Holding Gains</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Holding Losses</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government-related obligations:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bank certificates of deposit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369.0 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369.0 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 246900000 0 0 246900000 24300000 0 0 24300000 70400000 0 0 70400000 27400000 0 0 27400000 369000000.0 0 0 369000000.0 21500000 <div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of available-for-sale debt securities by classification in the condensed consolidated balance sheets were as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369.0 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 328100000 0 40900000 0 369000000.0 28900000 23100000 Derivative Instruments and Hedging Activities<div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate internationally and, in the normal course of business, are exposed to fluctuations in foreign currency exchange rates. The exposures result from portions of our revenues, as well as the related receivables, and expenses that are denominated in currencies other than the U.S. dollar, primarily the Euro and Japanese Yen. We are also exposed to fluctuations in interest rates on outstanding borrowings under our revolving credit facility, if any, and term loan facility. We manage these exposures within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign exchange forward contracts, with durations of up to</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 60 m</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">onths, to hedge exposures resulting from portions of our forecasted revenues, including intercompany revenues, and certain forecasted expenses that are denominated in currencies other than the U.S. dollar. The purpose of these hedges is to reduce the volatility of exchange rate fluctuations on our operating results. These hedges are designated as cash flow hedges upon contract inception. As of September 30, 2020, we had open revenue related foreign exchange forward contracts with notional amounts totaling $1,029.0 that qualified for hedge accounting with current contract maturities through June 2022. As of September 30, 2020, we had open expense related foreign exchange forward contracts with notional amounts totaling $10.0 that qualified for hedge accounting with contract maturities through September 2022.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve a desired mix of floating and fixed interest rates on our term loan, we enter into interest rate swap agreements that qualify for and are designated as cash flow hedges. These contracts convert the floating interest rate on a portion of our debt to a fixed rate, plus a borrowing spread.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total interest rate swap contracts executed as of September 30, 2020:</span></div><div style="margin-bottom:5pt;margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.984%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Interest Rate Swap Contract</span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Termination Date</span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fixed Interest Rate or Rate Range</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Floating to Fixed</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$450.0</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60% - 2.79%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Floating to Fixed</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,300.0</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.37% - 2.83%</span></div></td></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of gains and (losses) recognized in the condensed consolidated statements of operations for the three and nine months ended September 30, 2020 and 2019 from foreign exchange and interest rate swap contracts that qualified as cash flow hedges were as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2019</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Statement Line Item in which the Effects of Cash Flow Hedges are Recorded</span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Product Sales</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Expense</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Product Sales</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Expense</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amount presented in the Condensed Consolidated Statements of Operations</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.6)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Impact of cash flow hedging relationships:</span></td><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.3)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:49.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2019</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Statement Line Item in which the Effects of Cash Flow Hedges are Recorded</span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Product Sales</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Expense</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Product Sales</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Expense</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amount presented in the Condensed Consolidated Statements of Operations</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,477.4 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77.0)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,605.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Impact of cash flow hedging relationships:</span></td><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.9)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact on accumulated other comprehensive income (AOCI) and earnings from foreign exchange and interest rate swap contracts that qualified as cash flow hedges, for the three and nine months ended September 30, 2020 and 2019 were as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.569%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.569%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.716%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Exchange Forward Contracts:</span></td><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) gain recognized in AOCI, net of tax</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.9)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) gain reclassified from AOCI to net product sales, net of tax</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Rate Swap Contracts:</span></td><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in AOCI, net of tax</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.6)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) gain reclassified from AOCI to interest expense, net of tax</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.8)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.1)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming no change in foreign exchange rates from market rates at September 30, 2020, $13.6 of losses recognized in AOCI will be reclassified to revenue over the next 12 months. Assuming no change in LIBOR-based interest rates from market rates at September 30, 2020, $45.6 of losses recognized in AOCI will be reclassified to interest expense over the next 12 months. Amounts recognized in AOCI for expense related foreign exchange forward contracts were immaterial as of September 30, 2020.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign exchange forward contracts, with durations of up to 6 months, designed to limit the balance sheet exposure of monetary assets and liabilities. We enter into these hedges to reduce the impact of fluctuating exchange rates on our operating results. Hedge accounting is not applied to these derivative instruments as gains and losses on these hedge transactions are designed to offset gains and losses on underlying balance sheet exposures. As of September 30, 2020, the notional amount of foreign exchange contracts where hedge accounting is not applied was $1,253.0.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized a (loss) gain of $(6.2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $1.4, in other income and (expense) for the three months ended September 30, 2020 and 2019, respectively, associated with the foreign exchange contracts not designated as hedging instruments. We recognized a gain (loss) of $6.8 and $(1.2), in other income and (expense) for the nine months ended September 30, 2020 and 2019, respectively, associated with the foreign exchange contracts not designated as hedging instruments. These amounts were partially offset by gains or losses on monetary assets and liabilities.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the fair value of outstanding derivatives as of September 30, 2020 and December 31, 2019:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:28.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="21" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Assets</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet<br/>Location</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet<br/>Location</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.6 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.6 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total fair value of derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.1</span><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">128.3</span><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:28.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="21" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Assets</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet<br/>Location</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet<br/>Location</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total fair value of derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30.5</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">89.1</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not offset derivative assets and liabilities within our condensed consolidated balance sheets, our International Swap and Derivatives Association agreements provide for net settlement of transactions that are due to or from the same counterparty upon early termination of the agreement due to an event of default or other termination event. The following tables summarize the potential effect on our condensed consolidated balance sheets of offsetting our foreign exchange forward contracts and interest rate contracts subject to such provisions:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:18.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.643%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="33" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts of Recognized Assets/Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts Offset in the Condensed Consolidated Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Financial Instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Collateral Received (Pledged)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128.3)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128.3)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116.9)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:18.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.643%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="33" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts of Recognized Assets/Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts Offset in the Condensed Consolidated Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Financial Instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Collateral Received (Pledged)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> P60M 1029000000.0 10000000.0 <div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total interest rate swap contracts executed as of September 30, 2020:</span></div><div style="margin-bottom:5pt;margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.984%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Interest Rate Swap Contract</span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Termination Date</span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fixed Interest Rate or Rate Range</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Floating to Fixed</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$450.0</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60% - 2.79%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Floating to Fixed</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,300.0</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.37% - 2.83%</span></div></td></tr></table></div> 450000000.0 0.0260 0.0279 1300000000.0 0.0237 0.0283 <div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of gains and (losses) recognized in the condensed consolidated statements of operations for the three and nine months ended September 30, 2020 and 2019 from foreign exchange and interest rate swap contracts that qualified as cash flow hedges were as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2019</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Statement Line Item in which the Effects of Cash Flow Hedges are Recorded</span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Product Sales</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Expense</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Product Sales</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Expense</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amount presented in the Condensed Consolidated Statements of Operations</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.6)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Impact of cash flow hedging relationships:</span></td><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.3)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:49.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2019</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Statement Line Item in which the Effects of Cash Flow Hedges are Recorded</span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Product Sales</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Expense</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Product Sales</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Expense</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amount presented in the Condensed Consolidated Statements of Operations</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,477.4 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77.0)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,605.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Impact of cash flow hedging relationships:</span></td><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.9)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact on accumulated other comprehensive income (AOCI) and earnings from foreign exchange and interest rate swap contracts that qualified as cash flow hedges, for the three and nine months ended September 30, 2020 and 2019 were as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.569%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.569%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.716%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Exchange Forward Contracts:</span></td><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) gain recognized in AOCI, net of tax</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.9)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) gain reclassified from AOCI to net product sales, net of tax</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Rate Swap Contracts:</span></td><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in AOCI, net of tax</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.6)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) gain reclassified from AOCI to interest expense, net of tax</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.8)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.1)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1588300000 27600000 1263100000 17900000 -5000000.0 0 11000000.0 0 0 -11300000 0 3400000 4477400000 77000000.0 3605800000 56100000 15900000 0 27100000 0 0 -25900000 0 12500000 -22900000 30500000 -3000000.0 40800000 -4000000.0 8600000 12200000 21000000.0 100000 -7100000 -52600000 -45900000 -8800000 2600000 -20100000 9600000 13600000 45600000 P6M 1253000000.0 -6200000 1400000 6800000 -1200000 <div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the fair value of outstanding derivatives as of September 30, 2020 and December 31, 2019:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:28.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="21" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Assets</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet<br/>Location</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet<br/>Location</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.6 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.6 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total fair value of derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.1</span><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">128.3</span><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:28.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="21" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Assets</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet<br/>Location</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet<br/>Location</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total fair value of derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30.5</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">89.1</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3000000.0 16800000 400000 300000 0 45600000 0 57600000 8700000 8000000.0 12100000 128300000 12700000 6200000 600000 1100000 0 19500000 0 41900000 17200000 20400000 30500000 89100000 The following tables summarize the potential effect on our condensed consolidated balance sheets of offsetting our foreign exchange forward contracts and interest rate contracts subject to such provisions:<div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:18.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.643%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="33" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts of Recognized Assets/Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts Offset in the Condensed Consolidated Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Financial Instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Collateral Received (Pledged)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128.3)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128.3)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116.9)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:18.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.643%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="33" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts of Recognized Assets/Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts Offset in the Condensed Consolidated Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Financial Instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Collateral Received (Pledged)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 12100000 0 12100000 11400000 0 700000 128300000 0 128300000 11400000 0 116900000 30500000 0 30500000 21400000 0 9100000 89100000 0 89100000 21400000 0 67700000 <span style="color:#002f6c;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:21.81pt">Other Investments</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other investments include strategic investments in equity securities of certain biotechnology companies which we acquired in connection with strategic business development transactions, including license and option agreements. These investments are included in other assets in our condensed consolidated balance sheets.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moderna</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2014, we purchased $37.5 of preferred stock of Moderna Therapeutics, Inc. (Moderna), a privately held biotechnology company, which was initially recorded at cost. We began recording the investment at fair value, with the effects of a holding period restriction estimated using an option pricing valuation model, upon Moderna's completion of its initial public offering (IPO) in 2018. </span><span style="color:#212529;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2019, we recognized an unrealized gain of $12.3 and $13.1, respectively, in investment income to adjust our investment in Moderna to fair value. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 9, 2019, we sold our investment in Moderna for </span><span style="color:#212529;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$114.7 in net proceeds, resulting in a realized gain of $77.2 on our initial investment.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dicerna</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we purchased $10.3 of Dicerna Pharmaceuticals Inc. (Dicerna) common stock in connection with an agreement that we entered into with Dicerna, a publicly-traded biopharmaceutical company. As our equity investment in Dicerna common stock has a readily determinable fair value, we are recording the investment at fair value. During the three and nine months ended September 30, 2020, we recognized an unrealized</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> loss </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.2 and $3.4, respectively, in investment income to adjust our equity investment in Dicerna to fair value. During the three and nine months ended September 30, 2019, we recognized an unrealized loss of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#212529;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.1 and unrealized gain of $3.1, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively, in investment income to adjust our equity investment in Dicerna to fair value.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of this investment was</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$15.0 and $18.4 as of September 30, 2020 and December 31, 2019, respectively.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Caelum</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2019, we purchased $41.0 of preferred stock of Caelum Biosciences (Caelum), a privately-held biotechnology company, and a $16.1 option to acquire the remaining equity in Caelum, based on Phase II data, in connection with an agreement that we entered into with Caelum. Following discussions with the FDA, Caelum changed its clinical development plan for CAEL-101 in the fourth quarter 2019. A Phase II trial for CAEL-101 subsequently commenced during the first quarter of 2020 and met its primary objectives, supporting the safety and tolerability of CAEL-101 and confirmed the dose and regimen to be adopted for the Phase III studies. In December 2019, we amended the terms of the agreement with respect to the option to acquire the remaining equity in Caelum based on data from the modified Phase II/III trials. We accounted for the amendment as an exchange transaction as the terms of the modified option were determined to be substantially different than the terms of the original option. In conjunction with this amendment, we recognized a gain of $32.0 during the fourth quarter 2019 in other income and (expense), which reflects an increase in the fair value of the option, less $20.0 in incremental upfront funding which we accrued as of December 31, 2019 and paid during the first quarter 2020, and $4.1 associated with the change in the fair value of contingent payments which we also modified as part of the amendment. See Note 16, Commitments and Contingencies, for additional information on the agreement. As our equity investment in Caelum and the option to acquire the remaining equity in Caelum do not have a readily determinable fair value, we only adjust the carrying value of the assets for impairment and any subsequent changes resulting from an observable price change in an orderly transaction for identical or similar equity securities of the same issuer.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no observable price changes associated with these assets during the three and nine months ended September 30, 2020 and 2019. As of September 30, 2020, the carrying value of the investment and option, respectively, was $41.0 and $64.0. As of December 31, 2019, the carrying value of the investment and option, respectively, was $41.0 and $64.0. The investment and option were not impaired as of September 30, 2020.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zealand</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, we purchased $13.8 of Zealand Pharma A/S (Zealand) common stock in connection with an agreement that we entered into with Zealand, a publicly-traded biopharmaceutical company based in Copenhagen, Denmark. See Note 16, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information on the agreement. As our equity investment in Zealand common stock has a readily determinable fair value, we are recording the investment at fair value. During the three and nine months ended September 30, 2020, we recognized an unrealized</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gain of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.8 and $0.8, respectively, in investment income to adjust our equity investment in Zealand to fair value. During the three and nine months ended September 30, 2019, we recognized an unrealized gain of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#212529;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.7 and $7.3, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively, in investment income to adjust our equity investment in Zealand to fair value.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of this investment was $30.5 and $28.5 as of September 30, 2020 and December 31, 2019, respectively.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Eidos</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we purchased $19.9 of Eidos Therapeutics, Inc. (Eidos) common stock, in connection with an agreement that we entered into with Eidos, a publicly-traded biopharmaceutical company and subsidiary of BridgeBio Pharma, Inc. See Note 16, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information on the agreement. As our equity investment in Eidos common stock has a readily determinable fair value, we are recording the investment at fair value. During the three and nine months ended September 30, 2020, we recognized an unrealized</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gain </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.4 and $0.3, respectively, in investment income to adjust our equity investment in Eidos to fair value. During the three and nine months ended September 30, 2019, we recognized an unrealized loss of $2.9, in investment income to adjust our equity investment in Eidos to fair value.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of this investment was $28.1 and $27.8 as of September 30, 2020 and December 31, 2019, respectively.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stealth</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, we purchased $9.6 of Stealth BioTherapeutics Corp. (Stealth) common stock, in connection with an agreement that we entered into with Stealth, a publicly traded clinical-stage biotechnology company. As our equity investment in Stealth common stock has a readily determinable fair value, we are recording the investment at fair value. During the three and nine months ended September 30, 2020, we recognized an unrealized loss of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.7 and $2.6, respectively, in investment income to adjust our equity investment in Stealth to fair value.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of this investment was $1.8 and $4.4 as of September 30, 2020 and December 31, 2019, respectively.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Portola</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April 2020,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> we purchased $14.5 and $3.6</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> respectively, of common stock of Portola Pharmaceuticals, Inc., a publicly traded commercial-stage biological company which we acquired on July 2, 2020. As our equity investment in Portola common stock had a readily determinable fair value, we recorded the investment at fair value. </span><span style="color:#212529;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2020, we recognized a net gain of $0.1 and $29.7 in investment income, respectively, relating to our Portola investment. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the closing of the acquisition of Portola on </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">July 2, 2020, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the fair value of the equity investment of $47.8 was derecognized and included in the fair value of consideration transferred, resulting in a realized gain of $29.7 on our initial investment.</span></div><div style="margin-top:5pt;text-align:justify"><span style="background-color:#ffffff;color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inozyme</span></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 17, 2020, we sold certain intellectual property rights and assets focusing on ENPP1 gene deficiencies to Inozyme Pharma (Inozyme), a publicly traded biopharmaceutical company, in exchange for $14.8 of Inozyme Pharma common stock, which was initially recorded at its IPO offering price, net of the effects of a nine month holding period restriction. We recognized the $14.8 of consideration received as a gain within gain on sale of asset in our condensed consolidated statement of operations. As our equity investment in Inozyme common stock has a readily determinable fair value, we are recording the investment at fair value, with the effects of a nine month holding period restriction estimated using an option pricing valuation model. During the three and nine months ended September 30, 2020, we recognized an unrealized gain of $10.2, in investment income to adjust our investment to fair value.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of this investment was $25.0 as of September 30, 2020.</span></div> 37500000 12300000 13100000 114700000 77200000 10300000 -6200000 -3400000 -1100000 3100000 15000000.0 18400000 41000000.0 16100000 32000000.0 20000000.0 4100000 41000000.0 41000000.0 64000000.0 64000000.0 41000000.0 41000000.0 64000000.0 64000000.0 13800000 1800000 800000 3700000 7300000 30500000 28500000 19900000 3400000 300000 -2900000 -2900000 28100000 27800000 9600000 -700000 -2600000 1800000 4400000 14500000 3600000 -100000 -29700000 47800000 29700000 14800000 14800000 10200000 10200000 25000000.0 Stockholders' Equity<div style="margin-top:5pt"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2012, our Board of Directors authorized a share repurchase program. In February 2017, our Board of Directors increased the amount that we are authorized to expend on future repurchases to $1,000.0 under our repurchase program, which superseded all prior repurchase programs. The entire amount authorized pursuant to this February 2017 Board approval has been utilized. On October 22, 2019, the Board of Directors approved a share repurchase authorization of up to $1,000.0. On July 28, 2020, the Board of Directors approved a new share repurchase authorization of up to an additional $1,500.0. The repurchase program does not have an expiration date and we are not obligated to acquire a particular number of shares. The repurchase program may be discontinued at any time at our discretion. Under the program, we repurchased 0.6 and 3.1 shares of our common stock at a cost of $73.5 and $334.6 during the three months ended September 30, 2020 and 2019, respectively. During the nine months ended September 30, 2020 and 2019, we repurchased 4.2 and 3.5 shares of our common stock at a cost of $434.3 and $383.5, respectively. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to September 30, 2020, we repurchased 0.4 shares of common stock under our repurchase program at a cost of $45.2. As of October 27, 2020, there is a total of $2,055.9 remaining for repurchases under the repurchase program.</span></div> 1000000000.0 1000000000.0 1500000000.0 600000 3100000 73500000 334600000 4200000 3500000 434300000 383500000 400000 45200000 2055900000 Other Comprehensive Income and Accumulated Other Comprehensive Income<div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in AOCI, by component, for the nine months ended September 30, 2020 and 2019:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) from Debt Securities</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) from Hedging Activities</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, December 31, 2019</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.1)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.4)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.8)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55.1)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60.3)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from other comprehensive income</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.2)</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.4)</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, September 30, 2020</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.3)</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.7)</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119.2)</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) from Debt Securities</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) from Hedging Activities</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, December 31, 2018</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from other comprehensive income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, September 30, 2019</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.1)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48.2)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides details regarding significant reclassifications from AOCI during the three and nine months ended September 30, 2020 and 2019:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"><tr><td style="width:1.0%"/><td style="width:26.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.937%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.125%"/><td style="width:0.1%"/></tr><tr style="height:38pt"><td colspan="3" rowspan="2" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Details about Accumulated Other Comprehensive Income Components</span></td><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount Reclassified From Accumulated Other Comprehensive Income during the three months ended September 30,</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount Reclassified From Accumulated Other Comprehensive Income during the nine months ended September 30,</span></td><td colspan="3" rowspan="2" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the Condensed Consolidated Statements of Operations</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c7fb8;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Gains (Losses) on Hedging Activity</span></td><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.3)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.9)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.3)</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.6 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.6 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div> <div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in AOCI, by component, for the nine months ended September 30, 2020 and 2019:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) from Debt Securities</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) from Hedging Activities</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, December 31, 2019</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.1)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.4)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.8)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55.1)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60.3)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from other comprehensive income</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.2)</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.4)</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, September 30, 2020</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.3)</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.7)</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119.2)</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) from Debt Securities</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) from Hedging Activities</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, December 31, 2018</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from other comprehensive income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, September 30, 2019</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.1)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48.2)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> -9200000 -100000 -40100000 -17400000 -66800000 0 100000 -55100000 -5300000 -60300000 0 0 -7900000 0 -7900000 0 100000 -47200000 -5300000 -52400000 -9200000 0 -87300000 -22700000 -119200000 -2600000 -300000 9600000 -16400000 -9700000 0 200000 -5100000 -3000000.0 -7900000 0 0 30600000 0 30600000 0 200000 -35700000 -3000000.0 -38500000 -2600000 -100000 -26100000 -19400000 -48200000 <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides details regarding significant reclassifications from AOCI during the three and nine months ended September 30, 2020 and 2019:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"><tr><td style="width:1.0%"/><td style="width:26.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.937%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.125%"/><td style="width:0.1%"/></tr><tr style="height:38pt"><td colspan="3" rowspan="2" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Details about Accumulated Other Comprehensive Income Components</span></td><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount Reclassified From Accumulated Other Comprehensive Income during the three months ended September 30,</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount Reclassified From Accumulated Other Comprehensive Income during the nine months ended September 30,</span></td><td colspan="3" rowspan="2" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the Condensed Consolidated Statements of Operations</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c7fb8;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Gains (Losses) on Hedging Activity</span></td><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.3)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.9)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.3)</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.6 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.6 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div> -5000000.0 11000000.0 15900000 27100000 -11300000 3400000 -25900000 12500000 -16300000 14400000 -10000000.0 39600000 -3500000 3200000 -2100000 9000000.0 -12800000 11200000 -7900000 30600000 Fair Value MeasurementAuthoritative guidance establishes a valuation hierarchy for disclosure of the inputs to the valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value.<div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2020 and December 31, 2019, and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair value.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.254%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at<br/>September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet<br/>Classification</span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Instrument</span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424.9 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424.9 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.9 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.9 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.4 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.4 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.8 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.8 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.6 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.6 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.6 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.6 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398.1 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398.1 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.254%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at<br/>December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet<br/>Classification</span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Instrument</span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bank certificates of deposit</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government-related obligations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government-related obligations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bank certificates of deposit</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other contingent payments</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no securities transferred between Level 1, 2 and 3 during the nine months ended September 30, 2020.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation Techniques</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify mutual fund investments and equity securities, which are valued based on quoted market prices in active markets with no valuation adjustment, as Level 1 assets within the fair value hierarchy. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents and marketable securities classified as Level 2 within the valuation hierarchy include money market funds, commercial paper, U.S. and foreign government-related debt, corporate debt securities and certificates of deposit. We estimate the fair values of these marketable securities by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for similar securities, issuer credit spreads, benchmark yields, and other observable inputs. We validate the prices provided by our third-party pricing sources by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other investments in equity securities of publicly traded companies which are subject to holding period restrictions are carried at fair value using an option pricing valuation model and classified as Level 2 equity securities within the fair value hierarchy. The most significant assumptions within the option pricing valuation model are the term of the restrictions and the stock price volatility, which is based upon the historical volatility of the applicable company or similar companies. We also use a constant maturity risk-free interest rate to match the remaining term of the restrictions on such investments.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our derivative assets and liabilities include foreign exchange and interest rate derivatives that are measured at fair value using observable market inputs such as forward rates, interest rates, our own credit risk as well as an evaluation of our counterparties’ credit risks. Based on these inputs, the derivative assets and liabilities are classified within Level 2 of the valuation hierarchy.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration liabilities related to business acquisitions and derivative liabilities associated with other contingent payments are classified as Level 3 within the valuation hierarchy and are valued based on various estimates, including probability of success, discount rates and amount of time until the conditions of the milestone payments are anticipated to be met.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, there has not been any impact to the fair value of our derivative liabilities due to our own credit risk. Similarly, there has not been any significant adverse impact to our derivative assets based on our evaluation of our counterparties’ credit risks.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition-Related Contingent Consideration</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our prior business combinations, we may be required to pay future consideration that is contingent upon the achievement of specified development, regulatory approvals or sales-based milestone events. We determine the fair value of these obligations using various estimates that are not observable in the market and represent a Level 3 measurement within the fair value hierarchy. As of September 30, 2020, the resulting probability-weighted cash flows were discounted using a cost of debt ranging from 3.9% to 4.3% for developmental and regulatory milestones and a weighted average cost of capital of 9.0% for sales-based milestones. As of December 31, 2019, the resulting probability-weighted cash flows were discounted using a weighted average cost of capital of 9.0% for sales-based milestones.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each reporting period, we adjust the contingent consideration to fair value with changes in fair value recognized in operating earnings. Changes in fair values reflect new information about the probability and anticipated timing of meeting the conditions of the milestone payments. In the absence of new information, changes in fair value will only reflect the interest component of contingent consideration related to the passage of time. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, estimated future contingent milestone payments related to our business combinations range from zero if no milestone events are achieved, to a maximum of $905.6 if all development, regulatory and sales-based milestones are reached.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, the fair value of acquisition-related contingent consideration was $398.1. Amounts issued during the nine months ended September 30, 2020, represent the fair value of the non-tradeable CVRs recorded in connection with the acquisition of Achillion. See Note 3, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The following table represents a roll-forward of our acquisition-related contingent consideration:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192.4 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts issued</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.7 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2020</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398.1 </span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Contingent Payments</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2019, we entered into an agreement with Caelum, a biotechnology company that is developing CAEL-101 for light chain (AL) amyloidosis.  Under the terms of the agreement, we acquired a minority equity interest in preferred stock of Caelum and an exclusive option to acquire the remaining equity in Caelum based on Phase II data, for pre-negotiated economics. We paid $30.0 during the first quarter 2019 and agreed to pay up to an additional $30.0 in contingent development milestones prior to our exercise of the option to acquire the remaining equity in Caelum. These contingent payments met the definition of a derivative liability and were initially recorded at fair value of $27.1, based on the probability-weighted cash flows, discounted using a cost of debt ranging from 3.3% to 3.5%.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, following FDA feedback which resulted in the redesign and expansion of Caelum's planned clinical development program for CAEL-101, we amended the terms of our existing option agreement with Caelum. The amendment modified the terms of the option to acquire the remaining equity in Caelum based on data from the expanded </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase II/III trials</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amendment also modified the development-related milestone events associated with the initial $30.0 in contingent payments, provided for an additional $20.0 in upfront funding, which we accrued as of December 31, 2019 and paid during the first quarter 2020, as well as funding of $60.0 in exchange for an additional equity interest at fair value upon achievement of a specific development-related milestone event. During the second quarter 2020, we paid an aggregate of $15.0 of contingent payments to Caelum related to two development-based milestones and during the third quarter 2020, we paid a $15.0 contingent payment to Caelum related to another development-based milestone.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each reporting period, we adjust the derivative liability associated with the contingent payments to fair value with changes in fair value recognized in other income and (expense). Changes in fair values reflect new information about the probability and anticipated timing of meeting the conditions of the milestone payments. In the absence of new information, changes in fair value will only reflect the interest component of the liability related to the passage of time. The aggregate $30.0</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> milestone payments made during the second and third quarter 2020 settled the derivative liability and reduced the derivative liability balance to zero. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded $3.6 and $6.0 of expense in other income and (expense) during the three and nine months ended September 30, 2020, respectively, related to the change in the fair value of the liability. We recorded $0.2 and $0.5 of expense in other income and (expense) during the three and nine months ended September 30, 2019, respectively, related to the change in the fair value of the liability.</span></div> <div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2020 and December 31, 2019, and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair value.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.254%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at<br/>September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet<br/>Classification</span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Instrument</span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424.9 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424.9 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.9 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.9 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.4 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.4 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.8 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.8 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.6 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.6 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.6 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.6 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398.1 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398.1 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.254%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at<br/>December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet<br/>Classification</span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Instrument</span></td><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bank certificates of deposit</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government-related obligations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government-related obligations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bank certificates of deposit</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other contingent payments</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div> 424900000 0 424900000 0 28900000 28900000 0 0 100400000 75400000 25000000.0 0 11700000 0 11700000 0 400000 0 400000 0 24800000 0 24800000 0 300000 0 300000 0 45600000 0 45600000 0 57600000 0 57600000 0 398100000 0 0 398100000 635900000 0 635900000 0 227900000 0 227900000 0 20600000 0 20600000 0 19200000 0 19200000 0 60400000 0 60400000 0 23100000 23100000 0 0 19000000.0 0 19000000.0 0 3700000 0 3700000 0 10000000.0 0 10000000.0 0 8200000 0 8200000 0 79000000.0 51200000 27800000 0 29900000 0 29900000 0 600000 0 600000 0 26600000 0 26600000 0 1100000 0 1100000 0 19500000 0 19500000 0 41900000 0 41900000 0 192400000 0 0 192400000 24000000.0 0 0 24000000.0 0.039 0.043 0.090 0.090 0 905600000 398100000 The following table represents a roll-forward of our acquisition-related contingent consideration:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192.4 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts issued</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.7 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2020</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398.1 </span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> -192400000 160700000 -45000000.0 -398100000 30000000.0 30000000.0 27100000 0.033 0.035 30000000.0 20000000.0 60000000.0 15000000.0 15000000.0 30000000.0 3600000 6000000.0 200000 500000 Revenue Recognition<div style="margin-top:5pt;text-align:justify"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates revenue from contracts with customers into product and geographical regions as summarized below. </span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#002f6c;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SOLIRIS</span></td><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562.8 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,672.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,456.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765.7 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.0 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.2 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.2 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042.3 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990.5 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,040.7 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,933.3 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#002f6c;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ULTOMIRIS</span></td><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.7 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.6 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.4 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.6 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289.3 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.9 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763.2 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.7 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#002f6c;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:100%">STRENSIQ</span></td><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418.1 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.6 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.7 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189.4 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.3 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545.9 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425.7 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#002f6c;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ANDEXXA</span></td><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.2 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.2 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.9 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.9 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#002f6c;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KANUMA</span></td><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.8 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.6 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.4 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.4 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.4 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.7 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.1 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#002f6c;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Product Sales</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588.3 </span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263.1 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,477.4 </span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,605.8 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract Balances and Receivables</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities primarily relate to consideration received and/or billed for goods that have not been delivered to the customer and for which the performance obligation has not yet been completed. These amounts are included within other current liabilities in the condensed consolidated balance sheets.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables and contract liabilities from our contracts with customers.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, which are included in "Trade accounts receivable, net"</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,437.1 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,243.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities, which are included in "Other current liabilities"</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.7 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract balances and receivables associated with collaboration agreements assumed through the acquisition of Portola in the third quarter 2020, which were included in the table above, were not material as of September 30, 2020.</span></div> <div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates revenue from contracts with customers into product and geographical regions as summarized below. </span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#002f6c;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SOLIRIS</span></td><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562.8 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,672.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,456.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765.7 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.0 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.2 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.2 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042.3 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990.5 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,040.7 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,933.3 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#002f6c;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ULTOMIRIS</span></td><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.7 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.6 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.4 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.6 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289.3 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.9 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763.2 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.7 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#002f6c;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:100%">STRENSIQ</span></td><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418.1 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.6 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.7 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189.4 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.3 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545.9 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425.7 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#002f6c;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ANDEXXA</span></td><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.2 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.2 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.9 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.9 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#002f6c;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KANUMA</span></td><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.8 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.6 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.4 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.4 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.4 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.7 </span></td><td style="background-color:#eaeaea;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.1 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#eaeaea;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#002f6c;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Product Sales</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588.3 </span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263.1 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,477.4 </span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,605.8 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 562800000 496800000 1672300000 1456800000 254300000 255500000 765700000 800200000 86000000.0 118000000.0 255500000 329200000 139200000 120200000 347200000 347100000 1042300000 990500000 3040700000 2933300000 170700000 65100000 460300000 143900000 46600000 21100000 112400000 21100000 69600000 3700000 186300000 3700000 2400000 0 4200000 0 289300000 89900000 763200000 168700000 149300000 118000000.0 418100000 323700000 19300000 19000000.0 61600000 56000000.0 16100000 14000000.0 44700000 36000000.0 4700000 3300000 21500000 10000000.0 189400000 154300000 545900000 425700000 36200000 0 36200000 0 2700000 0 2700000 0 0 0 0 0 0 0 0 0 38900000 0 38900000 0 15800000 16000000.0 47600000 45100000 9500000 6300000 25400000 19400000 1100000 1300000 2900000 3400000 2000000.0 4800000 12800000 10200000 28400000 28400000 88700000 78100000 1588300000 1263100000 4477400000 3605800000 <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, which are included in "Trade accounts receivable, net"</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,437.1 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,243.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities, which are included in "Other current liabilities"</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.7 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1437100000 1243200000 22700000 6800000 Income Taxes<div style="margin-top:5pt;text-align:justify"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Coronavirus Aid, Relief and Economic Security Act</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the market volatility and instability resulting from the COVID-19 pandemic, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was signed into law on March 27, 2020. The CARES Act lifts certain deduction limitations originally imposed by the Tax Cuts and Jobs Act of 2017 (2017 Tax Act). Under the 2017 Tax Act, federal net operating losses (NOLs) generated after 2017 could not be carried back and utilization was limited to 80% of taxable income. The CARES Act allows for a five-year carryback of federal NOLs generated in 2018 through 2020 and eliminates the 80% taxable income limitation by allowing corporate entities to fully utilize NOL carryforwards to offset taxable income in 2018 through 2020. In addition, the CARES Act generally allows taxpayers to deduct interest up to 50% of adjusted taxable income (30% limit under the 2017 Tax Act) for tax years 2019 and 2020. The CARES Act also allows taxpayers with prior year alternative minimum tax (repealed by the 2017 Tax Act) (AMT) credits to accelerate refund claims to tax years beginning in 2018 and 2019 instead of recovering the credits over a period of years, as originally enacted by the 2017 Tax Act.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the CARES Act raises the corporate charitable deduction limit to 25% of taxable income and provides a technical correction to the 2017 Tax Act to generally provide qualified improvement property a 15-year cost-recovery period and allow 100% bonus depreciation. The enactment of the CARES Act did not result in any material adjustments to our income tax provision for the three and nine months ended September 30, 2020, or to our U.S. federal and state net deferred tax liabilities as of September 30, 2020.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Rate</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a comparative summary of our income tax expense and effective income tax rate for the three and nine months ended September 30, 2020:</span></div><div style="margin-bottom:5pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:53.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.589%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 6pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.8</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89.2)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413.0 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense (benefit) is attributable to the U.S. federal, state and foreign income taxes on our profitable operations.</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter 2020, we recognized an impairment charge of $2,042.3 related to the KANUMA intangible asset, resulting in a deferred tax benefit of $377.3. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 5, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets and Goodwill,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information on the impairment charge. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These deferred tax benefits increased the effective tax rate for the nine months ended September 30, 2020 by approximately</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 399.6%</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense for the nine months ended September 30, 2019 includes one-time tax benefits recorded during the first quarter 2019, in connection with the future integration of intellectual property of Wilson </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therapeutics into the Alexion corporate structure. The deferred tax benefits included $95.7 and $30.3 associated with a tax election made with respect to intellectual property of Wilson Therapeutics and a valuation allowance release and corresponding recognition of net operating losses, respectively. These deferred tax benefits decreased the effective tax rate for the nine months ended September 30, 2019 by approximately 8.0%. Additionally, during the third quarter 2019, we completed a comprehensive analysis of our current and prior year estimates related to our foreign-derived intangible income based on additional guidance provided in the proposed regulations issued by the U.S. Treasury Department in 2019. The analysis resulted in income tax benefits of approximately $29.9, including $17.0 related to prior year estimated tax benefits, which were recorded as a change in estimate in income tax expense in our consolidated statements of operations during the three and nine months ended September 30, 2019. These tax benefits decreased the effective tax rate for the three and nine months ended September 30, 2019 by approximately 5.6% and 1.9%, respectively. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020 we became aware of a European withholding tax regulation that could be interpreted to apply to certain of our previous intra-group transactions. We continue to evaluate whether the interpretation of this regulation applies to our facts and circumstances, and, based on our preliminary analysis, we recorded an immaterial reserve related to this matter during the second quarter of 2020.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we received a notice of examination from the Dutch Tax Authorities (“DTA”) regarding certain matters relating to our 2014 through 2017 tax years. Discussions with the DTA are currently ongoing and, at Alexion’s request, we have expanded these discussions to include the 2018 and 2019 tax years as well. We have not received any final findings on any of these tax years, nor have we received any proposed adjustments or any tax assessments related to any of the tax years under discussion with the DTA. Accordingly, we have not recorded any related reserves and an estimate of the possible loss or range of loss, if any, cannot be made at this time. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2020, the U.S. Treasury Department released certain proposed and final regulations which were originally enacted under the 2017 Tax Act. The impact of these regulations did not have a material impact on our financial condition and results of operations.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Internal Revenue Service (IRS) commenced an examination of our U.S. income tax returns for 2015. During the second quarter of 2020 we received a Revenue Agent Report (RAR) and held discussions with the IRS regarding a proposed adjustment related to the valuation of certain intellectual property that was contributed into our captive partnership during 2015. The Company agreed with the adjustment outlined in the RAR and recognized a previously unrecognized tax benefit in the second quarter of 2020 that did not result in a significant impact to the financial statements. The IRS concluded its examination during the third quarter 2020 without additional adjustments.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recorded tax on the undistributed earnings of our controlled foreign corporation (CFC) subsidiaries. To the extent CFC earnings may not be repatriated to the U.S. as a dividend distribution due to limitations imposed by law, we have not recorded the related potential withholding, foreign, local, and U.S. state income taxes. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to maintain a valuation allowance against certain deferred tax assets where realization is not certain.</span></div> <div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a comparative summary of our income tax expense and effective income tax rate for the three and nine months ended September 30, 2020:</span></div><div style="margin-bottom:5pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:53.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.589%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="9" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 6pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.8</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89.2)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413.0 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 88800000 67900000 -89200000 61500000 0.133 0.127 4.130 0.039 2042300000 -377300000 3.996 -95700000 -30300000 0.080 -29900000 -17000000.0 0.056 0.019 Commitments and Contingencies<div style="margin-top:5pt"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Asset Acquisition and In-License Agreements</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into asset purchase agreements, license agreements, and option arrangements in order to advance and obtain technologies and services related to our business. These agreements generally require us to pay an initial fee and certain agreements call for future payments upon the attainment of agreed upon development, regulatory and/or commercial milestones. These agreements may also require minimum royalty payments based on sales of products developed from the applicable technologies, if any.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2019, we entered into an agreement with Caelum, a biotechnology company that is developing CAEL101 for light chain (AL) amyloidosis. Under the terms of the agreement, we acquired a minority equity interest in preferred stock of Caelum and an exclusive option to acquire the remaining equity in Caelum based on Phase II data, for pre-negotiated economics. We paid $30.0 in the first quarter 2019 and agreed to pay up to an additional $30.0 in contingent development milestones prior to the exercise the option to acquire the remaining equity in Caelum. These contingent payments meet the definition of a derivative liability and were initially recorded at fair value of $27.1. We allocated the total consideration of $57.1, inclusive of the fair value of the contingent payments, to the equity investment in Caelum and the option to acquire the remaining equity in Caelum based on the relative fair values of the assets. Following discussions with the FDA, Caelum changed its clinical development plan for </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CAEL-101 in the fourth quarter 2019. A Phase II trial for CAEL-101 subsequently commenced during the first quarter of 2020 and met its primary objectives, supporting the safety and tolerability of CAEL-101 and confirmed the dose and regimen to be adopted for the Phase III studies. In September 2020, Alexion and Caelum announced the initiation of the Cardiac Amyloid Reaching for Extended Survival (CARES) program. This includes two parallel Phase III trials to evaluate the survival benefits of CAEL-101. In December 2019, we amended the terms of the agreement with Caelum to modify the option to acquire the remaining equity in Caelum based on data from the modified Phase II/III trials. The amendment also modified the development-related milestone events associated with the initial $30.0 in contingent payments, provided for an additional $20.0 in upfront funding, which we accrued as of December 31, 2019 </span><span style="color:#212529;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and paid during the first quarter 2020</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as funding of $60.0 in exchange for an additional equity interest at fair value upon achievement of a specific development-related milestone event. The agreement with Caelum also provides for additional payments, in the event Alexion exercises the purchase option, for up to $500.0, which includes an upfront option exercise payment and potential regulatory and commercial milestone payments. During the second quarter 2020, we paid an aggregate of $15.0 of contingent payments to Caelum related to two development-based milestones and during the third quarter 2020, we paid a $15.0 contingent payment to Caelum related to another development-based milestone. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, we entered into an agreement with Zealand which provides us with exclusive worldwide licenses, as well as development and commercial rights, for subcutaneously delivered preclinical peptide therapies directed at up to four complement pathway targets. Pursuant to the agreement, Zealand will lead joint discovery and research efforts through the preclinical stage, and Alexion will lead development efforts beginning with the investigational new drug filing and Phase I studies. In addition to the agreement, we made an equity investment in Zealand (see Note 10, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Investments</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Under the terms of the agreement, we made an upfront payment of $40.0 for an exclusive license to the lead target and the equity investment, as well as for preclinical research services to be performed by Zealand in relation to the lead target. The market value of the equity investment was $13.8 as of the date of acquisition, which we recorded in other assets in our condensed consolidated balance sheets. We also recognized prepaid research and development expense of $5.0 within the condensed consolidated balance sheets associated with the research activities to be performed by Zealand. Due to the early stage of the asset we are licensing, we recorded the upfront license payment of $21.2 as research and development expense during the first quarter 2019. As of September 30, 2020, we could be required to pay up to $610.0, for the lead target, upon the achievement of specified development, regulatory and commercial milestones, as well as royalties on commercial sales. </span><span style="color:#212529;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we could be required to pay up to an additional $115.0 in development and regulatory milestones if both a long-acting and short-acting product are developed with respect to the lead target. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the three subsequent targets can be selected for an option fee of $15.0 and has the potential for additional development, regulatory and commercial milestones, as well as royalty payments, at a reduced price to the lead target.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, we entered into an agreement with Affibody AB (Affibody), through which Alexion obtained an exclusive worldwide license, as well as development and commercial rights, to ABY-039, a bivalent antibody-mimetic that targets the neonatal Fc receptor (FcRn). Under the terms of the agreement, we made an upfront payment of $25.0 for the exclusive license to ABY-039. Due to the early stage of the asset we licensed, we recorded the upfront license payment as research and development expense during the second quarter 2019. In February 2020, based on data from our Phase I study, we terminated the agreement to co-develop ABY-039 with Affibody. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we entered into an agreement with Eidos through which Alexion obtained an exclusive license to develop and commercialize AG10 in Japan. AG10 is a small molecule designed to treat the root cause of transthyretin amyloidosis (ATTR) and is currently in a Phase III study in the U.S. and Europe for ATTR cardiomyopathy (ATTR-CM). In addition, we made an equity investment in Eidos (see Note 10, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Investments</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Under the terms of the agreement, we made an upfront payment of $50.0 for the exclusive license to AG10 in Japan and the equity investment. The market value of the equity investment was $19.9 as of the date of acquisition, which we recorded in other assets in our condensed consolidated balance sheets. Due to the early stage of the asset we are licensing, we recorded the upfront license payment of $30.1 as research and development expense during the third quarter 2019. As of September 30, 2020, we could also be required to pay </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$30.0</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> upon achievement of a Japanese-based regulatory milestone as well as royalties on commercial sales.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#212529;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we entered into a collaboration agreement with Dicerna that provides us with exclusive worldwide licenses and development and commercial rights for two preclinical RNA interference (RNAi) subcutaneously delivered molecules for complement-mediated diseases, as well as an exclusive option for other preclinical RNAi molecules for two additional targets within the complement pathway. In addition to the collaboration agreement, we made an equity investment in Dicerna. Under the terms of the agreements, we made an upfront payment of $37.0 for the exclusive licenses and the equity investment. The market value of the equity investment </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#212529;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was $10.3 as of the date of acquisition, which we recorded in other assets in our condensed consolidated balance sheets. Due to the early stage of the assets we are licensing, we recorded the upfront license payment of $26.7 as research and development expense during the fourth quarter 2018. In December 2019, we exercised our option for exclusive rights to two additional targets within the complement pathway under an existing agreement with Dicerna, which expands our existing research collaboration and license agreement with Dicerna to include a total of four targets within the complement pathway. In connection with the option exercise, we paid Dicerna $20.0, which we recorded as research and development expense in the fourth quarter 201</span><span style="background-color:#ffffff;color:#212529;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9. </span><span style="color:#212529;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, excluding accrued milestones, we could be required to pay up to</span><span style="background-color:#ffffff;color:#212529;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $604.1</span><span style="color:#212529;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for amounts due upon the achievement of specified research, development, regulatory and commercial milestones on the four licensed targets, as well as royalties on commercial sales.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#212529;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we entered into a collaboration and license agreement with Halozyme Therapeutics, Inc. that allows us to use drug-delivery technology in the development of subcutaneous formulations for our portfolio of products for up to four targets. U</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nder the terms of the agreement, we made an upfront payment of </span><span style="color:#212529;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$40.0</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for an exclusive license to two of the four potential targets and due</span><span style="color:#212529;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the early stage of the assets we are licensing, we recorded an expense for the upfront payment during the fourth quarter 2017. During the second quarter 2020, we forfeited our rights to one of the two targets we initially licensed. As of September 30, 2020, we could be required to pay up to</span><span style="background-color:#ffffff;color:#212529;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$155.0 for the remaining licensed target upon </span><span style="color:#212529;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achievement of specified development, regulatory and sales-based milestones, as well as royalties on commercial sales. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the two subsequent targets can be licensed for an option fee of $8.0, with contingent payments of up to $160.0 per target, subject to development, regulatory and commercial milestones, as well as royalties on commercial sales.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our prior acquisition of Syntimmune, Inc., a clinical-stage biotechnology company developing an antibody therapy targeting the FcRn, we could be required to pay up to </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$800.0</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> upon the achievement of specified development, regulatory and commercial milestones,</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which $130.0 is specific to the subcutaneous formulation.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#212529;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, excluding accrued milestones, as of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2020</span><span style="color:#212529;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we have other license agreements under which we may be required to pay up to an additional</span><span style="background-color:#ffffff;color:#212529;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $114.0</span><span style="color:#212529;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for currently licensed targets, if certain development, regulatory and commercial milestones are met, including up to $71.5 for the development of cerdulatinib in multiple indications pursuant to an in-licensing agreement with Astellas Pharma, Inc. which was assumed through the acquisition of Portola in the third quarter 2020. Additional amounts may be payable if we elect to acquire licenses to additional targets, as applicable, under the terms of these agreements.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Asset Sale and Out-License Arrangements</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with prior asset sale and out-license arrangements, including those assumed by Alexion through the acquisition of Portola in the third quarter 2020, Alexion is entitled to receive contingent payments upon the achievement of various regulatory and commercial milestones and other events, as well as royalties on commercial sales. The amount of contingent consideration related to these agreements is fully constrained and therefore has not been recognized as of September 30, 2020.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing Agreements</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have various manufacturing development and license agreements to support our clinical and commercial product needs. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on Lonza, a third party manufacturer, to produce a portion of commercial and clinical quantities of our commercial products and product candidates. We have various manufacturing and license agreements with Lonza, with remaining total non-cancellable future commitments of approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1,432.3 </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through 2031</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This amount includes </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$105.5 </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of undiscounted, fixed payments applicable to our Contract Manufacturing Organization (CMO) embedded lease arrangement with Lonza. If we terminate certain supply agreements with Lonza without cause, we will be required to pay for product scheduled for manufacture under our arrangement. Under an existing arrangement with Lonza, we also pay Lonza a royalty on sales of SOLIRIS that was manufactured at the Alexion Rhode Island Manufacturing Facility (ARIMF facility) prior to the sale of the facility and a payment with respect to sales of SOLIRIS manufactured at Lonza facilities. We also pay Lonza a royalty on the sales of ULTOMIRIS.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our commitments with Lonza, as of September 30, 2020 we have non-cancellable commitments of approximatel</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y $78.6 </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through 2021 with other third party manufacturers.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Liabilities</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently involved in various claims, disputes, lawsuits, investigations, administrative proceedings and legal proceedings. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure. In accordance with generally accepted accounting principles, if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, we accrue a liability for the estimated loss. Because of uncertainties related to claims, proceedings and litigation, accruals are based on our best estimates based on information available at the time of the assessment. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation, court decisions or settlement of claims (and offers of settlement), we may reassess the potential liability related to these matters and may revise these estimates, which could result in a material adverse adjustment to our operating results. Costs associated with our involvement in legal proceedings are expensed as incurred. The outcome of any such proceedings, regardless of the merits, is inherently uncertain. If we were unable to prevail in any such proceedings, our consolidated financial position, results of operations, and future cash flows may be materially impacted.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received, and may in the future receive, notices from third parties claiming that their patents may be infringed by the use, development, manufacture, importation or sale of our products or product candidates. Under the guidance of ASC 450, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we record a royalty accrual based on our best estimate of the fair value percent of net sales of our products that we could be required to pay the owners of patents for technology used in the manufacture and sale of our products. A costly license, or inability to obtain a necessary license, could have a material adverse effect on our financial results.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2015, we received a subpoena in connection with an investigation by the Enforcement Division of the Securities and Exchange Commission (SEC) requesting information related to our grant-making activities and compliance with the Foreign Corrupt Practices Act (FCPA) in various countries. In addition, in October 2015, we received a request from the Department of Justice (DOJ) for the voluntary production of documents and other information pertaining to Alexion’s compliance with the FCPA. The SEC and DOJ also sought information related to Alexion’s recalls of specific lots of SOLIRIS and related securities disclosures. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The investigations focused on operations in various countries, including Brazil, Colombia, Japan, Russia and Turkey, and Alexion's compliance with the FCPA and other applicable laws.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, DOJ informed us that it has closed its inquiry into these matters. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 2, 2020, we reached a civil settlement with the SEC fully resolving the SEC’s investigation into possible violations of the FCPA. Alexion neither admitted nor denied any wrongdoing in connection with the settlement but agreed to pay </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$21.5</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the SEC, consisting of amounts attributable to disgorgement, civil penalties, and pre-judgment interest. In connection with this settlement, in July 2020, we paid </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$21.5</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the SEC.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the settlement with the SEC, the Ministry of Health in Turkey initiated an investigation regarding the matters referenced in the SEC Order as they relate to the Company’s operations in Turkey between 2010 and 2015. We are cooperating with this investigation.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alexion is committed to continually focusing on its compliance program and continues to enhance its comprehensive company-wide program that is designed to enhance our business processes, structures, controls, training, talent, and systems across Alexion’s global operations.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously reported, on December 29, 2016, a sharehold</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">er filed a putative class action against the Company and certain former employees in the U.S. District Court for the District of Connecticut, alleging that defendants made misrepresentations and omissions about SOLIRIS. On April 12, 2017, the court appointed a lead plaintiff. On July 14, 2017, the lead plaintiff filed an amended putative class action complaint against the Company and seven current or former employees. Defendants moved to dismiss the amended complaint on September 12, 2017. Plaintiffs filed an opposition to defendants’ motion to dismiss on November 13, 2017, and defendants filed a reply brief in further support of their motion on December 28, 2017. On March 26, 2019, the court held a telephonic status conference.  During that conference, the court informed counsel that it was preparing a ruling granting the defendants’ pending motion to dismiss.  The court inquired of plaintiffs’ counsel whether they intended to seek leave to amend their complaint, and indicated that if they wished to file a second amended complaint, they would be allowed to do so.  On April 2, 2019, the court granted plaintiffs until May 31, 2019 to file a second amended complaint, thereby rendering moot defendants’ pending motion to dismiss. On June 2, 2019, plaintiffs filed a second amended complaint against the same defendants. The complaint alleges that defendants engaged in securities </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fraud, including by making misrepresentations and omissions in its public disclosures concerning the Company’s SOLIRIS sales practices, management changes, and related investigations, between January 30, 2014 and May 26, 2017, and that the Company's stock price dropped upon the purported disclosure of the alleged fraud. The plaintiffs seek to recover unspecified monetary relief, unspecified equitable and injunctive relief, interest, and attorneys’ fees and costs. Defendants’ filed a motion to dismiss the amended complaint on August 2, 2019; plaintiffs’ filed their opposition to that motion on October 2, 2019; and defendants’ filed their reply in further support of their motion on November 15, 2019. Given the early stage of these proceedings, we cannot presently predict the likelihood of obtaining dismissal of the case (or the ultimate outcome of the case if the motion to dismiss is denied by the court), nor can we estimate the possible loss or range of loss at this time.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, we received a subpoena from the U.S. Attorney's Office for the District of Massachusetts requesting documents relating generally to our support of Patient Services, Inc. (PSI) and National Organization for Rare Disorders (NORD), 501(c)(3) organizations that provide financial assistance to Medicare patients taking drugs sold by Alexion; Alexion’s provision of free drug to Medicare patients; and Alexion compliance policies and training materials concerning the anti-kickback statute and information on donations to PSI and NORD from 2010 through 2016. In April 2019, we entered into a civil settlement agreement with the DOJ and the Office of Inspector General (OIG) of the U.S. Department of Health and Human Services to resolve this matter. As part of the settlement agreement, Alexion paid $13.1 to the DOJ and OIG. OIG did not require a Corporate Integrity Agreement with Alexion because it made fundamental organizational changes, including hiring a new executive leadership team, replacing half of the members of its Board of Directors, and effecting a significant change in the workforce.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, Brazilian authorities seized records and data from our São Paulo, Brazil offices as part of an investigation being conducted into Alexion’s Brazilian operations. We are cooperating with this inquiry.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, we received a demand to inspect certain of our books and records pursuant to Section 220 of the General Corporation Law of the State of Delaware on behalf of a purported stockholder. Among other things, the demand sought to determine whether to institute a derivative lawsuit against certain of the Company’s directors and officers in relation to the investigation by our Audit and Finance Committee announced in November 2016 and the investigations instituted by the SEC, DOJ, U.S. Attorney’s Office for the District of Massachusetts, and Brazilian law enforcement officials that are described above. We have responded to the demand. Given the early stages of this matter, an estimate of the possible loss or range of loss cannot be made at this time. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 27, 2017, a hearing panel of the Canadian Patented Medicine Prices Review Board (PMPRB) issued a decision in a previously pending administrative pricing matter that we had excessively priced SOLIRIS in a manner inconsistent with the Canadian pricing rules and guidelines. In its decision, the PMPRB ordered Alexion to decrease the price of SOLIRIS to an upper limit based upon pricing in certain other countries, and to forfeit excess revenues for the period between 2009 and 2017. The amount of excess revenues for the period between 2009 and 2017 was not determined to be a material amount and was paid in 2018. In October 2017, Alexion filed an application for judicial review of the PMPRB’s decision in the Federal Court of Canada. On May 23, 2019, the Federal Court of Canada dismissed Alexion's application for judicial review and, as a consequence, affirmed the decision of the PMPRB that we had excessively priced SOLIRIS. On June 21, 2019, Alexion filed a notice of appeal of the Federal Court of Canada's ruling, and, on October 17, 2019, Alexion filed a memorandum of fact and law in support of the appeal. On December 3, 2019, the Attorney General of Canada filed its memorandum of fact and law in support of the Federal Court of Canada's dismissal of Alexion's appeal of the PMPRB's decision. On December 19, 2019, the intervenor, the Minister of Health for the Province of British Columbia, filed a separate memorandum of fact and law in support of the Federal Court of Canada's decision. The Canadian Federal Court of Appeal heard the appeal on October 21 and 22, 2020, but has not issued a decision as of the date of this filing. Pursuant to an order made by the Federal Court of Canada, as of October 27, 2020, we have placed approximately $61.5 in escrow to secure our obligations pending the final resolution of all appeals in this matter. This amount reflects the difference between the list price for SOLIRIS and the price determined by the PMPRB to be non-excessive for sales of SOLIRIS in Canada for the period beginning September 2017 through September 30, 2020. In addition, on a quarterly basis, until the appeals process has concluded, Alexion will be required to place amounts into escrow for each vial of SOLIRIS sold in the applicable quarter equal to the list price for SOLIRIS and the price determined by the PMPRB to be non-excessive. Our revenues in Canada have been reduced by $42.2 cumulatively to date, which is our current best estimate of our liability through September 30, 2020 if we lose the appeal of this matter (the amount of our ultimate liability, however, may be greater than this estimate when the appeal process for this matter is concluded).</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chugai Pharmaceutical Co., Ltd. has filed three lawsuits against Alexion.  The first was filed in November 2018 in the United States District Court for the District of Delaware against Alexion Pharmaceuticals, Inc. alleging that </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ULTOMIRIS infringes one U.S. patent held by Chugai Pharmaceutical Co., Ltd.  Upon issuance of a new U.S. patent on November 12, 2019, Chugai filed a second lawsuit in the United States alleging that ULTOMIRIS infringes the new patent. The parties have agreed to consolidate the November 2018 and November 2019 lawsuits. Chugai filed a third lawsuit in December 2018 in the Tokyo District Court against Alexion Pharma GK (a wholly-owned subsidiary of Alexion) in Japan, and alleges that ULTOMIRIS infringes two Japanese patents held by Chugai Pharmaceutical Co., Ltd.  Chugai’s complaints seek unspecified damages and certain injunctive relief. On March 5, 2020, the Supreme Court of Japan dismissed Chugai's appeal against an earlier IP High Court of Japan decision which held that one of the Chugai patents-in-suit is invalid. Subsequently Chugai filed a correction to the claims of this patents-in-suit and Alexion has countered that the corrected claims are still invalid and not infringed. In all cases, Alexion has denied the charges and countered that the patents are neither valid nor infringed. A trial date for the U.S. case which was initially set for July 2021 has been re-scheduled for October 2021. The case is still at the briefing stage in Japan.  Given the early stages of these litigations, an estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2019, Amgen Inc. (Amgen) petitioned the U.S. Patent and Trademark Office (PTO) to institute Inter Partes Review (IPR) of three patents owned by Alexion that relate to SOLIRIS:  U.S. Patent Nos. 9,725,504; 9,718,880; and 9,732,149. In each case, Amgen alleged the patented subject matter was anticipated and/or obvious in view of prior art, and that the patent claims are therefore invalid. On August 30, 2019, the PTO instituted IPRs of each of the three patents. On May 28, 2020, we entered into a Confidential Settlement and License Agreement (the “Settlement Agreement”) with Amgen to settle the three IPRs at the Patent Trial and Appeal Board (“PTAB”) of the PTO. Pursuant to the Settlement Agreement, Alexion and Amgen have terminated each of the pending IPRs. In addition, effective March 1, 2025 (or an earlier date in certain circumstances), the Company grants to Amgen (and its affiliates and certain partners) a non-exclusive, royalty-free, license under U.S. patents and patent applications related to eculizumab and various aspects of the eculizumab product that Alexion currently markets and sells under the tradename SOLIRIS. This license will allow Amgen (and its affiliates and certain partners), effective March 1, 2025, the right to make, have made, use, import, have imported, sell, have sold, offer for sale, have offered for sale, distribute, and have distributed in, or for, the U.S., an eculizumab product.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with an ongoing matter, in August 2019, the Brazilian Federal Revenue Service provided a Notice of Tax and Description of the Facts (the “Tax Assessment”) to two Alexion subsidiaries (the "Brazil Subsidiaries"), as well as to two additional entities, a logistics provider utilized by Alexion and a distributor. The Tax Assessment focuses on the importation of SOLIRIS vials pursuant to Alexion’s free drug supply to patients program (referred to as Global Access to Medicines, or GATM) in Brazil. In September 2019, the Brazil Subsidiaries filed defenses to the Tax Assessment disputing the basis for liability under the Tax Assessment, based on, among others, the following: in connection with the operation of GATM, during the period from September 2014 to June 2019: (i) the importers responsible for the importation of the GATM SOLIRIS vials into Brazil were correctly identified and (ii) the correct customs value was utilized for the purpose of importing the GATM SOLIRIS vials provided to the patients free of charge. The defenses filed by Alexion are pending judgment at the first level of administrative appeals within the Brazilian federal administrative proceeding system. There are three separate levels of administrative appeals within the Brazilian federal administrative proceeding system and, if the outcome of these administrative appeals is unfavorable, the final decision of the federal administrative proceeding system can be disputed to the federal court systems in Brazil (at this time, Alexion intends to appeal the Tax Assessment if it is not overturned in the course of administrative appeals). Given the early stage of these proceedings, Alexion is unable to predict the duration, scope or outcome of this matter, but we expect that a final resolution will take three years or more. While it is possible that a loss related to the Tax Assessment may be incurred, given its ongoing nature, we cannot reasonably estimate the potential magnitude of any such possible loss or range of loss, or the cost of the ongoing administrative appeals (and potential appeals to the federal court system) of the Tax Assessment. Any determination that any aspects of the importation of free of charge medications into Brazil as set forth in the Tax Assessment are not, or were not, in compliance with existing laws or regulations could result in the imposition of fines, civil penalties and, potentially criminal penalties, and/or other sanctions against us, and could have an adverse impact on our Brazilian operations.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with Alexion’s acquisition of Portola, we have assumed litigation to which Portola was a party. Among the li</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tigation assumed is a securities fraud class action filed against Portola and certain of its officers, directors and underwriters (“Defendants”) under the Securities Act of 1933 and the Securities Exchange Act of 1934. Specifically, on January 16, 2020, February 7, 2020, and February 28, 2020, stockholders filed three putative class actions in the U.S. District Court for the Northern District of California, captioned </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hayden v. Portola Pharmaceuticals, Inc., et al., No. 3:20-cv-00367-VC (N.D. Cal.); McCutcheon v. Portola Pharmaceuticals, Inc., et al.,</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No. 3:20-cv-00949 (N.D. Cal.)</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">; and Southeastern Pennsylvania Transportation Authority v. Portola Pharmaceuticals, Inc., et </span></div><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 3:20-cv-01501 (N.D. Cal.). </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These cases have since been consolidated, and on April 22, 2020, the Court issued an Order appointing the Alameda County Employees’ Retirement Association (“ACERA”) as Lead Plaintiff in the litigation. ACERA filed its amended consolidated complaint on May 20, 2020, asserting that Defendants made misrepresentations and omissions in public disclosures (including in materials issued in connection with the August 7, 2019 securities offering) concerning Portola’s sales of andexanet alfa, marketed as ANDEXXA in the United States and ONDEXXYA in Europe, between January 8, 2019 and February 26, 2020. Specifically, plaintiffs allege that Defendants made materially false and/or misleading statements about the demand for ANDEXXA, usage of ANDEXXA by hospitals and healthcare organizations, and about Portola’s accounting for its return reserves. Plaintiffs contend that the alleged fraud was revealed on January 9, 2020, when Portola announced its preliminary unaudited financial results for the fourth quarter of 2019, and again on February 26, 2020, when </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portola issued its fourth quarter 2019 financial results. In July 2020, Portola and the Portola Defendants filed a motion to dismiss with the Court.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The court heard oral argument on September 24, 2020 and granted defendants’ pending motion to dismiss, but with leave for plaintiffs to amend further their complaint. Plaintiffs have until November 5, 2020 to file a second amended complaint. Plaintiffs seek to recover unspecified monetary relief, interest, and attorneys’ fees and costs. Given the early stage of these proceedings, we cannot presently predict the likelihood of obtaining dismissal of the case which the Company intends to submit following the filing of the second amended complaint (or the ultimate outcome of the case if that motion to dismiss is denied by the court), nor can we estimate the possible loss or range of loss at this time.</span> 30000000.0 30000000.0 27100000 57100000 30000000.0 20000000.0 60000000.0 500000000.0 15000000.0 15000000.0 40000000.0 13800000 5000000.0 21200000 610000000.0 115000000.0 15000000.0 25000000.0 50000000.0 19900000 30100000 30000000.0 37000000.0 10300000 26700000 20000000.0 604100000 40000000.0 155000000.0 8000000.0 160000000.0 800000000.0 130000000.0 114000000.0 71500000 1432300000 105500000 78600000 21500000 21500000 13100000 61500000 42200000 Restructuring and Related Expenses<div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter 2020, we initiated restructuring activities primarily within our commercial organization as part of an initiative intended to redefine our operating model. The actions are intended to reallocate resources necessary to align our organization with our diversifying portfolio of new products and strategic objectives, and will include investments in digital capabilities, technologies and solutions to support a more virtual and digital customer experience and tailored to the markets in which we operate.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actions are expected to be substantially completed by the end of 2021, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $25.0. We expect that the pretax costs will primarily result in cash outlays, as the costs primarily relate to employee separation expenses.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter 2019, we initiated corporate restructuring activities to re-align our international commercial organization through re-prioritization of certain geographical markets and to implement operational excellence through strategic reallocation of resources. Actions under the previous restructuring programs have been completed.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total expenses recorded related to the restructuring activities by type of activity and the locations recognized within the consolidated statements of operations:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="15" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="15" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="15" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="15" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Separation Costs</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Separation Costs</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring expenses</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c7fb8;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c7fb8;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c7fb8;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c7fb8;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c7fb8;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c7fb8;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="15" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="15" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="15" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="15" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Separation Costs</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Separation Costs</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring expenses</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c7fb8;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c7fb8;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c7fb8;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c7fb8;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c7fb8;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c7fb8;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the restructuring reserve recorded within accounts payable and accrued expenses on the Company's consolidated balance sheets as of September 30, 2020</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="15" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="15" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="15" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="15" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Separation Costs</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Separation Costs</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability, beginning of period</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to previous estimates</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability, end of period</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The restructuring reserve of</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $15.9</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $6.8 is recorded in accounts payable and accrued expenses on the Company's condensed consolidated balance sheet as of September 30, 2020 and December 31, 2019, respectively. The accrued amounts are expected to be paid in the next twelve months. We currently estimate incurring up to an additional $11.0 in restructuring expenses related to the third quarter 2020 action.</span></div> 25000000.0 <div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total expenses recorded related to the restructuring activities by type of activity and the locations recognized within the consolidated statements of operations:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="15" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="15" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="15" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="15" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Separation Costs</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Separation Costs</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring expenses</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c7fb8;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c7fb8;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c7fb8;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c7fb8;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c7fb8;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c7fb8;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="15" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="15" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="15" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="15" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Separation Costs</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Separation Costs</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring expenses</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c7fb8;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c7fb8;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c7fb8;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c7fb8;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c7fb8;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c7fb8;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the restructuring reserve recorded within accounts payable and accrued expenses on the Company's consolidated balance sheets as of September 30, 2020</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="15" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="15" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="15" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="15" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Separation Costs</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Separation Costs</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#0092cb;padding:0 1pt"/><td colspan="3" style="background-color:#0092cb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability, beginning of period</span></td><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3 </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to previous estimates</span></td><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td colspan="2" style="background-color:#eaeaea;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability, end of period</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#eaeaea;padding:0 1pt"/><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0092cb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#eaeaea;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 14300000 0 14300000 -2800000 3100000 300000 14000000.0 -500000 13500000 8700000 3200000 11900000 1600000 0 1600000 3300000 3500000 6800000 14300000 0 14300000 14300000 0 14300000 0 0 0 1400000 3000000.0 4400000 0 0 0 -300000 -500000 -800000 15900000 0 15900000 15900000 0 15900000 15900000 6800000 11000000.0 XML 39 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover Page - shares
 9 Months Ended
Sep. 30, 2020
Oct. 27, 2020
Document and Entity Information [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2020  
Document Transition Report false  
Entity File Number 0-27756  
Entity Registrant Name ALEXION PHARMACEUTICALS, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 13-3648318  
Entity Address, Address Line One 121 Seaport Boulevard  
Entity Address, City or Town Boston  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 02210  
City Area Code 475  
Local Phone Number 230-2596  
Title of 12(b) Security Common Stock $0.0001 par value  
Trading Symbol ALXN  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Central Index Key 0000899866  
Current Fiscal Year End Date --12-31  
Entity Common Stock, Shares Outstanding   218,845,432
Amendment Flag false  
Document Fiscal Year Focus 2020  
Document Fiscal Period Focus Q3  

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˳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�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